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 1  SUMMARY         9 
1.  Summary 
Integral membrane proteins (IMPs) account for 20-40% of all open reading frames in 
fully sequenced genomes and they are target of approximately 60% of all modern drugs. 
So far, cellular expression systems are often very insufficient for the high-level 
production of IMPs. Toxic effects, instability or formation of inclusion bodies are 
frequently observed effects that prevent the synthesis of sufficient amounts of functional 
protein. I have successfully established an individual cell-free (CF) expression system 
to overcome these IMP synthesis difficulties.  
The CF system was established in two different expression modes. If no hydrophobic 
compartment is provided, the IMPs precipitate in the reaction mixture. Interestingly, 
these insoluble proteins are found to differ from inclusion bodies as they readily 
solubilize in mild detergents and the bacterial small multi drug transporter EmrE, 
expressed in the insoluble mode was shown to reconstitute into liposomes in an active 
form. Alternatively, IMPs can be synthesized in a soluble way by supplementing the CF 
system with detergents. A comprehensive overview of 24 commonly used detergents 
was provided by analyzing their impact on the CF system as well as their ability to keep 
three structurally very different proteins in solution. The class of long chain 
polyoxyethylene-alkyl-ethers turned out to be most suitable for soluble expression of α-
helical EmrE, the bacterial β-barrel type nucleoside transporter Tsx and the porcine 
vasopressin receptor type 2, resulting in several mg of protein per mL of reaction 
mixture. 
So far IMPs have almost completely been excluded from solution nuclear magnetic 
resonance (NMR) analyses. I could demonstrate that CF expression enables efficient 
isotopic labeling of IMPs for NMR analysis and further facilitates selective labeling 
strategies with combinations of 
13C and 
15N enriched amino acids that have not been 
feasible before.  
Four different G-protein coupled receptors (GPCRs) were successfully CF expressed in 
preparative scale and for the human endothelin B receptor (ETB), ligand binding ability 
was observed. A series of truncated ETB derivatives containing nested terminal 
deletions have been CF produced and functionally characterized. The core area essential 
for Endothelin-1 binding as well as a central region responsible for ETB oligomer 
formation was confined to a 39 amino acid fragment including the proposed 
transmembrane segment 1. The binding constant (KD) of ETB was determined to 6 nM 
for circular ET-1 by SPR and 29 nM for linear ET-1 by TIRFS. This data indicate a 
large potential of the established individual CF expression system for functional IMP 
synthesis.
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2.  Zusammenfassung 
Funktionelle und strukturelle Analyse von zellfrei produzierten Transportern und 
G-Protein gekoppelten Rezeptoren: Entwicklung neuer Techniken zur schnellen 
und effizienten Produktion von integralen Membranproteinen 
Etwa 20-40% aller Gene in Organismen codieren für integrale Membranproteine (IMPs) 
und es wird angenommen, dass über 60% aller Arzneimittel direkt gegen sie gerichtet 
sind. Diese enorme Vielfalt und Wichtigkeit steht in einem großen Widerspruch zu dem 
derzeitigen Wissensstand über diese Proteinklasse. Über Erfolg und Misserfolg bei 
funktionellen und vor allem strukturellen Untersuchungen entscheidet vorerst die 
Herstellung des Zielproteins. Meist aber ist die Präparation ausreichender 
Proteinmengen äußerst problematisch. Die Überproduktion von IMPs in zellulären 
Expressionssystemen wird hierbei durch die Einlagerung in die Zellmembran und den 
dadurch bedingten toxischen Einfluss stark behindert. So ist es nicht verwunderlich, 
dass bis heute nur weniger als 100 Strukturen von Membranproteinen bestimmt werden 
konnten, wobei der Erfolg für diese wenigen Beispiele hauptsächlich durch ihre 
natürliche Häufigkeit begründet ist [1-3]. 
Ziel dieser Arbeit war ein individuelles zellfreies Expressionsverfahren zu etablieren, 
mit Hilfe dessen die Herstellung und somit funktionelle und strukturelle Untersuchung 
von bisher problematischen IMPs ermöglicht wird. Wie in dieser Arbeit gezeigt wird, 
konnten auf diesem zellunabhängigen Wege verschiedenste IMPs in einem präparativen 
Maßstab und in einem sehr kurzen Zeitrum von 12 bis 24 Stunden hergestellt werden.  
Die beschriebene zellfreie Proteinsynthese basiert auf einem optimierten Zellextrakt aus 
E. coli, dem alle nötigen Bestandteile, die eine gekoppelte Transkription/Translation 
erlauben, zugegeben werden, wie z.B. DNA, T7-RNA Polymerase, tRNA, Aminosäuren 
und Puffer. Ein hocheffizientes Energiesystem, basierend auf Phosphoenolpyruvat und 
Acetylphosphat in Kombination mit den zugehörigen Kinasen gewährleistet die 
benötigte Regeneration von Nukleotidtriphosphaten. Die Reaktion selbst wird in einem 
so genannten „continuous exchange cell-free“ CECF System [4, 5] angesetzt, in dem 
eine Dialysemembran die Reaktionslösung von einer Versorgungslösung trennt, die 
einen ständigen Zustrom von Substraten ermöglicht. Als Reaktionsmenge wurden 
hierbei im analytischen Maßstab 70 µl sowie im präparativen Ansatz 1000 µl 
verwendet. Im Gegensatz zu konventionellen zellulären Expressionssystemen, bei 
denen die Proteinsynthese innerhalb der Zelle abgeschottet durch die Zellmembran 
stattfindet, gewährleisten zellfreie Systeme eine vollständig offene Zugänglichkeit. Dies 
erlaubt die direkte Kontrolle der Reaktionsbedingungen zu jeder Zeit und ermöglicht 
erstmals eine genaue Anpassung der Reaktionsbedingungen auf das Zielprotein. So 2    ZUSAMMENFASSUNG  11
können Komponenten, wie z.B. Liganden, Detergenzien oder Protease Inhibitoren, die 
eine Proteinsynthese fördern und stabilisieren direkt zugegeben werden. Damit stellt die 
zellfreie Proteinsynthese eine viel versprechende Alternative für sonst zellulär nur 
unzureichend exprimierte Proteine dar, wie z.B. modifizierte Proteine, zytotoxische 
Proteine, instabile Proteine oder Disulfid-Brücken besitzende Proteine. So ist es z. B. 
möglich, funktionelle Antikörper herzustellen [6] und bis zu neun Disulfid-Brücken 
enthaltende Proteine zellfrei zu synthetisieren [7]. 
Für die zellfreie Expression wurden zwei Verfahren zur Herstellung von IMPs 
entwickelt. Zunächst konnte gezeigt werden, dass IMPs aufgrund fehlender 
hydrophober Bereiche im zellfreien System unlöslich exprimiert werden. Interessanter 
Weise verhalten sich diese Präzipitate völlig anders als Inclusion Bodies, wie man sie 
aus herkömmlichen E. coli Expressionen kennt, da sie sich bereits in milden 
Detergenzien lösen lassen und somit keine umfangreichen Rückfaltungsprotokolle 
benötigt werden. Das Detergenz 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-
glycerol)] (LMPG) wurde als generelles Mittel zum Resolubilisieren von IMPs 
identifiziert. Dass auf diesem neuen Wege nicht nur große Mengen sondern auch aktive 
IMPs hergestellt werden zeigt ein spezifischer Transport-Test des bakteriellen α-
helikalen Small Multi Drug Resistenz (SMR) Transporters EmrE. EmrE, zellfrei 
hergestellt und in E. coli Lipide rekonstituiert, zeigte eindeutig spezifischen 
Substrattransport.  
Eine weitere Möglichkeit zur zellfreien Herstellung von IMPs ist die Expression in 
Anwesenheit von Detergenzien und somit in löslicher Form. Bei dieser zweiten 
Methode war jedoch anfangs zu erwarten, dass einige Detergenzien die zellfreien 
Expressionsbedingungen stören oder aber das IMPs nicht ausreichend solubilisieren 
können. Um eine umfangreiche Analyse zu gewährleisten, wurden 24 der am häufigsten 
für IMPs verwendeten Detergenzien sowohl auf ihre Wechselwirkung mit den 
Reaktionskomponenten hin untersucht, als auch auf ihre Fähigkeit, IMPs löslich zu 
exprimieren. Zudem wurden drei strukturell sehr unterschiedliche Proteine, EmrE, das 
bakterielle aus β-Faltblättern bestehende Tsx, als auch der G-Protein gekoppelte 
Rezeptor (GPCR) Vasopressin 2 (V2R) auf zellfrei lösliche Expression in Gegenwart 
dieser Detergenzien hin untersucht. Etwa ein Drittel der untersuchten Detergenzien 
hatten innerhalb der verwendeten Konzentrationen so gut wie keinen Effekt auf die 
Löslichkeit der drei IMPs. Mindestens ein Detergenz von jeder analysierten Gruppe und 
insgesamt zehn der Detergenzien ermöglichten jedoch für mindestens eines der Proteine 
die lösliche Herstellung von präparativen Mengen, d.h. von mehr als 0,5 mg pro ml 
Reaktionslösung. Außergewöhnlich gute Ergebnisse erzielte jedoch die Gruppe von 
langkettigen Polyoxyethylen-Alkyl-Ethern, Brij35, Brij58, Brij78 und Brij98, die für 
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alle drei Proteine die lösliche Expression von mehr als 1 mg pro ml Reaktionslösung 
ermöglichte. 
Eine Vielzahl von verschiedenen IMPs konnte bisher zellfrei hergestellt werden. Neben 
Proteinen, die in dieser Arbeit beschriebenen werden, konnten auch andere 
Arbeitsgruppen die zellfreie Synthese von IMPs zeigen. Verschiedene SMR 
Transporter, wie EmrE [8-11], Hsmr, YdgF, Yfbw [12], Psmr [10], und TBsmr [10, 12, 
13] wurden in analytischen bis präparativen Mengen erhalten. Zudem konnte die 
funktionelle Synthese verschiedener G-Protein gekoppelter Rezeptoren in Fusion mit 
Thioredoxin [14] als auch die funktionelle Synthese des mechanosensitiven Ionenkanals 
MscL [15] gezeigt werden. Diese Arbeit demonstriert neben der präparativen zellfreien 
Synthese der SMR Transporter EmrE, SugE und TBsmr die Synthese von wesentlich 
größeren IMPs. Der 36 kDa und 10 Transmembran Segmente (TMS) enthaltende 
Metall-Ionen Transporter TehA und der 6 TMS umfassende Aminosäure-Exporter Yfik, 
welche in E. coli Zellen keinerlei Expression zeigten, konnten zellfrei sogar in Mengen 
von 3 mg pro ml Reaktionslösung hergestellt werden.  
Die absolute Kontrolle über die zellfreien Reaktionszusammensetzungen erlauben 
einzigartige Möglichkeiten für das gezielte Markieren von überproduzierten Proteinen 
wie sie speziell für die Kernmagnetische Resonanz (NMR) Spektroskopie von Nöten 
sind. Die zellfreie Proteinsynthese ermöglicht das einfache Ersetzen von unmarkierten 
Aminosäuren mit markierten Derivaten, welche ohne jegliches Aminosäure-Scrambling 
und ohne Expressionseinbußen zellfrei eingebaut werden [16-22]. Die Markierung von 
IMPs mit 
2H, 
13C und 
15N Isotopen war jedoch bisher, aufgrund extremer Probleme in 
der Proteinherstellung, fast undenkbar. Ein Problem, welches sich speziell für die 
Lösungs-NMR von IMPs ergibt ist die Erfordernis von Detergenz Lösungen. IMPs 
eingebettet in Mizellen, ergeben eine enorme Gesamtgröße, welche sich in deutlichen 
Linienverbreiterungen und somit Auflösungseinbußen im NMR Spektrum 
widerspiegeln. Weiter sind viele IMPs hauptsächlich aus α-helikalen Sekundärstruktur-
Elementen aufgebaut, die nur eine geringe chemische Verschiebungsverteilung 
aufweisen.  
Diese Arbeit zeigt, dass größere IMPs erstmals auch mit Lösungs-NMR untersucht 
werden können. Dies wird durch die Synergie von außergewöhnlichen zellfreien 
Expressionsraten für IMPs in Verbindung mit einzigartigen Markierungsmöglichkeiten 
und der Verwendung ultra hoher NMR Feldstärken (800 und 900 MHz), welche höhere 
Sensitivität und Auflösung gewährleisten, ermöglicht. Die Verwendung von LMPG, das 
als effizientes Detergenz zum Lösen von zellfreien IMPs Präzipitaten gefunden wurde 2    ZUSAMMENFASSUNG  13
und dem sehr gute Eigenschaften für die Lösungs-NMR zugesprochen werden [23], 
ermöglicht sogar eine NMR-Probenzubereitung innerhalb 24 Stunden. 
Am Anfang jeder NMR Analyse steht die Zuordnung der einzelnen Signale eines 
Spektrums. Als Modellbeispiel für eine strukturelle Untersuchung mit Hilfe von 
Lösungs-NMR kombiniert mit zellfreier IMPs Synthese wurde das 24 kDa und 7 TMS 
enthaltende c-terminal verkürzte TehA Protein (ΔTehA) ausgewählt. ΔTehA werden 
gleiche Aktivitätseigenschaften wie dem Gesamtprotein zugesprochen [24]. Obwohl das 
[
15N,
1H]-TROSY-HSQC Spektrum von ΔTehA für den Beginn einer Zuordnung der 
Aminosäure-Hauptkette Proton-Resonanzen eine ausreichende Dispersion besitzt, 
existiert eine starke Überlagerung von Signalen in bestimmten Bereichen des 
Spektrums. Für die Zuordnung von IMPs bedurfte es jedoch der Entwicklung neuer 
Strategien, da die Hürde der Signalüberlappung selbst durch Aminosäure spezifische 
Markierungen nicht genommen werden konnte.  
Eine Lösung brachte die gleichzeitige selektive Markierung mit einigen 
15N und 
anderen 
13C angereicherten Aminosäuren. Die Verwendung von [
15N,
1H]-TROSY-
HSQC und [
15N,
1H]-TROSY-HN(CO) Spektren erlaubte nun die Identifizierung von 
15N markierten Aminosäuren, denen eine 
13C angereicherte Aminosäure vorausging 
[25]. Die Verwendung dieses so genannten kombinatorischen Markierens ermöglicht 
somit die eindeutige Zuordnung von einzelnen Aminosäuren, die als Anhaltspunkte für 
weitere sequenzielle Zuordnungen verwendet werden konnten. Das kombinatorische 
zellfreie Markieren von IMPs bildet somit einen Kernpunkt für die Zuordnung dieser 
Proteine, wenngleich dieses Markieren auch nahezu exklusiv durch zellfreie Synthese 
möglich ist. In zellulären Systemen wäre dieses Markierungsschema fast undenkbar, da 
hier für jede erdenklichen Kombinationen doppelt auxotrophe Mutanten benötigt 
würden. 
Aufgrund einer limitierten Verteilung der chemischen Verschiebung in α-helikalen 
IMPs können Aminosäure-Seitenketten-Protonen nur erschwert zugeordnet werden. 
Somit ist eine schlechte Basis für klassische 
1H-
1H-NOE basierte Abstandsermittlungen 
gegeben, die für eine dreidimensionale Strukturbestimmung unabkömmlich sind. Eine 
weitere Methode zur Abstandbestimmung ist die Verwendung von paramagnetischen 
Markierungen, welche in paramagnetisch relaxationsverstärkungs (PRE) Experimenten 
eingesetzt werden [26, 27]. Mit Hilfe dieser Technik, angewendet auf das verkürzte 
TehA Protein, war es letztlich doch möglich, genügend Abstandsinformationen zu 
erhalten, um eine vorläufige dreidimensionale Struktur des 7 TMS enthaltenden IMPs 
aus 325 Abstandsbedingungen zu errechnen. 
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Innerhalb der Familie von IMPs bilden die GPCR die größte Gruppe von Zell-
Oberflächen-Rezeptoren und über 1000 Gene des menschlichen Genoms kodieren für 
GPCRs  [28]. Fast alle Signalmechanismen im menschlichen Körper werden durch 
GPCRs kontrolliert und so ist es nicht verwunderlich, dass über 60% aller modernen 
Medikamente mutmaßlich gegen GPCRs gerichtet sind [29]. Wie allgemein für IMPs 
gültig, existiert nur ein beschränktes Wissen über strukturelle und funktionelle 
Eigenschaften von GPCRs, hauptsächlich aufgrund der sehr schwierigen 
Proteinpräparation in zellulären Systemen. Verschiedene GPCRs, V2R aus Mensch und 
Schwein, der Corticotropin Releasing Factor Rezeptor (CRF) aus Ratte und humaner 
Endothelin B Rezeptor (ETB) konnten erfolgreich in präparativen Mengen mit Hilfe des 
individuellen zellfreien Systems ohne die Verwendung von großen Fusionsproteinen 
exprimiert werden. Der 12 Aminosäuren kleine c-terminale T7-Tag zeigte sich hierbei 
ausreichend für die zellfreie Expression von 3-6 mg per ml Reaktionslösung.  
Der humane ETB wurde in dieser Arbeit genauer untersucht. Unter Verwendung des 
fluoreszenz markierten Liganden Endothelin-1 (ET-1) konnte in Koelutions-Analysen 
gezeigt werden, dass nur für löslich in Anwesenheit von Detergenz synthetisiertes ETB 
eine Ligandenbindung erreicht wird und diese sogar in Abhängigkeit zu der 
verwendeten Detergenz steht. Unlöslich zellfrei hergestellter und in LMPG 
resulubilisierter Rezeptor zeigte keinerlei Ligandenbindung, wobei über 50% des in 
Brij78 hergestellten Rezeptors den Liganden ET-1 binden. Surface Plasmon Resonanz 
(SPR) und totale interne Reflektions-Fluoreszenz-Spektroskopie (TIRFS) 
Untersuchungen ergaben Bindungskonstanten (KD) von 6 nM für zirkuläres ET-1 und 
29 nM für lineares ET-1. Diese Ergebnisse stehen im Einklang mit bereits publizierten 
Werten, wenn auch diese Interaktionen erstmals in Mizellen gemessen wurden.  
Bislang ist nahezu ungeklärt, wie und wo die ET-1 Bindung an ETB stattfindet. Zur 
Lokalisierung der Ligandenbindung wurden verschiedenste verkürzte ETB Fragmente 
kloniert und zellfrei exprimiert. Die Untersuchung mit fluoreszenz markiertem ET-1 in 
Koelutions-Analysen, als auch Pull-Down Experimente mit biotinyliertem ET-1 auf 
Streptavidin Säulen wurde herangezogen. Nur Fragmente, die das erste TMS enthalten, 
zeigten Ligandenbindung. Die Region der Ligandenbindung konnte so auf 39 
Aminosäuren eingeschränkt werden. SPR Messungen ergaben zudem KD Werte für 
diese Konstrukte, die nur drei- bis fünffach schwächer als für den gesamten Rezeptor 
sind. 
Seit kurzem ist bekannt, dass ETB Homodimere ausbildet [30]. Es ist jedoch ungeklärt, 
welche Bereiche des Proteins an dieser Dimerisierung beteiligt sind. In dieser Arbeit 
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Histidin markierten ETB Fragmenten identifizieren eindeutig das erste TMS als 
maßgeblich beteiligt an der Dimerisierung. Für diese Untersuchungen wurden die 
verschiedenen ETB-Derivate sowohl einzeln zellfrei synthetisiert, aufgereinigt und 
äquimolar zusammengegeben als auch ko-exprimiert und auf Interaktionen hin 
untersucht. Die erhaltenen Daten werden durch Single Partikel Analysen, die deutlich 
die Ausbildung von Dimeren in Brij78 Mizellen zeigen, unterstützt. Beide ETB 
Monomere berühren sich in verschiedenen gemittelten Klassen eindeutig an einer Seite 
des Proteins, mutmaßlich der ersten TMS. Diese enge Kolokalisation mit der Liganden-
Bindungs-Domäne könnte durch eine spekulative dimermodulierte Ligandenbindung in 
ETB begründet sein. 
Letztlich wurden alle C-terminal verkürzten ETB Fragmente für Lösungs-NMR 
Untersuchungen zellfrei vollständig 
15N markiert. Während das gesamte Protein und 
größere Fragmente erwartungsgemäß mindere Spektrenqualität zeigten, sticht das 
Fragment ETB93 (TMS 1-3) mit einem relativ gut aufgelösten [
15N,
1H]-TROSY-HSQC 
Spektrum hervor. Dieses Ergebnis verdeutlicht erstmals, dass selbst relativ große 
GPCRs, bzw. deren verkürzte aktive Derivate in Zukunft mit Lösungs-NMR untersucht 
werden könnten. 
IMPs und vor allem GPCRs waren bislang von vielen biochemischen und 
strukturbiologischen Methoden aufgrund extremer Probleme in der Proteinpräparation 
nahezu ausgeschlossen. Diese Arbeit zeigt die erfolgreiche Etablierung eines 
individuellen zellfreien Systems zur präparativen und funktionellen IMPs Herstellung. 
Durch zellfreie Expression erreichbare IMPs-Mengen dieser begehrten Proteine öffnen 
nun neue Tore für funktionelle und strukturelle Untersuchungen. 
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3.  Introduction 
3.1.  Overproduction of integral membrane proteins (IMPs) 
Integral membrane proteins (IMPs) are embedded into cellular membranes by multiple 
hydrophobic transmembrane segments (TMSs). They control numerous essential 
functions like transport activities, energy regeneration, signal perception and 
communication of the cell with its environment (Fig. 1).  
 
 
Fig. 1 Integral membrane proteins inside the plasma membrane. 
Integral membrane proteins (IMPs) are crossing the plasma membrane allowing the transport 
of solutes and information. These IMPs can either be transporters, transporting in different 
directions or receptors allowing signal transduction from the outside to the inside of a cell. 
(Modified after Forschung Frankfurt 3/2005: Mit neuer Methode lassen sich 
Membranproteins “knacken”. Erstmals können ausreichende Mengen begehrter Proteine 
produziert werden – Auszeichnung für Christian Klammt (P 12)). 
 
IMPs account for 20-40% of all open reading frames in fully sequenced genomes, and 
in bacteria half of the IMPs are estimated to function as transporters. The topology of 
IMPs is generally dominated by α-helical structures while typical β-barrel arrangements 
are prevalent in IMPs inserted into the outer membrane of Gram-negative bacteria. As 
IMPs play key roles in a variety of global human diseases, many pharmaceutical studies 
focus currently on IMPs and they provide thus an estimate of approx. 60% of all 
modern drug targets.  
A basic prerequisite for directed drug design as well as for the understanding of 
biological functions is the knowledge of the three-dimensional structure of a protein. 
Relatively high amounts of protein in the range of several 100 mg are often needed for 
structural approaches by either X-ray crystallography or nuclear magnetic resonance 
(NMR) spectroscopy. With few exceptions where natural abundances of a protein offers 
the opportunity of high yield preparations, like in case of rhodopsin [2], aquaporin [3] 
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or a Ca
2+-ATPase  [1], heterologous cellular expression systems of prokaryotic or 
eukaryotic origin have to be used in order to produce sufficient amounts of protein. 
Unfortunately, the hydrophobic nature of IMPs and their distinct localization in cellular 
membranes does often cause tremendous problems upon their synthesis in conventional 
expression systems. Blocking of cellular protein targeting systems, complex formation 
with cellular membrane proteins or disintegration of membranes are frequent effects 
that result in toxicity to living cells leading to low expression rates. These tremendous 
difficulties obtained in IMP expression might explain why less than 100 different IMP 
structures are known compared to 38882 overall structures currently posted in the 
protein data bank. 
For successful overproduction the response of host cells to IMP expression and the 
mechanism of membrane proteins insertion are crucial and have to be understood [31]. 
Mammalian IMPs frequently cause large difficulties in bacterial systems and require an 
insect or mammalian cell host for activity or high level expression [32]. Using semliki 
forest virus vectors for IMP expression more than 50 G-protein coupled receptors 
(GPCRs) and several ion channels have been expressed at high levels [33]. E. g. the 
human endothelin B receptor (ETB) was expressed with 20 pmol per mg of membrane 
protein in baby hamster kidney (BHK) and simian fibroblasts (CV-1 cells) transformed 
by SV40 (COS) cells [34] or the β2 adrenergic receptor that has been expressed in BHK 
and COS cells with 5 mg per liter of cultured cells [35]. The baculovirus-insect cell 
system further constitutes a versatile tool for the maximal production of GPCRs [36], 
thus ETB could be produced in 100 pmol/ mg of total IMPs [37]. The comparison of 
seven different heterologous protein expression systems for the production of the 
serotonin transporter revealed functional expression in the baculovirus system and in 
three different mammalian cell lines, but not in E. coli or Pichia pastoris with 
nonfunctional expression levels of 2-3 mg per liter of cell culture [38]. A detailed 
review of heterologous GPCR expression is provided by Sarramegna and co-workers 
[39] whereas Lundstrom compares the GPCR productivity in different expression 
systems [40]. A remarkable expression result was obtained for the neurotensin receptor. 
A 200-liter scale E. coli expression provided 90 mg of functional receptor fusion 
protein, corresponding to approx. 0.5 mg per liter E. coli cell culture in cells [41] that 
further will have to be processed by purification and solubilization protocols. 
 
 
 
       INTRODUCTION    3  18 
3.2.  Cell-free expression techniques 
Cell-free (CF) protein synthesis is an attractive and promising alternative to the 
conventional technologies for protein production using bacterial or eukaryotic cell 
cultures. In contrast to in vivo gene expression methods where protein synthesis is 
carried out in the cellular context surrounded by cell walls and membranes, CF protein 
synthesis provides a completely open system. This allows direct control and access to 
the reaction at any time. Compounds that improve protein production or stabilize 
recombinant proteins, e. g. ligands, inhibitors, detergents or protease inhibitors, can 
easily be added without considering side-effects on the cellular metabolism or transport 
problems through the cell membrane. Most cellular functions with the exception of 
transcription and translation need not to be maintained during CF protein expression. In 
principal, applications can therefore be extended to proteins or conditions that would 
not be tolerated by living organisms. While in vivo protein production is often limited 
by the formation of inclusion bodies [42, 43] or protein instability caused by 
intracellular proteases [44, 45], the CF system offers new possibilities for the synthesis 
of complex proteins (Table 1).  
 
 
Table 1 General pros and cons of cell-free protein expression. 
 
Advantages Disadvantages 
Completely open system and easy access  Intensive optimization of reaction 
  → customized reaction conditions for        conditions is often required 
        each individual target protein  High quality control of reaction 
Efficient incorporation of labeled, modified    components essential 
  or unnatural amino acids  Relatively high costs 
Direct translation of PCR products  Preparation of CF extracts necessary 
  → high-throughput screening  Complexity of system requires 
Production of toxic proteins   experience 
Expression of proteins requiring cofactors       
Easy addition of chaperones or PDIs   
Miniaturization (e. g. 50 µl reactions) 
  → high throughput 
Working without living organisms 
  → no growth restrictions, 
       no template instability 
Fast isolation of products 
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Protein folding and stability can be promoted by direct addition of chaperones or 
specific cofactors. In contrast, overexpression of chaperones in vivo can result in cell 
filamentation, detrimental for the viability of E. coli cells and protein expression [46]. 
To assist the folding of proteins, chaperones like the GroEL/ ES system [47] or DnaK 
and DnaJ [6] had been added to the reaction mixture. Usually, lower temperatures will 
lead to higher yields of recombinant protein in the absence of chaperones, but not 
necessarily in their presence [48]. Reaction parameters such as pH, redox potential and 
ionic strength can be modified without harmful effects on the growth and viability of 
cells. This new opportunity of in vitro gene expression allows therefore full control and 
high flexibility of conditions. It offers new potentials to solve problems associated with 
cytotoxicity, proteolytic degradation, improper folding or aggregation of synthesized 
proteins. 
 
3.2.1. Extract sources and preparation 
CF expression systems are classified according to the origin of their extract. In 
principle, functional in vitro systems might be prepared from any cell type, but many 
factors contribute to the protein production efficiency. The most common CF reactions 
are based on extracts made from E. coli, wheat germ or rabbit reticulocyte lysates 
(Table 2). E. coli extracts consist of the so-called S30 supernatant fraction, named after 
the soluble fraction when centrifuged at 30000 g, containing endogenous ribosomes, 
enzymes like acetate kinase and factors necessary for transcription and translation, 
ARSases and tRNA. Endogenous mRNA is removed from the ribosomes during 
preincubation of the crude cell extract in a “run-off” step and destroyed by endogenous 
ribonucleases [49]. Another way to deploy bacterial extracts is described in the Gold-
Schweiger system [50, 51]. Ribosomes are added to the supernatant fraction of a S100 
extract especially purified from endogenous amino acids and nucleic acids by ion-
exchange chromatography. This system provides a very low background due to 
endogenous synthesis and better-controlled conditions at the expense of more 
complicated preparations. 
The E. coli system functions well in a temperature range of 24-38°C with an optimum at 
30°C [4, 49, 52]. Wheat germ extract possesses a low level of endogenously expressed 
messengers and therefore can be directly used for expression of exogenous templates. In 
the wheat germ system, the optimum temperature is in the range 20-27°C [53, 54], but 
can be increased to up to 32°C for higher expression of some templates [55]. 
Reticulocyte extract is prepared by directly lysing blood cells of anemic rabbits; this 
increases the number of proerythrocytes of reticulocytes that are subsequently treated 
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with micrococcal Ca
2+-dependent RNase to remove endogenous mRNA [56]. With 
regard to the reaction temperature, it should be noted that apart from any effect on the 
enzymatic process of transcription/ translation and mRNA degradation, the temperature 
affects the folding of the synthesized protein. 
 
Table 2 Overview of bacterial and eukaryotic cell-free expression systems. 
 
Bacterial systems  Eukaryotic systems 
Escherichia coli  Wheat germ  Rabbit reticulocyte (Rr) 
S30 extract preparation  S100 extract preparation  Wheat germ extract  Rr lysates 
Extract preparation:  Extract preparation:  Extract preparation:  Extract preparation: 
  Supernatant fraction at    Supernatant fraction at    Directly used for    Treated with  
  30,000 g centrifugation    100,000 g centrifugation    expression of     micrococcal  
 of  E. coli extract pre-    deprived of all nucleic    endogenous or     Ca2+ dependent  
  incubated to detract    acids, e.g. by DEAE    exogenous templates    RNase 
  endogenous DNA and    cellulose treatment 
 mRNA 
 
Advantages: Advantages: Advantages: Advantages: 
  High efficiency, high trans-    Deprived of all nucleic    Low nuclease activities,    eukaryotic system 
  lation rate, easy extract    acids, ribosome prepa-    long life-times up to     
  preparation, optimized     ration    several days, mRNA     
  protocols for various        as template possible, 
 applications  available,      preparative  eukaryotic 
 preparative  system      system 
 
Disadvantages: Disadvantages: Disadvantages: Disadvantages: 
  High variations, shorter    No preparative system    Difficult, low efficient    Very difficult extract 
  life-times, high rate of         extract preparation,     preparation, very  
  degradation of genetic        complex system, lower    complex non  
 messages,  proteins,  energy     translation  rate.   preparative  system 
 
References: References: References: References:   
  [4, 49, 52, 57, 58]   [50, 51]   [53-55]   [52, 56, 59, 60] 
 
 
With regard to the preparative CF expression of proteins, only E. coli and wheat germ 
extracts have been used. Shimizu et al. developed a CF translation system reconstructed 
from purified poly(His)-tagged translation factors [61]. Their system, termed the 
“protein synthesis using recombinant elements” (PURE) system, contains 32 
individually purified components with high specific activity, allowing efficient protein 
production. An advantage of the PURE system, apart from the absence of inhibitory 
substances such as nucleases, proteases and enzymes that hydrolyze nucleoside 
triphosphates, is a new possibility of synthesized protein purification by removing 
tagged protein factors with affinity chromatography. 
One limitation of the CF system is the degradation of exogenous added mRNA. Various 
RNase activities present in cell extracts usually restrict the lifetime of mRNA, and 
subsequently the efficiency of protein synthesis is inhibited. This problem could be 
solved by the periodical reintroduction of messengers into the reaction mixture in a 
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is continuously synthesized from DNA templates added to the reaction mixture, can be 
advantageous to translation systems containing presynthesized messengers. Direct 
transcription in the reaction mixture is achieved by exogenous phage T7-RNA 
polymerase in bacterial systems [63] or in eukaryotic systems [52, 59]. To avoid rapid 
messenger degradation, especially in E. coli cell-free systems, partially ribonuclease-
depleted extracts or RNase inhibitors are used. A good choice of template DNA in the 
prokaryotic system is circular plasmid DNA. In the wheat germ system with lower 
nuclease activities, both plasmid DNAs [64] and linear PCR fragments function well 
[65-67], but more recently even bacterial systems have been optimized for efficient 
expression of PCR products [68, 69]. 
 
3.2.2. Components and design of cell-free expression 
Components 
In CF systems all components involved in gene expression and protein synthesis are 
combined in a reaction mixture (Fig.2). A significant problem in CF protein synthesis is 
the high consumption of biochemical energy provided by ATP and GTP. Creatine 
phosphate concomitant with creatine kinase is usually used for ATP and GTP 
regeneration in eukaryotic CF systems, whereas the combination of phosphoenol 
pyruvate (PEP) and pyruvate kinase, acetyl phosphate and acetate kinase or a 
combination of both has been applied for bacterial in vitro protein synthesis. The acetyl 
phosphate energy system may have the advantage that the ATP level is maintained 
twice as long as in the presence of PEP. Since acetate kinase is present at sufficient 
levels in bacterial extracts, it does not need to be added exogenously in the E. coli 
system [70]. Studies of the biochemical energy levels in different CF systems observed 
a high rate of triphosphate hydrolysis to mono- and diphosphates during protein 
synthesis in wheat germ extracts [71] as well as in E. coli S30 extracts [72]. It is 
reported that more than 80% of ATP and GTP hydrolysis in the wheat germ system 
initially occurs independently of protein synthesis and it was suggested that acid 
phosphatases are responsible for the nonspecific hydrolysis of the nucleotide 
triphosphates [53, 71]. 
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Fig. 2 Components of the cell-free system.  
All high molecular-weight compounds necessary for transcription and translation are present in the 
reaction compartment. The CF reaction is based on a crude cell-extract containing ribosomes (green), 
translation factors like initiation factors (IFs), elongation factors (EFs) and release factors (RFs), acetate 
kinase and aminoacyl-tRNA synthetases (ARSases). Substrates like amino acids, the energy-regenerating 
system components or nucleoside triphosphates (NTPs) and salts are added to the extract, and protein 
synthesis is initiated by adding the template DNA. The DNA is transcribed by an added RNA polymerase 
(blue). Added tRNA is loaded with amino acids by ARSases and they are used in the translation of 
mRNA. The incorporation of some stable isotope-labeled amino acids (red) can easily be done in the CF 
system, leading to a selective isotope-labeled protein. Regeneration of ATP and GTP and even the NTPs 
in the cell-free system is achieved by an ATP-regenerating energy system based on the hydrolysis of 
high-energy substrates in the presence of their kinases. Chaperones can easily be added to the reaction 
mixture to assist the folding of the target protein and in order to increase the solubility of membrane 
proteins, detergents can be supplemented directly to the reaction- and feeding mixture. (Modified after  
(P 08)). 
 
Design 
In CF reactions carried out in a “batch” mode, the reaction conditions change as a result 
of substrate consumption and the accumulation of products. Translation stops as soon as 
any essential substrate is exhausted, or any product or by-product reaches an inhibiting 
concentration. Actually, the bacterial CF systems are active only for 10-30 min at 37°C. 
Systems based on rabbit reticulocyte lysates or wheat germ extract are typically capable 3    INTRODUCTION  23
of working for up to 1 h. However, in vitro protein-synthesizing systems in batch mode 
work well for most analytical purposes, but short lifetimes and low productivities limit 
their application for the synthesis of preparative amounts of protein. The reasons for the 
low yield are degradation of mRNA, depletion of nucleotide triphosphates and 
accumulation of their hydrolysates. Prolonged reaction times in CF expression were 
first achieved by Spirin and co-workers [60, 73, 74] by using a continuous-flow CF 
(CFCF) translation device (Fig. 3 A).  
 
 
Fig. 3 Cell-free reactors. 
Illustration of cell-free reactors for continuous flow (A and B) and continuous exchange (C) cell-free 
expression systems. A, Schematic drawing of a direct flow CFCF reactor where substrates are supplied 
and products are removed by the flow of a feeding solution, forced by a pump. B, Y-flow CFCF reactor, 
containing two ultrafiltration membranes of different pore size, separating protein product and low 
molecular weight (LMW) waste outflows [75]. C, CECF reactor design with explanation of feeding 
solution (light green) and reaction mixture components (purple). Compartments are separated by a semi 
permeable dialysis membrane, providing the diffusion exchange of substrates and LMW products, and 
the retention of reaction mixture components. Taken from (P 08), modified after Shirokov et al. [76]. 
 
The basic idea of CFCF systems is to continuously supply amino acids, energy-
regenerating components (AcP, CrP or PEP) and NTPs from a feeding solution, and to 
remove small byproducts of triphosphate hydrolysis like inorganic phosphate and 
nucleotide monophosphates from the reaction mixture (RM), by active exchange across 
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an ultrafiltration membrane. The molecular weight cut-off of these membranes typically 
ranges 10-300 kDa (Fig. 3 A). Permanent stirring of the RM and in some set-ups upright 
flow of the feeding solution are applied to minimize membrane clogging [77]. The 
CFCF system can function for more than 20 hours and results in preparative protein 
expression of about 0.1-1 mg protein per mL of RM. The advantage of the CFCF 
system is the continuous removal of synthesized proteins from the RM, which can result 
in 80-85% purity of the protein product. To reduce the dilution effect, the so-called Y-
flow reactor with a split outflow has been proposed [75]. The Y-flow reactor (Fig. 3 B) 
has two membranes with different pore sizes. Initially the low molecular weight (LMW) 
products are removed through a small-pore membrane at a high rate and the synthesized 
protein is subsequently collected through a large-pore membrane at a low rate. Here, the 
flow of the protein product is controlled by a separate pump.  
Continuous-exchange CF system (CECF) [5] or semi-continuous-flow CF (SFCF) 
system [4] are alternatives to obtain prolonged protein synthesis, by separating RM 
from a feeding mixture (FM) through a dialysis membrane (Fig. 3 C). The simplest 
CECF device is a dialysis bag [5]. The pore size of these dialysis membranes is usually 
in the range of 10-50 kDa and better performance of larger pore membrane has been 
reported  [20]. Stirring of either the FM or both, the FM and RM, is necessary for 
efficient exchange of compounds. 
 
3.2.3. Applications 
Due to its independence of a living organism CF expression systems in principle can be 
individually optimized to allow the production of all those proteins causing problems in 
conventional expression systems (Fig. 4). Thus, the production of cytotoxic proteins 
[78] or functional antibodies using PDI and chaperones [6] became possible. Disulfide 
bridged proteins are hardly expressed in cellular systems due to the reducing 
environment inside the cell. CF systems have been optimized for the production of 
those proteins by using modified E. coli extracts, by supplementation of DsbC disulfide 
isomerase and by using an optimized redox potential [79]. Thus the nine disulfide 
bridges of recombinant plasminogen activator protein could successfully be formed in 
the bacterial system [7]. Optimized eukaryotic wheat germ systems, supplemented with 
protein disulfide isomerase further allowed the production of a single-chain antibody 
variable fragment [80]. 
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Fig. 4 Expression of difficult proteins by using an individual cell-free system. 
 
Another promising potential for CF synthesis can be found in its suitability for high-
throughput expression of proteins by direct translation of linear polymerase chain 
reaction (PCR) products [68, 69, 81]. Bacterial as well as eukaryotic system have thus 
been optimized for high-throughput (HT) applications of soluble proteins [82, 83]. 
Expression screening in 96 well formats [84] as well as in even smaller nanowell chip 
formats is possible [85]. Problems, related to instability of linear DNA templates can be 
addressed by preparing CF extracts from nuclease deficient strains [69, 86]. 
Alternatively, modifications of the mRNA, like the addition of poly(G) tails or mini-
hairpin sequences, or the positioning of a stem-loop structure at the 3’ end can 
substantially help to increase the half-life of the transcripts [68, 86, 87]. Further a 
platform that utilizes wheat germ CF technology to produce protein samples for NMR 
structure determination in structural genomics has recently been described by Vinarov 
and co-workers [88-90], showing the potential of CF HT approaches. 
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The open nature of CF systems provides unique labeling possibilities. Nonlabeled 
amino acids in the CF mixtures are simply exchanged against the labeled derivatives. 
No other changes of conditions are required and labeled proteins are synthesized in 
same amounts like unlabeled ones. Moreover, CF production provides significantly 
reduced scrambling or background labeling problems [16-22]. Besides the incorporation 
of isotopically labeled amino acids for nuclear magnetic resonance (NMR) analysis, 
unnatural and chemically modified amino acids can efficiently become incorporated 
into CF synthesized proteins [91-93]. This allows new possibilities in functional studies, 
protein engineering and pharmaceutical research. 
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4.  Results and Achievements  
– High level cell-free expression of integral membrane proteins – 
4.1.  Set-up of an individual cell-free system 
4.1.1. Cell-free protocol 
The individual CF system is based on a crude cell-extract, prepared form E. coli strain 
A19 (E. coli Genetic Stock Center CGSC) by a procedure after Zubay [49] with several 
modifications. In the modified protocol, the cells were grown in terrific broth medium 
up to an optical density (OD600) of 3 and washed in washing buffer (10 mM Tris-
acetate, pH 8.2, 14 mM Mg(oAc)2), with 6 mM 2-mercaptoethanol and 0.6 mM KCl. 
Rapid cooling prior harvesting the cells turned out to be crucial. The lysis buffer was 
the washing buffer supplemented with 1 mM dithiotreitol (DTT) and 0.1 mM 
phenylmethanesulfonyl fluoride. The extract was dialyzed in washing buffer 
supplemented with 0.5 mM DTT and 0.6 mM KoAc. The run-off procedure was 
optimized by removing endogenous mRNA from the ribosomes by incubating the 
extract with 400 mM NaCl at 42°C for 45 min. Aliquots of the S30 extract were frozen 
in liquid nitrogen and stored at -80°C. The extract preparation was carried out in one 
day instead of freezing the harvested cells before continuing with cell-disruption by 
French press. Approximately 60 ml of extract were obtained from a 10 liter fermentor. 
The CF reaction conditions have been optimized for high level protein expression by 
titration of each component and by using the expression of green fluorescent protein 
(GFP) as a monitor, yielding more than 4 mg soluble folded GFP per mL of RM (Fig. 
5). The most critical parameters appeared to be the concentrations of Mg
2+-, K
+-Ions 
and the amino acids, and the quality of the prepared S30 extract. The energy 
regenerating system was most efficient if a combination of phosphoenol pyruvate, 
acetyl phosphate and pyruvate kinase was used. The final protocol containing an 
optimized stock-solution concentration as well as the optimal final concentration of 
reaction components (Table 3) is capable to synthesize protein up to 4 mg per mL of 
reaction mixture (RM) and almost 80% of the protein is synthesized during the first 7 h 
of incubation (Fig. 5). 
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Table 3 Components of the individual CF system for soluble MP expression. 
 
Component stock  concentration final  concentration 
 
in RM 
S30-extract / S30-buffer  100%  35 %     
plasmid DNA   0.3 mg/ml  ≥ 15 µg/ml   
RNAguard  39.8 U/µl  0.3 U/µl   
T7-RNA polymerase  40 U/µl  ≥ 3 U/µl   
E. coli tRNA  40 mg/ml  500 µg/ml   
pyruvate kinase  10 mg/ml  40 µg/ml 
 
in RM + FM    
amino acids (aa)  4 mM  1 mM 
aa RCWMDE  16.7 mM  2 mM each 
acetyl phosphate  1 M  20 mM   
phosphoenol pyruvate  1 M  20 mM   
ATP  360 mM  1.2 mM   
CTP, GTP, UTP  240 mM  0.8 mM each 
1.4-dithiothreitol (DTT)  500 mM  2 mM     
folinic acid  10 mg/ml  0.2 mM     
complete protease inhibitor  50 x (1 tablet /1 ml)  1 tablet /50 ml   
HEPES-KOH pH 8.0  2.5 M  100 mM     
magnesium acetate  2 M  15 mM     
potassium acetate  4 M  290 mM     
polyethylenglycol 8000  40 %  2 %     
sodium azide  10 %  0.05 % 
detergent (Brij78)   10%   1% 
 
Note: Concentrations of Mg
2+ and K
+ are highly critical and should be subject of 
optimization. 9.1 mM magnesium acetate and 150.8 mM potassium acetate are added, 
4.9 mM Mg
2+ results from the S30-extract and 139.2 mM K
+ results from other reaction 
components. Amino acids and T7-RNA-polymerase are limiting compounds and only 
minimal concentrations are given. 
 
For CECF a RM and FM are needed. In order to avoid pipetting errors and save time, 
the reaction components are combined to a master mixture, subsequently divided into 
FM and RM (Table 4). Whereas the RM is kept on ice, the FM is preincubated at 30°C 
in order to immediately start the reaction after bringing both together. 
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Table 4 Pipetting protocol for a preparative 1 ml cell-free reaction. 
 
Stock solution                    master-mix FRM 
10% NaN3    93 µl 
40% PEG8000   926 µl 
4 M KoAc   698 µl 
2 M Mg(oAc)2    94 µl 
25x Buffer   741 µl 
50x Complete + EDTA   370 µl 
10 mg/ml folinic acid   185 µl 
0.5 M DTT    74 µl 
75x NTP-mix   247 µl 
1 M PEP   370 µl 
1 M AcP   370 µl 
4 mM aa-mix  2315 µl 
16.7 mM aa RCWMDE-mix  1111 µl 
10% Brij-78  1852 µl 
 9447  µl 
 
     FM     RM 
Master-mix FRM   8927 µl   520 µl 
4 mM aa-Mix   2188 µl     - 
S30-buffer   6125 µl     - 
10 mg/ml pyruvate kinase     -     4 µl 
40 mg/ml E. coli tRNA     -    13 µl 
420 U/µl T7-RNA-Polym.     -    15 µl 
21.5 U/µl RNAsin     -    14 µl 
S30-Extract     -   357 µl 
0.3 mg/ml Plasmid-DNA     -    51 µl 
H2O    261 µl    46 µl 
  17500 µl  1020 µl 
 
   Note: All volumes less then one μl have been rounded up. 
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Fig. 5 Protein production kinetics in the cell-free system. 
Soluble GFP production in a standard cell-free reaction with 
a membrane cut-off of 25 kDa and an RM/FM ratio of 1 : 
17 was monitored by fluorescence at an emission at 509 nm 
and after excitation at 395 nm. Data are averages of at least 
three determinations. (Modified after (P 01)) 
 
 
4.1.2. Analytical and preparative scale set-up 
Generally, the reaction can be set up in analytical design for optimization and screening 
reactions as well as in preparative configuration for the production of mg amounts of 
recombinant protein. As a device for analytical scale reactions with a RM volume of 70 
µl, Microdialysers® (MDs) (Spectrum, Rancho Dominquez, USA) that are 
commercially available with different molecular weight cut-offs (MWCOs) are used 
with 15 kDa or 25 kDa MWCO (Fig. 6 A). Those MDs holding the RM are placed in a 
suitable tank holding a 14 fold excess volume of FM. The MD reactions are incubated 
over night in a lab-shaker at 30°C. 
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Fig. 6 Design of cell-free reaction containers for analytical and preparative scale set-up. 
A, for optimization and screening reactions, commercially available Microdialyser® units holding 
up to 100 µl RM where placed in a suitable vial containing a 14 times volume excess of FM, fixed 
with a sealing tape and incubated in a standard lab-shaker at 30°C over night. B, for preparative 
scale cell-free protein expression, commercially available Dispodialysers® holding 500 to 1000 µl 
RM where placed into a plastic vial containing a 17 times volume excess of FM. The set-up is 
incubated on a roller at 30°C. (Modified after (P 03)). 
 
For preparative reactions with RM volumes of 500-1000 µl, larger Dispodialysers® 
(DDs) (Spectrum, Rancho Dominquez, USA) are used with MWCOs of 15 kDa and 25 
kDa. Those closable dialysis tubes are placed in a suitable vial containing a 17 fold 
excess of FM (Fig. 6 B), which was proven to give the highest efficiency. In order to 
allow sufficient diffusion between the RM and FM in DDs, the preparative scale set-up 
is rolled at 40 RPM on a roller device at 30°C in an incubation oven over night. In DDs, 
the use of regenerated cellulose membranes is preferred to that of ester-cellulose 
membranes. 
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4.1.3. Cell-free modes of IMP expression 
Most cellular membranes have been removed during extract preparation and only 
spurious amounts of lipids might remain. Standard CF reactions therefore result 
consequently in the production of IMPs as precipitates as no hydrophobic compartments 
are present in the RM. The supplementation of CF reactions with detergents or lipids 
generates preformed micelles or liposomes in the RM and could enable the direct 
synthesis of IMPs into micelles composed of the desired detergents or into liposomes of 
defined compositions. In principle one can think of three different CF expression modes 
of IMPs: (A) the production of IMP precipitates without any hydrophobic additives [10, 
11], (B) the synthesis of IMPs into micelles in presence of detergents [9, 10, 14, 15] and 
(C) the synthesis of IMPs into liposomes in presence of lipids which has not been 
proved yet (Fig. 7). 
 
 
Fig. 7 Cell-free expression modes. 
The CF expression of IMPs can be run in three different modes: IMPs can be expressed as 
precipitate (Mode A), solubilized in an appropriate detergent and further reconstituted into 
proteoliposmes, alternatively the IMPs can be soluble expressed in presence of detergents 
(Mode B), purified and reconstituted into proteoliposomes, or expressed in presence of 
preformed liposomes (Mode C) and isolated from the RM by density gradient 
centrifugation. (Modified after (P 05)). 4    RESULTS AND ACHIEVEMENTS  33
This option is an attractive feature specific to CF expression and it is not possible with 
any other expression system. Critical steps in common IMP preparation protocols like 
the disintegration of cellular membranes or repeated transfers of IMPs into micelles of 
different compositions can thus be reduced or even completely avoided. In the best case, 
the IMPs can become inserted in the desired environment right after translation and the 
resulting proteomicelles or proteoliposomes could be directly used for further analysis. 
However, diverse IMPs have to be expected to behave different in the CF expression 
modes. To give a comprehensive overview about the variety of IMP behavior, we 
analyzed three structurally very different IMPs (Fig. 8). The synthesis of the bacterial 
four transmembrane segments (TMS) containing α-helical small multi drug transporter 
EmrE [8], the bacterial β-barrel type nucleoside transporter Tsx [94] and the eukaryotic 
α-helical and seven TMS containing GPCR Vasopressin 2 Receptor (V2R) has been 
analyzed by CF expression in presence of detergents.  
 
 
Fig. 8 Overview of analyzed IMPs for soluble cell-free expression in presence of detergents. 
The structurally very diverse IMPs have been analyzed for their cell-free expression in presence 
of detergents. Information of these proteins is given below the figures. 
It has to be expected that some detergents are detrimental to the CF system whereas 
others might not be tolerated enough to keep the different IMPs in solution. In order to 
give a comprehensive overview, 24 different commonly used detergents of six different 
classes, have been evaluated for their CF system properties. Some physicochemical 
properties of these detergents are summarized in Table 5. 
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Table 5 Physicochemical properties of analyzed detergents. 
 
Detergent    short name  charge
a   MW  CMC
b 
     [Da]  [mM] 
Alkyl-glucosides: 
n-dodecyl-β-D-maltoside DDM  N  511  0.12 
 
n-decyl-β-D-maltoside DM  N  483  1.8 
 
n-octyl-β-D-glucopyranoside  β-OG N 292  19 
 
  
Steroid-derivatives: 
Digitonin   Digitonin  N  1229  0.73 
 
3-[(3-cholamidopropyl)dimethly-  CHAPS  Z  615  2.4 – 8.6 
ammonio]-1-propansulfonat 
 
 
Long chain-phosphoglycerols: 
1-myristoyl-2-hydroxy-sn-glycero-3- LMPG    A  479  0.05 
[phospho-rac-(1-glycerol)] 
  
1-palmitoyl-2-hydroxy-sn-glycero-3- LPPG  A  507  n.a. 
[phospho-rac-(1-glycerol)] 
  
 
 
 
 
 
 
 
 
 
a A: anionic; N: nonionic; Z: zwitterionic. 
b estimated CMCs, averaged values are given if different CMCs for a detergent have been 
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Table 5 (continued) 
Detergent    short name  charge
a   MW   CMC
b 
     [Da]    [mM] 
 
Mono-/Bi-chain-phosphocholines: 
1,2-dioctanoyl-sn-glycero-3-phosphocholine   diC8PC Z    510    0.22 
 
 
 
 
1,2-diheptanoyl-sn-glycero-3-phosphocholine DHPC  Z    482    1.4 
 
1,2-dihexanoyl-sn-glycero-3-phosphocholine diC6PC Z    454    14 
 
Dodecyl-phosphocholine  DPC  Z    352   0.9 - 1.5 
 
  
Polyoxyethylene-alkyl-ether: 
polyoxyethylene-(23)-lauryl-ether, (C12/23) Brij35    N    1200  0.08 
 
polyoxyethylene-(10)-dodecyl-ether, (C12/10) Genapol  C-100  N    627    0.1 
polyoxyethylene-(10)-cetyl-ether, (C16/10) Brij56  N    682    0.035 
polyoxyethylene-(20)-cetyl-ether, (C16/20) Brij58    N    1123  0.075 
polyoxyethylene-(2)-stearyl-ether, (C18/2) Brij72  N    359    n.a. 
polyoxyethylene-(20)-stearyl-ether, (C18/20) Brij78  N   1152  0.046 
polyoxyethylene-(10)-oleyl-ether, (C18-1/10) Brij97    N    709    0.217 
polyoxyethylene-(20)-oleyl-ether, (C18-1/20) Brij98  N    1150  0.025 
polyoxyethylene-sorbitan-monolaurate 20  Tween 20  N    1228  0.059 
 
 
Polyethylene-glycol derivatives: 
polyethylene-glycol P-1,1,3,3-tetramethyl-  Triton X-100   N    647   0.23 
butylphenyl-ether 
 
polyethylene-glycol 400 dedecyl-ether  Thesit  N    583   0.1 
 
nonylphenyl-polyethylene-glycol  NP40  N    603   0.05 - 0.3 
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Mode A, insoluble expression 
For the CF production of IMP precipitates, the standard protocol can instantly be used 
and no time-consuming evaluation of detergents is needed. High yields of synthesized 
IMPs are ensured as no inhibitory effects of supplied detergents are present. In addition, 
the IMPs can be obtained in highly purified form by only few washing steps in 
detergents inefficiently solubilizing the IMPs [see publication (P 01)]. This expression 
mode mostly resembles conventional in-vivo approaches of the production of IMPs in 
form of inclusion bodies. However, structural differences might exist between cellular 
inclusion bodies and CF produced precipitates. IMP precipitates obtained by CF 
reactions usually solubilize rapidly upon addition of relatively mild detergents and they 
do not require intensive denaturation and refolding steps as it is known from the 
solubilization of inclusion bodies. Denaturating agents like Guanidinium HCl or 
excessive amounts of urea could thus be avoided and already gentle mixing of the IMP 
precipitate with a suitable detergent at a final concentration of 2 % at 30°C is often 
sufficient for a quantitative solubilization as analyzed for the three structural very 
different proteins Tsx, V2R and EmrE. Whereas the small multi drug transporter EmrE 
was readily resolubilized in high quantities in most of the detergents analyzed, the 
quantitative resolubilization of the GPCR protein V2R was only possible with the long-
chain phosphocholine, 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] 
(LMPG). Other detergents had no or only minor resolubilization effects. In addition, 
only LMPG and dodecyl-phosphocholine (DPC) were highly effective for the 
resolubilization of the β-barrel type transporter Tsx [see publication (P 02)]. LMPG and 
probably similar long chain-phosphoglycerols appear therefore to be the primary choice 
for a general and efficient resolubilization of even structurally diverse types of IMPs in 
mild detergents. 
 
Mode B, soluble expression in presence of detergents 
For direct soluble CF expression into detergent micelles, the detergents have to be 
added above their specific critical micellar concentration (CMC) in order to become 
effective for the solubilization of IMPs. The quantitative analysis in analytical scale CF 
reactions of the proteins in the soluble and insoluble fractions turned out that only few 
detergents become inhibitory to the CF system at low concentrations and resulted in an 
at least considerably reduced production of all three IMPs. In particular, some of the 
phosphocholine derivatives seemed to be problematic as additives in CF systems, while 
the mono-chain phosphocholines were clearly more critical than the bi-chain 
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the bi-chain phosphocholine 1,2-dioctanoyl-sn-glycero-3-phosphocholine (diC8PC), still 
resulted in the production of up to 0.6 mg of soluble EmrE per mL of RM. Negative 
effects on the CF system were further observed with the nonionic alkyl-glucoside n-
octy-β-glucopyransoide (β-OG), the steroid Chaps and the long-chain phosphoglycerol 
LMPG. Chaps and β-OG are generally considered to be relatively mild detergents, but 
their high CMC, resulting in relatively high final detergent concentrations in the RM, 
might be a reason for the observed inhibitory effect on protein expression. LMPG, 
which was found to be highly suitable for the resolubilization of CF produced 
precipitates, resulted only with Tsx in the production of some 100 µg of soluble protein, 
while the total yield of protein was considerably affected for all three IMPs. 
Approximately one-third of the tested detergents did not have any, or only a marginal 
effect on the solubility of any of the expressed IMPs. But they did not cause marked 
decreases of the total protein production in the range of the supplied concentrations. 
This group includes polyethylene glycol 400 dedecyl-ether (Thesit), nonylphenyl- 
polyethylene-glycol (NP40), 1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-
glycerol)] (LPPG) and the polyoxyethylene derivatives polyoxyethylene-(10)-cetyl-
ether (Brij56), polyoxyethylene-(2)-stearyl-ether (Brij72), polyoxyethylene-(10)-oleyl-
ether (Brij97), polyoxyethylene-(10)-dodecyl-ether (Genapol C-100), polyoxyethylene-
sorbitan-monolaurate 20 (Tween 20). These detergents are obviously tolerated by the 
CF system, even at higher CMC concentrations, and they might still be beneficial for 
the soluble expression of other IMPs. However, they are clearly not suitable for general 
usage. 
Several detergents from almost all analyzed groups were found to be suitable for the 
soluble CF expression of IMPs, yielding protein rates of more than 0.5 mg of soluble 
IMP per mL of RM. With a total of 10 detergents one obtains preparative scale soluble 
expression yields for at least one of the analyzed MPs, while the individual proteins 
behave quite differently. The most outstanding group of effective detergents covered the 
long chain polyoxyethylene-alkyl-ethers, polyoxyethylene-(23)-lauryl-ether (Brij35), 
polyoxyethylene-(20)-cetyl-ether (Brij58), polyoxyethylene-(20)-stearyl-ether (Brij78) 
and polyoxyethylene-(20)-oleyl-ether (Brij98), and they resulted in the high-level 
soluble expression of all three IMPs analyzed. The steroid derivative Digitonin was 
identified as a second relatively general solubilizing detergent. However, the yields 
obtained in the case of EmrE and V2R remained mostly below 0.5 mg per mL in the 
RM and were thus lower by comparison with the above mentioned Brij derivatives. The 
alkyl glucosides n-dodecyl-β-D-maltoside (DDM) and n-decyl-β-maltoside (DM) 
resulted in the soluble expression of only EmrE and Tsx in the range between 0.5 mg 
and 1.5 mg per mL of RM. The beneficial effect of polyethylene glycol P-1,1,3,3-
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tetramethyl-butylphenyl-ether  (Triton X-100) was specific for the Tsx protein and 
yielded soluble protein at a concentration of nearly 1 mg per mL in the RM. 
 
4.2.  Cell-free expressed IMPs 
Various IMPs have been successfully synthesized in preparative amounts using CF 
expression techniques and reviewed in the FEBS Mini Review [13]. Besides my 
contribution to this field, different small multi drug resistance transporters, EmrE [8-
11], Hsmr, YdgF, Yfbw [12], Psmr [10] and TBsmr [10, 12] have been expressed in 
analytical to preparative amounts. In addition the mechanosensitive ion channel MscL 
[15] and a bacterial light-harvesting membrane protein [95] have been CF expressed in 
preparative amounts using the Roche RTS™ system. Besides these bacterial IMPs, the 
rat neurotensin receptor, the muscarinic acetylcholine M2 receptor and the β2-
adrenergic receptor, all members of the GPCR family, have been CF synthesized in 
fusion to thioredoxin [14]. 
A variety of different bacterial transporters were successfully synthesized in the 
individual CF system using the insoluble expression mode (Fig. 9). SugE, EmrE and 
TBsmr have been synthesized in amounts of 2, 3 and 1 mg per mL of RM, respectively. 
In addition, the six TMS comprising amino acid transporter YfiK and the putative 
tellurite transporter TehA, containing 10 TMS were CF expressed in amounts of 3 mg 
per mL of RM each. Beside this α-helical IMPs of the inner bacterial membrane, the β-
barrel type nucleoside outer membrane transporter Tsx was synthesized in amounts up 
to 4 mg per mL of RM. For preparative CF expression the amino acid composition in 
RM and FM was optimized for each protein regarding their amino acid distribution 
(Table 6). The least abundant amino acids (present at ≤ 3% in the protein) were added at 
1.25 mM, medium abundant (between 3 and ≤ 8%) at 1.8 mM and highly abundant 
(more than 8%) at 2.5 mM final concentration. Besides these bacterial transporters four 
different GPCRs were CF expressed at preparative amounts as will be discussed later in 
section 6 (unpublished results). All of the CF produced IMP precipitates could be 
solubilized in mild detergents like LMPG.  
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Fig. 9 IMPs from different families that have been produced as a precipitate by CF expression. 
The precipitate of an analytical reaction was suspended in the corresponding volume of buffer and 
the proteins in 1 µl of each suspension were separated by electrophoresis in a 12 % SDS-
polyacrylamide-gel. The arrows indicate the overproduced recombinant IMPs. OMP: outer 
membrane proteins, SMR: small multidrug transporter. (Modified after (P03)). 
 
 
Table 6 Information about preparative CF expressed IMPs. 
 
name EmrE SugE TBsmr YfiK TehA ΔTehA Tsx V2R (h) V2R (p) CRF (rat) ETB (h)
origin procaryotic procaryotic procaryotic procaryotic procaryotic procaryotic procaryotic eukaryotic eukaryotic eukaryotic eukaryotic
type α-helical α-helical α-helical α-helical α-helical α-helical β-barrel α-helical α-helical α-helical α-helical
function multidrug multidrug multidrug amino acid heavy-metal heavy-metal nucleoside vasopressin vasopressin corticotropin endothelin-1
transport transport transporter transporter transporter transporter transporter receptor receptor releasing facor receptor
receptor
familiy SMR SMR SMR RhtB TDT TDT OMP GPCR GPCR GPCR GPCR
predicted TMS 4446 1 0 7 77 7 7
size  13.02 kDa  10.9 kDa 11.08 kDa  21.25 kDa  37.0 kDa  24.66 kDa  32.48 kDa  43.59 kDa  42.85 kDa  47.76 kDa 52.51 kDa
aa number 118 105 107 195 338 227 280 392 391 414 467
theoretical pI  7.04  9.82  6.69  9.72  8.49  7.87  5.32  9.49  10.00  9.58  9.15
tags c-H6 no tag no tag no tag c-H6 c-H6 c-H6 n-T7, c-H6 n-T7, c-H6 n-T7, c-H6 n-T7, c-H10
aa content
Ala (A)  9 (7.6%) 14 (13.3%) 14 (13.1%) 24 (12.3%) 35 (10.4%) 26 (11.5%) 15 (5.4%) 48 (12.2%) 51 (13.0%) 26 (6.3%) 32 (6.9%)
Arg (R)  3 (2.5%) 2 (1.9%) 1 (0.9%) 6 (3.1%) 13 (3.8%) 9 (4.0%) 9 (3.2%) 30 (7.7%) 37 (9.5%) 29 (7.0%) 21 (4.5%)
Asn (N)  2 (1.7%) 1 (1.0%) 1 (0.9%) 5  (2.6%) 7 (2.1%) 4 (1.8%) 25 (8.9%) 6 (1.5%) 5 (1.3%) 22 (5.3%) 18 (3.9%)
Asp (D)  1 (0.8%) 0 1 (0.9%) 2 (1.0%) 6 (1.8%) 3 (1.3%) 23 (8.2%) 10 (2.6%) 12 (3.1%) 7 (1.7%) 14 (3.0%)
Cys (C)  3 (2.5%) 0 2 (1.9%) 3 (1.5%) 3 (0.9%) 3 (1.3%) 0 11 (2.8%) 10 (2.6%) 13 (3.1%) 20 (4.3%)
Gln (Q)  2 (1.7%) 0 1 (0.9%) 8  (4.1%) 10 (3.0%) 7 (3.1%) 8 (2.9%) 11 (2.8%) 10 (2.6%) 14 (3.4%) 14 (3.0%)
Glu (E)  3 (2.5%) 2 (1.9%) 2 (1.9%) 1 (0.5%) 10 (3.0%) 6 (2.6%) 10 (3.6%) 12 (3.1%) 12 (3.1%) 15 (3.6%) 18 (3.9%)
Gly (G)  12 (10.2%) 11 (10.5%) 11 (10.3%) 13 (6.7%) 31 (9.2%) 20 (8.8%) 30 (10.7%) 28 (7.1%) 29 (7.4%) 22 (5.3%) 25 (5.4%)
His (H)  7 ( 5.9%) 2  (1.9%) 2 (1.9%) 3 (1.5%) 12 (3.6%) 10 (4.4%) 13 (4.6%) 15 (3.8%) 12 (3.1%) 16 (3.9%) 15 (3.2%)
Ile (I)  15 (12.7%) 11 (10.5%) 8 (7.5%) 13 (6.7%) 16 (4.7%) 11 (4.8%) 13 (4.6%) 12 (3.1%) 11 (2.8%) 28 (6.8%) 34 (7.3%)
Leu (L)  17 (14.4%) 16 (15.2%) 17 (15.9%) 30 (15.4%) 54 (16.0%) 33 (14.5%) 16 (5.7%) 50 (12.8%) 49 (12.5%) 39 (9.4%) 58 (12.4%)
Lys (K)  1 (0.8%) 3 (2.9%) 2 (1.9%) 4 (2.1%) 5 (1.5%) 1 (0.4%) 11 (3.9%) 4 (1.0%) 3 (0.8%) 13 (3.1%) 29 (6.2%)
Met (M)  4 (3.4%) 5 (4.8%) 3 (2.8%) 5 (2.6%) 10 (3.0%) 5 (2.2%) 5 (1.8%) 12 (3.1%) 13 (3.3%) 9 (2.2%) 12 (2.6%)
Phe (F)  5 (4.2%) 1 (1.0%) 4 (3.7%) 12 (6.2%) 25 (7.4%) 13 (5.7%) 18 (6.4%) 14 (3.6%) 15 (3.8%) 27 (6.5%) 21 (4.5%)
Pro (P)  5 (4.2%) 3 (2.9%) 2 (1.9%) 7 (3.6%) 15 (4.4%) 12 (5.3%) 8 (2.9%) 26 (6.6%) 26 (6.6%) 13 (3.1%) 28 (6.0%)
Ser (S)  8  (6.8%) 8 (7.6%) 7 (6.5%) 15 (7.7%) 25 (7.4%) 18 (7.9%) 18 (6.4%) 37 (9.4%) 33 (8.4%) 31 (7.5%) 35 (7.5%)
Thr (T)  7 (5.9%) 8 (7.6%) 7 (6.5%) 14 (7.2%) 18 (5.3%) 11 (4.8%) 12 (4.3%) 18 (4.6%) 14 (3.6%) 22 (5.3%) 21 (4.5%)
Trp (W)  4 (3.4%) 4 (3.8%) 2 (1.9%) 7 (3.6%) 11 (3.3%) 9 (4.0%) 14 (5.0%) 11 (2.8%) 12 (3.1%) 12 (2.9%) 10 (2.1%)
Tyr (Y)  5 (4.2%) 2 (1.9%) 4 (3.7%) 6 (3.1%) 7 (2.1%) 5 (2.2%) 21 (7.5%) 7 (1.8%) 8 (2.0%) 18 (4.3%) 14 (3.0%)
Val (V)  5 (4.2%) 12 (11.4%) 16 (15.0%) 17 (8.7%) 25 (7.4%) 21 (9.3%) 11 (3.9%) 30 (7.7%) 29 (7.4%) 38 (9.2%) 28 (6.0%)
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4.2.1. Reconstitution of cell-free expressed IMPs into proteoliposomes 
Two different modes for CF expression of IMPs have been established so far. The 
soluble expression of IMPs in presence of detergents as well as the insoluble expression 
in combination with easy detergent solubilization results in proteomicelles. For 
analyzing IMPs in their natural environment of a lipid bilayer, they have to be further 
reconstituted into proteoliposomes (Fig. 10). 
 
 
 
Fig. 10 Freeze-fracture analysis of proteoliposomes with reconstituted cell-free produced IMPs. 
Detergents were removed with biobeads and the proteins were reconstituted into E. coli lipid mixture. 
Big arrows indicate the liposome; small arrows show the reconstituted IMPs. A, EmrE; B, SugE; C, 
TehA, D, V2Rp; E, ETB; F, V2Rh; G, CRF. The pictures where provided by W. Haase. 4    RESULTS AND ACHIEVEMENTS  41
In principle, the reconstitution procedure includes the addition of lipids and 
subsequently the removal of detergents. In these studies E. coli lipids where added at a 
molar ratio of protein : lipid between 1 : 500 and 1 : 2500 to the proteomicelles. After 1 
h incubation at 30°C the detergents were removed by the incubation with biobeads SM-
2 (Bio-Rad, Hercules, USA), hydrophilic absorbing compounds, that have been added 
in 10-fold excess to the detergent and have been exchanged within 36 hours for 2-3 
times. The successful reconstitution of the CF insoluble expressed and detergent 
resolubilized IMPs, EmrE, SugE, TehA, porcine vasopressin receptor type 2 (V2R), 
human endothelin B receptor (ETB), human V2R and rat corticotropin releasing factor 
receptor (CRF) were analyzed by freeze fracture electron microscopy (Fig. 10). The 
evenly and homogeneously distributed IMP particles in the membranes gave evidence 
for a structural folding of those proteins. 
 
4.2.2. Activity assay of the α-helical transporters EmrE 
The small multi drug transporter EmrE was cell-free expressed as precipitate, 
solubilized in 1% DDM and reconstituted into E. coli lipids. One substrate of the proton 
antiporter EmrE is ethidium bromide and the uptake of this dye into proteoliposomes 
can be measured by a specific transport assay [96]. In this assay a proton gradient 
between the DNA containing liposome and the solute is generated. Intercalation of 
ethidium into DNA causes an effect on the quantum yield of its fluorescence. Active 
EmrE protein should therefore generate a significant increase in the fluorescence 
intensity, by pumping ethidium against the pH gradient into the proteoliposomes where 
it is accumulated in the DNA molecules. Approximately 140 nM EmrE embedded in E. 
coli lipids were assayed in a total volume of 1 mL. Once the baseline was established, 
proteoliposomes where added, followed by ethidium bromide after 10 s to a final 
concentration of 2.5 µM and an immediate large biphasic increase in the fluorescence 
was monitored (Fig. 11). The first phase of the increase can be attributed to the binding 
of ethidium to the residual DNA in the extraliposomal space [96], while the second 
phase represents the accumulation of ethidium inside the liposomes due to the transport 
activity of EmrE. This ethidium uptake could be inhibited by preincubation of the 
proteoliposomes with an excess of 50 µM of the high affinity substrate 
tetraphenylphosphonium (TPP
+), probably through competition with the ethidium 
binding site at EmrE. In addition, the collapse of the pH gradient upon supplementation 
of nigericine also prevented the accumulation of ethidium in the proteoliposomes, 
resulting only in the single phase increase of fluorescence after addition of ethidium 
bromide. The results clearly demonstrate that the ethidium/ H
+ antiport was responsible 
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for the observed increase in fluorescence, indicating the functional reconstitution of 
cell-free expressed EmrE in E. coli lipids. 
 
 
Fig. 11 Ethidium transport assay of EmrE proteo-liposomes. 
Transport of ethidium (EtBr) into reconstituted EmrE 
proteoliposomes in 15 mM Tris/Cl, pH 9.5, 2 mM dithiothreitol, 
150 mM KCl was measured by an increase in fluorescence at 
excitation and emission wavelengths of 545 and 610 nm, 
respectively. Ten micro liters of proteoliposomes, approximately 
140 nM EmrE, were added after 30 or 60 s. If appropriate, 
substances were added at the following final concentrations: 
TPP (50 µM), ethidium bromide (2.5 µM) and nigericine (5 
µg/mL). Arrows indicate the time points of addition. (Modified 
after (P01)). 
 
 
4.3.  Synergies of cell-free expression and high field NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a powerful tool to investigate the 
structure and function of proteins. An indispensable prerequisite for NMR spectroscopy 
is the large scale preparation of samples that have been labeled with the stable isotopes 
2H, 
13C and 
15N. Depending on the complexity of the spectra and the strategy chosen for 
their assignment, NMR samples may be labeled uniformly or selectively with 
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15N and, in particular for larger proteins, with 
2H. The uniformly labeling of a protein 
requires the growth of the expression strain in defined medium supplemented with 
precursors that are labeled with the desired isotope. For amino acid specific labeling 
approaches, usually E. coli strains containing auxotrophic mutations corresponding to 
the provided labeled amino acid have to be employed. Thus, conventional cellular 
labeling techniques are often accompanied by low protein yields due to retarded growth 
in a minimal medium. CF protein expression overcomes those drastic expression 
limitations and especially in the case of IMP synthesis it allows the fast and efficient 
NMR sample preparation. Complete label incorporation is ensured as no unlabelled 
amino acids are present in the reaction. Moreover, no auxotrophic mutations are needed 
as any amino acid can be simply replaced in the reaction mixtures by a labeled 
derivative.  
For NMR spectroscopy the often large size of IMPs resulting in slow rotational 
tumbling and broad line width constitutes a significant problem. This problem is 
aggravated by the fact that membrane proteins have to be solubilized in micelles, which 
contribute considerably to the overall molecular weight of the protein/ micelle complex. 
Furthermore,  α-helical proteins tend to display narrower chemical shift dispersions, 
resulting in peak overlap, and the transmembrane sections of these proteins consist 
predominantly of hydrophobic amino acids often leading to clustering of identical 
amino acids with very similar chemical shifts. Solution NMR using ultra high-field 
spectrometers (800 and 900 MHz 
1H frequencies) reduces those difficulties, by 
increased sensitivity and higher resolution.  
The size limitation of detergent solubilized proteins was recently addressed by using 
specific detergents. A systematic screen for liquid-state NMR compatible detergents 
with regard to maximal signal detection, high spectral resolution as well as long sample 
lifetimes, distinguished the class of lyso-phosphoglycerols including LMPG and LPPG, 
providing outstanding benefits [23, 26]. LMPG micelles obviously do not restrict the 
tumbling rates of the inserted solubilized IMP and therefore do not result in excessive 
line-broadening. Interestingly we could show that LMPG and its derivatives are in 
addition highly suitable for the solubilization of CF produced IMP precipitates. 
Obviously several limitations in IMP analysis by solution NMR can now be addressed 
by virtue of CF expression, giving the structural analysis of IMP by high field NMR 
analysis new hope. 
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4.3.1. [
15N,
1H]-TROSY-HSQC NMR measurements of IMP samples 
The CF expression technique for IMPs allows the fast production of several mg of 
isotopically labeled samples. Here a typical NMR sample can be produced within 24 h 
since no complicated cell disruption and purification schemes are involved. In fact, 
since the synthesized target protein is the only labeled macromolecule in the RM, NMR 
spectra can, in principle, be measured without any chromatographic purification steps 
directly in the RM [19]. However, the insoluble CF expression mode of IMPs results in 
almost pure precipitates. Those precipitates can be solubilized in organic solvents or by 
using mild detergents like LMPG. The small multi drug transporter EmrE was 
selectively 
15N-alanine and 
15N-glycine labeled, insoluble CF expressed and dissolved 
in a mixture of deuterated chloroform (CDCl3), deuterated methanol (CD3OH) and 
water in a ratio of 6 : 6 : 1 and analyzed by NMR (Fig. 12 A).  
 
 
Fig. 12 Liquid-state NMR of EmrE. 
A, [
15N,
1H]-TROSY-HSQC spectrum of selectively 
15N-alanine (blue) and 
15N-glycine (red) 
labeled EmrE, CF expressed as precipitates and solubilized in CDCl3/CD3OH/H2O (6:6:1) 
plus 200 mM ammonium acetate (pH 6.2) 10 mM dithiothreitol. The spectra of 0.1 mM EmrE 
was measured at 15°C with a 600 MHz spectrometer equipped with cryogenic 
1H [
13C/
15N] 
triple-resonance probe. B, in vivo expressed EmrE (taken from [97] recorded under the same 
conditions), for comparison. 
 
 
The chemical shift dispersion of the corresponding glycine and alanine residues in a 
[
15N,
1H]-TROSY-HSQC spectrum could be assigned as they are completely identical to 4    RESULTS AND ACHIEVEMENTS  45
the published spectrum of EmrE that has been uniformly labeled by in vivo expression 
and measured under the same conditions [97] (Fig. 12 B). This demonstrates that CF 
expressed and in vivo expressed EmrE are completely identical. 
The combination of CF IMP expression levels with the use of high field NMR 
spectrometers for the first time allowed to record spectra of proteins that have not even 
been expressed in cellular systems yet. The 26 kDa amino acid transporter YfiK 
comprising 6 TMS was CF uniformly labeled with 
15N-amino acids and analyzed in 
LMPG micelles (Fig. 13 A). The bacterial protein TehA is a 36 kDa membrane protein 
that shows limited homology to the SMR family [24]. In vivo it confers resistance to 
tellurite compounds as well as to lipophilic cation dyes. In vivo experiments have 
demonstrated that a 24 kDa fragment of TehA (ΔTehA), containing seven out of 10 
predicted TMS, shows the same biological effects as the full length protein [24]. The 
NMR sample preparation for ΔTehA was systematically optimized. Whereas the LMPG 
solubilized CF ΔTehA precipitate in standard phosphate buffer showed only a 
reasonable good spectral quality, the soluble CF expression of ΔTehA in presence of 
Brij78 followed by buffer exchange to LMPG during Ni-chelate purification resulted in 
enhanced spectral quality.  
However, insoluble expressed protein that was additionally purified by Ni-chelate 
chromatography and subsequently buffered in MES-TRIS buffer pH 6, optimized for 
NMR measurements [98] resulted in so far best NMR spectral quality (Fig. 13 B). This 
sample behavior of ΔTehA enabled collection of sufficient data to start the assignment 
for a structural analysis. However, there arise extreme difficulties as α-helical IMPs 
show a relatively narrow chemical shift dispersion and peak overlap in the centre of the 
spectrum. This overlap might be overcome by using selectively amino acid labeled 
samples, indicating all one type amino acids in this region (Fig. 13 C-H). In addition the 
unique possibility of the combinatorial labeling possibility by CF expression, explained 
previously, can be used to identify distinct amino acids in the protein backbone. 
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Fig. 13 Liquid-state NMR of the CF produced transporters YfiK and ΔTehA. 
[
15N-
1H]-TROSY-HSQC spectra of cell-free expressed 15N labeled transporters, expressed as 
precipitates and dissolved in 25 mM potassium phosphate buffer (pH. 6.0) containing 5% 
LMPG (A, C-H) or solubilized in 1% LMPG, purified by Ni-NTA chromatography and 
equilibrated in 20 mM MES/Bis-Tris (pH 6.0) with 2% LMPG (B). A, U-
15N labeled YfiK; B, 
U-
15N labeled ΔTehA; C, 
15N-threonine labeled ΔTehA; D, 
15N-tryptophane labeled ΔTehA; E, 
15N-isoleucine labeled ΔTehA; F, 
15N-methionine labeled ΔTehA; G, 
15N-phenylalanine labeled 
ΔTehA; H, 
15N-arginine labeled ΔTehA. The spectra were taken with protein concentrations of 
1 mM for YfiK (A), 0.1 mM for ΔTehA (B) and 0.9 mM for selectively ΔTehA samples (C-H) 
at 40°C on a 700 MHz (A), 900 MHz (B) or on a 800 MHz NMR spectrometer (C-H), all 
equipped with cryogenic 
1H [
13C/
15N] triple-resonance probes. 
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4.3.2. Selectively cell-free isotopically labeling of IMPs and combinatorial labeling 
The first step in structural analysis of a protein by solution NMR is the assignment of 
the protein backbone resonances. Unfortunately α-helical proteins tend to display 
narrower chemical shift dispersion [26, 99, 100] as compared to that of proteins 
containing β-sheets. Since the majority of IMPs consist exclusively of α-helices, their 
NMR spectra tend to show a significant degree of peak overlap. Along with line 
broadening due to protein/ detergent complexes sizes, these disadvantages of IMPs pose 
a considerable challenge for the chemical shift assignment, suggesting that new 
strategies might be necessary in order to make backbone assignment of IMPs as routine.  
A simple way to overcome the overlap problem is selective isotopically amino acid 
labeling of the target protein identifying all signals of one amino acid type. However, 
this does not usually result in sequence specific assignments. This difficulty can now be 
approached by a mixture of amino acid specific and combinatorial labeling strategies 
[101]. Here, the IMP is simultaneously labeled with selected 
15N-enriched amino acids 
in combination with distinct 
13C-labeled amino acids (Fig. 14). The application of a 
transverse relaxation optimized spectroscopy (TROSY) version of a [
15N,
1H] 
heteronuclear single quantum correlation (HSQC) experiment in combination with two-
dimensional [
15N,
1H]-TROSY-HN(CO) (HNCO) spectra helps to identify only those 
15N-labeled amino acids that were N-terminally preceded by a 
13C-labeled amino acid 
type. This strategy enables the unambiguous identification of consecutive amino acids 
pairs that can be subsequently used as anchor points for further backbone resonance 
assignments (Fig. 14). This combinatorial labeling strategy of IMPs is just possible due 
to the unique properties of CF expression. Whereas amino acid type selective labeling is 
also possible in auxotrophic bacteria, for combinatorial labeling multiple auxotrophic 
strains in almost any combination would be needed. The combination of enormous 
expression levels of IMPs, unique labeling possibilities coming along with no cross 
labeling problems [19], and the fact that just small amounts of isotopically labeled 
amino acids are needed makes CF expression promising for the structural analysis of 
IMPs by high field NMR. 
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Fig. 14 Combinatorial labeling approach. 
Example of a combinatorial labeling scheme with three differentially 
15N and 
13C labeled samples 
of the tellurite transporter ΔTehA. The labeling scheme is shown in the table on top. In the 
[
15N,
1H]-TROSY spectra, correlations of the 
15N-labeled amino acids are visible. The crossed 
lines indicate the peak to become identified. The peak at position 117.5/7.78 must be due to a 
phenylalanine as it is present in samples 1 and 2 (green circles) but not in sample 3 (red round 
edge square). The corresponding HNCO spectra show the amide cross peaks after carbonyl 
transfer (big arrow) and indicate that the preceding residue of this phenylalanine must be a 
glycine, as no cross peaks are visible in sample 2 and 3 (red round edge squares) without 
13C-
glycine. The analyzed phenylalanine residue can now be localized in a Gly-Phe pair in the primary 
sequence which in that example was identified as Phe97 of ΔTehA. All spectra were recorded at a 
Bruker Avance 600 MHz spectrometer. (Modified after (P 05)). 
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4.3.3. Protein-detergent interactions analyzed by NMR 
Once the amino acids of the protein backbone resonances are assigned, NMR 
spectroscopy offers versatile possibilities for further analyzes like the determination of 
protein-detergent interactions. Nuclear Overhauser enhanced and exchange 
spectroscopy (NOESY) allows the determination of spatial proximity of protons. Thus, 
amino acids of ΔTehA that are close to atoms of the detergent LMPG could be 
identified (Fig. 15).  
 
 
Fig. 15 Protein-LMPG interactions. 
F1-F3 Strips are taken from a 3D NOESY-[
15N,
1H]-TROSY spectrum (250 ms 
mixing time, 900 MHz) of U-
2H
15N-labeled ΔTehA in 5% LMPG at 
15N positions 
indicated at the top of each slice. Strips are grouped according to: A, backbone 
amides of residues in helical regions; B, backbone regions of residues in loop 
regions; C, tryptophan side-chain N
e1 protons; D, arginine side-chain N
e protons. 
Cross beaks outside the marked positions are intraresidual NOEs either involving 
exchangeable protons or incompletely deuterated α-carbons.  
(The figure was kindly provided by Frank Löhr). 
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It can further be demonstrated that backbone amides of residues in helical regions are in 
direct proximity to the hydrophobic part of LMPG (Fig. 15 A), whereas backbone 
residues in loop regions show NOEs to water (Fig. 15 B). This information supports the 
determination of α-helical and loop regions of the protein. 
 
4.3.4. Paramagnetic Resonance Enhancement (PRE) measurements 
Whereas the secondary structure is mainly based on the 
13Cα and 
13Cβ chemical shifts 
as well as on the pattern of sequential and medium-range NOEs in the 
15N-edited 
[
1H,
1H]-NOESY spectrum, investigations of the three-dimensional (3D) structure relies 
on different strategies. A limited chemical shift dispersion observed in the spectra of α-
helical IMPs limits the assignment of side chain resonances to very few residues only. 
In addition, the high molecular weight of the protein/micelle complexes requires 
deuteration, which eliminates most of the protons that can be used in classical 
1H-
1H 
NOE-based structure determination procedures. Another possibility getting distance 
constrains for IMPs is the use of paramagnetic relaxation enhancement (PRE) 
experiments  [8]. This type of distance constraints has been developed with soluble 
proteins that are too big for classical structure determination procedures [27]. In these 
experiments the line broadening effect of a paramagnetic tag, like 1-oxy(-2,2,5,5-
tetramethyl-Δ3-pyrroline-3-methyl) methanethiosulfonate (MTSL)) that is attached to a 
protein through a specific cysteine side chain on the surrounding amide proton is 
analyzed. Since the line broadening is proportional to 1/r
6, a quantitative measurement 
of the line broadening can be used for obtaining distance constraints. The structure of 
the membrane-associated protein Mistic [26] as well as the refinement of the outer 
membrane  β-barrel protein OmpA [102] already took advantage of PRE derived 
distance information. 
In order to use PRE to obtain distance constrains of ΔTehA, all three naturally occurring 
cysteins where mutated to alanins and at specific locations, mostly at the beginning or 
the end of helices, cysteine residues have been reintroduced by quick change PCR. As 
uniformly 
15N amino acid labeled ΔTehA show significant peak overlap in the [
15N,
1H]-
TROSY-HSQC spectrum, several selectively amino acid labeled samples where 
prepared by CF expression. Figure 16 shows as a comparison of the [
15N,
1H]-TROSY-
HSQC spectra of ΔTehA, labeled with a paramagnetic tag at amino acid position 11, 98 
and 193 and the same sample after reducing the spin label to a diamagnetic compound 
with ascorbic acid. Some signals, in case of paramagnetic labeled protein, are 
completely absent in the paramagnetic species whereas others show significant line 
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Fig. 16 Paramagnetic labeling of ΔTehA. 
Comparison of [
15N,
1H]-TROSY-HSQC spectra of ΔTehA in its reduced, diamagnetic form 
(upper spectra) and in its paramagnetic form with a spin label (MTSL) attached (lower 
spectra). The significant overlap of the fully labeled spectrum makes amino acid-type 
selective labeling necessary. The site of the spin label attached as well as the type of 
labeling pattern is indicated on the top. Peaks that are completely absent in the paramagnetic 
spectrum are marked with a red symbol and those that show significant line broadening with 
a yellow symbol. The spectra were measured on an 800 MHz instrument. The assignment of 
these affected beaks is shown in the diamagnetic spectrum. (The figure was kindly provided 
by Frank Löhr and has been modified after (P 10)). 
 
 
4.3.5. Preliminary structural data of ΔTehA 
The unique advantages of CF IMP expression and accompanied labeling possibilities in 
combination with high field NMR spectroscopy allowed the assignment of 85% of the 
amide backbone resonances of ΔTehA [Trbovic, Diplomarbeit 2005]. Using the PRE 
technique allowed the determination of approx. 120 meaningful distance constrains as a 
pair of upper and lower limit for an individual defined amide-amide distance. This 
information combined with 205 distance constraints based on unambiguous NOEs from 
4D-[
15N,
1H]-HMQC-NOESY-[
15N,
1H]-TROSY and 3D-[
15N,
1H,
15N]-NOESY-[
15N,
1H]-
TROSY spectra, defining inter-helical distances, allowed the calculation of a 
preliminary backbone model of ΔTehA [Fig. 17 B]. The model comprises all seven 
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predicted α-helices [Fig. 17 A], of which helix no. 4 (green) seems to be flexible and 
not transmembrane oriented. 
 
 
Fig. 17 Secondary and preliminary structure of the putative tellurite transporter ΔTehA. 
A, The proposed secondary structure of TehA is shown. The 10 transmembrane segments of TehA 
(green, red) are shown. The C-terminal truncated version ΔTehA is indicated in green. A homology 
alignment to the related multi-drug-transporter EmrE regarding conservative replacements is indicated 
in yellow. B, Preliminary model of ΔTehA as derived from dyana 1.05 simulated annealing protocol. A 
first model of a protein with seven transmembrane helices could derive from 325 distance constraints 
using dyana 1.05 simulated annealing in vacuum. This calculated model symbolizes the proposed 
averaged topology of ΔTehA in LMPG micelles. N-terminus (blue) and C-terminus (red) are oriented 
on opposite sites of a assumed conformational space of a membrane. (This model was calculated by 
Alexander Koglin). 
 
This shows the first model of an α-helical IMP of this size, containing seven TMS and 
analyzed by solution NMR in detergent micelles. 
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5.  Summary of publications 
5.1.  Establishment of high level cell-free expression of IMPs 
In the following section, the publications that contribute to this work will be reviewed 
shortly. In addition I will highlight my contribution to these publications. The aim of 
this work was to establish a CF system for preparative IMP expression for functional 
and structural analysis. The individual CF expression method used was further 
optimized from the system that has been established in Frankfurt during my Diploma 
Thesis in the year 2002 (Development and set-up of a cell-free expression system for 
preparative protein synthesis).  
 
5.1.1. Method development 
5.1.1.1.  High level cell-free expression and specific labeling of IMPs (P 01) 
C. Klammt, F. Löhr, B. Schäfer, W. Haase, V. Dötsch, H. Rüterjans, C. Glaubitz and F. 
Bernhard:  High level cell-free expression and specific labeling of integral 
membrane proteins. Eur. J. Biochem., 271, 568-580. (2004) 
This article was judged to be the best one published in the FEBS Journal during the year 
2004 and honored with the FEBS Journal Prize for Young Scientists award 2004. In this 
article we demonstrate for the first time the high level expression of IMPs in a CF 
system. Using an optimized protocol the E. coli small multi drug transporters EmrE and 
SugE and even the heavy metal transporter TehA and the cysteine transporter YfiK, 
both not overexpressed in E. coli, were produced at high levels of up to 2.7 mg per 
single mL of RM. As no hydrophobic compartment was supplemented to the CF system 
all IMPs were insoluble synthesized in the RM. Those precipitates are found to 
solubilize in already mild detergents, and modifications to the solubilization procedure 
yielded in almost pure protein. Solubilized IMPs were successfully reconstituted in 
proteoliposomes, demonstrated by freeze fracture electron microscopy (EM). The 
function of CF expressed, solubilized and reconstituted EmrE was analyzed by the 
specific binding of ethidium. In addition the CF expression technique allowed the 
efficient amino acid specific labeling of the synthesized proteins and NMR analysis 
indicated a correctly folded conformation of the proteins. 
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Major results: 
  Protocol for an optimized individual CF expression system. 
  The preparative scale expression of diverse IMPs (EmrE, SugE, TehA and 
YfiK) using an individual CF system is demonstrated for the first time. 
  It is observed that CF IMP synthesis produce insoluble proteins that can 
easily be resolubilized in already mild detergents, and purified by 
modifications of the solubilization procedure. This makes these precipitates 
completely different to inclusion bodies, known from cellular expression 
systems. 
  IMP precipitates solubilized in mild detergents can functionally be 
reconstituted into proteoliposomes, analyzed by freeze fracture EM and a 
specific ethidium transport assay for EmrE. 
  The secondary structure of IMPs is analyzed by circular dichroism (CD) 
spectroscopy, solubilized in various detergents. 
  CF 
15N-isotopic labeling allows the solution NMR analysis of IMPs in 
detergent micelles. 
My contribution to this publication: 
I have established the CF system in Frankfurt and optimized for the high level 
expression of IMPs. I have labeled the analyzed IMPs with 
15N-isotopes for NMR 
analysis, performed by Frank Löhr. I reconstituted the CF expressed and detergent 
solubilized proteins, I carried out the EmrE ethidium transport assay and have done the 
CD analyzes. The freeze fracture EM analysis was done by Winfried Haase.  
 
5.1.1.2.  Soluble cell-free expression of IMPs in presence of detergents (P 02) 
C. Klammt, D. Schwarz, K. Fendler, W. Haase, V. Dötsch and F. Bernhard: Evaluation 
of detergents for the soluble expression of α-helical and β-barrel-type integral 
membrane proteins by a preparative scale individual cell-free expression system. 
FEBS Journal, 272, 6024-6038. (2005) 
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This paper evaluates 24 of the most commonly used detergents for their suitability as 
supplement to CF systems for the direct soluble expression of IMPs. In order to give a 
comprehensive overview, the soluble CF synthesis of three structurally very diverse 
IMPs, the α-helical small multi drug transporter EmrE, the β-barrel type nucleoside 
transporter Tsx and the eukaryotic vasopressin 2 receptor (V2R), a member of the G-
protein coupled receptor (GPCR) family, were analyzed regarding to their soluble 
expression. Some members of the long chain poly-oxyethylene-alkyl-ether family were 
identified to be most suitable for the soluble expression of all three types of membrane 
proteins. Furthermore, the yield of soluble expressed membrane protein was found to 
remain relatively stable above a certain detergent threshold concentration. In addition, 
for insoluble CF IMP synthesis, several detergents were analyzed for their ability in 
solubilizing precipitates of these structurally divers proteins. Here the detergent 1-
myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] (LMPG) was found to be 
most effective for the resolubilization. Finally, the high-level CF expression of a β-
barrel type membrane protein in a functional form was reported for the first time and a 
structural and functional variation of the analyzed membrane protein in dependence of 
the CF expression mode and the supplied detergent was demonstrated. 
  Major results: 
  The evaluation of 24 different commonly used detergents for their suitability 
for soluble CF expression of structurally very different IMPs revealed that 
some members of the Brij-family (Brij35, Brij58, Brij78 and Brij98) give 
outstanding results. 
  Above a certain detergent threshold concentration the yield of soluble 
expressed protein remains relatively stable. 
  The detergent LMPG is the most effective for the resolubilization of diverse 
IMP precipitates, obtained form insoluble CF IMP expression. 
  The functional and preparative expression of a β-barrel type protein is 
demonstrated for the first time and the functionality can be related to the 
mode of CF expression and the type of detergent used. 
  The GPCR V2R is soluble CF expressed in amounts up to 6 mg of one mL 
of the RM in the presence of Brij58 and Brij78. This is the highest 
expression rate of a GPCR protein ever reported. 
  CF insoluble produced V2R show homogenous insertion in reconstituted 
proteoliposomes, analyzed by freeze fracture EM. 
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  The secondary (2D) structure of the insoluble and soluble expressed proteins 
Tsx and V2R, analyzed by CD-spectroscopy, differ from each other.  
My contribution to this publication: 
I have cloned and performed all analyzes regarding the E. coli small multi drug 
transporter EmrE and the GPCR V2R, whereas my coauthor Daniel Schwarz took care 
of all Tsx experiments, including the activity assay. The freeze fracture EM was 
performed by Winfried Haase. 
 
5.1.2. Reviews 
Several review articles about CF expression of IMPs have been prepared highlighting 
different aspects of CF IMP synthesis. 
 
5.1.2.1.  Cell-free production of IMPs on a preparative scale (P 03) 
C. Klammt, D. Schwarz, V. Dötsch and F. Bernhard: Cell-free production of integral 
membrane proteins on a preparative scale. Meth. Mol. Biol., accepted. (2006) 
This article focuses on the high level CF expression of IMPs by using an individual 
coupled transcription/ translation system. It describes in detail the set-up and 
optimization of the CF expression technique in order to obtain the maximum yield of 
recombinant proteins. The protocol can be used for the expression of soluble IMPs as 
well as for their production as precipitates. In addition, it provides detailed protocols for 
the solubilization of CF expressed detergent precipitates and for further reconstitution. 
Major results: 
  Detailed description for the establishment of an individual CF expression 
system for high level expression of IMPs, including stock concentration 
tables and a pipetting protocol. 
  Protocols for solubilization of CF produced IMP precipitates and further 
reconstitution. 
  Guide for the soluble CF expression of IMPs and the resolubilization of the 
three proteins EmrE, V2R and Tsx, including 11 different detergents. 5    SUMMARY OF PUBLICATIONS 
 
57
  Successful reconstitution of CF insoluble expressed YfiK solubilized in 
detergent, analyzed by freeze fracture EM. 
My contribution to this work: 
I have supplied the detailed protocols for the high level expression of IMPs, the 
solubilization of precipitates and the reconstitution. I provided all of the figures and 
reconstituted YfiK for freeze fracture analysis. Regarding the soluble CF expression of 
IMPs, I have analyzed EmrE and V2R, whereas Daniel Schwarz investigated the β-
barrel type nucleoside transporter Tsx. 
 
5.1.2.2.  Cell-free expression as an emerging technique for the large scale 
production of IMP (P 04) 
C. Klammt, D. Schwarz, F. Löhr, B. Schneider, V. Dötsch and F. Bernhard: Cell-free 
expression as an emerging technique for the large scale production of integral 
membrane protein. FEBS Journal, 273, 4141-4153. (2006) 
This article gives an overview about the current state of the art of CF IMP expression 
with special focus on technical aspects as well as on the functional and structural 
characterization of CF produced IMPs. Besides the structural analysis of CF produced 
IMPs, applications like oligomerization studies of CF expressed IMPs and high 
throughput expression screening of IMPs are discussed. 
Major results: 
  Comparison of the two expression modes of insoluble and direct soluble 
synthesis of IMPs in CF systems. 
  Detailed compilation of IMPs synthesized in preparative scale CF expression 
systems. 
  Detailed overview comparing the activities of CF synthesized and 
conventionally in vivo expressed IMPs. 
  High resolution [
15N,
1H]-TROSY-HSQC NMR spectra of the CF uniformly 
2H
15N-labeled cysteine transporter YfiK in LMPG micelles measured at a 
900 MHz spectrometer. 
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My contribution to this work: 
I provided all the figures and tables for the manuscript and have uniformly 
2H
15N-
labeled YfiK for the high field NMR analysis in LMPG micelles, performed by Frank 
Löhr. 
 
5.1.2.3.  Cell-free synthesis of IMPs for structural studies (P 05) 
C. Klammt, D. Schwarz, B. Schneider, F. Löhr, I. Lehner, C. Glaubitz, V. Dötsch and F. 
Bernhard:  Cell-free expression of integral membrane proteins for structural 
studies. In: Cell-free expression techniques, A. Spirin (ed.), Wiley-VCH, Weinheim, 
submitted. (2006) 
This manuscript compares the two already established CF IMP expression modes of 
insoluble and direct soluble IMP expression with a third possible but not yet sufficient 
analyzed mode of direct supplementation of preformed liposomes. In addition it 
demonstrates the variety of different successfully high level CF expressed IMPs. In 
addition several high resolution solution NMR spectra, including the proteins Yfik, 
SecE and ΔTehA of uniformly and single amino acid labeled IMPs and first solid state 
NMR experiments of selectively labeled CF produced EmrE are shown. 
Major results: 
  Comparison of the two already established CF IMP expression modes and a 
potential third method using supplemented preformed liposomes for direct 
reconstitution of IMPs. 
  Detailed description of detergents used for the solubilization of IMPs and the 
soluble expression in presence of detergents. 
  Detailed presentation showing the variety of different high level expressed 
IMPs including four different GPCRs. 
  Discussion of state of the art achievements of combined approaches CF 
expression and NMR. Several high resolution [
15N,
1H]-TROSY-HSQC 
spectra of uniformly and selective amino acid labeled SecE, YfiK and 
ΔTehA are presented. 
  Description of combinatorial labeling schemes using CF expression of IMPs. 5    SUMMARY OF PUBLICATIONS  59
My contribution to this work: 
I supplied all figures except of the solid state NMR information (6 B), that was supplied 
by my coauthor Ines Lehner. The detailed detergent table was prepared by Daniel 
Schwarz. The proteins SecE and YfiK were expressed by Solmaz Sobhanifar and the 
NMR analysis was done by Frank Löhr. 
 
5.1.2.4.  Preparative scale cell-free expression systems for functional and structural 
studies (P 06) 
D. Schwarz, C. Klammt, A. Koglin, F. Löhr, B. Schneider, V. Dötsch and F. Bernhard: 
Preparative scale cell-free expression systems: New tools for the large scale 
preparation of integral membrane proteins for functional and structural studies. 
Methods, in press. (2006) 
This manuscript presents detailed protocols for the CF production of IMPs in different 
modes and summarizes the current knowledge of this technique. Here, the production of 
soluble and functionally folded IMPs in presence of detergents is emphasized. In 
addition, the advantages of CF expression for the structural analysis of IMPs especially 
by liquid state NMR is highlighted and new strategies for structural approaches are 
discussed. 
  Major results: 
  Detailed protocols for CF expression including CF extract preparation, 
design of DNA templates and reaction conditions. 
  Detailed protocols for CF IMP expression in both modes as insoluble protein 
or direct soluble synthesized in detergent micelles. 
  Comprehensive summary of all published results with CF expressed IMPs in 
the presence of detergents. 
  CF expression kinetics of the β-barrel nucleoside transporter Tsx.  
  Comparison of ΔTehA expressed in both modes and buffered in LMPG by 
[
15N,
1H]-TROSY-HSQC NMR spectra. 
  Optimization of soluble CF Tsx expression regarding the detergent 
concentration. 
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  Discussion of combinatorial labeling strategies for the rapid assignment of 
CF produced IMPs. 
My contribution to this work: 
I supplied the detailed table of CF soluble expressed IMPs reported in the literature, 
prepared the ΔTehA samples for NMR analysis and drew the figure explaining the 
combinatorial labeling scheme. The rest of the manuscript was done by the first author 
Daniel Schwarz. 
 
5.1.2.5.  DNA recombination and protein expression systems (P 07) 
F. Bernhard,  C. Klammt, and H. Rüterjans: DNA recombination and protein 
expression. In: Comprehensive Medicinal Chemistry II, in press. (2006) 
This book chapter reviews the currently most promising expression systems in bacterial 
and eukaryotic cells as well as in CF environments. It intends to serve as a guideline for 
making decisions in order to receive the highest yields of recombinant proteins. Critical 
details and features that have to be considered upon the in-vitro recombination of 
expression vectors and during the process of protein production are addressed. In 
addition, key elements of expression systems are discussed individually and modified 
techniques that have been approved for the production of distinct and difficult groups of 
proteins; e. g. membrane proteins or disulfide bonded proteins are especially 
highlighted. A special focus is also the preparative scale CF production of recombinant 
proteins as this relatively new technique provides several unique characteristics with a 
high potential for the future. 
Major results: 
  Reviews the variety of promoters and control mechanisms of gene 
expression in detail in combination with codon usage and regulatory DNA 
sequences important for protein expression. 
  Comprehensive overview of translation fusion constructs for optimized 
protein expression. 
  Discussion and comparison of the currently most promising expression 
systems including the E. coli, yeast, mammalian, viral (baculovirus and 
semliki forest virus expression vector systems) and CF expression systems in 
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  Description of applications in E. coli expression, including inclusion body 
formation, co-expression of chaperones, solubility tags, expression of IMPs 
and disulfide bonded proteins. 
  Comparison of all preparative scale protein expression techniques for the 
optimized expression of recombinant proteins. 
  Detailed presentation of CF expression systems, including the preparation of 
CF extracts and the advantages in CF IMP synthesis and the expression of 
disulfide bridged proteins. 
My contribution to this work: 
I supplied all figures and reviewed the mammalian expression system, (like baby 
hamster kidney (BHK), Chinese hamster ovary (CHO), human embryonic kidney 
(HEK) and simian fibroblasts (CV-1 cells) transformed by SV40 (COS) cell lines), the 
viral expression systems, including the baculovirus and semliki forest virus expression 
systems, and the CF expression system paragraphs.  
 
5.2.  Unique labeling possibilities for IMPs by cell-free expression 
Nuclear magnetic resonance (NMR) spectroscopy has experienced a tremendous growth 
over the past decade, and has been developed as a widely used technique with enormous 
potential for the study of the structure and dynamics of biological macromolecules. In 
particular; structural analysis of proteins has greatly benefited from recent 
advancements of high field solution NMR. Improvements in the hardware and the 
development of NMR spectrometers with field strength up to 900 MHz considerably 
increased the sensitivity and reduced the requirements for high amounts of samples. 
However, IMPs have almost been completely excluded form this studies as they are 
rarely expressed in cellular expression systems and even more difficult to label with 
stable isotopes, an indispensable prerequisite for multi-dimensional NMR analysis. 
CF expression methods provide unique labeling possibilities. These advantages in 
combination with high level IMP expression and ultra-high field NMR spectrometers 
open a new avenue for the functional and structural analysis of IMPs. 
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5.2.1. 
13C- and 
15N-isotopic labeling of proteins (P 08) 
C. Klammt, F. Bernhard and H. Rüterjans: 
13C- and 
15N-Isotopic Labeling of Proteins. 
In: Molecular Biology in Medical Chemistry, T. Dingermann, G. Folkers, H. Steinhilber 
(eds.), pp. 269-292, Wiley-VCH, Weinheim. (2004) 
This book chapter reviews recently developed strategies for the incorporation of 
15N and 
13C labels into proteins. Conventional labeling strategies require the overproduction of 
proteins in bacterial or eukaryotic expression systems and we give an overview of the 
most advanced systems as they are indispensable prerequisites for the efficient 
incorporation of isotopes into proteins. Furthermore, we focus on newly developed in 
vitro techniques, utilizing CF extracts for the generation of protein samples. While CF 
production of proteins in an analytical scale has been possible for several years, 
preparative protein synthesis using extracts from E. coli or other sources has become 
one of the most powerful tools for the production of labeled samples suitable for NMR 
analysis. We therefore especially address the recent advantages in CF expression and 
labeling strategies. 
  Major results: 
  Review of all commonly used expression systems for the production of 
13C- 
and 
15N-labeled protein samples, including E. coli expression systems, the P. 
pastoris system and the Chinese Hamster Ovary (CHO) cell system. 
  Description of the main strategies for the production of selectively 
13C- and 
15N-labeled proteins. Here selective labeling of amino acids, specific isotope 
labeling with 
13C isotopes and segmental isotope labeling are included. 
  Discussion of advantages and disadvantages of CF expression systems. 
Comprehensive review of this method regarding bacterial and eukaryotic 
systems, reaction set-ups, extract preparation and preparative CF protein 
synthesis. 
  Demonstration of unique labeling possibilities that arise from CF protein 
expression and comparison of in vivo uniformly labeled protein with CF 
selectively labeled one. 
  Protocols for the expression of up to 4 mg soluble CF expressed GFP per mL 
of RM. 
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My contribution to this work: 
I have prepared all of the figures and reviewed the CF paragraph. In addition I have 
selectively labeled the soluble protein cRcsB and prepared the NMR sample. 
 
5.2.2. Efficient Strategy for the Rapid Backbone Assignment of IMPs (P 09) 
 N. Trbovic, C. Klammt, A. Koglin, F. Löhr, F. Bernhard, and V. Dötsch: Efficient 
Strategy for the Rapid Backbone Assignment of Membrane Proteins. J. Am. Chem. 
Soc., 127, 13504-13505. (2005)  
This JACS communication describes the efforts in assigning the NMR backbone 
resonances of the completely α-helical IMP TehA using unique advantages of CF 
expression by a combinatorial labeling strategy. The 24 kDa fragment of the putative 
tellurite transporter TehA was CF isotopically labeled and solubilized in LMPG 
micelles for solution NMR analysis. Although the obtained NMR spectra behaves 
extremely well for an IMP of this size incorporated in detergent micelles, severe overlap 
in some regions of the spectra allowed the assignment only of 55% of the protein’s 
backbone resonances. Selectively labeling, usually performed to solve this problem, 
using 10 different amino acid types obtained only further 10% of unambiguous 
assignments. Finally a specific labeling procedure, unique for the CF system, based on 
the simultaneous labeling of certain amino acid types with 
15N and other amino acid 
types with 
13C on the backbone carbonyls helped to overcome this problem. The 
measurement of a two-dimensional [
15N,
1H]-TROSY-HN(CO) (HNCO) experiment 
now allowed selecting only those 
15N-labeled amino acids that are N-terminally 
preceded by a 
13C-labeled amino acid type. In order to optimize this procedure and 
reduce the sample preparation, a combinatorial labeling scheme has been developed. 
The preparation of 3 combinatorial labeled samples measured with [
15N,
1H]-TROSY-
HSQC spectra as well as two-dimensional HNCO spectra obtained new distinct amino 
acid assignments that served as specific starting points fore more residues, bringing the 
total backbone assignment to 85%. 
  Major results: 
  CF expression of IMPs LMPG solubilized in combination with high field 
NMR spectrometry allows the generation of NMR samples sufficient to start 
the assignment and structural investigations on even large IMPs of 24 kDa 
and comprising 7 TMS. 
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  Program for combinatorial labeling provided on the internet 
(http://www.biophyschem.uni-frankfurt.de/AK_Doetsch/projects/download/ 
combilabel.m). 
  First high resolution [
15N,
1H]-TROSY-HSQC spectra of a 24 kDa α-helical 
IMP in detergent micelles. 
  CF expression provides unique labeling possibilities like the use of a 
combinatorial labeling strategy that has not been able in this timescale in 
cellular systems. 
  CF expression allows the fast generation of isotopically labeled IMP NMR 
samples within 24 hours. 
My contribution to this work: 
I have cloned the c-terminal truncated TehA construct, optimized the CF protein 
expression of this protein and prepared all NMR samples. This includes all uniformly 
and selectively and combinatorial labeled ΔTehA samples. The NMR analysis was done 
by Frank Löhr whereas Nicola Trbovic assigned the ΔTehA backbone resonances 
during his Diploma work. 
 
5.2.3. Combination of CF expression and NMR for structural assignment of IMPs 
(P 10) 
A. Koglin, C. Klammt, N. Trbovic, D. Schwarz, B. Schneider, B. Schäfer, F. Löhr, F. 
Bernhard and V. Dötsch: Combination of cell-free expression and NMR 
spectroscopy as a new approach for structural investigation of membrane proteins. 
Magn. Res. Chem., 44, 17-23. (2006) 
This Mini-review article discusses the combination of CF membrane protein expression 
and liquid state NMR spectroscopy. Recently, the application of CF expression systems 
to membrane proteins has demonstrated that this technique can be used to produce 
quantities sufficient for structural investigations form many different membrane 
proteins. In particular for NMR spectroscopy, CF expression provides major advantages 
since it allows for amino acid type selective and even amino acid position specific 
labeling. 
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Major results: 
  Reviews CF expression systems showing the successful expression of 
diverse IMPs like the cysteine transporter YfiK, TehA, EmrE and SugE as 
precipitates that can easily be resolubilized in mild detergents and purified 
by modified solubilization strategies. 
  Reviews NMR approached for the investigations of α-helical membrane 
proteins, in particular the assignment and structural analysis of TehA. 
  Description of the paramagnetic resonance enhanced (PRE) technology, 
using paramagnetic labels in order to receive additional distance constrains 
that can be used along NOE information for the structural analysis of IMPs 
in detergent micelles. 
  Description of the [
15N,
1H]-TROSY-HSQC spectrum of the soluble CF 
expressed 
2H-
15N-labeled 24 kDa fragment of TehA. 
My contribution to this work: 
I have provided the SDS gel figures of CF expressed and detergent purified IMPs. I 
overexpressed solubilized and purified all of the mentioned IMPs. I optimized the 
expression of ΔTehA for successful NMR sample preparation. I have further prepared 
all NMR samples including the mutant samples used for PRE measurements. The NMR 
measurements were done by Frank Löhr, whereas Nicola Trbovic assignment the 
ΔTehA backbone resonances and performed site specific mutagenesis to provide PRE 
samples during his diploma work. 
 
5.2.4. Incorporation of Fluorescence Labels into cell-free produced proteins (P 11) 
K. Sengupta, C. Klammt, F. Bernhard and H. Rüterjans: Incorporation of fluorescence 
labels into cell-free produced proteins. In: Cell-Free Protein Expression, J.R. Swartz 
(ed.) pp. 81-88, Springer Verlag, Berlin, Heidelberg, New York. (2003) 
This book chapter describes the incorporation of unnatural amino acids into proteins by 
using a CF expression system. Here spectrally enhanced tryptophan residues were 
incorporated in the transcription regulator protein RcsB. This incorporation did not 
affect the protein activity but changed the protein tryptophan spectral properties. Steady 
state fluorescence spectroscopy analysis of differently tryptophan labeled proteins 
allowed studying the interaction between two RcsB proteins titrating non-labeled and       SUMMARY OF PUBLICATIONS   5  66 
labeled RcsB. In addition, the use of N- and C-terminal RcsB fragments gave evidence 
for an involvement of the C-terminal effector domain in the oligomerization of RcsB. 
  Major results: 
  Unnatural amino acids like tryptophan analogues can easily be incorporated 
into proteins by using CF expression. 
  The transcription regulator protein RcsB was found to act as a multimer, 
analyzed by steady state fluorescence spectroscopy of differently tryptophan 
labeled proteins. Further the C-terminus of the protein gave evidence for an 
involvement in the oligomerization process. 
My contribution to this work: 
I have performed the steady state fluorescence titration measurements of differently 
tryptophan labeled RcsB proteins and constructs and provided the fluorescence spectra 
figure. The proteins were CF expressed in the commercially available RTS™ system 
(Roche, Penzberg, Germany) by Frank Bernhard. Kaushik Sengupta further purified 
those soluble proteins out of the RM and performed the activity assay for CF 
synthesized RcsB. 
 
5.3.  FEBS Journal prize award of 2004 for Christian Klammt (P 12) 
Mit neuer Methode lassen sich Membranproteine “knacken”. Erstmals können 
ausreichende Mengen begehrter Proteine produziert werden – Auszeichnung für 
Christian Klammt. Forschung Frankfurt, 3, 9-10. (2005) 
This article describes the FEBS Journal Prize of 2004 award given to me for being the 
first author of the paper judged to be the best one published in the FEBS Journal during 
the year 2004 for the paper: 
C. Klammt, F. Löhr, B. Schäfer, W. Haase, V. Dötsch, H. Rüterjans, C. Glaubitz 
and F. Bernhard: High level cell-free expression and specific labeling of 
integral membrane proteins. Eur. J. Biochem., 271, 568-580. (2004) 
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6.  Unpublished Results – Structural and functional analysis of the 
human endothelin B receptor (ETB) 
6.1.  Introduction 
6.1.1. G-protein coupled receptors (GPCRs) 
The G-protein coupled receptors (GPCRs) are the largest class of cell-surface receptors 
and are encoded by more than 1000 genes in the human genome [28]. GPCRs are 
involved in the recognition and transduction of messages as diverse as odorants, small 
molecules including amino-acid residues, nucleotides and peptides, proteins, Ca
2+ as 
well as light. They control the activity of ion channels, enzymes and transport of 
vesicles via the catalysis of the GDP-GTP exchange on heterotrimeric G proteins (Gα-
βγ). Almost all physiological regulatory mechanisms in the human body are controlled 
by GPCRs and thus more than 60% of modern drugs are supposed to be directed against 
GPCRs  [29]. Their structural characterization has been inhibited due to extreme 
difficulties in the preparation of sufficient amounts of functionally folded protein. While 
mammalian expression systems can be optimized in order to produce highly functional 
GPCRs, the final yields are still low and do not warrant structural approaches in most 
cases  [103]. CF expression might overcome this problem as it was successful in 
synthesizing large amounts of bacterial transporters that do not overexpress in E. coli. 
GPCRs are divided into six Groups according to the GPCR database online 
(www.GPCR.org), whereas they comprise three major families (Fig. 18). Family A, also 
referred to as the rhodopsin-like family is by far the largest subgroup and contains 
receptors of odorants, small molecules, peptides and glycoprotein hormones. This 
family is further classified into 3 sub classes with regard to their different ligand 
binding site locations (Fig. 18). All Family A class GPCRs are activated by small 
ligands. Members of the first sub class bind ligands in a cavity formed by the third and 
fourth TMS. In the case of the light-activated receptor rhodopsin, the target of photons, 
retinal, is covalently linked in this cavity and its change in conformation induced by 
light activates the receptor. The second sub class is activated by short peptides which 
interact with the extracellular loops and the N-terminal domain. However, the C-
terminal end of these peptides has been proposed to interact within a cavity similar to 
that of the first sub family [104]. Family B is characterized by a relatively long amino 
terminus that contains several cysteins, which presumably form a network of disulfide 
bridges and plays a role in the binding of the ligand [105]. Family C receptors are 
characterized by a long amino terminus, which is often described as being like a “Venus 
fly trap”. A unique characteristic of the family C receptors is that the third intracellular 
loop is short and highly conserved.  
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Fig. 18 Overview of the G-protein coupled receptor family 
G-protein-coupled receptors (GPCRs) can be divided phylogenetically into six families. A schematic 
representation of the three main families is shown, illustrating some mayor differences between these 
families besides highly conserved amino acid residues. In addition the main receptor targets of the 
corresponding families are listed. Receptors of family A are characterized by several highly conserved 
amino acids, indicated in the diagram, and a disulfide bridge that connects the first and second extra 
cellular loops and most of these receptors also have a palmitoylated cysteine in the carboxy-terminal 
tail. In addition the family A is sub classified into a, b and c. Family Aa contains GPCRs for small 
ligands including rhodopsin and ß-adrenergic receptors. The binding site is localized within the seven 
TMS. Family Ab contains receptors for peptides whose binding site includes the N-terminal, the 
extracellular loops and the superior parts of TMS. Family Ac contains GPCRs for glycoprotein 
hormones. (Modified after [106, 107]). 
 
All GPCRs share a similar architecture of seven membrane-spanning α-helices 
connected by three intracellular and three extracellular loops [108]. GPCR families 
show no sequence homology to one another, indicating that they might be unrelated 
phylogenetically and that the similarity of their TMS structure might be the result of 
common functional requirements. Two cysteine residues, one in the first and one in the 
second extracellular loop, which are conserved in most GPCRs, form a disulfide link 
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number of conformations of these seven TMS [107]. Besides sequence variations, 
GPCR families differ in the length and function of their N-terminal extracellular 
domain, their C-terminal intracellular domain and their intracellular loops (Fig. 18). 
Virtually all therapeutics that are directed towards GPCRs have been designed using 
assays that presume that these receptors are monomeric [106]. However, over the past 
years it has widely been accepted that GPCRs form oligomers. For several receptors a 
homooligomerization have been shown, whereas others are able to even oligomerize as 
heterooligomers (reviewed by [106]). It is further assumed that heteromeric receptor 
complexes have functional characteristics that differ form homogeneous populations of 
their individual constituents. Regarding the number of oligomers, many GPCR 
oligomerization studies do not make a clear distinction between dimers and larger 
receptor complexes. 
 
6.1.2. Endothelin B receptor (ETB) 
Endothelin-1 (ET-1) is identified as a potent vasoconstrictor peptide secreted from 
vascular endothelial cells [109]. The entire endothelin family comprises endogenous 
isoforms of 21-aminoacid peptides named ET-1, ET-2 and ET-3, each one coded by a 
different gene [110]. All isopeptides are synthesized from biological inactive precursors 
by the endothelin-converting enzymes that belong to a subgroup of membrane-bound 
zinc metalloproteases [109]. The active isopeptides are distributed in many tissues and 
cell types, and play important roles in the modulation of hemodynamics, cardiac, 
pulmonary, renal, and neural function, and in mitogenesis and neural development [111-
114]. Most abundantly expressed along those three endothelins is ET-1, the only 
isoform constitutively released by vascular endothelium [115]. 
The action of ET-1 in humans occurs via two endothelin receptor subtypes: The 
endothelin A receptor (ETA) and the endothelin B receptor (ETB) [116, 117]. Both 
receptors, belonging to the large family of GPCRs, are responsible for the whole range 
of physiological effects mediated by ET-1. Whereas the ETA is predominantly 
expressed in smooth muscle cells, and its stimulation causes a long-lasting 
vasoconstriction  [118], the mainly in endothelial cells expressed ETB’s activation 
results in a transient vasodilatation [119], including NO release upon stimulation [120]. 
Another difference between both receptor subtypes that comprises 63% homology in 
primary structure is their affinity to ET isopeptides. ETA possesses higher affinity for 
ET-1 than for ET-2 and ET-3, whereas ETB binds the three ET isoforms with similar 
affinity [121]. Besides controlling the vascular tone, the endothelin system is involved 
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in many other physiological processes such as neurotransmission, embryonic 
development, renal function, and regulation of cell proliferation. It thus plays an 
important role in physiopathological disorders like congestive heart failure, diabetes, 
arteriosclerosis or primary pulmonary hypertension [122-124]. 
In contrast to a wealth of information form in vivo approaches, the detailed in vitro 
characterization of functional and structural properties of ETB has not been feasible so 
far due to the restricted availability of protein samples. CF expression overcomes these 
limitations and further allows the fast and efficient preparation of ETB protein samples. 
Here the human ETB can be synthesized in a soluble form in micelles of selected 
detergents and besides small terminal peptide tags that facilitate detection and 
purification no large fusion proteins are needed for the stabilization of the receptor. 
Ligand binding studies and pull down assays demonstrate that the CF produced ETB 
protein is functionally folded. Electron microscopy and single particle analysis of 
negatively stained samples indicate a dimeric state. Construction of terminal deletions 
in combination with functional analysis revealed a relatively small region including 
TMS1 as absolutely essential for ligand binding as well as for oligomerization. Further, 
recorded solution NMR spectra of a truncated ETB construct containing TMS1-3 show 
reasonable spectral quality compared to the full-length receptor. The presented results 
demonstrate a new and highly efficient approach for the rapid production and functional 
characterization of GPCRs like ETB.  
 
6.2.  Results 
6.2.1. Preparative cell-free expression of various GPCRs 
Four different GPCRs have been analyzed for the high level CF expression. The human 
and porcine V2R and the human ETB, belonging to the first class of Rhodopsin like 
GPCRs (family Ab) and the rat corticotropin releasing factor receptor (CRF) that 
belongs to the second GPCR class, have been tested in the CF system. Using standard 
unmodified expression, no expression has been found at al. However, using the eleven 
amino acids containing T7-tag at the N-terminus, all four GPCRs could successfully be 
CF expressed as precipitates in amounts of 3 mg per mL of RM (Fig. 19). It could be 
shown that all GPCR precipitates dissolve in 1% LMPG and can be purified by Ni-
chelat chromatography (Fig. 19). 
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Fig. 19 SDS gel of cell-free expressed GPCRs. 
The human vasopressin receptor type 2 (V2R), the porcine V2R, the rat corticotropin 
releasing factor receptor (CRF) and the human endothelin B receptor (ETB) have been 
expressed in the cell-free system in the insoluble mode, resolubilized in 1% LMPG and 
purified by His-tag purification. 1 µl of the CF expressed precipitate (P), the resolubilized 
protein in LMPG (L) and the elution (E) from the Nickel-column was analyzed on a 12% 
SDS-gel. 
 
The CF expression results obtained for those GPCRs again reflect the great potential of 
this alternative method. It further demonstrates that besides bacterial transporters, 
complex eukaryotic IMPs can be synthesized in large amounts. Here the addition of the 
T7-tag at the N-terminus was proven to be highly beneficial for expression of the 
GPCRs. A nonoptimal initiation of translation in the E. coli system, caused by the 
eukaryotic codon sequences of the GPCR genes, might account for that observation.  
 
6.2.2. Expression and purification of ETB and various ETB truncations 
The CF reaction protocol was optimized in order to obtain the preparative scale 
expression of His tagged ETB (ETBcHx). Protease inhibitors were supplied in order to 
prevent ETBcHx degradation and the concentration of Mg
2+ and K
+ ion concentration 
was optimized in the range between 12-16 mM and 250-340 mM, respectively. 
Besides the full-length receptor a series of truncated ETB derivatives containing nested 
deletions have been designed (Table 7). For successful expression the construction of a 
translational fusion with the small 12 amino acid containing T7-tag at the N-terminus of 
ETB (Fig. 20) was crucial as essentially no expression of the non-fused full-length 
ETBΔT7 was detectable.  
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Table 7 Structural characteristics of CF produced ETB derivatives. 
 
                       Included domains
2                              C-terminus 
Fragment
1 Region  [kDa]  ND  T1 C1 T2 E1 T3 C2 T4 E2 T5 C3 T6 E3 T7 CDO  Tag_ 
ETB∆T7 M1-S443  50.7    x   x   x  x   x  x   x  x   x   x   x   x   x   x   x cH6 
ETBcHx  Q2-S443 52.5    x   x   x   x   x   x   x   x   x   x   x   x   x   x   x cHx 
ETBstrep E 27-S443  49.5   x    x   x   x   x   x   x   x   x   x   x   x   x   x   x strep 
ETB131 E 27-C131 14.4   x    x   /    -   -   -   -   -   -   -   -   -   -   -   - cHx 
ETB168 E 27-P168 18.5   x   x   x   x   /    -   -   -   -   -   -   -   -   -   - cHx 
ETB203 E 27-V203 22.2   x    x   x   x   x   x   /    -   -   -   -   -   -   -   - cHx 
ETB306 E 27-G306 34.1   x    x   x   x   x   x   x   x   x   x   /    -   -   -   - cHx 
ETB132 M 132-S443 38.6    -    -   /   x   x   x   x   x   x   x   x   x   x   x   x cHx 
ETB204 A 204-S443 30.8    -    -   -   -   -   -   /   x   x   x   x   x   x   x   x cHx 
ETB307 M 307-S443 18.8    -    -   -   -   -   -   -   -   -   -   /   x   x   x   x cHx 
ETB93 P 93-V203 15.3   /    x   x   x   x   x   /    -   -   -   -   -   -   -   -      cHx 
1, with exception of ETB∆T7, all proteins contain additionally a N-terminal T7-tag. 
2, ND, N-terminal domain; T1-7, transmembrane segment 1-7; C1-3, cytoplasmatic loop 1-3;  
  E1-3, extracellular loop 1-3; x, included; -, deleted; /, partially truncated. 
 
At optimized conditions, ETBcHx could be synthesized at yields of up to 3 mg per ml 
reaction mixture (RM). The calculated molecular weight (MW) of ETBcHx is 52 kDa but 
a prominent band of approx. 48 kDa was visible after separation of the RM by SDS-
PAGE (Fig. 21 A).  
ETBcHx was CF produced either as soluble protein in presence of detergents or as 
precipitate in the absence of detergents. In a previous screen comprising a variety of 24 
detergents most commonly used in membrane protein analysis, only digitonin and long 
chain Brij derivatives have been effective in the soluble expression of the porcine V2R 
[9]. I focused therefore primarily on these two detergent classes for the soluble 
expression of ETBcHx. The presence of 1 % Brij78 and 1.5 % Brij58 resulted in the 
complete solubilization of ETBcHx with final yields of approx. 3 mg soluble protein per 
ml RM. With the detergents Brij35 (0.1 %) and digitonin (0.4 %) only 500 μg and 100 
μg of soluble ETBcHx per ml RM was obtained, respectively, in addition to ETBcHx 
precipitate. The majority of the synthesized protein thus still precipitated after 
translation in presence of the two latter detergents. Soluble produced ETBcHx was 
purified in one step by Ni-chelate chromatography as described in the methods section. 
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after purification and buffer exchange. The purified ETBcHx could be homogenously 
reconstituted into proteoliposmes with E. coli lipid mixtures as evaluated by freeze 
fracture electron microscopy (Fig. 10 E). 
Besides the direct soluble CF expression mode, ETBcHx precipitate which has been CF 
produced in the absence of detergents could be completely solubilized in 1 % LMPG. 
The detergent DPC at a final concentration of 2 % was slightly less effective with 
solubilization of approx. 80 % of the precipitated ETBcHx. With the detergents Brij35 (1 
%), DDM (2 %), DM (2 %), Chaps (5 %) and DHPC (2 %) only 5-20 % of the ETBcHx 
precipitate could be solubilized. The detergents Thesit (1 %), Tween20 (1 %), Triton X-
100 (2 %) and digitonin (2 %) were completely ineffective for solubilization of the CF 
produced ETBcHx precipitate. 
In order to confine the ETB region essential for binding of the ligand ET-1 and for 
oligomerization, a series of eight plasmids encoding for truncated ETB fragments 
starting from either end and containing different secondary structural elements were 
constructed (Table 7, Fig. 20). All fragments could be overexpressed in amounts of at 
least 1 mg per ml RM in the individual CF system as soluble proteins in presence of 1% 
Brij78 (Fig. 21 B). The fragments were purified subsequently after expression in one 
step by Ni-chelate chromatography and the purity was evaluated by SDS-PAGE 
analysis (Fig. 21 B). In addition all ETB-fragments were successfully reconstituted into 
E. coli lipids (Fig. 21 C). 
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Fig. 20 Proposed secondary structure of ETB and overview of ETB truncations. 
Besides the GPCR-typical seven transmembrane topology, ETB is predicted to have a 
glycosylation site at asparagine 59 (orange), a disulfide bridge connecting the extracellular 
loops two and three and several palmitoylated cysteine residues in the C-terminal loop 
(yellow). For cell-free expression ETB was N-terminally supplemented with the 12 amino 
acid containing T7-tag (light blue) and c-terminally tagged by either a deca histidine tag 
(red) or a strepII-tag (blue). The last amino acid of C-terminal truncations (dark red) and 
start of N-terminal truncations (green) and the start of the ETB93a truncation (purple) is 
indicated. ETB truncated fragments all containing a N-terminal T7-tag and a C-terminal 
deca histidine tag are illustrated in black (B-I). A, ETB; B, ETB131; C, ETB168; D, ETB203; 
E, ETB306; F, ETB132; G, ETB93; H, ETB204; I, ETB307. 6    UNPUBLISHED RESULTS  75
 
Fig. 21 SDS gels of cell-free expressed ETB and ETB truncations on standard 16.5% SDS gels. 
A, Cell-free expression of ETB in presence of Brij58 (2), Brij78 (3-6) and as insoluble precipitate (7). 
M, marker; 1, reaction mixture before incubation; 2, soluble fraction of RM after ETBcHx expression 
in presence of Brij58; 3, soluble fraction of RM after ETBcHx expression in presence of Brij78; 4, 
Elution fraction of ETBcHx after His-tag purification; 5, soluble fraction of ETBstrep expression in 
presence of Brij78; 6, elution fraction of Strep-Tactin™ purification; 7, insoluble fraction of the RM 
in the insoluble mode; 8, resolubilized precipitate in 1% LMPG; 9, Elution fraction of resolubilized 
ETB in LMPG after His-purification. The overproduced and purified receptors are marked with 
arrows. B, Analysis of the cell-free expression of ETB fragments in presence of Brij78. 0.7 µl of the 
supernatant after 20 hrs reaction (S) and 2 µl of the elution fraction (E) after His-purification have 
been analyzed. The overproduced and purified ETB truncations are indicated by arrows. C, soluble 
expressed ETB fragments where reconstituted into proteoliposomes and 9 ml where analyzed on an 
SDS-gel. 1, ETB93a; 2, ETB131; 3, ETB168; 4, ETB203, 5, ETB306; 6, ETB132; 7, ETB204; 8, ETB307; 9, 
ETBcHx. 
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6.2.3. Functional analysis of full-length protein and ETB-truncations 
The affinity to its natural peptide ligand Endothelin-1 (ET-1) as one of the two main 
functions of a GPCR was analyzed by using different ET-1 ligands. Besides the non-
tagged circular wild type ET-1, circular ET-1 labeled with one Cy3-dye at lysine 9 
(cET-1), double biotinylated ET-1 (bET-1) at position cysteine 1 and lysine 9 and linear 
1,3,11,15 alanine ET-1, N-terminally labeled with fluorescein (fET-1A(1,3,11,15)), have 
been used (Fig. 22). 
 
 
Fig. 22 ETB-ligands overview. 
Illustration of used ETB ligands Endothelin-1 (ET-1), explaining the sites where 
labels are situated. The circular ET-1 was used Cy3 labeled and biotinylated, 
whereas the linear ET-1 was used in the fluorescein labeled form. 
 
6.2.3.1.  Fluorescent ligand coelution 
The ETBcHx protein can be CF produced at high levels in a variety of different 
conditions. However, the mode of CF expression, i.e. the expression as precipitate or as 
soluble protein, as well as the type of supplied detergent could have a significant impact 
on the folding of ETBcHx into a functional conformation. The affinity to its natural 
peptide ligand ET-1 was therefore analyzed with purified ETBcHx samples that have 
been produced under different conditions. Mixtures of the cET-1 with purified ETBcHx 
either CF produced as precipitate and solubilized in 1 % LMPG or directly produced as 
soluble protein in presence of 0.1% Triton X-100, 0.2% Brij35, 1.5 % Brij58, 1 % 
Brij78 or 0.4 % digitonin, respectively, were separated by gelfiltration and the elution 6    UNPUBLISHED RESULTS  77
fractions were analyzed by taking advantage of the different absorbencies of the two 
compounds (Fig. 23). The 52 kDa ETBcHx elutes at a retention volume of 1.6 ml 
whereas the 21-mer cET-1 will start to elute at a volume of 2.1 ml. Co-elution of cET-1 
with ETBcHx therefore indicates complex formation of the receptor with its ligand 
giving evidence of a native and active protein conformation. In contrast, addition of CF 
produced protein present in an unfolded or inactive conformation should result in the 
separation of the two compounds.  
 
 
Fig. 23 Activity correlation of ETB with the soluble CF expression in different detergents. 
ETB was CF expressed in presence of different detergents, purified by Ni-chelat chromatography 
and the binding of cET-1, after 3 hrs incubation at RT was analyzed on a Superose 6 PC 3.2/30 
column. The elution chromatograms show the total protein absorption at 280 nm (black solid line) 
and the ligand absorption of cET-1 at 550 nm (red dotted line) The retention volume of ETB and 
bound ligand is indicated by arrows. A, ETB was CF expressed as precipitate without the presence 
of detergents and resolubilized in 1% LMPG; B, ETB was soluble expressed in presence of 0.1% 
Triton X-100; C, ETB was soluble expressed in presence of 0.2 % Brij35; D, ETB was soluble 
expressed in presence of 1.5% Brij58; E, ETB was soluble expressed in presence of 0.4% Digitonin; 
F, ETB was soluble expressed in presence of 1% Brij78. (The gel-filtration analysis was done in 
collaboration with Ankita Srivastava). 
 
The ligand cET-1 was completely separated from ETBcHx samples that were CF 
produced as precipitate and solubilized in LMPG, indicating that despite solubilization, 
the receptor might not have adopted its native conformation (Fig. 23 A). In contrast, 
significant amounts of cET-1 co-eluted with ETBcHx synthesized in the soluble mode of 
CF expression in presence of the detergents digitonin, Brij58 and Brij78 whereas little 
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coelution was obtained in ETB soluble expressed in the presence of Triton X-100 and 
Brij35. The highest apparent binding of cET-1 was obtained with protein CF expressed 
in presence of Brij78 (Fig. 23 F). This expression condition was therefore chosen for 
further sample preparations of ETBcHx and its derivatives. 
The percentage of ligand binding receptor present in the purified ETBcHx sample 
obtained after soluble CF expression in presence of 1 % Brij78 was determined by 
correlation of the molar ratio of complexed cET-1 with the known amount of supplied 
ETBcHx. The amount of bound cET-1 in the gelfiltration elution profile was first 
estimated by standardizing the corresponding peak area with a calibration curve 
obtained from the peak areas of varying amounts of cET-1 subjected to gelfiltration at 
identical conditions. After subtracting non-specifically bound cET-1, the amount of 
ligand binding ETBcHx present in samples was estimated with the described conditions 
at approx. 50 %.  
In order to confine the ETB region essential for ligand binding, all eight ETB 
truncations were tested for their ligand binding ability. Ligand binding activity was 
assessed by analyzing co-elution profiles of ETB truncations mixed with the linear 
fluorescein labeled ligand fET-1A(1,3,11,15) (Fig. 24). The fET-1A(1,3,11,15) derivative has a 
co-elution profile with full-length ETBcHx (Fig. 24 A)comparable to that with cET-1 
(Fig 23 A). All truncated ETB fragments containing at least TMS1 like ETB131 (N-
terminal domain (ND)-TMS1) showed ligand binding activity. Interestingly, also 
fragment ETB93a (TMS1-TMS3) that is deleted for almost the complete ND still is able 
to bind fET-1A(1,3,11,15). However, co-elution with fET-1A(1,3,11,15) was largely reduced 
with truncations deleted of TMS1 like the 39 kDa ETB132 covering the ETB regions 
from TMS2 to C-terminal domain (CDO) (Fig. 24 D).  
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Fig. 24 Gelfiltration co-elution chromatograms of ETB and ETB fragments with fET-1A(1,3,11,15). 
ETBcHx and ETB fragments were CF expressed in the presence of Brij78, purified by Ni-chelat 
chromatography and incubated with fET-1A(1,3,11,15) for 3 hrs at 21°C and subsequently analyzed on 
a Superose 12 PC 3.2/30 (A) or Superose 6 PC 3.2/30 (B-E) column. The elution chromatograms show 
the total protein absorption at 280 nm (black solid line) and the ligand absorption of of linear-
fluorescein-ET-1 at 495 nm (green dotted line). The retention volume of ETB and bound ligand is 
indicated by arrows. A, ETBcHx analyzed on a Superose 12 PC 3.2/30 column; B, ETB93a fragment; C, 
ETB131 fragment; D, ETB132 fragment; E, ETB168 fragment. (The gel-filtration analysis was done in 
collaboration with Ankita Srivastava). 
 
 
6.2.3.2.  Biotinylated ligand binding 
The ligand binding of ETBcHx and truncated derivatives was further characterized by 
pull-down assays of purified proteins with the immobilized bET-1 ligand as described 
in the methods section. Fractions containing complexes of bET-1 with ETB derivatives 
were separated by SDS-PAGE, blotted and the proteins were identified by 
immunodetection with the anti-T7-tag antibody (Fig. 25). In agreement with the results 
presented above, only fragments containing TMS1 like full-length ETBcHx, ETB131 
(ND-TMS1), ETB168 (ND-TMS2), ETB203 (ND-TMS3) and also again the ND deleted 
fragment ETB93 (TMS1-TMS3) were detected in the eluted fractions and complexed 
with bET-1. Accordingly, proteins devoid of TMS1 like ETB132 (TMS2-CDO) and 
ETB204 (TMS4-CDO) did not interact with bET-1. 
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Fig. 25 Western blot of biotinylated ET-1 binding. 
Elution fraction of pull-down experiments with bET-1 
and ETB truncations analyzed by western blot using a 
HRP-coupled T7-tag antibody. Different ETB truncations 
are used as mentioned. Eluted ETB fragments are 
indicated by arrows for monomer (green), dimer (blue) 
and no elution (red); M, marker. 
 
6.2.3.3.  Analysis of ETBcHx-ligand interaction by SPR 
Total internal reflection of light at a surface-solution interface produces an 
electromagnetic field, or evanescent wave, that extends a short distance (~100-200 nm) 
into the solution. This so called evanescent-wave phenomenon occurs at certain metallic 
surfaces and describes surface plasmon resonance (SPR). SPR allows the detection of 
changes in the refractive index in the immediate vicinity of the surface layer of a sensor 
chip and it is observed as a sharp shadow in the reflected light from the surface at an 
angle that is dependent on the mass of material at the surface. In case biomolecules like 
ETB bind to the surface or to its ligand immobilized on the surface, the mass on the 
surface layer changes. This change in resonant angle can be monitored non-invasively 
in real time as a plot of resonance signal (proportional to mass change) versus time 
[125]. The recorded diagram further allows the determination of kassociation (ka) and 
kdissociation (kd) and further the rate constant (KD = 1/KA = kd/ka). Thus SPR allows the 
sensitive detection of molecular interactions in real time without labels. Biacore 
instruments (Biacore, Uppsala, Sweden) uses SPR for determining binding constants of 
interaction partners. The principle of biacore measurements is illustrated in Fig. 26. 
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Fig. 26 Principle of biacore measurements. 
A, Flow cell containing two cells for on-line referencing, allowing direct background subtraction for 
accurate kinetic analyses; B, zoom into sensor surface designed for immobilization of interacting 
partners via a streptavidin capture molecule; C, as molecules are immobilized on a sensor surface, the 
refractive index at the interface changes, altering the angle at which reduced intensity polarized light is 
reflected from the supporting glass plane. The change in angle caused by association or dissociation of 
molecules from the sensor surface is proportional to the mass of bound material and is recorded in a 
sensogram; D, the sensogram provides real-time information about an entire interaction, with binding 
responses measured in resonance units (RU). (Modified after Biacore technology note 23 from 
http://www.biacore.com).  
 
Although the co-elution approach gives good evidence for a ligand binding activity of 
CF produced ETB samples, it is primarily not a quantitative assay. Here SPR was used 
to detect and quantify the molecular interactions of ETBcHx and the ETB truncations 
ETB131 (ND-TMS1) and ETB93a (TMS1-3) in real time. Therefore, the biotinylated 
ligand bET-1 was immobilized on the surface of the biosensor chip and the direct 
binding of functionally active ETBcHx has been analyzed. ETBcHx solutions with 
increasing concentrations from 10 nM to 250 nM were loaded on the bET-1 chip and 
binding kinetics were evaluated using the BIAevaluation software. The binding constant 
KD of ETBcHx to bET-1 was determined at 6.2 ± 1.7 x 10
-9 (Fig. 27, Table 8). Similar 
assays with the C-terminal truncated derivatives ETB131 and ETB93a revealed KD values 
of 2.7 ± 1.9 x 10
-8 and 1.7 ± 0.5 x 10
-8, respectively.  
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Fig. 27 Biacore data of ETB, ETB131 and 
ETB93a. 
SRP response curves for the bET-
1/ETBcHx, /ETB131 and /ETB93a interaction 
using immobilized bET-1. 400 to 500 RU 
of bET-1 have been loaded on Biacore 
Sensor Chips SA and analyzed in a buffer 
containing 20 mM HEPES-NaOH (pH 
7.4), 500 mM NaCl and 0.1% Brij78. The 
measurements were performed at 25°C and 
the response obtained for the blank Sensor 
Chip SA reference flow cell was 
subtracted from the curves, revealing 
negligible non-specific binding to the 
control peptide surface. A, ETBcHx has 
been titrated between 10 and 250 nM; B, 
ETB131 has been analyzed between 200 
and 1600 nM; C, ETB93a has been titrated 
between 10 and 200 nM. 
 
 
 
Table 8 SPR binding constants of ETB, ETB131 and ETB93a and circular bET-1. 
 
construct k a [1/Ms]  kd [1/s]  KA [1/M]  KD [M] 
 
ETBcHx 2.3E+05 ± 1.7E+05  1.2E-03 ± 0.6E-03  1.7E+08 ± 0.4E+08  6.2E-09 ± 1.7E-09 
ETB131  1.1E+05 ± 1.9E+05  1.4E-03 ± 1.6E-03  5.4E+07 ± 3.3E+07  2.7E-08 ± 1.9E-08 
ETB93a  3.6E+04 ± 1.3E+04  5.7E-04 ± 0.2E-04  6.3E+07 ± 2.1E+07  1.7E-08 ± 0.5E-08 6    UNPUBLISHED RESULTS  83
6.2.3.4.  Analysis of ETBcHx-ligand interaction by TIRFS  
Like SPR, total internal reflection fluorescence spectroscopy (TIRFS) enables the 
determination of ka and kd rates and thus the dissociation constant KD. In this study, 
ETBcHx was immobilized after CF expression in Brij78 and purification on Tris-NTA 
Chips loaded with Nickel Ions as described by Lata and co-workers [126] and analyzed 
on a custom made TIRFS-reflectance interferometry (RIf) combined set-up [127]. The 
linear fluorescent labeled ligand fET-1A(1,3,11,15), once bound to immobilized ETBcHx at 
the surface will be excited by the evanescent illumination, whereas other fET-1A(1,3,11,15) 
in solution will remain dark (Fig. 28). Thus ka and kd of fET-1A(1,3,11,15) to ETBcHx can be 
determined. 
 
 
Fig. 28 Principle of total internal reflection fluorescence spectroscopy (TIRFS). 
The fluorescence labeled ligand, bound to the receptor immobilized by NiNTA on 
the chip is excited by a laser beam and the TIRFS and RIf signal is measured. 
 
fET-1A(1,3,11,15) concentrations between 0.25 and 2 µM have been titrated before and 
after loading the surface with ETBcHx. Whereas the RIf signal indicates the 
immobilization of ETBcHx to the Ni-NTA surface, the TIRFS signal illustrates the 
amount of excited fET-1A(1,3,11,15) bound to the receptor (Fig. 29). Little background 
fluorescence is observed that has to be subtracted form the TIRFS signal after 
immobilizing ETBcHx prior analysis. The binding constant KD of fET-1A(1,3,11,15)  to 
ETBcHx was determined at 2.9 ± 2.0 x 10
-8 M (Table 9) by using the BIAevaluation 
software. 
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Fig. 29 TIRFS spectrum of ETBcHx immobilized on Ni-NTA chip titrated with fET-1A(1,3,11,15). 
Concentrations of fET-1A(1,3,11,15) of 0.25 to 2 µM have been titrated to an empty chip as negative 
control first, subsequently ETBcHx was loaded to 1.5 RU and titrated with the same concentrations 
of linear fluorescein-ET-1. The chromatogram show the RIf signal (red) and the TIRFS signal in 
blue. The length of fET-1A(1,3,11,15) and ETBcHx injections are indicated by black bars. 
 
 
 
Table 9 TIRFS binding constants for ETBcHx and fET-1A(1,3,11,15). 
 
construct k a [1/Ms]  kd [1/s]  KA [1/M]  KD [M] 
 
ETBcHx 2.5E+05 ± 0.1E+05  6.1E-03 ± 2.7E-03  4.9E+07 ± 0.2E+07  2.9E-08 ± 2.0E-08 
 
 
 
 
 
 
 
 6    UNPUBLISHED RESULTS  85
6.2.4. Analysis of the oligomerization state 
6.2.4.1.  Pull down experiment with full-length protein and truncated constructs 
Several GPCRs are known to form dimers that remain stable even after SDS-PAGE 
analysis. ETB is known to form homodimers in the membrane environment, as 
determined by fluorescence resonance energy transfer analysis [30]. Protein bands with 
MWs corresponding to dimers or even higher oligomers of full-length ETBcHx and of 
most of the truncated derivatives are visible after separation of purified protein samples 
by SDS-PAGE (Fig. 21 B, C).  
However, nothing is known about the regions where ETB oligomerization takes place. 
In order to identify structural elements responsible for ETB oligomerization, 
heterodimer formation between full-length ETBStrep and the various truncated ETB 
fragments was analyzed in two different pull down assays. At first, purified ETB 
fragments and full-length ETBStrep were incubated at equimolar concentrations and then 
loaded on Strep-Tactin® columns. In a second assay, the full-length ETBStrep receptor 
was co-expressed with the various truncated fragments in CF reactions and the RMs 
were then loaded on Strep-Tactin® columns. In both assays, the interacting protein 
fragments were identified after washing, elution and SDS-PAGE separation by 
immunoblotting with the anti-T7-tag antibody (Fig. 30).  
In the co-expression assays, the synthesis of full-length ETBStrep and that of the 
corresponding ETB fragment was always visible by immunoblotting (Fig. 30 A). After 
loading of the RMs on Strep-Tactin® columns the fragments ETB93 (TMS1-TMS3), 
ETB131 (ND-TMS1), ETB168 (ND-TMS2), ETB203 (ND-TMS3) and ETB306 (ND-
TMS5) were co-eluted together with ETBStrep indicating an interaction of the proteins. 
However, fragment ETB132 (TMS2-CDO) lacking the TMS1 region was not detectable 
in the eluted fraction and therefore seems not to interact with ETBStrep. Upon interaction 
of the purified proteins, again the fragments ETB131 (ND-TMS1), ETB168 (ND-TMS2), 
ETB203 (ND-TMS3) and ETB306 (ND-TMS5) were identified to interact with ETBStrep, 
while fragments lacking TMS1 like ETB132 (TMS2-CDO) and ETB204 (TMS4-CDO) 
could not be co-eluted with full-length ETB and were localized only in the flow-through 
of the Strep-Tactin® column (Fig. 30 B).  
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Fig. 30 Dimerization analysis of ETB fragments with ETBstrep. 
ETBstep and ETB fragments containing a deca Histidine tag have been analyzed by pull-down 
experiments on Strep-Tactin® spin columns. A, ETBstrep and different fragments have been 
coexpressed in presence of Brij78 and the soluble part (S) before pull-down and after elution (E) 
from the Strep-Tactin® spin columns was analyzed by western blot against T7-tag. ETB fragment 
monomers are indicated by green arrows in case of pull-down or red arrows if not, ETBstrep by a 
purple dotted arrow and hetero-oligomers by dark blue arrows. M, marker; B, ETB fragments have 
been purified separately and incubated in equal amounts with purified ETBstrep construct. Flow-
through (F) or elution of Strep-Tactin® spin columns are analyzed by western blot against T7-tag. 
M, marker; 1, elution of ETB131; 2, elution of ETB168; 3, elution of ETB203; 4, elution of ETB306; 5, 
flow-through of ETB132; 6, elution of ETB132; 7, flow-through of ETB204; 8, elution of ETB204. 
Monomer fragments are indicated by green arrows in case of pull-down or red if not, hetero-
dimers by dark blue arrows and ETBstrep by a purple dotted arrow. 
 
6.2.4.2.  Single particle analysis of ETB 
Besides validating the formation of ETB dimers in detergent micelles, the quality of CF 
expressed and purified ETBcHx was analyzed by negative stain electron microscopy. In 
agreement with the observed inability to bind the ligand cET-1, ETBcHx produced as 
precipitate and solubilized in LMPG was found to be mostly aggregated and is therefore 6    UNPUBLISHED RESULTS  87
probably present in an non-native instable state (Fig. 31 A). In contrast, ETBcHx protein 
that was CF synthesized in presence of the detergent Brij78 revealed mono-disperse 
particles displaying no detectable signs for aggregation (Fig. 31 B). ETBcHx synthesized 
at these conditions appears to be predominantly dimeric and the good quality of the 
sample allowed further structural assessment using single particle analysis. 500 side 
views were reference-free aligned, classified and averaged within the classes (Fig. 31 
B). ETBcHx side view averages display a pair of rods with a length of 63 – 68 Å. The 
distance between the centers of the rods corresponds to 35 – 38 Å and the rods are 
closely associated at one end - potentially at TMS1. These values are in excellent 
agreement with the dimensions observed for the rhodopsin dimer [128, 129]. Single 
rods presumably representing ETBcHx monomers are also present but they represent less 
than 10 % of all particles. 
 
 
Fig. 31 Single particle analysis of ETB. 
Electron-micrograph of negatively stained ETBcHx construct purified by Nickel-chelate chromatography. 
A, ETBcHx was CF expressed as precipitate and resolubilized in 1% LMPG. B, ETBcHx was CF expressed 
in presence of Brij78. Here, ETBcHx particles appear to be predominantly dimeric (black arrow); ETBcHx 
monomers can be seen occasionally (white big arrow). The scale bar corresponds to 40 nm for A and B. 
Side view class averages of reference-free aligned ETB dimers are displayed in the gallery on the right. 
The scale bar corresponds to 3 nm and is valid for all averages. Regions where ETBcHx dimerization takes 
place is indicated by small white arrows in side view class averages. (The single particle analysis was 
done in cooperation with Nora Eifler). 
 
6.2.5.  Solution NMR spectra of isotopically labeled ETB and its truncations 
NMR samples are usually first analyzed by [
15N,
1H]-TROSY-HSQC measurements, 
providing a first impression of the sample behavior, displayed by the chemical shift 
distribution of the amide backbone resonances. However, GPCRs have so far almost 
been excluded from NMR analysis due to extreme difficulties in preparation of 
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isotopically labeled samples and the requirement for detergent solutions. The individual 
CF expression system overcome expression and labeling limitations and the use of 
LMPG micelles provides relatively good solution NMR spectra, considering the size of 
protein plus surrounding detergent micelle [23]. ETBcHx and the C-terminal truncations 
of ETB have been uniformly isotopically labeled with 
15N by CF expression in the 
insoluble mode. ETBcHx, containing 467 amino acids surrounded by LMPG micelles, 
seems way too large for solution NMR analysis (Fig 32 F). Interestingly, ETB131 (ND-
TMS1) and ETB93a (TMS1-3) provide reasonable good spectral quality (Fig. 32 A + B), 
promising for further investigations by solution NMR.  
 
 
Fig. 32 [
15N-
1H]-TROSY-HSQC spectra of U-
15N labeled ETBcHx and ETB truncations. 
The proteins have been U-
15N labeled by CF expression in the insoluble mode and the precipitate 
was solubilized in 25 mM potassium phosphate buffer (pH 6.0), 2% TCEP, 1 % LMPG and 
concentrated 6 times for NMR analysis. A, 0.5 mM ETB93 purified by His-tag purification; B, 0.3 
mM ETB131; C, 0.5 mM ETB168; D, ETB203; E, ETB306; F, ETBcHx. The spectra where recorded on 
an Avance 900 MHz spectrometer (A, C-F) or on an drx 800 MHz spectrometer (B) both equipped 
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6.3.  Discussion and conclusions 
Structural as well as functional evaluation of GPCRs requires milligram quantities of 
purified and functional protein. GPCRs are typically expressed at very low levels in 
vivo and cell-based functional assays by using fluorescently labeled or radiolabeled 
ligands are difficult to interpret due to the presence of an undefined variety of other 
cellular components. Overexpression and native purification of GPCRs as a prerequisite 
for in vitro studies would therefore be essential for the understanding of their functional 
and structural properties. The high-level production of GPCRs in conventional in vivo 
systems like E. coli or Pichia pastoris cells is despite numerous efforts still very 
difficult. Expression of aggregated inclusion bodies or the construction of large fusion 
proteins are common strategies [130]. In addition, a variety of critical steps like kinetics 
of membrane insertion, saturation of the biosynthetic translocation machinery, control 
of proteolysis, growth conditions and solubilization out of the membrane deserve 
intensive optimizations.  
I have established a fast and efficient protocol for the high level production of 
functionally folded human ETB that eliminates most critical steps of conventional 
expression systems as membranes are no longer involved. Furthermore, instability of 
synthesized membrane proteins due to proteolysis can easily be avoided by addition of 
protease inhibitors. N-terminal digestion of ETB that is frequently observed upon in 
vivo expression [131] was not detectable by CF expression. Terminal truncated 
derivatives of ETB that are often very difficult to express in vivo due to proteolysis or 
translocation problems [37] can be produced at high levels in the CF system. As a 
unique advantage of CF expression systems, the proteins can be directly inserted into 
detergent micelles upon translation. The solubilization efficiency in case of ETB was 
nearly 100 % as no residual precipitate was detectable and expression levels were 
similar to those obtained in absence of detergent. The protocol is most straightforward 
and purified ETB protein sufficient for structural analysis can now be obtained in less 
than two days. It should also be highlighted that the production of labeled membrane 
proteins, even with complicated label combinations, is easily feasible by CF expression 
without the need for extensive optimization screens and without any loss of productivity 
[18, 19, 101]. Thus ETBcHx and its C-terminal truncations were successfully labeled 
with 
15N isotopes and NMR sample preparation was performed within 24 hours. 
As observed upon the production of the porcine vasopressin type 2 receptor [9], only the 
steroid detergent digitonin and several long chain polyoxyethylene derivatives like 
Bri35, Brij58 and Brij78 were suitable for the CF synthesis of soluble ETB in milligram 
amounts. However, the production of functionally folded receptor can vary dramatically 
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with the type of supplied detergent and the highest apparent ET-1 binding was obtained 
with Brij78 with some lower activity in digitonin and some other Brij derivatives. 
Accordingly, only digitonin was found to be suitable to isolate fully active ligand free 
ETB out of cell membranes [37]. It is known that the binding activity and structural 
integrity of GPCRs can be sensitive to the supplied detergents during solubilization 
[132]. Also the functional folding of other membrane proteins like the nucleoside 
transporter Tsx was found to require the presence of specific detergents during CF 
expression [9]. CF produced precipitates of Tsx as well as of ETB did not adopt a 
functional conformation upon solubilization after expression. Expression in the soluble 
mode and the initial screen for suitable detergents allowing the functional folding of the 
target proteins are therefore most important for the CF production of functionally folded 
membrane proteins. ETB is known to become posttranslationally modified by 
palmitoylation, phosphorylation and glycosylation. However, these modifications do not 
play a role in the ligand binding capacities of ETB [133] and they are most likely absent 
in CF produced ETB resulting in more homogenous sample preparations which might 
be even better suitable for crystallization studies. 
SPR studies of GPCRs are generally difficult due to the intrinsic properties of these 
proteins. Hydrophobic environments are necessary and the SPR sensitivity level 
requires high receptor concentrations on the biosensor surface in order to detect the 
binding of low molecular weight ligands. Therefore, only few SPR measurements with 
GPCRs have been successful so far [132, 134], but these reports already demonstrate 
that ligands can bind solubilized GPCRs even in lipid-free environments and without 
the need for membrane reconstitution. Most recently, a modified assay by using the 
detergent solubilized neurotensin receptor (NTR) as the analyte has been described 
[135] and I could successfully apply this approach to the characterization of ETB. 
Interestingly, for both GPCRs the amplitude of the observed response is lower than 
might be expected if the relatively high mass of the receptor used as analyte is 
considered. Ligand occlusion by immobilization on the sensor chip surface as well as 
limited access to the ligand binding site of the receptor due to the presence of detergent 
molecules might account for this effect. While some potential for the optimization of 
this technique, e.g. by systematic evaluation of sensor chip surfaces or of linker 
structures, still might remain, the nice correlation of the presented study with the 
published results obtained with NTR indicate that the SPR system could be utilized for 
the optimization of GPCR expression conditions, for the localization of ligand binding 
sites and for the identification of compounds with new properties important for the 
pharmaceutical industry. TIRFS has so far not been reported for investigating GPCRs. 
Here the immobilization of ETB on Ni-NTA chips allowed the determination of the 
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observed while association of fET-1A(1,3,11,15)  to ETBcHx, probably due to detergent 
effects, the spectra could successfully interpreted for determining the binding constant, 
that is about 5 times lower than obtained with SPR. This is in great agreement with the 
literature. Independent groups found exactly a five fold difference in ETB ligand 
binding by comparing the dissociation constants of wild type circular ET-1 to the linear 
ET-1A(1,3,11,15) derivative [136, 137]. 
Human ETB forms a very tight complex with its ligand ET-1 that remains stable even in 
2 % SDS [138]. ET-1 binds with high affinity to purified ETB in Brij78 micelles which 
is indicated by the determined kD of 6 nM for bET-1 as well as 29 nM for fET-
1A(1,3,11,15). Nevertheless, dissociation constants between 40 – 50 pM of ligand/ETB 
complexes in various cell environments have been reported [139, 140]. It is known that 
the ligand binding kinetics of ETB in intact cells is already different from that in the 
corresponding membrane preparations [141]. In this work, I first determined the 
dissociation constant of ETB in the environment of detergent micelles and it is also the 
first analysis of ETB by SPR and TIRFS measurements. The different assay conditions 
in addition to the use of a modified biotinylated ET-1 or fluorescein labeled linear ET-1 
derivative as a ligand most likely have therefore resulted in the modified binding 
kinetics. 
The direct in vitro analysis of purified N- and C-terminally truncated ETB derivatives 
confined the ET-1 binding site to a 39 amino acid area between P93 in the N-terminal 
domain (ND) and C131 in the first cytoplasmic loop C1. A previous estimation of the 
ETB ligand binding site with radiolabeled ET-1 followed by chemical crosslinking and 
trypsin-digest analysis defined the ET-1 binding domain between residues I85 in ND and 
Y200 in the second cytoplasmic loop C2 [142]. The observed data is therefore in 
agreement with these findings and I further show that primarily TMS1 alone is the 
central determinant for ET-1 binding. In addition, deletions, mutations and the lack of 
glycosylation in ND did not impair ET-1 binding to ETB [37]. It is thus interesting to 
note that rather the presumably membrane embedded TMS1 than the relatively large 
extracellular domain ND is necessary for ET-1 binding. Based on further indirect 
analysis by using chimeric ETB derivatives and binding of antagonists, Wada and 
coworkers proposed a 60 amino acid area spanning I138 to I197 and thus covering TMS2 
and TMS3 as ET-1 binding site. This result might have been caused by side effects of 
the crosslink approach, different binding sites of the supplied antagonists or by 
conformational changes of the chimeric ETB derivatives. I could clearly show that ETB 
truncations devoid of TMS1 but still retaining TMS2 and TMS3 are not able to bind 
ET-1 in detectable amounts. Nevertheless, the affinity of ETB93 and ETB131 to ET-1 
was reduced approx. one order of magnitude, indicating that other regions of ETB still 
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might contribute to the ligand binding. Evidence for several and partially overlapping 
binding sites of ETB for different ligands has been documented [143]. 
Homooligomerization of rhodopsin–like GPCRs is observed with increasing frequency 
in recent times and it might represent an important platform for the modulation of 
GPCR activities like ligand binding, signaling or trafficking properties [128, 144-146]. 
Even SDS-resistant dimerization of ß2-adrenergic receptor and V2 vasopressin receptor 
has been reported [146] and SDS resistant dimers of the CF produced porcine 
vasopressin type 2 receptor could also be detected [9]. The ETB dimer bands observed 
during SDS PAGE analysis indicate a similar stable association also of this GPCR type. 
First evidence of homodimer formation of ETB and also its homologue ETA in vivo 
was recently obtained by fluorescence resonance energy transfer analysis in HEK293 
cells [30]. Interestingly, ETB dimer formation in vivo did not depend on the presence of 
the ligand ET-1. This is in accordance with the observed oligomerization of CF 
produced ETB in absence of any ligand. The ETB dimer formation is furthermore 
strongly supported by single particle analysis and the bi-lobed structures are almost 
identical to that of rhodopsin [128]. By analyzing CF produced truncated ETB 
fragments, I could confine the site essential for dimer formation to a 39 amino acid 
region from P93 to C131 and covering TMS1 and part of the adjacent loops. The two 
fragments ETB131 and ETB93 overlapping in that region did still form homodimers as 
well as heterodimers with full-length ETB. These results therefore indicate that TMS1 is 
a key area for two main functions of ETB, the binding of ET-1 as one of the main 
natural peptide ligands and for providing the interface for ETB dimerization. This close 
co-localization might raise speculations whether dimer formation could modulate the 
ligand binding of ETB. 
In summary, the presented work might provide a new alternative approach for the 
functional and structural characterization of ETB and similar GPCRs. Furthermore, the 
identified ETB131 and ETB93 fragments retaining ligand binding activity and 
dimerization properties are even small enough for structural studies by high-resolution 
NMR analysis. 
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6.4.  Material and methods 
6.4.1. Cell-free expression 
Proteins were produced in the CECF system based essentially on the previously 
described protocol [9, 11]. CF extracts were prepared from E. coli strain A19. 
Analytical scale reactions for the optimization of reaction conditions were performed in 
Microdialysers® (Spectrum Laboratories, Rancho Dominguez, USA) with a molecular 
weight cut-off (MWCO) of 25 kDa in a RM volume of 70 μl with a RM : feeding 
mixture (FM) ratio of 1 : 14. Preparative scale reactions were carried out in 
Dispodialysers® (Spectrum Laboratories, Rancho Dominguez, USA) in a RM volume 
of 1 ml with a RM : FM ratio of 1 : 17. Dispodialysers were placed in suitable plastic 
tubes holding the FM and incubated overnight for approx. 20 h. with gentle shaking at 
30
oC. The reaction was optimized for the concentrations of the ions Mg
2+ (15 mM) and 
K
+ (290 mM). DTT was replaced by 2 mM Tris(2-carboxyethyl)phosphine 
hydrochloride (Pierce, Rockford, USA). For soluble expression, detergent was supplied 
during the reaction at the following final concentrations: TX-100 (0.1%), Brij-35 (0.1 
%), Brij-58 (1.5 %), Brij-78 (1 %), digitonin (0.4 %).  
 
6.4.2. Cloning procedures and protein analysis 
Coding regions of full-length ETB and of truncated derivatives were amplified from 
cDNA by standard polymerase chain reaction (PCR) techniques using VentDNA-
polymerase (NewEnglandBiolabs, Frankfurt, Germany). Purified PCR fragments were 
cleaved with the restriction enzymes XhoI and either BamHI or NdeI and inserted into 
the corresponding cloning sites of the expression vector pET21a(+) (Merck Biosciences, 
Darmstadt, Germany). Suitable restriction sites were added to the DNA fragments by 
PCR with suitable oligonucleotide primers (Table 10). Additional codons for an 
extended poly(His)10 tag or for the StrepII-tag were inserted by the Quickchange 
procedure (Stratagene, La Jolla, USA). Plasmid DNA used as templates for CF 
expression were isolated by using commercial kits (Qiagen, Hilden, Germany).  
For SDS-gel analysis, protein samples supplemented with SDS sample buffer were 
loaded on 12 % or 16.5 % (w/v) Tris/glycine/SDS gels and stained with coomassie blue. 
For western blot analysis, the gels were blotted on a 0.45 µm Immobilon-P 
poly(vinylidene difluoride) membrane (Millipore, Eschborn, Germany) in a Hoefer 
TE22 (GE Healthcare, Freiburg, Germany) wet western blot apparatus for 1 h at 400 
mA. The membrane was then blocked for 1 h in blocking-buffer containing 1 x Tris 
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buffered saline, 7 % skim milk powder (Fluka, Bucks, Switzerland), 0.1 % (w/v) Triton 
X-100. The horseradish peroxidase-conjugated T7-tag antibody (Merck Biosciences, 
Darmstadt, Germany) were used at a dilution of 1 : 5000 and incubated for 1 h with the 
membrane. After extensive washing, the blots were analyzed by chemiluminescence in 
a Lumi-imager F1™ (Roche Diagnostics, Penzberg, Germany). Protein concentrations 
were routinely determined by the BCA assay (Sigma, Taufkirchen, Germany). 
 
Table 10 Oligonucleotide primers for the construction of ETB derivatives
1. 
 
Construct Primer 
pET21cHx ETBh10_up   CTC GAG CAC CAC CAC CAC CAC CAC CAT CAT CAT CAT TGA GAT CCG GCT 
  ETBh10_low   AGC CGG ATC TCA ATG ATG ATG ATG GTG GTG GTG GTG GTG GTG CTC GAG 
 
ETB∆T7  ETB-up  CGG CATATG CAG CCG CCT CCA AGT CTG TGC GGA CGC 
  ETB-low CGG  CTC GAG AGA TGA GCT GTA TTT ATT ACT GGA ACG 
 
ETBcHx  ETB_upB  CGG GGA TCC CAG CCG CCT CCA AGT CTG TGC GGA CGC 
 ETB_low CGG  CTC GAG AGA TGA GCT GTA TTT ATT ACT GGA ACG 
 
ETBstrep  ETB1-bam_up CGG  GGA TCC GAG GAG AGA GGC TTC CCG CCT GAC AGG 
  ETBstrep_low1  CTG CGG GTG GCT CCA CCA TGG AGA TGA GCT GTA TTT ATT ACT GGA 
 ETBstrep_low2  GGC  CTC GAG TTA TTT TTC GAA CTG CGG GTG GCT CCA CCA TGG 
 
ETB131  ETB1-bam_up CGG  GGA TCC GAG GAG AGA GGC TTC CCG CCT GAC AGG 
 ETB131_low  CGG  CTC GAG GCA CTT GTT CTT GTA GAT AAT TCT CAG AAG 
 
ETB168  ETB1-bam_up CGG  GGA TCC GAG GAG AGA GGC TTC CCG CCT GAC AGG 
 ETB168_low  CGG CTC GAG TGG CCA GTC CTC TGC CAG CAG CTT GTA GAC 
 
ETB203  ETB1-bam_up CGG  GGA TCC GAG GAG AGA GGC TTC CCG CCT GAC AGG 
 ETBn3Txho_low    CGG  CTC GAG AGC TCG ATA TCT GTC AAT ACT CAG AGC 
 
ETB306 ETB1-bam_up  CGG  GGA TCC GAG GAG AGA GGC TTC CCG CCT GAC AGG 
 ETB1-xho_low    CGG  CTC GAG GCC ACT TTT CTT TCT CAA CAT TTC ACA 
 
ETB132  ETB132_up   CGG GGA TCC ATG CGA AAC GGT CCC AAT ATC TTG ATC 
 ETB_low   CGG  CTC GAG AGA TGA GCT GTA TTT ATT ACT GGA ACG 
 
ETB204  ETBc4Tbam_up   CGG GGA TCC GTT GCT TCT TGG AGT AGA ATT AAA GGA ATT 
 ETB_low   CGG  CTC GAG AGA TGA GCT GTA TTT ATT ACT GGA ACG 
 
ETB307  ETB2-bam_up   CGG GGA TCC ATG CAG ATT GCT TTA AAT GAT CAC CTA AAG 
 ETB_low   CGG  CTC GAG AGA TGA GCT GTA TTT ATT ACT GGA ACG 
 
ETB93  ETB93_up   CGG GGA TCC CCC ATC GAG ATC AAG GAG ACT TTC AAA 
 ETBn3Txho_low    CGG  CTC GAG AGC TCG ATA TCT GTC AAT ACT CAG AGC  
 
1, restriction linkers are in bold, inserted sequences encoding for tags are underlined. 
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6.4.3. Protein purification, solubilization and reconstitution 
After CF expression, precipitated material was separated from the RM by centrifugation 
at 20000 x g for 10 min. After expression in the soluble mode in presence of detergent, 
the RM was diluted 1:10 in 20 mM Tris, pH 8.0, 500 mM NaCl in order to reduce the 
detergent concentration from 1 % to 0.1 % in case of Brij78 and to ensure a better 
binding to the column in the subsequent purification step. The diluted RMs were then 
applied on 1 ml HistrapHP columns (GE Healthcare, Freiburg, Germany) equilibrated in 
20 mM Tris, pH 8.0, 500 mM NaCl, 0.1 % Brij78. Chromatography was performed 
with 1 ml/min flow-rate with washing steps of 6 column volumes of column buffer 
supplemented with 10 mM, 20 mM and 50 mM imidazol, respectively. The bound 
protein was finally eluted with 375 mM imidazol in column buffer and 0.5 ml fractions 
were collected. For buffer exchange, protein containing fractions of 0.5 ml were applied 
on 5 ml desalting columns (GE-Healthcare, Freiburg, Germany) equilibrated with 
suitable buffer at a flow-rate of 3 ml/min. StrepII-tagged full-length ETB was purified 
by Strep-Tactin® Spin columns (IBA GmbH, Göttingen, Germany) according to 
manufacturers recommendations. 1 ml RM was diluted 1 : 15 in 20 mM Tris-HCl, pH 
8.0, 150 mM NaCl and divided onto equilibrated 6 columns and supplemented with 
0.05 % Brij78. ETB and all its derivatives were further analyzed without removal of the 
small terminal peptide tags. 
CF produced precipitate containing recombinant protein expressed in absence of 
detergent was suspended in 1 % LMPG in 20 mM phosphate buffer, pH 7.0, in a 
volume equal to the RM volume. The suspension was incubated for 1 h at RT with 
gentle shaking followed by centrifugation for 10 min at 20000 x g in order to remove 
residual precipitate.   For  reconstitution, a volume of 400 µl purified ETB at a 
concentration of approx. 0.3 mg/ml in 20 mM Tris, pH 8.0, 500 mM NaCl was mixed 
with E. coli lipid mixture at a molar protein : lipid ratio of 1 : 750. The mixture was 
incubated at 30
oC for 1 h and the detergent was subsequently removed with washed 
biobeads SM-2 (BioRad, Hercules, USA) by gentle shaking at 25
oC for another 36 h 
with three exchanges of the biobeads.  
 
6.4.4. Ligand binding analysis 
The Cy3-dye was attached at position Lys9 of the 21-mer peptide ET-1 (cET-1). Biotin 
was covalently attached to Cys1 and Lys9 of ET-1 resulting in bET-1. The N-terminal 
fluorescein labeled linear derivative fET-1A(1,3,11,15) was commercially synthesized 
(Biosyntan, Berlin, Germany). 
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For co-elution studies of ET-1 with ETB and its derivatives, 10-30 µg of the purified 
receptor in 20 mM Hepes, pH 7.4, 150 mM NaCl, 0.02 % DDM was mixed with cET-1 
dissolved in 20 % DMSO or fET-1A(1,3,11,15) dissolved in water at a molar ratio of 1 : 5. 
The mixtures were incubated for 2 hrs at 21
oC, filtered and then separated on a 
Superose 6 PC column (3.2 mm/30 cm) (GE Healthcare, Freiburg, Germany) 
equilibrated with 20 mM Hepes, pH 7.4, 150 mM NaCl, 0.02 % DDM with a flow-rate 
of 0.05 ml/min on a SMART chromatography station (GE Healthcare, Freiburg, 
Germany). The cET-1 ligand was detected by its specific absorption at 550 nm. The 
linear fluorescein labeled ligand fET-1A(1,3,11,15) was monitored by absorption at 495 nm. 
Peak area values were calculated by the SMART Manager software. Peak area values 
obtained for the cET-1 calibration curve were plotted with the Kaleidagraph 3.52 
software. Non-specific binding of cET-1 was monitored by saturation of the ETB 
sample with unlabelled ET-1 ligand for 2 hrs at 21
oC followed by incubation with 
supplied cET-1 for additional 2 hrs and subsequent gelfiltration. 
For pull-down assays, the biotinylated ligand bET-1 was mixed with purified ETB or its 
derivatives in 20 mM Tris, pH 8.0, 500 mM NaCl, 0.1 % Brij78 in a molar ratio of 5 : 1 
and incubated for 1 h at 25
oC. The mixture was then added to 100 μl of monomeric 
avidin matrix (Pierce, Rockford, USA) and incubated for 1 h at 4
oC with gentle mixing. 
The irreversible covalent binding sites of the avidin matrix had already been blocked by 
2 mM biotin. The matrix was subsequently packed in 2 ml gravity flow columns and 
washed with approx. 5 column volumes of 20 mM Hepes, pH 7.4, 150 mM NaCl, 0.02 
% DDM. The bound bET-1/protein complex was finally eluted with 20 mM Hepes, pH 
7.4, 150 mM NaCl, 0.02 % DDM and 2 mM biotin in a total volume of 1 ml. To 1 ml of 
the elution fraction 25 μl of 1 % sodium deoxycholate was added, mixed and incubated 
for 15 min at 25
oC. Then 1 ml 12 % ice-cold trichloric acid was added, mixed and 
centrifuged at 10.000 x g for 20 min. at 4
oC. The resulting pellet was dried, suspended 
in 50 μl 0.1 % SDS and analyzed by SDS-PAGE. 
 
6.4.5. Biacore measurements 
Kinetic measurements were done with a Biacore T100 (Biacore, Uppsala, Sweden) in 
20 mM Hepes-NaOH (pH 7.4), 500 mM NaCl and 0.1 % Brij78 at 25°C. The ligand 
bET-1 was loaded at 400 to 450 resonance unites (RU) on Biacore Sensor Chips SA 
with 60 s contact time, a flow rate of 10 μl/min and 1.500 s stabilization time. 
Responses obtained for the reference flow cell were directly subtracted from the curves, 
revealing negligible non-specific binding to the control surface. ETB binding was 6    UNPUBLISHED RESULTS  97
analyzed at a flow rate of 30 μl/min. with 480 s contact time and 1.500 s dissociation 
time. Data were processed with the BIAevaluation 3.1 software. 
 
6.4.6. TIRFS measurements 
TIRFS measurements were done with a custom made TIRFS-RIf combined set-up [127] 
using home made Tris-NTA chips loaded with Nickel Ions as described elsewhere [126] 
in 20 M Hepes-NaOH (pH 7.4), 500 mM NaCl and 0.1% Brij78 at 25°C. As negative 
control the ligand fET-1A(1,3,11,15) have been titrated at concentrations between 0.25 and 
2 µM on an empty chip first with for 36 s at a flow rate of 0.42 mL/min and dissociation 
times of 500 s with a flow rate of 0,6 mL/min. ETBcHx, CF expressed in presence of 
Brij78 and purified by Nickel-chelat chromatography has been loaded to 1.5 RU on the 
Nickel-NTA surface (36s at 0.42 mL/min) and subsequently fET-1A(1,3,11,15) was titrated 
as before. The obtained TIRFS signals have been processed with the BIAevalution 3.1 
software and the calculated dissociation constant (KD) is the mean of 6 measurements. 
 
6.4.7. Single particle analysis 
Different concentrations of purified ETB particles were adsorbed to glow discharged 
400 mesh carbon coated Parlodion grids and negatively stained with 2 % (w/v) uranyl 
acetate. Images were recorded at 50.000 x magnification on Kodak SO163 film using a 
Hitachi H-8.000 microscope operating at an acceleration voltage of 200 kV. Negatives 
were digitized on a Heidelberg PrimescanD 7100 drum scanner at a resolution of 2 
Å/pixel at the specimen level. The EMAN boxer program [147] was used to select a 
total of approx. 500 particles from electron micrographs. Particle projections were 
subjected to reference-free alignment [148] and classification by multivariate statistical 
analysis [149] employing the SPIDER package [150]. 
 
6.4.8. Protein interaction studies 
For binding of ETBStrep the Strep-Tactin® Spin Column Kit (IBA GmbH, Göttingen, 
Germany) was used. For interaction analysis of soluble co-expressed proteins in Brij78, 
the soluble fraction of an analytical CF reaction obtained after centrifugation of the RM 
at 20000 x g for 10 min containing ETBStrep and the various His-tagged ETB fragments 
was 20 times diluted 1 : 20 with 100 mM Tris-HCl, pH 8.0, 150 mM NaCl to a final 
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volume of 1.4 ml. The solution was split into 2 x 0.7 ml and loaded on pre-equilibrated 
Strep-Tactin® Spin columns. Washing and elution was essentially followed according 
to the manufacturers’ recommendations with the exception that all buffers were adjusted 
to 0.05 % Brij78. For interaction of purified proteins, approx. equimolar concentrations 
of ETBStrep and ETB fragments were combined in 20 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 0.05 % Brij78, incubated for 1 h at 25
oC and purified by Strep-Tactin® columns 
as described above. 
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AcP acetyl  phosphate 
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CECF continuous  exchange  cell-free 
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CF cell-free 
CFCF  continuous flow cell-free 
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COS  simian fibroblast (CV-1 cells) transformed by SV40 
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We demonstrate the high level expression of integral
membrane proteins (IMPs) in a cell-free coupled tran-
scription/translation system using a modiﬁed Escherichia
coli S30 extract preparation and an optimized protocol.
The expression of the E. coli small multidrug transporters
EmrE and SugE containing four transmembrane segments
(TMS), the multidrug transporter TehA with 10 putative
TMS, and the cysteine transporter YﬁK with six puta-
tive TMS, were analysed. All IMPs were produced at high
levels yielding up to 2.7 mg of protein per mL of reaction
volume. Whilst the vast majority of the synthesized IMPs
were precipitated in the reaction mixture, the expression
of a ﬂuorescent EmrE-sgGFP fusion construct showed
evidence that a small part of the synthesized protein
‘remained soluble and this amount could be signiﬁcantly
increased by the addition of E. coli lipids into the cell-free
reaction. Alternatively, the majority of the precipitated
IMPs could be solubilized in detergent micelles, and
modiﬁcations to the solubilization procedures yielded
proteins that were almost pure. The folding induced 1 by
formation of the proposed a-helical secondary structures
of the IMPs after solubilization in various micelles was
monitored by CD spectroscopy. Furthermore, the recon-
stitution of EmrE, SugE and TehA into proteoliposomes
was demonstrated by freeze-fracture electron microscopy,
and the function of EmrE was additionally analysed by
the speciﬁc transport of ethidium. The cell-free expression
technique allowed eﬃcient amino acid speciﬁc labeling of
the IMPs with
15N isotopes, and the recording of solution
NMR spectra of the solubilized EmrE, SugE and YﬁK
proteins further indicated a correctly folded conformation
of the proteins.
Keywords: amino acid speciﬁc labeling; cell-free expression;
integral membrane proteins; multidrug transporter; solution
NMR.
Integral membrane proteins (IMPs) account for 20–25%
of all open reading frames in fully sequenced genomes, and
in bacteria half of all IMPs are estimated to function as
transporters. The active efﬂux of antibiotics caused by
multidrug transporter proteins results in the development of
clinical resistance to antimicrobial agents and represents an
increasing problem in the treatment of bacterial infections.
Despite their importance, no high-resolution structure has
been determined thus far from any secondary transporter,
from either eukaryotic sources or from the bacterial inner
membrane. This is due mainly to the tremendous difﬁculties
generally encountered during the preparation of these
multispan integral IMPs to the required purity and
amounts [1]. Only some 20 IMPs have been overexpressed
in Escherichia coli at a level of at least 1 mgÆL
)1 of culture
[2,3]. Problems encountered by using conventional in vivo
systems, such as toxicity of the overproduced protein upon
insertion into the cytoplasmic membrane, poor growth of
overexpressing strains and the proteolytic degradation of
the proteins, could easily be eliminated by cell-free expres-
sion. Our primary goal was therefore to analyse whether
these restrictions could be solved by the production of IMPs
in a cell-free expression system. We have analyzed the
efﬁciency of IMP production in a T7 based cell-free
approach using an E. coli S30 cell extract in a coupled
transcription/translationsystem[4,5].Duringincubationthe
reactionmixture,containingallenzymesandhighmolecular
mass compounds necessary for gene expression, was
dialyzed against a low molecular mass substrate solution
providing precursors to extend the protein synthesis for
Correspondence to F. Bernhard, Centre for Biomolecular Magnetic
Resonance, University of Frankfurt/Main, Institute for Biophysical
Chemistry, Marie-Curie-Str. 9, D-60439 Frankfurt/Main, Germany.
Fax: + 49 69 798 29632, Tel.: + 49 69 798 29620,
E-mail: fbern@bpc.uni-frankfurt.de
Abbreviations: b-OG, n-octyl-b-glucopyranoside; CMC, critical
micellar concentrations; DDM, n-dodecyl-b-D-maltoside; DMPC,
1,2-dimyristoyl-sn-glycero-3-phosphocholine; DPC, dodecyl-
phosphocholine; FID, free induction decay; FM, feeding mixture;
GFP, green ﬂuorescent protein;HSQC, heteronuclear single quantum
correlation; IMP, integral membrane protein; LPC, L-a-phospha-
tidylcholine; MAS-NMR, magic angle spinning nuclear magnetic
resonance; MHPG, 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-
rac-(1-glycerol)]; NDSB, nondetergent sulfobetaines; NM, n-nonyl-b-
maltoside; POGP, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine;
RM, reaction mixture; sgGFP, super-glow green ﬂuorescent protein;
TMS, transmembrane segment; TPP
+, tetraphenylphosphonium;
TROSY, transverse relaxation optimized spectroscopy.
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Eur. J. Biochem. 271, 568–580 (2004)   FEBS 2004 doi:10.1111/j.1432-1033.2003.03959.xmore than 10 h [6,7]. Essential components 2 of the cell-free
system such as the bacterial S30 extract preparation, the
energy system, the concentrations of precursors and of
beneﬁcial additives, have been optimized to yield up to 5 mg
of recombinant protein per mL of reaction during a 12 h
incubation.
For our expression studies we have chosen secondary
transporter proteins from E. coli belonging to the families;
small multidrug resistance (EmrE, SugE), TDT 3 (TehA)
and RhtB 4 (YﬁK) [8,9]. The small multidrug resistance
(SMR) transporters are typically 110 amino acids in
length and they are supposed to consist of four trans-
membrane segments (TMS) forming a tightly packed
four-helix bundle [8–10]. EmrE is a polyspeciﬁc antiporter
that exchanges hydrogen ions with aromatic toxic cations
[11]. Its molecular transport mechanism, and probably
also that of the homologous protein SugE, is an
electrogenic drug/proton antiport. EmrE is thought to
form homooligomeric complexes and speciﬁcally trans-
ports aromatic dyes, quaternary amines and tetraphenyl-
phosphonium (TPP
+) derivatives [8,11], whilst SugE is
presumably only speciﬁc for quaternary ammonium
compounds [12]. The 36 kDa transporter TehA contains
10 TMS and is responsible for potassium tellurite efﬂux
[13]. Overexpression of TehA further increases the resist-
ance against monovalent cations such as tetraphenylarso-
nium and ethidium bromide and it decreases the resistance
against divalent cations like dequalinium and methyl
viologen [13]. A region including TMS 2 to 5, and
homologous to proteins of the SMR family, might be
primarily responsible for the activity of TehA. YﬁK is a
22 kDa transporter with six putative TMS and part of a
putative cysteine efﬂux system [14,15].
Large amounts of pure detergent solubilized IMPs are
needed for biochemical characterization or even structural
analysis by X-ray crystallography and NMR spectroscopy.
This work istheﬁrst report of the fast cell-free productionof
milligram amounts of four different integral transporter
proteins, three of which have been amino acid speciﬁcally
labeled. Whilst a small part of the overproduced proteins
could be stabilized post-translationally by the addition of
lipids into the cell-free reaction, the precipitated major part
of the IMPs could be folded efﬁciently and solubilized by
various detergents. The structural reconstitution of EmrE,
SugE, YﬁK and TehA was demonstrated by CD spectros-
copy, freeze fracturing electron microscopy, NMR spectro-
scopy and by functional assays.
Experimental procedures
5Strains, plasmids, oligonucleotides and DNA techniques
6Strains and plasmids used in this study are listed in 6 Table 1.
Standard DNA techniques were performed as described
elsewhere [17]. The coding sequences for the E. coli EmrE,
SugE, TehA and YﬁK proteins were ampliﬁed by standard
PCR using the corresponding oligonucleotide primers
from MWG-Biotech (Ebersberg, Germany) ( 7 Table 2), Vent
polymerase 7 (New England Biolabs, Frankfurt/Main,
Germany) and chromosomal DNA from strain C600 as
a template. The puriﬁed ampliﬁed DNA fragments were
cloned with the enzymes NdeIa n dHindIII (New England
Biolabs) into the expression vector pET21a(+) resulting in
the plasmids pET-emrE, pET-sugE, pET-tehA and pET-
yﬁK. Expression from these plasmids produced the wild
type proteins without any modiﬁcations or additional tags.
In vitro expression of proteins
Bacterial cell-free extracts were prepared from the E. coli
strain A19 8 (E. coli Genetic Stock Center CGSC) in a
procedure modiﬁed after Zubay [18]. The cells were washed
in washing buffer [10 mM Tris-acetate, pH 8.2, 14 mM
Mg(OAc)2], with 6 mM 2-mercaptoethanol and 0.6 mM
KCl. The lysis buffer was the washing buffer supplemented
with 1 mM dithiothreitol and 0.1 mM phenylmethanesulfo-
nyl ﬂuoride. The extract was dialysed in washing buffer
supplemented with 0.5 mM dithiothreitol and 0.6 mM
KOAc. Endogenous mRNA was removed from the ribo-
somes by incubation of the extract with 400 mM NaCl at
42  C for 45 min. Aliquots of the cell-free extract were
frozen in liquid nitrogen and stored at )80  C. The cell-free
expression was performed in the continuous exchange mode
using a membrane with a cutoff of 15 kDa to separate the
reaction mixture (RM) containing ribosomes and all
enzymes, from the feeding mixture (FM) providing the
low molecular mass precursors. The ratio of RM/FM was
1 : 17 (v/v). Reactions in the analytical scale of 70 lLR M
Table 1. Bacterial strains and plasmids used in this study.
Strains and plasmids Relevant genotype Reference
BL21 (DE3) Star E. coli B ompT rne131 Novagen
C600 thr-1 leuB6 thi-1 lacY1 glnV44 rfbD1 CGSC
a
XL1-Blue recA1 lac[F’Tn10 (Tet
r) lacI
q lacZM15] [16]
A19 rna19 gdhA2 his95 relA1 spoT1 metB1 CGSC
a
pET21a(+) T7 promoter Ap
r Novagen
pQB1-T7-gfp super glow gfp, Ap
r QBiogene
pQB1-emrE-gfp emrE NheI in pQB1 this study
pET-gfp Ap
r, gfp Roche
pET-emrE emrE NdeI-HindIII in pET21a(+) this study
pET-sugE sugE NdeI-HindIII in pET21a(+) this study
pET-tehA tehA NdeI-HindIII in pET21a(+) this study
pET-yﬁK yﬁK NdeI-HindIII in pET21a(+) this study
a E. coli Genetic Stock Center.
  FEBS 2004 Cell-free expression of membrane proteins (Eur. J. Biochem. 271) 569were performed in microdialysers (Spectrum Laboratories
Inc., Breda, the Netherlands) 9 , and larger dispodialysers
(Spectrum Laboratories Inc.) were used for preparative
scale reactions with RM volumes of 500 lLt o1m L .T h e
reactions were incubated at 30  C in a suitable shaker for
20 h. The protocol for the cell-free reaction mixtures is given
in Table 3. Amino acid concentrations were adjusted with
regard to the amino acid composition of the overproduced
proteins. The least abundant amino acids (present at £3%
in the protein) were added at 1.25 mM, medium abundant
(between 3 and £8%) at 1.8 mM and highly abundant
(more than 8%) at 2.5 mM ﬁnal concentration. Amino acid
speciﬁc labeling was achieved by replacing the correspond-
ing amino acids by their isotopically labeled derivatives.
Detergent solubilization of precipitated IMPs
10The pellets of cell-free reaction containing the IMPs were
suspended in three volumes of washing buffer (15 mM
sodium phosphate, pH 6.8, 10 mM dithiothreitol) and
centrifuged for 5 min at 5000 g.T h ew a s h i n gs t e pw a s
repeated twice. For the reconstitution of proteoliposomes,
EmrE was dissolved in one volume of 2% n-dodecyl-b-D-
maltoside (DDM) in 15 mM Tris/HCl, pH 6.5, and 2 mM
dithiothreitol. The mixture was soniﬁed for 1 min in a water
bath and then incubated for 1 h at 75  C. Non dissolved
protein was removed by centrifugation at 20 000 g at 15  C
for 5 min. TehA and SugE were additionally washed in 3%
n-octyl-b-glucopyranoside (b-OG) in 15 mM sodium phos-
p h a t e ,p H6 . 8 ,2m M dithiothreitol for 1 h at 40  C. YﬁK
was ﬁrst washed in 1% n-nonyl-b-maltoside (NM) in 25 mM
sodium phosphate, pH 7.0, 5 mM dithiothreitol for 1 h at
40  C. Impurities were removed by centrifugation and the
pellet was further washed with 1% dodecyl-phosphocholine
(DPC) at the previous conditions. Dissolved impurities were
removed by centrifugation at 20 000 g for 5 min. The
pellets were then dissolved with various concentrations
of DDM, DPC, 1-myristoyl-2-hydroxy-sn-glycero-3-[phos-
pho-rac-(1-glycerol)] (MHPG) or SDS if appropriate. b-OG
and SDS were from Sigma, DDM, DPC, NM and MHPG
were from Avanti Polar Lipids (Alabaster, AL).
Protein analysis
Protein production was analyzed by SDS/PAGE in 17.5%
(v/v) Tricine gels 11 [19]. The proteins were silver stained or
visualized with Coomassie-Blue (Sigma) 12 as described [17].
Dissolvedproteinswerequantiﬁedaccordingtotheirspeciﬁc
molar extinction coefﬁcient by measuring the UV absorb-
ance at 280 nm in 6 M guanidine hydrochloride 13 ,p H6 . 5 .
Circular dichroism spectroscopy
Circular dichroism (CD) spectrometry of IMPs dissolved in
15 mMsodium phosphate, pH 6.8, 2 mMdithiothreitol, and
containing the appropriate detergents was performed with a
Jasco J-810 spectropolarimeter 14 (Jasco Labortechnik, Gross-
Umstadt, Germany). Assays were carried out at standard
sensitivity with a band width of 3 nm and a response of 1 s.
The data pitch was 0.2 nm and the scanning rate
50 nmÆmin
)1. The spectra were recorded from 188 to
260 nm. The presented data are the average of three scans
and smoothed by means-movement with a convolution
width of 15 15 .T h ea-helical content of the analyzed proteins
w a st h e nc a l c u l a t e db yt h eJ a s c oSECONDARY STRUCTURE
ESTIMATION software. In addition, the a-helical content of
proteins was calculated according to their primary structure
with the PREDICT PROTEIN server at http://cubic.bioc.
columbia.edu/pp/ [20].
Reconstitution of proteoliposomes
The protein concentration of membrane proteins solubilized
in1%DDMwasdeterminedbyUVmeasurementat280 nm
in 6 M guanidine hydrochloride, pH 6.5, according to their
molar extinction coefﬁcients. Approximately 200 lM of the
individual protein samples were used for the reconstitution,
Table 2. Oligonucleotides used in this study.
Oligonucleotide Sequence
SugE-upNd cgg cat atg tcc tgg att atc tta gtt att gc
SugE-low gga aag ctt tta gtg agt gct gag ttt cag acc
EmrE-upNd cgg cat atg aac cct tat att tat ctt ggt ggt gc
EmrE-low cgg aag ctt tta atg tgg tgt gct tcg tga c
TehA-up cgg cat atg cag agc gat aaa gtg ctc aat ttg
TehA-low cgg aag ctt tta ttc ttt gtc ctc tgc ttt cat taa aac
YﬁK-up cgg cat atg aca ccg acc ctt tta agt gct ttt tgg
YﬁK-low cgg aag ctt tta ata gaa aat gcg tac cgc gca ata gac
EmrE-upNh cgg gct agc aac cct tat att tat ctt ggt gg
EmrE-lowNh cgg gct agc atg tgg tgt gct tcg tga c
SugE-upNh cgg gct agc tcc tgg att atc tta gtt att gc
SugE-lowNh gga gct agc gtg agt gct gag ttt cag acc
Table 3. Protocol for cell-free protein expression. Amino acids were
adjusted according to the composition of the expressed protein. RM,
reaction mixture; FM, feeding mixture.
Component
Final concentration
in RM
Final concentration
in FM
S30-extract 35% –
Tris-acetate, pH 8.2 3.5 mM 3.5 mM
plasmid DNA 15 lgÆmL –
RNasin
a 0.3 UÆlL
)1 –
T7-RNA polymerase 3 UÆlL
)1 –
E. coli tRNA
b 500 lgÆmL –
pyruvate kinase 40 lgÆmL –
amino acids 0.5–1 mM 1–1.5 mM
acetyl phosphate 20 mM 20 mM
phosphoenol pyruvate 20 mM 20 mM
ATP 1.2 mM 1.2 mM
CTP 0.8 mM 0.8 mM
GTP 0.8 mM 0.8 mM
UTP 0.8 mM 0.8 mM
1.4-dithiothreitol 2 mM 2m M
folinic acid 0.2 mM 0.2 mM
complete protease
inhibitor
b
1 tablet per 10 mL 1 tablet per 10 mL
Hepes-KOH pH 8.0 100 mM 100 mM
EDTA 2.8 mM 2.8 mM
magnesium acetate 13 mM 13 mM
potassium acetate 290 mM 290 mM
polyethylenglycol 8000 2% 2%
sodium azide 0.05% 0.05%
a Amersham Biosciences.
b Roche Diagnostics.
570 C. Klammt et al. (Eur. J. Biochem. 271)   FEBS 2004and E. coli lipids were added at a molar ratio of protein :
lipid of 1 : 500. The solutions were then adjusted to 150 mM
NH4Cl and incubated at 40  C for 30 min. Washed
biobeads SM-2 (Bio-Rad), presaturated with E. coli lipids
were then added in 10-fold excess to the detergent, and the
mixture was incubated overnight at 30  Co nas h a k e r .T h e
biobeads were exchanged twice. The supernatant was then
removed, soniﬁed for 1 min in a water bath sonicator, and
a s s a y e di m m e d i a t e l yo rs t o r e di nl i q u i dn i t r o g e n .
Freeze-fracture electron microscopy
Droplets of the vesicle suspension were placed between two
copper blades used as sample holders and then frozen by
plunging into liquid ethane cooled to )180  C by liquid
nitrogen.Freeze-fracturing wasperformedin a Balzers 400T
freeze-fracture apparatus (Balzers, Lichtenstein) with the
specimenstageat)160  C.Platinum/carbonshadowingwas
at 45  (with respect to the specimen stage) whereas pure
carbon was evaporated at 90  onto the sample. After thor-
oughly cleaning the metal replicas in chromosulfuric acid,
theywereplacedoncoppergridsandanalyzedinanEM208S
electron microscope (Philips, Eindhoven, the Netherlands).
Ethidium transport by EmrE proteoliposomes
Transport of ethidium bromide into reconstituted EmrE
proteoliposomes was carried out as described [11]. Uni-
lamelar vesicles were prepared by extrusion using 400 nm
micropore ﬁlters. Fluorescence was measured at excitation
and emission wavelengths of 545 and 610 nm, respectively,
w i t hab a n dw i d t ho f2 . 5n ma n dad a t ap i t c ho f0 . 1s .
Ten microliters of proteoliposomes (approximately 140 nM
EmrE) in 15 mM Tris/HCl, pH 6.5; 2 mM dithiothreitol,
150 mM NH4Cl and 20 lgÆmL
)1 circular plasmid DNA
(pUC18) were suspended in 980 lL of outside buffer
(15 mM Tris/HCl, pH 8.5; 2 mM dithiothreitol; 150 mM
KCl) and measured immediately. If appropriate, ligands
were added at the following ﬁnal concentrations: tetraphe-
nylphosphonium (TPP; 50 lM), ethidium bromide (2.5 lM)
and nigericine 16 (5 lgÆmL
)1) (Sigma). Green ﬂuorescent
protein (GFP) ﬂuorescence was measured at excitation
and emission wavelengths of 395 and 509 nm, and at 474
and 509 nm for the red shifted mutant superglow (sgGFP).
NMR spectroscopy
Two dimensional 17 1H,
15N correlated spectra of [98%
15N]Gly,[98%
15N]Ala labeled samples of 0.1 mM EmrE
and 0.5 mM SugE in CDCl3/CD3OH/H2O (6 : 6 : 1, v/v/v)
with 200 mM ammonium acetate (pH 6.2) and 10 mM
dithiothreitol, and of 0.3 mM YﬁK in 4% MHPG (v/v) in
25 mM sodium phosphate (pH 7.0) and 5 mM dithiothreitol
wereobtainedwithagradient-sensitivityenhanced[
15N,
1H]-
transverse relaxation optimized spectroscopy (TROSY)
pulse sequence [21,22]. The spectra of EmrE (T ¼ 15  C)
and YﬁK (T ¼ 30  C) were recorded on a Bruker DRX600
spectrometer 18 (BrukerBioSpinGmbH,Karlsruhe,Germany)
equipped with a
1H{
13C,
15N} triple-resonance cryoprobe
withz-gradientaccessory.Acquisitiontimeswereadjustedto
140 ms in both dimensions for EmrE. Accumulation of four
scans per free induction decay (FID) resulted in a measure-
ment time of 1 h. The spectrum of YﬁK resulted from
200 · 768 time-domain data points corresponding to acqui-
sition times of 55 and 53 ms in the
15Na n d
1H dimensions,
respectively. The total recording time was 16 h using 128
scans per FID. The spectrum of SugE was taken at a Bruker
DMX500 spectrometer using a xyz-gradient
1H{
13C,
15N}
triple-resonance probe at 15  C. Acquisition times were
102 msinbothdimensions.Thirty-twotransientswererecor-
ded for each FID, giving rise to a measurement time of 6 h.
Results
Cell-free expression of integral transporter proteins
The cell-free reaction conditions were ﬁrst optimized in
order to obtain high yields of protein production by
titration of each component and by using the expression
of green ﬂuorescent protein (GFP) as a monitor. The most
critical parameters appeared to be the concentrations of
potassium, magnesium and amino acids, and the quality of
the prepared S30 extract. The energy regenerating system
was most efﬁcient if a combination of phosphoenol
pyruvate, acetyl phosphate and pyruvate kinase was used.
With the ﬁnal protocol (Table 3) we received approximately
3 mg of soluble and ﬂuorescent GFP per mL of reaction
mixture and almost 80% of the protein was synthesized
during the ﬁrst 7 h of incubation (Fig. 1). Identical reaction
conditions were then subsequently used for the expression
of the selected IMPs with the only modiﬁcation being that
the amino acid concentrations of the reaction mixtures were
speciﬁcally adjusted according to the composition of each
target protein. The coding sequences of the genes emrE,
sugE, tehA and yﬁK were ampliﬁed from the E. coli genome
by PCR and cloned into the expression vector pET21a(+)
containing the T7 regulatory sequences. All four proteins
were expressed without any modiﬁcations and in each case
we obtained a high level production in our cell-free system
(Fig. 2). In contrast, the conventional in vivo expression
Fig. 1. Protein production kinetics in the cell-free system. Soluble GFP
production in a standard cell-free reaction with a membrane cut-oﬀ of
25 kDa and an RM/FM ratio of 1 : 17 was monitored by ﬂuorescence
at an emission at 509 nm and after excitation at 395 nm. Data are
averages of at least three determinations.
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plasmids yielded no expression detectable by SDS/PAGE
analysis. The production rate of all four proteins in the cell-
free system was estimated to be at least 1 mg IMP per mL of
reaction mixture. However, most of the synthesized IMPs
precipitated during the cell-free expression remained insol-
uble. In order to detect whether a small part of the
overproduced proteins might stay soluble, we constructed a
fusion of emrE to the 5¢ end of the gene of the reporter
protein sgGFP, resulting in the expression of an EmrE-
sgGFP fusion protein. Soluble and correctly folded sgGFP
protein can be monitored by its ﬂuorescence at 509 nm and
in addition to the more than 1 mg of insoluble fusion
protein we could calculatean average of approximately 6 lg
of soluble EmrE-sgGFP protein per mL of reaction mixture
after standard cell-free expressions.
Modiﬁcation of the cell-free expression system
by addition of detergents and lipids
The results obtained with the EmrE-sgGFP fusion gave
evidence that a cell-free expression of IMPs in a soluble
condition might be feasible and a major reason for the
observed precipitation of the vast majority of the IMPs
might be the lack of any hydrophobic environment in the
cell-free reaction. We therefore analysed whether the
addition of detergents or lipids could increase the solubility
of overproduced IMPs. As the addition of those substances
might impact the general efﬁciency of the cell-free reaction,
we ﬁrst tested the production of GFP in the presence of
various detergents which have been known to support the
functional reconstitution of certain IMPs. DDM, DPC,
b-OG, Thesit (Avanti Polar Lipids) 19 , Triton X-100 and
Triton X-114 (Sigma) were added to the reaction mixtures
in concentrations starting from the speciﬁc critical micellar
concentrations (CMC) up to 1.5-fold CMC. With the
highest concentrations tested, all detergents showed a
negative effect on the GFP expression, and with DPC and
b-OG no synthesized GFP was detectable even at the CMC
concentrations (Fig. 3). The detergents DDM, Thesit,
Triton X-110 and Triton X-114 showed less drastic effects
on the GFP expression and even at the highest concentra-
tion analysed, only reductions of  60–80% of that of the
control were observed. A slight increase in amount of
soluble EmrE-sgGFP expression was only detectable after
addition of Triton X-100 at 1.5-fold CMC (Fig. 4). As
expected, DPC and b-OG also completely inhibited the
EmrE-sgGFP production when at the CMC (data not
shown).
We next analysed the effect of lipids on the cell-free GFP
expression. L-a-phosphatidylcholine (LPC), 1,2-dimyris-
toyl-sn-glycero-3-phosphocholine (DMPC), 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POGP) and an E. coli
lipid mixture were added in increasing concentration only
to the RM. POGP resulted in a slight reduction of GFP
expression down to approximately 80%, while no negative
effects even at the highest analysed concentration of 4 mg
lipid per mL RM was noticed with the other three lipids
(Fig. 3). Theadditionof POGP, DMPC and E. coli lipidsto
the cell-free reaction proved to be beneﬁcial for the soluble
expression of EmrE-sgGFP protein. An increase in ﬂuor-
escent EmrE-sgGFP of up to >threefold could be obtained
upon addition of E. coli lipids (Fig. 4), resulting in a
concentration of soluble fusion protein of 20 lgÆmL.
Detergent solubilization of EmrE, SugE, YﬁK and TehA
As the vast majority of the IMPs still remained insoluble
we next approached the solubilization of the precipitated
proteins using membrane mimicking detergent micelles.
Fig. 2. Cell-free production of membrane proteins. Lanes 1 and 2,
in vivo expression. Samples of total cell extracts containing 10 lgo f
protein were analysed by SDS/PAGE in 17.5% (v/v) tricine gels. Lane
1, total protein of BL21 (DE3) Star · pET21-tehA before induction;
lane 2, total protein of BL21 (DE3) Star · pET21-tehA 4 h after
induction with 1 mM IPTG. Lanes 3–9, cell-free reactions, samples of
1 lL of the reaction mixtures were analysed. Lane 3, pET21-tehA total
protein;lane 4, pET21-tehA soluble protein; lane5,pET21-tehApellet;
lane 6, pET21-emrE pellet; lane 7, pET21-emrE-GFP pellet; lane 8,
pET21-sugE pellet; lane 9, pET21-yﬁK pellet. M, marker from top to
bottom: 116, 66, 45, 35, 25, 18 and 14 kDa. Arrows indicate the
overproduced proteins.
Fig. 3. Eﬀect of selected lipids and detergents on the eﬃciency of cell-
free GFP expression. The reactions were incubated for 7 h at 30  C.
The ﬂuorescence of GFP in a standard cell-free reaction corresponding
to an average concentration of 2.6 mgÆmL
)1 was set as 100%. Blank
bars, detergents; hatched bars, lipids. Detergent concentrations were
1.5-fold CMC. Lipid concentrations were 4 mgÆmL
)1.D D M ,n-do-
decyl-b-D-maltoside; DPC, dodecyl phosphocholine; b-OG, n-octyl-b-
glucopyranoside; TX-100, Triton X-100; TX-114, Triton X-114; LPC,
L-a-phosphatidylcholine; DMPC, 1,2-dimyristoyl-sn-glycero-3-phos-
phocholine; POGP, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line; EL, E. coli lipid mixture.
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dissolved in 15 mM sodium phosphate, pH 6.8, and 2 mM
dithiothreitol was analysed, and impurities present in the
insoluble pellets of the cell-free reactions were removed
where possible. The detergents tested for their ability to
solubilize the IMPs were b-OG, DDM, DPC, MHPG, NM,
nondetergent sulfobetaines (NDSB-195, -201 and -256),
SDS, Thesit, Triton X-100 and Triton X-114. The protein
pellets containing the overproduced IMPs and other
impurities were ﬁrst washed twice with 15 mM sodium
phosphate, pH 6.8, and 10 mM dithiothreitol. EmrE could
then be almost quantitatively dissolved in a buffered 2%
(v/v) DDM solution. Co-solubilized impurities could be
removed easily by heating the solution to 75  Cf o r1ha n d
apparently pure EmrE remained in solution (Fig. 5). The
precipitated SugE and TehA proteins could be further
puriﬁed by washing the pellets ﬁrst with 3% (v/v) b-OG or
with 20% (v/v) NDSBs. These IMPs dissolved only barely
in b-OG or NDSB derivatives, and could be harvested by
centrifugation, while most impurities remained b-OG or
NDSB soluble (Fig. 5). SugE could then be solubilized in
2% (v/v) DPC, 0.1% (v/v) SDS or 1% (v/v) DDM and
TehA solubilized best in 3%(v/v) DPC, 1% (v/v) DDM, or
1% (v/v) SDS. YﬁK was washed with 1% (v/v) NM and
with 1% (v/v) DPC and then solubilized in 3% (v/v)
MHPG. For an efﬁcient solubilization, the proteins were
incubated on a shaker at 40  C for 1 h. In addition, the
presence of dithiothreitol was important and a higher
molecular mass of the proteins observed after SDS/PAGE
analysis without reducing agents indicated the formation of
disulﬁde bridges in the protein precipitates (data not
shown).
Structural analysis of solublized EmrE, SugE and TehA
by CD spectroscopy
The solubilization of precipitated IMPs into detergent
micelles might result in the refolding of the proteins. We
therefore analysed the formation of secondary structures of
the solubilized IMPs. SugE (15 lM) and TehA (10 lM)w e r e
measured in 15 mM sodium phosphate buffer, pH 6.8,
2m M dithiothreitol, and supplemented with DPC, DDM
and SDS, respectively. EmrE was measured in 10 mM
sodium phosphate, pH 7.4, 2 mM dithiothreitol and with
2% (v/v) DDM. The spectra measured in the various
detergent micelles at 25  C, showing minima at 208 and
222 nm and a large peak of positive ellipticity centered at
193 nm, were characteristic of a-helical proteins (Fig. 6).
The analysis of the spectra yielded an estimate of 55 ± 4%
a-helical content for EmrE, 72 ± 11% (DPC), 60 ± 11%
(SDS) and 84 ± 10% (DDM) for SugE and 78 ± 8%
(DDM), 49 ± 3% (DPC) and 40 ± 15% (SDS) for TehA.
The predicted a-helical contents, after primary stuctural
analysis, were 69% for EmrE, 67% for SugE and 70% for
TehA. According to these data, the adoption of the mostly
folded conformation of SugE might be favoured upon
solubilization with DPC, and with DDM for TehA,
respectively.
Reconstitution of solubilized EmrE, SugE and TehA
into proteoliposomes
The precipitated proteins produced by cell-free reactions
were solubilized in a 1% (v/v) DDM solution in 15 mM
sodium phosphate, pH 6.8, and 2 mM dithiothreitol.
Fig. 4. Increase of soluble EmrE-sgGFP expression in presence of
selected lipids and detergents. The ﬂuorescence was measured at
509 nm. The reactions were incubated for 7 h at 30  C. The ﬂuores-
cence ofEmrE-sgGFPinastandardcell-free reactioncorresponding to
an average concentration of 5.8 lgÆmL
)1 was set as 100%. Blank bars,
detergents; hatched bars, lipids. Detergent concentrations were 1.5-
fold CMC (TX-110, TX-114, DDM) and twofold CMC (Thesit). Lipid
concentrations were 4 mgÆmL
)1.D D M ,n-dodecyl-b-D-maltoside; TX-
100, Triton X-100; TX-114, Triton X-114; LPC, L-a-phosphatidyl-
choline; DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine; POGP,
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; EL, E. coli lipid
mixture.
Fig. 5. Puriﬁcation ofcell-freeexpressed membraneproteins by selective
solubilization. Pellets containing the precipitated membrane proteins
were dissolved in various detergents in a volume corresponding to the
volumes of the original reaction mixtures, and nonsolubilized proteins
were removed by centrifugation. 5 lL samples of the soluble fractions
were analysed by SDS/PAGE in 17.5% (v/v) tricine gels. Lane 1,
EmrE in 2% (v/v) DDM after 1 h at 45  C; lane 2, EmrE in 2% (v/v)
DDM after 1 h at 75  C; lane 3, SugE in 3% (v/v) b-OG after 2 h
at 40  C; lane 4, SugE in 20% (v/v) NDSB-201 after 2 h at 40  C; lane
5, SugE in 1% (v/v) DDM after washing with 20% (v/v) NDSB-201;
lane 6, TehA in 1% (v/v) DDM after washing with 3% (v/v)
b-OG; lane 7, TehA in 1% (v/v) SDS after washing with 3% (v/v)
b-OG; lane 8, TehA in 3% (v/v) DPC; lane 9, YﬁK in 1% (v/v) DDM
after washing with 25% (v/v) NDSB-256. M, marker from top to
bottom: 116, 66, 45, 35, 25, 18 and 14 kDa. Arrows indicate the
overproduced membrane proteins.
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carried out at a molar protein/lipid ratio of 1 : 500. The
insertion of EmrE, SugE and TehA into the lipid mem-
branes was monitored by freeze-fracture electron micros-
copy (Fig. 7). As would be expected by a functional
reconstitution, all three proteins inserted as homogenously
dispersed particles into the vesicles 20 . The efﬁciency of
insertion of SugE and EmrE was comparable and an
estimated 80% of the vesicles contained inserted proteins.
In the case of TehA, the efﬁciency of proteoliposome
generation was less, and  10% of the vesicles contained
proteins.
Ethidium/H
+ antiport in reconstituted EmrE
proteoliposomes
The functional reconstitution of EmrE into proteolipo-
somes was tested with an established transport assay using
ethidium bromide as a ligand [11]. Intercalation of
ethidium into DNA causes an effect on the quantum
yield of its ﬂuorescence. Active EmrE protein should
therefore generate a signiﬁcant increase in the ﬂuorescence
intensity, by pumping ethidium into the proteoliposomes
where it is accumulated in the DNA molecules. Approxi-
mately 140 nM EmrE embedded in E. coli lipids were
assayed in a total volume of 1 mL. After establishing the
baseline, proteoliposomes were added, followed by ethi-
dium bromide after 10 s to a ﬁnal concentration of
2.5 lM. An immediate large biphasic increase in the
ﬂuorescence was monitored (Fig. 8). The ﬁrst phase of the
increase can be attributed to the binding of ethidium to
residual DNA in the extraliposomal space [11], while the
second phase represents the accumulation of ethidium
inside the liposomes due to the transport activity of
EmrE. Preincubation of the proteoliposomes with an
excess of 50 lM of the high afﬁnity substrate TPP
+
completely eliminated the second phase, probably through
competition with the ethidium binding site at EmrE. In
addition, the collapse of the pH gradient upon addition of
nigericine also prevented the accumulation of ethidium in
the proteoliposomes, resulting only in the single phase
increase of ﬂuorescence after addition of ethidium bro-
mide. The results clearly demonstrate that the ethidium/
H
+ antiport was responsible for the observed increase in
ﬂuorescence, indicating the functional reconstitution of
EmrE in E. coli lipids.
Structural analysis of selectively labeled EmrE, SugE
and YﬁK by NMR spectroscopy
One advantage of the cell-free expression technique is the
rapid and efﬁcient uniform or amino acid speciﬁc labeling
of the overproduced proteins. Selected amino acids can be
replaced by their labeled derivatives and provided in the
reaction mixtures. We selected the relatively abundant
amino acids glycine and alanine for a speciﬁc labeling
approach of EmrE, SugE and YﬁK and for the genera-
tion of samples suitable for NMR spectroscopy. The
quality and dispersion of recorded two dimentional
1H,
15N correlation spectra could provide information on
whether the solubilized IMPs are either aggregated or
present in a folded conformation. However, in addition to
Fig. 6. CD spectroscopy of solubilized multidrug transporter in deter-
gent micelles. Far-UV spectra were taken at 25  C in buﬀered detergent
solutions. (A) 24 lM EmrE in 2% (v/v) DDM in 10 mM sodium
phosphate, pH 7.4. (B) 15 lM SugE in 15 mM sodium phosphate,
pH 6.8, 2 mM dithiothreitol with various detergents. (C) 15 lM TehA
in 15 mM sodium phosphate, pH 6.8, 2 mM dithiothreitol with various
detergents. SDS, sodium dodecylsulfate; DDM, n-dodecyl-b-D-
maltoside; DPC, dodecyl phosphocholine.
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NMR analysis of IMPs, is the size of the detergent
micelles necessary for the solubilization. We therefore
took advantage of the reported high stability of EmrE
in the organic solvent mixture CDCl3/CD3OH/H2O
(6 : 6 : 1, v/v/v) with 200 mM ammonium acetate,
pH 6.2, and 10 mM dithiothreitol [11,23]. The pellets of
preparative scale cell-free reactions with a total of 2 mL
RM were washed twice with 15 mM sodium phosphate,
pH 6.8, and 2 mM dithiothreitol and then suspended in
the chloroform mixture in a volume corresponding to one
fourth of the volume of the RM. The suspension was
i n c u b a t e do nas h a k e rf o r2 ha t4 0  Ca n dt h e n
centrifuged at 20 000 g for 5 min at 15  C. The super-
natant was then used directly for NMR analysis. Inter-
estingly, the SugE protein shared this stability in the
chloroform mixture with its homologue EmrE and could
be dissolved by using identical procedures. Both proteins
were apparently pure in the chloroform mixture as judged
by SDS/PAGE analysis and the impurities obviously
remained insoluble during this treatment.
The YﬁK protein did not dissolve in the chloroform
mixture but it showed good solubility in buffered MHPG
solutions. The pellets of six preparative reactions with
0.5 mL RM, each containing the YﬁK protein, were
combined, washed in 1% (v/v) NM and in 1% (v/v) DPC
and dissolved in 2 mL of 1% (v/v) MHPG in 25 mM
sodium phosphate, pH 6.0, with 5 mM dithiothreitol. After
removal of insoluble protein by centrifugation, the sample
was concentrated fourfold and measured by NMR. The
ﬁnal protein concentration of YﬁK in the sample was
calculated at approximately 6 mgÆmL
)1, indicating a yield
of solubilized labeled YﬁK of approximately 1 mg per ml of
cell-free RM.
Fig. 7. Freeze-fracture electron microscopical
analysis of reconstituted proteoliposomes. The
membrane proteins EmrE (A), SugE (B) and
TehA (C) were solubilized in 1% (v/v) DDM
and reconstituted in E. coli lipid vesicles (bold
arrows). Randomly distributed particles
(small arrows) in the fracture faces indicate
incorporation of proteins into vesicular
membranes. Scale bar ¼ 100 nm.
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lysed by heteronuclear [
15N,
1H]-TROSY experiments at 500
or 600 MHz
1H frequency. In the EmrE spectrum, all nine
alanine residues and 12 glycine residues are visible and well
resolved, spanning an area between 7.5 and 9 p.p.m and
indicating a speciﬁc folded conformation of the solubilized
EmrE protein (Fig. 9A). The spectrum could be nicely
aligned with a previously published [
15N,
1H]-HSQC spec-
trum of uniformly labeled EmrE, prepared by conventional
in vivo expression and labeling in E. coli [23], and all signals
of the speciﬁcally labeled residues could be assigned
accordingly. The dispersion of the amide proton signals
also indicated a monomeric conformation of EmrE. The
[
15N,
1H]-TROSY spectrum of the SugE protein also
showed a good resolution, and signals of all the 14 alanine
and 11 glycine residues were detectable, spanning an area
between 7.5 and 8.9 p.p.m, and indicating again a folded
conformation of the solubilized protein (Fig. 9B). Despite
the size of the 21.3 kDa YﬁK protein, the dispersion of its
[
15N,
1H]-TROSY spectrum in MHPG micelles showed a
reasonable resolution, and signals of most of the 24 alanine
and 13 glycine residues were visible (Fig. 9C).
Discussion
We describe a new and versatile approach for the rapid
production, puriﬁcation and reconstitution of large
amounts of structurally folded IMPs, and for the generation
of amino acid speciﬁc labeled samples suitable for NMR
spectroscopy. The production of sufﬁcient amounts of
protein is the major bottleneck for the structural and
functional analysis of membrane proteins in vitro.I n
addition, if a protein is produced it has to be isolated from
complex cellular membranes by time consuming procedures
that frequently involve considerable losses. The small
multidrug transporter EmrE is one of the few 21 exceptions
of IMPs which can also be produced in relatively high
amounts by in vivo expression. Yields of up to 1 mgÆL
)1
after intensive optimizations in E. coli systems have been
reported [24] and a hemagglutinin epitope-tagged functional
EmrE derivative was expressed in the yeast Saccharomyces
cerevisiae at levels of approximately 0.5 mgÆL
)1 [25]. For
SugE, TehA and YﬁK are no quantitative data available for
in vivo expression, and this is the ﬁrst report of preparative
expression of these proteins. We have been able to
demonstrate the cell-free production of at least 1 mgÆmL
)1
of reaction mixture of all of our four target proteins. In
the case of SugE and TehA, the production rates were
considerably higher. After puriﬁcation and solubilization
into detergent micelles, we could calculate a yield of
resolubilizable protein of 1 mgÆmL
)1 RM for YﬁK,
1.5 mgÆmL
)1 RM for SugE and of 2.7 mgÆmL
)1 RM for
TehA. These calculations did not take into account the
amount of proteins which remained insoluble. The obtained
production rates of membrane proteins by cell-free expres-
sion are therefore comparable to that of other proteins
[7,26,27].
The structural reconstitution of EmrE, SugE, YﬁK and
TehA was monitored by different techniques. EmrE repre-
sents one of the best characterized model systems of an
integral membrane transporter and its reconstitution is a
very well established technique. We included a simple
incubation step at 75  C for the rapid puriﬁcation of EmrE
as it was previously reported that the exposure of EmrE to
80  C did not affect its transport activity after reconstitution
[28]. EmrE is tightly packed without any hydrophilic
cytoplasmatic domains [29] and this conformation might
cause its somewhat unique solubility and stability in organic
solvents [11], and might also favour the observed rapid
reconstitution in micelles or liposomes. Homologous pro-
teins of EmrE such as SugE and probably also YﬁK and
TehA, seem to share these properties and the presented
strategy of a cell-free production as precipitate might
therefore be advantageous even for this class of IMPs, in
Fig. 8. Ethidium transport assay of EmrE
proteoliposomes. T r a n s p o r to fe t h i d i u mi n t o
reconstituted EmrE proteoliposomes in
15 mM Tris/Cl, pH 8.5, 2 mM dithiothreitol,
150 mM KCl was measured by an increase in
ﬂuorescence at excitation and emission wave-
lengths of 545 and 610 nm, respectively. Ten
microliters of proteoliposomes (approximately
140 nM EmrE) were added after 30 or 60 s.
If appropriate, substances were added at the
following ﬁnal concentrations: TPP (50 lM),
ethidium bromide (2.5 lM) and nigericine
(5 lgÆmL
)1). Arrows indicate the time points
of addition.
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15N,
1H]-TROSY spectra of solubilized membrane proteins. The proteins were speciﬁcally labeled with [
15N]alanine and [
15N]glycine by cell-
free expression. (A) 0.1 mM EmrE dissolved in CDCl3/CD3OH/H2O (6 : 6 : 1, v/v/v) with 200 mM ammonium acetate (pH 6.2) and 10 mM
dithiothreitol. The assignments for the amide proton-nitrogen pairs according to Schwaiger et al. [23 31 ] are indicated. The spectrum was taken at
15  C with a 600 MHz spectrometer. (B) 0.5 mM SugE dissolved in CDCl3/CD3OH/H2O (6 : 6 : 1, v/v/v) with 200 mM ammonium acetate
(pH 6.2) and 10 mM dithiothreitol. The spectrum was taken at 15  C with a 500 MHz spectrometer. (C) YﬁK (0.3 mM) solubilized with 4% (v/v)
MHPG in 25 mM sodium phosphate (pH 7.0) and 5 mM dithiothreitol. The spectrum was taken at 30  C with a 600 MHz spectrometer.
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just by using selective resolubilization protocols in suitable
detergents. We could demonstrate for the ﬁrst time that
SugE has a high stability in organic solvents comparable to
that of EmrE and that it was able to refold into a structural
conformation in the identical chloroform mixture. SugE,
like EmrE, appears to be monomeric in chloroform 22 as
judged by the dispersion of its [
15N,
1H]-TROSY spectrum.
The spectra of both proteins were well resolved, and the
[
15N,
1H]-TROSY spectrum of the cell-free produced and
reconstituted EmrE protein is comparable to that of EmrE
prepared after in vivo expression [23].
Far-UV CD spectroscopy of solubilized EmrE, SugE and
TehA in various detergents revealed spectra typical for
predominantly a-helical proteins [30]. EmrE has a-helical
estimates of 78% and 80% in chloroform/methanol/water
and DMPC, respectively [29,31]. Accordingly, the predicted
predominantly a-helical secondary structures of SugE and
TehA were in good agreement with the data obtained from
CD spectroscopy of the solubilized proteins. The observed
differences in a-helicity, in combination with the various
detergents, might reﬂect variations in the protein confor-
mations depending on the type of micelles 23 [32]. An extensive
analysis of the effects of different membrane mimetic
environments on the conformation of EmrE has recently
been published and remarkably, differences in the conform-
ational dynamics, were monitored [33]. The largest amount
of a-helical content of EmrE was observed in DDM and the
authors assumed that the protein is in a slightly more
denatured state in other environments. Their data are in full
agreement with our results. Additionally, SugE and TehA
also showed the highest a-helicity in DDM.
In MHPG micelles, the YﬁK protein showed a reason-
able resolution in the [
15N]-TROSY spectrum, as would be
expected from a protein with a mass in the range  50–
100 kDa. Classical multidrug transporters contain 12 TMS
per monomer or functional unit. The EmrE monomer
would therefore be three times smaller than this 12 TMS
consensus, and it is speculated that functional EmrE might
be composed of three subunits [10,34]. It could therefore be
possible that the six TMS containing YﬁK monomers might
reconstitute as oligomers. Considering the estimated micel-
lar size of DPC of ‡25 kDa, even as a monomer the
analysed molecules would have a minimum size of 47 kDa,
w h i c hi st h e ni na g r e e m e n tw i t ht h eo b s e r v e dd a t a .
For the functional analysis of the multidrug transporter
EmrE, we could take advantage of a previously established
activity assay [11], and the functional reconstitution of the
cell-free produced and solubilized protein into proteolipo-
somes could be clearly demonstrated. The ethidium trans-
port could be speciﬁcally competed against the high afﬁnity
substrate TPP
+ [34], and it was eliminated by affecting the
membrane proton gradient with nigericine. Unfortunately,
ethidium is not a substrate for SugE and as only nonﬂu-
orescent quarternary ammonium compounds have been
reported as potential ligands [12], analoguous assays have
not be established to date. Ethidium is a potential substrate
of TehA but we have not been able to detect any transport
activity with proteoliposomes of TehA solubilized either
in DPC, DDM or SDS and reconstituted with an E. coli
lipid mixture (data not shown). However, the analysis of
proteoliposomes by freeze-fracture electron microscopy
gave evidence of a structural reconstitution of SugE, EmrE
and TehA in E. coli lipid vesicles, and no differences
between SugE and EmrE proteoliposomes could be
observed. It should also be noted that the function of TehA
is not very well analysed yet, and it is not clear so far
whether the transport activity requires TehA alone or in a
complex with other proteins or cofactors [13].
GFP has been shown to be a sensitive folding indicator
for the study of globular and membrane protein over-
expression in E. coli [35,36], and it is most likely to become
correctly folded as a C-terminal fusion that is not translo-
cated through the membrane into the periplasm. Therefore,
at least the C-terminus of the target protein should remain
in the cytoplasm. Approximately 70% of all predicted
membrane proteins are believed to have this topology.
For EmrE, the cytoplasmic localization of the N- and
C-terminal ends has been shown [29], and the C-terminal
fusion of GFP should therefore not prevent its reconstitu-
tion into membranes. In addition, a fully functional chimera
between EmrE and GFP was expressed in S. cerevisiae
and it conferred resistance against TPP
+, acriﬂavine and
ethidium [25]. It can therefore be assumed that the observed
ﬂuorescent part of the cell-free produced EmrE-sgGFP
fusion also contains a functionally folded EmrE protein.
Despite optimized conditions upon addition of E. coli
lipids, only an estimate of approximately 1% of the total
overproduced protein stayed soluble. While this could
already be sufﬁcient for certain analytical assays, higher
yields of soluble membrane proteins might be possible by
increasing the added amounts of lipids or by providing
alternative hydrophobic environments. Dog pancreas
microsomes have, for example, been used to produce
analytical amounts of completely assembled human T-cell
receptor by in vitro expression [37]. The cell-free expression
principally offers the opportunity to insert the translated
protein directly into the desired membrane of choice.
Tedious efforts of delipidation and reinsertion of the
overproduced membrane proteins into artiﬁcial membranes
could therefore be avoided, and the possibility of soluble
cell-free membrane protein expression might be considered
if the reconstitution of a protein is not possible or if only
analytical amounts of protein are needed.
Membrane proteins are difﬁcult to analyse by solution
NMR techniques, and the main problems are caused by the
sizes of the detergent micelles needed for solubilization.
Spectra are frequently very crowded and the low dispersion
of signals prevents the effective assignment of residues. A
valuable tool to approach this problem is the amino acid
speciﬁc labeling of membrane proteins by cell-free expres-
sion. Whilst the selective labeling of proteins for NMR
studies in both individual and commercial cell-free expres-
sion systems 24 has already been demonstrated [26,38–41], this
report shows the ﬁrst application of this technique to
membrane proteins. The selective labeling of proteins by
cell-free expression is highly efﬁcient and advantageous
compared with the in vivo labeling. No auxotrophic strains
and minimal media are needed, and commonly encountered
problems with reduced expression rates are thus eliminated.
In addition, due to the lack of any metabolism during cell-
free expression, cross-labeling problems usually do not
occur. The presented [
15N,
1H]-TROSY spectra of EmrE,
SugE and YﬁK nicely demonstrate the highly efﬁcient
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any losses in the protein yields. Together with the fast
generation of samples, the selective cell-free labeling of
membrane proteins could considerably accelerate the
assignment of proteins showing a reasonable resolution.
The approach presented here might become especially
valuable for solid-state NMR studies. The possibility of
producing mg quantites of membrane proteins, with the
option of using a range of different isotope labeling
schemes, enables structural studies of IMPs reconstituted
into lipid membranes. So far, only ligand studies by MAS-
NMR have been feasible for these protein families [42], but
solid-state NMR studies on some of the presented proteins
are already in progress.
Cell-free expression has a high potential to become a
valuable tool for the rapid generation of samples suitable for
structural analysis [43], and commercially available systems
have been developed for the efﬁcient production of proteins
on a preparative scale [39,44]. In addition, cell-free expres-
sion might also yield more homogenous protein samples
more readily suitable for crystallization. The main advan-
tages of the cell-free expression of IMPs were the high level
production of insoluble protein and the efﬁcient selective
labeling. This is the ﬁrst report of the solubilization of SugE,
YﬁK and TehA in micelles and of their reconstitution into
membranes. The dissolving of the proteins in suitable
detergents obviously resulted in the refolding of the
proteins, and renaturation procedures with strong denatu-
rants such as guanidine hydrochloride could be omitted 25 .
At least for the family of small multidrug transporters, the
cell-free expression technique seems to be a highly appealing
way to generate samples suitable for NMR spectroscopy.
The production rate of membrane proteins in the cell-free
system was not related to the number of transmembrane
domains, and the cell-free expression of even larger mem-
brane proteins might therefore be possible. Regardless of
this, the cell-free expression could be a suitable tool for the
rapid screening of the general likelihood of expression of
membrane proteins.
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Cell-free expression has become a highly promising tool for the fast and
efﬁcient production of integral membrane proteins. The proteins can be
produced as precipitates that solubilize in mild detergents usually without
any prior denaturation steps. Alternatively, membrane proteins can be syn-
thesized in a soluble form by adding detergents to the cell-free system.
However, the effects of a representative variety of detergents on the pro-
duction, solubility and activity of a wider range of membrane proteins
upon cell-free expression are currently unknown. We therefore analyzed
the cell-free expression of three structurally very different membrane pro-
teins, namely the bacterial a-helical multidrug transporter, EmrE, the
b-barrel nucleoside transporter, Tsx, and the porcine vasopressin receptor
of the eukaryotic superfamily of G-protein coupled receptors. All three
membrane proteins could be produced in amounts of several mg per one
ml of reaction mixture. In general, the detergent 1-myristoyl-2-hydroxy-sn-
glycero-3-[phospho-rac-(1-glycerol)] was found to be most effective for the
resolubilization of membrane protein precipitates, while long chain poly-
oxyethylene-alkyl-ethers proved to be most suitable for the soluble expres-
sion of all three types of membrane proteins. The yield of soluble
expressed membrane protein remained relatively stable above a certain
threshold concentration of the detergents. We report, for the ﬁrst time, the
high-level cell-free expression of a b-barrel type membrane protein in a
functional form. Structural and functional variations of the analyzed mem-
brane proteins are evident that correspond with the mode of expression
and that depend on the supplied detergent.
Abbreviations
BLM, black lipid membrane; b-OG, n-octy-b-glucopyranoside; Brij-35, polyoxyethylene-(23)-lauryl-ether; Brij-56, polyoxyethylene-(10)-cetyl-
ether; Brij-58, polyoxyethylene-(20)-cetyl-ether; Brij-72, polyoxyethylene-(2)-stearyl-ether; Brij-78, polyoxyethylene-(20)-stearyl-ether; Brij-97,
polyoxyethylene-(10)-oleyl-ether; Brij-98, polyoxyethylene-(20)-oleyl-ether; CE, continuous exchange; CF, cell-free; CMC, critical micellar
concentration; Cmic, micellar concentration; DDM, N-dodecyl-b-D-maltoside; DHPC, 1,2-diheptanoyl-sn-glycero-3-phosphocholine; diC6PC,
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translation systems resulted in the design of the con-
tinuous-exchange cell-free (CECF) expression system
[1]. A semipermeable membrane separates the reaction
mixture (RM), holding all high molecular mass com-
pounds, from the feeding mixture (FM), providing low
molecular mass precursors and removing undesirable
breakdown products. CECF systems based on Escheri-
chia coli CF extracts have been shown to be especially
promising for the high-level production of a-helical
integral membrane proteins (MPs) [2–6]. Potential
toxic effects caused by the overproduced MPs in vivo
are eliminated by using CF expression systems, and
even proteins with no detectable expression in E. coli
cells can be produced in milligram quantities in 1 mL
of RM. In addition, speciﬁc amino acids of the CF
expressed MPs can be efﬁciently labeled with stable
isotopes, without any reduction in productivity [4].
Samples of MPs that are ready for structural analysis
by NMR spectroscopy can therefore now be generated
in less than 2 days. The fact that nearly 40% of all
identiﬁed proteins are MPs is in strong contrast with
their highly underrepresented structural information
deposited in data banks. This discrepancy is mainly
determined by the tremendous difﬁculties encountered
when sufﬁcient amounts of MPs for a structural analy-
sis have to be produced by conventional in vivo expres-
sion techniques. The observed high-level production of
MPs by CF expression might therefore have important
potential for the fast and efﬁcient generation of protein
samples suitable for structural analysis by NMR tech-
niques or by crystallization.
Owing to the lack of any membranes or other hydro-
phobic compartments, the MPs expressed in a standard
CF system are primarily insoluble and can be isolated
only as a precipitate. Interestingly, the resolubilization
of CF produced MP precipitates is faster and more efﬁ-
cient if compared with the resolubilization of in vivo
produced inclusion bodies, indicating that signiﬁcant
structural differences between MPs obtained by the two
different modes of expression might exist [4]. However,
the precipitation of the MPs in the RM could cause
their partial or complete denaturation, and enzymatic
activities or other functions could be affected. The CF
expression of MPs in the presence of detergents, result-
ing in the production of soluble MPs inserted into
micelles, could therefore represent an interesting alter-
native to the CF expression of protein precipitates.
Initial data suggest that CF expression systems might
be tolerant for some detergents, and this would open
the unique opportunity to insert the target protein,
directly after translation, into the detergent micelles of
choice [2,3,5]. It is evident that the appropriate choice
of detergent, and also its concentration, should have a
major impact on its tolerance by the expression system
as well as on the expression efﬁciency and on the solu-
bility of a speciﬁc MP. In this report, we therefore
intended to evaluate the suitability of a representative
range of detergents for the soluble expression of MPs
in a deﬁned individual CF system.
To date, only a-helical MPs have been produced in
CF systems based on S30 extracts of E. coli cells [2–6].
It was unclear whether the preparative CF production
is applicable to a wider range of structurally diverse
MPs. We therefore included, in our work, the expres-
sion of three very different MPs (a) the a-helical
multidrug transporter, EmrE, of E. coli, with four
transmembrane segments (TMS), (b) the b-barrel type
nucleoside transporter, Tsx, of the outer membrane of
E. coli and (c) the a-helical eukaryotic porcine vaso-
pressin type 2 receptor of the family of G-protein
coupled receptors (GPCRs) with seven TMS. The pro-
duction of the three MPs in the presence of different
detergents was quantiﬁed and resulted in the identiﬁca-
tion of several detergents that are generally useful for
the high-level soluble expression of structurally very
diverse MPs. Representative samples of CF expressed
MPs have been structurally and functionally analyzed
and we present evidence for variations in the func-
tional folding of MPs that depend on their mode of
CF expression. This report extends the application of
the high-level CF production of MPs to b-barrel-type
proteins and will provide a comprehensive support for
the general CF production of soluble and functional
complex integral MPs with multiple TMS in the pres-
ence of detergents.
Results
Cell-free expression of EmrE, Tsx and V2R
as precipitates
All three proteins were expressed with an N-terminal
T7 tag and with a C-terminal poly(His)6 tag, by using
the plasmids pET21-emrE2, pET21-tsx and pET21-
v2R, in order to accelerate their puriﬁcation and to
enable a fast quantiﬁcation. The addition of the two
tags did not affect the protein expression, and the
obtained yields per 1 mL of RM were  2 mg for
EmrE, 4 mg for Tsx and 2 mg for V2R, by using the
standard protocol of our individual CF system [4]
without the addition of any detergents. All of the
detectable recombinant protein was produced as preci-
pitate (Fig. 1). Addition of the T7 tag proved to be
highly beneﬁcial for expression of the V2R protein as
almost no expression was detectable without the tag
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tion in the E. coli system, caused by the eukaryotic
codon sequence of the V2R gene, might account for
that observation. The CF expressed V2R protein has
an apparent molecular mass (m) of 36 kDa after analy-
sis by SDS⁄PAGE (Fig. 1), whereas the calculated
m should be 43 kDa. Incomplete denaturation of MPs
upon SDS⁄PAGE analysis is often considered to be
the reason for variations of the apparent and calcula-
ted m values. However, in order to exclude the pos-
sibility of premature termination during the CF
translation caused, for example, by rare codon usage
of the v2R gene, we veriﬁed the full-length expression
of V2R by detecting the C-terminal poly(His)6 tag with
the commercial Invision
TM in a gel staining procedure
(Invitrogen, Carlsbad, CA, USA) (Fig. 1). The addi-
tional larger band detected, with an m-value of
 70 kDa, can probably be attributed to an oligomeric
form of V2R.
Selected detergents from the types of phosphocho-
lines, long-chain phosphoglycerols, alkyl-glucosides,
steroids, polyoxyethylene-alkyl-ethers and polyethylene-
glycol derivatives were tested for their efﬁciency in the
resolubilization of the CF produced precipitates at
a ﬁnal concentration of 2% (Table 1). The strong
denaturating anionic detergent, sodium dodecyl sulfate
(SDS), was included into the analysis as a control for
the complete solubilization of the proteins. The washed
precipitates of CF produced MPs were suspended in
various detergents in 15 mm sodium phosphate, pH 8.0,
and incubated for 90 min on a shaker at 30  C. The
A
B
C
Fig. 1. Cell free (CF) production of the membrane proteins (MPs)
Tsx, V2R and EmrE, in different modes. The molecular mass (m)v a l -
ues of the marker proteins are shown. The arrows indicate the
expressed MPs. The protein concentration in 1 lL of reaction mix
(RM) is  10 lg. The nonsoluble parts of the RM were resolubilized
in suitable detergents in volumes equal to the corresponding RM
volume. Nonsolubilized protein was removed by centrifugation. (A)
CF expression of the b-barrel-type nucleoside transporter, Tsx, after
20 h of incubation. Samples of 0.8 lL were analyzed on a 12%
(w⁄v) SDS⁄Tris⁄glycine gel. Lane 1, marker; lane 2, supernatant
without added detergent; lane 3, suspended pellet without added
detergent; lane 4, pellet without added detergent resolubilized
in 2% (w/v) 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-gly-
cerol)] (LMPG); lane 5, supernatant with 0.1% (w/v) polyethylene
glycol P-1,1,3,3 tetramethyl butylphenyl ether (Triton X-100); lane 6,
8 lg of puriﬁed Tsx in 0.1% (w/v) Triton X-100; lane 7, supernatant
with 0.2% (w/v) polyoxyethylene-(20)-cetyl-ether (Brij-58); lane 8,
8 lg of puriﬁed Tsx in 0.2% (w/v) Brij-58. (B) CF expression of the
G-protein coupled receptor (GPCR) protein, V2R, after 20 h of incu-
bation. If not otherwise stated, samples of 1 lL were analyzed on a
12% SDS⁄Tris⁄glycine gel. Lane 1, marker; lane 2, suspended pellet
without added detergent; lane 3, suspended pellet without added
detergent stained with the Invision staining kit (Invitrogen) directed
against the poly(His)6 tag; lane 4, pellet without added detergent
resolubilized in 1% (w/v) LMPG; lane 5, supernatant with 1.5%
(w/v) Brij-58 at time ¼ 0 h; lane 6, supernatant with 1.5% (w/v)
Brij-58 at time ¼ 20 h; lane 7, 5 lg of puriﬁed V2R in 0.5% (w/v)
Brij-58; lane 8, 0.01 lL of supernatant with 0.5% (w/v) Brij-58
stained with an anti-(T7-tag) immunoglobulin coupled to horseradish
peroxidase. (C) CF expression of the small multidrug transporter,
EmrE, after 20 h of incubation. Samples of 0.5 lL were analyzed on
a 4–12% gradient gel (lanes 1–6) or on a 10% tricine gel (lanes 7
and 8). Lane 1, marker; lane 2, suspended pellet without added
detergent; lane 3, supernatant with 1.5% (w/v) Brij-58; lane 4,
supernatant with 0.2% 1,2-diheptanoyl-sn-glycero-3-phosphocholine
(DHPC); lane 5, supernatant with 0.1% (w/v) n-dodecyl-b-D-malto-
side (DDM); lane 6, supernatant with 0.75% (w/v) Chaps; lane 7,
0.2 lL of supernatant with 0.2% (w/v) Digitonin stained with an
anti-(T7-tag) immunoglobulin coupled to horseradish peroxidase;
lane 8, 0.2 lL of supernatant with 0.1% (w/v) dodecyl-phosphocho-
line (DPC) stained with an anti-(T7-tag) immunoglobulin coupled with
horseradish peroxidase.
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24  C) and the supernatant was analyzed on appropri-
ate SDS gels. The small multidrug transporter, EmrE,
was readily resolubilized in high quantities in most of
the detergents analyzed (Table 1). However, this is
obviously not a general attribute for all CF produced
MP precipitates. The quantitative resolubilization of
the GPCR protein, V2R, was only possible with the
long-chain phosphocholine, 1-myristoyl-2-hydroxy-sn-
glycero-3-[phospho-rac-(1-glycerol)] (LMPG), with the
other detergents having no, or only minor, resolubiliza-
tion effects. In addition, only LMPG and dodecyl
phosphocholine (DPC) were highly effective for the
resolubilization of the b-barrel type transporter, Tsx.
LMPG and probably similar long chain-phosphoglyce-
rols appear therefore to be the primary choice for a gen-
eral and efﬁcient resolubilization of even structurally
diverse types of MPs in mild detergents.
Cell-free expression of EmrE, Tsx and V2R
in the presence of detergents
CF expression provides, in general, an open system
without any membrane barriers, as in living cells,
and many additives that could potentially become
beneﬁcial for the recombinant protein can be added.
The supply of detergents to the CF reaction could thus
provide an important alternative approach in order to
produce directly soluble MPs. We therefore started
a systematic evaluation of a comprehensive selection
of detergents with respect (a) to their impact on the
productivity of a CF expression system, (b) to their
efﬁciencies in the direct solubilization of CF produced
MPs and (c) to their effects on the activity of the solu-
bilized MPs. In order to obtain relatively representa-
tive results, we analyzed the synthesis of the three
structurally very different MPs: EmrE, Tsx and V2R.
A total of 24 detergents, selected from the major types
commonly used for the solubilization of MPs, were tes-
ted for their suitability as an additive for the CF
expression of the three MPs; some important physico-
chemical characteristics of the selected detergents are
summarized in Table 2. All detergents were supple-
mented above their speciﬁc critical micellar concentra-
tions (CMCs), as speciﬁed in Table 2, and most were
added initially in concentration ranges from 0.1% to
0.2% (w/v). The production of MPs was analyzed in
analytical scale CF reactions after incubation for 20 h,
and the proteins in the soluble and unsoluble fractions
were quantiﬁed separately by western blot analysis
using speciﬁc antibodies directed against the terminal
T7- or poly(His)6 tags.
Few detergents turned out to become inhibitory to
the CF system at low concentrations and resulted in
an at least considerably reduced production of all three
MPs (Table 3). In particular, some of the phosphocho-
line derivatives seemed to be problematic as additives
in CF systems, while the mono-chain phosphocholines
were clearly more critical than the bi-chain phospho-
cholines. DPC almost completely inhibited general pro-
tein synthesis. However, the bi-chain phosphocholine,
1,2-dioctanoyl-sn-glycero-3-phosphocholine (diC8PC),
still resulted in the production of up to 0.6 mg of sol-
uble EmrE per mL of RM. The production of soluble
Tsx was not as effective and remained below
0.5 mgÆmL
)1 in the RM, while soluble V2R was only
spuriously detectable. Reducing the chain length in
diC7PC [1,2-diheptanoyl-sn-glycero-3-phosphocholine
(DHPC)] and 1,2-dihexanoyl-sn-glycero-3-phosphocho-
line (diC6PC) decreased the soluble expression of
EmrE to 0.47 mgÆmL
)1 and to 2 lgÆmL
)1 in the RM,
respectively. The detergent, diC6PC, clearly affected
the general CF protein synthesis, while DHPC and
diC8PC were still tolerated at even higher CMCs and
both were also relatively effective in the solubilization
of the Tsx protein. However, none of the phosphocho-
line derivatives tested was suitable for the high-level
CF expression of soluble V2R protein. Negative effects
on the CF system were further observed with the
Table 1. Solubilization of cell free (CF) produced protein precipi-
tates. Solubilization assays of CF produced membrane protein pre-
cipitates were carried out with  30 lg of protein in 2% (w⁄v)
detergent solution at 30  C for 90 min. Nonsoluble protein was
removed by centrifugation. Brij-35, polyoxyethylene-(23)-lauryl-ether;
b-OG, n-octy-b-glucopyranoside; CHAPS, 3-[(3-cholamidopropyl)
dimethylammonio]-1-propansulfonate; DDM, n-dodecyl-b-D-malto-
side; DHPC, 1,2-diheptanoyl-sn-glycero-3-phosphocholine; DPC,
dodecyl-phosphocholine; LMPG, 1-myristoyl-2-hydroxy-sn-glycero-3-
[phospho-rac-(1-glycerol)]; SDS, sodium dodecylsulfate; Thesit, poly-
ethylene glycol 400 dedecyl ether; Tween 20, polyoxyethylene sor-
bitan monolaurate 20.
Detergent
Solubilized
Tsx (%)
Solubilized
V2R (%)
Solubilized
EmrE (%)
SDS 100 100 100
DPC 90 10 90
DHPC 40 2 80
LMPG 90 90 95
b-OG 10 2 20
DDM 40 15 90
Digitonin 25 2 0
Chaps 20 0 90
Brij-35 10 10 10
Triton X-100 20 5 90
Thesit 5 0 50
Tween 20 0 0 60
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(b-OG), the steroid, Chaps, and the long-chain phos-
phoglycerol, LMPG. Chaps and b-OG are generally
considered to be relatively mild detergents, but their
high CMC, resulting in relatively high ﬁnal detergent
concentrations in the RM, might be a reason for the
observed inhibitory effect on protein expression.
LMPG, which was found to be highly suitable for the
resolubilization of CF produced precipitates, resulted,
only with Tsx, in the production of some 100 lgo f
soluble protein, while the total yield of protein was
considerably affected for all three MPs.
Approximately one-third of the tested detergents did
not have any, or only a marginal, effect on the solubility
of any of the expressed MPs, but they did not cause
marked decreases of the total protein production in the
range of the supplied concentrations. This group
includes polyethylene glycol 400 dedecyl ether (Thesit),
nonylphenyl polyethylene glycol (NP40), 1-palmitoyl-2-
hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] (LPPG)
and the polyoxyethylene derivatives polyoxyethylene-
(10)-cetyl-ether (Brij-56), polyoxyethylene-(2)-stearyl-
ether (Brij-72), polyoxyethylene-(10)-oleyl-ether
(Brij-97), polyoxyethylene-(10)-dodecyl-ether (Genapol
C-100) and polyoxyethylene sorbitan monolaurate 20
(Tween 20). Even with concentrations as high as
209· CMC in the case of Brij-56, only precipitated Tsx
protein was obtained in high yields. These detergents are
obviously tolerated by the CF system, even at higher
CMC concentrations, and they might still be beneﬁcial
for the soluble expression of other MPs. However, they
are clearly not suitable for general usage.
Several detergents from almost all analyzed groups
were found to be suitable for the soluble CF expression
of MPs, yielding production rates of more than 0.5 mg
of soluble MP per mL of RM (Table 3). With a total of
10 detergents, we obtained preparative scale soluble
expression yields for at least one of the analyzed MPs,
while the individual proteins behaved quite differently.
Again, EmrE and also Tsx could be solubilized by
numerous detergents, while the V2R protein was much
more selective. The most outstanding group of effective
Table 2. Physicochemical properties of the analyzed detergents
Detergent Short name Charge
a m (Da) CMC
b (mM)
Alkyl glucosides
n-Dodecyl-b-D-maltoside DDM N 511 0.12
n-Decyl-b-D-maltoside DM N 483 1.8
n-Octyl-b-D-glucopyranoside b-OG N 292 19
Steroid derivatives
Digitonin Digitonin N 1229 0.73
3-[(3-Cholamidopropyl)dimethylammonio]-1-propansulfonat Chaps Z 615 2.4–8.6
Long chain-phosphoglycerols:
1-Myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] LMPG A 479 0.05
1-Palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] LPPG A 507 NA
Mono-⁄bi-chain phosphocholines
1,2-Dioctanoyl-sn-glycero-3-phosphocholine diC8PC Z 510 0.22
1,2-Diheptanoyl-sn-glycero-3-phosphocholine DHPC Z 482 1.4
1,2-Dihexanoyl-sn-glycero-3-phosphocholine diC6PC Z 454 14
Dodecyl-phosphocholine DPC Z 352 0.9–1.5
Polyoxyethylene alkyl-ether
Polyoxyethylene-(23)-lauryl-ether (C12 ⁄ 23) Brij-35 N 1200 0.08
Polyoxyethylene-(10)-dodecyl-ether (C12 ⁄ 10) Genapol C-100 N 627 0.1
Polyoxyethylene-(10)-cetyl-ether (C16 ⁄ 10) Brij-56 N 682 0.035
Polyoxyethylene-(20)-cetyl-ether (C16 ⁄ 20) Brij-58 N 1123 0.075
Polyoxyethylene-(2)-stearyl-ether (C18 ⁄ 2) Brij-72 N 359 NA
Polyoxyethylene-(20)-stearyl-ether (C18 ⁄ 20) Brij-78 N 1152 0.046
Polyoxyethylene-(10)-oleyl-ether (C18-1 ⁄ 10) Brij-97 N 709 0.217
Polyoxyethylene-(20)-oleyl-ether (C18-1 ⁄ 20) Brij-98 N 1150 0.025
Polyoxyethylene-sorbitan-monolaurate 20 Tween 20 N 1228 0.059
Polyethylene glycol derivatives
Polyethylene-glycol P-1,1,3,3-tetramethyl-butylphenyl-ether Triton X-100 N 647 0.23
Polyethylene-glycol 400 dedecyl-ether Thesit N 583 0.1
Nonylphenyl-polyethylene-glycol NP40 N 603 0.05–0.3
a A, anionic; N, nonionic; Z, zwitterionic.
b Estimated critical micellar concentrations (CMCs). Averaged values are given if different CMCs for
a detergent have been published; NA, not available.
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alkyl-ethers, polyoxyethylene-(23)-lauryl-ether (Brij-35),
polyoxyethylene-(20)-cetyl-ether (Brij-58), polyoxyethyl-
ene-(20)-stearyl-ether (Brij-78) and polyoxyethylene-
(20)-oleyl-ether (Brij-98), and they resulted in the
high-level soluble expression of all three MPs analyzed.
In particular, in the case of V2R, production rates of
more than 1 mgÆmL
)1 in the RM were only possible
with Brij derivatives. Both the number of polyoxyethyl-
ene groups, as well as the length of the alkyl group, were
identiﬁed as important parameters for the solubilization
effect. The reduction in the number of polyoxyethylene
moieties to £10 almost completely abolished the solubi-
lization of all three MPs produced (Table 3). In addi-
tion, the chain length of the alkyl moiety speciﬁcally
affected the efﬁciency of soluble MP production. The
chain length of the alkyl moiety had a clear optimum at
C16 and C18 for the soluble expression of V2R, yielding
up to 3 mg of protein per mL of RM (Fig. 2). The
double bond in the oleyl-ether of Brij-98 and the short
chain lauryl-ether in Brij-35 considerably reduced the
yield of soluble V2R. The solubilization of the Tsx
protein was less sensitive to the chain length, but was
Fig. 2. Soluble expression of membrane proteins (MPs) in the pres-
ence of polyoxyethylene derivatives. The total amount (monomers
and oligomers) of soluble expressed protein was quantiﬁed after
20 h of CF expression. Values represent the means of at least two
determinations, and the variations were in the range of not more
than 15%.
Table 3. Cell free expression of membrane proteins in the presence of detergents. CMC, critical micellar concentration; S, soluble protein
production; P, protein produced as precipitate; NA, not analyzed; u, unknown.
a Detergents that result at least in one instance of the produc-
tion of > 500 lgÆmL
)1 soluble membrane proteins are given in bold.
b The ﬁnal concentrations of the detergents in the cell-free system for
the expression of the a-helical proteins EmrE and V2R are given. The numbers in parentheses indicate instances where different concentra-
tions were used for expression of the Tsx protein.
Detergent
Concentration EmrE
a Tsx
a V2R
a
(%) (x CMC) S⁄PS ⁄PS ⁄P
None – 0, 0⁄4, NA 0⁄40 , 0⁄4, NA
DDM 0.1 15.0 3, 1⁄1, 0 4⁄41 , 2⁄2, 3
DM 0.2 2.3 4, 1⁄3, 0 3⁄21 , 0⁄1, 0
b-OG 0.75 1.3 1, 2⁄0, 0 0⁄00 , 0⁄2, 1
Digitonin 0.4 4.5 3, 0⁄0, 0 4⁄43 , 3⁄2, 2
Chaps 0.75 1.5 1, 0⁄3, 0 2⁄30 , 0⁄0, 1
LMPG 0.01 4.2 1, 0⁄3, 0 3⁄31 , 1⁄3, 3
LPPG 0.025 U 0, 0⁄3, 1 0⁄42 , 1⁄4, 4
diC8PC 0.1 8.9 4, 2⁄4, 2 3⁄41 , 2⁄3, 3
DHPC 0.2 3.0 3, 3⁄2, 0 4⁄31 , 1⁄3, 3
diC6PC 0.75 1.2 1, 2⁄2, 2 3⁄31 , 1⁄3, 2
DPC 0.1 1.9 0, 1⁄0, 0 0⁄02 , 0⁄0, 1
Brij-35 0.1 10.4 4, 0⁄0, 2 4⁄03 , 3⁄2, 2
Brij-58 1.5 178.1 4, 0⁄2, 0 4⁄34 , 4⁄2, 2
Brij-78 1.0 189.0 4, 3⁄1, 0 4⁄24 , 4⁄2, 2
Brij-98 0.2 69.6 4, 0⁄0, 0 3⁄44 , 4⁄2, 2
Brij-56 0.01 (0.5) 4.2 (209) 1, 0⁄2, 2 0⁄42 , 2⁄1, 1
Brij-72 0.2 (0.33) U 2, 0⁄3, 0 0⁄32 , 2⁄2, 2
Brij-97 0.2 (0.5) 13.0 (17) 0, 0⁄4, 4 0⁄42 , 1⁄0, 0
Genapol C-100 0.1 21.3 2, 0⁄3, 2 0⁄42 , 2⁄1, 2
Tween 20 0.075 10.4 0, 0⁄4, 0 0⁄40 , 0⁄2, 2
Triton X-100 0.1 (0.2) 6.7 (13.4) 1, 0⁄4, 0 4⁄42 , 2⁄2, 2
Thesit 0.1 17.2 0, 0⁄3, 0 3⁄41 , 2⁄2, 2
NP40 0.1 (0.4) 9.8 (39) 2, 0⁄4, 3 2⁄41 , 1⁄1, 0
a The production of recombinant proteins, in lgÆmL
)1 of reaction mixture, was classiﬁed into ﬁve groups: 0, no detectable expression;
1, spurious expression (< 10 lgÆmL
)1); 2, 10–100 lgÆmL
)1; 3, 101–500 lgÆmL
)1; and 4, > 500 lgÆmL
)1. The estimated amounts of the
detected putatively oligomeric forms of the EmrE and V2R proteins are shown separately with italic numbers.
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moiety. In contrast, the highest amounts of the soluble
small multidrug transporter, EmrE, were produced with
Brij-35, containing the shorter lauryl-ether, and with
Brij-98, containing a double bond in the alkyl chain.
The steroid derivative, Digitonin, was identiﬁed as
a second relatively general solubilizing detergent
(Table 3). However, the yields obtained in the case of
EmrE and V2R remained mostly below 0.5 mgÆmL
)1
in the RM and were thus lower by comparison with
the above-mentioned Brij derivatives. The alkyl gluco-
sides, n-dodecyl-b-d-maltoside (DDM) and n-decyl-
b-maltoside (DM) resulted in the soluble expression of
only EmrE and Tsx in the range between 0.5 mg and
1.5 mg per mL of RM. The beneﬁcial effect of poly-
ethylene glycol P-1,1,3,3-tetramethyl-butylphenyl ether
(Triton X-100) was speciﬁc for the Tsx protein and
yielded soluble protein at a concentration of nearly
1m g ÆmL
)1 in the RM.
High yields of soluble MPs can be obtained
within a wide range of detergent concentrations
Besides the detergent structure, the supplied ﬁnal deter-
gent concentration in the RM is an important param-
eter for the production of soluble MP. As a critical
factor, the micellar concentration (Cmic) of the detergent
in the RM should be considered. The Cmic is calculated
from the molar detergent concentration minus the speci-
ﬁc CMC and divided by the speciﬁc aggregation num-
ber (number of detergent molecules per micelle). In the
optimal case, all protein can become solubilized as soon
the Cmic equals the molar concentration of the synthes-
ized MP. A further increase in detergent concentration
would then only result in the production of additional
and empty micelles. Likewise, with a Cmic below the
molar protein concentration, either heterogeneous
micelles with protein aggregates or residual protein pre-
cipitates in addition to the solubilized protein should be
formed. The titration of soluble expression of the Tsx
protein with different detergent concentrations com-
pletely agreed with this assumption (Fig. 3). With Tri-
ton X-100, a concentration of 7· CMC resulted in
maximal production of soluble protein and the yield
remained relatively constant upon further increases of
the detergent concentration. Similar results were
obtained with the detergents Brij-58 and Brij-78, with
threshold concentrations of  47· CMC and 76· CMC,
respectively (Fig. 3). However, it should be noted that
some residual precipitate of the Tsx protein remained,
even if the optimal detergent concentration was
exceeded several times (Table 3, data not shown). Some
protein obviously escapes; therefore, the solubilization
process in the CF reaction. With Digitonin and DDM,
concentration optima for the soluble Tsx production
were obtained with 2.2· CMC and 15· CMC, and
higher detergent concentrations resulted in a drastic
decrease of soluble protein. However, this reduction did
not favor an increase of nonsoluble precipitate and
could thus be attributed to an inhibitory effect of these
detergents at higher concentrations that generally
affects the efﬁciency of the CF expression system.
Secondary structure analysis of the V2R and Tsx
proteins and reconstitution into proteoliposomes
The functional folding and the structural conformation
of MPs are likely to depend on their mode of expres-
sion. Variations in the speciﬁc activity of a MP could
be obtained regardless of whether it has been produced
primarily as a precipitate or whether it could be inser-
ted in a hydrophobic environment, such as detergent
micelles, directly after translation. The transport activ-
ity of CF expressed EmrE protein, either as soluble
protein or resolubilized from precipitates, has already
been published [3,4]. CD spectroscopy is a ﬁrst and fast
technique for the analysis of secondary structures, and
V2R and Tsx samples produced by different CF expres-
sion modes were therefore analyzed using CD spectros-
copy (Fig. 4). The b-sheet content of the Tsx protein
varied between 45% and 58%, depending on whether
the protein was produced as a precipitate with subse-
quent resolubilization in LMPG, or whether it was syn-
thesized directly as soluble protein in the presence of
various detergents. Accordingly, the a-helical content
of the V2R protein varied considerably, between 32%
and almost 77%, depending on its mode of expression.
The soluble expression in the detergent, Brij-58, should
therefore result in the most native-like conformation
if a proposed, mostly a-helical, composition is
Fig. 3. Effect of detergent concentration on the soluble expression
of the transporter, Tsx. The total amount of soluble expressed pro-
tein was quantiﬁed after 20 h of cell free (CF) expression. Values
represent the means of at least two determinations and variations
were in the range of not more than 15%.
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native like conformation might also become induced
upon its transfer from detergent micelles into a lipid
membrane environment. LMPG-resolubilized V2R pro-
tein, with a relatively low calculated a-helical content
of  35%, was therefore reconstituted into membranes
composed of an E. coli lipid mixture, and the resulting
proteoliposomes were analyzed by freeze-fracture
electron microscopy (Fig. 5). The evenly and homo-
geneously distributed V2R particles in the membranes
gave evidence for a structural folding of the protein.
Functional folding of the CF expressed
nucleoside transporter, Tsx, depends on its mode
of expression
The activity of the nucleoside transporter, Tsx, syn-
thesized in different CF expression modes, was
Fig. 5. Freeze-fracture electron microscopy
of reconstituted V2R protein. Cell free (CF)
produced precipitate of V2R was resolubi-
lized in 1% (w/v) 1-myristoyl-2-hydroxy-
sn-glycero-3-[phospho-rac-(1-glycerol)]
(LMPG) in 15 mM sodium phosphate, pH 7.5,
and reconstituted into Escherichia coli
lipid mixture at a molar protein⁄lipid ratio
of 1 : 2500. The large arrow indicates
liposomes and the small arrow indicates
reconstituted protein.
Fig. 4. Secondary structure analysis of cell free (CF) produced membrane proteins (MPs) by CD spectroscopy. Approximately 15 lM protein
solubilized in detergent was analyzed at 25  Ci n1 0m M sodium phosphate, pH 8.0, containing 0.5 mM dithiothreitol. The proteins were
expressed either in the soluble form with Brij derivatives, n-dodecyl-b-D-maltoside (DDM) and Triton X-100 or resolubilized from CF produced
precipitates in 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] (LMPG). The proteins were puriﬁed by Ni-chelate chromatography
prior to analysis. The secondary structure composition was calculated by JASCO secondary structure estimation software. (A) Tsx; b-sheet:
Brij-58 (0.2% w/v), 58.5%; Brij-78 (0.4% w/v), 51.2%; DDM (0.1% w/v), 43.6%; Triton X-100 (0.1% w/v), 47.5%; LMPG (2% w/v), 45.4%.
(B) V2R; a-helix: Brij-35 (0.1% w/v), 31.8%; Brij-58 (0.5% w/v), 76.6%; Brij-78 (0.5% w/v), 27.3%; LMPG (1% w/v), 35.4%.
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assay. Tsx precipitates produced by standard CF reac-
tions without any supplemented detergent were resolu-
bilized in the detergents LMPG and DPC. In addition,
Tsx was soluble expressed in the presence of the deter-
gents Brij-35 and Triton X-100. All soluble Tsx sam-
ples were puriﬁed by Ni-chelate chromatography and
aliquots of  100 ng of protein, dissolved in a small
volume (5 lL maximum), were injected into preformed
BLMs separating two buffer chambers. An electric cur-
rent was measured between the two chambers, and the
functional reconstitution of the Tsx protein was deter-
mined by its pore-forming activity in the BLM, result-
ing in an increase of the conductance. The speciﬁcity
of the pore-forming activity for Tsx was further dem-
onstrated by inhibition with the substrate deoxyuri-
dine. A high activity, with a 200-fold increase in
conductance that speciﬁcally could be inhibited by the
nucleoside substrate, was observed with the Tsx sample
directly produced in a soluble form in the presence of
Triton X-100 (Fig. 6). The Tsx sample, soluble
expressed in the presence of Brij-35, showed a consid-
erably lower, but still signiﬁcant, 15-fold increase in
conductance if compared with the control. In contrast,
with the two resolubilized Tsx samples, only a three-
fold increase of the protein in DPC, and no increase at
all of the sample in LMPG, was detected.
Discussion
The choice of type and concentration of a detergent
can have an enormous impact on the yield and solubil-
ity of an individual MP, and the inﬂuence of deter-
gents on the CF reaction may further limit their
application. Few reports on the soluble expression of
integral MPs are available [2,3,5], but the relevance of
the nature of a detergent is not clear as extensive sys-
tematic studies have not been carried out and different
CF systems have been used. We therefore analyzed the
soluble synthesis of representatives of prokaryotic and
eukaryotic a-helical MPs with multiple TMS, as well
as a b-barrel type outer membrane protein, in an indi-
vidual and highly productive coupled transcrip-
tion⁄translation CF system in the continuous exchange
mode. In order to avoid the unfolding of the solubi-
lized MPs or of essential components of the CF sys-
tem, we focused, in our work, on relatively mild
detergents. A representative cross-section of biological
and industrial detergents, including nonionic detergents
[alkyl-glycosides (b-OG, DDM, DM)], polyoxyethyl-
ene-alkyl-ethers (Brij derivatives, Thesit, Genapol),
polyethylene-glycol derivatives (Triton, Tween, NP40),
steroid derivatives (Chaps, Digitonin), zwitterionic
detergents (DPC, DHPC, diC6PC, diC8PC), and long-
chain ionic detergents (LMPG, LPPG), were analyzed
for their suitability for the production of soluble MPs.
The addition of the alkyl-glycoside, b-OG, and of the
phosphocholine derivatives, DPC and diC6PC, abol-
ished any signiﬁcant protein expression or reduced it
to levels of £100 lgÆmL
)1 in the RM at relatively low
concentrations of 1–2· CMC. Common features of
this group are the short chain lengths and relatively
high CMCs of >1 mm (and up to 19 mm in the case
of b-OG). The relatively high concentration required
of those detergents in the CF system, in order to
obtain the required CMC levels for the MP solubiliza-
tion, could therefore be one reason for the observed
marked reduction in protein expression.
A B
Fig. 6. Functional analysis of the cell free (CF) expressed nucleoside transporter, Tsx, by the black lipid membrane (BLM) assay. Approxi-
mately 100 ng of puriﬁed Tsx protein solubilized in different detergents was reconstituted into black lipid membranes. A pore-forming activity
of Tsx was measured by an increase in conductance after 20 min of incubation. The Tsx pores were speciﬁcally blocked by addition of the
substrate, deoxyuridine. The background conductance of the membrane in the control was  10 nSÆcm
)1. (A) Resolubilized Tsx in 1-myris-
toyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] (LMPG) and dodecyl-phosphocholine (DPC). (B) soluble expressed Tsx in Triton X-100
and Brij-35.
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gents, the polyoxyethylene-alkyl-ethers, with a higher
polymerization number of the polyoxyethylene moiet-
ies, is especially suitable for the soluble CF expression
of even structurally diverse MPs. Polyoxyethylenes
with a shorter alkyl-chain length have a higher aggre-
gation number, and extensive ﬂuctuations in the micel-
lar shape could affect the stability of an inserted
protein and reduce its solubility [7]. The inﬂuence of
detergents on protein conformations becomes stronger
with an increase of their own ﬂexibility and with a
decrease in the size of their hydrophilic head [8,9]. This
might explain why especially long chain polyoxyethyl-
ene-alkyl-ethers have this generally high potential of
MP solubilization. It is noteworthy that Brij deriva-
tives, together with Digitonin, have been found to be
the only detergents suitable for the high-level soluble
expression of the V2R protein and also for other
GPCR proteins [5]. In contrast, the smaller MPs –
EmrE and Tsx – could also be effectively solubilized
by a much wider range of detergents, such as Triton
X-100, DDM, DM, DHPC and diC8PC. Accordingly,
Triton X-100, Brij 58, DDM and Chaps were found to
be compatible with a commercial CF system upon
expression of the a-helical bacterial mechanosensitive
channel, MscL [2]. Most of those detergents were also
optimal for the crystallization of several MPs [10].
The solubilization properties of a detergent depend
on its structure as well as on its concentration. In par-
ticular, the actual micellar concentration, Cmic, which
is determined by the speciﬁc aggregation number of a
detergent, has to be considered. The CMC is not a
constant parameter and is difﬁcult to measure with
high accuracy as it depends on experimental conditions
such as pH, salt concentrations and temperature.
Micelles do not have static structures, and even within
one type of detergent, the polydispersity of micelles
can vary considerably with the chain length [11,12].
Furthermore, the CMC and the effective m of protein–
detergent aggregates are believed to be determined
more by the structural properties of the protein than
by the properties of the detergent [13]. However, it is
generally assumed that the amount of detergent bind-
ing to the hydrophobic surface of an integral MP is
relatively constant above CMC [12] and an increase in
detergent concentration above Cmic barely inﬂuences
the protein solubility [14]. This is consistent with our
observation that the detergent concentrations for the
optimal solubilization of MPs follow a plateau-like
kinetics, and similar observations have been made
upon the expression of several GPCR proteins in a
batch mode CF system [5]. Further increased concen-
trations do not affect the protein expression as long as
the detergent is tolerated by the CF system. The speci-
ﬁc threshold concentration for an MP–detergent com-
bination might therefore be considered as the point of
molar equilibrium between Cmic and MP.
Several detergents are tolerated to some extent by
the CF system, but have no, or only minor, effects on
the solubilization of the analyzed MPs. Those deter-
gents comprise the long-chain phosphoglycerols,
LMPG and LPPG, the bile acid derivative, Chaps, and
the nonionic detergents, Tween 20, Thesit, Genapol
C-100, NP40 alternative and Brij-72. In this report, we
focused on the solubilization effects of pure detergent
micelles. Micelles mostly do not have regular spherical
shapes but are more of rather disorganized and com-
pact structures [12]. The inability of certain detergents
to solubilize or to stabilize an MP could thus arise
from an unstable or unfavorable packing of detergent
monomers on the surface of the protein and they still
might become beneﬁcial for the production of soluble
MPs in combination with other amphipathic solutes
[12]. The addition of lipids or other detergents could
help to eliminate packing defects upon the formation
of mixed micelles or bicelles. It is well known that spe-
ciﬁc lipids are often tightly associated with MPs [15]
and they can become important elements for the stabil-
ization of MPs and sometimes they can even be essen-
tial for a functional folding. In addition, the refolding
of precipitated MPs in detergents might beneﬁt from
added lipids [16].
Inclusion body formation is a well-known phenom-
enon upon conventional cellular expression of proteins,
especially in E. coli. The overproduced proteins precipi-
tate in a nonstructured and inactive form, and their
structural reconstitution usually requires solubilization
in a strong detergent, a chaotrope or in organic solvent
[17,18]. It should therefore be noted that the CF pro-
duced precipitates of MPs could be solubilized by much
milder conditions. In particular, LMPG was found to
have outstanding properties in the efﬁcient solubiliza-
tion of structurally different MPs. Lysolipids, such as
LMPG and the related LPPG, have been used in the
past to isolate large MPs in native and functional form
and to analyze small MPs by NMR spectroscopy
[19,20]. A survey of 25 different detergents revealed
lyso-phosphatidyl-glycerols as superior in stabilizing
protein conformations and in preventing the aggrega-
tion of monotopic and polytopic MPs at high concen-
trations [20]. This type of detergent might therefore
become highly interesting for the structural analysis of
CF produced MPs, especially when analyzed by NMR
techniques. However, solubilized precipitate of the Tsx
transporter in LMPG did not show any pore-forming
activity in the BLM assay, in contrast to the directly
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100. The functionality, but also the efﬁciency, of recon-
stitution of a MP can be clearly affected by the type of
detergent [21]. Despite the use of equal amounts of pro-
tein in the different BLM assays, the deﬁnite amount of
effectively reconstituted protein into the membrane
cannot be assessed. It can therefore not be differenti-
ated whether LMPG has inactivated Tsx by adoption
of a nonfunctional conformation or whether LMPG-
solubilized Tsx is just unable to effectively reconstitute
into the membrane of the BLM assay.
In general, the CF expression of MPs in the pres-
ence, as well as in the absence, of detergent can result
in functionally active protein. The EmrE protein was
highly active after resolubilization from a CF produced
precipitate in DPC [4], as well as after soluble expres-
sion in the presence of DDM [3]. The bacterial MscL
protein was functional after soluble expression in the
presence of Triton X-100 [2], and, moreover, CF pro-
duced precipitate of a bacterial light-harvesting MP
that has been solubilized in Triton X-100 was found to
be functionally folded [6]. The type of detergent is
clearly crucial in the solubilization process for the
recovery of MP activity, and high variations in the
speciﬁc activity can be obtained [11,22]. The secondary
structure analysis of the CF expressed V2R and Tsx
proteins revealed considerable variations that were
dependent on the mode of expression or on the added
type of detergent. EmrE, and also V2R, build multi-
mers in their native state, whereas the nucleoside
transporter, Tsx, only forms monomers [23–25]. The
detection of putative multimeric forms of EmrE in the
presence of, for example, Brij-78, DHPC or DM, while
only monomers could be observed in the presence of
Digitonin or other Brij derivatives, were further evi-
dence of structural variations that correlate with the
provided detergent. Furthermore, the marked differ-
ences in the speciﬁc activity of Tsx after soluble
expression in the presence of either Triton X-100 or
Brij-35 might also be attributed to structural varia-
tions. However, unfavourable detergents could be
exchanged after CF expression by gel ﬁltration with
another detergent that is more likely to support the
functional conformation of an MP [26]. Detergents
that have even reported to be deleterious for the activ-
ity of a solubilized MP could furthermore still be
effective in reconstitution trials because the addition of
lipids and the removal of detergent often protects the
MP against denaturation [27].
Integral outer membrane proteins of Gram-negative
bacteria are characteristic in using amphipathic
b-strands to traverse the membrane. All known struc-
tures show a typical meander topology of a closed
b-barrel in which the last b-strand is hydrogen bonded
to the ﬁrst. However, a considerable versatility of
b-barrels is illustrated by the variety of solved struc-
tures, such as those of general or speciﬁc porins [16,28].
Owing to the limitations on membrane-targeted expres-
sion, the majority of structurally analyzed outer mem-
brane proteins have been produced by the refolding of
inclusion bodies [16]. The 34 kDa outer membrane
protein, Tsx, of E. coli is functionally and structurally
highly conserved within enteric bacteria, with an over-
all identity of 78% [29]. Three different functions
could be assigned to Tsx: ﬁrst, the transport of desoxy-
nucleosides and nucleosides; second, the uptake of coli-
cine-like antibiotics; and third, the binding of speciﬁc
bacteriophages. According to its recently solved 3D
crystal structure, Tsx forms a monomeric, 12-stranded
b-barrel with six surface-exposed loops and a long and
narrow channel spanning the outer membrane and
containing several distinct nucleoside-binding sites [25].
The production of Tsx in concentrations of up to
4m g ÆmL
)1 in the RM is the ﬁrst example of the high-
level expression of a b-barrel protein in CF systems.
Moreover, the demonstrated functionality of the CF
produced Tsx opens a new avenue for the fast and efﬁ-
cient generation of correctly folded outer membrane
proteins for functional and structural analysis, and
conventional denaturation and tedious refolding steps
could be completely avoided.
GPCR proteins transmit a remarkable diversity of
endogenous signals into cellular responses by their lig-
and-induced association with hetero-trimeric G-protein
complexes that initiate downstream signalling cascades
involving effector enzymes, such as adenylate cyclase
and a variety of second messengers. The V2R receptor
belongs to the rhodopsin or A-type family of GPCRs,
having relatively short loop regions and the proposed
classical structure with seven TMS. GPCRs are linked
to a number of human hereditary diseases and it is
estimated that over 50% of all modern drugs are tar-
geted at GPCRs. The high-level CF expression of
GPCRs could provide an interesting alternative tool
for structural approaches. Besides the vasopressin type
2 receptor, the CF expression of the b2 adrenergic
receptor, the muscarinic acetylcholine receptor and the
neurotensin receptor in a batch mode CF system, in
concentrations of up to 150 lg per mL of RM, has
been reported [5]. The ligand-binding activity of the
CF-produced and refolded b2 adrenergic receptor
could be demonstrated, and also the V2R protein
appears to become folded in the presence of certain
detergents. It should be noted that the GPCRs men-
tioned had to be produced as a fusion with the relat-
ively large thioredoxin and were not expressed with
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ded that thioredoxin might confer a certain stabiliza-
tion effect to the MPs. Accordingly, the production of
the V2R protein was not detectable with a DNA
construct that generated the protein with its native
N-terminal end. However, we obtained a high-level
expression of the V2R protein with an N-terminal
extension of only 14 amino acids, comprising the small
T7 tag to the N-terminal end. In addition, the same
effect was observed with three further GPCR proteins,
(a) the endothelin B receptor, (b) the corticotropin-
releasing factor receptor and (c) the human vasopressin
type 2 receptor (data not shown). We therefore specu-
late that not a stabilization effect of an N-terminal
fusion protein, but rather an efﬁcient initiation of
translation provided by the codon region of the T7 tag
is effective for the high-level CF production of the
analyzed GPCR proteins.
There are marked differences in the solubilization of
MPs, during or after synthesis in a CF system, com-
pared with conventional solubilization from biological
membranes. The most obvious difference is that no
membranes have to be destabilized that might cause
conformational changes or even denaturation of the
inserted MPs [30]. The sudden loss of lateral pressure,
exposure of hydrophobic surfaces to water, and tran-
sient contacts with different solution conditions during
extensive puriﬁcation steps, often cause the structural
perturbation of MPs. During CF expression, the large
hydrophobic sector of integral MPs could become sur-
rounded by a detergent–micellar-like structure immedi-
ately after translation and⁄or folding, and the
exposure to aqueous solution conditions is extremely
minimized or even prevented. In addition, the elimin-
ation of puriﬁcation steps further avoids the structural
perturbation of MPs. The absence of any labelling
background enables the analysis of labelled MP sam-
ples by NMR spectroscopy directly in the CF reaction
mixture or after simple puriﬁcation steps [4,31]. Upon
solubilization of membranes, often a balance must be
found between the mildness of a detergent and its efﬁ-
ciency in covering the hydrophobic surfaces of the
membrane lipids. Suitable for the solubilization of
MPs out of membranes in a functional form are sev-
eral detergents that have also been involved in our
study, such as derivatives of Brij, Triton, bile-acid salts
and short-chain phospholipids, like DHPC [32]. The
latter, in particular, seem to be superior to most other
detergents as they better resemble the typical mem-
brane phospholipids as the natural environment of
MPs [11].
While similar results cannot be guaranteed for every
MP, our results strongly suggest several detergents that
should be among the ﬁrst of choice when testing the
soluble CF expression of a new protein, and that can
generally be recommended for the production of a
broader range of structurally different MPs. However,
optimized methods must certainly be elaborated for
each protein individually. The high-level CF produc-
tion of integral MPs, in combination with the signiﬁ-
cantly decreased concentration of proteins needed for
the production and X-ray analysis of microcrystals,
could enable new perspectives for combined structural
approaches.
Experimental procedures
DNA techniques
The tsx coding sequence was ampliﬁed from plasmid pTX5
[33] by standard PCR using the primers Tsx-up7
(CGGGGATCCGCTGAAAACGACAAACCGCAGTATC)
and Tsx-low7 (CGGCTCGAGGAAGTTGTAACCTACTA
CCAGGTAAC). The PCR product was restricted with
BamHI and XhoI, and ligated into the vector pET21a (Merck
Biosciences, Darmstadt, Germany), resulting in the plasmid
pET-tsx. The Tsx protein was produced without signal pep-
tide and, in addition to the native 272 amino acids, it was
modiﬁed at its N terminus with an additional 14 amino acids
(MASMTGGQQMGRGS) containing a T7 tag and with
the C-terminal poly(His)6 tag-containing sequence, LE-
HHHHHH. The coding sequence for the porcine V2R pro-
tein was ampliﬁed from cDNA [34] using standard PCR
and the primers V2R-upB (CGGGGATCCCTCAGAGCC
ACCACCTCGGCTGTG) and V2R-low (CGGCTCGA
GGGACGAGGTGTCCCTGGCCGAGAAGG). The PCR
product was ligated into the vector pET21a using BamHI
and XhoI restriction sites, resulting in plasmid pET-v2r. The
recombinant V2R protein contained, in addition to its native
370 amino acids, an N-terminal T7 tag and a C-terminal
poly(His)6 tag identical to that of the Tsx protein. The emrE
gene was ampliﬁed from chromosomal DNA of E. coli using
the primers EmrE-upB (CGGGGATCCATGAACCCTTA
TATTTATCTTGGTGG) and EmrE-lowX (CGGCTCG
AGATGTGGTGTGCTTCGTGACAA). The PCR product
was inserted into the BamHI and XhoI restriction sites of
the vector pET21a, and the resulting plasmid, pET21-
emrE2, was used for the expression of EmrE with an
N-terminal T7 tag and a C-terminal poly(His)6 tag.
Black lipid transport assay
The transport assay of the Tsx protein with black lipid
bilayer experiments was carried out as described in previous
publications [35,36] with minor modiﬁcations. The device
consists of a Teﬂon chamber with two aqueous compart-
ments ﬁlled with 100 mm potassium phosphate, pH 7.4,
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compartments had an area of  1m m
2. Membranes were
formed across the holes by applying a 1.25% diphytanoyl
phosphatidylcholine and 0.025% octadecylamin solution in
n-decane. Inactivation of Tsx by high-salt concentrations
was prevented by adding  100 ng of protein to the aque-
ous phase after the membranes had turned completely
black. The membrane current was measured at different
voltages by using a pair of matched calomel electrodes,
containing salt bridges, inserted into the aqueous solutions
on both sides of the membrane. The macroscopic conduct-
ance measurements were performed with an ITHACO
electrometer (ITHACO, NY, USA) and monitored using
an oscilloscope (Nicolet 310, Nicolet, WI, USA). The
experiments were carried out at 20–24  C, and an aqueous
solution of 200 mm deoxyuridine was used for the speciﬁc
inhibition of Tsx.
Cell-free expression
The bacterial CF extracts were prepared from the E. coli
strain, A19 (E. coli Genetic Stock Center CGSC, Depart-
ment of Molecular, Cellular and Development Biology,
Yale University, New Haven, CT, USA), as described
previously [4]. The reaction was performed in the CECF
mode using a membrane with a cut-off of 15 kDa, either
in the analytical scale of 70 lL of RM with an RM⁄FM
ratio of of 1 : 14 (v⁄v) in microdialysers (Spectrum
Laboratories Inc., Breda, the Netherlands) or in a pre-
parative scale of 1 mL of RM using a ratio of RM⁄FM
of 1 : 17 (v⁄v) in suitable dispodialysers (Spectrum
Laboratories Inc.). The reactions were incubated for 20 h
at 30  C in a shaker. The reaction conditions for the CF
reaction were as follows. RM and FM: 290 mm potas-
sium acetate; 15 mm magnesium acetate; 100 mm Hepes-
KOH, pH 8.0; 3.5 mm Tris-acetate, pH 8.2; 1.8 mm
EDTA; 0.2 mm folinic acid; 0.05% sodium azide; 2%
polyethylenglycol 8000; 2 mm 1,4-dithiothreitol; 1.2 mm
ATP; 0.8 mm each of CTP, UTP, and GTP; 20 mm ace-
tyl phosphate; 20 mm phosphoenol pyruvate; 1 tablet per
10 mL of complete protease inhibitor (Roche Diagnostics,
Mannheim, Germany); 2 mm of each of the amino acids
R, C, W, M, D and E; 1 mm of each of the other amino
acids; RM: 40 lgÆmL
)1 pyruvate kinase (Roche Diagnos-
tics); 500 lgÆmL
)1 E. coli tRNA (Roche Diagnostics);
0.3 UÆlL
)1 RNasin (Amersham Biosciences, Freiburg,
Germany); 6 UÆlL
)1 T7 RNA polymerase; 35% S30
extract and 15 lgÆmL
)1 plasmid DNA.
Detergents were obtained from Avanti Polar Lipids (Ala-
baster, AL, USA) (DHPC, DPC, LMPG, LPPG), Merck
Biosciences [Genapol C-100, Karlsruhe, Germany NP-40],
Carl Rothe (Chaps), Glycon (Luckenwalde, Germany)
(DDM, DM) and Sigma (Taufkirchen, Germany) (Brij-35,
Brij-56, Brij-58, Brij-72, Brij-78, Brij-97, Brij-98, diC6PC,
diC8PC, Digitonin, b-OG, Thesit, Triton X-100, Tween 20).
CD spectroscopy
CD spectroscopy was performed with a Jasco J-810 spectro-
polarimeter (Jasco Labortechnik, Gross-Umstadt, Germany)
in 10 mm sodium phosphate, pH 8.0, 0.5 mm 1,4-dithiothre-
itol, and with the appropriate detergent. Assays were carried
out at standard sensitivity with a band width of 2 nm and a
response of 4 s. The data pitch was 0.2 nm and the scanning
rate 100 nmÆmin
)1. The spectra were recorded from 190 to
260 nm at 25  C in a cuvette of 1 mm cell length. The pre-
sented data are the average of ﬁve scans and smoothed if
necessary by means-movement with a convolution width of
25. The a-helical and b-barrel content of proteins was calcu-
lated according to their secondary structure with the Jasco
secondary structure estimation program.
Preparation and analysis of proteoliposomes
The protein concentration of the GPCR V2R solubilized in
1% (w⁄v) LMPG was determined by UV measurement at
280 nm in 6 m guanidinum hydrochloride, pH 6.5, accord-
ing to its molar extinction coefﬁcient. Approximately 10 lm
of the protein sample in 15 mm sodium phosphate, pH 7.5,
was used for the reconstitution, and an E. coli lipid mixture
was added at a molar ratio of protein⁄lipid of 1 : 2500.
The solution was incubated at 30  C for 60 min. The deter-
gent was removed with washed biobeads SM-2 (Bio-Rad,
Hercules, CA, USA), presaturated with E. coli lipids that
were added in 10-fold excess to the detergent. The mixture
was incubated for 18 h at 30  C on a shaker while the bio-
beads were exchanged twice. The supernatant was then
removed, soniﬁed for 1 min in a water bath sonicator and
analyzed immediately or stored in liquid nitrogen. The pro-
teoliposomes were analyzed by freeze-fracture electron
microscopy, as described previously [4].
Analysis and puriﬁcation of proteins
For MP puriﬁcation, the RM was ﬁrst buffer exchanged on
a HiTrap-desalting column of an A ¨ kta Basic system (Amer-
sham Bioscience), at 4  C, in 20 mm Tris⁄HCl, pH 8.0,
containing the desired detergent. The proteins were further
puriﬁed by afﬁnity chromatography using a 1 mL HisTrap-
HP column at 4  C with a stepwise elution at 10, 20, 50,
250 and 500 mm imidazole in 20 mm Tris⁄HCl, pH 8.0,
500 mm sodium chloride and detergent. The Tsx and V2R
proteins eluted at 50 mm and 250 mm imidazole, respect-
ively. Suitable fractions were pooled and, if necessary, the
buffer was exchanged with HiTrap-desalting columns and
concentrated to  10 lm using a Vivaspin 0.5 mL concen-
trator (Vivascience AG, Hannover, Germany) with an m
cut-off of 10 kDa.
For western blot analysis, the proteins were separated
on a 10% (w⁄v) Tricine⁄SDS gel (EmrE) or on 12% (w⁄v)
Tris⁄glycine⁄SDS gels (Tsx and V2R). The gels were
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(Immobilon-P; Millipore, Eschborn, Germany) in a Hoefer
TE22 (Amersham Bioscience) wet western blot apparatus
for 1 h at 400 mA. The membrane was then blocked for
1 h in blocking-buffer containing 1 · NaCl⁄Tris (TBS),
7% (w⁄v) skim milk powder (Fluka, Buchs, Switzerland),
0.1% (w⁄v) sodium azide and 0.1% (w⁄v) Triton X-100.
The horseradish peroxidase-conjugated T7 tag antibody
(Merck Biosciences) and the primary mouse anti-His immu-
noglobulin (Merck Biosciences) were used at a dilution of
1 : 5000. After extensive washing, the blots were analyzed
by chemiluminescence in a Lumi-imager F1
TM (Roche
Diagnostics).
Proteins were quantiﬁed either according to a T7-tagged
standard protein (Merck Biosciences) on western blots, or
with SDS gels and appropriate mass standards by densi-
tometry using the biodocanalyze software (Biometra,
Go ¨ ttingen, Germany).
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l
i
 
l
i
p
i
d
 
m
i
x
t
u
r
e
 
(
A
v
a
n
t
i
-
L
i
p
i
d
s
,
 
A
l
a
b
a
s
t
e
r
,
 
U
S
A
)
 
s
t
o
c
k
 
s
u
s
p
e
n
s
i
o
n
,
 
5
0
 
m
g
/
m
l
 
i
n
 
 
d
i
s
t
i
l
l
e
d
 
w
a
t
e
r
.
 
3
.
 
B
T
 
B
i
o
-
b
e
a
d
s
 
S
M
-
2
 
(
B
i
o
r
a
d
,
 
M
ü
n
c
h
e
n
,
 
G
e
r
m
a
n
y
)
.
 
 
3
.
 
M
e
t
h
o
d
s
 
3
.
1
.
 
C
o
n
s
t
r
u
c
t
i
o
n
 
o
f
 
e
x
p
r
e
s
s
i
o
n
 
p
l
a
s
m
i
d
s
 
T
h
e
 
t
r
a
n
s
c
r
i
p
t
i
o
n
 
o
f
 
t
h
e
 
t
a
r
g
e
t
 
g
e
n
e
 
d
e
p
e
n
d
s
 
o
n
 
t
h
e
 
T
7
 
R
N
A
-
p
o
l
y
m
e
r
a
s
e
 
a
n
d
 
t
h
e
r
e
f
o
r
e
 
t
h
e
 
e
s
s
e
n
t
i
a
l
 
T
7
 
r
e
g
u
l
a
t
o
r
y
 
s
e
q
u
e
n
c
e
s
 
(
p
r
o
m
o
t
e
r
,
 
ε
-
e
n
h
a
n
c
e
r
 
o
r
 
g
1
0
 
s
e
q
u
e
n
c
e
,
 
r
i
b
o
s
o
m
a
l
 
b
i
n
d
i
n
g
 
s
i
t
e
 
(
R
B
S
)
,
 
t
e
r
m
i
n
a
t
o
r
)
 
n
e
e
d
 
t
o
 
f
l
a
n
k
 
t
h
e
 
c
o
d
i
n
g
 
r
e
g
i
o
n
 
(
s
e
e
 
F
i
g
.
 
1
)
.
 
S
t
a
n
d
a
r
d
 
e
x
p
r
e
s
s
i
o
n
 
v
e
c
t
o
r
s
 
l
i
k
e
 
t
h
a
t
 
o
f
 
t
h
e
 
p
E
T
 
s
e
r
i
e
s
 
c
a
n
 
b
e
 
u
s
e
d
 
f
o
r
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
(
s
e
e
 
N
o
t
e
 
6
)
.
 
 
3
.
2
.
 
P
r
e
p
a
r
a
t
i
o
n
 
o
f
 
t
h
e
 
S
3
0
 
c
e
l
l
-
f
r
e
e
 
e
x
t
r
a
c
t
 
T
h
e
 
p
r
e
p
a
r
a
t
i
o
n
 
o
f
 
t
h
e
 
S
3
0
-
e
x
t
r
a
c
t
 
i
n
c
l
u
d
e
s
 
f
e
r
m
e
n
t
a
t
i
o
n
 
a
n
d
 
h
a
r
v
e
s
t
i
n
g
 
o
f
 
t
h
e
 
c
e
l
l
s
,
 
t
h
e
 
c
e
l
l
 
d
i
s
r
u
p
t
i
o
n
,
 
r
u
n
-
o
f
f
 
p
r
o
c
e
d
u
r
e
 
a
n
d
 
d
i
a
l
y
s
i
s
.
 
W
h
i
l
e
 
w
e
 
r
e
c
o
m
m
e
n
d
 
t
o
 
f
i
n
i
s
h
 
t
h
e
 
c
o
m
p
l
e
t
e
 
p
r
o
c
e
s
s
 
c
o
n
s
e
c
u
t
i
v
e
l
y
,
 
t
h
e
 
p
r
o
t
o
c
o
l
 
c
o
u
l
d
 
o
p
t
i
o
n
a
l
l
y
 
b
e
 
i
n
t
e
r
r
u
p
t
e
d
 
a
f
t
e
r
 
t
h
e
 
h
a
r
v
e
s
t
i
n
g
 
s
t
e
p
 
(
s
e
e
 
N
o
t
e
 
7
)
.
 
T
h
e
 
q
u
a
l
i
t
y
 
o
f
 
i
n
d
i
v
i
d
u
a
l
 
b
a
t
c
h
e
s
 
o
f
 
S
3
0
-
e
x
t
r
a
c
t
s
 
c
a
n
 
v
a
r
y
 
c
o
n
s
i
d
e
r
a
b
l
y
 
a
n
d
 
a
t
 
l
e
a
s
t
 
a
n
 
o
p
t
i
m
i
z
a
t
i
o
n
 
f
o
r
 
t
h
e
 
M
g
2
+
 
a
n
d
 
K
+
 
i
o
n
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
s
h
o
u
l
d
 
b
e
 
m
a
d
e
 
f
o
r
 
e
a
c
h
 
n
e
w
 
p
r
e
p
a
r
a
t
i
o
n
.
 
 
 
1
.
 
 
T
a
k
e
 
a
 
f
r
e
s
h
 
o
v
e
r
n
i
g
h
t
 
c
u
l
t
u
r
e
 
f
r
o
m
 
t
h
e
 
E
.
 
c
o
l
i
 
s
t
r
a
i
n
 
A
1
9
 
i
n
 
T
B
 
m
e
d
i
u
m
 
a
n
d
 
 
i
n
o
c
u
l
a
t
e
 
1
0
 
l
i
t
e
r
s
 
o
f
 
T
B
 
m
e
d
i
u
m
 
i
n
 
a
 
f
e
r
m
e
n
t
e
r
 
a
t
 
a
 
r
a
t
i
o
 
o
f
 
1
:
1
0
 
(
s
e
e
 
N
o
t
e
 
8
)
.
 
2
.
 
 
I
n
c
u
b
a
t
e
 
t
h
e
 
c
e
l
l
s
 
a
t
 
3
7
o
C
 
w
i
t
h
 
v
i
g
o
r
o
u
s
 
s
t
i
r
r
i
n
g
 
a
n
d
 
g
o
o
d
 
a
e
r
a
t
i
o
n
.
  
7
 
3
.
 
 
C
o
n
t
r
o
l
 
t
h
e
 
b
a
c
t
e
r
i
a
l
 
g
r
o
w
t
h
s
 
b
y
 
m
e
a
s
u
r
i
n
g
 
t
h
e
 
o
p
t
i
c
a
l
 
d
e
n
s
i
t
y
 
a
t
 
5
9
5
 
n
m
 
u
n
t
i
l
 
t
h
e
 
c
e
l
l
s
 
 
r
e
a
c
h
 
t
h
e
 
m
i
d
-
l
o
g
 
p
h
a
s
e
 
c
o
r
r
e
s
p
o
n
d
i
n
g
 
t
o
 
a
n
 
O
D
5
9
5
 
o
f
 
a
p
p
r
.
 
3
.
5
 
(
s
e
e
 
N
o
t
e
 
9
)
.
 
 
4
.
 
 
S
w
i
t
c
h
 
o
f
f
 
t
h
e
 
h
e
a
t
i
n
g
 
o
f
 
t
h
e
 
f
e
r
m
e
n
t
e
r
 
a
n
d
 
c
h
i
l
l
 
d
o
w
n
 
t
h
e
 
b
r
o
t
h
 
t
o
 
≤
 
1
0
o
C
 
a
s
 
q
u
i
c
k
l
y
 
a
s
 
 
p
o
s
s
i
b
l
e
 
(
≤
 
4
5
 
m
i
n
.
)
 
i
n
 
o
r
d
e
r
 
t
o
 
s
t
a
l
l
 
t
h
e
 
g
r
o
w
t
h
 
o
f
 
t
h
e
 
b
a
c
t
e
r
i
a
 
(
s
e
e
 
N
o
t
e
 
1
0
)
.
 
T
h
e
 
f
i
n
a
l
 
 
O
D
5
9
5
 
o
f
 
t
h
e
 
b
r
o
t
h
 
a
f
t
e
r
 
c
o
o
l
i
n
g
 
s
h
o
u
l
d
 
b
e
 
≤
 
4
.
5
.
 
 
5
.
 
 
H
a
r
v
e
s
t
 
t
h
e
 
c
e
l
l
s
 
b
y
 
c
e
n
t
r
i
f
u
g
a
t
i
o
n
 
a
t
 
4
o
C
 
f
o
r
 
1
0
 
m
i
n
.
 
a
t
 
7
.
0
0
0
 
x
 
g
 
i
n
 
p
r
e
-
c
o
o
l
e
d
 
b
e
a
k
e
r
s
.
 
6
.
 
 
R
e
s
u
s
p
e
n
d
 
t
h
e
 
p
e
l
l
e
t
 
w
i
t
h
 
a
 
g
l
a
s
s
-
r
o
d
 
o
r
 
s
i
m
i
l
a
r
 
i
n
 
1
0
0
 
m
l
 
o
f
 
S
3
0
-
A
 
b
u
f
f
e
r
 
p
r
e
-
c
o
o
l
e
d
 
t
o
 
 
4
o
C
.
 
C
e
n
t
r
i
f
u
g
e
 
a
t
 
8
.
0
0
0
 
x
 
g
 
a
t
 
4
o
C
 
f
o
r
 
1
0
 
m
i
n
.
 
R
e
p
e
a
t
 
t
h
e
 
w
a
s
h
i
n
g
 
s
t
e
p
 
t
w
o
 
m
o
r
e
 
t
i
m
e
s
 
 
w
h
i
l
e
 
t
h
e
 
f
i
n
a
l
 
c
e
n
t
r
i
f
u
g
a
t
i
o
n
 
s
t
e
p
 
s
h
o
u
l
d
 
l
a
s
t
 
3
0
 
m
i
n
.
 
O
u
t
 
o
f
 
a
 
1
0
 
l
i
t
e
r
 
f
e
r
m
e
n
t
e
r
 
w
i
t
h
 
T
B
 
 
m
e
d
i
u
m
,
 
y
o
u
 
s
h
o
u
l
d
 
n
o
w
 
y
i
e
l
d
 
a
p
p
r
.
 
6
0
 
g
 
-
7
0
 
g
 
w
e
t
-
w
e
i
g
h
t
 
o
f
 
b
a
c
t
e
r
i
a
l
 
c
e
l
l
s
.
 
7
.
 
 
S
u
s
p
e
n
d
 
t
h
e
 
c
e
l
l
 
p
e
l
l
e
t
 
i
n
 
a
n
 
e
q
u
a
l
 
v
o
l
u
m
e
 
(
e
.
g
.
 
f
o
r
 
6
5
 
g
 
c
e
l
l
s
 
u
s
e
 
6
5
 
m
l
 
o
f
 
b
u
f
f
e
r
)
 
o
f
 
S
3
0
-
 
B
 
b
u
f
f
e
r
 
p
r
e
-
c
o
o
l
e
d
 
a
t
 
4
o
C
.
 
 
8
.
 
 
D
i
s
r
u
p
t
 
t
h
e
 
c
e
l
l
s
 
b
y
 
p
a
s
s
i
n
g
 
t
h
r
o
u
g
h
 
a
 
F
r
e
n
c
h
-
P
r
e
s
s
 
c
e
l
l
 
p
r
e
-
c
o
o
l
e
d
 
a
t
 
4
o
C
 
w
i
t
h
 
o
n
e
 
p
a
s
s
 
a
t
 
 
1
.
2
0
0
 
p
s
i
 
(
s
e
e
 
N
o
t
e
 
1
1
)
.
 
 
9
.
 
 
P
e
l
l
e
t
 
c
e
l
l
 
d
e
b
r
i
s
 
b
y
 
c
e
n
t
r
i
f
u
g
a
t
i
o
n
 
a
t
 
3
0
.
0
0
0
 
x
 
g
 
a
t
 
4
o
C
 
f
o
r
 
3
0
 
m
i
n
.
 
T
h
e
 
p
e
l
l
e
t
 
c
a
n
 
b
e
 
q
u
i
t
e
 
 
s
m
o
o
t
h
 
a
t
 
t
h
i
s
 
s
t
a
g
e
 
a
n
d
 
a
 
t
u
r
b
i
d
 
s
o
l
u
t
i
o
n
 
i
m
m
e
d
i
a
t
e
l
y
 
a
b
o
v
e
 
t
h
e
 
p
e
l
l
e
t
,
 
i
f
 
p
r
e
s
e
n
t
,
 
s
h
o
u
l
d
 
 
n
o
t
 
b
e
 
t
r
a
n
s
f
e
r
r
e
d
.
 
1
0
.
 
T
r
a
n
s
f
e
r
 
t
h
e
 
u
p
p
e
r
 
2
/
3
 
o
f
 
t
h
e
 
s
u
p
e
r
n
a
t
a
n
t
 
i
n
 
a
 
f
r
e
s
h
 
v
i
a
l
 
a
n
d
 
r
e
p
e
a
t
 
t
h
e
 
c
e
n
t
r
i
f
u
g
a
t
i
o
n
 
s
t
e
p
.
 
1
1
.
 
R
e
m
o
v
e
 
t
h
e
 
u
p
p
e
r
 
2
/
3
 
o
f
 
t
h
e
 
s
u
p
e
r
n
a
t
a
n
t
 
c
a
r
e
f
u
l
l
y
,
 
a
d
j
u
s
t
 
t
o
 
a
 
f
i
n
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
4
0
0
 
 
m
M
 
N
a
C
l
 
a
n
d
 
i
n
c
u
b
a
t
e
 
a
t
 
4
2
o
C
 
f
o
r
 
4
5
 
m
i
n
.
 
i
n
 
a
 
w
a
t
e
r
 
b
a
t
h
 
(
s
e
e
 
N
o
t
e
 
1
2
)
.
 
T
h
e
 
s
o
l
u
t
i
o
n
 
 
w
i
l
l
 
b
e
c
o
m
e
 
t
u
r
b
i
d
.
 
1
2
.
 
F
i
l
l
 
t
h
e
 
t
u
r
b
i
d
 
s
o
l
u
t
i
o
n
 
i
n
 
a
 
d
i
a
l
y
s
i
s
 
t
u
b
i
n
g
 
(
c
u
t
-
o
f
f
 
1
4
 
k
D
a
)
 
a
n
d
 
d
i
a
l
y
s
e
 
a
t
 
4
o
C
 
a
g
a
i
n
s
t
 
6
0
 
 
v
o
l
u
m
e
s
 
o
f
 
S
3
0
-
C
 
b
u
f
f
e
r
 
w
i
t
h
 
g
e
n
t
l
e
 
s
t
i
r
r
i
n
g
.
 
E
x
c
h
a
n
g
e
 
t
h
e
 
d
i
a
l
y
s
i
s
 
b
u
f
f
e
r
 
a
f
t
e
r
 
2
 
h
 
a
n
d
 
 
c
o
n
t
i
n
u
e
 
t
o
 
d
i
a
l
y
s
e
 
o
v
e
r
n
i
g
h
t
.
 
 
1
3
.
 
C
e
n
t
r
i
f
u
g
e
 
t
h
e
 
e
x
t
r
a
c
t
 
a
t
 
3
0
.
0
0
0
 
x
 
g
 
a
t
 
4
o
C
 
f
o
r
 
3
0
 
m
i
n
.
 
 
 
8
 
1
4
.
 
R
e
m
o
v
e
 
t
h
e
 
c
l
e
a
r
 
s
u
p
e
r
n
a
t
a
n
t
,
 
f
i
l
l
 
s
u
i
t
a
b
l
e
 
a
l
i
q
u
o
t
s
 
(
s
e
e
 
N
o
t
e
 
1
3
)
 
i
n
 
p
l
a
s
t
i
c
 
t
u
b
e
s
 
a
n
d
 
 
f
r
e
e
z
e
 
i
n
 
l
i
q
u
i
d
 
n
i
t
r
o
g
e
n
.
 
T
h
e
 
f
r
o
z
e
n
 
e
x
t
r
a
c
t
 
c
a
n
 
b
e
 
s
t
o
r
e
d
 
a
t
 
-
8
0
o
C
 
f
o
r
 
m
o
n
t
h
s
.
 
O
n
e
 
1
0
 
 
l
i
t
e
r
 
f
e
r
m
e
n
t
e
r
 
y
i
e
l
d
s
 
a
p
p
r
.
 
5
0
 
m
l
 
–
 
6
0
 
m
l
 
o
f
 
e
x
t
r
a
c
t
.
 
1
5
.
 
O
p
t
i
o
n
a
l
 
s
t
e
p
:
 
B
e
f
o
r
e
 
a
l
i
q
u
o
t
i
n
g
,
 
t
h
e
 
e
x
t
r
a
c
t
 
c
o
u
l
d
 
b
e
 
c
o
n
c
e
n
t
r
a
t
e
d
 
t
o
 
a
p
p
r
.
 
h
a
l
f
 
o
f
 
t
h
e
 
 
o
r
i
g
i
n
a
l
 
v
o
l
u
m
e
 
b
y
 
u
s
i
n
g
 
m
i
c
r
o
c
o
n
c
e
n
t
r
a
t
o
r
 
d
e
v
i
c
e
s
 
w
i
t
h
 
a
 
c
u
t
-
o
f
f
 
o
f
 
1
0
 
k
D
a
 
(
s
e
e
 
N
o
t
e
 
 
1
4
)
.
 
 
 
3
.
3
.
 
S
e
t
-
u
p
 
o
f
 
a
 
c
e
l
l
-
f
r
e
e
 
r
e
a
c
t
i
o
n
 
G
e
n
e
r
a
l
l
y
,
 
t
h
e
 
r
e
a
c
t
i
o
n
 
c
a
n
 
b
e
 
s
e
t
 
u
p
 
i
n
 
a
n
a
l
y
t
i
c
a
l
 
m
o
d
e
s
 
f
o
r
 
o
p
t
i
m
i
z
a
t
i
o
n
 
a
n
d
 
s
c
r
e
e
n
i
n
g
 
r
e
a
c
t
i
o
n
s
 
a
s
 
w
e
l
l
 
a
s
 
i
n
 
p
r
e
p
a
r
a
t
i
v
e
 
m
o
d
e
s
 
f
o
r
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
m
g
 
a
m
o
u
n
t
s
 
o
f
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
.
 
A
s
 
a
 
d
e
v
i
c
e
 
f
o
r
 
a
n
a
l
y
t
i
c
a
l
 
s
c
a
l
e
 
r
e
a
c
t
i
o
n
s
 
w
i
t
h
 
a
 
R
M
 
v
o
l
u
m
e
 
o
f
 
7
0
 
µ
l
,
 
m
i
c
r
o
d
i
a
l
y
s
e
r
s
 
t
h
a
t
 
a
r
e
 
c
o
m
m
e
r
c
i
a
l
l
y
 
a
v
a
i
l
a
b
l
e
 
w
i
t
h
 
d
i
f
f
e
r
e
n
t
 
M
W
C
O
’
s
 
c
a
n
 
b
e
 
u
s
e
d
 
(
s
e
e
 
F
i
g
.
 
2
A
 
a
n
d
 
N
o
t
e
 
1
5
)
.
 
F
o
r
 
p
r
e
p
a
r
a
t
i
v
e
 
r
e
a
c
t
i
o
n
s
 
w
i
t
h
 
R
M
 
v
o
l
u
m
e
s
 
o
f
 
5
0
0
 
µ
l
 
a
n
d
 
l
a
r
g
e
r
 
d
i
s
p
o
d
i
a
l
y
s
e
r
s
 
(
o
r
 
s
i
m
p
l
e
 
d
i
a
l
y
s
i
s
 
t
u
b
e
s
)
 
c
a
n
 
b
e
 
u
s
e
d
 
(
s
e
e
 
F
i
g
.
 
2
B
)
.
 
T
h
e
 
r
a
t
i
o
 
o
f
 
R
M
/
F
M
 
s
h
o
u
l
d
 
b
e
 
1
:
1
4
 
(
m
i
c
r
o
d
i
a
l
y
s
e
r
s
)
 
o
r
 
1
:
1
7
 
(
d
i
s
p
o
d
i
a
l
y
s
e
r
s
)
 
(
v
/
v
)
 
(
s
e
e
 
N
o
t
e
 
1
6
)
.
 
T
h
e
 
f
i
n
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
o
f
 
t
h
e
 
i
n
d
i
v
i
d
u
a
l
 
c
o
m
p
o
n
e
n
t
s
 
a
r
e
 
l
i
s
t
e
d
 
i
n
 
T
a
b
l
e
 
1
.
 
A
n
 
e
x
a
m
p
l
e
 
o
f
 
a
 
p
i
p
e
t
t
i
n
g
 
p
r
o
t
o
c
o
l
 
i
s
 
g
i
v
e
n
 
f
o
r
 
a
 
p
r
e
p
a
r
a
t
i
v
e
 
r
e
a
c
t
i
o
n
 
w
i
t
h
 
1
 
m
l
 
R
M
 
a
n
d
 
1
7
 
m
l
 
o
f
 
F
M
 
i
n
 
T
a
b
l
e
 
2
.
 
 
1
.
 
T
h
a
w
 
a
l
i
q
u
o
t
e
d
 
s
t
o
c
k
 
s
o
l
u
t
i
o
n
s
 
a
n
d
 
m
i
x
 
c
a
r
e
f
u
l
l
y
.
 
T
h
e
 
e
n
z
y
m
e
s
,
 
t
R
N
A
 
a
n
d
 
t
h
e
 
S
3
0
 
 
e
x
t
r
a
c
t
 
s
h
o
u
l
d
 
b
e
 
k
e
p
t
 
o
n
 
i
c
e
 
a
f
t
e
r
 
t
h
a
w
i
n
g
.
 
2
.
 
F
i
r
s
t
 
m
a
k
e
 
t
h
e
 
m
a
s
t
e
r
-
m
i
x
 
F
R
M
 
b
y
 
p
i
p
e
t
t
i
n
g
 
t
h
e
 
c
o
m
p
o
n
e
n
t
s
 
c
o
m
m
o
n
 
t
o
 
F
M
 
a
n
d
 
R
M
 
 
(
s
e
e
 
T
a
b
l
e
 
2
)
.
 
 
3
.
 
T
a
k
e
 
t
h
e
 
a
p
p
r
o
p
r
i
a
t
e
 
a
l
i
q
u
o
t
s
 
f
r
o
m
 
t
h
e
 
m
a
s
t
e
r
-
m
i
x
 
F
R
M
 
(
s
e
e
 
T
a
b
l
e
 
2
)
 
a
n
d
 
f
i
r
s
t
 
 
c
o
m
p
l
e
t
e
 
t
h
e
 
F
M
.
 
4
.
 
P
r
e
-
i
n
c
u
b
a
t
e
 
t
h
e
 
F
M
 
a
t
 
3
0
o
C
 
i
n
 
a
 
w
a
t
e
r
 
b
a
t
h
.
 
  
9
 
5
.
 
S
t
a
r
t
 
c
o
m
p
l
e
t
i
n
g
 
t
h
e
 
R
M
 
(
s
e
e
 
T
a
b
l
e
 
2
)
.
 
A
l
l
 
s
t
e
p
s
 
s
h
o
u
l
d
 
b
e
 
c
a
r
r
i
e
d
 
o
u
t
 
o
n
 
i
c
e
.
 
M
i
x
 
b
u
t
 
d
o
 
 
n
o
t
 
v
o
r
t
e
x
.
 
K
e
e
p
 
t
h
e
 
s
o
l
u
t
i
o
n
 
o
n
 
i
c
e
.
 
6
.
 
F
i
l
l
 
1
7
 
m
l
 
o
f
 
t
h
e
 
F
M
 
i
n
t
o
 
t
h
e
 
F
M
-
c
o
m
p
a
r
t
m
e
n
t
.
 
(
s
e
e
 
N
o
t
e
 
1
7
)
.
 
 
7
.
 
F
i
l
l
 
1
 
m
l
 
o
f
 
R
M
 
i
n
t
o
 
t
h
e
 
R
M
-
c
o
m
p
a
r
t
m
e
n
t
.
 
A
v
o
i
d
 
a
n
y
 
a
i
r
-
b
u
b
b
l
e
s
 
a
t
 
t
h
e
 
d
i
a
l
y
s
i
s
 
 
m
e
m
b
r
a
n
e
 
t
h
a
t
 
m
i
g
h
t
 
r
e
s
t
r
i
c
t
 
a
n
 
e
f
f
i
c
i
e
n
t
 
e
x
c
h
a
n
g
e
 
b
e
t
w
e
e
n
 
t
h
e
 
t
w
o
 
c
o
m
p
a
r
t
m
e
n
t
s
.
 
A
l
l
 
 
d
i
a
l
y
s
e
r
s
 
s
h
o
u
l
d
 
b
e
 
t
h
o
r
o
u
g
h
l
y
 
r
i
n
s
e
d
 
w
i
t
h
 
d
i
s
t
i
l
l
e
d
 
w
a
t
e
r
 
b
e
f
o
r
e
 
u
s
e
.
 
8
.
 
I
n
c
u
b
a
t
e
 
t
h
e
 
r
e
a
c
t
i
o
n
 
o
n
 
a
 
s
u
i
t
a
b
l
e
 
s
h
a
k
i
n
g
 
o
r
 
r
o
l
l
i
n
g
 
d
e
v
i
c
e
,
 
e
.
g
.
 
t
h
e
 
U
n
i
v
e
r
s
a
l
 
T
u
r
n
i
n
g
 
 
D
e
v
i
c
e
 
w
i
t
h
 
a
t
 
l
e
a
s
t
 
4
0
 
r
p
m
 
a
t
 
3
0
o
C
 
f
o
r
 
1
5
 
h
 
t
o
 
2
0
 
h
.
 
9
.
 
H
a
r
v
e
s
t
 
t
h
e
 
R
M
 
c
o
n
t
a
i
n
i
n
g
 
t
h
e
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
.
 
D
e
p
e
n
d
i
n
g
 
o
n
 
t
h
e
 
c
u
t
-
o
f
f
 
o
f
 
t
h
e
 
 
d
i
a
l
y
s
i
s
 
m
e
m
b
r
a
n
e
,
 
t
h
e
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
 
m
i
g
h
t
 
a
l
s
o
 
b
e
 
p
r
e
s
e
n
t
 
i
n
 
t
h
e
 
F
M
.
 
 
3
.
4
.
 
O
p
t
i
m
i
z
a
t
i
o
n
 
o
f
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
y
i
e
l
d
s
 
T
h
i
s
 
s
t
e
p
 
i
s
 
e
s
p
e
c
i
a
l
l
y
 
i
m
p
o
r
t
a
n
t
 
i
n
 
o
r
d
e
r
 
t
o
 
a
c
h
i
e
v
e
 
t
h
e
 
h
i
g
h
e
s
t
 
y
i
e
l
d
s
 
p
o
s
s
i
b
l
e
,
 
i
.
e
.
 
i
n
c
o
r
p
o
r
a
t
i
o
n
 
e
f
f
i
c
i
e
n
c
i
e
s
 
o
f
 
t
h
e
 
a
d
d
e
d
 
a
m
i
n
o
 
a
c
i
d
s
 
o
f
 
u
p
 
t
o
 
2
0
 
%
.
 
W
e
 
r
e
c
o
m
m
e
n
d
 
t
o
 
r
u
n
 
a
n
 
o
p
t
i
m
i
z
a
t
i
o
n
 
e
x
p
e
r
i
m
e
n
t
 
a
t
 
l
e
a
s
t
 
f
o
r
 
t
h
e
 
h
i
g
h
l
y
 
c
r
i
t
i
c
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
o
f
 
M
g
2
+
 
a
n
d
 
K
+
 
i
o
n
s
 
w
i
t
h
 
e
a
c
h
 
n
e
w
l
y
 
p
r
e
p
a
r
e
d
 
b
a
t
c
h
 
o
f
 
S
3
0
-
e
x
t
r
a
c
t
.
 
T
h
e
 
f
i
n
a
l
 
M
g
2
+
 
a
n
d
 
K
+
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
s
h
o
u
l
d
 
b
e
 
v
a
r
i
e
d
 
b
y
 
a
d
d
i
t
i
o
n
 
o
f
 
s
u
i
t
a
b
l
e
 
a
m
o
u
n
t
s
 
o
f
 
M
g
(
O
A
c
)
2
 
o
r
 
K
O
A
c
 
i
n
 
t
h
e
 
r
a
n
g
e
 
b
e
t
w
e
e
n
 
1
2
 
-
 
1
7
 
m
M
 
a
n
d
 
2
7
0
 
-
 
3
3
0
 
m
M
,
 
r
e
s
p
e
c
t
i
v
e
l
y
 
(
s
e
e
 
N
o
t
e
 
1
8
)
.
 
T
h
e
 
M
g
2
+
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
s
h
o
u
l
d
 
b
e
 
t
i
t
r
a
t
e
d
 
i
n
 
1
 
m
M
 
s
t
e
p
s
 
a
n
d
 
t
h
e
 
K
+
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
i
n
 
1
0
 
m
M
 
s
t
e
p
s
.
 
C
o
n
s
i
d
e
r
 
t
h
a
t
 
t
h
e
 
o
p
t
i
m
a
 
o
f
 
t
h
e
 
t
w
o
 
i
o
n
s
 
d
e
p
e
n
d
 
o
n
 
e
a
c
h
 
o
t
h
e
r
.
 
 
3
.
5
.
 
C
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
a
s
 
a
 
p
r
e
c
i
p
i
t
a
t
e
 
M
P
’
s
 
c
a
n
 
b
e
 
e
x
p
r
e
s
s
e
d
 
i
n
 
t
h
e
 
c
e
l
l
-
f
r
e
e
 
s
y
s
t
e
m
 
e
i
t
h
e
r
 
a
s
 
a
 
p
r
e
c
i
p
i
t
a
t
e
 
o
r
 
a
s
 
s
o
l
u
b
l
e
 
p
r
o
t
e
i
n
s
 
b
y
 
t
h
e
 
a
d
d
i
t
i
o
n
 
o
f
 
s
u
i
t
a
b
l
e
 
d
e
t
e
r
g
e
n
t
s
 
o
r
 
l
i
p
i
d
s
 
d
i
r
e
c
t
l
y
 
i
n
t
o
 
t
h
e
 
r
e
a
c
t
i
o
n
 
(
s
e
e
 
F
i
g
.
 
3
)
.
 
W
h
i
l
e
 
i
t
 
m
i
g
h
t
 
b
e
 
m
o
r
e
 
l
i
k
e
l
y
 
t
o
 
o
b
t
a
i
n
 
h
i
g
h
e
r
 
y
i
e
l
d
s
 
i
f
 
a
 
M
P
 
i
s
 
p
r
o
d
u
c
e
d
 
a
s
 
a
 
p
r
e
c
i
p
i
t
a
t
e
,
 
p
r
e
p
a
r
a
t
i
v
e
 
a
m
o
u
n
t
s
 
o
f
 
p
r
o
t
e
i
n
 
c
a
n
 
g
e
n
e
r
a
l
l
y
 
b
e
 
s
y
n
t
h
e
s
i
z
e
d
 
b
y
 
b
o
t
h
 
w
a
y
s
.
 
T
h
e
 
p
r
e
c
i
p
i
t
a
t
e
s
 
a
r
e
 
 
1
0
 
p
r
e
d
o
m
i
n
a
n
t
l
y
 
f
o
r
m
e
d
 
b
y
 
t
h
e
 
t
a
r
g
e
t
 
p
r
o
t
e
i
n
 
b
u
t
 
t
h
e
y
 
s
t
i
l
l
 
c
a
n
 
c
o
n
t
a
i
n
 
a
 
c
o
n
s
i
d
e
r
a
b
l
e
 
v
a
r
i
e
t
y
 
o
f
 
c
o
-
p
r
e
c
i
p
i
t
a
t
e
d
 
p
r
o
t
e
i
n
s
 
o
r
i
g
i
n
a
t
i
n
g
 
f
r
o
m
 
t
h
e
 
S
3
0
-
e
x
t
r
a
c
t
 
(
s
e
e
 
F
i
g
.
 
4
)
.
 
T
h
e
 
c
e
l
l
-
f
r
e
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
M
P
’
s
 
i
n
 
f
o
r
m
 
o
f
 
a
 
p
r
e
c
i
p
i
t
a
t
e
 
f
o
l
l
o
w
s
 
e
x
a
c
t
l
y
 
t
h
e
 
s
t
a
n
d
a
r
d
 
p
r
o
t
o
c
o
l
 
(
s
e
e
 
3
.
3
)
.
 
T
h
e
 
s
y
n
t
h
e
s
i
s
 
o
f
 
t
h
e
 
M
P
 
c
a
n
 
b
e
 
f
o
l
l
o
w
e
d
 
b
y
 
t
h
e
 
i
n
c
r
e
a
s
i
n
g
 
t
u
r
b
i
d
i
t
y
 
o
f
 
t
h
e
 
R
M
.
 
A
f
t
e
r
 
i
n
c
u
b
a
t
i
o
n
,
 
t
h
e
 
M
P
 
c
a
n
 
b
e
 
h
a
r
v
e
s
t
e
d
 
b
y
 
c
e
n
t
r
i
f
u
g
a
t
i
o
n
 
o
f
 
t
h
e
 
R
M
 
a
t
 
1
0
.
0
0
0
 
x
 
g
 
f
o
r
 
1
0
 
m
i
n
.
 
 
 
3
.
6
.
 
S
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
C
F
-
e
x
p
r
e
s
s
e
d
 
M
P
’
s
 
I
n
t
e
r
e
s
t
i
n
g
l
y
,
 
t
h
e
 
p
r
e
c
i
p
i
t
a
t
e
d
 
M
P
’
s
 
d
o
 
n
o
t
 
s
e
e
m
 
t
o
 
b
e
 
c
o
m
p
l
e
t
e
l
y
 
u
n
f
o
l
d
e
d
 
i
f
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
t
h
e
 
i
n
c
l
u
s
i
o
n
 
b
o
d
y
 
f
o
r
m
a
t
i
o
n
 
b
y
 
c
o
n
v
e
n
t
i
o
n
a
l
 
i
n
-
v
i
v
o
 
e
x
p
r
e
s
s
i
o
n
.
 
T
h
e
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
t
h
e
 
c
e
l
l
-
f
r
e
e
 
p
r
o
d
u
c
e
d
 
M
P
 
p
r
e
c
i
p
i
t
a
t
e
s
 
u
s
u
a
l
l
y
 
d
o
e
s
 
n
o
t
 
r
e
q
u
i
r
e
 
e
x
t
e
n
s
i
v
e
 
u
n
f
o
l
d
i
n
g
 
a
n
d
 
r
e
f
o
l
d
i
n
g
 
s
t
e
p
s
 
l
i
k
e
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
w
i
t
h
 
g
u
a
n
i
d
i
n
i
u
m
 
h
y
d
r
o
c
h
l
o
r
i
d
e
 
o
r
 
u
r
e
a
.
 
M
o
s
t
 
M
P
 
p
r
e
c
i
p
i
t
a
t
e
s
 
s
t
a
r
t
 
t
o
 
s
o
l
u
b
i
l
i
z
e
 
m
o
r
e
 
o
r
 
l
e
s
s
 
i
m
m
e
d
i
a
t
e
l
y
 
a
f
t
e
r
 
a
d
d
i
t
i
o
n
 
o
f
 
a
 
s
u
i
t
a
b
l
e
 
d
e
t
e
r
g
e
n
t
.
 
T
h
e
 
c
h
o
i
c
e
 
o
f
 
t
h
e
 
d
e
t
e
r
g
e
n
t
 
c
e
r
t
a
i
n
l
y
 
d
e
p
e
n
d
s
 
o
n
 
t
h
e
 
n
a
t
u
r
e
 
o
f
 
t
h
e
 
r
e
c
o
m
b
i
n
a
n
t
 
M
P
.
 
A
 
l
i
s
t
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
t
h
a
t
 
h
a
v
e
 
b
e
e
n
 
u
s
e
f
u
l
 
f
o
r
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
i
s
 
g
i
v
e
n
 
i
n
 
T
a
b
l
e
 
3
.
 
I
t
 
i
s
 
i
m
p
o
r
t
a
n
t
 
t
o
 
m
e
n
t
i
o
n
 
t
h
a
t
 
s
o
m
e
 
d
e
t
e
r
g
e
n
t
s
 
l
i
k
e
 
e
.
g
.
 
L
M
P
G
,
 
t
h
a
t
 
a
r
e
 
o
n
l
y
 
f
a
i
r
l
y
 
s
u
i
t
a
b
l
e
 
f
o
r
 
t
h
e
 
s
o
l
u
b
l
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
M
P
’
s
,
 
a
r
e
 
o
n
 
t
h
e
 
o
t
h
e
r
 
h
a
n
d
 
h
i
g
h
l
y
 
e
f
f
i
c
i
e
n
t
 
i
n
 
t
h
e
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
M
P
-
p
r
e
c
i
p
i
t
a
t
e
s
.
 
H
o
w
e
v
e
r
,
 
a
 
1
0
0
%
 
e
f
f
i
c
i
e
n
c
y
 
o
f
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
m
i
g
h
t
 
n
e
v
e
r
 
b
e
e
n
 
a
c
h
i
e
v
e
d
.
 
1
.
 
C
e
n
t
r
i
f
u
g
e
 
t
h
e
 
R
M
 
c
o
n
t
a
i
n
i
n
g
 
t
h
e
 
s
u
s
p
e
n
d
e
d
 
M
P
-
p
r
e
c
i
p
i
t
a
t
e
 
a
t
 
2
0
.
0
0
0
 
x
 
g
 
f
o
r
 
1
0
 
m
i
n
.
 
a
t
 
 
r
o
o
m
 
t
e
m
p
e
r
a
t
u
r
e
.
 
2
.
 
D
i
s
c
a
r
d
 
s
u
p
e
r
n
a
t
a
n
t
 
a
n
d
 
w
a
s
h
 
t
h
e
 
p
r
e
c
i
p
i
t
a
t
e
 
i
n
 
a
n
 
a
d
e
q
u
a
t
e
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
b
u
f
f
e
r
 
(
e
.
g
.
 
5
0
 
 
m
M
 
N
a
2
H
P
O
4
,
 
p
H
 
7
.
8
,
 
1
 
m
M
 
D
T
T
)
 
o
f
 
a
 
v
o
l
u
m
e
 
e
q
u
a
l
 
t
o
 
t
h
e
 
R
M
 
(
s
e
e
 
N
o
t
e
 
1
9
)
.
 
T
h
e
 
 
p
e
l
l
e
t
 
s
h
o
u
l
d
 
b
e
 
c
a
r
e
f
u
l
l
y
 
s
u
s
p
e
n
d
e
d
 
b
y
 
p
i
p
e
t
t
i
n
g
.
 
3
.
 
R
e
p
e
a
t
 
c
e
n
t
r
i
f
u
g
a
t
i
o
n
 
s
t
e
p
.
 
4
.
 
S
u
s
p
e
n
d
 
t
h
e
 
p
e
l
l
e
t
 
i
n
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
b
u
f
f
e
r
 
i
n
 
a
 
v
o
l
u
m
e
 
e
q
u
a
l
 
t
o
 
t
h
e
 
R
M
 
v
o
l
u
m
e
 
a
n
d
 
 
c
o
n
t
a
i
n
i
n
g
 
d
e
t
e
r
g
e
n
t
 
(
e
.
g
.
 
2
%
 
D
P
C
 
(
w
/
v
)
)
.
 
I
n
c
u
b
a
t
e
 
a
t
 
3
0
o
C
 
-
 
3
7
o
C
 
u
p
 
t
o
 
s
e
v
e
r
a
l
 
h
o
u
r
s
 
 
(
s
e
e
 
N
o
t
e
 
2
0
)
.
 
  
1
1
 
5
.
 
R
e
m
o
v
e
 
u
n
s
o
l
u
b
l
e
 
p
r
o
t
e
i
n
 
b
y
 
c
e
n
t
r
i
f
u
g
a
t
i
o
n
 
a
t
 
2
0
.
0
0
0
 
x
 
g
 
f
o
r
 
1
0
 
m
i
n
.
 
a
t
 
r
o
o
m
 
t
e
m
p
e
r
a
t
u
r
e
 
 
a
n
d
 
r
e
m
o
v
e
 
t
h
e
 
s
o
l
u
b
i
l
i
z
e
d
 
M
P
 
i
n
 
t
h
e
 
s
u
p
e
r
n
a
t
a
n
t
 
f
o
r
 
f
u
r
t
h
e
r
 
a
n
a
l
y
s
i
s
.
 
 
3
.
7
.
 
R
e
c
o
n
s
t
i
t
u
t
i
o
n
 
o
f
 
s
o
l
u
b
i
l
i
z
e
d
 
M
P
’
s
 
T
h
e
 
s
u
c
c
e
s
s
f
u
l
 
r
e
c
o
n
s
t
i
t
u
t
i
o
n
 
s
t
r
o
n
g
l
y
 
d
e
p
e
n
d
s
 
o
n
 
t
h
e
 
r
i
g
h
t
 
c
h
o
i
c
e
 
o
f
 
a
 
s
u
i
t
a
b
l
e
 
l
i
p
i
d
 
o
r
 
l
i
p
i
d
 
m
i
x
t
u
r
e
 
a
n
d
 
t
h
o
s
e
 
s
h
o
u
l
d
 
b
e
 
p
r
i
m
a
r
i
l
y
 
s
e
l
e
c
t
e
d
 
a
c
c
o
r
d
i
n
g
 
t
o
 
t
h
e
 
o
r
i
g
i
n
 
o
f
 
t
h
e
 
r
e
c
o
m
b
i
n
a
n
t
 
M
P
.
 
 
E
.
 
c
o
l
i
 
l
i
p
i
d
s
 
a
r
e
 
p
r
e
d
o
m
i
n
a
n
t
l
y
 
c
o
m
p
o
s
e
d
 
o
f
 
p
h
o
s
p
h
a
t
i
d
y
l
e
t
h
a
n
o
l
a
m
i
n
e
 
(
P
E
)
,
 
p
h
o
s
p
h
a
t
i
d
y
l
g
l
y
c
e
r
o
l
 
a
n
d
 
c
a
r
d
i
o
l
i
p
i
n
,
 
w
h
i
l
e
 
e
u
k
a
r
y
o
t
i
c
 
l
i
p
i
d
s
 
a
r
e
 
m
a
i
n
l
y
 
m
i
x
t
u
r
e
s
 
o
f
 
p
h
o
s
p
h
a
t
i
d
y
l
c
h
o
l
i
n
e
,
 
c
h
o
l
e
s
t
e
r
o
l
,
 
P
E
 
a
n
d
 
p
h
o
s
p
h
a
t
i
d
y
l
s
e
r
i
n
e
.
 
A
 
h
u
g
e
 
v
a
r
i
e
t
y
 
o
f
 
d
e
f
i
n
e
d
 
l
i
p
i
d
s
 
o
r
 
l
i
p
i
d
 
m
i
x
t
u
r
e
s
 
a
s
 
w
e
l
l
 
a
s
 
c
r
u
d
e
 
l
i
p
i
d
 
i
s
o
l
a
t
e
s
 
o
f
 
d
i
f
f
e
r
e
n
t
 
o
r
i
g
i
n
 
a
r
e
 
c
o
m
m
e
r
c
i
a
l
l
y
 
a
v
a
i
l
a
b
l
e
 
f
o
r
 
s
e
l
e
c
t
i
o
n
.
 
A
s
 
a
 
r
a
p
i
d
 
c
o
n
t
r
o
l
 
o
f
 
a
n
 
e
f
f
e
c
t
i
v
e
 
a
n
d
 
h
o
m
o
g
e
n
e
o
u
s
 
r
e
c
o
n
s
t
i
t
u
t
i
o
n
 
o
f
 
M
P
’
s
 
w
e
 
r
e
c
o
m
m
e
n
d
 
t
h
e
 
a
n
a
l
y
s
i
s
 
o
f
 
t
h
e
 
p
r
o
t
e
o
l
i
p
o
s
o
m
e
s
 
b
y
 
f
r
e
e
z
e
-
f
r
a
c
t
u
r
e
 
e
l
e
c
t
r
o
n
 
m
i
c
r
o
s
c
o
p
y
.
 
T
h
e
 
h
o
m
o
g
e
n
e
o
u
s
 
i
n
s
e
r
t
i
o
n
 
o
f
 
p
r
o
t
e
i
n
 
p
a
r
t
i
c
l
e
s
 
i
n
t
o
 
t
h
e
 
m
e
m
b
r
a
n
e
 
a
s
 
s
h
o
w
n
 
i
n
 
F
i
g
.
 
5
 
f
o
r
 
t
h
e
 
c
y
s
t
e
i
n
e
 
t
r
a
n
s
p
o
r
t
e
r
 
Y
f
i
K
 
p
r
o
v
i
d
e
s
 
f
i
r
s
t
 
e
v
i
d
e
n
c
e
 
o
f
 
a
 
s
t
r
u
c
t
u
r
a
l
 
a
n
d
 
f
u
n
c
t
i
o
n
a
l
 
r
e
c
o
n
s
t
i
t
u
t
i
o
n
 
o
f
 
t
h
e
 
M
P
.
 
A
s
 
a
n
 
e
x
a
m
p
l
e
,
 
w
e
 
d
e
s
c
r
i
b
e
 
t
h
e
 
r
e
c
o
n
s
t
i
t
u
t
i
o
n
 
o
f
 
a
 
C
F
 
p
r
o
d
u
c
e
d
 
M
P
 
i
n
 
a
n
 
E
.
 
c
o
l
i
 
l
i
p
i
d
 
m
i
x
t
u
r
e
.
 
 
1
.
 
A
d
d
 
E
.
 
c
o
l
i
 
l
i
p
i
d
s
 
(
5
0
 
m
g
/
m
l
 
i
n
 
w
a
t
e
r
)
 
i
n
 
a
 
m
o
l
a
r
 
r
a
t
i
o
 
o
f
 
2
0
0
0
 
:
 
1
 
(
l
i
p
i
d
 
:
 
M
P
)
 
t
o
 
t
h
e
 
 
s
o
l
u
b
i
l
i
z
e
d
 
p
r
o
t
e
i
n
.
 
2
.
 
I
n
c
u
b
a
t
e
 
a
t
 
3
0
o
C
 
f
o
r
 
o
n
e
 
h
o
u
r
.
 
3
.
 
W
a
s
h
 
7
5
0
 
m
g
 
b
i
o
b
e
a
d
s
 
i
n
 
1
0
 
m
l
 
o
f
 
1
0
0
 
%
 
m
e
t
h
a
n
o
l
,
 
l
e
t
 
t
h
e
 
b
i
o
b
e
a
d
s
 
s
e
t
t
l
e
 
d
o
w
n
 
a
n
d
 
 
d
i
s
c
a
r
d
 
t
h
e
 
s
u
p
e
r
n
a
t
a
n
t
.
 
4
.
 
W
a
s
h
 
t
h
e
 
b
i
o
b
e
a
d
s
 
t
h
r
e
e
-
t
i
m
e
s
 
w
i
t
h
 
1
0
 
m
l
 
o
f
 
d
i
s
t
i
l
l
e
d
 
w
a
t
e
r
 
5
.
 
F
i
n
a
l
l
y
 
w
a
s
h
 
t
h
e
 
b
i
o
b
e
a
d
s
 
t
w
o
-
t
i
m
e
s
 
i
n
 
t
h
e
 
b
u
f
f
e
r
 
u
s
e
d
 
f
o
r
 
t
h
e
 
d
e
t
e
r
g
e
n
t
 
s
o
l
u
t
i
o
n
 
6
.
 
P
r
e
s
a
t
u
r
a
t
i
o
n
 
w
i
t
h
 
l
i
p
i
d
s
:
 
A
d
d
 
1
0
0
 
u
l
 
o
f
 
t
h
e
 
l
i
p
i
d
 
s
u
s
p
e
n
s
i
o
n
 
t
o
 
1
 
m
l
 
o
f
 
w
a
s
h
e
d
 
b
i
o
b
e
a
d
s
 
 
i
n
 
1
0
 
m
l
 
o
f
 
d
e
t
e
r
g
e
n
t
 
b
u
f
f
e
r
 
(
e
.
g
.
 
2
5
 
m
M
 
H
E
P
E
S
,
 
p
H
 
7
.
4
,
 
1
5
0
 
m
M
 
N
a
C
l
)
 
a
n
d
 
i
n
c
u
b
a
t
e
 
f
o
r
 
 
3
0
 
m
i
n
.
 
a
t
 
R
T
.
 
 
1
2
 
7
.
 
A
d
d
 
l
i
p
i
d
-
p
r
e
s
a
t
u
r
a
t
e
d
 
b
i
o
b
e
a
d
s
 
i
n
 
a
 
r
a
t
i
o
 
b
i
o
b
e
a
d
s
 
:
 
d
e
t
e
r
g
e
n
t
 
o
f
 
1
0
0
 
:
 
1
 
(
w
/
w
)
 
t
o
 
a
 
v
i
a
l
 
 
c
o
n
t
a
i
n
i
n
g
 
t
h
e
 
m
i
c
e
l
l
e
 
s
u
s
p
e
n
s
i
o
n
 
a
n
d
 
l
e
t
 
t
h
e
 
d
e
t
e
r
g
e
n
t
 
a
d
s
o
r
b
 
t
o
 
t
h
e
 
b
i
o
b
e
a
d
s
 
b
y
 
 
i
n
c
u
b
a
t
i
o
n
 
o
n
 
a
 
s
h
a
k
e
r
 
a
t
 
3
0
o
C
.
 
8
.
 
I
n
c
u
b
a
t
e
 
o
v
e
r
-
n
i
g
h
t
 
o
n
 
a
 
s
h
a
k
e
r
 
a
t
 
3
0
o
C
.
 
9
.
 
 
N
e
x
t
 
m
o
r
n
i
n
g
,
 
r
e
m
o
v
e
 
t
h
e
 
v
i
a
l
 
f
r
o
m
 
t
h
e
 
s
h
a
k
e
r
,
 
l
e
t
 
t
h
e
 
b
i
o
b
e
a
d
s
 
s
e
t
t
l
e
 
d
o
w
n
 
a
n
d
 
t
r
a
n
s
f
e
r
 
 
t
h
e
 
s
u
p
e
r
n
a
t
a
n
t
 
i
n
t
o
 
a
 
n
e
w
 
v
i
a
l
.
 
T
h
e
n
 
i
n
c
u
b
a
t
e
 
w
i
t
h
 
a
 
s
e
c
o
n
d
 
a
l
i
q
u
o
t
 
o
f
 
l
i
p
i
d
-
p
r
e
s
a
t
u
r
a
t
e
d
 
 
b
i
o
b
e
a
d
s
 
f
o
r
 
6
 
h
o
u
r
s
 
a
t
 
3
0
o
C
 
o
n
 
a
 
s
h
a
k
e
r
.
 
1
0
.
 
H
a
r
v
e
s
t
 
t
h
e
 
s
u
p
e
r
n
a
t
a
n
t
 
c
o
n
t
a
i
n
i
n
g
 
t
h
e
 
p
r
o
t
e
o
l
i
p
o
s
o
m
e
s
.
 
T
h
e
 
p
r
o
t
e
o
l
i
p
o
s
o
m
e
s
 
c
a
n
 
b
e
 
 
s
t
o
r
e
d
 
a
t
 
4
o
C
 
u
n
t
i
l
 
o
r
 
f
r
o
z
e
n
 
i
n
 
l
i
q
u
i
d
 
n
i
t
r
o
g
e
n
 
u
n
t
i
l
 
f
u
r
t
h
e
r
 
a
n
a
l
y
s
i
s
.
 
 
3
.
8
.
 
C
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
s
o
l
u
b
l
e
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
1
.
 
T
h
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
s
o
l
u
b
l
e
 
M
P
’
s
 
i
n
 
t
h
e
 
p
r
e
p
a
r
a
t
i
v
e
 
s
c
a
l
e
 
c
a
n
 
r
e
q
u
i
r
e
 
f
i
r
s
t
 
s
o
m
e
 
 
o
p
t
i
m
i
z
a
t
i
o
n
 
s
t
e
p
s
 
i
n
 
o
r
d
e
r
 
t
o
 
e
v
a
l
u
a
t
e
 
t
h
e
 
o
p
t
i
m
a
l
 
r
e
a
c
t
i
o
n
 
c
o
n
d
i
t
i
o
n
s
.
 
A
t
 
t
h
e
 
b
e
g
i
n
n
i
n
g
,
 
 
o
n
l
y
 
s
o
m
e
 
μ
g
 
o
f
 
p
r
o
t
e
i
n
 
m
i
g
h
t
 
b
e
 
p
r
o
d
u
c
e
d
.
 
W
e
 
t
h
e
r
e
f
o
r
e
 
r
e
c
o
m
m
e
n
d
 
t
h
e
 
a
d
d
i
t
i
o
n
 
o
f
 
a
n
 
 
a
n
t
i
g
e
n
 
e
p
i
t
o
p
e
 
t
a
g
 
l
i
k
e
 
t
h
e
 
T
7
-
t
a
g
 
a
t
 
t
h
e
 
N
-
t
e
r
m
i
n
a
l
 
e
n
d
 
o
f
 
t
h
e
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
 
i
n
 
 
o
r
d
e
r
 
t
o
 
f
a
c
i
l
i
t
a
t
e
 
t
h
e
 
d
e
t
e
c
t
i
o
n
 
o
f
 
t
h
e
 
e
x
p
r
e
s
s
e
d
 
M
P
 
i
n
 
w
e
s
t
e
r
n
-
b
l
o
t
s
.
 
F
u
r
t
h
e
r
m
o
r
e
,
 
a
n
 
 
a
d
d
i
t
i
o
n
a
l
 
p
o
l
y
(
H
i
s
)
6
-
t
a
g
 
a
t
 
t
h
e
 
C
-
t
e
r
m
i
n
a
l
 
e
n
d
 
o
f
 
t
h
e
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
 
w
o
u
l
d
 
e
n
a
b
l
e
 
 
t
h
e
 
f
a
s
t
 
p
u
r
i
f
i
c
a
t
i
o
n
 
o
u
t
 
o
f
 
t
h
e
 
R
M
 
b
y
 
s
t
a
n
d
a
r
d
 
m
e
t
a
l
-
c
h
e
l
a
t
e
-
c
h
r
o
m
a
t
o
g
r
a
p
h
y
 
.
 
2
.
 
T
h
e
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
 
i
s
 
c
o
n
s
i
d
e
r
a
b
l
y
 
t
o
l
e
r
a
n
t
 
a
g
a
i
n
s
t
 
a
 
v
a
r
i
e
t
y
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
 
e
v
e
n
 
i
f
 
s
u
p
p
l
i
e
d
 
i
n
 
r
e
l
a
t
i
v
e
l
y
 
h
i
g
h
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
(
4
-
6
)
.
 
D
e
t
e
r
g
e
n
t
s
 
t
h
a
t
 
a
r
e
 
c
o
m
p
a
t
i
b
l
e
 
 
w
i
t
h
 
t
h
e
 
C
F
 
s
y
n
t
h
e
s
i
s
 
c
a
n
 
b
e
 
e
i
t
h
e
r
 
i
o
n
i
c
 
o
r
 
n
o
n
-
i
o
n
i
c
,
 
b
u
t
 
i
n
 
m
o
s
t
 
c
a
s
e
s
 
t
h
e
y
 
h
a
v
e
 
a
 
 
r
e
l
a
t
i
v
e
l
y
 
l
o
w
 
c
r
i
t
i
c
a
l
 
m
i
c
e
l
l
a
r
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
C
M
C
)
.
 
F
i
r
s
t
,
 
t
h
e
 
m
o
s
t
 
a
p
p
r
o
p
r
i
a
t
e
 
 
d
e
t
e
r
g
e
n
t
s
 
h
a
v
e
 
t
o
 
b
e
 
i
d
e
n
t
i
f
i
e
d
 
a
s
 
t
h
e
i
r
 
e
f
f
e
c
t
s
 
o
n
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
a
n
d
 
s
o
l
u
b
i
l
i
t
y
 
o
f
 
s
p
e
c
i
f
i
c
 
 
M
P
’
s
 
c
a
n
 
b
e
 
v
e
r
y
 
d
i
f
f
e
r
e
n
t
 
(
s
e
e
 
F
i
g
.
 
6
)
.
 
O
v
e
r
a
l
l
,
 
B
r
i
j
-
3
5
 
h
a
s
 
s
o
 
f
a
r
 
t
u
r
n
e
d
 
o
u
t
 
t
o
 
b
e
 
o
n
e
 
o
f
 
 
t
h
e
 
m
o
s
t
 
e
f
f
e
c
t
i
v
e
 
d
e
t
e
r
g
e
n
t
s
 
f
o
r
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
s
o
l
u
b
l
e
 
M
P
’
s
 
(
s
e
e
 
T
a
b
l
e
 
3
 
a
n
d
 
F
i
g
.
 
6
)
.
 
 
A
 
d
e
t
e
r
g
e
n
t
 
s
c
r
e
e
n
 
i
n
c
l
u
d
i
n
g
 
a
 
v
a
r
i
e
t
y
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
(
s
e
e
 
T
a
b
l
e
 
3
)
 
s
h
o
u
l
d
 
b
e
 
s
e
t
 
u
p
 
i
n
 
t
h
e
  
1
3
 
 
a
n
a
l
y
t
i
c
a
l
 
s
c
a
l
e
 
m
o
d
e
.
 
A
n
 
e
x
a
m
p
l
e
 
f
o
r
 
t
h
e
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
t
h
e
 
n
u
c
l
e
o
s
i
d
e
 
t
r
a
n
s
p
o
r
t
e
r
 
T
s
x
 
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
d
i
f
f
e
r
e
n
t
 
d
e
t
e
r
g
e
n
t
s
 
i
s
 
s
h
o
w
n
 
i
n
 
F
i
g
.
 
6
.
 
I
n
 
t
h
a
t
 
c
a
s
e
,
 
B
r
i
j
-
3
5
,
 
T
r
i
t
o
n
 
X
-
1
0
0
 
 
a
n
d
 
D
D
M
 
w
o
u
l
d
 
c
l
e
a
r
l
y
 
b
e
 
t
h
e
 
b
e
s
t
 
c
h
o
i
c
e
s
 
i
n
 
o
r
d
e
r
 
t
o
 
p
r
o
d
u
c
e
 
s
o
l
u
b
l
e
 
p
r
o
t
e
i
n
.
 
A
l
s
o
 
t
h
e
 
 
a
d
d
i
t
i
o
n
 
o
f
 
m
i
x
e
d
 
m
i
c
e
l
l
e
s
 
c
o
m
p
o
s
e
d
 
o
f
 
t
w
o
 
o
r
 
m
o
r
e
 
d
e
t
e
r
g
e
n
t
s
 
m
i
g
h
t
 
b
e
 
c
o
n
s
i
d
e
r
e
d
.
 
T
h
e
 
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
M
P
’
s
 
c
a
n
 
b
e
 
m
o
n
i
t
o
r
e
d
 
b
y
 
C
o
o
m
a
s
s
i
e
-
B
l
u
e
 
s
t
a
i
n
i
n
g
 
o
r
 
w
e
s
t
e
r
n
-
b
l
o
t
t
i
n
g
 
 
a
f
t
e
r
 
s
e
p
a
r
a
t
i
o
n
 
o
f
 
t
h
e
 
R
M
 
b
y
 
S
D
S
-
p
o
l
y
a
c
r
y
l
a
m
i
d
e
 
g
e
l
-
e
l
e
c
t
r
o
p
h
o
r
e
s
i
s
.
 
I
n
 
o
r
d
e
r
 
t
o
 
 
d
i
f
f
e
r
e
n
t
i
a
t
e
 
b
e
t
w
e
e
n
 
s
o
l
u
b
l
e
 
M
P
’
s
 
a
n
d
 
p
r
e
c
i
p
i
t
a
t
e
,
 
t
h
e
 
R
M
 
s
h
o
u
l
d
 
b
e
 
f
r
a
c
t
i
o
n
a
t
e
d
 
b
y
 
 
c
e
n
t
r
i
f
u
g
a
t
i
o
n
 
a
t
 
2
0
.
0
0
0
 
x
 
g
 
f
o
r
 
3
0
 
m
i
n
.
 
a
t
 
R
T
 
p
r
i
o
r
 
t
o
 
a
n
a
l
y
s
i
s
.
 
3
.
 
A
f
t
e
r
 
t
h
e
 
m
o
s
t
 
s
u
i
t
a
b
l
e
 
d
e
t
e
r
g
e
n
t
s
 
f
o
r
 
y
o
u
r
 
s
p
e
c
i
f
i
c
 
p
r
o
t
e
i
n
 
h
a
v
e
 
b
e
e
n
 
i
d
e
n
t
i
f
i
e
d
,
 
r
u
n
 
a
 
 
s
e
c
o
n
d
 
s
e
r
i
e
s
 
o
f
 
a
n
a
l
y
t
i
c
a
l
 
s
c
a
l
e
 
r
e
a
c
t
i
o
n
s
 
i
n
 
o
r
d
e
r
 
t
o
 
d
e
f
i
n
e
 
t
h
e
 
o
p
t
i
m
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
 
t
h
e
 
p
r
e
f
e
r
r
e
d
 
d
e
t
e
r
g
e
n
t
.
 
E
.
g
.
 
t
h
e
 
h
i
g
h
e
s
t
 
y
i
e
l
d
s
 
o
f
 
s
o
l
u
b
l
e
 
T
s
x
 
p
r
o
t
e
i
n
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
T
r
i
t
o
n
 
 
X
-
1
0
0
 
w
e
r
e
 
o
n
l
y
 
o
b
t
a
i
n
e
d
 
a
t
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
o
f
 
4
x
 
C
M
C
 
a
n
d
 
a
b
o
v
e
 
(
s
e
e
 
F
i
g
.
 
6
)
.
 
 
4
.
 
T
h
e
 
s
o
l
u
b
i
l
i
z
e
d
 
M
P
’
s
 
i
n
 
m
i
c
e
l
l
e
s
 
m
i
g
h
t
 
n
o
t
 
n
e
c
e
s
s
a
r
i
l
y
 
a
d
o
p
t
 
a
 
s
t
r
u
c
t
u
r
e
d
 
a
n
d
 
f
u
n
c
t
i
o
n
a
l
 
 
c
o
n
f
o
r
m
a
t
i
o
n
.
 
A
 
r
a
p
i
d
 
f
i
r
s
t
 
a
n
a
l
y
s
i
s
 
o
f
 
t
h
e
 
M
P
 
s
t
r
u
c
t
u
r
e
 
s
h
o
u
l
d
 
t
h
e
r
e
f
o
r
e
 
b
e
 
c
a
r
r
i
e
d
 
o
u
t
 
i
n
 
 
o
r
d
e
r
 
t
o
 
v
e
r
i
f
y
 
t
h
e
 
s
t
r
u
c
t
u
r
e
d
 
f
o
l
d
i
n
g
 
o
f
 
t
h
e
 
C
F
 
e
x
p
r
e
s
s
e
d
 
M
P
.
 
S
u
i
t
a
b
l
e
 
t
e
c
h
n
i
q
u
e
s
 
m
i
g
h
t
 
 
b
e
 
C
i
r
c
u
l
a
r
 
D
i
c
h
r
o
i
s
m
 
s
p
e
c
t
r
o
s
c
o
p
y
 
o
r
 
t
h
e
 
r
e
c
o
r
d
i
n
g
 
o
f
 
h
e
t
e
r
o
n
u
c
l
e
a
r
 
s
i
n
g
l
e
 
q
u
a
n
t
u
m
 
 
c
o
r
r
e
l
a
t
i
o
n
 
s
p
e
c
t
r
a
 
b
y
 
s
o
l
u
t
i
o
n
 
N
M
R
 
s
p
e
c
t
r
o
s
c
o
p
y
.
 
H
i
g
h
l
y
 
v
a
l
u
a
b
l
e
 
w
o
u
l
d
 
b
e
 
c
e
r
t
a
i
n
l
y
 
t
h
e
 
 
a
v
a
i
l
a
b
i
l
i
t
y
 
o
f
 
a
n
y
 
a
c
t
i
v
i
t
y
 
o
r
 
b
i
n
d
i
n
g
 
a
s
s
a
y
.
 
 
 
4
.
 
N
o
t
e
s
 
1
.
 
T
7
 
R
N
A
-
p
o
l
y
m
e
r
a
s
e
 
w
i
l
l
 
b
e
 
t
h
e
 
m
o
s
t
 
e
x
p
e
n
s
i
v
e
 
c
o
m
p
o
n
e
n
t
 
o
f
 
t
h
e
 
r
e
a
c
t
i
o
n
 
a
n
d
 
i
n
 
 
a
d
d
i
t
i
o
n
,
 
c
o
m
m
e
r
c
i
a
l
 
e
n
z
y
m
e
s
 
a
r
e
 
o
f
t
e
n
 
t
o
o
 
l
o
w
 
c
o
n
c
e
n
t
r
a
t
e
d
.
 
A
t
 
l
e
a
s
t
 
3
 
u
n
i
t
s
 
f
i
n
a
l
 
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
T
7
 
R
N
A
-
p
o
l
y
m
e
r
a
s
e
 
p
e
r
 
μ
l
 
o
f
 
R
M
 
s
h
o
u
l
d
 
b
e
 
a
d
d
e
d
 
b
u
t
 
u
p
 
t
o
 
4
0
 
u
n
i
t
s
 
 
p
e
r
 
μ
l
 
c
a
n
 
b
e
 
u
s
e
d
.
 
W
e
 
t
h
e
r
e
f
o
r
e
 
h
i
g
h
l
y
 
r
e
c
o
m
m
e
n
d
 
t
h
e
 
o
v
e
r
p
r
o
d
u
c
t
i
o
n
 
o
f
 
t
h
e
 
e
n
z
y
m
e
 
i
n
 
 
E
.
 
c
o
l
i
 
(
1
1
)
.
 
W
e
 
i
s
o
l
a
t
e
 
t
h
e
 
T
7
-
R
N
A
-
p
o
l
y
m
e
r
a
s
e
 
f
r
o
m
 
s
t
r
a
i
n
 
B
L
2
1
 
(
D
E
3
)
 
b
y
 
a
 
s
i
n
g
l
e
-
s
t
e
p
 
 
p
u
r
i
f
i
c
a
t
i
o
n
 
w
i
t
h
 
a
 
Q
-
s
e
p
h
a
r
o
s
e
 
c
o
l
u
m
n
.
 
O
u
t
 
o
f
 
a
 
4
 
l
i
t
e
r
 
f
e
r
m
e
n
t
a
t
i
o
n
,
 
t
h
e
 
y
i
e
l
d
 
c
a
n
 
b
e
 
 
1
4
 
 
a
p
p
r
.
 
5
 
x
 
1
0
5
 
u
n
i
t
s
.
 
T
h
e
 
i
s
o
l
a
t
e
d
 
T
7
 
R
N
A
-
p
o
l
y
m
e
r
a
s
e
 
c
a
n
 
b
e
 
s
t
o
r
e
d
 
i
n
 
g
l
y
c
e
r
o
l
 
a
t
 
-
8
0
o
C
 
 
f
o
r
 
m
a
n
y
 
m
o
n
t
h
s
.
 
 
2
.
 
L
-
t
y
r
o
s
i
n
e
 
i
s
 
p
r
e
p
a
r
e
d
 
a
s
 
2
0
 
m
M
,
 
t
h
e
 
o
t
h
e
r
 
1
9
 
a
m
i
n
o
 
a
c
i
d
s
 
a
r
e
 
m
a
d
e
 
a
s
 
1
0
0
 
m
M
 
s
t
o
c
k
 
s
o
l
u
t
i
o
n
s
 
d
i
s
s
o
l
v
e
d
 
i
n
 
w
a
t
e
r
.
 
T
h
e
 
s
o
l
u
b
i
l
i
t
y
 
o
f
 
L
-
a
s
p
a
r
t
i
c
 
a
c
i
d
,
 
L
-
c
y
s
t
e
i
n
e
,
 
L
-
g
l
u
t
a
m
i
c
 
a
c
i
d
 
a
n
d
 
L
-
m
e
t
h
i
o
n
i
n
e
 
c
o
u
l
d
 
b
e
 
i
m
p
r
o
v
e
d
 
b
y
 
u
s
i
n
g
 
1
0
0
 
m
M
 
H
E
P
E
S
 
p
H
 
7
.
4
.
 
L
-
t
r
y
p
t
o
p
h
a
n
 
i
s
 
d
i
s
s
o
l
v
e
d
 
i
n
 
1
0
0
 
m
M
 
H
E
P
E
S
,
 
p
H
 
8
.
0
,
 
u
p
o
n
 
s
o
n
i
f
i
c
a
t
i
o
n
 
i
n
 
a
 
w
a
t
e
r
-
b
a
t
h
.
 
A
p
p
r
o
p
r
i
a
t
e
 
a
l
i
q
u
o
t
s
 
o
f
 
t
h
e
 
i
n
d
i
v
i
d
u
a
l
 
s
t
o
c
k
s
 
a
r
e
 
t
h
e
n
 
c
o
m
b
i
n
e
d
 
i
n
 
t
h
e
 
a
m
i
n
o
 
a
c
i
d
 
m
i
x
t
u
r
e
.
 
T
h
e
 
f
i
n
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
a
m
i
n
o
 
a
c
i
d
s
 
i
n
 
t
h
e
 
r
e
a
c
t
i
o
n
 
i
s
 
1
 
m
M
.
 
T
h
e
 
y
i
e
l
d
s
 
o
f
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
 
m
i
g
h
t
 
b
e
 
i
m
p
r
o
v
e
d
 
b
y
 
u
s
i
n
g
 
h
i
g
h
e
r
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
,
 
a
n
d
 
b
y
 
a
d
j
u
s
t
i
n
g
 
t
h
e
 
a
m
i
n
o
 
a
c
i
d
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
a
c
c
o
r
d
i
n
g
 
t
o
 
t
h
e
 
c
o
m
p
o
s
i
t
i
o
n
 
o
f
 
t
h
e
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
.
 
L
e
a
s
t
 
a
b
u
n
d
a
n
t
 
a
m
i
n
o
 
a
c
i
d
s
 
(
p
r
e
s
e
n
t
 
≤
 
3
 
%
 
i
n
 
t
h
e
 
p
r
o
t
e
i
n
)
 
s
h
o
u
l
d
 
t
h
e
n
 
b
e
 
a
d
d
e
d
 
a
t
 
1
.
2
5
 
m
M
,
 
m
e
d
i
u
m
 
a
b
u
n
d
a
n
t
 
(
b
e
t
w
e
e
n
 
3
 
a
n
d
 
≤
 
8
 
%
)
 
a
t
 
1
.
8
 
m
M
 
a
n
d
 
h
i
g
h
l
y
 
a
b
u
n
d
a
n
t
 
(
m
o
r
e
 
t
h
a
n
 
8
 
%
)
 
a
t
 
2
.
5
 
m
M
 
f
i
n
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
.
 
3
.
 
S
o
m
e
 
a
m
i
n
o
 
a
c
i
d
s
 
t
e
n
d
 
t
o
 
b
e
 
u
n
s
t
a
b
l
e
 
a
n
d
 
i
n
c
r
e
a
s
i
n
g
 
t
h
e
i
r
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
i
n
 
t
h
e
 
r
e
a
c
t
i
o
n
 
 
s
i
g
n
i
f
i
c
a
n
t
l
y
 
i
m
p
r
o
v
e
s
 
t
h
e
 
s
y
n
t
h
e
s
i
s
 
o
f
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
s
 
(
1
2
,
 
1
3
)
.
 
4
.
 
 
D
i
a
l
y
s
e
r
s
 
c
o
n
t
a
i
n
i
n
g
 
m
e
m
b
r
a
n
e
s
 
m
a
d
e
 
o
f
 
r
e
g
e
n
e
r
a
t
e
d
 
c
e
l
l
u
l
o
s
e
 
s
h
o
u
l
d
 
b
e
 
p
r
e
f
e
r
r
e
d
 
a
s
 
 
t
h
e
y
 
e
n
a
b
l
e
 
a
 
b
e
t
t
e
r
 
e
x
c
h
a
n
g
e
 
o
f
 
c
o
m
p
o
u
n
d
s
 
i
f
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
c
e
l
l
u
l
o
s
e
-
e
s
t
e
r
.
 
D
i
a
l
y
s
e
r
s
 
 
m
i
g
h
t
 
b
e
 
r
e
u
s
e
d
 
a
f
t
e
r
 
w
a
s
h
i
n
g
 
w
i
t
h
 
d
i
s
t
i
l
l
e
d
 
w
a
t
e
r
 
a
n
d
 
t
h
e
y
 
c
a
n
 
b
e
 
s
t
o
r
e
d
 
i
n
 
d
i
s
t
i
l
l
e
d
 
 
w
a
t
e
r
 
s
u
p
p
l
e
m
e
n
t
e
d
 
w
i
t
h
 
0
.
0
1
 
%
 
s
o
d
i
u
m
 
a
z
i
d
e
 
a
t
 
4
o
C
.
 
 
5
.
 
D
e
p
e
n
d
i
n
g
 
o
n
 
t
h
e
 
d
e
s
i
g
n
 
o
f
 
t
h
e
 
r
e
a
c
t
i
o
n
 
c
o
n
t
a
i
n
e
r
,
 
q
u
i
t
e
 
a
 
v
a
r
i
e
t
y
 
o
f
 
i
n
c
u
b
a
t
o
r
s
 
c
a
n
 
b
e
 
 
u
s
e
d
.
 
T
h
e
 
o
n
l
y
 
c
o
n
s
i
d
e
r
a
t
i
o
n
 
i
s
 
t
h
a
t
 
t
e
m
p
e
r
a
t
u
r
e
 
c
o
n
t
r
o
l
 
a
n
d
 
a
n
 
e
f
f
i
c
i
e
n
t
 
a
g
i
t
a
t
i
o
n
 
o
f
 
t
h
e
 
 
r
e
a
c
t
i
o
n
 
d
e
v
i
c
e
,
 
e
i
t
h
e
r
 
b
y
 
r
o
l
l
i
n
g
,
 
s
h
a
k
i
n
g
 
o
r
 
s
t
i
r
r
i
n
g
,
 
c
a
n
 
b
e
 
p
r
o
v
i
d
e
d
.
 
6
.
 
R
N
A
s
e
 
i
n
 
t
h
e
 
l
y
s
i
s
 
b
u
f
f
e
r
 
d
u
r
i
n
g
 
p
l
a
s
m
i
d
 
i
s
o
l
a
t
i
o
n
 
p
r
i
n
c
i
p
a
l
l
y
 
c
o
u
l
d
 
c
a
u
s
e
 
p
r
o
b
l
e
m
s
 
i
n
 
t
h
e
 
 
c
e
l
l
-
f
r
e
e
 
r
e
a
c
t
i
o
n
 
a
n
d
 
i
t
 
m
i
g
h
t
 
b
e
 
a
v
o
i
d
e
d
 
d
u
r
i
n
g
 
D
N
A
 
p
r
e
p
a
r
a
t
i
o
n
.
 
D
i
s
t
i
l
l
e
d
 
w
a
t
e
r
 
s
h
o
u
l
d
 
 
b
e
 
 
u
s
e
d
 
t
o
 
f
i
n
a
l
l
y
 
d
i
s
s
o
l
v
e
 
t
h
e
 
D
N
A
 
i
n
 
o
r
d
e
r
 
t
o
 
p
r
e
v
e
n
t
 
t
h
e
 
a
d
d
i
t
i
o
n
 
o
f
 
u
n
d
e
s
i
r
e
d
 
i
o
n
s
 
 
i
n
t
o
 
t
h
e
 
c
e
l
l
-
f
r
e
e
 
r
e
a
c
t
i
o
n
.
 
T
h
e
 
p
l
a
s
m
i
d
 
D
N
A
 
s
h
o
u
l
d
 
b
e
 
c
o
n
c
e
n
t
r
a
t
e
d
 
i
n
 
a
 
s
p
e
e
d
v
a
c
 
t
o
 
a
  
1
5
 
 
f
i
n
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
a
t
 
l
e
a
s
t
 
0
.
1
 
μ
g
/
μ
l
.
 
T
h
e
 
f
i
n
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
D
N
A
 
i
n
 
t
h
e
 
c
e
l
l
-
f
r
e
e
 
 
r
e
a
c
t
i
o
n
 
s
h
o
u
l
d
 
b
e
 
a
t
 
l
e
a
s
t
 
1
5
 
μ
g
 
p
e
r
 
o
n
e
 
m
l
 
o
f
 
R
M
.
 
7
.
 
A
t
 
t
h
i
s
 
s
t
a
g
e
,
 
t
h
e
 
c
e
l
l
s
 
c
o
u
l
d
 
b
e
 
f
r
o
z
e
n
 
a
t
 
-
8
0
o
C
 
a
s
 
a
 
t
h
i
n
 
p
l
a
t
e
 
w
r
a
p
p
e
d
 
i
n
 
a
 
s
h
e
e
t
 
o
f
 
 
a
l
u
m
i
n
u
m
 
f
o
i
l
 
a
n
d
 
s
t
o
r
e
d
 
u
n
t
i
l
 
f
u
r
t
h
e
r
 
u
s
a
g
e
.
 
H
o
w
e
v
e
r
,
 
i
n
 
o
u
r
 
h
a
n
d
s
 
t
h
e
 
q
u
a
l
i
t
y
 
o
f
 
t
h
e
 
S
3
0
 
 
e
x
t
r
a
c
t
 
w
a
s
 
a
l
w
a
y
s
 
c
o
n
s
i
d
e
r
a
b
l
y
 
i
m
p
r
o
v
e
d
 
i
f
 
t
h
e
 
p
r
e
p
a
r
a
t
i
o
n
 
w
a
s
 
c
o
n
s
e
c
u
t
i
v
e
l
y
 
c
o
m
p
l
e
t
e
d
 
 
w
i
t
h
o
u
t
 
i
n
t
e
r
r
u
p
t
i
o
n
.
 
8
.
 
A
 
v
a
r
i
e
t
y
 
o
f
 
b
a
c
t
e
r
i
a
l
 
s
t
r
a
i
n
s
 
i
n
c
l
u
d
i
n
g
 
E
.
 
c
o
l
i
 
A
1
9
,
 
D
1
0
 
o
r
 
B
L
2
1
 
h
a
s
 
b
e
e
n
 
d
e
s
c
r
i
b
e
d
 
a
s
 
 
s
o
u
r
c
e
 
f
o
r
 
c
e
l
l
-
f
r
e
e
 
S
3
0
-
e
x
t
r
a
c
t
s
.
 
I
n
 
o
u
r
 
h
a
n
d
s
,
 
A
1
9
 
y
i
e
l
d
e
d
 
t
h
e
 
m
o
s
t
 
e
f
f
i
c
i
e
n
t
 
 
e
x
t
r
a
c
t
s
 
w
i
t
h
 
t
h
e
 
b
e
s
t
 
r
e
p
r
o
d
u
c
i
b
l
e
 
q
u
a
l
i
t
y
.
 
U
s
i
n
g
 
a
 
f
e
r
m
e
n
t
e
r
 
t
o
 
g
r
o
w
 
t
h
e
 
b
a
c
t
e
r
i
a
 
m
i
g
h
t
 
 
b
e
 
e
s
s
e
n
t
i
a
l
 
b
e
c
a
u
s
e
 
o
f
 
t
h
e
 
b
e
t
t
e
r
 
s
u
p
p
l
y
 
o
f
 
o
x
y
g
e
n
.
 
 
9
.
 
H
a
r
v
e
s
t
i
n
g
 
t
h
e
 
c
e
l
l
s
 
i
n
 
t
h
e
 
m
i
d
-
l
o
g
 
p
h
a
s
e
 
i
s
 
e
s
s
e
n
t
i
a
l
.
 
F
o
r
 
n
e
w
 
m
o
d
i
f
i
c
a
t
i
o
n
s
 
o
f
 
t
h
e
 
 
f
e
r
m
e
n
t
a
t
i
o
n
 
c
o
n
d
i
t
i
o
n
s
,
 
a
n
 
i
n
i
t
i
a
l
 
p
i
l
o
t
 
e
x
p
e
r
i
m
e
n
t
 
s
h
o
u
l
d
 
a
l
w
a
y
s
 
b
e
 
c
a
r
r
i
e
d
 
o
u
t
 
i
n
 
o
r
d
e
r
 
 
t
o
 
d
e
f
i
n
e
 
t
h
e
 
e
x
a
c
t
 
o
p
t
i
c
a
l
 
d
e
n
s
i
t
y
 
o
f
 
t
h
e
 
c
u
l
t
u
r
e
 
a
t
 
m
i
d
-
l
o
g
 
p
h
a
s
e
.
 
1
0
.
 
I
t
 
i
s
 
c
r
i
t
i
c
a
l
 
t
o
 
c
o
o
l
 
d
o
w
n
 
t
h
e
 
b
r
o
t
h
 
a
s
 
q
u
i
c
k
l
y
 
a
s
 
p
o
s
s
i
b
l
e
.
 
A
s
 
t
h
e
 
c
e
l
l
s
 
r
a
p
i
d
l
y
 
d
i
v
i
d
e
,
 
t
o
o
 
 
s
l
o
w
 
c
o
o
l
i
n
g
 
m
i
g
h
t
 
r
e
s
u
l
t
 
i
n
 
e
n
t
e
r
i
n
g
 
t
h
e
 
l
a
t
e
-
l
o
g
 
o
r
 
e
v
e
n
 
s
t
a
t
i
o
n
a
r
y
 
p
h
a
s
e
 
o
f
 
g
r
o
w
t
h
 
a
n
d
 
 
t
h
a
t
 
c
o
u
l
d
 
c
o
n
s
i
d
e
r
a
b
l
y
 
r
e
d
u
c
e
 
t
h
e
 
q
u
a
l
i
t
y
 
o
f
 
t
h
e
 
e
x
t
r
a
c
t
.
 
F
o
r
 
t
h
e
 
d
e
s
c
r
i
b
e
d
 
c
o
n
d
i
t
i
o
n
s
,
 
t
h
e
 
 
r
e
d
u
c
t
i
o
n
 
o
f
 
t
e
m
p
e
r
a
t
u
r
e
 
f
r
o
m
 
3
7
o
C
 
t
o
 
1
0
o
C
 
s
h
o
u
l
d
 
b
e
 
o
p
t
i
m
a
l
l
y
 
c
o
m
p
l
e
t
e
d
 
i
n
 
n
o
t
 
m
o
r
e
 
 
t
h
a
n
 
4
5
 
m
i
n
u
t
e
s
.
 
A
n
 
e
x
t
e
r
n
a
l
 
c
o
o
l
i
n
g
-
u
n
i
t
 
c
o
u
l
d
 
b
e
 
c
o
n
n
e
c
t
e
d
 
o
r
 
t
h
e
 
b
r
o
t
h
 
i
n
 
t
h
e
 
 
f
e
r
m
e
n
t
e
r
 
c
o
u
l
d
 
b
e
 
c
o
o
l
e
d
 
d
o
w
n
 
b
y
 
a
d
d
i
n
g
 
b
l
o
c
k
s
 
o
f
 
f
r
o
z
e
n
 
T
B
 
m
e
d
i
u
m
.
 
 
1
1
.
 
U
s
i
n
g
 
a
 
F
r
e
n
c
h
 
P
r
e
s
s
 
d
e
v
i
c
e
 
f
o
r
 
c
e
l
l
 
d
i
s
r
u
p
t
i
o
n
 
i
s
 
i
m
p
o
r
t
a
n
t
.
 
D
i
s
r
u
p
t
i
o
n
 
b
y
 
u
l
t
r
a
-
 
s
o
n
i
f
i
c
a
t
i
o
n
 
w
o
u
l
d
 
r
e
s
u
l
t
 
i
n
 
b
a
d
 
q
u
a
l
i
t
y
 
o
f
 
t
h
e
 
e
x
t
r
a
c
t
,
 
p
r
o
b
a
b
l
y
 
b
y
 
d
i
s
i
n
t
e
g
r
a
t
i
o
n
 
o
f
 
t
h
e
 
 
r
i
b
o
s
o
m
e
s
.
 
 
1
2
.
 
T
h
i
s
 
s
t
e
p
 
c
a
u
s
e
s
 
t
h
e
 
d
i
s
s
o
z
i
a
t
i
o
n
 
o
f
 
e
n
d
o
g
e
n
o
u
s
 
m
R
N
A
 
f
r
o
m
 
t
h
e
 
r
i
b
o
s
o
m
e
s
.
 
O
t
h
e
r
 
r
u
n
-
o
f
f
 
 
p
r
o
c
e
d
u
r
e
s
 
b
y
 
a
d
d
i
n
g
 
s
u
b
s
t
r
a
t
e
s
 
i
n
 
o
r
d
e
r
 
t
o
 
t
e
r
m
i
n
a
t
e
 
t
r
a
n
s
c
r
i
p
t
i
o
n
s
 
h
a
v
e
 
b
e
e
n
 
d
e
s
c
r
i
b
e
d
 
 
(
1
0
,
 
1
4
)
 
a
n
d
 
a
r
e
 
s
i
m
i
l
a
r
 
e
f
f
e
c
t
i
v
e
,
 
b
u
t
 
m
o
r
e
 
e
x
p
e
n
s
i
v
e
.
 
T
h
e
 
i
n
c
u
b
a
t
i
o
n
 
a
t
 
t
h
e
 
r
e
l
a
t
i
v
e
l
y
 
 
h
i
g
h
 
h
e
a
t
 
s
h
o
c
k
 
t
e
m
p
e
r
a
t
u
r
e
 
o
f
 
4
2
o
C
 
h
a
s
 
b
e
e
n
 
p
r
o
v
e
n
 
t
o
 
b
e
 
e
s
s
e
n
t
i
a
l
.
 
U
s
i
n
g
 
l
o
w
e
r
 
 
1
6
 
 
t
e
m
p
e
r
a
t
u
r
e
s
 
l
i
k
e
 
3
7
o
C
 
a
r
e
 
b
y
 
f
a
r
 
n
o
t
 
a
s
 
e
f
f
e
c
t
i
v
e
.
 
A
 
l
o
t
 
o
f
 
p
r
o
t
e
i
n
s
 
i
n
 
t
h
e
 
e
x
t
r
a
c
t
 
 
p
r
e
c
i
p
i
t
a
t
e
 
d
u
r
i
n
g
 
t
h
i
s
 
s
t
e
p
 
w
h
i
l
e
 
t
h
e
 
p
r
o
t
e
i
n
s
 
n
e
c
e
s
s
a
r
y
 
f
o
r
 
t
h
e
 
t
r
a
n
s
l
a
t
i
o
n
 
p
r
o
c
e
s
s
 
r
e
m
a
i
n
 
 
s
t
a
b
l
e
.
 
1
3
.
 
M
a
k
e
 
a
l
i
q
u
o
t
s
 
o
f
 
d
i
f
f
e
r
e
n
t
 
a
p
p
r
o
p
r
i
a
t
e
 
s
i
z
e
s
 
a
c
c
o
r
d
i
n
g
 
t
o
 
y
o
u
r
 
r
e
q
u
i
r
e
m
e
n
t
s
 
(
e
.
g
.
 
1
0
0
 
μ
l
,
 
 
5
0
0
 
μ
l
,
 
1
m
l
)
 
a
s
 
t
h
e
 
i
n
d
i
v
i
d
u
a
l
 
a
l
i
q
u
o
t
s
 
m
u
s
t
 
n
o
t
 
b
e
 
r
e
-
f
r
o
z
e
n
.
 
1
4
.
 
C
o
n
d
e
n
s
i
n
g
 
t
h
e
 
e
x
t
r
a
c
t
 
t
w
o
-
f
o
l
d
 
c
a
n
 
i
n
c
r
e
a
s
e
 
t
h
e
 
e
f
f
i
c
i
e
n
c
y
 
t
o
 
a
p
p
r
.
 
1
.
5
 
t
i
m
e
s
.
 
T
h
e
 
f
i
n
a
l
 
 
p
r
o
t
e
i
n
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
i
n
 
t
h
e
 
e
x
t
r
a
c
t
 
s
h
o
u
l
d
 
b
e
 
b
e
t
w
e
e
n
 
2
0
 
a
n
d
 
3
0
 
m
g
/
m
l
.
 
 
1
5
.
 
R
e
l
a
t
i
v
e
l
y
 
l
a
r
g
e
 
c
u
t
-
o
f
f
s
 
u
p
 
t
o
 
5
0
 
k
D
a
 
c
a
n
 
b
e
 
u
s
e
d
 
w
i
t
h
o
u
t
 
h
a
v
i
n
g
 
s
i
g
n
i
f
i
c
a
n
t
 
l
e
a
c
h
i
n
g
 
o
f
 
 
t
h
e
 
p
r
o
t
e
i
n
s
 
r
e
l
e
v
a
n
t
 
f
o
r
 
t
h
e
 
t
r
a
n
s
c
r
i
p
t
i
o
n
/
t
r
a
n
s
l
a
t
i
o
n
 
p
r
o
c
e
s
s
.
 
I
t
 
i
s
 
t
h
e
r
e
f
o
r
e
 
a
s
s
u
m
e
d
 
t
h
a
t
 
 
t
h
o
s
e
 
p
r
o
t
e
i
n
s
 
f
o
r
m
 
a
 
l
a
r
g
e
 
m
a
c
r
o
m
o
l
e
c
u
l
a
r
 
c
o
m
p
l
e
x
 
t
o
g
e
t
h
e
r
 
w
i
t
h
 
t
h
e
 
m
R
N
A
.
 
T
h
e
 
o
n
l
y
 
 
p
r
o
t
e
i
n
 
t
h
a
t
 
i
s
 
r
e
l
e
a
s
e
d
 
f
r
o
m
 
t
h
a
t
 
c
o
m
p
l
e
x
 
i
s
 
t
h
e
 
s
y
n
t
h
e
s
i
z
e
d
 
r
e
c
o
m
b
i
n
a
n
t
 
t
a
r
g
e
t
 
p
r
o
t
e
i
n
.
 
 
T
h
e
 
s
e
l
e
c
t
i
o
n
 
o
f
 
t
h
e
 
M
W
C
O
 
o
f
 
t
h
e
 
r
e
a
c
t
i
o
n
 
d
e
v
i
c
e
 
s
h
o
u
l
d
 
t
h
e
r
e
f
o
r
e
 
d
e
p
e
n
d
 
o
n
 
t
h
e
 
M
W
 
 
o
f
 
t
h
e
 
t
a
r
g
e
t
 
p
r
o
t
e
i
n
 
a
n
d
 
w
h
e
t
h
e
r
 
i
t
 
s
h
o
u
l
d
 
r
e
m
a
i
n
 
i
n
 
t
h
e
 
R
M
.
 
G
e
n
e
r
a
l
l
y
,
 
M
W
C
O
’
s
 
<
 
1
0
 
 
k
D
a
 
t
e
n
d
 
t
o
 
r
e
d
u
c
e
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
y
i
e
l
d
s
 
p
r
o
b
a
b
l
y
 
d
u
e
 
t
o
 
a
 
m
o
r
e
 
r
e
s
t
r
i
c
t
e
d
 
e
x
c
h
a
n
g
e
 
o
f
 
 
l
o
w
 
m
o
l
e
c
u
l
a
r
 
w
e
i
g
h
t
 
s
u
b
s
t
a
n
c
e
s
 
a
n
d
 
w
e
 
r
e
c
o
m
m
e
n
d
 
t
o
 
r
o
u
t
i
n
e
l
y
 
u
s
e
 
a
 
M
W
C
O
 
o
f
 
1
5
 
 
k
D
a
.
 
 
1
6
.
 
T
h
e
 
r
a
t
i
o
 
R
M
/
F
M
 
i
s
 
c
e
r
t
a
i
n
l
y
 
i
m
p
o
r
t
a
n
t
 
f
o
r
 
a
n
 
e
f
f
i
c
i
e
n
t
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
r
e
c
o
m
b
i
n
a
n
t
 
 
p
r
o
t
e
i
n
.
 
T
h
e
 
h
i
g
h
e
r
 
t
h
e
 
v
o
l
u
m
e
 
o
f
 
t
h
e
 
F
M
,
 
t
h
e
 
m
o
r
e
 
p
r
o
t
e
i
n
 
c
a
n
 
b
e
 
p
r
o
d
u
c
e
d
.
 
H
o
w
e
v
e
r
,
 
 
t
h
e
 
F
M
 
c
o
n
t
a
i
n
s
 
r
e
l
a
t
i
v
e
l
y
 
e
x
p
e
n
s
i
v
e
 
p
r
e
c
u
r
s
o
r
s
 
l
i
k
e
 
P
E
P
,
 
a
c
e
t
y
l
 
p
h
o
s
p
h
a
t
e
,
 
n
u
c
l
e
o
t
i
d
e
s
 
o
r
 
 
e
v
e
n
 
l
a
b
e
l
l
e
d
 
a
m
i
n
o
 
a
c
i
d
s
.
 
W
e
 
f
o
u
n
d
 
t
h
e
 
g
i
v
e
n
 
r
a
t
i
o
 
t
o
 
b
e
 
a
n
 
o
p
t
i
m
a
l
 
c
o
m
p
r
o
m
i
s
e
 
i
n
 
o
r
d
e
r
 
 
t
o
 
y
i
e
l
d
 
h
i
g
h
 
l
e
v
e
l
s
 
o
f
 
p
r
o
t
e
i
n
 
a
t
 
r
e
a
s
o
n
a
b
l
e
 
c
o
s
t
s
.
 
T
h
e
 
e
x
c
h
a
n
g
e
 
o
f
 
t
h
e
 
F
M
 
a
f
t
e
r
 
s
e
v
e
r
a
l
 
 
h
o
u
r
s
 
o
f
 
i
n
c
u
b
a
t
i
o
n
 
w
o
u
l
d
 
a
d
d
i
t
i
o
n
a
l
l
y
 
i
n
c
r
e
a
s
e
 
t
h
e
 
y
i
e
l
d
 
o
f
 
t
h
e
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
.
 
 
H
o
w
e
v
e
r
,
 
a
s
 
t
h
e
 
i
n
c
r
e
a
s
e
 
u
s
u
a
l
l
y
 
i
s
 
o
n
l
y
 
s
o
m
e
 
3
0
 
%
,
 
i
t
 
w
o
u
l
d
 
b
e
 
m
o
r
e
 
e
c
o
n
o
m
i
c
a
l
l
y
 
t
o
 
 
r
u
n
 
t
w
o
 
i
d
e
n
t
i
c
a
l
 
r
e
a
c
t
i
o
n
s
 
s
e
p
a
r
a
t
e
l
y
.
 
1
7
.
 
F
o
r
 
p
r
e
p
a
r
a
t
i
v
e
 
s
c
a
l
e
 
r
e
a
c
t
i
o
n
s
,
 
e
.
g
.
 
i
n
 
d
i
s
p
o
d
i
a
l
y
s
e
r
s
,
 
s
t
a
n
d
a
r
d
 
g
l
a
s
s
 
v
i
a
l
s
 
o
f
 
s
u
i
t
a
b
l
e
 
s
i
z
e
s
 
 
c
a
n
 
b
e
 
u
s
e
d
 
a
s
 
F
M
 
c
o
m
p
a
r
t
m
e
n
t
.
 
F
o
r
 
a
n
a
l
y
t
i
c
a
l
 
s
c
a
l
e
 
r
e
a
c
t
i
o
n
s
,
 
e
.
g
.
 
i
n
 
m
i
c
r
o
d
i
a
l
y
s
e
r
s
,
  
1
7
 
 
s
u
i
t
a
b
l
e
 
p
l
a
s
t
i
c
 
c
o
n
t
a
i
n
e
r
s
 
l
i
k
e
 
t
h
e
 
l
o
w
e
r
 
p
a
r
t
 
o
f
 
5
0
 
m
l
 
p
o
l
y
p
r
o
p
y
l
e
n
e
 
t
e
s
t
-
t
u
b
e
s
 
(
G
r
e
i
n
e
r
,
 
 
S
o
l
i
n
g
e
n
,
 
G
e
r
m
a
n
y
,
 
c
a
t
.
 
n
o
.
:
 
2
1
0
2
6
1
)
 
t
h
a
t
 
c
a
n
 
b
e
 
f
i
x
e
d
 
t
o
 
t
h
e
 
m
i
c
r
o
d
i
a
l
y
s
e
r
s
 
w
i
t
h
 
a
 
t
a
p
e
 
 
(
e
.
g
.
 
N
e
s
c
o
f
i
l
m
,
 
A
z
w
e
l
l
,
 
O
s
a
k
a
,
 
J
a
p
a
n
)
 
c
a
n
 
b
e
 
u
s
e
d
.
 
1
8
.
 
F
o
r
 
t
h
e
 
c
a
l
c
u
l
a
t
i
o
n
 
o
f
 
t
h
e
 
f
i
n
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
,
 
i
t
 
h
a
s
 
t
o
 
b
e
 
c
o
n
s
i
d
e
r
e
d
 
t
h
a
t
 
5
 
m
M
 
o
f
 
M
g
2
+
 
 
a
n
d
 
1
4
0
 
m
M
 
o
f
 
K
+
 
a
r
e
 
a
l
r
e
a
d
y
 
p
r
e
s
e
n
t
 
i
n
 
t
h
e
 
r
e
a
c
t
i
o
n
 
f
r
o
m
 
o
t
h
e
r
 
c
o
m
p
o
n
e
n
t
s
.
 
 
1
9
.
 
I
t
 
c
o
u
l
d
 
b
e
 
b
e
n
e
f
i
c
i
a
l
 
t
o
 
i
n
c
l
u
d
e
 
d
e
t
e
r
g
e
n
t
s
 
t
h
a
t
 
a
r
e
 
n
o
t
 
s
u
i
t
a
b
l
e
 
f
o
r
 
d
i
s
s
o
l
v
i
n
g
 
t
h
e
 
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
 
i
n
t
o
 
t
h
e
 
w
a
s
h
i
n
g
 
b
u
f
f
e
r
.
 
C
o
-
p
r
e
c
i
p
i
t
a
t
e
d
 
c
o
n
t
a
m
i
n
a
n
t
s
 
m
i
g
h
t
 
t
h
e
n
 
b
e
 
 
d
i
s
s
o
l
v
e
d
,
 
r
e
s
u
l
t
i
n
g
 
i
n
 
a
 
p
u
r
e
r
 
s
a
m
p
l
e
 
o
f
 
t
h
e
 
M
P
.
 
 
2
0
.
 
C
o
n
s
i
d
e
r
a
b
l
y
 
h
i
g
h
e
r
 
d
e
t
e
r
g
e
n
t
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
c
a
n
 
b
e
 
u
s
e
d
 
f
o
r
 
t
h
e
 
r
e
-
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
 
p
r
e
c
i
p
i
t
a
t
e
d
 
M
P
’
s
 
i
f
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
t
h
e
 
d
i
r
e
c
t
 
a
d
d
i
t
i
o
n
 
o
f
 
d
e
t
e
r
g
e
n
t
 
i
n
t
o
 
t
h
e
 
C
F
 
r
e
a
c
t
i
o
n
 
 
f
o
r
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
s
o
l
u
b
l
e
 
M
P
’
s
.
 
 
A
c
k
n
o
w
l
e
d
g
e
m
e
n
t
s
 
W
e
 
a
r
e
 
g
r
a
t
e
f
u
l
 
t
o
 
V
l
a
d
i
m
i
r
 
S
h
i
r
o
k
o
v
,
 
A
l
e
x
a
n
d
e
r
 
S
p
i
r
i
n
 
a
n
d
 
H
e
i
n
z
 
R
ü
t
e
r
j
a
n
s
 
f
o
r
 
t
h
e
i
r
 
h
e
l
p
 
i
n
 
s
e
t
t
i
n
g
 
u
p
 
t
h
e
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
.
 
W
e
 
f
u
r
t
h
e
r
 
t
h
a
n
k
 
W
i
n
f
r
i
e
d
 
H
a
a
s
e
 
f
o
r
 
t
h
e
 
e
l
e
c
t
r
o
n
 
m
i
c
r
o
s
c
o
p
i
c
a
l
 
a
n
a
l
y
s
i
s
 
o
f
 
p
r
o
t
e
o
l
i
p
o
s
o
m
e
s
.
 
 
R
e
f
e
r
e
n
c
e
s
 
1
.
 
 
A
r
o
r
a
,
 
A
.
,
 
a
n
d
 
T
a
m
m
,
 
L
.
K
.
 
(
2
0
0
1
)
 
B
i
o
p
h
y
s
i
c
a
l
 
a
p
p
r
o
a
c
h
e
s
 
t
o
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
 
s
t
r
u
c
t
u
r
e
 
 
 
d
e
t
e
r
m
i
n
a
t
i
o
n
.
 
C
u
r
r
.
 
O
p
i
n
.
 
S
t
r
u
c
t
.
 
B
i
o
l
.
 
1
1
,
 
5
4
0
-
5
4
7
.
 
2
.
 
 
W
a
n
g
,
 
D
.
N
.
,
 
S
a
f
f
e
r
l
i
n
g
,
 
M
.
,
 
L
e
m
i
e
u
x
,
 
M
.
J
.
,
 
G
r
i
f
f
i
t
h
,
 
H
.
,
 
C
h
e
n
,
 
Y
.
,
 
a
n
d
 
L
i
,
 
X
.
D
.
 
(
2
0
0
3
)
 
P
r
a
c
t
i
c
a
l
 
a
s
p
e
c
t
s
 
o
f
 
o
v
e
r
e
x
p
r
e
s
s
i
n
g
 
b
a
c
t
e
r
i
a
l
 
s
e
c
o
n
d
a
r
y
 
m
e
m
b
r
a
n
e
 
t
r
a
n
s
p
o
r
t
e
r
s
 
f
o
r
 
s
t
r
u
c
t
u
r
a
l
 
s
t
u
d
i
e
s
.
 
B
i
o
c
h
i
m
.
 
B
i
o
p
h
y
s
.
 
A
c
t
a
 
1
6
1
0
,
 
2
3
-
3
6
5
.
 
3
.
 
 
T
a
t
e
,
 
C
.
G
.
 
(
2
0
0
1
)
 
O
v
e
r
e
x
p
r
e
s
s
i
o
n
 
o
f
 
m
a
m
m
a
l
i
a
n
 
i
n
t
e
g
r
a
l
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
f
o
r
 
 
s
t
r
u
c
t
u
r
a
l
 
s
t
u
d
i
e
s
.
 
F
E
B
S
 
L
e
t
t
.
 
5
0
4
,
 
9
4
-
9
8
.
 
 
1
8
 
4
.
 
K
l
a
m
m
t
,
 
C
.
,
 
L
ö
h
r
,
 
F
.
,
 
S
c
h
ä
f
e
r
,
 
B
.
,
 
H
a
a
s
e
,
 
W
.
,
 
D
ö
t
s
c
h
,
 
V
.
,
 
R
ü
t
e
r
j
a
n
s
,
 
H
.
,
 
G
l
a
u
b
i
t
z
,
 
C
.
,
 
a
n
d
 
 
B
e
r
n
h
a
r
d
,
 
F
.
 
(
2
0
0
4
)
 
H
i
g
h
 
l
e
v
e
l
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
a
n
d
 
s
p
e
c
i
f
i
c
 
l
a
b
e
l
i
n
g
 
o
f
 
i
n
t
e
g
r
a
l
 
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
.
 
E
u
r
.
 
J
.
 
B
i
o
c
h
e
m
.
 
2
7
1
,
 
5
6
8
-
5
8
0
.
 
5
.
 
E
l
b
a
z
,
 
Y
.
,
 
S
t
e
i
n
e
r
-
M
o
r
d
o
c
h
,
 
S
.
,
 
D
a
n
i
e
l
i
,
 
T
.
,
 
a
n
d
 
S
c
h
u
l
d
i
n
e
r
,
 
S
.
 
(
2
0
0
4
)
.
 
I
n
 
v
i
t
r
o
 
s
y
n
t
h
e
s
i
s
 
 
o
f
 
f
u
l
l
y
 
f
u
n
c
t
i
o
n
a
l
 
E
m
r
E
,
 
a
 
m
u
l
t
i
d
r
u
g
 
t
r
a
n
s
p
o
r
t
e
r
,
 
a
n
d
 
s
t
u
d
y
 
o
f
 
i
t
s
 
o
l
i
g
o
m
e
r
i
c
 
s
t
a
t
e
.
 
P
r
o
c
.
 
 
N
a
t
l
.
 
A
c
a
d
.
 
S
c
i
.
 
U
S
A
.
 
1
0
1
,
 
1
5
1
9
-
1
5
2
4
.
 
6
.
 
B
e
r
r
i
e
r
,
 
C
.
,
 
P
a
r
k
,
 
K
.
H
.
,
 
A
b
e
s
,
 
S
.
,
 
B
i
b
o
n
n
e
,
 
A
.
,
 
B
e
t
t
o
n
,
 
J
.
M
.
,
 
a
n
d
 
G
h
a
z
i
,
 
A
.
 
(
2
0
0
4
)
.
 
C
e
l
l
-
 
f
r
e
e
 
s
y
n
t
h
e
s
i
s
 
o
f
 
a
 
f
u
n
c
t
i
o
n
a
l
 
i
o
n
 
c
h
a
n
n
e
l
 
i
n
 
t
h
e
 
a
b
s
e
n
c
e
 
o
f
 
a
 
m
e
m
b
r
a
n
e
 
a
n
d
 
i
n
 
t
h
e
 
 
p
r
e
s
e
n
c
e
 
o
f
 
d
e
t
e
r
g
e
n
t
.
 
B
i
o
c
h
e
m
i
s
t
r
y
 
4
3
,
 
1
2
5
8
5
-
1
2
5
9
1
.
 
7
.
 
B
a
r
a
n
o
v
,
 
V
.
I
.
,
 
a
n
d
 
S
p
i
r
i
n
,
 
A
.
S
.
 
(
1
9
9
3
)
 
G
e
n
e
 
e
x
p
r
e
s
s
i
o
n
 
i
n
 
c
e
l
l
-
f
r
e
e
 
s
y
s
t
e
m
 
o
n
 
p
r
e
p
a
r
a
t
i
v
e
 
 
 
s
c
a
l
e
.
 
M
e
t
h
o
d
s
 
E
n
z
y
m
o
l
 
2
1
7
,
 
1
2
3
-
4
2
.
 
8
.
 
S
p
i
r
i
n
,
 
A
.
S
.
,
 
B
a
r
a
n
o
v
,
 
V
.
I
.
,
 
R
y
a
b
o
v
a
,
 
L
.
A
.
,
 
O
v
o
d
o
v
,
 
S
.
Y
.
,
 
a
n
d
 
A
l
a
k
o
v
,
Y
.
B
.
 
(
1
9
8
8
)
 
A
 
 
c
o
n
t
i
n
u
o
u
s
 
c
e
l
l
-
f
r
e
e
 
t
r
a
n
s
l
a
t
i
o
n
 
s
y
s
t
e
m
 
c
a
p
a
b
l
e
 
o
f
 
p
r
o
d
u
c
i
n
g
 
p
o
l
y
p
e
p
t
i
d
e
s
 
i
n
 
h
i
g
h
 
y
i
e
l
d
.
 
 
S
c
i
e
n
c
e
 
2
4
2
,
 
1
1
6
2
-
1
1
6
4
.
 
9
.
 
K
i
m
,
 
D
.
M
.
,
 
a
n
d
 
C
h
o
i
,
 
C
.
Y
.
 
(
1
9
9
6
)
 
A
 
s
e
m
i
c
o
n
t
i
n
u
o
u
s
 
p
r
o
k
a
r
y
o
t
i
c
 
c
o
u
p
l
e
d
 
 
t
r
a
n
s
c
r
i
p
t
i
o
n
/
t
r
a
n
s
l
a
t
i
o
n
 
s
y
s
t
e
m
 
u
s
i
n
g
 
a
 
d
i
a
l
y
s
i
s
 
m
e
m
b
r
a
n
e
.
 
B
i
o
t
e
c
h
n
o
l
.
 
P
r
o
g
.
 
1
2
,
 
6
4
5
-
 
 
6
4
9
.
 
1
0
.
 
Z
u
b
a
y
,
 
G
.
 
(
1
9
7
3
)
 
I
n
 
v
i
t
r
o
 
s
y
n
t
h
e
s
i
s
 
o
f
 
p
r
o
t
e
i
n
 
i
n
 
m
i
c
r
o
b
i
a
l
 
s
y
s
t
e
m
s
.
 
A
n
n
u
.
 
R
e
v
.
 
G
e
n
e
t
.
 
7
,
 
 
2
6
7
-
2
8
7
.
 
1
1
.
 
L
i
,
 
Y
.
,
 
W
a
n
g
,
 
E
.
,
 
a
n
d
 
W
a
n
g
,
 
Y
.
 
(
1
9
9
9
)
.
 
A
 
m
o
d
i
f
i
e
d
 
p
r
o
c
e
d
u
r
e
 
f
o
r
 
f
a
s
t
 
p
u
r
i
f
i
c
a
t
i
o
n
 
o
f
 
T
7
 
 
R
N
A
-
p
o
l
y
m
e
r
a
s
e
.
 
P
r
o
t
e
i
n
 
E
x
p
r
.
 
P
u
r
i
f
.
 
1
6
,
 
3
5
5
-
3
5
8
.
 
1
2
.
 
K
i
m
,
 
D
.
M
.
,
 
S
w
a
r
t
z
,
 
J
.
R
 
.
(
1
9
9
9
)
 
P
r
o
l
o
n
g
i
n
g
 
c
e
l
l
-
f
r
e
e
 
p
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
 
w
i
t
h
 
a
 
n
o
v
e
l
 
A
T
P
 
 
r
e
g
e
n
e
r
a
t
i
o
n
 
s
y
s
t
e
m
.
 
B
i
o
t
e
c
h
.
 
B
i
o
e
n
g
i
n
e
e
r
i
n
g
 
6
6
,
 
1
8
0
-
1
8
8
.
 
1
3
.
 
K
i
m
,
 
D
.
M
.
,
 
S
w
a
r
t
z
,
 
J
.
R
.
 
(
2
0
0
0
)
 
P
r
o
l
o
n
g
i
n
g
 
c
e
l
l
-
f
r
e
e
 
p
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
 
b
y
 
s
e
l
e
c
t
i
v
e
 
r
e
a
g
e
n
t
 
 
a
d
d
i
t
i
o
n
s
.
 
B
i
o
t
e
c
h
.
 
P
r
o
g
.
 
1
6
,
 
3
8
5
-
3
9
0
.
  
1
9
 
1
4
.
 
K
i
g
a
w
a
,
 
T
.
,
 
Y
a
b
u
k
i
,
 
T
.
,
 
M
a
t
s
u
d
a
,
 
N
.
,
 
M
a
t
s
u
d
a
,
 
T
.
,
 
N
a
k
a
j
i
m
a
,
 
R
.
,
 
T
a
n
a
k
a
,
 
A
.
,
 
a
n
d
 
 
Y
o
k
o
y
a
m
a
,
 
S
.
 
(
2
0
0
4
)
 
P
r
e
p
a
r
a
t
i
o
n
 
o
f
 
E
s
c
h
e
r
i
c
h
i
a
 
c
o
l
i
 
c
e
l
l
 
e
x
t
r
a
c
t
 
f
o
r
 
h
i
g
h
l
y
 
p
r
o
d
u
c
t
i
v
e
 
 
c
e
l
l
-
f
r
e
e
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
.
 
J
.
 
S
t
r
u
c
t
.
 
F
u
n
c
t
.
 
G
e
n
o
m
i
c
 
5
,
 
6
3
–
6
8
.
 
 
 
 
L
e
g
e
n
d
s
 
t
o
 
t
h
e
 
f
i
g
u
r
e
s
 
 
F
i
g
.
 
1
.
 
E
s
s
e
n
t
i
a
l
 
T
7
 
r
e
g
u
l
a
t
o
r
y
 
s
e
q
u
e
n
c
e
s
 
f
o
r
 
o
p
t
i
m
a
l
 
C
F
 
p
r
o
t
e
i
n
 
p
r
o
d
u
c
t
i
o
n
.
 
 
F
i
g
.
 
2
.
 
D
e
s
i
g
n
 
o
f
 
c
e
l
l
-
f
r
e
e
 
r
e
a
c
t
i
o
n
 
c
o
n
t
a
i
n
e
r
s
.
 
A
,
 
m
i
c
r
o
d
i
a
l
y
s
e
r
 
f
o
r
 
a
n
a
l
y
t
i
c
a
l
 
s
c
a
l
e
 
r
e
a
c
t
i
o
n
s
.
 
T
h
e
 
m
i
c
r
o
d
i
a
l
y
s
e
r
 
h
o
l
d
i
n
g
 
t
h
e
 
a
p
p
r
o
x
.
 
7
0
 
μ
l
 
o
f
 
R
M
 
i
s
 
p
l
a
c
e
d
 
i
n
t
o
 
a
 
s
u
i
t
a
b
l
e
 
v
i
a
l
 
(
e
.
g
.
 
b
o
t
t
o
m
 
p
a
r
t
 
o
f
 
a
 
5
0
 
m
l
 
F
a
l
c
o
n
 
p
l
a
s
t
i
c
 
t
u
b
e
)
 
h
o
l
d
i
n
g
 
t
h
e
 
1
 
m
l
 
o
f
 
F
M
.
 
T
h
e
 
v
i
a
l
 
i
s
 
f
i
x
e
d
 
t
o
 
t
h
e
 
m
i
c
r
o
d
i
a
l
y
s
e
r
 
b
y
 
a
 
s
e
a
l
i
n
g
 
t
a
p
e
 
(
e
.
g
.
 
n
e
s
c
o
f
i
l
m
)
.
 
T
h
e
 
s
e
t
-
u
p
 
i
s
 
t
h
a
n
 
i
n
c
u
b
a
t
e
d
 
o
n
 
a
 
s
h
a
k
e
r
 
a
t
 
3
0
o
C
.
 
B
,
 
D
i
s
p
o
d
i
a
l
y
s
e
r
 
f
o
r
 
p
r
e
p
a
r
a
t
i
v
e
 
s
c
a
l
e
 
r
e
a
c
t
i
o
n
s
.
 
A
 
d
i
s
p
o
d
i
a
l
y
s
e
r
 
h
o
l
d
i
n
g
 
a
 
s
u
i
t
a
b
l
e
 
v
o
l
u
m
e
 
o
f
 
R
M
 
i
s
 
p
l
a
c
e
d
 
i
n
t
o
 
a
 
p
l
a
s
t
i
c
 
v
i
a
l
 
c
o
n
t
a
i
n
i
n
g
 
t
h
e
 
c
o
r
r
e
s
p
o
n
d
i
n
g
 
v
o
l
u
m
e
 
o
f
 
F
M
.
 
T
h
e
 
s
e
t
-
u
p
 
i
s
 
t
h
e
n
 
i
n
c
u
b
a
t
e
d
 
o
n
 
a
 
r
o
l
l
e
r
 
a
t
 
3
0
o
C
.
 
 
 
F
i
g
.
 
3
.
 
D
i
f
f
e
r
e
n
t
 
m
o
d
e
s
 
o
f
 
M
P
 
p
r
o
d
u
c
t
i
o
n
 
b
y
 
C
F
 
e
x
p
r
e
s
s
i
o
n
.
 
A
:
 
P
r
o
d
u
c
t
i
o
n
 
o
f
 
M
P
 
p
r
e
c
i
p
i
t
a
t
e
s
 
f
o
l
l
o
w
e
d
 
b
y
 
r
e
-
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
a
f
t
e
r
 
a
d
d
i
t
i
o
n
 
o
f
 
d
e
t
e
r
g
e
n
t
s
.
 
B
:
 
P
r
o
d
u
c
t
i
o
n
 
o
f
 
s
o
l
u
b
l
e
 
M
P
’
s
 
b
y
 
a
d
d
i
t
i
o
n
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
d
i
r
e
c
t
l
y
 
i
n
t
o
 
t
h
e
 
C
F
 
s
y
s
t
e
m
.
 
T
h
e
 
M
P
’
s
 
s
o
l
u
b
i
l
i
z
e
d
 
i
n
 
m
i
c
e
l
l
e
s
 
b
y
 
t
h
e
 
t
w
o
 
d
i
f
f
e
r
e
n
t
 
m
o
d
e
s
 
c
a
n
 
b
e
 
d
i
r
e
c
t
l
y
 
a
n
a
l
y
z
e
d
 
o
r
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
i
n
t
o
 
l
i
p
o
s
o
m
e
s
 
f
o
r
 
f
u
r
t
h
e
r
 
a
n
a
l
y
s
i
s
.
 
 
F
i
g
.
 
4
.
 
M
P
’
s
 
f
r
o
m
 
d
i
f
f
e
r
e
n
t
 
f
a
m
i
l
i
e
s
 
t
h
a
t
 
h
a
v
e
 
b
e
e
n
 
p
r
o
d
u
c
e
d
 
a
s
 
a
 
p
r
e
c
i
p
i
t
a
t
e
 
b
y
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
.
 
T
h
e
 
p
r
e
c
i
p
i
t
a
t
e
 
o
f
 
a
n
 
a
n
a
l
y
t
i
c
a
l
 
r
e
a
c
t
i
o
n
 
(
7
0
 
μ
l
 
o
f
 
R
M
)
 
w
a
s
 
s
u
s
p
e
n
d
e
d
 
i
n
 
7
0
 
μ
l
 
o
f
 
b
u
f
f
e
r
 
a
n
d
 
t
h
e
 
p
r
o
t
e
i
n
s
 
i
n
 
1
 
μ
l
 
o
f
 
e
a
c
h
 
s
u
s
p
e
n
s
i
o
n
 
w
e
r
e
 
s
e
p
a
r
a
t
e
d
 
b
y
 
e
l
e
c
t
r
o
p
h
o
r
e
s
i
s
 
i
n
 
a
 
1
2
 
%
 
 
2
0
 
S
D
S
-
p
o
l
y
a
c
r
y
l
a
m
i
d
e
-
g
e
l
.
 
T
h
e
 
a
r
r
o
w
s
 
i
n
d
i
c
a
t
e
 
t
h
e
 
o
v
e
r
p
r
o
d
u
c
e
d
 
r
e
c
o
m
b
i
n
a
n
t
 
M
P
’
s
.
 
T
h
e
 
r
i
g
h
t
 
l
a
n
e
 
s
h
o
w
s
 
t
h
e
 
m
o
l
e
c
u
l
a
r
 
w
e
i
g
h
t
 
m
a
r
k
e
r
.
 
G
P
C
R
:
 
G
-
p
r
o
t
e
i
n
 
c
o
u
p
l
e
d
 
r
e
c
e
p
t
o
r
;
 
O
M
P
:
 
o
u
t
e
r
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
;
 
S
M
R
:
 
s
m
a
l
l
 
m
u
l
t
i
d
r
u
g
 
t
r
a
n
s
p
o
r
t
e
r
.
 
 
F
i
g
.
 
5
.
 
F
r
e
e
z
e
-
f
r
a
c
t
u
r
e
 
e
l
e
c
t
r
o
n
 
m
i
c
r
o
s
c
o
p
y
 
o
f
 
t
h
e
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
e
d
 
E
.
 
c
o
l
i
 
c
y
s
t
e
i
n
e
 
t
r
a
n
s
p
o
r
t
e
r
 
Y
f
i
K
 
a
f
t
e
r
 
r
e
c
o
n
s
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 MINIREVIEW
Cell-free expression as an emerging technique for the
large scale production of integral membrane protein
Christian Klammt, Daniel Schwarz, Frank Lo ¨hr, Birgit Schneider, Volker Do ¨tsch and Frank Bernhard
Centre for Biomolecular Magnetic Resonance, University of Frankfurt⁄Main, Institute for Biophysical Chemistry, Frankfurt⁄Main, Germany
Introduction
Integral membrane proteins (MPs) play key roles in
numerous human diseases and they currently represent
one of the most prevalent drug targets. However, low
expression levels, inefﬁcient puriﬁcation protocols and
problematic handling procedures have so far signiﬁ-
cantly hampered the functional and structural analysis
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Membrane proteins are highly underrepresented in structural data banks
due to tremendous difﬁculties that occur upon approaching their structural
analysis. Inefﬁcient sample preparation from conventional cellular expres-
sion systems is in many cases the ﬁrst major bottleneck. Preparative scale
cell-free expression has now become an emerging alternative tool for the
high level production of integral membrane proteins. Many toxic effects
attributed to the overproduction of recombinant proteins are eliminated by
cell-free expression as viable host cells are no longer required. A unique
characteristic is the open nature of cell-free systems that offers a variety of
options to manipulate the reaction conditions in order to protect or to sta-
bilize the synthesized recombinant proteins. Detergents or lipids can easily
be supplemented and membrane proteins can therefore be synthesized
directly into a deﬁned hydrophobic environment of choice that permits
solubility and allows the functional folding of the proteins. Alternatively,
cell-free produced precipitates of membrane proteins can efﬁciently be solu-
bilized in mild detergents after expression. Highly valuable for structural
approaches is the fast and efﬁcient cell-free production of uniformly or spe-
ciﬁcally labeled proteins. A considerable number of membrane proteins
from diverse families like prokaryotic small multidrug transporters or euk-
aryotic G-protein coupled receptors have been produced in cell-free systems
in high amounts and in functionally active forms. We will give an overview
about the current state of the art of this new approach with special empha-
sis on technical aspects as well as on the functional and structural charac-
terization of cell-free produced membrane proteins.
Abbreviations
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precursor; DHA, dihydroalprenolol; DHPC, 1,2-diheptanoyl-sn-glycero-3-phosphocholine; diC8PC, 1,2-dioctanoyl-sn-glycero-3-phosphocholine;
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integration of recombinant MPs upon their production
in conventional cell culture systems of bacterial, yeast,
mammalian or insect origin often affects the integrity
of the cellular membranes resulting in growth retarda-
tion or even lysis of the host cells. Blocking of cellular
transport and post-translational processing systems by
the overproduced heterologous MPs may cause further
toxic effects. Examples where MPs have been produced
in preparative amounts are therefore relatively rare
and even frequently associated with the aggregation
and inactivation of the recombinant MPs by inclusion
body formation. As a consequence, only some 80 dif-
ferent MP structures are currently deposited in the
protein data banks in contrast to several thousands of
nonmembrane-associated proteins [1].
Protein production by cell-free (CF) expression tech-
niques does not depend on cellular integrity and could
therefore provide a general advantage for the synthesis
of problematic MPs. CF expression has been used
since the early 1950s as a single compartment batch
system with only very low productivity of recombinant
proteins in the nanogram or microgram scale [2–4].
The lifetime of batch reactions was limited mainly by
the fast consumption of precursors and also by inhibi-
tion of the translation process through rapidly accu-
mulating breakdown products. The modiﬁcation of CF
expression systems by separation of the reaction cham-
ber into two compartments resulted in considerably
higher production rates reaching now preparative
scales [5–7]. All high molecular mass compounds of
the transcription and translation machinery in the
reaction mixture (RM) are separated by a semiperme-
able membrane from a feeding mixture (FM) that
deﬁnes a ﬁxed volume reservoir of low molecular mass
precursors. The new design ensures the removal of
undesired breakdown products from the RM concom-
itant with a continuous supply of fresh precursors and
energy substrates from the FM. This continuous
exchange setup of a CF system (continuous exchange
cell-free; CECF) extends protein synthesis for several
hours and is able to produce several mg of recombin-
ant protein per mL of RM [8]. The ﬁnal yield of
recombinant protein is furthermore determined by the
volume ratio of RM and FM that is usually between
1 : 10 and 1 : 30. Refreshing the FM during the reac-
tion could give an additional increase in productivity.
Two main sources of CF extracts have been estab-
lished; wheat germs [9–12] and Escherichia coli cells
[13–16]. The stability of eukaryotic wheat germ
extracts offers extended reaction times up to several
days. The very low endogenous RNAse activity allows
their use in translation systems with puriﬁed mRNA as
a template. In contrast, prokaryotic E. coli extracts are
generally used in coupled transcription⁄translation sys-
tems with double-stranded DNA as a template. Both
systems are comparable with respect to their produc-
tivities [17].
This minireview summarizes the current knowledge
on the preparative scale CF expression of MPs and
emphasizes on their production in the absence as well
as in the presence of detergents. We will give an over-
view on reported examples of CF produced MPs and
we further discuss effects on protein activity that corre-
late with the mode of CF expression. Finally we will
point out new applications that could become feasible
by the CF expression of MPs.
Cell-free expression of membrane
proteins
For the preparative scale expression of MPs, mostly
CF systems based on E. coli extracts have been used
so far. Individual [18–20] as well as commercially
available CF systems like the RTS
TM system (Roche
Diagnostics, Penzberg, Germany) [21–23] or the
Expressway
TM Milligram system (Invitrogen, Carlsbad,
CA, USA) [24] can give satisfying results. An import-
ant advantage of individual systems is the detailed
knowledge of the reaction protocol which is an essen-
tial prerequisite for rationally designed optimization
strategies. Basic parameters for optimization are ion
concentrations, quality and concentration of the DNA
template, reducing conditions, the composition of the
energy regenerating system and concentrations of
amino acids. Subject of target speciﬁc optimizations
are supplemented detergents, lipids and other poten-
tially beneﬁcial compounds like putative cofactors,
inhibitors or substrates. It should be realized that high
level CF expression of a particular MP with yields of
up to several mg of protein per mL RM often has to
be preceded by intensive optimization screens of sev-
eral individual parameters starting with only a few
micrograms of recombinant protein per mL RM.
Effective detection systems like immunoblotting with
tag-speciﬁc antibodies or radioactive labeling might
therefore be necessary for the evaluation of ﬁrst
expression screens.
Individual E. coli systems are based on crude cell
lysates supplemented with optimized buffer and salt
conditions and all additional components necessary for
transcription and translation. Extensive protocols for
the preparation of E. coli lysates have been published
[15,20,25–28]. An efﬁcient energy regenerating system
based on high energy phosphate donors like phospho-
enol pyruvate, acetyl phosphate or creatine phosphate
Cell-free expression of membrane proteins C. Klammt et al.
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the recycling of hydrolyzed nucleotide triphosphates
(NTPs). Transcription in the E. coli lysate depends on
the strong T7 promotor and is facilitated by addition
of puriﬁed T7 RNA polymerase, NTPs and DNA tem-
plates, either in the form of plasmid DNA or as linear
PCR products [29,30]. Furthermore, the translation
process requires the addition of E. coli tRNA mixtures
and of the 20 amino acids. Finally, the CF expression
system has to be stabilized by addition of protease-
and RNAse-inhibitors. Several detailed protocols for
individual CF expression systems are available [13–
15,20].
MPs can be produced in two different modes by CF
expression: As precipitate or as soluble protein in pres-
ence of detergents (Fig. 1). Both modes can result in
functionally active MPs after subsequent solubilization
and reconstitution procedures and the optimal expres-
sion strategy should be analysed for each new MP tar-
get. Production as precipitate might give higher yields
and it facilitates downstream puriﬁcation processes
while the soluble expression is obviously more likely to
result instantly into functionally folded MPs. However,
it should be considered that due to the relatively low
number of analysed MPs still only preliminary conclu-
sions can be made.
Expression of membrane proteins as
precipitate
Several diverse MPs of prokaryotic or eukaryotic ori-
gin could be produced in CF systems supplemented
with E. coli extracts, while their synthesis in E. coli
cells was much lower or even absent [18,20]. We pro-
pose that the elimination of the described negative
effects upon in vivo expression of MPs like membrane
insertion, blocking of transport systems and others
might for the most part contribute to this observation.
Hydrophobic environments like lipids or detergents are
essential for the solubility and proper folding of MPs.
Standard CF systems lack such hydrophobic compart-
ments and the synthesized recombinant MPs therefore
almost quantitatively precipitate in the RM (Fig. 2)
[18,20–23]. After the reaction, the precipitated MPs are
harvested from the RM by centrifugation. CF pro-
duced precipitates of many MPs solubilize quickly and
effectively in mild detergents during short incubation
with gentle shaking for a few minutes. This relatively
fast solubilization procedure distinguishes CF pro-
duced MP precipitates from inclusion bodies that can
often be observed after in vivo expression of MPs [31].
Solubilization of inclusion bodies usually requires
extensive denaturation steps involving SDS or high
concentrations of urea. In practice, the CF generated
MP pellets are suspended in a suitable buffer supple-
mented with  1–2% of an appropriate detergent and
in a volume that corresponds to the volume of the
RM. The suspension is incubated between 20  C and
30  C on a shaker for  1 h and residual precipitate is
removed by centrifugation for 15 min at 20 000 g. The
efﬁciency of solubilization of a particular MP depends
on the detergent type, and coprecipitated impurities
can be removed by subsequent washing steps using
detergents that do not dissolve the target MP. It can
further be effective to increase the incubation tempera-
ture in order to selectively eliminate impurities [20].
Various mild detergents of different classes like alkyl
glycosides, steroid derivatives, long chain phospho-
glycerols, phosphocholines, polyoxyethylene alkyl-
ethers or polyethylene glycols have been tested for
their suitability to solubilize CF produced precipitates
of even structurally very different MPs [19]. The deter-
gent 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-
(1-glycerol)] (LMPG) and closely related derivatives
like 1-palmitoyl-2-hydroxy-sn-glycero-3-[phosphor-rac-
(1-glycerol)] (LPPG) were found to be most useful for
general applications. Pellets of the bacterial a-helical
multidrug transporter EmrE, the b-barrel type nucleo-
side transporter Tsx, and the porcine vasopressin
receptor V2R of the eukaryotic family of G-protein
coupled receptors (GPCRs) could almost be
completely solubilized by LMPG, while other mild
detergents like n-dodecyl-b-d-maltoside (DDM) or do-
decyl-phosphocholine (DPC) are only efﬁcient in the
solubilization of some of the analysed MP pellets [19].
A detergent exchange after solubilization by standard
procedures might be considered if particular and
different detergents are required for the further down-
stream analysis of the MP.
The CF expression in the absence of any supplemen-
ted detergents or lipids is a reliable technique to direct
almost all of the synthesized MP into precipitate. Cer-
tainly, the precipitation could cause the partial or com-
plete unfolding of a MP and it should be considered
that an efﬁcient functional refolding into its native
conformation upon solubilization might not always
occur. We could reconstitute several CF produced and
solubilized MPs like the bacterial multidrug transport-
ers EmrE and SugE, the tellurite transporter TehA,
the cysteine exporter Yﬁk and the GPCR member
V2R into liposomes and freeze-fracture analysis
revealed homogenously distributed particles giving
evidence of a functional reconstitution [19,20]. The
bacterial multidrug transporter EmrE showed speciﬁc
transport activity with its cognate substrate ethidium
bromide after CF production as a precipitate,
C. Klammt et al. Cell-free expression of membrane proteins
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Fig. 1. Different modes for CF expression of MPs. MPs can be expressed as precipitate (Mode A), solubilized in an appropriate detergent
and further reconstituted into proteoliposomes, or they can be soluble expressed in the presence of detergent (Mode B), puriﬁed and recon-
stituted into proteoliposomes. EM, electron microscopy.
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lipids [20]. However, on the other hand, we have been
unable to functionally reconstitute the b-barrel type
E. coli outer membrane protein Tsx into membranes
after its solubilization in DPC or LMPG from CF pro-
duced precipitates [19].
Cell-free expression of membrane
proteins in soluble form
The intrinsic open nature of the CF system allows the
direct supplementation of almost any desired com-
pound into the RM. Selected detergents or lipids could
therefore already be present at the beginning of the
reaction in order to provide a suitable hydrophobic
environment for the synthesized MPs. This gives nas-
cent polypeptides the opportunity to become inserted
into preformed micelles or liposomes during or shortly
after translation. However, detergents are interfering
nonspeciﬁcally with hydrophobic protein regions and it
has to be expected that their addition to the RM might
generally affect transcriptional and translational pro-
cesses of the CF system by inactivation of essential
components. A total of 24 frequently used detergents
of a comprehensive variety have therefore been system-
atically evaluated with respect to (i) their impact on
the general productivity of a CF expression system, (ii)
their efﬁciency to keep synthesized MPs in solution,
and (iii) their effects on the activity of the solubilized
MPs [19]. Surprisingly, only a few of the analysed
detergents like DPC, n-octyl-b-d-glucopyranoside
(b-OG), the steroid Chaps and the members of the
long chain phosphoglycerols LPPG and LMPG signiﬁ-
cantly reduced the CF protein production [19]. In
addition, more aggressive detergents like sodium deo-
xycholate, sodium cholate and N-laurylsarcosine com-
pletely inhibit CF MP synthesis [18,23].
A considerable variety of mild detergents is suitable
for the CF expression of soluble MPs in preparative
scales. Most useful is the group of long chain polyoxy-
ethylene-alkyl-ethers. Polyoxyethylene-(23)-lauryl-ether
(Brij-35), polyoxyethylene-(20)-cetyl-ether (Brij-58),
polyoxyethylene-(20)-stearyl-ether (Brij-78) and poly-
oxyethylene-(20)-oleyl-ether (Brij-98) resulted in high
level soluble expression of all analysed MPs. Bacterial
a-helical and b-barrel proteins as well as the larger
eukaryotic GPCR could be synthesized with these
detergents as soluble proteins in amounts of 3–6 mg
per mL RM [19]. It is noteworthy that the correspond-
ing short chain derivatives with less than 10 polyoxy-
ethylene groups have not been effective at all. The
number of polyoxyethylene groups as well as the
length of the alkyl moiety is critical and both could
inﬂuence the solubilization efﬁciency and the ﬁnal yield
of a speciﬁc MP. The optimal Brij-derivative for the
solubilization of a speciﬁc MP should therefore ini-
tially be selected by an optimization screen. A second
detergent with a completely different structure but also
having a relatively general ability to solubilize MPs
during CF expression is the steroid derivative digitonin
[18,19].
Smaller MPs like the small multidrug resistance fam-
ily (SMR) transporter EmrE obviously solubilize in a
higher variety of detergents. The alkyl-glucosides n-do-
decyl-b-d-maltoside (DDM) and n-decyl-b-d-maltoside
(DM), the bi-chain-phosphocholines 1,2-dioctanoyl-sn-
glycero-3-phosphocholine (diC8PC), 1,2-diheptanoyl-
sn-glycero-3-phosphocholine (DHPC) and 1,2-dimyris-
toyl-sn-glycero-3-phosphocholine (DMPC) and the
polyethylene-glycol derivative polyethylene-glycol
Fig. 2. CF production of different MPs as precipitates. The nonsoluble part of the RM was resuspended in appropriate buffer in a volume equal
to the RM and 1 lL was analyzed on 10% tricine⁄SDS (lanes 2–6), 16.5% SDS (lane 7) or 12% SDS gels (lanes 8–12). The MPs are indicated
by arrows. Lane 1, marker, 14.4, 18.4, 25, 35, 45, 66.2, 116 kDa; lane 2, EmrE; lane 3, SugE; lane 4, Tbsmr; lane 5, YﬁK; lane 6, TehA; lane 7,
DTehA; lane 8, Tsx; lane 9, V2R (porcine); lane 10, V2R (human); lane 11, CRF; lane 12, human endothelin B receptor precursor (ETB).
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in the case of the CF soluble production of EmrE, as
efﬁcient as the above described long chain Brij-deriva-
tives [19,24].
Detergents are known to form micellar structures
above a speciﬁc threshold concentration, the critical
micellar concentration (CMC). The CMC and also the
aggregation number, i.e., the number of detergent mol-
ecules per micelle, is speciﬁc to each detergent type,
but they also depend on buffer conditions, inserted
proteins and other parameters. An important consid-
eration for the optimal production of soluble MPs in a
CF expression reaction is that sufﬁcient micelles are
provided. The micellar concentration (Cmic) should
therefore be at least as high as the molar concentration
of the MP in order to prevent aggregates or the forma-
tion of nonhomogenous proteomicelles. As the amount
of detergent that binds to the hydrophobic surfaces of
an integral MP remains relatively constant above the
CMC, excessive detergent will form additional empty
micelles but does not affect the solubility of a MP.
Depending on its tolerance by the CF system, high
detergent concentrations of several times CMC could
be added in order to ensure the possibility of complete
and homogenous MP solubilization. Polyoxyethylene-
alkyl-ethers like the highly effective Brij-derivatives can
be added to more than 100 times CMC [18,19]. How-
ever, the tolerated levels of other detergents like DDM
or TX-100 are much lower.
Disadvantages of the soluble CF expression of MPs
are sometimes lower ﬁnal yields of recombinant pro-
tein if compared with a CF production as precipitate.
It should furthermore be considered that the addition
of even high concentrations of detergents frequently
does not result in the complete soluble expression of
MPs, and rather mixtures of soluble and precipitated
MPs are produced. Finally it should be realized that
the type of supplemented detergent has an impact not
only on the yield of the synthesized MP but also on its
functional conformation, the speciﬁc activity and per-
haps even on its probability to form oligomers [19].
The choice of supplemented detergent should therefore
be one of the ﬁrst optimization parameters when the
CF expression of a new MP target is anticipated.
Examples of cell-free expressed
membrane proteins
Although only a limited number of CF expressed MPs
has been analysed so far, they already comprise a con-
siderable diverse pool of proteins of prokaryotic as
well as eukaryotic origin (Table 1). A common charac-
teristic is their almost completely integral nature, and
the analysed MPs are embedded in cellular membranes
with up to 10 transmembrane segments (TMSs). It still
remains to be shown whether, e.g., integral MPs with
large hydrophilic domains or peripheral MPs with only
short membrane anchors can also be produced in a
functional form by CF systems.
The vast majority of CF produced MPs of prokary-
otic origin belongs to the family of SMR efﬂux trans-
porters, having four TMSs and a molecular mass of
 12 kDa. A well characterized prototype of this fam-
ily is the E. coli protein EmrE that has been in vitro
expressed by different groups in individual or commer-
cial CF expression systems (Table 1). In all cases, pre-
parative amounts of protein ranging from 0.2 mg up
to several mgs per mL of RM could be achieved.
Other CF produced members of the SMR family
include SugE and YdgF from E. coli, Hsmr from
Halobacterium salinarium, Tbsmr from Mycobacterium
tuberculosis, Psmr from Pseudomonas aeruginosa,
BPsmr from Bacillus pertussis and YfbW from Salmon-
ella typhimurium [20,22,32]. All proteins could be
obtained in preparative amounts suitable for their
characterization by solution NMR [20], by functional
assays [22], by solid state NMR [32] and even by cry-
stallization [24].
Two small bacterial a-helical MPs, the mechanosen-
sitive channel MscL of E. coli and the light harvesting
protein a-LH1 of Rhodospirillum rubrum have been
produced in a commercial CECF system [21,23]. The
14 kDa MscL protein consists of two TMSs while the
6 kDa a-LH1 subunit has only one TMS. The authors
could document an activity of the two CF produced
MPs that was similar to samples analysed after con-
ventional in vivo expression in E. coli (Table 2). MscL
has been produced soluble in TX-100 micelles [23]
while a-LH1 was made as precipitate and solubilized
in TX-100 after the reaction [21]. These results demon-
strate nicely the versatility of CF expression and show
that both expression modes can result in functionally
folded protein. NMR spectra of CF produced samples
of the 21 kDa cysteine exporter YﬁK (Fig. 3), of the
36 kDa tellurite resistance transporter TehA and of its
24 kDa truncated version DTehA give evidence of
structurally folded proteins [20,33]. The amide proton
assignment of DTehA could be completed by using
rationally designed combinatorial labeling schemes that
are based on the CF production of labeled protein
samples [33].
The family of eukaryotic GPCRs currently attracts
considerable attention as potential drug targets for the
pharmaceutical industry. GPCRs represent the largest
single class of receptors and they play key roles
in many signaling pathways, cellular recognition
Cell-free expression of membrane proteins C. Klammt et al.
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numerous attempts, only the three-dimensional struc-
ture of bovine rhodopsin has been solved so far
[34,35]. GPCRs have a predicted similar topology, with
seven TMSs interconnected by loop regions. Several
GPCRs of human and other mammalian origin like
the human b2 adrenergic receptor (b2AR), the rat
muscarinic acetylcholine receptor M2 (M2) and the
human neurotensin receptor (NTR) could be synthes-
ized in individual CF systems at relatively high yields
[18] (Table 1). While the expression of the wildtype
GPCRs was found to be inefﬁcient, the construction of
translational fusions to the C-terminal end of the
11.7 kDa E. coli thioredoxin (TrxA) tremendously
Table 1. Membrane proteins synthesized in preparative scale CF expression systems. Type refers to main secondary structure element,
either a (a-helical) or b (b-sheets). Mode of expression is either as precipitate (P) or in the presence of different detergents. Reaction is
Batch (individual batch system set-up), CECF, RTS-100 [commercial batch system (Roche Diagnostics)], RTS-500 [commercial CECF system
(Roche Diagnostics)] or Expressway [commercial batch system (Invitogen)]. TrxA-M2, thioredoxin fused human muscarinic acetylcholine
receptor M2; TrxA-M2-Gi1a, TrxA-M2 fused with the Gi1a subunit of a G-protein; TrxA-NTR, thioredoxin fused rat neurotensin receptor; TrxA-
b2AR, thioredoxin fused human b2-adrenergic receptor; TrxA-b2AR-Gsa, TrxA-b2AR fused to the Gsa subunit of a G-protein. DMPC, 1,2-
dimyristoyl-sn-glycero-3-phosphocholine; TDT, tellurite-resistance⁄dicarboxylate transporter family; RhtB, resistance to homoserine⁄threonine
family; n.p., not published; n.r., not reported.
Protein TMS m [kDa] Family Type Reaction Expression mode Yield [mgÆmL
)1] Ref.
Eukaryotic
CRF 7 48 GPCR a CECF P 3 n. p.
ETB 7 52 GPCR a CECF P 3 n. p.
TrxA-M2 7 45 GPCR a Batch P 0.17 [18]
Brij-35, digitonin 0.15 [18]
TrxA-M2-Gi1a 7 95 GPCR a Batch P 0.17 [18]
TrxA-NTR 7 52 GPCR a Batch P 0.18 [18]
Brij-35, digitonin 0.15 [18]
TrxA-b2AR 7 66 GPCR a Batch P 0.16 [18]
Brij-35, digitonin 0.16 [18]
TrxA-b2AR-Gsa 7 105 GPCR a CECF Brij-35, digitonin 1 [18]
Batch P 0.15 [18]
V2Rh 7 43 GPCR a CECF P 3 n. p.
V2Rp 7 43 GPCR a CECF P, Brij-58, -78 6 [19]
Brij-98 2.9 [19]
Brij-35 0.9 [19]
Digitonin 0.38 [19]
Prokaryotic
BPsmr 4 12 SMR a RTS-100 P n. r. [22]
EmrE 4 12 SMR a CECF Brij-35, -98, 2.7 [19]
CECF P 3 [19]
RTS-500 P, DDM 3 [22]
CECF P 1 [20]
Expressway DMPC 0.2 [24]
Hsmr 4 15 SMR a CECF P n. r. [32]
Psmr 4 12 SMR a RTS-100 P n. r. [22]
SugE 4 11 SMR a CECF P 1.5 [20]
Tbsmr 4 11 SMR a CECF P n. r. [32]
RTS-100 P n. r. [22]
YdgF 4 SMR a CECF P n. r. [32]
Yfbw 4 SMR a CECF P n. r. [32]
TehA 10 36 TDT a CECF P 2.7 [20]
nTehA 7 24 TDT a CECF P 3 [33]
a-LH1 1 6.1 LHP a RTS-500 P 0.7 [21]
MscL 2 14 MscL a RTS-500 TX-100 3.6 [23]
YﬁK 6 21 RhtB a CECF P 1 [20]
Tsx – 31 OMP b CECF P 4 [19]
Brij-35, -58, -78 3 [19]
DDM 1.7 [19]
Digitonin, TX-100 4 [19]
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yields of several 100 lgÆmL
)1 in batch systems and
more than 1 mgÆmL
)1 in a commercial CECF system
were produced (Table 1). Those expression levels could
even be obtained with a 108 kDa construct of b2AR
that was fused at its N-terminus to TrxA and at its
C-terminal to the Gsa-protein [18]. The relatively large
TrxA fusion was essential in order to increase the
translation efﬁciency of GPCRs, but it can obviously
be replaced by short N-terminal tags like the T7 tag.
The porcine vasopressin receptor (V2R) was efﬁciently
produced in an individual CECF containing only the
short T7 tag with 14 amino acid residues [19]. Similar
observations were made by our group upon the CF
expression of the human V2R, the endothelin B recep-
tor (ETB) and the corticotropin releasing factor 1 pre-
cursor receptor (CRF). All three GPCRs were
synthesized in an individual CECF system with only
an N-terminal T7 tag in amounts of  3 mg per mL
RM (Table 1). In accordance with the results obtained
upon the CF expression of the GPCRs b2AR, M2 and
NTR this indicates that an efﬁcient initiation of trans-
lation might not occur with the wildtype GPCR
sequences. Only the steroid digitonin and long chain
Brij-derivatives have been suitable for the soluble CF
expression of mammalian GPCRs at elevated levels
and after optimization of the detergent concentration
up to 6 mg of soluble V2R could be obtained [19].
The 31 kDa nucleoside transporter Tsx of E. coli is
so far the only example of a CF produced outer mem-
brane protein (OMP) having a b-barrel type structure
[19]. Tsx is synthesized in both CF expression modes,
either as a precipitate or as soluble protein in the pres-
ence of detergents, in ﬁnal amounts of up to 4 mgÆmL
)1
in an individual CECF system (Table 1). The soluble
Tsx expression was quite tolerant for a wide range of
detergents and besides digitonin and Brij-derivatives,
also TX-100 and DDM were highly effective (Table 1).
The Tsx transporter is an example of where the CF
expression conditions might have a signiﬁcant impact
on the functional folding of the recombinant MP. CF
produced Tsx precipitate that was solubilized in deter-
gent micelles was not functionally active in speciﬁc
transport assays, in contrast to Tsx protein produced in
the soluble mode of CF expression (Table 2) [19].
Despite its efﬁcient solubilization in mild detergents,
the precipitated Tsx might have problems recovering its
fully functional conformation. In addition, remarkable
differences in the speciﬁc activity of soluble CF pro-
duced Tsx were noticed in dependency to the supple-
mented detergent. The functionally active conformation
of Tsx might therefore be relatively susceptible for its
hydrophobic environment, and a clear preference was
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expression should therefore focus not only on highest
yields but also on conditions that ensure a high speciﬁc
activity of the synthesized MPs.
Speciﬁc applications for cell-free
produced membrane proteins
Structural analysis of CF synthesized MPs
CF expression systems could help to accelerate the
production of MPs of diverse structure and origin,
especially for the purpose of structural characteriza-
tion. The two main directions of high resolution struc-
tural analysis, X-ray crystallography as well as
solution NMR spectroscopy, could considerably bene-
ﬁt from the advantages of CF expression. Both tech-
niques require protein samples that have been
speciﬁcally labeled either with seleno-methionine or
with stable isotopes. In conventional in vivo expression
systems those labeling procedures often require auxo-
trophic mutants of host cells and fermentation proto-
cols based on deﬁned minimal media. Frequent
consequences are growth retardation, signiﬁcantly
decreased productivities of the labeled proteins, incom-
plete label incorporation and scrambling problems due
to metabolic conversion of the label precursors. Time-
consuming and expensive optimization runs therefore
have to be performed before ﬁnal preparations can be
started. Those problems have ﬁnally prevented struc-
tural approaches in many cases of MPs that are
already difﬁcult to produce at normal conditions.
The open nature of CF systems in combination with
the complete control over the amino acid pool allows
the production of labeled MP samples as fast and as
efﬁciently as the production of nonlabeled proteins.
Nonlabeled amino acids in the CF mixtures are simply
exchanged against the labeled derivatives and no other
changes of conditions are required. This ensures a con-
stant yield of the recombinant MP concomitant with
Fig. 3.
1H-
15N TROSY spectrum of CF
expressed U-
2H-
15N-labeled YﬁK. The pro-
tein was expressed in the insoluble mode
as precipitate and resolubilized in LMPG.
The protein was dissolved in 25 mM potas-
sium phosphate buffer (pH 6.0) containing
5% LMPG. The spectrum was measured
with a protein concentration of 0.3 mM at
29  C on a 900 Mhz NMR spectrometer
(Bruker, Rheinstetten, Germany) equipped
with a cryo probe with eight scans per free
induction decay and 640 increments in the
indirect dimension.
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characteristic deﬁnes a precious advantage especially
for the purpose of NMR analysis. Moreover, CF pro-
duction provides signiﬁcantly reduced scrambling or
background labeling problems [8,13,14,26,36,37]. It is
even possible to analyse the CF produced labeled pro-
tein directly in the RM by NMR without prior puriﬁ-
cation [38]. This is especially important for MPs where
downstream puriﬁcation processes can result in tre-
mendous losses of protein. MP samples ready for
NMR analysis can thus be prepared virtually in less
than 24 h.
Solution NMR studies of MPs are still an exception
due to the so far limited availability of labeled samples
in combination with the required size restriction of the
analysed proteins. Proteins exceeding molecular masses
of  20 kDa increasingly generate signals of low dis-
persion with signiﬁcant spectral overlaps that retard or
even prevent a structural analysis by solution NMR.
The a-helical nature of many MPs and the resulting
concentration of most signals in the range between
7.5 p.p.m. and 8.5 p.p.m. often further reduce the size
limits. The insertion of MPs into detergent micelles
usually dramatically increases the MP–detergent com-
plex size and thus considerably inﬂuences the quality
of NMR spectra. The few available NMR structures
of MPs have therefore been recorded mostly from
b-barrel type outer membrane proteins. Fortunately,
recent screens for NMR suitable detergents helped to
identify the group of lyso-phosphoglycerols as highly
promising detergents that do not restrict the spectral
quality of solubilized MPs [39]. The detergent LMPG
that was found to be superior for the solubilization of
CF produced precipitates of MPs belongs to this group
and NMR spectra of [
15N]-labeled samples of the relat-
ively large E. coli a-helical MPs YﬁK (Fig. 3) and
TehA in LMPG micelles showed resolutions that are
very promising for structural approaches by solution
NMR [20,33].
A ﬁrst example of the NMR analysis of a CF pro-
duced MP is the putative multidrug resistance and
tellurite resistance transporter, TehA, of E. coli. The
36 kDa wildtype TehA with 10 TMSs as well as a
C-terminal truncated functionally active version
DTehA of 24 kDa and with seven TMSs can be pro-
duced in an individual CF system in amounts of
2–3 mg per mL RM [20,33]. The structural analysis of
DTehA has been approached by solution NMR as a
ﬁrst model system of a CF produced relatively large
a-helical integral MP. The almost complete backbone
assignment of DTehA has been obtained using the
explicit advantages of CF expression. While only
 40% of the backbone amide protons could be
assigned based on uniformly isotopically labeled
DTehA measured in LMPG micelles, the ﬁnal assign-
ment of the residual amide protons was successful by
using a combinatorial labeling scheme [33]. Selected
sets of amino acid combinations have been labeled
either with
15No r
13C by a rational designed strategy.
This technique allowed speciﬁc amino acid pairs hav-
ing a [
15N]-labeled amino acids N-terminally preceded
by a [
13C]-labeled amino acid type to be identiﬁed, and
it subsequently resulted in new anchor points for fur-
ther sequence-speciﬁc assignments. Such combinatorial
labeling schemes turned out to be superior in order to
obtain unambiguous assignments if compared with sin-
gle amino acid speciﬁc labeling approaches, but they
are almost exclusively feasible by using CF synthesis.
Oligomerization studies
The conventional analysis of the oligomeric state of
MPs is frequently performed by cross linking experi-
ments of puriﬁed protein. CF expression could offer
an alternative approach by providing two different
DNA templates with one encoding for the wildtype
MP and the other for a derivative that has been modi-
ﬁed by a translational tag. Plasmids of even identical
incompatibility groups could be used as DNA tem-
plates as no replication or selection is required. Even
linear DNA fragments generated by standard PCR
might be applicable. As an example, the CF produced
wildtype mutidrug transporter EmrE was successfully
pulled down by a poly(His)6 tagged EmrE derivative
that had been coexpressed in the same reaction, indica-
ting the formation of EmrE oligomers [22]. Moreover,
negative dominance studies with inactive coexpressed
EmrE mutants also gave insights into the functionality
of the oligomers. An advantage of CF expression is
that the ratios of both protein species can easily be
manipulated by titration of the corresponding DNA
templates. It would further be possible to add already
puriﬁed proteins that have been isolated from other
sources in order to analyse their interaction with the
synthesized target protein. This enables accurate quan-
titative experiments that are independent from the
expression rates and proper folding conditions of the
putative interaction partners.
High-throughput expression screening of MPs
CF expression has been optimized for direct PCR
product expression and high-throughput (HT) applica-
tions of soluble proteins [40,41]. Expression screening
in 96 well formats [42] as well as in even smaller nano-
well chip formats is possible [43]. Instability problems
Cell-free expression of membrane proteins C. Klammt et al.
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ing CF extracts from nuclease deﬁcient strains [29,44].
Alternatively, modiﬁcations of the mRNA, like the
positioning of a stem-loop structure at the 3¢ end, the
addition of poly(G) tails or mini-hairpin sequences,
can substantially help to increase the half-life of the
transcripts [30,44,45].
MPs have usually been excluded from common HT
proteome expression approaches as they are difﬁcult
to produce. However, the combined advances of CF
expression systems for HT applications and MP pro-
duction will open up new potentials for membrane
proteomics. The possibility to use linear PCR products
as expression templates will be highly valuable as a
variety of translational tags could be screened in a rel-
atively short time for potential beneﬁts, without the
need of time-consuming cloning procedures. Further-
more, the option to provide stabilizing agents like pro-
tease inhibitors, chaperones, ligands or others will
additionally increase the likeability of a detectable pro-
tein production. It will also be interesting to analyse
the potential of MP production in CF systems based
on wheat germ extracts, as folding pathways and
potential modiﬁcation patterns of eukaryotic MPs
might become improved in the eukaryotic background.
Labeling protocols for NMR-based structural proteo-
mics based on wheat germ extracts that can be exten-
ded to an automated platform have already been
established [46,47].
Conclusion and future challenges
The reported number of CF produced MPs is still lim-
ited and also comprises several well characterized
model proteins that can be produced in considerable
amounts in E. coli cells. However, GPCRs for instance
are known as problematic proteins and their high level
CF production in functional form gives the ﬁrst evi-
dence of an immense potential of this new technology
for the generation of difﬁcult MP samples. A current
restriction is that all analysed MPs so far have a more
or less completely membrane-integrated topology with
only relatively small hydrophilic loops. More compre-
hensive expression screenings are therefore needed in
order to evaluate the application of CF expression to a
wider range of MP families including those that con-
tain larger nonmembrane integrated domains. It
should be realized that besides the fast production of
MPs that are otherwise very difﬁcult to obtain, the CF
expression provides further unique and highly valuable
advantages. The destabilization of membranes by con-
ventional puriﬁcation protocols is often associated with
the denaturation of the inserted MPs by transient
exposure of hydrophobic surfaces to water. The direct
synthesis of MPs into the desired detergents avoids
such critical isolation steps. Most important is the fast
and efﬁcient labeling of MPs with modiﬁed amino
acids that is an essential prerequisite for structural
studies by NMR spectroscopy as well as by X-ray
crystallography. The sole fact that labeled samples
ready for analysis can now be obtained in less than
24 h will enable many new approaches for the struc-
tural analysis of MPs. Finally, it should be considered
that CF expression protocols are currently the subject
of a variety of optimization strategies. Usage of wheat
germ extracts, efﬁcient disulﬁde bridge formation, sup-
plementation of lipids and others will help to continu-
ously provide new options in order to improve the
quality of CF produced MPs.
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t
o
 
c
o
n
s
i
s
t
 
t
o
 
2
0
-
4
0
 
%
 
o
f
 
I
M
P
s
.
 
M
a
n
y
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
s
t
u
d
i
e
s
 
f
o
c
u
s
 
c
u
r
r
e
n
t
l
y
 
o
n
 
I
M
P
s
 
a
s
 
t
h
e
y
 
p
l
a
y
 
k
e
y
 
r
o
l
e
s
 
i
n
 
a
 
v
a
r
i
e
t
y
 
o
f
 
g
l
o
b
a
l
 
h
u
m
a
n
 
d
i
s
e
a
s
e
s
.
 
I
M
P
s
 
p
r
o
v
i
d
e
 
t
h
u
s
 
a
n
 
e
s
t
i
m
a
t
e
 
o
f
 
a
p
p
r
o
x
.
 
6
0
 
%
 
o
f
 
a
l
l
 
m
o
d
e
r
n
 
d
r
u
g
 
t
a
r
g
e
t
s
.
 
A
 
b
a
s
i
c
 
p
r
e
r
e
q
u
i
s
i
t
e
 
f
o
r
 
a
 
d
i
r
e
c
t
e
d
 
d
r
u
g
 
d
e
s
i
g
n
 
a
s
 
w
e
l
l
 
a
s
 
f
o
r
 
t
h
e
 
u
n
d
e
r
s
t
a
n
d
i
n
g
 
o
f
 
b
i
o
l
o
g
i
c
a
l
 
f
u
n
c
t
i
o
n
s
 
i
s
 
t
h
e
 
k
n
o
w
l
e
d
g
e
 
o
f
 
t
h
e
 
t
h
r
e
e
-
d
i
m
e
n
s
i
o
n
a
l
 
s
t
r
u
c
t
u
r
e
 
o
f
 
a
 
p
r
o
t
e
i
n
.
 
R
e
l
a
t
i
v
e
l
y
 
h
i
g
h
 
a
m
o
u
n
t
s
 
o
f
 
p
r
o
t
e
i
n
 
i
n
 
t
h
e
 
r
a
n
g
e
 
o
f
 
s
e
v
e
r
a
l
 
1
0
0
 
m
g
 
a
r
e
 
o
f
t
e
n
 
n
e
e
d
e
d
 
f
o
r
 
s
t
r
u
c
t
u
r
a
l
 
a
p
p
r
o
a
c
h
e
s
 
b
y
 
e
i
t
h
e
r
 
X
-
r
a
y
 
c
r
y
s
t
a
l
l
o
g
r
a
p
h
y
 
o
r
 
n
u
c
l
e
a
r
 
m
a
g
n
e
t
i
c
 
r
e
s
o
n
a
n
c
e
 
(
N
M
R
)
 
s
p
e
c
t
r
o
s
c
o
p
y
.
 
W
i
t
h
 
f
e
w
 
e
x
c
e
p
t
i
o
n
s
 
w
h
e
r
e
 
n
a
t
u
r
a
l
 
a
b
u
n
d
a
n
c
e
 
o
f
 
a
 
p
r
o
t
e
i
n
 
o
f
f
e
r
s
 
t
h
e
 
o
p
p
o
r
t
u
n
i
t
y
 
o
f
 
h
i
g
h
 
y
i
e
l
d
 
p
r
e
p
a
r
a
t
i
o
n
s
,
 
h
e
t
e
r
o
l
o
g
o
u
s
 
c
e
l
l
u
l
a
r
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
o
f
 
p
r
o
k
a
r
y
o
t
i
c
 
o
r
 
e
u
k
a
r
y
o
t
i
c
 
o
r
i
g
i
n
 
h
a
v
e
 
t
o
 
b
e
 
u
s
e
d
 
i
n
 
o
r
d
e
r
 
t
o
 
p
r
o
d
u
c
e
 
s
u
f
f
i
c
i
e
n
t
 
a
m
o
u
n
t
s
 
o
f
 
p
r
o
t
e
i
n
.
 
U
n
f
o
r
t
u
n
a
t
e
l
y
,
 
t
h
e
 
h
y
d
r
o
p
h
o
b
i
c
 
n
a
t
u
r
e
 
o
f
 
I
M
P
s
 
a
n
d
 
t
h
e
i
r
 
d
i
s
t
i
n
c
t
 
l
o
c
a
l
i
z
a
t
i
o
n
 
i
n
 
c
e
l
l
u
l
a
r
 
m
e
m
b
r
a
n
e
s
 
d
o
e
s
 
o
f
t
e
n
 
c
a
u
s
e
 
t
r
e
m
e
n
d
o
u
s
 
p
r
o
b
l
e
m
s
 
u
p
o
n
 
t
h
e
i
r
 
s
y
n
t
h
e
s
i
s
 
i
n
 
c
o
n
v
e
n
t
i
o
n
a
l
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
.
 
B
l
o
c
k
i
n
g
 
o
f
 
c
e
l
l
u
l
a
r
 
p
r
o
t
e
i
n
 
t
a
r
g
e
t
i
n
g
 
s
y
s
t
e
m
s
,
 
c
o
m
p
l
e
x
 
f
o
r
m
a
t
i
o
n
 
w
i
t
h
 
c
e
l
l
u
l
a
r
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
o
r
 
d
i
s
i
n
t
e
g
r
a
t
i
o
n
 
o
f
 
m
e
m
b
r
a
n
e
s
 
a
r
e
 
f
r
e
q
u
e
n
t
 
e
f
f
e
c
t
s
 
t
h
a
t
 
r
e
s
u
l
t
 
i
n
 
t
o
x
i
c
i
t
y
 
t
o
 
l
i
v
i
n
g
 
c
e
l
l
s
 
l
e
a
d
i
n
g
 
t
o
 
l
o
w
 
e
x
p
r
e
s
s
i
o
n
 
r
a
t
e
s
.
 
 
C
e
l
l
-
f
r
e
e
 
(
C
F
)
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
o
f
f
e
r
 
i
n
 
p
r
i
n
c
i
p
l
e
 
t
h
e
 
p
o
s
s
i
b
i
l
i
t
y
 
t
o
 
e
l
i
m
i
n
a
t
e
 
t
o
x
i
c
 
e
f
f
e
c
t
s
 
o
f
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
s
 
a
s
 
n
o
 
l
i
v
i
n
g
 
a
n
d
 
m
e
t
a
b
o
l
i
c
 
a
c
t
i
v
e
 
e
n
v
i
r
o
n
m
e
n
t
s
 
a
r
e
 
n
e
c
e
s
s
a
r
y
.
 
O
n
l
y
 
c
a
r
e
 
h
a
s
 
t
o
 
b
e
 
t
a
k
e
n
 
t
h
a
t
 
t
h
e
 
e
s
s
e
n
t
i
a
l
 
t
r
a
n
s
l
a
t
i
o
n
 
a
n
d
 
t
r
a
n
s
c
r
i
p
t
i
o
n
 
p
r
o
c
e
s
s
e
s
 
w
i
l
l
 
n
o
t
 
b
e
 
a
f
f
e
c
t
e
d
 
b
y
 
t
h
e
 
o
v
e
r
p
r
o
d
u
c
e
d
 
p
r
o
t
e
i
n
.
 
C
F
 
s
y
s
t
e
m
s
 
a
r
e
 
t
h
e
r
e
f
o
r
e
 
p
r
e
d
e
s
t
i
n
e
d
 
f
o
r
 
t
h
e
 
s
y
n
t
h
e
s
i
s
 
o
f
 
e
v
e
n
 
s
t
r
o
n
g
 
t
o
x
i
n
s
 
t
h
a
t
 
c
a
n
n
o
t
 
o
b
t
a
i
n
e
d
 
w
i
t
h
 
c
o
n
v
e
n
t
i
o
n
a
l
 
i
n
-
v
i
v
o
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
(
1
)
.
 
M
o
r
e
o
v
e
r
,
 
a
 
c
o
n
s
i
d
e
r
a
b
l
e
 
n
u
m
b
e
r
 
o
f
 
a
d
d
i
t
i
o
n
a
l
 
b
e
n
e
f
i
t
s
 
a
r
e
 
i
n
t
r
i
n
s
i
c
 
p
r
o
p
e
r
t
i
e
s
 
o
f
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
.
 
E
x
p
r
e
s
s
i
o
n
 
c
o
n
d
i
t
i
o
n
s
 
l
i
k
e
 
p
H
,
 
r
e
d
o
x
 
p
o
t
e
n
t
i
a
l
 
o
r
 
b
u
f
f
e
r
 
s
y
s
t
e
m
s
 
c
o
u
l
d
 
e
a
s
i
l
y
 
b
e
 
m
o
d
i
f
i
e
d
.
 
A
 
h
i
g
h
l
y
 
v
a
l
u
a
b
l
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
 
i
s
 
t
h
e
 
o
p
e
n
 
n
a
t
u
r
e
 
o
f
 
t
h
e
 
r
e
a
c
t
i
o
n
.
 
T
h
i
s
 
a
l
l
o
w
s
 
t
h
e
 
a
d
d
i
t
i
o
n
 
o
f
 
n
e
a
r
l
y
 
a
n
y
 
c
o
m
p
o
u
n
d
 
a
t
 
a
n
y
 
t
i
m
e
-
p
o
i
n
t
 
d
i
r
e
c
t
l
y
 
i
n
t
o
 
t
h
e
 
r
e
a
c
t
i
o
n
.
 
I
n
 
c
o
n
t
r
a
s
t
 
t
o
 
c
e
l
l
u
l
a
r
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
,
 
t
h
e
r
e
 
i
s
 
n
o
 
s
e
l
e
c
t
i
o
n
 
o
f
 
a
d
d
i
t
i
v
e
s
 
b
y
 
s
p
e
c
i
f
i
c
 
t
r
a
n
s
p
o
r
t
 
m
e
c
h
a
n
i
s
m
s
 
o
r
 
r
i
s
k
 
o
f
 
m
e
t
a
b
o
l
i
c
 
c
o
n
v
e
r
s
i
o
n
 
o
r
 
e
v
e
n
 
b
r
e
a
k
d
o
w
n
 
o
f
 
t
h
e
 
a
d
d
e
d
 
c
o
m
p
o
u
n
d
.
 
T
h
e
 
p
r
o
t
e
o
l
y
t
i
c
 
d
e
g
r
a
d
a
t
i
o
n
 
o
f
 
s
y
n
t
h
e
s
i
z
e
d
 
p
r
o
t
e
i
n
s
 
c
o
u
l
d
 
b
e
 
i
n
h
i
b
i
t
e
d
 
b
y
 
t
h
e
 
a
d
d
i
t
i
o
n
 
o
f
 
p
r
o
t
e
a
s
e
 
i
n
h
i
b
i
t
o
r
s
 
a
n
d
 
t
h
e
i
r
 
f
o
l
d
i
n
g
 
i
n
t
o
 
f
u
n
c
t
i
o
n
a
l
 
c
o
n
f
o
r
m
a
t
i
o
n
s
 
c
o
u
l
d
 
b
e
 
f
a
c
i
l
i
t
a
t
e
d
 
b
y
 
 
4
 
s
u
p
p
l
e
m
e
n
t
e
d
 
c
h
a
p
e
r
o
n
e
s
,
 
c
o
f
a
c
t
o
r
s
 
o
r
 
o
t
h
e
r
 
h
e
l
p
e
r
 
p
r
o
t
e
i
n
s
.
 
R
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
s
 
c
o
u
l
d
 
f
u
r
t
h
e
r
 
b
e
 
s
t
a
b
i
l
i
z
e
d
 
b
y
 
p
r
o
v
i
d
i
n
g
 
l
i
g
a
n
d
s
,
 
s
u
b
s
t
r
a
t
e
s
 
o
r
 
i
n
h
i
b
i
t
o
r
s
.
 
A
 
u
n
i
q
u
e
 
a
n
d
 
f
a
s
c
i
n
a
t
i
n
g
 
o
p
t
i
o
n
 
i
s
 
t
h
e
 
g
e
n
e
r
a
t
i
o
n
 
o
f
 
a
r
t
i
f
i
c
i
a
l
 
h
y
d
r
o
p
h
o
b
i
c
 
e
n
v
i
r
o
n
m
e
n
t
s
 
i
n
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
r
e
a
c
t
i
o
n
s
 
f
o
r
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
s
o
l
u
b
l
e
 
I
M
P
s
.
 
 
D
i
f
f
e
r
e
n
t
 
d
e
s
i
g
n
s
 
o
f
 
p
r
e
p
a
r
a
t
i
v
e
 
s
c
a
l
e
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
w
i
t
h
 
p
r
o
t
e
i
n
 
y
i
e
l
d
s
 
s
t
a
r
t
i
n
g
 
f
r
o
m
 
f
e
w
 
1
0
0
 
μ
g
 
u
p
 
t
o
 
s
e
v
e
r
a
l
 
m
g
 
p
e
r
 
o
n
e
 
m
l
 
o
f
 
r
e
a
c
t
i
o
n
 
v
o
l
u
m
e
 
a
r
e
 
p
o
s
s
i
b
l
e
.
 
B
a
t
c
h
 
s
y
s
t
e
m
s
 
w
i
t
h
 
o
n
l
y
 
o
n
e
 
c
o
m
p
a
r
t
m
e
n
t
 
c
a
n
 
b
e
 
c
a
r
r
i
e
d
 
o
u
t
 
i
n
 
v
a
r
i
o
u
s
 
c
o
m
m
o
n
 
l
a
b
w
a
r
e
 
c
o
n
t
a
i
n
e
r
s
 
l
i
k
e
 
s
i
m
p
l
e
 
p
l
a
s
t
i
c
 
r
e
a
c
t
i
o
n
 
t
u
b
e
s
.
 
M
o
r
e
 
a
d
v
a
n
c
e
d
 
s
y
s
t
e
m
s
 
l
i
k
e
 
t
h
e
 
c
o
n
t
i
n
u
o
u
s
 
e
x
c
h
a
n
g
e
 
C
F
 
(
C
E
C
F
)
 
r
e
a
c
t
i
o
n
s
 
a
r
e
 
c
o
m
p
o
s
e
d
 
o
f
 
t
w
o
 
c
o
m
p
a
r
t
m
e
n
t
s
 
h
o
l
d
i
n
g
 
a
 
r
e
a
c
t
i
o
n
 
m
i
x
t
u
r
e
 
(
R
M
)
 
a
n
d
 
a
 
f
e
e
d
i
n
g
 
m
i
x
t
u
r
e
 
(
F
M
)
 
w
i
t
h
 
a
 
v
o
l
u
m
e
 
r
a
t
i
o
 
o
f
 
R
M
/
F
M
 
u
s
u
a
l
l
y
 
i
n
 
b
e
t
w
e
e
n
 
1
:
1
0
 
a
n
d
 
1
:
2
0
 
(
2
-
4
)
.
 
T
h
e
 
t
w
o
 
c
o
m
p
a
r
t
m
e
n
t
s
 
a
r
e
 
s
e
p
a
r
a
t
e
d
 
b
y
 
a
 
s
e
m
i
p
e
r
m
e
a
b
l
e
 
m
e
m
b
r
a
n
e
 
t
h
a
t
 
e
n
s
u
r
e
s
 
a
n
 
e
f
f
i
c
i
e
n
t
 
e
x
c
h
a
n
g
e
 
o
f
 
p
r
e
c
u
r
s
o
r
s
 
f
r
o
m
 
t
h
e
 
F
M
 
i
n
t
o
 
t
h
e
 
R
M
.
 
I
n
h
i
b
i
t
o
r
y
 
b
r
e
a
k
d
o
w
n
 
p
r
o
d
u
c
t
s
 
a
r
e
 
c
o
n
t
i
n
u
o
u
s
l
y
 
r
e
m
o
v
e
d
 
f
r
o
m
 
t
h
e
 
t
r
a
n
s
l
a
t
i
o
n
 
m
a
c
h
i
n
e
r
y
 
b
y
 
d
i
f
f
u
s
i
o
n
 
i
n
t
o
 
t
h
e
 
F
M
.
 
C
E
C
F
 
s
y
s
t
e
m
s
 
a
r
e
 
s
u
p
e
r
i
o
r
 
i
n
 
y
i
e
l
d
s
 
i
f
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
b
a
t
c
h
 
s
y
s
t
e
m
s
 
w
h
i
l
e
 
c
o
n
s
i
d
e
r
a
b
l
e
 
e
f
f
o
r
t
s
 
h
a
v
e
 
r
e
c
e
n
t
l
y
 
b
e
e
n
 
m
a
d
e
 
i
n
 
o
r
d
e
r
 
t
o
 
i
m
p
r
o
v
e
 
t
h
e
 
p
r
o
d
u
c
t
i
v
i
t
y
 
a
n
d
 
l
o
n
g
e
v
i
t
y
 
o
f
 
b
a
t
c
h
 
C
F
 
r
e
a
c
t
i
o
n
s
 
(
5
-
1
0
)
.
 
 
 
R
e
l
i
a
b
l
e
 
a
n
d
 
d
e
t
a
i
l
e
d
 
p
r
o
t
o
c
o
l
s
 
f
o
r
 
t
h
e
 
s
e
t
-
u
p
 
o
f
 
C
F
 
r
e
a
c
t
i
o
n
s
 
h
a
v
e
 
b
e
e
n
 
p
u
b
l
i
s
h
e
d
 
b
y
 
s
e
v
e
r
a
l
 
g
r
o
u
p
s
 
(
1
1
-
1
3
)
.
 
I
n
 
a
d
d
i
t
i
o
n
 
t
o
 
t
h
e
 
i
n
d
i
v
i
d
u
a
l
 
C
F
 
d
e
s
i
g
n
s
,
 
a
l
s
o
 
c
o
m
m
e
r
c
i
a
l
 
s
y
s
t
e
m
s
 
a
r
e
 
a
v
a
i
l
a
b
l
e
 
t
h
a
t
 
c
a
n
 
r
e
s
u
l
t
 
i
n
 
t
h
e
 
h
i
g
h
-
l
e
v
e
l
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
I
M
P
s
 
(
1
4
-
1
6
)
.
 
K
e
y
 
c
o
m
p
o
u
n
d
 
o
f
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
i
s
 
a
 
c
e
l
l
u
l
a
r
 
e
x
t
r
a
c
t
 
t
h
a
t
 
c
a
n
 
b
e
 
d
e
r
i
v
e
d
 
f
r
o
m
 
e
i
t
h
e
r
 
b
a
c
t
e
r
i
a
l
 
o
r
i
g
i
n
,
 
m
o
s
t
l
y
 
E
s
c
h
e
r
i
c
h
i
a
 
c
o
l
i
 
c
e
l
l
s
,
 
o
r
 
f
r
o
m
 
e
u
k
a
r
y
o
t
i
c
 
o
r
i
g
i
n
,
 
p
r
e
f
e
r
e
n
t
i
a
l
l
y
 
s
e
l
e
c
t
e
d
 
w
h
e
a
t
 
g
e
r
m
s
.
 
H
i
g
h
 
q
u
a
l
i
t
y
 
b
a
c
t
e
r
i
a
l
 
e
x
t
r
a
c
t
s
 
c
a
n
 
b
e
 
o
b
t
a
i
n
e
d
 
f
r
o
m
 
v
a
r
i
o
u
s
 
c
o
m
m
o
n
 
l
a
b
 
s
t
r
a
i
n
s
 
l
i
k
e
 
B
L
2
1
 
d
e
r
i
v
a
t
i
v
e
s
 
(
1
2
)
 
o
r
 
R
N
A
s
e
 
d
e
f
i
c
i
e
n
t
 
s
t
r
a
i
n
s
 
l
i
k
e
 
A
1
9
 
o
r
 
D
1
0
 
(
1
7
,
 
1
8
)
.
 
T
h
e
 
p
r
e
p
a
r
a
t
i
o
n
 
o
f
 
b
a
c
t
e
r
i
a
l
 
e
x
t
r
a
c
t
s
 
i
s
 
a
 
r
e
l
i
a
b
l
e
 
a
n
d
 
r
o
u
t
i
n
e
 
t
e
c
h
n
i
q
u
e
 
(
1
1
,
 
1
8
-
2
1
)
 
a
n
d
 
a
n
 
i
m
p
o
r
t
a
n
t
 
s
t
e
p
 
i
s
 
t
h
e
 
r
e
m
o
v
a
l
 
o
f
 
t
h
e
 
c
e
l
l
u
l
a
r
 
m
R
N
A
 
t
h
a
t
 
v
i
r
t
u
a
l
l
y
 
e
l
i
m
i
n
a
t
e
s
 
a
n
y
 
b
a
c
k
g
r
o
u
n
d
 
e
x
p
r
e
s
s
i
o
n
 
i
n
 
s
u
b
s
e
q
u
e
n
t
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
r
e
a
c
t
i
o
n
s
.
 
N
u
c
l
e
o
t
i
d
e
s
 
a
n
d
 
a
m
i
n
o
 
a
c
i
d
s
 
c
a
n
 
b
e
 
a
d
d
e
d
 
i
n
 
o
r
d
e
r
 
t
o
 
r
e
l
e
a
s
e
 
r
e
s
i
d
u
a
l
 
m
R
N
A
 
f
r
o
m
 
t
h
e
 
r
i
b
o
s
o
m
e
s
 
i
n
 
a
 
“
r
u
n
-
o
f
f
”
 
t
r
a
n
s
l
a
t
i
o
n
 
p
r
o
c
e
d
u
r
e
 
(
1
9
,
 
2
0
)
.
 
T
h
e
 
n
o
n
-
p
r
o
t
e
c
t
e
d
 
m
R
N
A
 
w
i
l
l
 
t
h
e
n
 
r
a
p
i
d
l
y
 
b
e
c
o
m
e
 
d
e
g
r
a
d
e
d
 
b
y
 
e
n
d
o
g
e
n
o
u
s
 
R
N
A
s
e
s
.
 
W
e
 
p
r
e
f
e
r
 
a
 
m
o
d
i
f
i
c
a
t
i
o
n
 
o
f
 
t
h
i
s
 
s
t
e
p
 
b
y
 
a
d
j
u
s
t
i
n
g
 
t
h
e
 
e
x
t
r
a
c
t
 
t
o
 
4
0
0
 
m
M
 
N
a
C
l
 
f
o
l
l
o
w
e
d
 
b
y
 
i
n
c
u
b
a
t
i
o
n
 
a
t
 
4
2
°
C
 
f
o
r
 
4
5
 
m
i
n
 
(
1
1
)
.
 
T
h
i
s
 
t
r
e
a
t
m
e
n
t
 
c
a
u
s
e
s
 
t
h
e
 
e
f
f
i
c
i
e
n
t
 
d
i
s
s
o
c
i
a
t
i
o
n
 
o
f
 
m
R
N
A
 
a
n
d
 
r
i
b
o
s
o
m
e
s
 
w
h
i
l
e
 
n
o
 
a
d
d
i
t
i
o
n
 
o
f
 
p
r
e
c
u
r
s
o
r
s
 
i
s
 
n
e
c
e
s
s
a
r
y
.
 
S
o
 
f
a
r
 
o
n
l
y
 
E
.
 
c
o
l
i
 
e
x
t
r
a
c
t
s
 
h
a
v
e
 
b
e
e
n
 
u
s
e
d
 
f
o
r
 
t
h
e
 
C
F
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
I
M
P
s
.
 
T
h
i
s
 
f
a
c
t
 
m
i
g
h
t
 
b
e
 
m
o
s
t
l
y
 
a
t
t
r
i
b
u
t
e
d
 
t
o
 
t
h
e
 
m
o
r
e
 
d
i
f
f
i
c
u
l
t
 
p
r
e
p
a
r
a
t
i
o
n
 
p
r
o
c
e
d
u
r
e
 
o
f
 
w
h
e
a
t
 
g
e
r
m
 
e
x
t
r
a
c
t
s
 
(
2
2
)
.
 
H
o
w
e
v
e
r
,
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
b
a
s
e
d
 
o
n
 
e
u
k
a
r
y
o
t
i
c
 
c
e
l
l
 
e
x
t
r
a
c
t
s
 
m
i
g
h
t
 
b
e
 
c
o
n
s
i
d
e
r
e
d
 
i
n
 
t
h
e
 
f
u
t
u
r
e
 
a
s
 
t
h
e
y
 
c
o
u
l
d
 
p
r
o
v
i
d
e
 
s
e
v
e
r
a
l
  
5
 
a
d
v
a
n
t
a
g
e
s
 
e
s
p
e
c
i
a
l
l
y
 
f
o
r
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
e
u
k
a
r
y
o
t
i
c
 
I
M
P
s
 
l
i
k
e
 
i
m
p
r
o
v
e
d
 
f
o
l
d
i
n
g
 
p
a
t
h
w
a
y
s
 
o
r
 
t
h
e
 
p
o
s
s
i
b
i
l
i
t
y
 
o
f
 
p
o
s
t
t
r
a
n
s
l
a
t
i
o
n
a
l
 
m
o
d
i
f
i
c
a
t
i
o
n
s
.
 
C
F
 
r
e
a
c
t
i
o
n
s
 
w
i
t
h
 
E
.
 
c
o
l
i
 
e
x
t
r
a
c
t
s
 
a
r
e
 
o
p
e
r
a
t
e
d
 
a
s
 
c
o
u
p
l
e
d
 
t
r
a
n
s
c
r
i
p
t
i
o
n
/
t
r
a
n
s
l
a
t
i
o
n
 
s
y
s
t
e
m
s
 
w
i
t
h
 
a
d
d
e
d
 
c
i
r
c
u
l
a
r
 
p
l
a
s
m
i
d
 
D
N
A
 
o
r
 
l
i
n
e
a
r
 
D
N
A
 
f
r
a
g
m
e
n
t
s
 
a
s
 
a
 
t
e
m
p
l
a
t
e
 
(
3
)
.
 
E
v
e
n
 
s
e
v
e
r
a
l
 
d
i
f
f
e
r
e
n
t
 
t
e
m
p
l
a
t
e
s
 
c
o
u
l
d
 
b
e
 
t
r
a
n
s
c
r
i
b
e
d
 
s
i
m
u
l
t
a
n
e
o
u
s
l
y
 
i
n
 
a
 
C
F
 
r
e
a
c
t
i
o
n
,
 
t
h
u
s
 
e
n
a
b
l
i
n
g
 
t
h
e
 
c
o
e
x
p
r
e
s
s
i
o
n
 
o
f
 
d
i
f
f
e
r
e
n
t
 
p
r
o
t
e
i
n
s
,
 
e
.
g
.
 
v
a
r
i
o
u
s
 
s
u
b
u
n
i
t
s
 
o
f
 
h
e
t
e
r
o
o
l
i
g
o
m
e
r
i
c
 
I
M
P
 
c
o
m
p
l
e
x
e
s
.
 
T
h
e
 
r
a
t
i
o
 
o
f
 
t
h
e
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
s
 
c
o
u
l
d
 
f
u
r
t
h
e
r
m
o
r
e
 
e
a
s
i
l
y
 
b
e
 
m
a
n
i
p
u
l
a
t
e
d
 
b
y
 
v
a
r
y
i
n
g
 
t
h
e
 
a
m
o
u
n
t
s
 
o
f
 
t
h
e
 
s
u
p
p
l
i
e
d
 
t
e
m
p
l
a
t
e
s
.
 
A
n
 
e
f
f
i
c
i
e
n
t
 
t
r
a
n
s
c
r
i
p
t
i
o
n
 
i
s
 
p
r
o
v
i
d
e
d
 
b
y
 
p
l
a
c
i
n
g
 
t
h
e
 
t
a
r
g
e
t
 
g
e
n
e
s
 
u
n
d
e
r
 
c
o
n
t
r
o
l
 
o
f
 
a
 
T
7
 
p
r
o
m
o
t
e
r
 
a
n
d
 
b
y
 
a
d
d
i
t
i
o
n
 
o
f
 
T
7
 
R
N
A
 
p
o
l
y
m
e
r
a
s
e
 
i
n
t
o
 
t
h
e
 
r
e
a
c
t
i
o
n
.
 
 
 
T
h
i
s
 
c
h
a
p
t
e
r
 
w
i
l
l
 
s
u
m
m
a
r
i
z
e
 
r
e
c
e
n
t
 
a
d
v
a
n
c
e
m
e
n
t
s
 
i
n
 
t
h
e
 
C
F
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
I
M
P
s
 
i
n
 
p
r
e
p
a
r
a
t
i
v
e
 
s
c
a
l
e
s
,
 
w
h
i
l
e
 
r
e
s
u
l
t
s
 
w
i
t
h
 
n
o
n
-
p
r
e
p
a
r
a
t
i
v
e
 
s
c
a
l
e
 
C
F
 
s
y
s
t
e
m
s
 
w
i
l
l
 
n
o
t
 
b
e
 
c
o
v
e
r
e
d
.
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
g
e
n
e
r
a
l
l
y
 
p
r
o
v
i
d
e
 
a
n
 
a
t
t
r
a
c
t
i
v
e
 
a
l
t
e
r
n
a
t
i
v
e
 
t
e
c
h
n
i
q
u
e
 
f
o
r
 
p
r
o
t
e
i
n
 
t
a
r
g
e
t
s
 
t
h
a
t
 
c
a
n
n
o
t
 
e
f
f
i
c
i
e
n
t
l
y
 
b
e
 
p
r
o
d
u
c
e
d
 
i
n
 
c
o
n
v
e
n
t
i
o
n
a
l
 
i
n
-
v
i
v
o
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
.
 
T
h
e
 
t
e
c
h
n
i
q
u
e
 
d
o
e
s
 
n
o
t
 
r
e
q
u
i
r
e
 
s
p
e
c
i
a
l
 
e
q
u
i
p
m
e
n
t
s
 
a
n
d
 
c
a
n
 
b
e
 
o
p
e
r
a
t
e
d
 
i
n
 
m
o
s
t
 
s
t
a
n
d
a
r
d
 
b
i
o
c
h
e
m
i
c
a
l
 
l
a
b
s
.
 
T
h
e
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
I
M
P
s
 
i
s
 
s
t
i
l
l
 
a
n
 
e
m
e
r
g
i
n
g
 
a
p
p
l
i
c
a
t
i
o
n
 
b
u
t
 
t
h
e
 
a
l
r
e
a
d
y
 
o
b
t
a
i
n
e
d
 
a
c
h
i
e
v
e
m
e
n
t
s
 
a
r
e
 
h
i
g
h
l
y
 
p
r
o
m
i
s
i
n
g
 
a
n
d
 
m
a
k
e
 
a
 
r
a
p
i
d
l
y
 
i
n
c
r
e
a
s
i
n
g
 
r
e
q
u
e
s
t
 
f
o
r
 
t
h
i
s
 
t
e
c
h
n
o
l
o
g
y
 
v
e
r
y
 
l
i
k
e
l
y
.
 
 
1
.
 
S
p
e
c
i
f
i
c
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
f
o
r
 
t
h
e
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
 
 
D
i
f
f
e
r
e
n
t
 
m
o
d
e
s
 
a
r
e
 
f
e
a
s
i
b
l
e
 
f
o
r
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
I
M
P
s
 
i
n
 
C
F
 
s
y
s
t
e
m
s
 
(
F
i
g
.
 
1
)
.
 
M
o
s
t
 
c
e
l
l
u
l
a
r
 
m
e
m
b
r
a
n
e
s
 
h
a
v
e
 
b
e
e
n
 
r
e
m
o
v
e
d
 
d
u
r
i
n
g
 
e
x
t
r
a
c
t
 
p
r
e
p
a
r
a
t
i
o
n
 
a
n
d
 
o
n
l
y
 
s
p
u
r
i
o
u
s
 
a
m
o
u
n
t
s
 
o
f
 
l
i
p
i
d
s
 
m
i
g
h
t
 
r
e
m
a
i
n
 
(
1
4
)
.
 
S
t
a
n
d
a
r
d
 
C
F
 
r
e
a
c
t
i
o
n
s
 
t
h
e
r
e
f
o
r
e
 
r
e
s
u
l
t
 
c
o
n
s
e
q
u
e
n
t
l
y
 
i
n
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
I
M
P
s
 
a
s
 
p
r
e
c
i
p
i
t
a
t
e
s
 
a
s
 
n
o
 
h
y
d
r
o
p
h
o
b
i
c
 
c
o
m
p
a
r
t
m
e
n
t
s
 
a
r
e
 
p
r
e
s
e
n
t
 
i
n
 
t
h
e
 
R
M
.
 
T
h
e
 
C
F
 
r
e
a
c
t
i
o
n
 
p
r
o
t
o
c
o
l
 
i
n
 
t
h
a
t
 
m
o
d
e
 
i
s
 
v
i
r
t
u
a
l
l
y
 
i
d
e
n
t
i
c
a
l
 
t
o
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
g
l
o
b
u
l
a
r
 
p
r
o
t
e
i
n
s
 
(
1
1
,
 
1
4
)
.
 
C
r
i
t
i
c
a
l
 
c
o
m
p
o
n
e
n
t
s
 
a
r
e
 
t
h
e
 
i
o
n
s
 
M
g
2
+
 
a
n
d
 
K
+
 
b
e
c
a
u
s
e
 
o
f
 
t
h
e
i
r
 
n
a
r
r
o
w
 
o
p
t
i
m
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
r
a
n
g
e
s
 
u
s
u
a
l
l
y
 
i
n
 
b
e
t
w
e
e
n
 
1
2
 
-
 
1
7
 
m
M
 
a
n
d
 
2
7
0
 
-
 
3
3
0
 
m
M
,
 
r
e
s
p
e
c
t
i
v
e
l
y
.
 
O
p
t
i
m
i
z
a
t
i
o
n
 
s
c
r
e
e
n
s
 
h
a
v
e
 
t
h
e
r
e
f
o
r
e
 
o
f
t
e
n
 
t
o
 
b
e
 
e
m
p
l
o
y
e
d
 
b
e
f
o
r
e
 
h
i
g
h
 
l
e
v
e
l
s
 
o
f
 
p
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
 
c
a
n
 
b
e
 
o
b
t
a
i
n
e
d
.
 
T
h
e
 
s
u
p
p
l
e
m
e
n
t
a
t
i
o
n
 
o
f
 
C
F
 
r
e
a
c
t
i
o
n
s
 
w
i
t
h
 
d
e
t
e
r
g
e
n
t
s
 
o
r
 
l
i
p
i
d
s
 
g
e
n
e
r
a
t
e
s
 
p
r
e
f
o
r
m
e
d
 
m
i
c
e
l
l
e
s
 
o
r
 
l
i
p
o
s
o
m
e
s
 
i
n
 
t
h
e
 
R
M
.
 
T
h
i
s
 
o
p
t
i
o
n
 
i
s
 
a
n
 
a
t
t
r
a
c
t
i
v
e
 
f
e
a
t
u
r
e
 
s
p
e
c
i
f
i
c
 
t
o
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
a
n
d
 
n
o
t
 
p
o
s
s
i
b
l
e
 
w
i
t
h
 
a
n
y
 
o
t
h
e
r
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
.
 
I
t
 
e
n
a
b
l
e
s
 
t
h
e
 
d
i
r
e
c
t
 
s
y
n
t
h
e
s
i
s
 
o
f
 
I
M
P
s
 
i
n
t
o
 
m
i
c
e
l
l
e
s
 
c
o
m
p
o
s
e
d
 
o
f
 
t
h
e
 
d
e
s
i
r
e
d
 
d
e
t
e
r
g
e
n
t
s
 
o
r
 
i
n
t
o
 
l
i
p
o
s
o
m
e
s
 
o
f
 
d
e
f
i
n
e
d
 
c
o
m
p
o
s
i
t
i
o
n
s
.
 
C
r
i
t
i
c
a
l
 
s
t
e
p
s
 
i
n
 
c
o
m
m
o
n
 
I
M
P
 
p
r
e
p
a
r
a
t
i
o
n
 
p
r
o
t
o
c
o
l
s
 
l
i
k
e
 
t
h
e
 
d
i
s
i
n
t
e
g
r
a
t
i
o
n
 
o
f
 
c
e
l
l
u
l
a
r
 
m
e
m
b
r
a
n
e
s
 
o
r
 
r
e
p
e
a
t
e
d
 
t
r
a
n
s
f
e
r
s
 
o
f
 
I
M
P
s
 
i
n
t
o
 
m
i
c
e
l
l
e
s
 
o
f
 
d
i
f
f
e
r
e
n
t
 
c
o
m
p
o
s
i
t
i
o
n
s
 
c
a
n
 
t
h
u
s
 
b
e
 
r
e
d
u
c
e
d
 
o
r
 
e
v
e
n
 
c
o
m
p
l
e
t
e
l
y
 
a
v
o
i
d
e
d
.
 
I
n
 
t
h
e
 
b
e
s
t
 
c
a
s
e
,
 
t
h
e
 
I
M
P
s
 
c
a
n
 
 
6
 
b
e
c
o
m
e
 
i
n
s
e
r
t
e
d
 
i
n
 
t
h
e
 
d
e
s
i
r
e
d
 
e
n
v
i
r
o
n
m
e
n
t
 
r
i
g
h
t
 
a
f
t
e
r
 
t
r
a
n
s
l
a
t
i
o
n
 
a
n
d
 
t
h
e
 
r
e
s
u
l
t
i
n
g
 
p
r
o
t
e
o
m
i
c
e
l
l
e
s
 
o
r
 
p
r
o
t
e
o
l
i
p
o
s
o
m
e
s
 
c
o
u
l
d
 
b
e
 
d
i
r
e
c
t
l
y
 
u
s
e
d
 
f
o
r
 
f
u
r
t
h
e
r
 
a
n
a
l
y
s
i
s
.
 
A
 
h
i
g
h
 
l
e
v
e
l
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
I
M
P
s
 
i
s
 
t
h
e
r
e
f
o
r
e
 
g
e
n
e
r
a
l
l
y
 
p
o
s
s
i
b
l
e
 
w
i
t
h
 
t
h
r
e
e
 
d
i
f
f
e
r
e
n
t
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
m
o
d
e
s
:
 
(
A
)
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
I
M
P
 
p
r
e
c
i
p
i
t
a
t
e
s
 
w
i
t
h
o
u
t
 
a
n
y
 
h
y
d
r
o
p
h
o
b
i
c
 
a
d
d
i
t
i
v
e
s
 
(
1
1
,
 
2
3
)
,
 
(
B
)
 
t
h
e
 
s
y
n
t
h
e
s
i
s
 
o
f
 
I
M
P
s
 
i
n
t
o
 
m
i
c
e
l
l
e
s
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
(
1
3
,
 
1
4
,
 
2
3
,
 
2
4
)
 
a
n
d
 
(
C
)
 
t
h
e
 
s
y
n
t
h
e
s
i
s
 
o
f
 
I
M
P
s
 
i
n
t
o
 
l
i
p
o
s
o
m
e
s
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
l
i
p
i
d
s
 
(
1
6
)
 
(
F
i
g
.
 
1
)
.
 
 
 
1
.
1
.
 
C
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
o
r
 
l
i
p
i
d
s
 
 
D
e
t
e
r
g
e
n
t
s
 
h
a
v
e
 
t
o
 
b
e
 
a
d
d
e
d
 
a
t
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
a
b
o
v
e
 
t
h
e
i
r
 
s
p
e
c
i
f
i
c
 
c
r
i
t
i
c
a
l
 
m
i
c
e
l
l
a
r
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
(
C
M
C
)
 
i
n
 
o
r
d
e
r
 
t
o
 
b
e
c
o
m
e
 
e
f
f
e
c
t
i
v
e
 
f
o
r
 
t
h
e
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
I
M
P
s
.
 
H
o
w
e
v
e
r
,
 
d
e
t
e
r
g
e
n
t
s
 
a
l
s
o
 
i
n
t
e
r
f
e
r
e
 
n
o
n
-
s
p
e
c
i
f
i
c
a
l
l
y
 
w
i
t
h
 
a
n
y
 
h
y
d
r
o
p
h
o
b
i
c
 
p
r
o
t
e
i
n
 
r
e
g
i
o
n
s
 
a
n
d
 
t
h
e
y
 
m
a
y
 
t
h
u
s
 
a
f
f
e
c
t
 
t
h
e
 
p
r
o
d
u
c
t
i
v
i
t
y
 
o
f
 
t
h
e
 
C
F
 
s
y
s
t
e
m
.
 
S
e
v
e
r
a
l
 
d
e
t
e
r
g
e
n
t
s
 
l
i
k
e
 
s
o
d
i
u
m
 
d
e
o
x
y
c
h
o
l
a
t
e
,
 
s
o
d
i
u
m
 
c
h
o
l
a
t
e
 
a
n
d
 
N
-
l
a
u
r
y
l
s
a
r
c
o
s
i
n
e
 
a
s
 
w
e
l
l
 
a
s
 
d
o
d
e
c
y
l
-
p
h
o
s
p
h
o
c
h
o
l
i
n
e
 
(
D
P
C
)
 
a
n
d
 
n
-
o
c
t
y
l
-
ß
-
g
l
u
c
o
p
y
r
a
n
o
s
i
d
e
 
(
ß
-
O
G
)
 
s
e
v
e
r
e
l
y
 
i
n
h
i
b
i
t
 
C
F
 
s
y
s
t
e
m
s
 
a
l
r
e
a
d
y
 
a
t
 
l
o
w
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
a
n
d
 
t
h
e
y
 
a
r
e
 
n
o
t
 
s
u
i
t
a
b
l
e
 
f
o
r
 
t
h
e
 
s
o
l
u
b
l
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
I
M
P
s
 
(
1
3
,
 
1
4
,
 
2
4
)
.
 
H
o
w
e
v
e
r
,
 
t
h
e
 
m
a
j
o
r
i
t
y
 
o
f
 
t
h
e
 
c
o
m
m
o
n
l
y
 
e
m
p
l
o
y
e
d
 
r
e
l
a
t
i
v
e
l
y
 
m
i
l
d
 
d
e
t
e
r
g
e
n
t
s
 
a
p
p
e
a
r
 
t
o
 
b
e
 
t
o
l
e
r
a
t
e
d
 
b
y
 
C
F
 
s
y
s
t
e
m
s
 
a
t
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
t
h
a
t
 
e
x
c
e
e
d
 
s
e
v
e
r
a
l
 
t
i
m
e
s
 
t
h
e
 
p
r
o
p
o
s
e
d
 
s
p
e
c
i
f
i
c
 
C
M
C
s
 
(
1
3
,
 
1
4
,
 
2
4
)
 
(
T
a
b
l
e
 
1
)
.
 
 
 
T
h
e
 
e
v
a
l
u
a
t
i
o
n
 
o
f
 
t
h
e
 
m
o
s
t
 
e
f
f
e
c
t
i
v
e
 
d
e
t
e
r
g
e
n
t
 
f
o
r
 
t
h
e
 
C
F
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
a
 
s
p
e
c
i
f
i
c
 
I
M
P
 
s
h
o
u
l
d
 
b
e
 
o
n
e
 
o
f
 
t
h
e
 
p
r
i
m
a
r
y
 
s
u
b
j
e
c
t
s
 
o
f
 
i
n
i
t
i
a
l
 
o
p
t
i
m
i
z
a
t
i
o
n
 
s
c
r
e
e
n
s
.
 
M
o
s
t
 
I
M
P
s
 
a
r
e
 
p
r
o
b
a
b
l
y
 
l
i
k
e
l
y
 
t
o
 
b
e
c
o
m
e
 
s
o
l
u
b
l
e
 
e
x
p
r
e
s
s
e
d
 
i
n
 
a
 
v
a
r
i
e
t
y
 
o
f
 
d
i
f
f
e
r
e
n
t
 
d
e
t
e
r
g
e
n
t
s
.
 
T
h
e
 
b
i
-
c
h
a
i
n
-
p
h
o
s
p
h
o
c
h
o
l
i
n
e
s
 
1
,
2
-
d
i
o
c
t
a
n
o
y
l
-
s
n
-
g
l
y
c
e
r
o
-
3
-
p
h
o
s
p
h
o
c
h
o
l
i
n
e
 
(
d
i
C
8
P
C
)
,
 
1
,
2
-
d
i
h
e
p
t
a
n
o
y
l
-
s
n
-
g
l
y
c
e
r
o
-
3
-
p
h
o
s
p
h
o
c
h
o
l
i
n
e
 
(
D
H
P
C
)
,
 
t
h
e
 
a
l
k
y
l
-
g
l
u
c
o
s
i
d
e
s
 
n
-
d
o
d
e
c
y
l
–
ß
-
D
-
m
a
l
t
o
s
i
d
e
 
(
D
D
M
)
 
a
n
d
 
n
-
d
e
c
y
l
-
ß
-
D
-
m
a
l
t
o
s
i
d
e
 
(
D
M
)
,
 
t
h
e
 
a
l
k
y
l
-
e
t
h
e
r
 
p
o
l
y
o
x
y
e
t
h
y
l
e
n
e
-
s
o
r
b
i
t
a
n
-
m
o
n
o
l
a
u
r
a
t
e
 
2
0
 
(
T
w
e
e
n
 
2
0
)
 
a
s
 
w
e
l
l
 
a
s
 
t
h
e
 
p
o
l
y
e
t
h
y
l
e
n
e
-
g
l
y
c
o
l
 
d
e
r
i
v
a
t
i
v
e
s
 
p
o
l
y
e
t
h
y
l
e
n
e
-
g
l
y
c
o
l
 
P
-
1
,
1
,
3
,
3
-
t
e
t
r
a
m
e
t
h
y
l
-
b
u
t
y
l
p
h
e
n
y
l
-
e
t
h
e
r
 
(
T
X
-
1
0
0
)
 
a
n
d
 
p
o
l
y
e
t
h
y
l
e
n
e
-
g
l
y
c
o
l
 
4
0
0
 
d
o
d
e
c
y
l
-
e
t
h
e
r
 
(
T
h
e
s
i
t
)
 
a
r
e
 
s
o
m
e
 
d
e
t
e
r
g
e
n
t
s
 
t
h
a
t
 
r
e
s
u
l
t
e
d
 
i
n
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
p
r
e
p
a
r
a
t
i
v
e
 
a
m
o
u
n
t
s
 
o
f
 
p
r
o
t
e
i
n
 
(
1
3
,
 
1
4
,
 
2
3
,
 
2
4
)
 
(
T
a
b
l
e
 
1
)
.
 
I
n
 
c
o
n
t
r
a
s
t
,
 
a
l
l
 
t
h
e
s
e
 
d
e
t
e
r
g
e
n
t
s
 
h
a
v
e
 
n
o
t
 
b
e
e
n
 
v
e
r
y
 
e
f
f
e
c
t
i
v
e
 
f
o
r
 
t
h
e
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
o
t
h
e
r
 
I
M
P
s
 
l
i
k
e
 
t
h
e
 
p
o
r
c
i
n
e
 
v
a
s
o
p
r
e
s
s
i
n
 
t
y
p
e
 
2
 
r
e
c
e
p
t
o
r
 
(
V
2
R
)
,
 
a
 
m
e
m
b
e
r
 
o
f
 
t
h
e
 
f
a
m
i
l
y
 
o
f
 
G
-
p
r
o
t
e
i
n
 
c
o
u
p
l
e
d
 
r
e
c
e
p
t
o
r
s
 
(
G
P
C
R
s
)
.
 
 
 
A
 
v
a
r
i
e
t
y
 
o
f
 
p
o
l
y
o
x
y
e
t
h
y
l
e
n
e
-
a
l
k
y
l
-
e
t
h
e
r
s
 
a
n
d
 
t
h
e
 
s
t
e
r
o
i
d
 
d
e
r
i
v
a
t
i
v
e
 
d
i
g
i
t
o
n
i
n
 
a
r
e
 
e
x
c
e
p
t
i
o
n
a
l
l
y
 
s
u
i
t
a
b
l
e
 
f
o
r
 
t
h
e
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
s
t
r
u
c
t
u
r
a
l
l
y
 
d
i
f
f
e
r
e
n
t
 
I
M
P
s
 
(
1
3
,
 
1
4
,
 
2
4
)
.
 
E
m
r
E
,
 
T
s
x
 
a
n
d
 
e
v
e
n
 
t
h
e
 
V
2
R
 
p
r
o
t
e
i
n
 
a
n
d
 
o
t
h
e
r
 
m
e
m
b
e
r
s
 
o
f
 
t
h
e
 
G
P
C
R
 
f
a
m
i
l
y
 
c
o
u
l
d
 
b
e
 
p
r
o
d
u
c
e
d
 
i
n
 
a
m
o
u
n
t
s
 
o
f
 
u
p
 
t
o
 
s
e
v
e
r
a
l
 
m
g
 
o
f
 
s
o
l
u
b
l
e
 
p
r
o
t
e
i
n
 
i
n
 
o
n
e
 
m
l
 
o
f
 
R
M
.
 
S
o
m
e
 
s
t
r
u
c
t
u
r
a
l
 
d
e
t
a
i
l
s
 
o
f
 
t
h
e
s
e
 
d
e
t
e
r
g
e
n
t
s
 
l
i
k
e
 
t
h
e
 
l
e
n
g
t
h
 
o
f
 
p
o
l
y
o
x
y
e
t
h
y
l
e
n
e
 
c
h
a
i
n
s
 
a
r
e
 
i
m
p
o
r
t
a
n
t
 
f
o
r
 
t
h
e
 
e
f
f
i
c
i
e
n
c
y
 
o
f
  
7
 
I
M
P
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
.
 
L
o
n
g
 
c
h
a
i
n
 
d
e
r
i
v
a
t
i
v
e
s
 
l
i
k
e
 
p
o
l
y
o
x
y
e
t
h
y
l
e
n
e
-
(
2
3
)
-
l
a
u
r
y
l
-
e
t
h
e
r
 
(
B
r
i
j
-
3
5
)
,
 
p
o
l
y
o
x
y
e
t
h
y
l
e
n
e
-
(
2
0
)
-
c
e
t
y
l
-
e
t
h
e
r
 
(
B
r
i
j
-
5
8
)
,
 
p
o
l
y
o
x
y
e
t
h
y
l
e
n
e
-
(
2
0
)
-
s
t
e
a
r
y
l
-
e
t
h
e
r
 
(
B
r
i
j
-
7
8
)
 
a
n
d
 
p
o
l
y
o
x
y
e
t
h
y
l
e
n
e
-
(
2
0
)
-
o
l
e
y
l
-
e
t
h
e
r
 
(
B
r
i
j
-
9
8
)
 
r
e
s
u
l
t
e
d
 
i
n
 
t
h
e
 
h
i
g
h
 
l
e
v
e
l
 
s
o
l
u
b
l
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
t
h
e
 
d
i
f
f
e
r
e
n
t
 
I
M
P
s
.
 
I
n
 
p
r
e
s
e
n
c
e
 
o
f
 
s
h
o
r
t
e
r
 
c
h
a
i
n
 
l
e
n
g
t
h
 
d
e
r
i
v
a
t
i
v
e
s
 
l
i
k
e
 
p
o
l
y
o
x
y
e
t
h
y
l
e
n
e
-
(
1
0
)
-
c
e
t
y
l
-
e
t
h
e
r
 
(
B
r
i
j
-
5
6
)
 
o
r
 
p
o
l
y
o
x
y
e
t
h
y
l
e
n
e
-
(
1
0
)
-
o
l
e
y
l
-
e
t
h
e
r
 
(
B
r
i
j
-
9
7
)
,
 
t
h
e
 
I
M
P
s
 
h
a
v
e
 
s
t
i
l
l
 
b
e
e
n
 
s
y
n
t
h
e
s
i
z
e
d
 
a
t
 
h
i
g
h
 
a
m
o
u
n
t
s
 
b
u
t
 
t
h
e
y
 
r
e
m
a
i
n
e
d
 
a
l
m
o
s
t
 
q
u
a
n
t
i
t
a
t
i
v
e
l
y
 
a
s
 
p
r
e
c
i
p
i
t
a
t
e
.
 
 
 
T
h
e
 
s
u
p
p
l
i
e
d
 
f
i
n
a
l
 
d
e
t
e
r
g
e
n
t
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
d
e
s
e
r
v
e
s
 
s
p
e
c
i
a
l
 
c
o
n
s
i
d
e
r
a
t
i
o
n
s
.
 
M
o
s
t
 
d
e
t
e
r
g
e
n
t
 
w
i
l
l
 
b
e
c
o
m
e
 
i
n
h
i
b
i
t
o
r
y
 
a
b
o
v
e
 
c
e
r
t
a
i
n
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
a
n
d
 
s
o
m
e
 
g
u
i
d
e
l
i
n
e
s
 
f
o
r
 
t
h
e
 
s
u
p
p
l
y
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
i
n
t
o
 
C
F
 
r
e
a
c
t
i
o
n
s
 
h
a
v
e
 
t
o
 
b
e
 
c
o
n
s
i
d
e
r
e
d
 
(
1
3
,
 
1
4
,
 
2
4
)
.
 
T
h
e
 
p
a
r
t
i
c
u
l
a
r
 
m
i
c
e
l
l
a
r
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
C
m
i
c
)
 
o
f
 
a
 
d
e
t
e
r
g
e
n
t
 
i
n
 
t
h
e
 
R
M
 
s
h
o
u
l
d
 
b
e
 
a
t
 
l
e
a
s
t
 
e
q
u
a
l
 
t
o
 
t
h
e
 
e
s
t
i
m
a
t
e
d
 
m
o
l
a
r
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
t
h
e
 
s
y
n
t
h
e
s
i
z
e
d
 
I
M
P
 
a
t
 
t
h
e
 
e
n
d
 
o
f
 
a
 
C
F
 
r
e
a
c
t
i
o
n
.
 
A
n
 
e
x
c
e
s
s
 
o
f
 
s
y
n
t
h
e
s
i
z
e
d
 
I
M
P
 
m
i
g
h
t
 
f
o
r
m
 
u
n
d
e
s
i
r
e
d
 
p
r
e
c
i
p
i
t
a
t
e
s
 
o
r
 
e
v
e
n
 
h
e
t
e
r
o
g
e
n
e
o
u
s
 
m
i
c
e
l
l
e
s
 
t
h
a
t
 
c
o
u
l
d
 
p
r
e
v
e
n
t
 
f
u
r
t
h
e
r
 
s
t
r
u
c
t
u
r
a
l
 
a
p
p
r
o
a
c
h
e
s
.
 
T
h
e
 
C
m
i
c
 
i
s
 
d
i
f
f
i
c
u
l
t
 
t
o
 
c
a
l
c
u
l
a
t
e
 
a
s
 
i
t
 
i
s
 
a
 
r
e
s
u
l
t
 
o
f
 
t
h
e
 
s
p
e
c
i
f
i
c
 
C
M
C
 
a
s
 
w
e
l
l
 
a
s
 
o
f
 
t
h
e
 
a
g
g
r
e
g
a
t
i
o
n
 
n
u
m
b
e
r
,
 
t
h
e
 
p
r
o
p
o
s
e
d
 
n
u
m
b
e
r
 
o
f
 
d
e
t
e
r
g
e
n
t
 
m
o
l
e
c
u
l
e
s
 
p
e
r
 
m
i
c
e
l
l
e
.
 
T
h
e
s
e
 
p
a
r
a
m
e
t
e
r
s
,
 
h
o
w
e
v
e
r
,
 
a
r
e
 
h
i
g
h
l
y
 
v
a
r
i
a
b
l
e
 
a
s
 
t
h
e
y
 
d
e
p
e
n
d
 
o
n
 
s
e
v
e
r
a
l
 
e
n
v
i
r
o
n
m
e
n
t
a
l
 
f
a
c
t
o
r
s
 
l
i
k
e
 
p
H
 
a
n
d
 
t
e
m
p
e
r
a
t
u
r
e
 
a
s
 
w
e
l
l
 
a
s
 
o
n
 
t
h
e
 
t
o
p
o
l
o
g
y
 
o
f
 
t
h
e
 
s
o
l
u
b
i
l
i
z
e
d
 
I
M
P
 
(
2
5
)
.
 
A
 
g
o
o
d
 
c
o
m
p
r
o
m
i
s
e
 
o
f
 
C
m
i
c
 
h
a
s
 
t
h
u
s
 
t
o
 
b
e
 
f
o
u
n
d
 
i
n
 
o
r
d
e
r
 
t
o
 
e
n
s
u
r
e
 
o
p
t
i
m
a
l
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
t
h
e
 
s
y
n
t
h
e
s
i
z
e
d
 
a
m
o
u
n
t
 
o
f
 
p
r
o
t
e
i
n
 
b
u
t
 
t
o
 
a
v
o
i
d
 
i
n
h
i
b
i
t
o
r
y
 
e
f
f
e
c
t
s
 
o
f
 
t
o
o
 
h
i
g
h
 
d
e
t
e
r
g
e
n
t
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
.
 
D
e
t
e
r
g
e
n
t
s
 
w
i
t
h
 
a
 
l
o
w
 
a
g
g
r
e
g
a
t
i
o
n
 
n
u
m
b
e
r
 
r
e
s
u
l
t
i
n
g
 
i
n
 
a
 
h
i
g
h
 
C
m
i
c
 
a
t
 
s
t
i
l
l
 
r
e
l
a
t
i
v
e
l
y
 
l
o
w
 
m
o
l
a
r
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
a
p
p
e
a
r
 
g
e
n
e
r
a
l
l
y
 
t
o
 
b
e
 
b
e
t
t
e
r
 
s
u
i
t
a
b
l
e
 
f
o
r
 
t
h
e
 
e
f
f
i
c
i
e
n
t
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
C
F
 
p
r
o
d
u
c
e
d
 
I
M
P
s
.
 
H
o
w
e
v
e
r
,
 
s
p
e
c
i
f
i
c
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
f
u
r
t
h
e
r
 
c
o
n
t
r
i
b
u
t
e
 
t
o
 
t
h
e
i
r
 
b
e
h
a
v
i
o
u
r
 
i
n
 
C
F
 
r
e
a
c
t
i
o
n
s
.
 
D
D
M
 
a
n
d
 
D
i
g
i
t
o
n
i
n
 
b
e
c
a
m
e
 
a
l
r
e
a
d
y
 
i
n
h
i
b
i
t
o
r
y
 
a
b
o
v
e
 
1
5
 
x
 
C
M
C
 
(
1
.
8
 
m
M
)
 
a
n
d
 
4
.
5
 
x
 
C
M
C
 
(
3
.
3
 
m
M
)
,
 
r
e
s
p
e
c
t
i
v
e
l
y
,
 
w
h
i
l
e
 
e
.
g
.
 
B
r
i
j
-
5
8
 
a
n
d
 
B
r
i
j
-
7
8
 
a
r
e
 
c
o
m
p
l
e
t
e
l
y
 
t
o
l
e
r
a
t
e
d
 
a
t
 
e
v
e
n
 
1
7
0
 
x
 
C
M
C
 
(
1
2
.
8
 
m
M
)
 
a
n
d
 
2
8
0
 
x
 
C
M
C
 
(
1
2
.
9
 
m
M
)
.
 
T
h
e
 
a
m
o
u
n
t
 
o
f
 
s
o
l
u
b
l
e
 
p
r
o
d
u
c
e
d
 
I
M
P
 
i
n
 
a
 
C
F
 
r
e
a
c
t
i
o
n
 
a
s
 
a
 
f
u
n
c
t
i
o
n
 
o
f
 
d
e
t
e
r
g
e
n
t
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
f
o
l
l
o
w
s
 
p
l
a
t
e
a
u
-
l
i
k
e
 
k
i
n
e
t
i
c
s
 
a
n
d
 
t
h
e
 
y
i
e
l
d
 
r
e
m
a
i
n
s
 
c
o
n
s
t
a
n
t
 
a
b
o
v
e
 
a
 
c
e
r
t
a
i
n
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
l
e
v
e
l
.
 
H
o
w
e
v
e
r
,
 
n
o
t
 
a
l
l
 
o
f
 
t
h
e
 
s
y
n
t
h
e
s
i
z
e
d
 
p
r
o
t
e
i
n
 
m
i
g
h
t
 
b
e
c
o
m
e
 
s
o
l
u
b
l
e
 
a
n
d
 
i
t
 
i
s
 
c
o
m
m
o
n
 
t
h
a
t
 
s
o
m
e
 
r
e
s
i
d
u
a
l
 
p
r
e
c
i
p
i
t
a
t
e
d
 
I
M
P
 
i
s
 
s
t
i
l
l
 
p
r
e
s
e
n
t
 
a
t
 
t
h
e
 
e
n
d
 
o
f
 
t
h
e
 
C
F
 
r
e
a
c
t
i
o
n
.
 
F
o
r
 
t
h
e
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
s
o
l
u
b
l
e
 
T
s
x
 
p
r
o
t
e
i
n
,
 
o
p
t
i
m
a
l
 
d
e
t
e
r
g
e
n
t
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
h
a
v
e
 
b
e
e
n
 
d
e
t
e
r
m
i
n
e
d
 
f
o
r
 
T
X
-
1
0
0
 
(
7
 
x
 
C
M
C
)
,
 
B
r
i
j
-
5
8
 
(
4
7
 
x
 
C
M
C
)
,
 
B
r
i
j
-
7
8
 
(
7
6
 
x
 
C
M
C
)
,
 
D
i
g
i
t
o
n
i
n
 
(
2
.
2
 
x
 
C
M
C
)
 
a
n
d
 
D
D
M
 
(
1
5
 
x
 
C
M
C
)
 
(
2
4
)
.
 
 
 
I
n
c
r
e
a
s
e
d
 
y
i
e
l
d
s
 
o
f
 
f
u
n
c
t
i
o
n
a
l
l
y
 
f
o
l
d
e
d
 
m
e
c
h
a
n
o
s
e
n
s
i
t
i
v
e
 
c
h
a
n
n
e
l
 
M
s
c
L
 
w
e
r
e
 
o
b
t
a
i
n
e
d
 
i
n
 
C
F
 
r
e
a
c
t
i
o
n
s
 
w
i
t
h
 
m
i
x
e
d
 
m
i
c
e
l
l
e
s
 
o
f
 
T
X
-
1
0
0
 
a
n
d
 
E
.
 
c
o
l
i
 
l
i
p
i
d
s
 
o
r
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
l
i
p
o
s
o
m
e
s
 
p
r
e
p
a
r
e
d
 
f
r
o
m
 
E
.
 
c
o
l
i
 
l
i
p
i
d
 
m
i
x
t
u
r
e
s
 
(
1
4
)
.
 
I
n
 
a
d
d
i
t
i
o
n
,
 
s
e
l
e
n
o
-
m
e
t
h
i
o
n
i
n
e
 
l
a
b
e
l
l
e
d
 
E
m
r
E
 
w
a
s
 
 
8
 
s
y
n
t
h
e
s
i
z
e
d
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
1
,
2
-
d
i
m
y
r
i
s
t
o
y
l
-
s
n
-
g
l
y
c
e
r
o
-
3
-
p
h
o
s
p
h
o
c
h
o
l
i
n
e
 
(
D
M
P
C
)
 
l
i
p
o
s
o
m
e
s
 
a
n
d
 
t
h
e
 
q
u
a
l
i
t
y
 
o
f
 
t
h
e
 
i
s
o
l
a
t
e
d
 
p
r
o
t
e
i
n
 
w
a
s
 
s
u
f
f
i
c
i
e
n
t
 
f
o
r
 
s
t
r
u
c
t
u
r
a
l
 
a
n
a
l
y
s
i
s
 
b
y
 
X
-
r
a
y
 
c
r
y
s
t
a
l
l
o
g
r
a
p
h
y
 
(
1
6
)
.
 
H
o
w
e
v
e
r
,
 
n
o
 
f
u
r
t
h
e
r
 
c
h
a
r
a
c
t
e
r
i
z
a
t
i
o
n
 
o
f
 
t
h
e
 
p
r
o
t
e
o
l
i
p
o
s
o
m
e
s
 
e
.
g
.
 
b
y
 
f
r
e
e
z
e
-
f
r
a
c
t
u
r
e
 
a
n
a
l
y
s
i
s
 
h
a
s
 
b
e
e
n
 
d
o
n
e
.
 
S
u
b
s
e
q
u
e
n
t
 
p
u
r
i
f
i
c
a
t
i
o
n
 
s
t
e
p
s
 
i
n
v
o
l
v
e
d
 
t
h
e
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
t
h
e
 
I
M
P
s
 
w
i
t
h
 
d
e
t
e
r
g
e
n
t
s
 
a
n
d
 
t
h
e
 
e
f
f
i
c
i
e
n
c
i
e
s
 
o
f
 
I
M
P
 
r
e
c
o
n
s
t
i
t
u
t
i
o
n
 
i
n
t
o
 
t
h
e
 
p
r
o
v
i
d
e
d
 
l
i
p
o
s
o
m
e
s
 
d
u
r
i
n
g
 
t
h
e
 
C
F
 
r
e
a
c
t
i
o
n
 
r
e
m
a
i
n
e
d
 
u
n
c
l
e
a
r
 
s
o
 
f
a
r
.
 
N
e
v
e
r
t
h
e
l
e
s
s
,
 
t
h
e
s
e
 
f
i
r
s
t
 
d
a
t
a
 
p
r
o
v
i
d
e
 
p
r
o
m
i
s
i
n
g
 
r
e
s
u
l
t
s
 
a
n
d
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
I
M
P
s
 
i
n
t
o
 
a
r
t
i
f
i
c
i
a
l
 
l
i
p
o
s
o
m
e
s
 
m
i
g
h
t
 
h
a
v
e
 
a
 
h
i
g
h
 
p
o
t
e
n
t
i
a
l
 
t
o
 
b
e
c
o
m
e
 
a
n
 
i
m
p
o
r
t
a
n
t
 
t
e
c
h
n
i
q
u
e
 
f
o
r
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
 
a
n
a
l
y
s
i
s
.
 
 
 
1
.
2
.
 
D
e
t
e
r
g
e
n
t
s
 
f
o
r
 
t
h
e
 
e
f
f
i
c
i
e
n
t
 
r
e
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
c
e
l
l
-
f
r
e
e
 
p
r
o
d
u
c
e
d
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
F
o
r
 
t
h
e
 
C
F
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
I
M
P
 
p
r
e
c
i
p
i
t
a
t
e
s
,
 
s
t
a
n
d
a
r
d
 
r
e
a
c
t
i
o
n
 
p
r
o
t
o
c
o
l
s
 
c
o
u
l
d
 
i
n
s
t
a
n
t
l
y
 
b
e
 
u
s
e
d
 
a
n
d
 
n
o
 
t
i
m
e
-
c
o
n
s
u
m
i
n
g
 
e
v
a
l
u
a
t
i
o
n
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
i
s
 
n
e
e
d
e
d
.
 
H
i
g
h
 
y
i
e
l
d
s
 
o
f
 
s
y
n
t
h
e
s
i
z
e
d
 
I
M
P
 
a
r
e
 
e
n
s
u
r
e
d
 
a
s
 
n
o
 
i
n
h
i
b
i
t
o
r
y
 
e
f
f
e
c
t
s
 
o
f
 
s
u
p
p
l
i
e
d
 
d
e
t
e
r
g
e
n
t
s
 
a
r
e
 
p
r
e
s
e
n
t
.
 
I
n
 
a
d
d
i
t
i
o
n
,
 
t
h
e
 
I
M
P
s
 
c
o
u
l
d
 
b
e
 
o
b
t
a
i
n
e
d
 
i
n
 
h
i
g
h
l
y
 
p
u
r
i
f
i
e
d
 
f
o
r
m
 
b
y
 
o
n
l
y
 
f
e
w
 
s
t
e
p
s
 
(
1
1
)
.
 
T
h
i
s
 
e
x
p
r
e
s
s
i
o
n
 
m
o
d
e
 
m
o
s
t
l
y
 
r
e
s
e
m
b
l
e
s
 
c
o
n
v
e
n
t
i
o
n
a
l
 
i
n
-
v
i
v
o
 
a
p
p
r
o
a
c
h
e
s
 
o
f
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
I
M
P
s
 
i
n
 
f
o
r
m
 
o
f
 
i
n
c
l
u
s
i
o
n
 
b
o
d
i
e
s
.
 
H
o
w
e
v
e
r
,
 
s
t
r
u
c
t
u
r
a
l
 
d
i
f
f
e
r
e
n
c
e
s
 
m
i
g
h
t
 
e
x
i
s
t
 
b
e
t
w
e
e
n
 
c
e
l
l
u
l
a
r
 
i
n
c
l
u
s
i
o
n
 
b
o
d
i
e
s
 
a
n
d
 
C
F
 
p
r
o
d
u
c
e
d
 
p
r
e
c
i
p
i
t
a
t
e
s
.
 
I
M
P
 
p
r
e
c
i
p
i
t
a
t
e
s
 
o
b
t
a
i
n
e
d
 
b
y
 
C
F
 
r
e
a
c
t
i
o
n
s
 
u
s
u
a
l
l
y
 
s
o
l
u
b
i
l
i
z
e
 
r
a
p
i
d
l
y
 
u
p
o
n
 
a
d
d
i
t
i
o
n
 
o
f
 
r
e
l
a
t
i
v
e
l
y
 
m
i
l
d
 
d
e
t
e
r
g
e
n
t
s
 
a
n
d
 
t
h
e
y
 
d
o
 
n
o
t
 
r
e
q
u
i
r
e
 
i
n
t
e
n
s
i
v
e
 
d
e
n
a
t
u
r
a
t
i
o
n
 
a
n
d
 
r
e
f
o
l
d
i
n
g
 
s
t
e
p
s
 
a
s
 
i
t
 
i
s
 
k
n
o
w
n
 
f
r
o
m
 
t
h
e
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
i
n
c
l
u
s
i
o
n
 
b
o
d
i
e
s
 
(
1
4
,
 
2
3
,
 
2
4
)
.
 
D
e
n
a
t
u
r
a
t
i
n
g
 
a
g
e
n
t
s
 
l
i
k
e
 
G
u
a
n
i
d
i
n
i
u
m
 
H
C
l
 
o
r
 
e
x
c
e
s
s
i
v
e
 
a
m
o
u
n
t
s
 
o
f
 
u
r
e
a
 
c
o
u
l
d
 
t
h
u
s
 
b
e
 
a
v
o
i
d
e
d
 
a
n
d
 
a
l
r
e
a
d
y
 
g
e
n
t
l
e
 
m
i
x
i
n
g
 
o
f
 
t
h
e
 
I
M
P
 
p
r
e
c
i
p
i
t
a
t
e
 
w
i
t
h
 
a
 
s
u
i
t
a
b
l
e
 
d
e
t
e
r
g
e
n
t
 
a
t
 
a
 
f
i
n
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
1
-
5
 
%
 
a
t
 
r
o
o
m
 
t
e
m
p
e
r
a
t
u
r
e
 
i
s
 
o
f
t
e
n
 
s
u
f
f
i
c
i
e
n
t
 
f
o
r
 
a
 
q
u
a
n
t
i
t
a
t
i
v
e
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
.
 
I
n
 
p
a
r
t
i
c
u
l
a
r
,
 
1
-
m
y
r
i
s
t
o
y
l
-
2
-
h
y
d
r
o
x
y
-
s
n
-
g
l
y
c
e
r
o
-
3
-
[
p
h
o
s
p
h
o
-
r
a
c
-
(
1
-
g
l
y
c
e
r
o
l
)
]
 
(
L
M
P
G
)
 
a
n
d
 
r
e
l
a
t
e
d
 
d
e
r
i
v
a
t
i
v
e
s
 
l
i
k
e
 
1
-
p
a
l
m
i
t
o
y
l
-
2
-
h
y
d
r
o
x
y
-
s
n
-
g
l
y
c
e
r
o
-
3
-
[
p
h
o
s
p
h
o
-
r
a
c
-
(
1
-
g
l
y
c
e
r
o
l
)
]
 
(
L
P
P
G
)
 
w
e
r
e
 
f
o
u
n
d
 
t
o
 
h
a
v
e
 
o
u
t
s
t
a
n
d
i
n
g
 
p
r
o
p
e
r
t
i
e
s
 
i
n
 
t
h
e
 
e
f
f
i
c
i
e
n
t
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
C
F
 
p
r
o
d
u
c
e
d
 
p
r
e
c
i
p
i
t
a
t
e
s
 
o
f
 
s
t
r
u
c
t
u
r
a
l
l
y
 
d
i
f
f
e
r
e
n
t
 
I
M
P
s
 
(
2
4
,
 
2
6
)
.
 
O
t
h
e
r
 
m
i
l
d
 
d
e
t
e
r
g
e
n
t
s
 
l
i
k
e
 
D
D
M
,
 
D
P
C
,
 
T
X
-
1
0
0
,
 
D
H
P
C
 
o
r
 
3
-
[
(
3
-
c
h
o
l
a
m
i
d
o
p
r
o
p
y
l
)
d
i
m
e
t
h
y
l
a
m
m
o
n
i
o
]
-
1
-
p
r
o
p
a
n
s
u
l
f
o
n
a
t
 
(
C
H
A
P
S
)
 
a
r
e
 
f
u
r
t
h
e
r
 
e
f
f
e
c
t
i
v
e
 
i
n
 
t
h
e
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
s
p
e
c
i
f
i
c
 
I
M
P
s
 
l
i
k
e
 
E
m
r
E
,
 
T
s
x
 
o
r
 
t
h
e
 
m
e
c
h
a
n
o
s
e
n
s
i
t
i
v
e
 
c
h
a
n
n
e
l
 
M
c
s
L
,
 
b
u
t
 
t
h
e
y
 
f
a
i
l
e
d
 
t
o
 
s
o
l
u
b
i
l
i
z
e
 
t
h
e
 
G
P
C
R
 
p
r
o
t
e
i
n
 
V
2
R
 
(
1
4
,
 
2
4
)
 
(
T
a
b
l
e
 
1
)
.
 
 
 
M
o
s
t
 
i
m
p
o
r
t
a
n
t
 
i
s
 
a
l
w
a
y
s
 
t
h
e
 
p
r
e
p
a
r
a
t
i
o
n
 
o
f
 
f
u
n
c
t
i
o
n
a
l
l
y
 
f
o
l
d
e
d
 
p
r
o
t
e
i
n
s
 
a
n
d
 
t
h
e
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
f
 
p
r
e
c
i
p
i
t
a
t
e
d
 
I
M
P
s
 
m
i
g
h
t
 
g
e
n
e
r
a
l
l
y
 
b
e
 
m
o
r
e
 
c
r
i
t
i
c
a
l
 
t
h
a
n
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
a
s
 
s
o
l
u
b
l
e
 
p
r
o
t
e
i
n
s
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
d
e
t
e
r
g
e
n
t
s
.
 
S
o
m
e
 
p
r
o
t
e
i
n
s
 
l
i
k
e
 
t
h
e
 
t
r
a
n
s
p
o
r
t
e
r
 
E
m
r
E
 
o
r
 
t
h
e
 
c
h
a
n
n
e
l
 
M
s
c
L
 
c
a
n
 
b
e
 
p
r
o
d
u
c
e
d
 
i
n
 
a
 
f
u
n
c
t
i
o
n
a
l
 
f
o
r
m
 
i
n
 
b
o
t
h
 
w
a
y
s
.
 
S
o
l
u
b
i
l
i
z
a
t
i
o
n
 
o
u
t
 
o
f
 
C
F
  
9
 
p
r
o
d
u
c
e
d
 
p
r
e
c
i
p
i
t
a
t
e
s
 
a
s
 
w
e
l
l
 
a
s
 
t
h
e
 
d
i
r
e
c
t
 
s
o
l
u
b
l
e
 
e
x
p
r
e
s
s
i
o
n
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
r
e
s
u
l
t
e
d
 
i
n
 
a
c
t
i
v
e
 
p
r
o
t
e
i
n
s
 
(
1
4
,
 
2
3
,
 
2
4
)
.
 
H
o
w
e
v
e
r
,
 
s
o
m
e
 
I
M
P
s
 
l
i
k
e
 
t
h
e
 
n
u
c
l
e
o
s
i
d
e
 
t
r
a
n
s
p
o
r
t
e
r
 
T
s
x
 
c
o
u
l
d
 
o
n
l
y
 
p
r
o
d
u
c
e
d
 
i
n
 
f
u
l
l
y
 
f
u
n
c
t
i
o
n
a
l
 
f
o
r
m
 
w
i
t
h
 
t
h
e
 
s
o
l
u
b
l
e
 
m
o
d
e
 
o
f
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
(
2
4
)
.
 
 
2
.
 
C
a
s
e
 
s
t
u
d
i
e
s
 
f
o
r
 
t
h
e
 
h
i
g
h
 
l
e
v
e
l
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
T
h
e
 
a
p
p
l
i
c
a
t
i
o
n
 
o
f
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
t
o
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
i
s
 
a
n
 
e
m
e
r
g
i
n
g
 
t
e
c
h
n
i
q
u
e
 
a
n
d
 
w
e
 
w
i
l
l
 
d
e
s
c
r
i
b
e
 
r
e
c
e
n
t
 
a
p
p
r
o
a
c
h
e
s
 
o
f
 
t
h
e
 
p
r
e
p
a
r
a
t
i
v
e
 
s
c
a
l
e
 
C
F
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
s
t
r
u
c
t
u
r
a
l
l
y
 
d
i
f
f
e
r
e
n
t
 
I
M
P
s
.
 
T
h
e
 
a
v
a
i
l
a
b
l
e
 
d
a
t
a
 
a
r
e
 
s
t
i
l
l
 
c
o
n
f
i
n
e
d
 
t
o
 
a
 
r
e
l
a
t
i
v
e
l
y
 
l
i
m
i
t
e
d
 
n
u
m
b
e
r
 
o
f
 
p
r
o
t
e
i
n
s
,
 
b
u
t
 
t
h
e
 
c
o
n
s
i
d
e
r
a
b
l
e
 
s
t
r
u
c
t
u
r
a
l
 
d
i
v
e
r
s
i
t
y
 
o
f
 
t
h
e
 
s
y
n
t
h
e
s
i
z
e
d
 
I
M
P
s
 
a
n
d
 
t
h
e
 
r
e
c
e
n
t
 
s
u
c
c
e
s
s
 
i
n
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
G
P
C
R
 
p
r
o
t
e
i
n
s
 
a
l
r
e
a
d
y
 
i
n
d
i
c
a
t
e
 
a
n
 
e
n
o
r
m
o
u
s
 
p
o
t
e
n
t
i
a
l
 
o
f
 
t
h
e
 
C
F
 
t
e
c
h
n
i
q
u
e
 
f
o
r
 
t
h
e
 
h
i
g
h
-
l
e
v
e
l
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
d
i
f
f
i
c
u
l
t
 
I
M
P
s
 
(
F
i
g
s
.
 
2
 
a
n
d
 
3
)
.
 
T
h
e
 
f
u
n
c
t
i
o
n
a
l
i
t
y
 
o
f
 
t
h
e
 
s
y
n
t
h
e
s
i
z
e
d
 
I
M
P
s
 
a
n
d
 
a
l
s
o
 
c
o
r
r
e
s
p
o
n
d
i
n
g
 
y
i
e
l
d
s
 
o
b
t
a
i
n
e
d
 
w
i
t
h
 
i
n
-
v
i
v
o
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
w
i
l
l
 
b
e
 
d
i
s
c
u
s
s
e
d
 
i
f
 
d
a
t
a
 
a
r
e
 
a
v
a
i
l
a
b
l
e
.
 
T
h
e
 
y
i
e
l
d
s
 
o
f
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
 
o
b
t
a
i
n
e
d
 
f
r
o
m
 
C
E
C
F
 
s
y
s
t
e
m
s
 
c
a
n
 
e
a
s
i
l
y
 
b
e
 
m
a
n
i
p
u
l
a
t
e
d
 
b
y
 
v
a
r
y
i
n
g
 
t
h
e
 
R
M
/
F
M
 
r
a
t
i
o
 
o
r
 
b
y
 
r
e
f
r
e
s
h
i
n
g
 
t
h
e
 
c
o
m
p
l
e
t
e
 
F
M
 
d
u
r
i
n
g
 
t
h
e
 
r
e
a
c
t
i
o
n
.
 
T
h
e
 
s
p
e
c
i
f
i
c
 
r
e
a
c
t
i
o
n
 
c
o
n
d
i
t
i
o
n
s
 
s
h
o
u
l
d
 
t
h
e
r
e
f
o
r
e
 
b
e
 
c
o
n
s
i
d
e
r
e
d
 
w
h
e
n
 
t
h
e
 
e
f
f
i
c
i
e
n
c
i
e
s
 
o
f
 
d
i
f
f
e
r
e
n
t
 
C
F
 
r
e
a
c
t
i
o
n
s
 
a
r
e
 
c
o
m
p
a
r
e
d
.
 
I
t
 
i
s
 
e
v
e
n
 
m
o
r
e
 
d
i
f
f
i
c
u
l
t
 
t
o
 
c
o
m
p
a
r
e
 
y
i
e
l
d
s
 
o
f
 
C
F
 
r
e
a
c
t
i
o
n
s
 
w
i
t
h
 
t
h
a
t
 
o
f
 
i
n
-
v
i
v
o
 
r
e
a
c
t
i
o
n
s
.
 
I
f
 
c
e
l
l
 
v
o
l
u
m
e
s
 
s
h
o
u
l
d
 
b
e
 
c
o
m
p
a
r
e
d
,
 
o
n
e
 
c
o
u
l
d
 
c
o
n
s
i
d
e
r
 
t
h
a
t
 
o
n
e
 
l
i
t
r
e
 
o
f
 
a
n
 
o
u
t
g
r
o
w
n
 
E
.
 
c
o
l
i
 
c
u
l
t
u
r
e
 
i
n
 
s
t
a
n
d
a
r
d
 
L
u
r
i
a
 
b
r
o
t
h
 
(
1
0
 
g
 
t
r
y
p
t
o
n
e
,
 
1
0
 
g
 
y
e
a
s
t
 
e
x
t
r
a
c
t
,
 
5
 
g
 
N
a
C
l
)
 
c
o
n
t
a
i
n
s
 
a
 
c
e
l
l
 
v
o
l
u
m
e
 
e
q
u
i
v
a
l
e
n
t
 
t
o
 
a
p
p
r
o
x
.
 
5
 
-
 
1
0
 
m
l
 
o
f
 
R
M
.
 
H
o
w
e
v
e
r
,
 
t
h
i
s
 
c
a
l
c
u
l
a
t
i
o
n
 
d
o
e
s
 
n
e
i
t
h
e
r
 
c
o
n
s
i
d
e
r
 
t
h
e
 
p
r
e
p
a
r
a
t
i
o
n
 
o
f
 
S
3
0
 
e
x
t
r
a
c
t
s
,
 
e
n
z
y
m
e
s
 
o
r
 
r
e
a
c
t
i
o
n
 
m
i
x
t
u
r
e
s
 
n
o
r
 
f
e
r
m
e
n
t
a
t
i
o
n
 
a
n
d
 
p
u
r
i
f
i
c
a
t
i
o
n
 
p
r
o
c
e
d
u
r
e
s
.
 
I
n
 
g
e
n
e
r
a
l
,
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
i
s
 
a
 
r
e
l
a
t
i
v
e
l
y
 
e
x
p
e
n
s
i
v
e
 
t
e
c
h
n
i
q
u
e
 
a
n
d
 
i
t
 
m
i
g
h
t
 
t
h
e
r
e
f
o
r
e
 
r
e
p
r
e
s
e
n
t
 
t
h
e
 
f
i
r
s
t
 
c
h
o
i
c
e
 
p
r
i
m
a
r
i
l
y
 
f
o
r
 
s
p
e
c
i
f
i
c
 
l
a
b
e
l
l
i
n
g
 
p
u
r
p
o
s
e
s
 
o
r
 
i
f
 
a
 
t
a
r
g
e
t
 
p
r
o
t
e
i
n
 
c
a
n
n
o
t
 
b
e
c
o
m
e
 
e
x
p
r
e
s
s
e
d
 
a
t
 
a
l
l
 
o
r
 
o
n
l
y
 
a
t
 
l
o
w
 
a
m
o
u
n
t
s
 
i
n
 
o
t
h
e
r
 
s
y
s
t
e
m
s
.
 
 
 
2
.
1
.
 
α
-
h
e
l
i
c
a
l
 
t
r
a
n
s
p
o
r
t
e
r
s
 
T
r
a
n
s
p
o
r
t
e
r
s
 
c
o
n
t
r
o
l
 
t
h
e
 
c
o
n
d
i
t
i
o
n
s
 
b
e
t
w
e
e
n
 
i
n
-
 
a
n
d
 
o
u
t
s
i
d
e
 
o
f
 
t
h
e
i
r
 
h
o
s
t
-
m
e
m
b
r
a
n
e
 
l
i
k
e
 
t
h
e
 
u
p
t
a
k
e
 
o
f
 
s
u
b
s
t
r
a
t
e
s
,
 
t
h
e
 
e
f
f
l
u
x
 
o
f
 
t
o
x
i
c
 
s
u
b
s
t
a
n
c
e
s
 
o
r
 
t
h
e
 
r
e
g
u
l
a
t
i
o
n
 
o
f
 
i
o
n
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
.
 
T
h
e
 
1
1
0
 
a
m
i
n
o
 
a
c
i
d
 
s
m
a
l
l
 
m
u
l
t
i
d
r
u
g
 
t
r
a
n
s
p
o
r
t
e
r
 
E
m
r
E
 
w
a
s
 
s
u
b
j
e
c
t
 
o
f
 
s
e
v
e
r
a
l
 
a
p
p
r
o
a
c
h
e
s
 
o
f
 
h
i
g
h
-
l
e
v
e
l
 
p
r
o
d
u
c
t
i
o
n
 
b
y
 
C
F
 
e
x
p
r
e
s
s
i
o
n
.
 
C
o
n
v
e
n
t
i
o
n
a
l
 
i
n
-
v
i
v
o
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
E
m
r
E
 
r
o
u
t
i
n
e
l
y
 
y
i
e
l
d
s
 
a
p
p
r
o
x
.
 
o
n
e
 
m
g
 
o
f
 
p
r
o
t
e
i
n
 
p
e
r
 
l
i
t
r
e
 
E
.
 
c
o
l
i
 
c
u
l
t
u
r
e
 
(
2
7
)
.
 
I
n
 
C
F
 
s
y
s
t
e
m
s
 
b
a
s
e
d
 
o
n
 
E
.
 
c
o
l
i
 
S
3
0
 
e
x
t
r
a
c
t
s
 
a
m
o
u
n
t
s
 
o
f
 
2
-
3
 
m
g
 
p
e
r
 
o
n
e
 
m
l
 
o
f
 
R
M
 
i
n
 
p
r
e
p
a
r
a
t
i
v
e
 
s
c
a
l
e
 
s
e
t
-
u
p
s
 
a
n
d
 
1
-
2
 
µ
g
 
o
f
 
p
r
o
t
e
i
n
 
p
e
r
 
2
0
 
µ
l
 
o
f
 
R
M
 
i
n
 
a
n
a
l
y
t
i
c
a
l
 
s
e
t
-
u
p
s
 
w
e
r
e
 
r
e
p
o
r
t
e
d
 
(
2
3
)
.
 
S
u
p
p
l
i
e
d
 
d
e
t
e
r
g
e
n
t
s
 
d
i
d
 
n
o
t
 
a
l
t
e
r
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
r
a
t
e
 
o
f
 
E
m
r
E
 
a
n
d
 
d
i
r
e
c
t
e
d
 
m
o
s
t
 
o
f
 
t
h
e
 
p
r
o
t
e
i
n
 
i
n
t
o
 
t
h
e
 
s
o
l
u
b
l
e
 
f
r
a
c
t
i
o
n
.
 
 
1
0
 
P
u
l
l
 
d
o
w
n
 
e
x
p
e
r
i
m
e
n
t
s
 
a
s
 
w
e
l
l
 
a
s
 
c
r
o
s
s
-
l
i
n
k
i
n
g
 
s
t
u
d
i
e
s
 
w
i
t
h
 
C
F
 
p
r
o
d
u
c
e
d
 
E
m
r
E
 
r
e
v
e
a
l
e
d
 
a
 
h
o
m
o
d
i
m
e
r
 
a
s
 
t
h
e
 
f
u
n
c
t
i
o
n
a
l
 
c
o
n
f
o
r
m
a
t
i
o
n
 
a
n
d
 
a
c
t
i
v
i
t
y
 
a
s
s
a
y
s
 
o
f
 
t
h
e
 
t
r
a
n
s
p
o
r
t
e
r
 
i
n
 
D
D
M
 
m
i
c
e
l
l
e
s
 
s
h
o
w
e
d
 
s
p
e
c
i
f
i
c
 
s
u
b
s
t
r
a
t
e
 
b
i
n
d
i
n
g
 
o
f
 
[
3
H
]
 
t
e
t
r
a
p
h
e
n
y
l
p
h
o
s
p
h
o
n
i
u
m
 
(
T
P
P
+
)
.
 
T
h
e
 
d
e
t
e
r
m
i
n
e
d
 
K
d
 
v
a
l
u
e
 
o
f
 
2
.
3
 
n
M
 
m
a
t
c
h
e
s
 
v
e
r
y
 
n
i
c
e
l
y
 
w
i
t
h
 
t
h
e
 
K
d
 
o
f
 
2
.
8
 
n
M
 
o
b
t
a
i
n
e
d
 
f
r
o
m
 
i
n
-
v
i
v
o
 
p
r
o
d
u
c
e
d
 
E
m
r
E
 
(
2
8
)
.
 
T
h
e
 
m
e
t
h
y
l
 
v
i
o
l
o
g
e
n
 
u
p
t
a
k
e
 
o
f
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
E
m
r
E
 
w
a
s
 
m
e
a
s
u
r
e
d
 
t
o
 
v
e
r
i
f
y
 
t
h
e
 
s
p
e
c
i
f
i
c
 
s
u
b
s
t
r
a
t
e
 
t
r
a
n
s
p
o
r
t
 
a
c
r
o
s
s
 
a
 
m
e
m
b
r
a
n
e
.
 
A
n
 
H
+
 
g
r
a
d
i
e
n
t
 
d
e
p
e
n
d
e
n
t
 
a
c
c
u
m
u
l
a
t
i
o
n
 
o
f
 
t
h
e
 
s
u
b
s
t
r
a
t
e
 
a
g
a
i
n
s
t
 
i
t
s
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
g
r
a
d
i
e
n
t
 
c
o
u
l
d
 
b
e
 
d
e
t
e
r
m
i
n
e
d
 
t
o
 
a
 
r
a
t
e
 
o
f
 
7
.
5
 
n
m
o
l
 
p
e
r
 
m
i
n
 
p
e
r
 
µ
g
 
o
f
 
C
F
 
p
r
o
d
u
c
e
d
 
E
m
r
E
 
w
h
i
c
h
 
i
s
 
v
e
r
y
 
s
i
m
i
l
a
r
 
t
o
 
t
h
a
t
 
o
f
 
E
m
r
E
 
i
s
o
l
a
t
e
d
 
f
r
o
m
 
E
.
 
c
o
l
i
 
c
e
l
l
s
 
w
i
t
h
 
5
.
5
 
n
m
o
l
 
p
e
r
 
m
i
n
 
a
n
d
 
µ
g
 
(
2
3
)
.
 
C
F
 
p
r
o
d
u
c
e
d
 
E
m
r
E
 
p
r
e
c
i
p
i
t
a
t
e
 
c
o
u
l
d
 
b
e
 
s
o
l
u
b
i
l
i
z
e
d
 
i
n
 
D
D
M
 
a
n
d
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
i
n
t
o
 
l
i
p
o
s
o
m
e
s
 
b
a
s
e
d
 
o
n
 
E
.
 
c
o
l
i
 
l
i
p
i
d
s
.
 
T
h
e
s
e
 
p
r
o
t
e
o
l
i
p
o
s
o
m
e
s
 
a
l
s
o
 
s
h
o
w
e
d
 
s
p
e
c
i
f
i
c
 
t
r
a
n
s
p
o
r
t
 
o
f
 
t
h
e
 
s
u
b
s
t
r
a
t
e
 
e
t
h
i
d
i
u
m
 
b
r
o
m
i
d
e
 
(
1
1
)
.
 
R
e
c
o
r
d
e
d
 
N
M
R
-
s
p
e
c
t
r
a
 
i
n
d
i
c
a
t
e
d
 
i
n
 
a
d
d
i
t
i
o
n
 
a
n
 
i
d
e
n
t
i
c
a
l
 
c
o
n
f
o
r
m
a
t
i
o
n
 
o
f
 
C
F
 
p
r
o
d
u
c
e
d
 
E
m
r
E
 
t
o
 
t
h
a
t
 
o
b
t
a
i
n
e
d
 
b
y
 
i
n
-
v
i
v
o
 
e
x
p
r
e
s
s
i
o
n
.
 
I
n
 
f
u
r
t
h
e
r
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
s
t
u
d
i
e
s
,
 
t
h
e
 
f
o
u
r
 
h
o
m
o
l
o
g
o
u
s
 
b
a
c
t
e
r
i
a
l
 
m
u
l
t
i
d
r
u
g
 
t
r
a
n
s
p
o
r
t
e
r
s
 
T
B
s
m
r
,
 
B
P
s
m
r
,
 
P
s
m
r
 
a
n
d
 
H
s
m
r
 
c
o
u
l
d
 
b
e
 
p
r
o
d
u
c
e
d
 
(
2
3
)
 
(
F
i
g
.
 
2
)
.
 
A
l
l
 
f
o
u
r
 
p
r
o
t
e
i
n
s
 
c
a
n
 
a
l
s
o
 
b
e
 
p
r
o
d
u
c
e
d
 
i
n
 
a
n
 
i
n
-
v
i
v
o
 
E
.
 
c
o
l
i
 
s
y
s
t
e
m
 
b
u
t
 
a
t
 
l
e
a
s
t
 
t
h
e
 
P
s
m
r
 
p
r
o
t
e
i
n
 
a
p
p
a
r
e
n
t
l
y
 
s
h
o
w
e
d
 
h
i
g
h
e
r
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
 
i
n
 
t
h
e
 
C
F
 
s
y
s
t
e
m
.
 
 
T
h
e
 
h
i
g
h
-
l
e
v
e
l
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
t
h
e
 
m
e
c
h
a
n
o
s
e
n
s
i
t
i
v
e
 
c
h
a
n
n
e
l
 
M
s
c
L
 
f
r
o
m
 
E
.
 
c
o
l
i
,
 
a
 
h
o
m
o
p
e
n
t
a
m
e
r
 
o
f
 
1
4
 
k
D
a
 
s
u
b
u
n
i
t
s
 
t
h
a
t
 
e
a
c
h
 
c
o
n
s
i
s
t
 
o
f
 
t
w
o
 
T
M
S
s
,
 
r
e
s
u
l
t
e
d
 
i
n
 
f
u
n
c
t
i
o
n
a
l
 
p
r
o
t
e
i
n
 
(
1
4
)
.
 
C
o
n
d
u
c
t
a
n
c
e
 
m
e
a
s
u
r
e
m
e
n
t
s
 
o
n
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
M
s
c
L
 
p
r
o
t
e
i
n
 
i
n
 
g
i
a
n
t
 
l
i
p
o
s
o
m
e
s
 
w
e
r
e
 
p
e
r
f
o
r
m
e
d
 
b
y
 
p
a
t
c
h
 
c
l
a
m
p
 
a
s
s
a
y
s
.
 
S
o
l
u
b
l
e
 
C
F
 
p
r
o
d
u
c
e
d
 
M
s
c
L
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
T
X
-
1
0
0
 
s
h
o
w
e
d
 
a
 
c
o
m
p
a
r
a
b
l
e
 
a
c
t
i
v
i
t
y
 
w
i
t
h
 
8
.
3
 
±
1
.
8
 
o
p
e
n
 
c
h
a
n
n
e
l
s
 
p
e
r
 
p
a
t
c
h
 
t
o
 
t
h
e
 
i
n
 
E
.
 
c
o
l
i
 
c
e
l
l
s
 
o
v
e
r
p
r
o
d
u
c
e
d
 
c
h
a
n
n
e
l
 
w
i
t
h
 
9
.
3
 
±
 
5
.
5
 
o
p
e
n
 
c
h
a
n
n
e
l
s
 
p
e
r
 
p
a
t
c
h
.
 
T
h
e
 
a
d
d
i
t
i
o
n
 
o
f
 
a
n
 
a
m
i
n
o
-
t
e
r
m
i
n
a
l
 
p
o
l
y
(
H
i
s
)
6
-
t
a
g
 
l
o
w
e
r
e
d
 
t
h
e
 
n
u
m
b
e
r
s
 
o
f
 
c
h
a
n
n
e
l
s
 
p
e
r
 
p
a
t
c
h
 
o
f
 
M
s
c
L
 
p
r
o
t
e
i
n
 
i
s
o
l
a
t
e
d
 
f
r
o
m
 
b
o
t
h
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
.
 
T
h
e
 
f
u
l
l
 
a
c
t
i
v
i
t
y
 
o
f
 
M
s
c
L
 
c
o
u
l
d
 
b
e
 
r
e
s
t
o
r
e
d
 
b
y
 
r
e
m
o
v
i
n
g
 
t
h
e
 
t
a
g
 
u
p
o
n
 
c
l
e
a
v
a
g
e
 
w
i
t
h
 
t
h
e
 
f
a
c
t
o
r
 
X
a
 
p
r
o
t
e
a
s
e
.
 
C
r
o
s
s
-
l
i
n
k
 
e
x
p
e
r
i
m
e
n
t
s
 
i
n
d
i
c
a
t
e
d
 
t
h
e
 
f
o
r
m
a
t
i
o
n
 
o
f
 
t
h
e
 
f
u
n
c
t
i
o
n
a
l
 
p
e
n
t
a
m
e
r
i
c
 
s
t
a
t
e
 
o
f
 
M
s
c
L
 
a
l
r
e
a
d
y
 
i
n
 
d
e
t
e
r
g
e
n
t
 
m
i
c
e
l
l
e
s
.
 
T
h
e
 
i
n
-
v
i
t
r
o
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
 
c
o
u
l
d
 
b
e
 
i
n
c
r
e
a
s
e
d
 
t
o
 
a
 
f
i
n
a
l
 
y
i
e
l
d
 
o
f
 
a
p
p
r
o
x
.
 
3
.
6
 
m
g
 
M
s
c
L
 
p
r
o
t
e
i
n
 
p
e
r
 
m
l
 
R
M
 
b
y
 
a
d
d
i
n
g
 
1
8
 
µ
g
/
m
l
 
E
.
 
c
o
l
i
 
l
i
p
i
d
s
.
 
 
 
T
h
e
 
b
a
c
t
e
r
i
a
l
 
α
-
h
e
l
i
c
a
l
 
t
e
l
l
u
r
i
t
e
 
t
r
a
n
s
p
o
r
t
e
r
 
T
e
h
A
 
(
3
6
 
k
D
a
,
 
1
0
 
T
M
S
s
)
 
a
n
d
 
t
h
e
 
c
y
s
t
e
i
n
e
 
t
r
a
n
s
p
o
r
t
e
r
 
Y
f
i
k
 
(
2
2
 
k
D
a
,
 
6
 
T
M
S
s
)
 
w
e
r
e
 
n
o
t
 
p
r
o
d
u
c
e
d
 
i
n
 
d
e
t
e
c
t
a
b
l
e
 
a
m
o
u
n
t
s
 
i
n
 
E
.
 
c
o
l
i
 
c
e
l
l
s
.
 
T
h
e
 
y
i
e
l
d
s
 
i
n
 
C
E
C
F
 
s
y
s
t
e
m
s
 
f
o
r
 
b
o
t
h
 
p
r
o
t
e
i
n
 
a
n
d
 
o
f
 
t
h
e
 
C
-
t
e
r
m
i
n
a
l
 
t
r
u
n
c
a
t
e
d
 
d
e
r
i
v
a
t
i
v
e
 
∆
T
e
h
A
 
(
2
4
 
k
D
a
,
 
7
 
T
M
S
s
)
 
r
e
a
c
h
e
d
 
l
e
v
e
l
s
 
u
p
 
t
o
 
2
.
7
 
m
g
 
p
e
r
 
m
l
 
R
M
 
(
F
i
g
.
 
2
)
.
 
N
o
 
f
u
n
c
t
i
o
n
a
l
 
a
n
a
l
y
s
i
s
 
o
f
 
t
h
e
 
t
w
o
 
p
r
o
t
e
i
n
s
 
h
a
s
 
b
e
e
n
 
m
a
d
e
 
b
u
t
 
t
h
e
 
s
t
r
u
c
t
u
r
a
l
 
e
v
a
l
u
a
t
i
o
n
 
b
y
 
N
M
R
 
s
p
e
c
t
r
o
s
c
o
p
y
 
r
e
v
e
a
l
e
d
 
s
t
r
o
n
g
 
e
v
i
d
e
n
c
e
 
o
f
 
f
o
l
d
e
d
 
p
r
o
t
e
i
n
s
 
(
1
1
,
 
2
6
)
.
 
 
  
1
1
 
 
E
x
p
r
e
s
s
i
o
n
 
i
n
 
a
n
 
E
.
 
c
o
l
i
 
b
a
s
e
d
 
s
y
s
t
e
m
 
a
s
 
w
e
l
l
 
a
s
 
t
h
e
 
C
F
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
t
h
e
 
6
.
1
 
k
D
a
 
α
 
a
p
o
p
r
o
t
e
i
n
 
o
f
 
t
h
e
 
l
i
g
h
t
 
h
a
r
v
e
s
t
i
n
g
 
c
o
m
p
l
e
x
 
(
L
H
1
)
 
f
r
o
m
 
R
h
o
d
o
s
p
i
r
i
l
l
u
m
 
r
u
b
r
u
m
 
y
i
e
l
d
e
d
 
a
m
o
u
n
t
s
 
o
f
 
1
.
2
 
m
g
 
p
e
r
 
l
i
t
r
e
 
c
e
l
l
-
c
u
l
t
u
r
e
 
a
n
d
 
0
.
7
 
m
g
 
p
e
r
 
m
l
 
R
M
,
 
r
e
s
p
e
c
t
i
v
e
l
y
 
(
1
5
)
.
 
T
h
e
 
C
F
 
o
b
t
a
i
n
e
d
 
α
-
L
H
1
 
p
r
e
c
i
p
i
t
a
t
e
 
c
o
u
l
d
 
b
e
 
f
u
n
c
t
i
o
n
a
l
l
y
 
r
e
f
o
l
d
e
d
 
i
n
 
a
 
b
u
f
f
e
r
 
s
y
s
t
e
m
 
c
o
n
t
a
i
n
i
n
g
 
0
.
5
 
t
o
 
2
.
0
 
%
 
T
X
-
1
0
0
.
 
R
e
c
o
r
d
e
d
 
C
D
-
s
p
e
c
t
r
a
 
w
e
r
e
 
e
s
s
e
n
t
i
a
l
l
y
 
i
d
e
n
t
i
c
a
l
 
t
o
 
t
h
a
t
 
o
f
 
n
a
t
i
v
e
 
α
−
L
Η
1
 
p
r
o
t
e
i
n
 
a
n
d
 
t
h
e
 
i
n
-
v
i
t
r
o
 
f
o
r
m
a
t
i
o
n
 
o
f
 
a
 
s
t
r
u
c
t
u
r
a
l
 
c
o
m
p
l
e
x
 
w
i
t
h
 
t
h
e
 
ß
-
s
u
b
u
n
i
t
 
o
f
 
t
h
e
 
L
H
1
 
c
o
m
p
l
e
x
 
w
a
s
 
d
e
m
o
n
s
t
r
a
t
e
d
 
b
y
 
i
t
s
 
s
p
e
c
i
f
i
c
 
s
p
e
c
t
r
a
l
 
a
b
s
o
r
b
a
n
c
e
 
p
a
t
t
e
r
n
.
 
 
T
h
e
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
h
o
m
o
l
o
g
u
e
s
 
o
f
 
e
u
k
a
r
y
o
t
i
c
 
g
l
u
t
a
m
a
t
e
 
t
r
a
n
s
p
o
r
t
e
r
s
 
f
r
o
m
 
t
h
e
 
f
o
u
r
 
b
a
c
t
e
r
i
a
l
 
s
p
e
c
i
e
s
 
E
.
 
c
o
l
i
,
 
A
e
r
o
p
y
r
u
m
 
p
e
r
n
i
x
,
 
P
y
r
o
c
o
c
c
u
s
 
f
u
r
i
o
s
u
s
 
a
n
d
 
P
y
r
o
c
o
c
c
u
s
 
h
o
r
i
k
o
s
h
i
i
 
h
a
v
e
 
b
e
e
n
 
c
o
m
p
a
r
e
d
 
(
F
i
g
.
 
3
)
.
 
T
h
e
 
a
p
p
r
o
x
.
 
4
5
 
k
D
a
 
p
r
o
t
e
i
n
s
 
h
a
v
e
 
e
i
g
h
t
 
p
r
o
p
o
s
e
d
 
T
M
S
s
 
a
n
d
 
f
o
r
m
 
p
u
t
a
t
i
v
e
 
t
r
i
m
e
r
s
.
 
A
l
l
 
f
o
u
r
 
p
r
o
t
e
i
n
s
 
h
a
v
e
 
b
e
e
n
 
p
r
o
d
u
c
e
d
 
a
s
 
p
r
e
c
i
p
i
t
a
t
e
 
a
n
d
 
c
o
u
l
d
 
s
u
b
s
e
q
u
e
n
t
l
y
 
b
e
 
s
o
l
u
b
i
l
i
z
e
d
 
i
n
 
t
h
e
 
d
e
t
e
r
g
e
n
t
s
 
z
w
i
t
t
e
r
g
e
n
t
 
3
-
1
2
 
o
r
 
z
w
i
t
t
e
r
g
e
n
t
 
3
-
1
4
.
 
H
i
g
h
e
s
t
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
 
w
a
s
 
o
b
t
a
i
n
e
d
 
f
o
r
 
t
h
e
 
E
.
 
c
o
l
i
 
h
o
m
o
l
o
g
u
e
 
w
i
t
h
 
a
p
p
r
o
x
.
 
2
 
m
g
 
p
e
r
 
m
l
 
R
M
 
f
o
l
l
o
w
e
d
 
w
i
t
h
 
a
p
p
r
o
x
.
 
3
0
 
%
 
o
f
 
t
h
a
t
 
y
i
e
l
d
 
f
r
o
m
 
t
h
e
 
h
o
m
o
l
o
g
u
e
 
o
f
 
P
.
 
f
u
r
i
o
s
u
s
.
 
T
h
e
 
t
w
o
 
o
t
h
e
r
 
p
r
o
t
e
i
n
s
 
h
a
v
e
 
b
e
e
n
 
p
r
o
d
u
c
e
d
 
o
n
l
y
 
a
t
 
a
 
s
i
g
n
i
f
i
c
a
n
t
l
y
 
l
o
w
e
r
 
l
e
v
e
l
 
i
n
 
t
h
e
 
C
F
 
s
y
s
t
e
m
.
 
T
h
e
 
d
a
t
a
 
d
e
m
o
n
s
t
r
a
t
e
 
t
h
a
t
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
e
f
f
i
c
i
e
n
c
i
e
s
 
o
f
 
e
v
e
n
 
c
l
o
s
e
l
y
 
r
e
l
a
t
e
d
 
I
M
P
s
 
c
a
n
 
b
e
 
v
e
r
y
 
d
i
f
f
e
r
e
n
t
.
 
O
p
t
i
m
i
z
e
d
 
c
o
d
o
n
 
u
s
a
g
e
 
o
f
 
t
h
e
 
t
a
r
g
e
t
 
g
e
n
e
s
,
 
s
u
p
p
l
e
m
e
n
t
a
t
i
o
n
 
o
f
 
r
a
r
e
 
c
o
d
o
n
 
t
R
N
A
s
 
o
r
 
a
d
j
u
s
t
i
n
g
 
t
h
e
 
a
m
i
n
o
 
a
c
i
d
 
p
o
o
l
 
a
c
c
o
r
d
i
n
g
 
t
o
 
t
h
e
 
c
o
m
p
o
s
i
t
i
o
n
 
o
f
 
t
h
e
 
s
p
e
c
i
f
i
c
 
t
a
r
g
e
t
 
p
r
o
t
e
i
n
s
 
m
i
g
h
t
 
b
e
 
c
o
n
s
i
d
e
r
e
d
 
a
s
 
f
u
r
t
h
e
r
 
a
p
p
r
o
a
c
h
e
s
 
i
n
 
o
r
d
e
r
 
t
o
 
i
m
p
r
o
v
e
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
y
i
e
l
d
s
.
 
 
2
.
2
.
 
G
-
p
r
o
t
e
i
n
 
c
o
u
p
l
e
d
 
r
e
c
e
p
t
o
r
s
 
E
u
k
a
r
y
o
t
i
c
 
G
P
C
R
s
 
r
e
p
r
e
s
e
n
t
 
t
h
e
 
l
a
r
g
e
s
t
 
s
i
n
g
l
e
 
c
l
a
s
s
 
o
f
 
r
e
c
e
p
t
o
r
s
 
a
n
d
 
t
h
e
y
 
a
r
e
 
p
r
e
d
i
c
t
e
d
 
t
o
 
c
o
n
s
i
s
t
 
o
f
 
7
 
T
M
S
s
.
 
L
i
g
a
n
d
 
b
i
n
d
i
n
g
 
i
n
d
u
c
e
s
 
c
o
n
f
o
r
m
a
t
i
o
n
a
l
 
c
h
a
n
g
e
s
 
l
e
a
d
i
n
g
 
t
o
 
t
h
e
 
a
c
t
i
v
a
t
i
o
n
 
o
f
 
c
y
t
o
p
l
a
s
m
a
t
i
c
 
G
-
p
r
o
t
e
i
n
s
.
 
G
P
C
R
s
 
a
n
d
 
G
P
C
R
 
d
e
p
e
n
d
e
n
t
 
s
i
g
n
a
l
l
i
n
g
 
p
a
t
h
w
a
y
s
 
o
f
 
h
i
g
h
e
r
 
o
r
g
a
n
i
s
m
s
 
h
a
v
e
 
b
e
c
o
m
e
 
p
r
o
m
i
n
e
n
t
 
d
r
u
g
 
t
a
r
g
e
t
s
 
a
n
d
 
t
h
e
r
e
 
i
s
 
a
 
r
a
p
i
d
l
y
 
i
n
c
r
e
a
s
i
n
g
 
d
e
m
a
n
d
 
f
o
r
 
t
h
e
 
i
d
e
n
t
i
f
i
c
a
t
i
o
n
 
o
f
 
n
e
w
 
G
P
C
R
 
l
i
g
a
n
d
 
a
n
a
l
o
g
u
e
s
.
 
T
h
e
 
s
t
r
u
c
t
u
r
a
l
 
c
h
a
r
a
c
t
e
r
i
z
a
t
i
o
n
 
o
f
 
t
h
e
s
e
 
p
r
o
t
e
i
n
s
 
i
s
 
a
n
 
e
s
s
e
n
t
i
a
l
 
p
r
e
r
e
q
u
i
s
i
t
e
 
f
o
r
 
d
i
r
e
c
t
e
d
 
d
r
u
g
 
s
c
r
e
e
n
i
n
g
 
a
p
p
r
o
a
c
h
e
s
.
 
H
o
w
e
v
e
r
,
 
G
P
C
R
s
 
a
r
e
 
g
e
n
e
r
a
l
l
y
 
o
f
 
l
o
w
 
n
a
t
u
r
a
l
 
a
b
u
n
d
a
n
c
e
 
a
n
d
 
e
f
f
i
c
i
e
n
t
 
o
v
e
r
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
a
r
e
 
t
h
e
r
e
f
o
r
e
 
i
n
d
i
s
p
e
n
s
a
b
l
e
.
 
E
.
 
c
o
l
i
 
s
t
r
a
i
n
s
 
s
h
o
w
 
i
n
 
m
o
s
t
 
c
a
s
e
s
 
o
n
l
y
 
v
e
r
y
 
l
o
w
 
G
P
C
R
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
 
w
i
t
h
 
o
f
t
e
n
 
l
e
s
s
 
t
h
a
n
 
2
0
0
 
r
e
c
e
p
t
o
r
s
 
p
e
r
 
c
e
l
l
 
(
2
9
,
 
3
0
)
.
 
A
 
r
a
r
e
 
e
x
c
e
p
t
i
o
n
 
w
i
t
h
 
u
p
 
t
o
 
3
5
0
0
 
c
o
p
i
e
s
 
p
e
r
 
E
.
 
c
o
l
i
 
c
e
l
l
 
(
r
e
s
u
l
t
i
n
g
 
i
n
 
0
.
6
6
 
m
g
 
p
e
r
 
l
i
t
r
e
 
c
u
l
t
u
r
e
)
 
o
f
 
f
u
n
c
t
i
o
n
a
l
 
m
u
s
c
a
r
i
n
i
c
 
m
1
 
r
e
c
e
p
t
o
r
 
i
s
 
r
e
p
o
r
t
e
d
 
(
3
1
)
.
 
H
o
w
e
v
e
r
,
 
t
h
e
 
o
v
e
r
p
r
o
d
u
c
e
d
 
G
P
C
R
s
 
g
e
n
e
r
a
l
l
y
 
a
c
c
u
m
u
l
a
t
e
 
i
n
 
E
.
 
c
o
l
i
 
a
s
 
i
n
c
l
u
s
i
o
n
 
b
o
d
i
e
s
.
 
T
h
e
 
p
o
s
s
i
b
i
l
i
t
y
 
o
f
 
p
o
s
t
-
t
r
a
n
s
l
a
t
i
o
n
a
l
 
m
o
d
i
f
i
c
a
t
i
o
n
s
 
m
a
k
e
 
y
e
a
s
t
 
s
t
r
a
i
n
s
 
i
n
t
e
r
e
s
t
i
n
g
 
f
o
r
 
t
h
e
 
o
v
e
r
p
r
o
d
u
c
t
i
o
n
 
o
f
 
t
h
e
 
e
u
k
a
r
y
o
t
i
c
 
G
P
C
R
s
 
a
n
d
 
i
m
p
r
o
v
e
d
 
e
x
p
r
e
s
s
i
o
n
 
c
o
n
d
i
t
i
o
n
s
 
r
e
s
u
l
t
e
d
 
i
n
 
 
1
2
 
t
h
e
 
d
e
t
e
c
t
i
o
n
 
o
f
 
s
e
v
e
r
a
l
 
f
u
n
c
t
i
o
n
a
l
l
y
 
s
y
n
t
h
e
s
i
z
e
d
 
G
P
C
R
s
 
(
3
2
)
.
 
R
e
p
o
r
t
e
d
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
 
w
e
r
e
 
g
e
n
e
r
a
l
l
y
 
a
p
p
r
o
x
 
1
-
2
 
p
m
o
l
/
m
g
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
 
w
i
t
h
 
s
o
m
e
 
e
x
c
e
p
t
i
o
n
s
 
o
f
 
1
0
 
p
m
o
l
/
m
g
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
 
i
n
 
c
a
s
e
 
o
f
 
t
h
e
 
s
e
r
o
t
o
n
i
n
 
5
-
H
T
5
A
,
 
ß
2
-
 
a
n
d
 
α
2
-
a
d
r
e
n
e
r
g
i
c
 
a
n
d
 
e
n
d
o
t
h
e
l
i
n
 
B
 
r
e
c
e
p
t
o
r
s
 
(
3
3
)
.
 
T
h
e
 
c
l
o
s
e
s
t
 
a
l
t
e
r
n
a
t
i
v
e
 
t
o
 
t
h
e
i
r
 
n
a
t
i
v
e
 
e
n
v
i
r
o
n
m
e
n
t
 
i
s
 
t
h
e
 
o
v
e
r
e
x
p
r
e
s
s
i
o
n
 
o
f
 
G
P
C
R
s
 
i
n
 
m
a
m
m
a
l
i
a
n
 
o
r
 
i
n
s
e
c
t
 
c
e
l
l
s
 
e
s
p
e
c
i
a
l
l
y
 
w
h
e
n
 
p
o
s
t
-
t
r
a
n
s
l
a
t
i
o
n
a
l
 
m
o
d
i
f
i
c
a
t
i
o
n
s
 
a
r
e
 
a
 
p
r
e
r
e
q
u
i
s
i
t
e
 
f
o
r
 
f
u
n
c
t
i
o
n
a
l
 
s
t
u
d
i
e
s
.
 
T
h
e
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
 
u
s
u
a
l
l
y
 
d
o
 
n
o
t
 
e
x
c
e
e
d
 
5
-
1
0
 
p
m
o
l
/
m
g
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
 
i
n
 
a
d
h
e
r
e
n
t
 
c
e
l
l
-
l
i
n
e
s
 
a
n
d
 
t
h
e
y
 
a
r
e
 
o
f
t
e
n
 
l
o
w
e
r
 
i
n
 
s
u
s
p
e
n
s
i
o
n
 
c
u
l
t
u
r
e
s
 
(
3
4
)
.
 
 
T
h
e
 
h
u
m
a
n
 
ß
2
 
a
d
r
e
n
e
r
g
i
c
 
r
e
c
e
p
t
o
r
 
(
ß
2
A
R
)
,
 
t
h
e
 
h
u
m
a
n
 
M
2
 
m
u
s
c
a
r
i
n
i
c
 
a
c
e
t
y
l
c
h
o
l
i
n
e
 
r
e
c
e
p
t
o
r
 
(
M
2
)
 
a
n
d
 
t
h
e
 
r
a
t
 
n
e
u
r
o
t
e
n
s
i
n
 
r
e
c
e
p
t
o
r
 
(
N
T
R
)
 
c
o
u
l
d
 
b
e
 
s
y
n
t
h
e
s
i
z
e
d
 
i
n
 
b
a
t
c
h
 
C
F
 
s
y
s
t
e
m
s
 
i
n
 
a
m
o
u
n
t
s
 
o
f
 
1
5
0
-
2
0
0
 
µ
g
 
s
y
n
t
h
e
s
i
z
e
d
 
p
r
o
t
e
i
n
 
p
e
r
 
m
l
 
R
M
 
(
1
3
)
.
 
T
h
e
 
p
r
o
t
e
i
n
s
 
h
a
d
 
t
o
 
b
e
 
p
r
o
d
u
c
e
d
 
a
s
 
t
r
a
n
s
l
a
t
i
o
n
a
l
 
f
u
s
i
o
n
s
 
C
-
t
e
r
m
i
n
a
l
 
t
o
 
t
h
i
o
r
e
d
o
x
i
n
 
a
n
d
 
a
l
m
o
s
t
 
n
o
 
p
r
o
t
e
i
n
 
p
r
o
d
u
c
t
i
o
n
 
w
a
s
 
d
e
t
e
c
t
e
d
 
w
i
t
h
 
t
h
e
 
n
a
t
i
v
e
 
n
o
n
-
f
u
s
e
d
 
c
o
d
i
n
g
 
r
e
g
i
o
n
s
.
 
T
h
e
 
a
u
t
h
o
r
s
 
s
p
e
c
u
l
a
t
e
d
 
t
h
a
t
 
s
t
a
b
i
l
i
z
a
t
i
o
n
 
o
f
 
t
h
e
 
G
P
C
R
s
 
b
y
 
t
h
e
 
N
-
t
e
r
m
i
n
a
l
 
t
h
i
o
r
e
d
o
x
i
n
 
o
r
 
i
m
p
r
o
v
e
d
 
t
r
a
n
s
l
a
t
i
o
n
 
e
f
f
i
c
i
e
n
c
i
e
s
 
m
i
g
h
t
 
a
c
c
o
u
n
t
 
f
o
r
 
t
h
a
t
 
o
b
s
e
r
v
a
t
i
o
n
.
 
T
h
e
 
f
i
n
a
l
 
s
i
z
e
 
o
f
 
t
h
e
 
r
e
c
o
m
b
i
n
a
n
t
 
I
M
P
s
 
w
a
s
 
i
n
 
b
e
t
w
e
e
n
 
5
3
 
-
 
1
0
9
 
k
D
a
 
a
n
d
 
e
v
e
n
 
t
h
e
 
l
a
r
g
e
r
 
c
o
n
s
t
r
u
c
t
s
 
w
e
r
e
 
s
y
n
t
h
e
s
i
z
e
d
 
w
i
t
h
o
u
t
 
s
i
g
n
i
f
i
c
a
n
t
 
l
o
s
s
 
o
f
 
e
f
f
i
c
i
e
n
c
y
.
 
I
n
 
C
E
C
F
 
s
y
s
t
e
m
s
,
 
t
h
e
 
f
i
n
a
l
 
y
i
e
l
d
 
w
a
s
 
i
m
p
r
o
v
e
d
 
t
o
 
a
p
p
r
o
x
.
 
1
 
m
g
 
G
P
C
R
 
p
e
r
 
m
l
 
R
M
 
w
i
t
h
i
n
 
8
 
h
o
u
r
s
 
o
f
 
r
e
a
c
t
i
o
n
.
 
T
h
e
 
C
F
 
p
r
o
d
u
c
e
d
 
t
h
i
o
r
e
d
o
x
i
n
 
f
u
s
e
d
 
ß
2
A
R
 
p
r
o
t
e
i
n
 
w
a
s
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
i
n
t
o
 
p
r
e
f
o
r
m
e
d
 
p
h
o
s
p
h
o
l
i
p
i
d
 
v
e
s
i
c
l
e
s
 
b
y
 
d
i
a
l
y
s
i
s
 
a
n
d
 
b
i
n
d
i
n
g
 
s
t
u
d
i
e
s
 
w
e
r
e
 
p
e
r
f
o
r
m
e
d
 
w
i
t
h
 
t
h
e
 
r
a
d
i
o
a
c
t
i
v
e
 
l
a
b
e
l
l
e
d
 
s
u
b
s
t
r
a
t
e
 
[
3
H
]
d
i
h
y
d
r
o
a
l
p
r
e
n
o
l
o
l
 
(
1
3
)
.
 
T
h
e
 
c
a
l
c
u
l
a
t
e
d
 
K
d
 
o
f
 
t
h
e
 
C
F
 
e
x
p
r
e
s
s
e
d
 
ß
2
A
R
 
w
a
s
 
d
e
t
e
r
m
i
n
e
d
 
t
o
 
5
.
5
 
n
M
 
a
n
d
 
i
t
 
i
s
 
c
o
m
p
a
r
a
b
l
e
 
t
o
 
t
h
e
 
K
d
 
o
f
 
3
.
9
 
n
M
 
o
f
 
ß
2
A
R
 
i
s
o
l
a
t
e
d
 
f
r
o
m
 
S
f
9
 
i
n
s
e
c
t
 
c
e
l
l
s
.
 
C
o
m
p
e
t
i
t
i
o
n
 
s
t
u
d
i
e
s
 
w
i
t
h
 
n
o
n
-
l
a
b
e
l
l
e
d
 
d
i
h
y
d
r
o
a
l
p
r
e
n
o
l
o
l
 
r
e
s
u
l
t
e
d
 
i
n
 
E
C
5
0
 
v
a
l
u
e
s
 
o
f
 
2
.
2
 
x
 
1
0
-
8
 
M
 
w
i
t
h
 
C
F
 
e
x
p
r
e
s
s
e
d
 
ß
2
A
R
 
a
n
d
 
o
f
 
1
.
0
 
x
 
1
0
-
8
 
M
 
w
i
t
h
 
S
f
9
-
e
x
p
r
e
s
s
e
d
 
ß
2
A
R
 
i
n
 
o
n
e
-
s
i
t
e
 
c
o
m
p
e
t
i
t
i
o
n
 
a
n
a
l
y
s
e
s
.
 
 
 
A
m
o
u
n
t
s
 
o
f
 
u
p
 
t
o
 
3
 
m
g
 
p
e
r
 
m
l
 
R
M
 
c
a
n
 
b
e
 
o
b
t
a
i
n
e
d
 
f
o
r
 
t
h
e
 
p
o
r
c
i
n
e
 
v
a
s
o
p
r
e
s
s
i
n
 
r
e
c
e
p
t
o
r
 
t
y
p
e
 
2
 
(
V
2
R
)
 
c
o
n
t
a
i
n
i
n
g
 
o
n
l
y
 
a
 
s
m
a
l
l
 
a
m
i
n
o
-
t
e
r
m
i
n
a
l
 
T
7
 
t
a
g
 
f
u
s
i
o
n
 
i
n
 
a
n
 
i
n
d
i
v
i
d
u
a
l
 
C
E
C
F
 
s
e
t
-
u
p
 
(
2
4
)
.
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
w
i
t
h
o
u
t
 
t
h
e
 
1
4
 
a
m
i
n
o
 
a
c
i
d
 
T
7
 
t
a
g
 
f
u
s
i
o
n
 
r
e
s
u
l
t
e
d
 
o
n
l
y
 
i
n
 
s
p
u
r
i
o
u
s
 
e
x
p
r
e
s
s
i
o
n
 
w
h
i
c
h
 
i
s
 
i
n
 
a
g
r
e
e
m
e
n
t
 
t
o
 
t
h
e
 
a
b
o
v
e
 
m
e
n
t
i
o
n
e
d
 
o
b
s
e
r
v
a
t
i
o
n
s
 
w
i
t
h
 
t
h
e
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
t
h
e
 
G
P
C
R
s
 
ß
2
A
R
,
 
M
2
 
a
n
d
 
N
T
R
.
 
S
a
m
e
 
o
b
s
e
r
v
a
t
i
o
n
s
 
w
e
r
e
 
m
a
d
e
 
f
o
r
 
t
h
r
e
e
 
f
u
r
t
h
e
r
 
G
P
C
R
 
p
r
o
t
e
i
n
s
,
 
t
h
e
 
h
u
m
a
n
 
e
n
d
o
t
h
e
l
i
n
 
B
 
r
e
c
e
p
t
o
r
 
(
E
T
B
)
,
 
t
h
e
 
r
a
t
 
c
o
r
t
i
c
o
t
r
o
p
i
n
 
r
e
l
e
a
s
i
n
g
 
f
a
c
t
o
r
 
r
e
c
e
p
t
o
r
 
(
C
R
F
)
 
a
n
d
 
t
h
e
 
h
u
m
a
n
 
V
2
R
 
(
F
i
g
.
 
2
)
.
 
 
 
2
.
3
.
 
ß
-
b
a
r
r
e
l
 
p
r
o
t
e
i
n
s
 
T
h
e
 
o
u
t
e
r
 
m
e
m
b
r
a
n
e
 
o
f
 
g
r
a
m
-
n
e
g
a
t
i
v
e
 
b
a
c
t
e
r
i
a
 
f
o
r
m
s
 
a
 
p
r
o
t
e
c
t
i
v
e
 
p
e
r
m
e
a
b
i
l
i
t
y
 
b
a
r
r
i
e
r
 
a
r
o
u
n
d
 
t
h
e
 
c
e
l
l
s
 
a
n
d
 
s
e
r
v
e
s
 
a
s
 
a
 
m
o
l
e
c
u
l
a
r
 
f
i
l
t
e
r
 
f
o
r
 
h
y
d
r
o
p
h
i
l
i
c
 
s
u
b
s
t
a
n
c
e
s
.
 
O
u
t
e
r
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
  
1
3
 
(
O
M
P
s
)
 
o
f
t
e
n
 
s
h
o
w
 
t
h
e
 
g
e
n
e
r
a
l
 
a
r
c
h
i
t
e
c
t
u
r
e
 
o
f
 
m
e
m
b
r
a
n
e
-
s
p
a
n
n
i
n
g
 
ß
-
b
a
r
r
e
l
s
 
w
h
i
c
h
 
a
r
e
 
s
e
l
f
-
c
l
o
s
e
d
 
ß
-
s
h
e
e
t
s
.
 
T
h
i
s
 
t
o
p
o
l
o
g
y
 
c
o
n
t
r
a
s
t
s
 
t
h
e
 
t
y
p
i
c
a
l
 
s
t
r
u
c
t
u
r
e
 
o
f
 
i
n
n
e
r
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
w
i
t
h
 
s
i
n
g
l
e
 
o
r
 
m
u
l
t
i
p
l
e
 
m
e
m
b
r
a
n
e
-
s
p
a
n
n
i
n
g
 
α
-
h
e
l
i
c
e
s
.
 
B
a
s
e
d
 
o
n
 
t
h
e
i
r
 
t
r
a
n
s
p
o
r
t
 
m
e
c
h
a
n
i
s
m
s
,
 
O
M
P
s
 
c
a
n
 
b
e
 
d
i
v
i
d
e
d
 
i
n
t
o
 
t
h
e
 
c
l
a
s
s
e
s
 
o
f
 
g
e
n
e
r
a
l
 
p
o
r
i
n
s
,
 
s
u
b
s
t
r
a
t
e
 
s
p
e
c
i
f
i
c
 
t
r
a
n
s
p
o
r
t
e
r
s
 
a
n
d
 
a
c
t
i
v
e
 
t
r
a
n
s
p
o
r
t
e
r
s
.
 
T
h
e
 
s
u
b
s
t
r
a
t
e
-
s
p
e
c
i
f
i
c
 
t
r
a
n
s
p
o
r
t
e
r
s
 
c
o
n
t
a
i
n
 
l
o
w
-
a
f
f
i
n
i
t
y
 
s
u
b
s
t
r
a
t
e
-
b
i
n
d
i
n
g
 
s
i
t
e
s
 
t
h
a
t
 
a
r
e
 
s
a
t
u
r
a
b
l
e
 
a
n
d
 
a
l
l
o
w
 
e
f
f
i
c
i
e
n
t
 
d
i
f
f
u
s
i
o
n
 
o
f
 
s
u
b
s
t
r
a
t
e
s
 
a
t
 
v
e
r
y
 
s
h
a
l
l
o
w
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
g
r
a
d
i
e
n
t
s
.
 
T
h
e
 
E
.
 
c
o
l
i
 
n
u
c
l
e
o
s
i
d
e
 
t
r
a
n
s
p
o
r
t
e
r
 
T
s
x
 
b
e
l
o
n
g
s
 
t
o
 
t
h
i
s
 
c
l
a
s
s
 
(
3
5
,
 
3
6
)
.
 
T
s
x
 
i
s
 
s
o
 
f
a
r
 
t
h
e
 
o
n
l
y
 
C
F
 
p
r
o
d
u
c
e
d
 
O
M
P
 
a
n
d
 
e
x
a
m
p
l
e
 
f
o
r
 
t
h
e
 
h
i
g
h
 
l
e
v
e
l
 
p
r
o
d
u
c
t
i
o
n
 
a
n
d
 
f
u
n
c
t
i
o
n
a
l
 
r
e
c
o
n
s
t
i
t
u
t
i
o
n
 
o
f
 
t
h
i
s
 
g
r
o
u
p
 
o
f
 
t
r
a
n
s
p
o
r
t
 
p
r
o
t
e
i
n
s
 
(
2
4
)
.
 
T
s
x
 
w
a
s
 
e
x
p
r
e
s
s
e
d
 
i
n
 
s
t
a
n
d
a
r
d
 
C
F
 
s
e
t
-
u
p
s
 
i
n
 
l
e
v
e
l
s
 
u
p
 
t
o
 
4
 
m
g
 
p
e
r
 
s
i
n
g
l
e
 
m
l
 
o
f
 
R
M
 
e
i
t
h
e
r
 
a
s
 
p
r
e
c
i
p
i
t
a
t
e
 
o
r
 
a
s
 
s
o
l
u
b
l
e
 
p
r
o
t
e
i
n
s
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
v
a
r
i
o
u
s
 
d
e
t
e
r
g
e
n
t
s
 
l
i
k
e
 
B
r
i
j
-
3
5
,
 
B
r
i
j
-
7
8
,
 
T
X
-
1
0
0
 
o
r
 
o
t
h
e
r
s
 
(
F
i
g
.
 
2
)
.
 
C
o
n
d
u
c
t
a
n
c
e
 
m
e
a
s
u
r
e
m
e
n
t
s
 
o
f
 
C
F
 
p
r
o
d
u
c
e
d
 
T
s
x
 
i
n
 
p
l
a
n
a
r
 
m
e
m
b
r
a
n
e
s
 
i
n
d
i
c
a
t
e
d
 
a
 
c
l
e
a
r
 
d
e
p
e
n
d
e
n
c
e
 
o
f
 
a
c
t
i
v
i
t
y
 
o
n
 
t
h
e
 
m
o
d
e
 
o
f
 
e
x
p
r
e
s
s
i
o
n
.
 
O
n
l
y
 
s
o
l
u
b
l
e
 
e
x
p
r
e
s
s
e
d
 
T
s
x
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
d
i
s
t
i
n
c
t
 
d
e
t
e
r
g
e
n
t
s
 
s
h
o
w
e
d
 
p
o
r
e
 
f
o
r
m
i
n
g
 
a
c
t
i
v
i
t
y
.
 
T
h
e
 
h
i
g
h
-
l
e
v
e
l
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
I
M
P
s
 
d
o
e
s
 
t
h
e
r
e
f
o
r
e
 
n
o
t
 
a
l
w
a
y
s
 
r
e
s
u
l
t
 
i
n
 
f
u
n
c
t
i
o
n
a
l
l
y
 
f
o
l
d
e
d
 
p
r
o
t
e
i
n
.
 
S
o
l
u
b
i
l
i
z
e
d
 
T
s
x
 
p
r
e
c
i
p
i
t
a
t
e
 
d
i
d
 
n
o
t
 
s
h
o
w
 
a
n
y
 
a
c
t
i
v
i
t
y
 
a
n
d
 
t
h
e
 
e
f
f
i
c
i
e
n
t
 
f
o
l
d
i
n
g
 
o
f
 
s
o
l
u
b
l
e
 
p
r
o
d
u
c
e
d
 
p
r
o
t
e
i
n
 
i
n
t
o
 
i
t
s
 
a
c
t
i
v
e
 
c
o
n
f
o
r
m
a
t
i
o
n
 
d
e
p
e
n
d
e
d
 
a
l
s
o
 
o
n
 
t
h
e
 
p
r
e
s
e
n
c
e
 
o
f
 
s
p
e
c
i
f
i
c
 
d
e
t
e
r
g
e
n
t
s
 
l
i
k
e
 
T
X
-
1
0
0
.
 
 
 
3
.
 
S
t
r
u
c
t
u
r
a
l
 
c
h
a
r
a
c
t
e
r
i
z
a
t
i
o
n
 
o
f
 
c
e
l
l
-
f
r
e
e
 
p
r
o
d
u
c
e
d
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
I
M
P
s
 
a
r
e
 
g
r
o
s
s
l
y
 
u
n
d
e
r
r
e
p
r
e
s
e
n
t
e
d
 
i
n
 
t
h
e
 
p
r
o
t
e
i
n
 
s
t
r
u
c
t
u
r
a
l
 
d
a
t
a
 
b
a
s
e
.
 
T
h
e
 
r
a
r
e
 
a
n
d
 
o
f
t
e
n
 
i
n
h
o
m
o
g
e
n
e
o
u
s
 
I
M
P
 
s
a
m
p
l
e
s
 
o
b
t
a
i
n
e
d
 
f
r
o
m
 
e
u
k
a
r
y
o
t
i
c
 
i
n
-
v
i
v
o
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
w
i
t
h
 
o
f
t
e
n
 
i
n
c
o
m
p
l
e
t
e
 
p
o
s
t
-
t
r
a
n
s
l
a
t
i
o
n
a
l
 
m
o
d
i
f
i
c
a
t
i
o
n
s
 
m
a
k
e
 
s
t
r
u
c
t
u
r
a
l
 
d
e
t
e
r
m
i
n
a
t
i
o
n
s
 
v
e
r
y
 
d
i
f
f
i
c
u
l
t
.
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
c
o
u
l
d
 
n
o
w
 
p
r
o
v
i
d
e
 
a
c
c
e
s
s
 
t
o
 
o
t
h
e
r
w
i
s
e
 
d
i
f
f
i
c
u
l
t
 
t
o
 
o
b
t
a
i
n
 
I
M
P
s
.
 
T
h
e
 
a
v
a
i
l
a
b
i
l
i
t
y
 
o
f
 
h
i
g
h
 
a
m
o
u
n
t
s
 
o
f
 
o
v
e
r
p
r
o
d
u
c
e
d
 
I
M
P
s
,
 
t
h
e
 
o
p
t
i
o
n
 
o
f
 
I
M
P
 
e
x
p
r
e
s
s
i
o
n
 
d
i
r
e
c
t
l
y
 
i
n
t
o
 
a
 
d
e
t
e
r
g
e
n
t
 
m
i
c
e
l
l
e
 
r
e
p
r
e
s
e
n
t
i
n
g
 
t
h
e
 
d
e
s
i
r
e
d
 
p
r
o
p
e
r
t
i
e
s
 
a
n
d
 
m
a
n
y
 
o
t
h
e
r
 
p
o
s
s
i
b
i
l
i
t
i
e
s
 
t
o
 
s
t
a
b
i
l
i
z
e
 
o
r
 
t
o
 
m
o
d
i
f
y
 
t
h
e
 
s
y
n
t
h
e
s
i
z
e
d
 
I
M
P
s
 
a
r
e
 
v
a
l
u
a
b
l
e
 
p
r
o
p
e
r
t
i
e
s
 
o
f
 
t
h
e
 
C
F
 
t
e
c
h
n
i
q
u
e
.
 
T
h
e
 
v
e
r
s
a
t
i
l
i
t
y
,
 
s
p
e
e
d
i
n
e
s
s
 
a
n
d
 
t
h
e
 
a
d
v
a
n
t
a
g
e
s
 
o
f
 
C
F
 
s
y
s
t
e
m
s
 
i
n
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
l
a
b
e
l
l
e
d
 
I
M
P
s
 
p
r
o
m
i
s
e
 
t
h
e
r
e
f
o
r
e
 
c
o
n
s
i
d
e
r
a
b
l
e
 
p
r
o
g
r
e
s
s
 
f
o
r
 
h
i
g
h
 
r
e
s
o
l
u
t
i
o
n
 
s
t
r
u
c
t
u
r
a
l
 
a
n
a
l
y
s
i
s
 
b
y
 
N
M
R
 
s
p
e
c
t
r
o
s
c
o
p
y
 
a
s
 
w
e
l
l
 
a
s
 
b
y
 
X
-
r
a
y
 
c
r
y
s
t
a
l
l
o
g
r
a
p
h
y
.
 
 
 
 
3
.
1
.
 
C
r
y
s
t
a
l
l
i
z
a
t
i
o
n
 
o
f
 
c
e
l
l
-
f
r
e
e
 
p
r
o
d
u
c
e
d
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
C
r
y
s
t
a
l
l
i
z
a
t
i
o
n
 
o
f
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
i
s
 
a
 
c
o
m
p
l
i
c
a
t
e
d
 
p
r
o
c
e
s
s
 
d
u
e
 
t
o
 
n
o
n
p
r
e
d
i
c
t
a
b
l
e
 
i
n
f
l
u
e
n
c
e
s
 
o
f
 
a
d
d
i
t
i
v
e
s
 
l
i
k
e
 
d
e
t
e
r
g
e
n
t
s
 
o
r
 
l
i
p
i
d
s
 
a
n
d
 
i
t
 
i
s
 
m
o
s
t
l
y
 
l
i
m
i
t
e
d
 
b
y
 
t
h
e
 
l
a
c
k
 
o
f
 
s
u
f
f
i
c
i
e
n
t
 
a
m
o
u
n
t
s
 
o
f
 
p
r
o
t
e
i
n
.
 
M
o
r
e
 
t
h
a
n
 
2
5
.
0
0
0
 
p
r
o
t
e
i
n
 
s
t
r
u
c
t
u
r
e
s
 
h
a
v
e
 
b
e
e
n
 
s
o
l
v
e
d
 
b
y
 
X
-
r
a
y
 
 
1
4
 
c
r
y
s
t
a
l
l
o
g
r
a
p
h
y
 
b
u
t
 
o
n
l
y
 
s
o
m
e
 
6
0
 
o
f
 
t
h
e
m
 
r
e
p
r
e
s
e
n
t
 
m
e
m
b
e
r
s
 
o
f
 
t
h
e
 
f
a
m
i
l
y
 
o
f
 
I
M
P
s
.
 
R
e
c
e
n
t
l
y
 
t
h
e
 
f
i
r
s
t
 
X
-
r
a
y
 
s
t
r
u
c
t
u
r
e
 
b
y
 
t
a
k
i
n
g
 
a
d
v
a
n
t
a
g
e
 
o
f
 
a
 
C
F
 
p
r
o
d
u
c
e
d
 
I
M
P
 
w
a
s
 
p
r
e
s
e
n
t
e
d
 
(
1
6
)
.
 
S
e
M
e
t
-
l
a
b
e
l
l
e
d
 
s
a
m
p
l
e
s
 
o
f
 
t
h
e
 
s
m
a
l
l
 
m
u
l
t
i
d
r
u
g
 
t
r
a
n
s
p
o
r
t
e
r
 
E
m
r
E
 
w
e
r
e
 
p
r
o
d
u
c
e
d
 
i
n
 
a
 
c
o
m
m
e
r
c
i
a
l
l
y
 
a
v
a
i
l
a
b
l
e
 
C
F
 
b
a
t
c
h
 
s
y
s
t
e
m
 
(
I
n
v
i
t
r
o
g
e
n
,
 
C
a
r
l
s
b
a
d
,
 
U
S
A
)
 
b
a
s
e
d
 
o
n
 
E
.
 
c
o
l
i
 
l
y
s
a
t
e
s
.
 
T
h
e
 
R
M
 
c
o
n
t
a
i
n
e
d
 
4
.
5
 
m
M
 
S
e
M
e
t
 
a
n
d
 
w
a
s
 
s
u
p
p
l
e
m
e
n
t
e
d
 
w
i
t
h
 
2
 
m
g
 
D
M
P
C
 
p
e
r
 
m
l
 
a
n
d
 
w
i
t
h
 
s
u
b
s
t
r
a
t
e
s
 
l
i
k
e
 
T
P
P
+
.
 
E
m
r
E
 
w
a
s
 
p
r
o
d
u
c
e
d
 
a
s
 
s
o
l
u
b
l
e
 
p
r
o
t
e
i
n
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
t
h
e
 
p
r
e
f
o
r
m
e
d
 
D
M
P
C
 
l
i
p
o
s
o
m
e
s
 
a
t
 
a
n
 
a
v
e
r
a
g
e
 
o
f
 
0
.
2
 
m
g
 
p
e
r
 
o
n
e
 
m
l
 
R
M
.
 
E
m
r
E
 
c
r
y
s
t
a
l
s
 
u
s
e
d
 
f
o
r
 
s
t
r
u
c
t
u
r
e
 
d
e
t
e
r
m
i
n
a
t
i
o
n
 
a
n
d
 
S
e
M
e
t
-
E
m
r
E
-
T
P
P
+
 
c
r
y
s
t
a
l
s
 
w
e
r
e
 
g
r
o
w
n
 
u
s
i
n
g
 
s
i
m
i
l
a
r
 
c
o
n
d
i
t
i
o
n
s
.
 
T
h
e
 
a
n
a
l
y
s
i
s
 
r
e
v
e
a
l
e
d
 
a
n
 
a
n
t
i
p
a
r
a
l
l
e
l
 
E
m
r
E
 
h
o
m
o
d
i
m
e
r
 
w
i
t
h
 
o
n
e
 
b
o
u
n
d
 
T
P
P
+
 
t
h
a
t
 
i
s
 
c
o
n
s
i
s
t
e
n
t
 
w
i
t
h
 
o
t
h
e
r
 
b
i
o
c
h
e
m
i
c
a
l
 
s
t
u
d
i
e
s
.
 
T
h
e
 
t
w
o
 
s
u
b
u
n
i
t
s
 
a
d
o
p
t
 
s
l
i
g
h
t
l
y
 
d
i
f
f
e
r
e
n
t
 
t
e
r
t
i
a
r
y
 
f
o
l
d
s
 
w
h
i
c
h
 
s
e
e
m
 
t
o
 
p
l
a
y
 
a
n
 
i
m
p
o
r
t
a
n
t
 
r
o
l
e
 
i
n
 
s
u
b
s
t
r
a
t
e
 
t
r
a
n
s
p
o
r
t
 
a
n
d
 
H
+
 
a
n
t
i
p
o
r
t
.
 
T
h
i
s
 
f
i
r
s
t
 
r
e
p
o
r
t
 
d
e
m
o
n
s
t
r
a
t
e
s
 
t
h
a
t
 
t
h
e
 
q
u
a
l
i
t
y
 
o
f
 
C
F
 
p
r
o
d
u
c
e
d
 
I
M
P
 
s
a
m
p
l
e
s
 
i
s
 
s
u
f
f
i
c
i
e
n
t
 
f
o
r
 
c
r
y
s
t
a
l
l
i
z
a
t
i
o
n
 
a
n
d
 
t
h
e
 
t
e
c
h
n
i
q
u
e
 
m
i
g
h
t
 
t
h
e
r
e
f
o
r
e
 
a
t
t
r
a
c
t
 
i
n
c
r
e
a
s
i
n
g
 
a
t
t
e
n
t
i
o
n
 
f
o
r
 
t
h
e
 
s
a
m
p
l
e
 
p
r
e
p
a
r
a
t
i
o
n
 
f
o
r
 
X
-
r
a
y
 
a
n
a
l
y
s
i
s
 
s
t
u
d
i
e
s
.
 
 
3
.
2
.
 
C
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
a
s
 
t
o
o
l
 
f
o
r
 
h
i
g
h
 
r
e
s
o
l
u
t
i
o
n
 
N
M
R
 
s
p
e
c
t
r
o
s
c
o
p
y
 
T
h
i
s
 
s
e
c
t
i
o
n
 
d
e
s
c
r
i
b
e
s
 
s
t
r
a
t
e
g
i
e
s
 
i
n
 
s
a
m
p
l
e
 
p
r
e
p
a
r
a
t
i
o
n
 
o
f
 
I
M
P
s
 
b
y
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
i
n
 
c
o
m
b
i
n
a
t
i
o
n
 
w
i
t
h
 
h
i
g
h
 
r
e
s
o
l
u
t
i
o
n
 
N
M
R
 
s
p
e
c
t
r
o
s
c
o
p
y
.
 
S
a
m
p
l
e
 
p
r
e
p
a
r
a
t
i
o
n
 
h
a
s
 
c
o
n
s
i
d
e
r
a
b
l
e
 
i
n
f
l
u
e
n
c
e
 
o
n
 
s
p
e
c
t
r
u
m
 
q
u
a
l
i
t
y
.
 
A
n
 
i
n
d
i
s
p
e
n
s
a
b
l
e
 
p
r
e
r
e
q
u
i
s
i
t
e
 
f
o
r
 
t
h
e
 
N
M
R
 
s
p
e
c
t
r
o
s
c
o
p
y
 
o
f
 
l
a
r
g
e
r
 
p
r
o
t
e
i
n
s
 
i
s
 
t
h
e
 
p
r
e
p
a
r
a
t
i
o
n
 
o
f
 
s
a
m
p
l
e
s
 
t
h
a
t
 
h
a
v
e
 
b
e
e
n
 
l
a
b
e
l
l
e
d
 
i
n
d
i
v
i
d
u
a
l
l
y
 
o
r
 
w
i
t
h
 
c
o
m
b
i
n
a
t
i
o
n
s
 
o
f
 
t
h
e
 
s
t
a
b
l
e
 
i
s
o
t
o
p
e
s
 
2
H
,
 
1
3
C
 
a
n
d
 
1
5
N
.
 
T
h
e
 
f
u
l
l
 
l
a
b
e
l
l
i
n
g
 
o
f
 
a
 
p
r
o
t
e
i
n
 
r
e
q
u
i
r
e
s
 
t
h
e
 
g
r
o
w
t
h
 
o
f
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
s
t
r
a
i
n
 
i
n
 
d
e
f
i
n
e
d
 
m
e
d
i
u
m
 
s
u
p
p
l
e
m
e
n
t
e
d
 
w
i
t
h
 
p
r
e
c
u
r
s
o
r
s
 
t
h
a
t
 
a
r
e
 
l
a
b
e
l
l
e
d
 
w
i
t
h
 
t
h
e
 
d
e
s
i
r
e
d
 
i
s
o
t
o
p
e
.
 
F
o
r
 
a
m
i
n
o
 
a
c
i
d
 
s
p
e
c
i
f
i
c
 
l
a
b
e
l
l
i
n
g
 
a
p
p
r
o
a
c
h
e
s
,
 
u
s
u
a
l
l
y
 
E
.
 
c
o
l
i
 
s
t
r
a
i
n
s
 
h
a
v
e
 
t
o
 
b
e
 
e
m
p
l
o
y
e
d
 
c
o
n
t
a
i
n
i
n
g
 
a
u
x
o
t
r
o
p
h
i
c
 
m
u
t
a
t
i
o
n
s
 
t
h
a
t
 
c
o
r
r
e
s
p
o
n
d
 
t
o
 
t
h
e
 
p
r
o
v
i
d
e
d
 
l
a
b
e
l
l
e
d
 
a
m
i
n
o
 
a
c
i
d
.
 
C
o
n
v
e
n
t
i
o
n
a
l
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
c
a
n
 
c
a
u
s
e
 
c
o
n
s
i
d
e
r
a
b
l
e
 
p
r
o
b
l
e
m
s
 
u
p
o
n
 
p
r
o
t
e
i
n
 
l
a
b
e
l
l
i
n
g
 
l
i
k
e
 
i
n
c
o
m
p
l
e
t
e
 
l
a
b
e
l
 
i
n
c
o
r
p
o
r
a
t
i
o
n
,
 
l
a
b
e
l
 
s
c
r
a
m
b
l
i
n
g
,
 
m
e
t
a
b
o
l
i
c
 
c
o
n
v
e
r
s
i
o
n
 
o
f
 
t
h
e
 
l
a
b
e
l
l
e
d
 
p
r
e
c
u
r
s
o
r
s
 
o
r
 
r
e
d
u
c
e
d
 
y
i
e
l
d
s
 
i
f
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
t
h
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
t
h
e
 
u
n
l
a
b
e
l
l
e
d
 
r
e
c
o
m
b
i
n
a
n
t
 
p
r
o
t
e
i
n
.
 
E
s
p
e
c
i
a
l
l
y
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
a
p
p
r
o
a
c
h
e
s
 
i
n
 
w
h
i
c
h
 
s
e
v
e
r
a
l
 
d
i
f
f
e
r
e
n
t
 
a
m
i
n
o
 
a
c
i
d
 
t
y
p
e
s
 
h
a
v
e
 
t
o
 
b
e
 
l
a
b
e
l
l
e
d
 
c
a
n
 
b
e
c
o
m
e
 
e
x
t
r
e
m
e
l
y
 
d
i
f
f
i
c
u
l
t
 
a
n
d
 
i
n
e
f
f
i
c
i
e
n
t
.
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
p
r
o
v
i
d
e
s
 
g
e
n
e
r
a
l
l
y
 
a
n
 
i
n
t
e
r
e
s
t
i
n
g
 
a
l
t
e
r
n
a
t
i
v
e
 
t
o
o
l
 
f
o
r
 
t
h
e
 
f
a
s
t
 
a
n
d
 
e
f
f
i
c
i
e
n
t
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
l
a
b
e
l
l
e
d
 
p
r
o
t
e
i
n
 
s
a
m
p
l
e
s
.
 
T
h
e
 
c
o
m
p
l
e
t
e
 
l
a
b
e
l
 
i
n
c
o
r
p
o
r
a
t
i
o
n
 
i
s
 
e
n
s
u
r
e
d
 
a
s
 
n
o
 
u
n
l
a
b
e
l
l
e
d
 
a
m
i
n
o
 
a
c
i
d
s
 
a
r
e
 
p
r
e
s
e
n
t
 
i
n
 
t
h
e
 
r
e
a
c
t
i
o
n
.
 
M
o
r
e
o
v
e
r
,
 
n
o
 
a
u
x
o
t
r
o
p
h
i
c
 
m
u
t
a
t
i
o
n
s
 
a
r
e
 
n
e
e
d
e
d
 
a
s
 
a
n
y
 
a
m
i
n
o
 
a
c
i
d
 
c
a
n
 
b
e
 
s
i
m
p
l
y
 
r
e
p
l
a
c
e
d
 
i
n
 
t
h
e
 
r
e
a
c
t
i
o
n
 
m
i
x
t
u
r
e
s
 
b
y
 
a
 
l
a
b
e
l
l
e
d
 
d
e
r
i
v
a
t
i
v
e
.
 
T
h
i
s
 
o
p
t
i
o
n
 
i
s
 
v
e
r
y
 
a
t
t
r
a
c
t
i
v
e
 
f
o
r
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
l
a
b
e
l
l
i
n
g
 
a
p
p
r
o
a
c
h
e
s
 
a
n
d
 
p
r
o
t
e
i
n
 
d
e
r
i
v
a
t
i
v
e
s
 
w
i
t
h
  
1
5
 
a
n
y
 
l
a
b
e
l
 
c
o
m
b
i
n
a
t
i
o
n
s
 
c
a
n
 
b
e
 
g
e
n
e
r
a
t
e
d
 
w
i
t
h
 
t
h
e
 
s
a
m
e
 
e
f
f
i
c
i
e
n
c
i
e
s
 
a
s
 
t
h
e
 
u
n
l
a
b
e
l
l
e
d
 
p
r
o
t
e
i
n
s
 
a
s
 
t
h
e
 
o
v
e
r
a
l
l
 
r
e
a
c
t
i
o
n
 
c
o
n
d
i
t
i
o
n
s
 
h
a
v
e
 
n
o
t
 
t
o
 
b
e
 
m
o
d
i
f
i
e
d
.
 
S
a
m
p
l
e
 
p
r
e
p
a
r
a
t
i
o
n
 
w
i
t
h
 
i
n
-
v
i
v
o
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
c
a
n
 
f
u
r
t
h
e
r
m
o
r
e
 
t
a
k
e
 
s
e
v
e
r
a
l
 
d
a
y
s
 
t
o
 
w
e
e
k
s
 
(
3
7
,
 
3
8
)
 
w
h
i
l
e
 
C
F
 
r
e
a
c
t
i
o
n
s
 
a
r
e
 
c
o
m
p
l
e
t
e
d
 
w
i
t
h
i
n
 
1
2
 
h
o
u
r
s
.
 
 
 
A
 
f
u
r
t
h
e
r
 
a
s
p
e
c
t
 
i
s
 
t
h
e
 
p
r
e
p
a
r
a
t
i
o
n
 
o
f
 
h
i
g
h
l
y
 
d
e
u
t
e
r
a
t
e
d
 
p
r
o
t
e
i
n
 
s
a
m
p
l
e
s
 
i
n
 
o
r
d
e
r
 
t
o
 
a
t
t
e
n
u
a
t
e
 
t
r
a
n
s
v
e
r
s
e
 
r
e
l
a
x
a
t
i
o
n
 
r
a
t
e
s
 
a
n
d
 
t
o
 
i
m
p
r
o
v
e
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
d
 
r
e
s
o
l
u
t
i
o
n
 
i
n
 
N
M
R
 
s
p
e
c
t
r
a
.
 
D
e
u
t
e
r
a
t
e
d
 
p
r
o
t
e
i
n
 
s
a
m
p
l
e
s
 
a
r
e
 
u
s
u
a
l
l
y
 
g
e
n
e
r
a
t
e
d
 
b
y
 
g
r
o
w
i
n
g
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
s
t
r
a
i
n
s
 
i
n
 
a
l
m
o
s
t
 
p
u
r
e
 
D
2
O
 
s
u
p
p
l
e
m
e
n
t
e
d
 
w
i
t
h
 
t
h
e
 
r
e
q
u
i
r
e
d
 
n
u
t
r
i
e
n
t
s
.
 
H
o
w
e
v
e
r
,
 
s
t
a
t
e
 
o
f
 
t
h
e
 
a
r
t
 
N
M
R
 
m
e
t
h
o
d
o
l
o
g
i
e
s
 
f
o
r
 
p
r
o
t
e
i
n
 
b
a
c
k
b
o
n
e
 
a
s
s
i
g
n
m
e
n
t
 
r
e
l
y
 
o
n
 
t
h
e
 
b
a
c
k
-
e
x
c
h
a
n
g
e
 
o
f
 
2
H
 
t
o
 
1
H
 
o
r
 
a
t
 
l
e
a
s
t
 
o
n
 
a
 
h
i
g
h
 
o
c
c
u
p
a
n
c
y
 
o
f
 
p
r
o
t
o
n
s
 
a
t
 
t
h
e
 
a
m
i
d
e
 
p
o
s
i
t
i
o
n
s
 
o
f
 
d
e
u
t
e
r
a
t
e
d
 
p
r
o
t
e
i
n
s
 
d
u
r
i
n
g
 
t
h
e
i
r
 
i
s
o
l
a
t
i
o
n
 
i
n
 
a
q
u
e
o
u
s
 
s
o
l
u
t
i
o
n
s
 
(
3
9
)
.
 
A
n
 
i
n
c
o
m
p
l
e
t
e
 
b
a
c
k
-
e
x
c
h
a
n
g
e
 
m
a
y
 
l
e
a
d
 
t
o
 
s
i
g
n
i
f
i
c
a
n
t
 
l
o
s
s
 
o
f
 
s
i
g
n
a
l
s
 
a
n
d
 
p
o
o
r
 
b
a
c
k
-
e
x
c
h
a
n
g
e
 
m
a
y
 
b
e
 
a
g
g
r
a
v
a
t
e
d
 
f
o
r
 
h
y
d
r
o
p
h
o
b
i
c
 
I
M
P
s
 
a
n
d
 
i
n
 
p
a
r
t
i
c
u
l
a
r
 
f
o
r
 
r
e
s
i
d
u
e
s
 
i
n
 
t
h
e
 
h
y
d
r
o
p
h
o
b
i
c
 
T
M
S
 
r
e
g
i
o
n
s
 
(
4
0
)
.
 
T
h
e
r
e
f
o
r
e
,
 
u
n
f
o
l
d
i
n
g
 
a
n
d
 
r
e
f
o
l
d
i
n
g
 
o
f
 
i
s
o
l
a
t
e
d
 
p
r
o
t
e
i
n
s
 
t
h
a
t
 
h
a
v
e
 
b
e
e
n
 
p
r
o
d
u
c
e
d
 
i
n
 
c
o
n
v
e
n
t
i
o
n
a
l
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
b
y
 
e
m
p
l
o
y
i
n
g
 
d
e
n
a
t
u
r
a
n
t
s
 
s
u
c
h
 
a
s
 
6
 
M
 
u
r
e
a
 
o
r
 
G
u
a
n
i
d
i
u
m
 
H
C
l
 
a
r
e
 
o
f
t
e
n
 
n
e
c
e
s
s
a
r
y
 
(
4
1
)
.
 
W
i
t
h
 
C
F
 
e
x
p
r
e
s
s
i
o
n
,
 
d
e
u
t
e
r
a
t
e
d
 
a
m
i
n
o
 
a
c
i
d
s
 
c
a
n
 
b
e
 
p
r
o
v
i
d
e
d
 
a
n
d
 
a
l
l
 
l
a
b
i
l
e
 
d
e
u
t
e
r
a
t
e
d
 
p
o
s
i
t
i
o
n
s
 
w
i
l
l
 
a
l
r
e
a
d
y
 
e
f
f
i
c
i
e
n
t
l
y
 
b
a
c
k
-
e
x
c
h
a
n
g
e
 
i
n
 
t
h
e
 
a
q
u
e
o
u
s
 
r
e
a
c
t
i
o
n
 
m
i
x
t
u
r
e
s
 
b
e
f
o
r
e
 
t
h
e
 
a
m
i
n
o
 
a
c
i
d
s
 
w
i
l
l
 
b
e
c
o
m
e
 
i
n
s
e
r
t
e
d
 
i
n
t
o
 
t
h
e
 
g
r
o
w
i
n
g
 
p
e
p
t
i
d
e
 
c
h
a
i
n
.
 
A
 
c
o
m
p
l
e
t
e
 
b
a
c
k
-
e
x
c
h
a
n
g
e
 
o
f
 
d
e
u
t
e
r
a
t
e
d
 
I
M
P
s
 
a
n
d
 
o
t
h
e
r
 
p
r
o
t
e
i
n
s
 
a
t
 
t
h
e
i
r
 
a
m
i
d
e
 
p
o
s
i
t
i
o
n
s
 
i
s
 
t
h
e
r
e
f
o
r
e
 
g
e
n
e
r
a
l
l
y
 
e
n
s
u
r
e
d
 
a
n
d
 
n
o
 
c
r
i
t
i
c
a
l
 
d
e
n
a
t
u
r
a
t
i
o
n
 
s
t
e
p
s
 
a
r
e
 
n
e
c
e
s
s
a
r
y
.
 
 
I
n
 
o
r
d
e
r
 
t
o
 
s
t
u
d
y
 
p
r
o
t
e
i
n
 
s
t
r
u
c
t
u
r
e
 
a
n
d
 
d
y
n
a
m
i
c
s
 
b
y
 
N
M
R
 
s
p
e
c
t
r
o
s
c
o
p
y
,
 
t
h
e
 
b
a
c
k
b
o
n
e
 
o
f
 
a
 
p
r
o
t
e
i
n
 
m
u
s
t
 
f
i
r
s
t
 
b
e
 
a
s
s
i
g
n
e
d
.
 
G
i
v
e
n
 
t
h
e
 
l
i
m
i
t
a
t
i
o
n
s
 
i
n
v
o
l
v
e
d
 
i
n
 
t
h
e
 
a
n
a
l
y
s
i
s
 
o
f
 
I
M
P
s
,
 
c
e
r
t
a
i
n
 
s
t
r
a
t
e
g
i
e
s
 
m
u
s
t
 
b
e
 
i
m
p
l
e
m
e
n
t
e
d
 
f
o
r
 
a
n
 
e
f
f
i
c
i
e
n
t
 
d
e
s
i
g
n
a
t
i
o
n
.
 
A
 
s
i
g
n
i
f
i
c
a
n
t
 
c
h
a
l
l
e
n
g
e
 
i
n
 
a
s
s
i
g
n
m
e
n
t
 
i
n
h
e
r
e
n
t
 
i
n
 
N
M
R
 
s
t
u
d
i
e
s
 
r
e
m
a
i
n
s
 
i
n
 
t
h
e
 
s
i
z
e
 
l
i
m
i
t
a
t
i
o
n
 
f
o
r
 
p
r
o
t
e
i
n
s
.
 
M
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
t
e
n
d
 
t
o
 
b
e
 
l
a
r
g
e
 
w
i
t
h
 
m
u
l
t
i
p
l
e
 
d
o
m
a
i
n
s
,
 
a
n
d
 
t
h
e
 
n
e
c
e
s
s
i
t
y
 
f
o
r
 
s
u
b
s
e
q
u
e
n
t
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
i
n
 
d
e
t
e
r
g
e
n
t
 
m
a
y
 
f
u
r
t
h
e
r
 
s
i
g
n
i
f
i
c
a
n
t
l
y
 
i
n
c
r
e
a
s
e
 
t
h
e
 
f
i
n
a
l
 
s
i
z
e
 
o
f
 
t
h
e
 
p
r
o
t
e
i
n
/
m
i
c
e
l
l
e
 
c
o
m
p
o
s
i
t
e
,
 
l
e
a
d
i
n
g
 
t
o
 
c
o
n
s
i
d
e
r
a
b
l
e
 
l
i
n
e
 
b
r
o
a
d
e
n
i
n
g
 
d
u
e
 
t
o
 
r
e
s
t
r
i
c
t
e
d
 
m
o
l
e
c
u
l
a
r
 
t
u
m
b
l
i
n
g
.
 
F
o
r
t
u
n
a
t
e
l
y
,
 
t
h
i
s
 
p
r
o
b
l
e
m
 
c
a
n
 
b
e
 
a
l
l
e
v
i
a
t
e
d
 
t
o
 
a
 
c
e
r
t
a
i
n
 
e
x
t
e
n
t
 
b
y
 
u
s
i
n
g
 
s
u
i
t
a
b
l
e
 
d
e
t
e
r
g
e
n
t
s
 
t
h
a
t
 
o
b
v
i
o
u
s
l
y
 
a
l
l
o
w
 
r
e
l
a
t
i
v
e
l
y
 
f
r
e
e
 
m
o
v
e
m
e
n
t
s
 
o
f
 
i
n
s
e
r
t
e
d
 
p
r
o
t
e
i
n
.
 
T
h
e
 
d
e
t
e
r
g
e
n
t
 
c
l
a
s
s
 
o
f
 
l
y
s
o
-
p
h
o
s
p
h
o
g
l
y
c
e
r
o
l
s
 
i
n
c
l
u
d
i
n
g
 
L
M
P
G
 
a
n
d
 
L
P
P
G
 
h
a
s
 
b
e
e
n
 
f
o
u
n
d
 
e
s
p
e
c
i
a
l
l
y
 
s
u
i
t
a
b
l
e
 
f
o
r
 
t
h
i
s
 
p
u
r
p
o
s
e
 
(
2
6
,
 
4
2
,
 
4
3
)
.
 
T
h
r
e
e
 
E
.
 
c
o
l
i
 
I
M
P
s
,
 
t
h
e
 
c
y
s
t
e
i
n
e
 
e
x
p
o
r
t
e
r
 
Y
f
i
k
 
(
2
1
.
2
 
k
D
a
)
,
 
t
h
e
 
C
-
t
e
r
m
i
n
a
l
l
y
 
t
r
u
n
c
a
t
e
d
 
t
e
l
l
u
r
i
t
e
 
t
r
a
n
s
p
o
r
t
e
r
 
∆
T
e
h
A
 
(
2
4
 
k
D
a
)
,
 
a
n
d
 
S
e
c
E
 
(
1
3
.
6
 
k
D
a
)
,
 
a
 
c
o
m
p
o
n
e
n
t
 
o
f
 
t
h
e
 
s
e
c
r
e
t
i
o
n
 
m
a
c
h
i
n
e
r
y
,
 
h
a
v
e
 
g
i
v
e
n
 
p
r
o
m
i
s
i
n
g
 
N
M
R
 
h
e
t
e
r
o
n
u
c
l
e
a
r
 
s
i
n
g
l
e
 
q
u
a
n
t
u
m
 
c
o
r
r
e
l
a
t
i
o
n
 
(
H
S
Q
C
)
 
s
p
e
c
t
r
a
 
w
h
e
n
 
d
i
s
s
o
l
v
e
d
 
i
n
 
L
M
P
G
 
(
F
i
g
.
 
4
A
-
C
)
.
 
I
n
 
a
l
l
 
c
a
s
e
s
,
 
m
o
r
e
 
t
h
a
n
 
9
0
 
 
1
6
 
%
 
o
f
 
t
h
e
 
e
x
p
e
c
t
e
d
 
s
i
g
n
a
l
s
 
a
r
e
 
d
e
t
e
c
t
a
b
l
e
 
a
n
d
 
b
a
c
k
b
o
n
e
 
a
s
s
i
g
n
m
e
n
t
s
 
a
s
 
a
 
p
r
e
r
e
q
u
i
s
i
t
e
 
f
o
r
 
t
h
e
i
r
 
s
t
r
u
c
t
u
r
a
l
 
a
n
a
l
y
s
i
s
 
a
p
p
e
a
r
 
t
h
e
r
e
f
o
r
e
 
f
e
a
s
i
b
l
e
.
 
A
 
l
i
m
i
t
a
t
i
o
n
 
w
i
t
h
 
m
o
s
t
 
I
M
P
s
 
i
s
 
t
h
e
i
r
 
o
f
t
e
n
 
h
i
g
h
 
c
o
n
t
e
n
t
 
o
f
 
α
-
h
e
l
i
c
a
l
 
s
e
c
o
n
d
a
r
y
 
s
t
r
u
c
t
u
r
e
s
 
g
i
v
i
n
g
 
r
i
s
e
 
t
o
 
p
o
o
r
 
c
h
e
m
i
c
a
l
 
s
h
i
f
t
 
d
i
s
p
e
r
s
i
o
n
 
a
n
d
 
l
e
a
d
i
n
g
 
t
o
 
c
o
n
s
i
d
e
r
a
b
l
e
 
s
p
e
c
t
r
a
l
 
o
v
e
r
l
a
p
 
i
f
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
o
t
h
e
r
 
s
t
r
u
c
t
u
r
a
l
 
e
l
e
m
e
n
t
s
 
s
u
c
h
 
a
s
 
β
-
s
h
e
e
t
s
.
 
H
o
w
e
v
e
r
,
 
s
p
e
c
t
r
a
l
 
o
v
e
r
l
a
p
 
e
s
p
e
c
i
a
l
l
y
 
i
n
 
t
h
e
 
r
a
n
g
e
 
b
e
t
w
e
e
n
 
7
.
5
 
p
p
m
 
a
n
d
 
8
.
5
 
p
p
m
 
c
a
n
 
s
i
g
n
i
f
i
c
a
n
t
l
y
 
b
e
 
d
i
m
i
n
i
s
h
e
d
 
b
y
 
t
h
e
 
a
n
a
l
y
s
i
s
 
o
f
 
a
m
i
n
o
 
a
c
i
d
 
t
y
p
e
 
s
p
e
c
i
f
i
c
a
l
l
y
 
l
a
b
e
l
l
e
d
 
s
a
m
p
l
e
s
 
(
F
i
g
.
 
4
D
-
I
)
.
 
L
i
m
i
t
e
d
 
s
p
e
c
t
r
a
l
 
d
i
s
p
e
r
s
i
o
n
 
h
a
s
 
f
u
r
t
h
e
r
 
b
e
e
n
 
a
d
d
r
e
s
s
e
d
 
b
y
 
t
h
e
 
u
s
e
 
o
f
 
c
e
r
t
a
i
n
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
l
a
b
e
l
l
i
n
g
 
s
t
r
a
t
e
g
i
e
s
 
c
o
m
b
i
n
e
d
 
w
i
t
h
 
s
a
m
p
l
e
 
a
n
a
l
y
s
i
s
 
i
n
 
h
i
g
h
 
f
i
e
l
d
 
s
p
e
c
t
r
o
m
e
t
e
r
s
 
(
2
6
,
 
4
4
,
 
4
5
)
.
 
A
n
 
i
m
p
o
r
t
a
n
t
 
a
d
v
a
n
c
e
m
e
n
t
 
i
s
 
t
h
e
 
d
e
v
e
l
o
p
m
e
n
t
 
o
f
 
t
h
e
 
T
r
a
n
s
v
e
r
s
e
 
R
e
l
a
x
a
t
i
o
n
 
O
p
t
i
m
i
z
e
d
 
S
p
e
c
t
r
o
s
c
o
p
y
 
(
T
R
O
S
Y
)
 
e
x
p
e
r
i
m
e
n
t
,
 
w
h
i
c
h
 
r
e
d
u
c
e
s
 
t
r
a
n
s
v
e
r
s
e
 
r
e
l
a
x
a
t
i
o
n
 
a
n
d
 
a
l
l
o
w
s
 
t
o
 
o
b
t
a
i
n
 
h
i
g
h
 
r
e
s
o
l
u
t
i
o
n
 
s
p
e
c
t
r
a
 
f
o
r
 
m
o
l
e
c
u
l
e
s
 
w
i
t
h
 
h
i
g
h
e
r
 
m
o
l
e
c
u
l
a
r
 
w
e
i
g
h
t
s
 
(
4
6
)
.
 
O
n
e
 
o
f
 
t
h
e
 
p
r
i
m
a
r
y
 
s
t
e
p
s
 
i
n
 
a
s
s
i
g
n
m
e
n
t
 
s
t
r
a
t
e
g
i
e
s
 
i
s
 
t
h
e
 
m
e
a
s
u
r
e
m
e
n
t
 
o
f
 
3
D
 
o
r
 
4
D
 
t
r
i
p
l
e
 
r
e
s
o
n
a
n
c
e
 
(
1
3
C
/
1
5
N
-
l
a
b
e
l
l
e
d
)
 
s
p
e
c
t
r
a
 
a
n
d
 
o
f
t
e
n
 
p
r
o
t
e
i
n
 
b
a
c
k
b
o
n
e
s
 
c
a
n
 
b
e
 
a
s
s
i
g
n
e
d
 
b
y
 
m
e
a
s
u
r
i
n
g
 
t
h
e
 
T
R
O
S
Y
-
t
y
p
e
 
e
x
p
e
r
i
m
e
n
t
s
 
s
u
c
h
 
a
s
 
H
N
C
A
,
 
H
N
(
C
O
)
C
A
,
 
H
N
C
A
C
B
,
 
H
N
(
C
O
)
C
A
C
B
,
 
H
N
C
O
 
a
n
d
 
H
N
(
C
A
)
C
O
 
t
h
a
t
 
a
l
l
o
w
 
t
h
e
 
s
e
q
u
e
n
t
i
a
l
 
i
d
e
n
t
i
f
i
c
a
t
i
o
n
 
o
f
 
b
a
c
k
b
o
n
e
 
r
e
s
i
d
u
e
s
.
 
 
 
T
h
e
 
2
4
 
k
D
a
 
t
r
u
n
c
a
t
e
d
 
v
e
r
s
i
o
n
 
o
f
 
t
h
e
 
p
u
t
a
t
i
v
e
 
b
a
c
t
e
r
i
a
l
 
t
e
l
l
u
r
i
t
e
 
t
r
a
n
s
p
o
r
t
e
r
 
T
e
h
A
 
w
i
t
h
 
s
e
v
e
n
 
T
M
S
s
 
w
a
s
 
t
h
e
 
f
i
r
s
t
 
I
M
P
 
w
h
o
s
e
 
b
a
c
k
b
o
n
e
 
a
s
s
i
g
n
m
e
n
t
 
w
a
s
 
a
p
p
r
o
a
c
h
e
d
 
b
y
 
t
a
k
i
n
g
 
a
d
v
a
n
t
a
g
e
 
o
f
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
s
t
r
a
t
e
g
i
e
s
 
(
2
6
)
.
 
S
t
a
n
d
a
r
d
 
n
o
n
-
s
e
l
e
c
t
i
v
e
 
t
r
i
p
l
e
 
r
e
s
o
n
a
n
c
e
 
e
x
p
e
r
i
m
e
n
t
s
 
r
e
s
u
l
t
e
d
 
o
n
l
y
 
i
n
 
a
p
p
r
o
x
.
 
5
5
 
%
 
a
s
s
i
g
n
m
e
n
t
 
a
n
d
 
h
i
g
h
 
d
e
g
r
e
e
s
 
o
f
 
s
i
g
n
a
l
 
o
v
e
r
l
a
p
 
i
n
 
t
h
e
 
α
-
h
e
l
i
c
a
l
 
I
M
P
 
r
e
q
u
i
r
e
d
 
f
u
r
t
h
e
r
 
s
t
r
a
t
e
g
i
e
s
 
f
o
r
 
t
h
e
 
f
u
l
l
 
b
a
c
k
b
o
n
e
 
a
s
s
i
g
n
m
e
n
t
.
 
T
h
e
 
a
n
a
l
y
s
i
s
 
o
f
 
1
0
 
f
u
r
t
h
e
r
 
s
a
m
p
l
e
s
 
h
a
v
i
n
g
 
e
a
c
h
 
a
 
d
i
f
f
e
r
e
n
t
 
a
m
i
n
o
 
a
c
i
d
 
t
y
p
e
 
s
p
e
c
i
f
i
c
a
l
l
y
 
l
a
b
e
l
l
e
d
 
r
e
s
u
l
t
e
d
 
o
n
l
y
 
i
n
 
a
p
p
r
o
x
.
 
1
0
 
%
 
a
d
d
i
t
i
o
n
a
l
 
a
s
s
i
g
n
m
e
n
t
s
.
 
T
h
e
 
r
e
a
s
o
n
 
f
o
r
 
t
h
i
s
 
l
o
w
 
r
a
t
e
 
o
f
 
s
u
c
c
e
s
s
 
w
a
s
 
a
c
c
r
e
d
i
t
e
d
 
t
o
 
r
e
d
u
n
d
a
n
c
y
,
 
s
u
c
h
 
t
h
a
t
 
i
n
 
m
a
n
y
 
c
a
s
e
s
 
a
n
 
i
d
e
n
t
i
f
i
e
d
 
a
m
i
n
o
 
a
c
i
d
 
t
y
p
e
 
w
a
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
m
o
r
e
 
t
h
a
n
 
o
n
e
 
N
 
o
r
 
C
-
t
e
r
m
i
n
a
l
 
c
o
n
n
e
c
t
i
v
i
t
y
,
 
l
e
a
d
i
n
g
 
t
o
 
a
m
b
i
g
u
o
u
s
 
s
e
q
u
e
n
c
e
 
a
s
s
i
g
n
m
e
n
t
s
.
 
O
f
 
m
u
c
h
 
h
i
g
h
e
r
 
s
u
c
c
e
s
s
 
w
a
s
 
t
h
e
 
a
p
p
l
i
c
a
t
i
o
n
 
o
f
 
a
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
s
e
l
e
c
t
i
v
e
 
l
a
b
e
l
l
i
n
g
 
m
e
t
h
o
d
 
w
h
i
c
h
 
r
e
l
i
e
s
 
o
n
 
t
h
e
 
1
3
C
 
l
a
b
e
l
l
i
n
g
 
o
f
 
c
e
r
t
a
i
n
 
a
m
i
n
o
 
a
c
i
d
 
t
y
p
e
s
 
c
o
n
c
o
m
i
t
a
n
t
 
w
i
t
h
 
t
h
e
 
s
i
m
u
l
t
a
n
e
o
u
s
 
1
5
N
 
l
a
b
e
l
l
i
n
g
 
o
f
 
o
t
h
e
r
s
 
(
4
4
)
.
 
I
n
 
t
h
i
s
 
a
p
p
r
o
a
c
h
,
 
t
h
r
e
e
 
s
a
m
p
l
e
s
 
w
e
r
e
 
p
r
o
d
u
c
e
d
 
h
a
v
i
n
g
 
e
a
c
h
 
t
w
o
 
t
o
 
t
h
r
e
e
 
d
i
f
f
e
r
e
n
t
 
1
5
N
 
l
a
b
e
l
l
e
d
 
a
m
i
n
o
 
a
c
i
d
s
 
t
y
p
e
s
 
t
o
g
e
t
h
e
r
 
w
i
t
h
 
t
w
o
 
1
3
C
 
l
a
b
e
l
l
e
d
 
t
y
p
e
s
 
(
F
i
g
.
 
5
)
.
 
T
h
e
 
r
a
t
i
o
n
a
l
e
 
b
e
h
i
n
d
 
t
h
i
s
 
s
t
r
a
t
e
g
y
 
i
s
 
t
h
a
t
 
b
y
 
u
s
i
n
g
 
t
h
i
s
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
b
a
s
e
 
t
o
g
e
t
h
e
r
 
w
i
t
h
 
2
D
 
v
e
r
s
i
o
n
s
 
o
f
 
t
h
e
 
H
N
C
O
 
e
x
p
e
r
i
m
e
n
t
 
a
n
d
 
1
5
N
/
1
H
 
T
R
O
S
Y
 
s
p
e
c
t
r
a
,
 
1
5
N
-
l
a
b
e
l
l
e
d
 
a
m
i
n
o
 
a
c
i
d
s
 
t
y
p
e
s
 
t
h
a
t
 
a
r
e
 
p
r
e
c
e
d
e
d
 
b
y
 
1
3
C
-
l
a
b
e
l
l
e
d
 
t
y
p
e
s
 
c
a
n
 
r
e
a
d
i
l
y
 
b
e
 
s
e
l
e
c
t
e
d
 
(
F
i
g
.
 
5
)
.
 
I
f
 
t
h
e
 
i
d
e
n
t
i
f
i
e
d
 
c
o
m
b
i
n
a
t
i
o
n
 
o
f
 
t
w
o
 
a
m
i
n
o
 
a
c
i
d
s
 
i
n
 
t
h
e
 
p
r
o
t
e
i
n
 
h
a
s
 
a
 
s
i
n
g
u
l
a
r
 
o
c
c
u
r
r
e
n
c
e
,
 
t
h
e
 
s
p
e
c
i
f
i
c
 
s
i
t
e
 
c
a
n
 
b
e
 
u
n
a
m
b
i
g
u
o
u
s
l
y
 
a
s
s
i
g
n
e
d
 
a
n
d
 
m
a
y
 
a
c
t
 
a
s
 
a
n
 
a
n
c
h
o
r
 
p
o
i
n
t
 
f
o
r
 
f
u
r
t
h
e
r
 
s
e
q
u
e
n
t
i
a
l
 
a
s
s
i
g
n
m
e
n
t
s
.
  
1
7
 
I
t
 
i
s
 
p
r
e
d
i
c
t
e
d
 
t
h
a
t
 
4
0
-
5
0
 
%
 
o
f
 
a
l
l
 
a
m
i
n
o
 
a
c
i
d
s
 
w
i
t
h
i
n
 
a
 
p
r
o
t
e
i
n
 
a
r
e
 
p
a
r
t
 
o
f
 
a
 
u
n
i
q
u
e
 
a
m
i
n
o
 
a
c
i
d
 
p
a
i
r
,
 
a
n
d
 
a
l
g
o
r
i
t
h
m
 
p
r
o
g
r
a
m
s
 
w
h
i
c
h
 
a
s
s
i
s
t
 
w
i
t
h
 
t
h
e
 
s
e
l
e
c
t
i
o
n
 
o
f
 
a
m
i
n
o
 
a
c
i
d
 
t
y
p
e
s
 
t
o
 
b
e
 
u
s
e
d
 
f
o
r
 
s
u
c
h
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
s
p
e
c
i
f
i
c
 
l
a
b
e
l
l
i
n
g
 
s
c
h
e
m
e
s
 
h
a
v
e
 
b
e
e
n
 
m
a
d
e
 
a
v
a
i
l
a
b
l
e
:
 
h
t
t
p
:
/
/
w
w
w
.
B
i
o
p
h
y
s
c
h
e
m
.
u
n
i
-
f
r
a
n
k
f
u
r
t
.
d
e
/
A
K
D
o
e
t
s
c
h
/
 
p
r
o
j
e
c
t
s
/
d
o
w
n
l
o
a
d
/
c
o
m
b
i
l
a
b
e
l
.
m
)
.
 
 
 
 
I
n
 
c
o
m
b
i
n
a
t
i
o
n
 
w
i
t
h
 
t
h
e
 
i
n
f
o
r
m
a
t
i
o
n
 
o
b
t
a
i
n
e
d
 
f
r
o
m
 
t
h
e
 
n
o
n
-
s
e
l
e
c
t
i
v
e
 
a
n
d
 
f
r
o
m
 
t
h
e
 
a
m
i
n
o
 
a
c
i
d
 
s
p
e
c
i
f
i
c
 
l
a
b
e
l
l
e
d
 
s
a
m
p
l
e
s
 
r
e
s
u
l
t
e
d
 
t
h
e
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
a
p
p
r
o
a
c
h
 
i
n
 
a
 
t
o
t
a
l
 
o
f
 
8
5
 
%
 
a
s
s
i
g
n
m
e
n
t
s
 
t
h
a
t
 
i
s
 
s
u
f
f
i
c
i
e
n
t
 
f
o
r
 
s
t
r
u
c
t
u
r
a
l
 
a
n
a
l
y
s
i
s
.
 
H
o
w
e
v
e
r
,
 
d
a
t
a
 
r
e
-
a
n
a
l
y
s
i
s
 
r
e
v
e
a
l
e
d
 
t
h
a
t
 
t
h
e
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
a
p
p
r
o
a
c
h
 
a
l
o
n
e
 
a
l
o
n
g
 
w
i
t
h
 
t
h
e
 
n
o
n
-
s
e
l
e
c
t
i
v
e
 
l
a
b
e
l
l
i
n
g
 
e
x
p
e
r
i
m
e
n
t
s
 
w
o
u
l
d
 
h
a
v
e
 
b
e
e
n
 
e
n
o
u
g
h
 
t
o
 
y
i
e
l
d
 
t
h
e
s
e
 
8
5
 
%
 
a
s
s
i
g
n
m
e
n
t
 
o
f
 
∆
T
e
h
A
.
 
E
x
p
e
n
s
i
v
e
 
a
n
d
 
t
i
m
e
 
c
o
n
s
u
m
i
n
g
 
s
i
n
g
l
e
 
s
e
l
e
c
t
i
v
e
 
l
a
b
e
l
l
i
n
g
 
e
x
p
e
r
i
m
e
n
t
s
 
m
i
g
h
t
 
t
h
e
r
e
f
o
r
e
 
n
o
t
 
b
e
 
n
e
c
e
s
s
a
r
y
 
f
o
r
 
f
u
t
u
r
e
 
a
s
s
i
g
n
m
e
n
t
s
 
o
f
 
I
M
P
s
.
 
A
c
c
o
r
d
i
n
g
l
y
,
 
f
i
v
e
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
1
5
N
 
l
a
b
e
l
l
e
d
 
s
a
m
p
l
e
s
 
o
f
 
t
h
e
 
C
-
t
e
r
m
i
n
a
l
 
1
6
 
k
D
a
 
d
o
m
a
i
n
 
o
f
 
t
h
e
 
τ
 
s
u
b
u
n
i
t
 
o
f
 
t
h
e
 
E
.
 
c
o
l
i
 
D
N
A
 
p
o
l
y
m
e
r
a
s
e
 
I
I
I
 
h
o
l
o
e
n
z
y
m
e
 
y
i
e
l
d
e
d
 
t
h
e
 
s
a
m
e
 
i
n
f
o
r
m
a
t
i
o
n
 
a
s
 
d
e
r
i
v
e
d
 
f
r
o
m
 
1
9
 
i
n
d
i
v
i
d
u
a
l
 
a
m
i
n
o
 
a
c
i
d
 
t
y
p
e
 
s
e
l
e
c
t
i
v
e
l
y
 
l
a
b
e
l
l
e
d
 
s
a
m
p
l
e
s
 
(
4
3
)
.
 
G
i
v
e
n
 
t
h
e
 
c
o
n
s
i
d
e
r
a
b
l
e
 
d
e
g
r
e
e
 
o
f
 
s
i
g
n
a
l
 
o
v
e
r
l
a
p
 
i
n
 
I
M
P
s
 
i
t
 
c
a
n
 
b
e
 
e
x
p
e
c
t
e
d
 
t
h
a
t
 
t
h
e
 
u
s
e
 
o
f
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
s
 
f
o
r
 
t
h
e
 
g
e
n
e
r
a
t
i
o
n
 
o
f
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
a
n
d
 
n
o
n
-
s
p
e
c
i
f
i
c
a
l
l
y
 
l
a
b
e
l
l
e
d
 
s
a
m
p
l
e
s
 
i
n
 
c
o
m
b
i
n
a
t
i
o
n
 
w
i
t
h
 
1
5
N
-
H
S
Q
C
-
T
R
O
S
Y
 
s
p
e
c
t
r
a
 
a
n
d
 
t
h
e
i
r
 
a
n
a
l
y
s
i
s
 
b
y
 
t
h
e
 
d
i
f
f
e
r
e
n
t
i
a
l
 
H
N
C
O
 
s
t
r
a
t
e
g
y
 
m
a
y
 
s
i
g
n
i
f
i
c
a
n
t
l
y
 
a
s
s
i
s
t
 
b
a
c
k
b
o
n
e
 
a
s
s
i
g
n
m
e
n
t
s
 
i
n
 
t
h
e
 
n
e
x
t
 
f
u
t
u
r
e
.
 
 
 
 
3
.
3
.
 
A
p
p
l
i
c
a
t
i
o
n
s
 
o
f
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
f
o
r
 
s
o
l
i
d
 
s
t
a
t
e
 
N
M
R
 
 
S
o
l
i
d
 
s
t
a
t
e
 
N
M
R
 
(
s
s
N
M
R
)
 
l
i
k
e
 
t
h
e
 
m
o
r
e
 
f
r
e
q
u
e
n
t
 
s
o
l
u
t
i
o
n
 
s
t
a
t
e
 
N
M
R
 
t
e
c
h
n
i
q
u
e
 
o
f
f
e
r
s
 
t
h
e
 
p
o
s
s
i
b
i
l
i
t
y
 
t
o
 
s
t
u
d
y
 
t
h
e
 
a
t
o
m
i
c
 
s
t
r
u
c
t
u
r
e
,
 
e
x
c
h
a
n
g
e
 
p
r
o
c
e
s
s
e
s
,
 
s
p
i
n
 
d
i
f
f
u
s
i
o
n
 
a
n
d
 
m
o
l
e
c
u
l
a
r
 
d
y
n
a
m
i
c
s
 
o
f
 
p
r
o
t
e
i
n
s
.
 
A
d
d
i
t
i
o
n
a
l
 
i
n
f
o
r
m
a
t
i
o
n
 
i
s
 
p
r
o
v
i
d
e
d
 
o
n
 
t
o
r
s
i
o
n
 
a
n
g
l
e
s
,
 
a
t
o
m
i
c
 
o
r
i
e
n
t
a
t
i
o
n
 
a
n
d
 
v
e
r
y
 
p
r
e
c
i
s
e
 
i
n
t
e
r
n
u
c
l
e
a
r
 
d
i
s
t
a
n
c
e
s
 
u
p
 
t
o
 
1
5
 
Å
 
b
y
 
u
s
i
n
g
 
t
h
e
 
a
v
a
i
l
a
b
l
e
 
c
h
e
m
i
c
a
l
 
s
h
i
f
t
 
a
n
i
s
o
t
r
o
p
y
,
 
q
u
a
d
r
u
p
o
l
e
 
c
o
u
p
l
i
n
g
 
a
n
d
 
s
t
r
o
n
g
 
d
i
p
o
l
a
r
 
c
o
u
p
l
i
n
g
s
.
 
T
h
e
 
s
s
N
M
R
 
t
e
c
h
n
i
q
u
e
 
i
s
 
v
e
r
y
 
v
e
r
s
a
t
i
l
e
 
a
s
 
n
o
 
i
n
h
e
r
e
n
t
 
s
i
z
e
 
l
i
m
i
t
 
o
n
 
m
o
l
e
c
u
l
e
s
 
f
o
r
 
i
n
v
e
s
t
i
g
a
t
i
o
n
 
e
x
i
s
t
s
.
 
H
o
w
e
v
e
r
,
 
s
s
N
M
R
 
i
s
 
h
a
m
p
e
r
e
d
 
b
y
 
f
a
s
t
 
r
e
l
a
x
a
t
i
o
n
,
 
i
n
s
e
n
s
i
t
i
v
i
t
y
 
(
>
 
1
µ
m
o
l
 
p
r
o
t
e
i
n
 
a
r
e
 
r
e
q
u
i
r
e
d
 
f
o
r
 
2
D
 
s
p
e
c
t
r
o
s
c
o
p
y
)
 
a
n
d
 
b
r
o
a
d
e
r
 
l
i
n
e
w
i
d
t
h
 
i
f
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
s
o
l
u
t
i
o
n
 
s
t
a
t
e
 
N
M
R
.
 
W
e
l
l
 
r
e
s
o
l
v
e
d
 
s
p
e
c
t
r
a
 
c
o
n
t
a
i
n
i
n
g
 
o
n
l
y
 
s
e
l
e
c
t
e
d
 
i
n
t
e
r
a
c
t
i
o
n
s
 
c
a
n
 
n
e
v
e
r
t
h
e
l
e
s
s
 
b
e
 
o
b
t
a
i
n
e
d
 
u
s
i
n
g
 
m
a
g
i
c
 
a
n
g
l
e
 
s
a
m
p
l
e
 
s
p
i
n
n
i
n
g
 
(
M
A
S
)
 
N
M
R
 
r
e
c
o
u
p
l
i
n
g
 
t
e
c
h
n
i
q
u
e
s
.
 
T
h
e
s
e
 
r
e
m
o
v
e
 
a
n
i
s
o
t
r
o
p
i
c
 
i
n
t
e
r
a
c
t
i
o
n
s
 
b
y
 
f
a
s
t
 
s
a
m
p
l
e
 
r
o
t
a
t
i
o
n
 
(
i
n
 
p
r
a
c
t
i
c
e
 
5
-
2
0
 
k
H
z
)
 
a
b
o
u
t
 
t
h
e
 
m
a
g
i
c
 
a
n
g
l
e
 
(
5
4
.
7
°
 
w
i
t
h
 
r
e
s
p
e
c
t
 
t
o
 
t
h
e
 
m
a
g
n
e
t
i
c
 
f
i
e
l
d
)
 
a
n
d
 
r
e
i
n
t
r
o
d
u
c
e
 
s
e
l
e
c
t
i
v
e
l
y
 
d
e
s
i
r
e
d
 
i
n
t
e
r
a
c
t
i
o
n
s
 
u
s
i
n
g
 
a
p
p
r
o
p
r
i
a
t
e
 
p
u
l
s
e
 
s
e
q
u
e
n
c
e
s
 
(
4
7
)
.
 
 
 
T
h
e
 
s
s
N
M
R
 
e
n
a
b
l
e
s
 
t
h
e
 
s
t
u
d
y
 
o
f
 
p
r
o
t
e
i
n
s
 
i
n
 
a
 
m
u
l
t
i
t
u
d
e
 
o
f
 
d
i
f
f
e
r
e
n
t
 
s
t
a
t
e
s
 
i
n
c
l
u
d
i
n
g
 
f
r
o
z
e
n
 
s
o
l
u
t
i
o
n
 
(
4
8
)
,
 
p
r
o
t
e
i
n
 
a
g
g
r
e
g
a
t
e
s
 
(
4
9
)
,
 
2
D
 
c
r
y
s
t
a
l
s
 
(
5
0
)
,
 
3
D
 
c
r
y
s
t
a
l
s
 
(
5
1
)
 
a
n
d
 
i
n
 
p
r
o
t
e
o
l
i
p
o
s
o
m
e
s
 
(
5
2
)
.
 
P
r
o
t
e
o
l
i
p
o
s
o
m
e
s
 
a
r
e
 
c
l
e
a
r
l
y
 
t
h
e
 
s
a
m
p
l
e
s
 
o
f
 
c
h
o
i
c
e
 
f
o
r
 
I
M
P
s
 
a
s
 
t
h
e
y
 
a
r
e
 
 
1
8
 
c
l
o
s
e
s
t
 
t
o
 
t
h
e
 
p
r
o
t
e
i
n
s
 
n
a
t
i
v
e
 
e
n
v
i
r
o
n
m
e
n
t
.
 
L
i
p
i
d
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
s
a
m
p
l
e
s
 
a
l
s
o
 
o
f
f
e
r
 
t
h
e
 
o
p
t
i
o
n
 
o
f
 
i
n
v
e
s
t
i
g
a
t
i
n
g
 
t
h
e
 
d
y
n
a
m
i
c
s
 
o
f
 
a
n
 
I
M
P
 
u
p
o
n
 
l
i
g
a
n
d
 
b
i
n
d
i
n
g
 
(
5
3
)
 
o
r
 
i
n
 
r
e
s
p
o
n
s
e
 
t
o
 
c
h
a
n
g
e
s
 
i
n
 
t
h
e
 
l
i
p
i
d
 
e
n
v
i
r
o
n
m
e
n
t
 
(
5
4
)
.
 
O
n
e
 
o
f
 
t
h
e
 
k
e
y
 
p
r
o
b
l
e
m
s
 
i
n
 
t
h
e
 
s
t
u
d
y
 
o
f
 
u
n
i
f
o
r
m
l
y
 
l
a
b
e
l
l
e
d
 
l
a
r
g
e
 
I
M
P
s
 
i
s
 
s
p
e
c
t
r
a
l
 
o
v
e
r
l
a
p
.
 
H
o
w
e
v
e
r
,
 
s
s
N
M
R
 
i
s
 
n
o
t
 
o
n
l
y
 
f
o
c
u
s
e
d
 
o
n
 
s
t
r
u
c
t
u
r
a
l
 
b
i
o
l
o
g
y
 
b
u
t
 
o
f
f
e
r
s
 
u
n
i
q
u
e
 
p
o
s
s
i
b
i
l
i
t
i
e
s
 
f
o
r
 
f
u
n
c
t
i
o
n
a
l
 
b
i
o
p
h
y
s
i
c
a
l
 
s
t
u
d
i
e
s
 
a
n
d
 
i
t
 
h
a
s
 
b
e
e
n
 
w
i
d
e
l
y
 
u
s
e
d
 
i
n
 
o
r
d
e
r
 
t
o
 
s
t
u
d
y
 
m
e
m
b
r
a
n
e
 
b
o
u
n
d
 
p
e
p
t
i
d
e
s
.
 
T
h
o
s
e
 
s
t
u
d
i
e
s
 
r
e
q
u
i
r
e
 
t
h
e
 
e
f
f
i
c
i
e
n
t
 
r
e
s
i
d
u
e
-
 
a
n
d
 
s
i
t
e
-
s
e
l
e
c
t
i
v
e
 
l
a
b
e
l
l
i
n
g
 
o
f
 
e
.
g
.
 
a
c
t
i
v
e
 
s
i
t
e
s
 
i
n
 
I
M
P
s
.
 
F
o
r
 
t
h
e
s
e
 
l
a
b
e
l
l
i
n
g
 
s
c
h
e
m
e
s
,
 
t
h
e
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
s
y
s
t
e
m
 
o
f
f
e
r
s
 
t
h
e
 
s
o
 
f
a
r
 
l
a
r
g
e
s
t
 
p
o
s
s
i
b
l
e
 
f
l
e
x
i
b
i
l
i
t
y
.
 
P
r
e
l
i
m
i
n
a
r
y
 
s
s
N
M
R
 
s
p
e
c
t
r
a
 
o
f
 
C
F
 
e
x
p
r
e
s
s
e
d
 
a
n
d
 
a
m
i
n
o
 
a
c
i
d
 
s
e
l
e
c
t
i
v
e
l
y
 
l
a
b
e
l
l
e
d
 
S
M
R
 
p
r
o
t
e
i
n
s
 
a
r
e
 
s
h
o
w
n
 
i
n
 
f
i
g
u
r
e
 
6
.
 
C
F
 
g
e
n
e
r
a
t
e
d
 
1
5
N
 
a
m
i
n
o
 
a
c
i
d
 
s
p
e
c
i
f
i
c
a
l
l
y
 
l
a
b
e
l
l
e
d
 
s
a
m
p
l
e
s
 
o
f
 
E
m
r
E
 
a
n
d
 
i
t
s
 
h
o
m
o
l
o
g
u
e
 
H
s
m
r
 
h
a
v
e
 
b
e
e
n
 
p
r
e
p
a
r
e
d
 
a
s
 
p
r
e
c
i
p
i
t
a
t
e
,
 
f
r
o
z
e
n
 
D
D
M
 
m
i
c
e
l
l
e
s
 
a
n
d
 
a
s
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
p
r
o
t
e
i
n
 
i
n
 
E
.
 
c
o
l
i
 
l
i
p
i
d
 
m
i
x
t
u
r
e
 
a
n
d
 
a
n
a
l
y
s
e
d
 
b
y
 
s
s
N
M
R
 
(
F
i
g
.
 
6
I
)
.
 
B
e
s
t
 
r
e
s
o
l
u
t
i
o
n
 
w
a
s
 
o
b
t
a
i
n
e
d
 
o
f
 
t
h
e
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
H
s
m
r
 
p
r
o
t
e
i
n
 
a
n
d
 
s
o
m
e
 
s
i
g
n
a
l
s
 
o
f
 
i
n
d
i
v
i
d
u
a
l
 
a
m
i
n
o
 
a
c
i
d
 
r
e
s
i
d
u
e
s
 
a
r
e
 
a
l
r
e
a
d
y
 
v
i
s
i
b
l
e
.
 
A
m
o
n
g
 
S
M
R
 
p
r
o
t
e
i
n
s
 
t
h
e
 
r
e
s
i
d
u
e
 
G
l
u
1
4
 
i
s
 
h
i
g
h
l
y
 
c
o
n
s
e
r
v
e
d
 
a
n
d
 
s
u
g
g
e
s
t
e
d
 
t
o
 
b
e
 
i
n
v
o
l
v
e
d
 
i
n
 
s
u
b
s
t
r
a
t
e
 
b
i
n
d
i
n
g
 
(
2
8
)
.
 
A
 
1
3
C
 
g
l
u
t
a
m
a
t
e
 
s
e
l
e
c
t
i
v
e
 
l
a
b
e
l
l
i
n
g
 
o
f
 
E
m
r
E
 
w
a
s
 
p
e
r
f
o
r
m
e
d
 
b
y
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
i
n
 
o
r
d
e
r
 
t
o
 
m
o
n
i
t
o
r
 
t
h
e
 
a
c
t
i
v
e
 
s
i
t
e
 
(
F
i
g
.
 
6
I
I
)
.
 
T
h
e
 
p
r
o
t
e
i
n
 
w
a
s
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
i
n
 
1
,
2
-
d
i
o
l
e
o
y
l
-
s
n
-
g
l
y
c
e
r
o
-
3
-
p
h
o
s
p
h
o
c
h
o
l
i
n
e
 
(
D
O
P
C
)
 
l
i
p
o
s
o
m
e
s
 
a
n
d
 
s
i
g
n
a
l
 
o
v
e
r
l
a
p
 
d
u
e
 
t
o
 
t
h
e
 
n
a
t
u
r
a
l
 
a
b
u
n
d
a
n
c
e
 
o
f
 
1
3
C
 
s
i
g
n
a
l
s
 
f
r
o
m
 
t
h
e
 
l
i
p
i
d
 
a
n
d
 
f
r
o
m
 
s
i
d
e
 
c
h
a
i
n
s
 
o
f
 
t
h
e
 
p
r
o
t
e
i
n
 
c
o
u
l
d
 
b
e
 
r
e
d
u
c
e
d
 
b
y
 
a
p
p
l
y
i
n
g
 
s
p
e
c
i
f
i
c
 
d
o
u
b
l
e
-
q
u
a
n
t
u
m
 
f
i
l
t
e
r
i
n
g
 
t
e
c
h
n
i
q
u
e
s
.
 
O
n
l
y
 
s
i
g
n
a
l
s
 
o
f
 
t
h
e
 
l
a
b
e
l
e
d
 
G
l
u
 
r
e
s
i
d
u
e
s
 
r
e
m
a
i
n
 
v
i
s
i
b
l
e
 
a
n
d
 
p
o
s
s
i
b
l
e
 
a
p
p
l
i
c
a
t
i
o
n
s
 
o
f
 
t
h
i
s
 
a
p
p
r
o
a
c
h
 
a
r
e
 
t
h
e
 
o
b
s
e
r
v
a
t
i
o
n
 
o
f
 
t
h
e
 
g
l
u
t
a
m
a
t
e
 
p
r
o
t
o
n
a
t
i
o
n
 
s
t
a
t
e
 
a
n
d
 
i
t
s
 
m
o
d
u
l
a
t
i
o
n
 
b
y
 
s
u
b
s
t
r
a
t
e
 
b
i
n
d
i
n
g
 
a
s
 
w
e
l
l
 
a
s
 
p
r
e
c
i
s
e
 
d
i
s
t
a
n
c
e
 
m
e
a
s
u
r
e
m
e
n
t
s
 
b
e
t
w
e
e
n
 
t
h
e
 
a
c
t
i
v
e
 
s
i
t
e
 
g
l
u
t
a
m
a
t
e
 
a
n
d
 
b
o
u
n
d
 
s
u
b
s
t
r
a
t
e
s
.
 
  
1
9
 
R
e
f
e
r
e
n
c
e
s
 
 
1
.
 
M
a
r
t
e
m
y
a
n
o
v
 
K
A
,
 
S
h
i
r
o
k
o
v
 
V
A
,
 
K
u
r
n
a
s
o
v
 
O
V
,
 
G
u
d
k
o
v
 
A
T
 
&
 
S
p
i
r
i
n
 
A
S
 
(
2
0
0
1
)
 
C
e
l
l
-
 
f
r
e
e
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
b
i
o
l
o
g
i
c
a
l
l
y
 
a
c
t
i
v
e
 
p
o
l
y
p
e
p
t
i
d
e
s
:
 
A
p
p
l
i
c
a
t
i
o
n
 
t
o
 
t
h
e
 
s
y
n
t
h
e
s
i
s
 
o
f
 
 
a
n
t
i
b
a
c
t
e
r
i
a
l
 
p
e
p
t
i
d
e
 
c
e
c
r
o
p
i
n
.
 
P
r
o
t
e
i
n
 
E
x
p
r
 
P
u
r
i
f
 
2
1
,
 
4
5
6
-
4
6
1
.
 
2
.
 
 
A
l
a
k
o
v
 
Y
B
,
 
B
a
r
a
n
o
v
 
V
I
,
 
O
v
o
d
o
v
 
S
J
,
 
R
y
a
b
o
v
a
 
L
A
,
 
S
p
i
r
i
n
 
A
S
 
&
 
M
o
r
o
z
o
v
 
I
J
.
 
(
1
9
9
5
)
 
 
M
e
t
h
o
d
 
o
f
 
p
r
e
p
a
r
i
n
g
 
p
o
l
y
p
e
p
t
i
d
e
s
 
i
n
 
c
e
l
l
-
f
r
e
e
 
t
r
a
n
s
l
a
t
i
o
n
 
s
y
s
t
e
m
 
i
n
,
 
U
.
S
.
 
P
a
t
e
n
t
 
5
,
4
7
8
,
7
3
0
.
 
 
3
.
 
K
i
m
 
D
M
 
&
 
C
h
o
i
 
C
Y
 
(
1
9
9
6
)
 
A
 
s
e
m
i
c
o
n
t
i
n
u
o
u
s
 
p
r
o
k
a
r
y
o
t
i
c
 
c
o
u
p
l
e
d
 
 
t
r
a
n
s
c
r
i
p
t
i
o
n
/
t
r
a
n
s
l
a
t
i
o
n
 
s
y
s
t
e
m
 
u
s
i
n
g
 
a
 
d
i
a
l
y
s
i
s
 
m
e
m
b
r
a
n
e
.
 
B
i
o
t
e
c
h
n
o
l
 
P
r
o
g
 
1
2
,
 
6
4
5
-
9
.
 
4
.
 
K
i
g
a
w
a
 
T
,
 
Y
a
b
u
k
i
 
T
,
 
Y
o
s
h
i
d
a
 
Y
,
 
T
s
u
t
s
u
i
 
M
,
 
I
t
o
 
Y
,
 
S
h
i
b
a
t
a
 
T
 
&
 
Y
o
k
o
y
a
m
a
 
S
 
(
1
9
9
9
)
 
C
e
l
l
-
 
f
r
e
e
 
p
r
o
d
u
c
t
i
o
n
 
a
n
d
 
s
t
a
b
l
e
-
i
s
o
t
o
p
e
 
l
a
b
e
l
i
n
g
 
o
f
 
m
i
l
l
i
g
r
a
m
 
q
u
a
n
t
i
t
i
e
s
 
o
f
 
p
r
o
t
e
i
n
s
.
 
F
E
B
S
 
L
e
t
t
 
 
4
4
2
,
 
1
5
-
9
.
 
5
.
 
K
i
m
 
D
M
 
&
 
S
w
a
r
t
z
 
J
R
 
(
1
9
9
9
)
 
P
r
o
l
o
n
g
i
n
g
 
c
e
l
l
-
f
r
e
e
 
p
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
 
w
i
t
h
 
a
 
n
o
v
e
l
 
A
T
P
 
 
r
e
g
e
n
e
r
a
t
i
o
n
 
s
y
s
t
e
m
.
 
B
i
o
t
e
c
h
n
o
l
 
B
i
o
e
n
g
 
6
6
,
 
1
8
0
-
8
.
 
6
.
 
K
i
m
 
D
M
 
&
 
S
w
a
r
t
z
 
J
R
 
(
2
0
0
0
)
 
O
x
a
l
a
t
e
 
i
m
p
r
o
v
e
s
 
p
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
 
b
y
 
e
n
h
a
n
c
i
n
g
 
A
T
P
 
 
s
u
p
p
l
y
 
i
n
 
a
 
c
e
l
l
-
f
r
e
e
 
s
y
s
t
e
m
 
d
e
r
i
v
e
d
 
f
r
o
m
 
E
s
c
h
e
r
i
c
h
i
a
 
c
o
l
i
.
 
b
i
o
t
e
c
h
n
o
l
 
l
e
t
t
e
r
s
 
2
2
,
 
1
5
3
7
-
 
1
5
4
2
.
 
7
.
 
K
i
m
 
D
M
 
&
 
S
w
a
r
t
z
 
J
R
 
(
2
0
0
0
)
 
P
r
o
l
o
n
g
i
n
g
 
c
e
l
l
-
f
r
e
e
 
p
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
 
b
y
 
s
e
l
e
c
t
i
v
e
 
r
e
a
g
e
n
t
 
 
a
d
d
i
t
i
o
n
s
.
 
B
i
o
t
e
c
h
n
o
l
 
P
r
o
g
 
1
6
,
 
3
8
5
-
9
0
.
 
8
.
 
 
J
e
w
e
t
t
 
M
C
 
&
 
S
w
a
r
t
z
 
J
R
 
(
2
0
0
4
)
 
M
i
m
i
c
k
i
n
g
 
t
h
e
 
E
s
c
h
e
r
i
c
h
i
a
 
c
o
l
i
 
c
y
t
o
p
l
a
s
m
i
c
 
e
n
v
i
r
o
n
m
e
n
t
 
 
a
c
t
i
v
a
t
e
s
 
l
o
n
g
-
l
i
v
e
d
 
a
n
d
 
e
f
f
i
c
i
e
n
t
 
c
e
l
l
-
f
r
e
e
 
p
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
.
 
B
i
o
t
e
c
h
n
o
l
 
B
i
o
e
n
g
 
8
6
,
 
1
9
-
2
6
.
 
9
.
 
 
J
e
w
e
t
t
 
M
C
 
&
 
S
w
a
r
t
z
 
J
R
 
(
2
0
0
4
)
 
S
u
b
s
t
r
a
t
e
 
r
e
p
l
e
n
i
s
h
m
e
n
t
 
e
x
t
e
n
d
s
 
p
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
 
w
i
t
h
 
a
n
 
 
i
n
 
v
i
t
r
o
 
t
r
a
n
s
l
a
t
i
o
n
 
s
y
s
t
e
m
 
d
e
s
i
g
n
e
d
 
t
o
 
m
i
m
i
c
 
t
h
e
 
c
y
t
o
p
l
a
s
m
.
 
B
i
o
t
e
c
h
n
o
l
 
B
i
o
e
n
g
 
8
7
,
 
4
6
5
-
 
7
2
.
 
1
0
.
 
M
i
c
h
e
l
-
R
e
y
d
e
l
l
e
t
 
N
,
 
C
a
l
h
o
u
n
 
K
 
&
 
S
w
a
r
t
z
 
J
 
(
2
0
0
4
)
 
A
m
i
n
o
 
a
c
i
d
 
s
t
a
b
i
l
i
z
a
t
i
o
n
 
f
o
r
 
c
e
l
l
-
f
r
e
e
 
 
p
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
 
b
y
 
m
o
d
i
f
i
c
a
t
i
o
n
 
o
f
 
t
h
e
 
E
s
c
h
e
r
i
c
h
i
a
 
c
o
l
i
 
g
e
n
o
m
e
.
 
M
e
t
a
b
 
E
n
g
 
6
,
 
1
9
7
-
2
0
3
.
 
1
1
.
 
K
l
a
m
m
t
 
C
,
 
L
o
h
r
 
F
,
 
S
c
h
a
f
e
r
 
B
,
 
H
a
a
s
e
 
W
,
 
D
o
t
s
c
h
 
V
,
 
R
u
t
e
r
j
a
n
s
 
H
,
 
G
l
a
u
b
i
t
z
 
C
 
&
 
B
e
r
n
h
a
r
d
 
 
F
 
(
2
0
0
4
)
 
H
i
g
h
 
l
e
v
e
l
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
a
n
d
 
s
p
e
c
i
f
i
c
 
l
a
b
e
l
i
n
g
 
o
f
 
i
n
t
e
g
r
a
l
 
m
e
m
b
r
a
n
e
 
 
p
r
o
t
e
i
n
s
.
 
E
u
r
 
J
 
B
i
o
c
h
e
m
 
2
7
1
,
 
5
6
8
-
8
0
.
 
1
2
.
 
T
o
r
i
z
a
w
a
 
T
,
 
S
h
i
m
i
z
u
 
M
,
 
T
a
o
k
a
 
M
,
 
M
i
y
a
n
o
 
H
 
&
 
K
a
i
n
o
s
h
o
 
M
 
(
2
0
0
4
)
 
E
f
f
i
c
i
e
n
t
 
p
r
o
d
u
c
t
i
o
n
 
 
o
f
 
i
s
o
t
o
p
i
c
a
l
l
y
 
l
a
b
e
l
e
d
 
p
r
o
t
e
i
n
s
 
b
y
 
c
e
l
l
-
f
r
e
e
 
s
y
n
t
h
e
s
i
s
:
 
a
 
p
r
a
c
t
i
c
a
l
 
p
r
o
t
o
c
o
l
.
 
J
 
B
i
o
m
o
l
 
N
M
R
 
 
3
0
,
 
3
1
1
-
2
5
.
 
 
2
0
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t
u
r
e
 
o
f
 
t
h
e
 
b
a
c
t
e
r
i
a
l
 
n
u
c
l
e
o
s
i
d
e
 
t
r
a
n
s
p
o
r
t
e
r
 
 
T
s
x
.
 
E
m
b
o
 
J
 
2
3
,
 
3
1
8
7
-
9
5
.
 
3
7
.
 
K
i
g
a
w
a
 
T
,
 
M
u
t
o
 
Y
 
&
 
Y
o
k
o
y
a
m
a
 
S
 
(
1
9
9
5
)
 
C
e
l
l
-
f
r
e
e
 
s
y
n
t
h
e
s
i
s
 
a
n
d
 
a
m
i
n
o
 
a
c
i
d
-
s
e
l
e
c
t
i
v
e
 
 
s
t
a
b
l
e
 
i
s
o
t
o
p
e
 
l
a
b
e
l
i
n
g
 
o
f
 
p
r
o
t
e
i
n
s
 
f
o
r
 
N
M
R
 
a
n
a
l
y
s
i
s
.
 
J
 
B
i
o
m
o
l
 
N
M
R
 
6
,
 
1
2
9
-
3
4
.
 
3
8
.
 
O
z
a
w
a
 
K
,
 
D
i
x
o
n
 
N
E
 
&
 
O
t
t
i
n
g
 
G
 
(
2
0
0
5
)
 
C
e
l
l
-
f
r
e
e
 
s
y
n
t
h
e
s
i
s
 
o
f
 
1
5
N
-
l
a
b
e
l
e
d
 
p
r
o
t
e
i
n
s
 
f
o
r
 
 
N
M
R
 
s
t
u
d
i
e
s
.
 
I
U
B
M
B
 
L
i
f
e
 
5
7
,
 
6
1
5
-
2
2
.
 
 
2
2
 
3
9
.
 
T
u
g
a
r
i
n
o
v
 
V
,
 
M
u
h
a
n
d
i
r
a
m
 
R
,
 
A
y
e
d
 
A
 
&
 
K
a
y
 
L
E
 
(
2
0
0
2
)
 
F
o
u
r
-
d
i
m
e
n
s
i
o
n
a
l
 
N
M
R
 
 
s
p
e
c
t
r
o
s
c
o
p
y
 
o
f
 
a
 
7
2
3
-
r
e
s
i
d
u
e
 
p
r
o
t
e
i
n
:
 
c
h
e
m
i
c
a
l
 
s
h
i
f
t
 
a
s
s
i
g
n
m
e
n
t
s
 
a
n
d
 
s
e
c
o
n
d
a
r
y
 
s
t
r
u
c
t
u
r
e
 
 
o
f
 
m
a
l
a
t
e
 
s
y
n
t
h
a
s
e
.
 
J
 
A
m
 
C
h
e
m
 
S
o
c
 
1
2
4
,
 
1
0
0
2
5
-
3
5
.
 
4
0
.
 
C
h
i
l
l
 
J
H
,
 
L
o
u
i
s
 
J
M
,
 
M
i
l
l
e
r
 
C
 
&
 
B
a
x
 
A
 
(
2
0
0
6
)
 
N
M
R
 
s
t
u
d
y
 
o
f
 
t
h
e
 
t
e
t
r
a
m
e
r
i
c
 
K
c
s
A
 
 
p
o
t
a
s
s
i
u
m
 
c
h
a
n
n
e
l
 
i
n
 
d
e
t
e
r
g
e
n
t
 
m
i
c
e
l
l
e
s
.
 
P
r
o
t
e
i
n
 
S
c
i
 
1
5
,
 
6
8
4
-
6
9
8
.
 
4
1
.
 
T
u
g
a
r
i
n
o
v
 
V
,
 
H
w
a
n
g
 
P
M
 
&
 
K
a
y
 
L
E
 
(
2
0
0
4
)
 
N
u
c
l
e
a
r
 
m
a
g
n
e
t
i
c
 
r
e
s
o
n
a
n
c
e
 
s
p
e
c
t
r
o
s
c
o
p
y
 
o
f
 
 
h
i
g
h
-
m
o
l
e
c
u
l
a
r
-
w
e
i
g
h
t
 
p
r
o
t
e
i
n
s
.
 
A
n
n
u
 
R
e
v
 
B
i
o
c
h
e
m
 
7
3
,
 
1
0
7
-
4
6
.
 
4
2
.
 
K
r
u
e
g
e
r
-
K
o
p
l
i
n
 
R
D
,
 
S
o
r
g
e
n
 
P
L
,
 
K
r
u
e
g
e
r
-
K
o
p
l
i
n
 
S
T
,
 
R
i
v
e
r
a
-
T
o
r
r
e
s
 
I
O
,
 
C
a
h
i
l
l
 
S
M
,
 
H
i
c
k
s
 
 
D
B
,
 
G
r
i
n
i
u
s
 
L
,
 
K
r
u
l
w
i
c
h
 
T
A
 
&
 
G
i
r
v
i
n
 
M
E
 
(
2
0
0
4
)
 
A
n
 
e
v
a
l
u
a
t
i
o
n
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
f
o
r
 
N
M
R
 
 
s
t
r
u
c
t
u
r
a
l
 
s
t
u
d
i
e
s
 
o
f
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
.
 
J
 
B
i
o
m
o
l
 
N
M
R
 
2
8
,
 
4
3
-
5
7
.
 
4
3
.
 
R
o
o
s
i
l
d
 
T
P
,
 
G
r
e
e
n
w
a
l
d
 
J
,
 
V
e
g
a
 
M
,
 
C
a
s
t
r
o
n
o
v
o
 
S
,
 
R
i
e
k
 
R
 
&
 
C
h
o
e
 
S
 
(
2
0
0
5
)
 
N
M
R
 
 
s
t
r
u
c
t
u
r
e
 
o
f
 
M
i
s
t
i
c
,
 
a
 
m
e
m
b
r
a
n
e
-
i
n
t
e
g
r
a
t
i
n
g
 
p
r
o
t
e
i
n
 
f
o
r
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
.
 
 
S
c
i
e
n
c
e
 
3
0
7
,
 
1
3
1
7
-
2
1
.
 
4
4
.
 
P
a
r
k
e
r
 
M
J
,
 
A
u
l
t
o
n
-
J
o
n
e
s
 
M
,
 
H
o
u
n
s
l
o
w
 
A
M
 
&
 
C
r
a
v
e
n
 
C
J
 
(
2
0
0
4
)
 
A
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
 
s
e
l
e
c
t
i
v
e
 
l
a
b
e
l
i
n
g
 
m
e
t
h
o
d
 
f
o
r
 
t
h
e
 
a
s
s
i
g
n
m
e
n
t
 
o
f
 
b
a
c
k
b
o
n
e
 
a
m
i
d
e
 
N
M
R
 
r
e
s
o
n
a
n
c
e
s
.
 
J
 
A
m
 
 
C
h
e
m
 
S
o
c
 
1
2
6
,
 
5
0
2
0
-
1
.
 
4
5
.
 
W
u
 
P
S
,
 
O
z
a
w
a
 
K
,
 
J
e
r
g
i
c
 
S
,
 
S
u
 
X
C
,
 
D
i
x
o
n
 
N
E
 
&
 
O
t
t
i
n
g
 
G
 
(
2
0
0
6
)
 
A
m
i
n
o
-
a
c
i
d
 
t
y
p
e
 
 
i
d
e
n
t
i
f
i
c
a
t
i
o
n
 
i
n
 
1
5
N
-
H
S
Q
C
 
s
p
e
c
t
r
a
 
b
y
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
s
e
l
e
c
t
i
v
e
 
1
5
N
-
l
a
b
e
l
l
i
n
g
.
 
J
 
B
i
o
m
o
l
 
 
N
M
R
 
3
4
,
 
1
3
-
2
1
.
 
4
6
.
 
P
e
r
v
u
s
h
i
n
 
K
,
 
R
i
e
k
 
R
,
 
W
i
d
e
r
 
G
 
&
 
W
u
t
h
r
i
c
h
 
K
 
(
1
9
9
7
)
 
A
t
t
e
n
u
a
t
e
d
 
T
2
 
r
e
l
a
x
a
t
i
o
n
 
b
y
 
m
u
t
u
a
l
 
 
c
a
n
c
e
l
l
a
t
i
o
n
 
o
f
 
d
i
p
o
l
e
-
d
i
p
o
l
e
 
c
o
u
p
l
i
n
g
 
a
n
d
 
c
h
e
m
i
c
a
l
 
s
h
i
f
t
 
a
n
i
s
o
t
r
o
p
y
 
i
n
d
i
c
a
t
e
s
 
a
n
 
a
v
e
n
u
e
 
 
t
o
 
N
M
R
 
s
t
r
u
c
t
u
r
e
s
 
o
f
 
v
e
r
y
 
l
a
r
g
e
 
b
i
o
l
o
g
i
c
a
l
 
m
a
c
r
o
m
o
l
e
c
u
l
e
s
 
i
n
 
s
o
l
u
t
i
o
n
.
 
P
r
o
c
 
N
a
t
l
 
A
c
a
d
 
 
S
c
i
 
U
 
S
 
A
 
9
4
,
 
1
2
3
6
6
-
7
1
.
 
4
7
.
 
L
a
w
s
 
D
D
,
 
B
i
t
t
e
r
 
H
M
 
&
 
J
e
r
s
c
h
o
w
 
A
 
(
2
0
0
2
)
 
S
o
l
i
d
-
s
t
a
t
e
 
N
M
R
 
s
p
e
c
t
r
o
s
c
o
p
i
c
 
m
e
t
h
o
d
s
 
 
i
n
 
c
h
e
m
i
s
t
r
y
.
 
A
n
g
e
w
 
C
h
e
m
 
I
n
t
 
E
d
 
E
n
g
l
 
4
1
,
 
3
0
9
6
-
1
2
9
.
 
 
4
8
.
 
L
u
c
a
 
S
,
 
W
h
i
t
e
 
J
F
,
 
S
o
h
a
l
 
A
K
,
 
F
i
l
i
p
p
o
v
 
D
V
,
 
v
a
n
 
B
o
o
m
 
J
H
,
 
G
r
i
s
s
h
a
m
m
e
r
 
R
 
&
 
B
a
l
d
u
s
 
M
 
 
(
2
0
0
3
)
 
T
h
e
 
c
o
n
f
o
r
m
a
t
i
o
n
 
o
f
 
n
e
u
r
o
t
e
n
s
i
n
 
b
o
u
n
d
 
t
o
 
i
t
s
 
G
 
p
r
o
t
e
i
n
-
c
o
u
p
l
e
d
 
r
e
c
e
p
t
o
r
.
 
P
r
o
c
 
 
N
a
t
l
 
A
c
a
d
 
S
c
i
 
U
 
S
 
A
 
1
0
0
,
 
1
0
7
0
6
-
1
1
.
 
4
9
.
 
R
i
t
t
e
r
 
C
,
 
M
a
d
d
e
l
e
i
n
 
M
L
,
 
S
i
e
m
e
r
 
A
B
,
 
L
u
h
r
s
 
T
,
 
E
r
n
s
t
 
M
,
 
M
e
i
e
r
 
B
H
,
 
S
a
u
p
e
 
S
J
 
&
 
R
i
e
k
 
R
 
 
(
2
0
0
5
)
 
C
o
r
r
e
l
a
t
i
o
n
 
o
f
 
s
t
r
u
c
t
u
r
a
l
 
e
l
e
m
e
n
t
s
 
a
n
d
 
i
n
f
e
c
t
i
v
i
t
y
 
o
f
 
t
h
e
 
H
E
T
-
s
 
p
r
i
o
n
.
 
N
a
t
u
r
e
 
4
3
5
,
 
 
8
4
4
-
8
.
 
5
0
.
 
H
i
l
l
e
r
 
M
,
 
K
r
a
b
b
e
n
 
L
,
 
V
i
n
o
t
h
k
u
m
a
r
 
K
R
,
 
C
a
s
t
e
l
l
a
n
i
 
F
,
 
v
a
n
 
R
o
s
s
u
m
 
B
J
,
 
K
u
h
l
b
r
a
n
d
t
 
W
 
&
 
 
O
s
c
h
k
i
n
a
t
 
H
 
(
2
0
0
5
)
 
S
o
l
i
d
-
s
t
a
t
e
 
m
a
g
i
c
-
a
n
g
l
e
 
s
p
i
n
n
i
n
g
 
N
M
R
 
o
f
 
o
u
t
e
r
-
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
 
G
 
 
f
r
o
m
 
E
s
c
h
e
r
i
c
h
i
a
 
c
o
l
i
.
 
C
h
e
m
b
i
o
c
h
e
m
 
6
,
 
1
6
7
9
-
8
4
.
  
2
3
 
5
1
.
 
L
o
r
c
h
 
M
,
 
F
a
h
e
m
 
S
,
 
K
a
i
s
e
r
 
C
,
 
W
e
b
e
r
 
I
,
 
M
a
s
o
n
 
A
J
,
 
B
o
w
i
e
 
J
U
 
&
 
G
l
a
u
b
i
t
z
 
C
 
(
2
0
0
5
)
 
H
o
w
 
t
o
 
 
P
r
e
p
a
r
e
 
M
e
m
b
r
a
n
e
 
P
r
o
t
e
i
n
s
 
f
o
r
 
S
o
l
i
d
-
S
t
a
t
e
 
N
M
R
:
 
A
 
C
a
s
e
 
S
t
u
d
y
 
o
n
 
t
h
e
 
a
l
p
h
a
-
H
e
l
i
c
a
l
 
 
I
n
t
e
g
r
a
l
 
M
e
m
b
r
a
n
e
 
P
r
o
t
e
i
n
 
D
i
a
c
y
l
g
l
y
c
e
r
o
l
 
K
i
n
a
s
e
 
f
r
o
m
 
E
.
 
c
o
l
i
.
 
C
h
e
m
b
i
o
c
h
e
m
 
6
,
 
1
6
9
3
-
 
1
7
0
0
.
 
5
2
.
 
M
a
s
o
n
 
A
J
,
 
S
i
a
r
h
e
y
e
v
a
 
A
,
 
H
a
a
s
e
 
W
,
 
L
o
r
c
h
 
M
,
 
v
a
n
 
V
e
e
n
 
H
W
 
&
 
G
l
a
u
b
i
t
z
 
C
 
(
2
0
0
4
)
 
A
m
i
n
o
 
 
a
c
i
d
 
t
y
p
e
 
s
e
l
c
t
i
v
e
 
i
s
o
t
o
p
e
 
l
a
b
e
l
l
i
n
g
 
o
f
 
t
h
e
 
m
u
l
t
i
d
r
u
g
 
A
B
C
 
t
r
a
n
s
p
o
r
t
e
r
 
L
m
r
A
 
f
o
r
 
s
o
l
i
d
-
s
t
a
t
e
 
 
N
M
R
 
s
t
u
d
i
e
s
.
 
F
E
B
S
 
L
e
t
t
e
r
s
 
5
6
8
,
 
1
1
7
-
1
2
1
.
 
5
3
.
 
P
a
t
c
h
i
n
g
 
S
G
,
 
B
r
o
u
g
h
 
A
R
,
 
H
e
r
b
e
r
t
 
R
B
,
 
R
a
j
a
k
a
r
i
e
r
 
J
A
,
 
H
e
n
d
e
r
s
o
n
 
P
J
 
&
 
M
i
d
d
l
e
t
o
n
 
D
A
 
 
(
2
0
0
4
)
 
S
u
b
s
t
r
a
t
e
 
a
f
f
i
n
i
t
i
e
s
 
f
o
r
 
m
e
m
b
r
a
n
e
 
t
r
a
n
s
p
o
r
t
 
p
r
o
t
e
i
n
s
 
d
e
t
e
r
m
i
n
e
d
 
b
y
 
1
3
C
 
c
r
o
s
s
-
 
p
o
l
a
r
i
z
a
t
i
o
n
 
m
a
g
i
c
-
a
n
g
l
e
 
s
p
i
n
n
i
n
g
 
n
u
c
l
e
a
r
 
m
a
g
n
e
t
i
c
 
r
e
s
o
n
a
n
c
e
 
s
p
e
c
t
r
o
s
c
o
p
y
.
 
J
 
A
m
 
C
h
e
m
 
 
S
o
c
 
1
2
6
,
 
3
0
7
2
-
8
0
.
 
5
4
.
 
Y
a
m
a
g
u
c
h
i
 
S
,
 
T
u
z
i
 
S
,
 
B
o
w
i
e
 
J
U
 
&
 
S
a
i
t
o
 
H
 
(
2
0
0
4
)
 
S
e
c
o
n
d
a
r
y
 
s
t
r
u
c
t
u
r
e
 
a
n
d
 
b
a
c
k
b
o
n
e
 
 
d
y
n
a
m
i
c
s
 
o
f
 
E
s
c
h
e
r
i
c
h
i
a
 
c
o
l
i
 
d
i
a
c
y
l
g
l
y
c
e
r
o
l
 
k
i
n
a
s
e
,
 
a
s
 
r
e
v
e
a
l
e
d
 
b
y
 
s
i
t
e
-
d
i
r
e
c
t
e
d
 
s
o
l
i
d
-
s
t
a
t
e
 
 
1
3
C
 
N
M
R
.
 
B
i
o
c
h
i
m
 
B
i
o
p
h
y
s
 
A
c
t
a
 
1
6
9
8
,
 
9
7
-
1
0
5
.
 
 
 
 
 
 
2
4
 
L
e
g
e
n
d
s
 
t
o
 
t
h
e
 
f
i
g
u
r
e
s
 
 
F
i
g
.
 
1
.
 
C
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
m
o
d
e
s
.
 
T
h
e
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
I
M
P
s
 
c
a
n
 
b
e
 
r
u
n
 
i
n
 
t
h
r
e
e
 
d
i
f
f
e
r
e
n
t
 
m
o
d
e
s
:
 
I
M
P
s
 
c
a
n
 
b
e
 
e
x
p
r
e
s
s
e
d
 
a
s
 
p
r
e
c
i
p
i
t
a
t
e
 
(
M
o
d
e
 
A
)
,
 
s
o
l
u
b
i
l
i
z
e
d
 
i
n
 
a
n
 
a
p
p
r
o
p
r
i
a
t
e
 
d
e
t
e
r
g
e
n
t
 
a
n
d
 
f
u
r
t
h
e
r
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
i
n
t
o
 
p
r
o
t
e
o
l
i
p
o
s
o
m
e
s
.
 
A
l
t
e
r
n
a
t
i
v
e
l
y
 
t
h
e
 
I
M
P
s
 
c
a
n
 
b
e
 
s
o
l
u
b
l
e
 
e
x
p
r
e
s
s
e
d
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
d
e
t
e
r
g
e
n
t
s
 
(
M
o
d
e
 
B
)
,
 
p
u
r
i
f
i
e
d
 
a
n
d
 
r
e
c
o
n
s
t
i
t
u
t
e
d
 
i
n
t
o
 
p
r
o
t
e
o
l
i
p
o
s
o
m
e
s
,
 
o
r
 
e
x
p
r
e
s
s
e
d
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
p
r
e
f
o
r
m
e
d
 
l
i
p
o
s
o
m
e
s
 
(
M
o
d
e
 
C
)
 
a
n
d
 
i
s
o
l
a
t
e
d
 
f
r
o
m
 
t
h
e
 
R
M
 
b
y
 
d
e
n
s
i
t
y
 
g
r
a
d
i
e
n
t
 
c
e
n
t
r
i
f
u
g
a
t
i
o
n
.
 
C
D
,
 
c
i
r
c
u
l
a
r
 
d
i
c
h
r
o
i
s
m
;
 
E
M
,
 
e
l
e
c
t
r
o
n
 
m
i
c
r
o
s
c
o
p
y
;
 
N
M
R
,
 
n
u
c
l
e
a
r
 
m
a
g
n
e
t
i
c
 
r
e
s
o
n
a
n
c
e
.
 
 
F
i
g
.
 
2
.
 
O
v
e
r
p
r
o
d
u
c
t
i
o
n
 
o
f
 
i
n
t
e
g
r
a
l
 
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
s
 
b
y
 
c
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
.
 
S
D
S
-
p
o
l
y
a
c
r
y
l
a
m
i
d
e
 
g
e
l
 
a
n
a
l
y
s
i
s
 
o
f
 
I
M
P
s
 
f
r
o
m
 
d
i
f
f
e
r
e
n
t
 
f
a
m
i
l
i
e
s
 
t
h
a
t
 
h
a
v
e
 
b
e
e
n
 
C
F
 
p
r
o
d
u
c
e
d
 
e
i
t
h
e
r
 
a
s
 
p
r
e
c
i
p
i
t
a
t
e
 
o
r
 
i
n
 
s
o
l
u
b
l
e
 
f
o
r
m
 
i
n
 
p
r
e
s
e
n
c
e
 
o
f
 
d
e
t
e
r
g
e
n
t
s
.
 
1
 
µ
l
 
s
a
m
p
l
e
s
 
o
f
 
t
h
e
 
s
o
l
u
b
l
e
 
o
r
 
o
f
 
t
h
e
 
r
e
s
u
s
p
e
n
d
e
d
 
i
n
s
o
l
u
b
l
e
 
p
a
r
t
 
o
f
 
t
h
e
 
R
M
 
w
e
r
e
 
a
n
a
l
y
z
e
d
 
o
n
 
1
0
 
%
 
t
r
i
c
i
n
e
 
S
D
S
 
g
e
l
s
 
(
l
a
n
e
s
 
1
-
3
,
 
1
0
)
,
 
1
2
 
%
 
S
D
S
 
g
e
l
s
 
(
l
a
n
e
s
 
4
,
 
1
3
-
1
6
)
 
o
r
 
1
6
.
5
 
%
 
S
D
S
 
g
e
l
s
 
(
l
a
n
e
s
 
5
-
9
,
 
1
1
,
 
1
2
)
.
 
T
h
e
 
o
v
e
r
p
r
o
d
u
c
e
d
 
I
M
P
s
 
a
r
e
 
i
n
d
i
c
a
t
e
d
 
b
y
 
a
r
r
o
w
s
,
 
p
r
o
p
o
s
e
d
 
s
e
c
o
n
d
a
r
y
 
s
t
r
u
c
t
u
r
e
s
 
a
r
e
 
i
l
l
u
s
t
r
a
t
e
d
 
o
n
 
t
o
p
 
a
n
d
 
d
e
t
e
r
g
e
n
t
s
 
a
r
e
 
g
i
v
e
n
 
i
n
 
p
a
r
e
n
t
h
e
s
i
s
 
i
f
 
a
p
p
l
i
c
a
b
l
e
.
 
L
a
n
e
 
1
,
 
E
m
r
E
;
 
l
a
n
e
 
2
,
 
S
u
g
E
;
 
l
a
n
e
 
3
,
 
T
b
s
m
r
;
 
l
a
n
e
 
4
,
 
H
s
m
r
 
(
D
P
C
)
 
p
u
r
i
f
i
e
d
 
b
y
 
N
i
-
N
T
A
 
a
n
d
 
a
d
d
i
t
i
o
n
a
l
 
a
r
r
o
w
s
 
i
n
d
i
c
a
t
e
 
o
l
i
g
o
m
e
r
s
;
 
l
a
n
e
 
5
,
 
R
M
 
c
o
n
t
r
o
l
;
 
l
a
n
e
 
6
,
 
Y
f
i
K
 
(
B
r
i
j
-
5
8
)
;
 
l
a
n
e
 
7
,
 
Y
f
i
K
 
(
B
r
i
j
-
9
8
)
;
 
l
a
n
e
 
8
,
 
Y
f
i
K
,
 
l
a
n
e
 
9
,
 
T
e
h
A
,
 
l
a
n
e
 
1
0
,
 
Δ
T
e
h
A
;
 
l
a
n
e
 
1
1
,
 
S
e
c
E
;
 
l
a
n
e
 
1
2
,
 
T
s
x
;
 
l
a
n
e
 
1
3
,
 
p
o
r
c
i
n
e
 
V
2
R
;
 
l
a
n
e
 
1
4
,
 
h
u
m
a
n
 
V
2
R
;
 
l
a
n
e
 
1
5
,
 
r
a
t
 
C
R
F
;
 
l
a
n
e
 
1
6
,
 
h
u
m
a
n
 
E
T
B
.
 
P
,
 
p
r
e
c
i
p
i
t
a
t
e
,
 
S
,
 
s
o
l
u
b
l
e
 
e
x
p
r
e
s
s
e
d
,
 
p
,
 
p
u
r
i
f
i
e
d
.
 
 
F
i
g
.
 
3
.
 
C
e
l
l
-
f
r
e
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
b
a
c
t
e
r
i
a
l
 
g
l
u
t
a
m
a
t
e
 
t
r
a
n
s
p
o
r
t
e
r
.
 
C
F
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
d
i
f
f
e
r
e
n
t
 
e
u
k
a
r
y
o
t
i
c
 
g
l
u
t
a
m
a
t
e
 
t
r
a
n
s
p
o
r
t
e
r
 
h
o
m
o
l
o
g
u
e
s
 
a
s
 
p
r
e
c
i
p
i
t
a
t
e
.
 
A
f
t
e
r
 
C
F
 
r
e
a
c
t
i
o
n
,
 
t
h
e
 
I
M
P
 
p
e
l
l
e
t
s
 
w
e
r
e
 
s
u
s
p
e
n
d
e
d
 
i
n
 
a
 
v
o
l
u
m
e
 
e
q
u
a
l
 
t
o
 
t
h
e
 
R
M
 
a
n
d
 
5
 
μ
l
 
s
a
m
p
l
e
s
 
w
e
r
e
 
a
n
a
l
y
z
e
d
 
o
n
 
a
 
1
2
 
%
 
S
D
S
 
g
e
l
.
 
S
i
z
e
s
 
o
f
 
m
a
r
k
e
r
 
p
r
o
t
e
i
n
s
 
(
k
D
a
)
 
a
r
e
 
i
n
d
i
c
a
t
e
d
.
 
T
h
e
 
a
r
r
o
w
s
 
i
n
d
i
c
a
t
e
 
t
h
e
 
s
y
n
t
h
e
s
i
z
e
d
 
g
l
u
t
a
m
a
t
e
 
t
r
a
n
s
p
o
r
t
e
r
 
h
o
m
o
l
o
g
u
e
s
.
 
 
F
i
g
.
 
4
.
 
L
i
q
u
i
d
-
s
t
a
t
e
 
N
M
R
 
o
f
 
c
e
l
l
-
f
r
e
e
 
p
r
o
d
u
c
e
d
 
t
r
a
n
s
p
o
r
t
e
r
s
.
 
1
H
-
1
5
N
 
T
R
O
S
Y
-
H
S
Q
C
 
s
p
e
c
t
r
a
 
o
f
 
C
F
 
e
x
p
r
e
s
s
e
d
 
1
5
N
 
l
a
b
e
l
l
e
d
 
I
M
P
s
.
 
T
h
e
 
p
r
o
t
e
i
n
s
 
w
e
r
e
 
e
x
p
r
e
s
s
e
d
 
a
s
 
p
r
e
c
i
p
i
t
a
t
e
s
 
a
n
d
 
s
o
l
u
b
i
l
i
z
e
d
 
i
n
 
L
M
P
G
.
 
A
,
 
U
-
1
5
N
 
l
a
b
e
l
l
e
d
 
S
e
c
E
;
 
B
,
 
U
-
1
5
N
 
l
a
b
e
l
l
e
d
 
Y
f
i
K
;
 
C
,
 
U
-
1
5
N
 
l
a
b
e
l
l
e
d
 
Δ
T
e
h
A
;
 
D
,
 
1
5
N
-
t
h
r
e
o
n
i
n
e
 
l
a
b
e
l
l
e
d
 
Δ
T
e
h
A
;
 
E
,
 
1
5
N
-
t
r
y
p
t
o
p
h
a
n
 
l
a
b
e
l
l
e
d
 
Δ
T
e
h
A
;
 
F
,
 
1
5
N
-
i
s
o
l
e
u
c
i
n
e
 
l
a
b
e
l
l
e
d
 
Δ
T
e
h
A
;
 
G
,
 
1
5
N
-
m
e
t
h
i
o
n
i
n
e
 
l
a
b
e
l
l
e
d
 
Δ
T
e
h
A
;
 
H
,
 
1
5
N
-
p
h
e
n
y
l
a
l
a
n
i
n
e
 
l
a
b
e
l
l
e
d
 
Δ
T
e
h
A
;
 
I
,
 
1
5
N
-
a
r
g
i
n
i
n
e
 
l
a
b
e
l
l
e
d
 
Δ
T
e
h
A
.
 
T
h
e
 
p
r
o
t
e
i
n
 
p
r
e
c
i
p
i
t
a
t
e
s
 
w
e
r
e
 
d
i
s
s
o
l
v
e
d
 
i
n
 
2
5
 
m
M
  
2
5
 
p
o
t
a
s
s
i
u
m
 
p
h
o
s
p
h
a
t
e
 
b
u
f
f
e
r
 
(
p
H
 
6
.
0
)
 
c
o
n
t
a
i
n
i
n
g
 
5
 
%
 
L
M
P
G
 
(
A
,
 
B
,
 
D
-
I
)
 
o
r
 
d
i
s
s
o
l
v
e
d
 
i
n
 
L
M
P
G
,
 
p
u
r
i
f
i
e
d
 
b
y
 
N
i
-
N
T
A
 
c
h
r
o
m
a
t
o
g
r
a
p
h
y
 
a
n
d
 
e
q
u
i
l
i
b
r
a
t
e
d
 
i
n
 
2
0
 
m
M
 
M
E
S
/
B
i
s
-
T
r
i
s
 
(
p
H
 
6
.
0
)
 
w
i
t
h
 
2
 
%
 
L
M
P
G
 
(
C
)
.
 
T
h
e
 
s
p
e
c
t
r
a
 
w
e
r
e
 
t
a
k
e
n
 
w
i
t
h
 
p
r
o
t
e
i
n
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
o
f
 
1
 
m
M
 
f
o
r
 
S
e
c
E
,
 
1
 
m
M
 
f
o
r
 
Y
f
i
K
,
 
0
.
1
 
m
M
 
f
o
r
 
Δ
T
e
h
A
 
a
n
d
 
0
.
9
 
m
M
 
f
o
r
 
s
e
l
e
c
t
i
v
e
l
y
 
Δ
T
e
h
A
 
s
a
m
p
l
e
s
 
(
D
-
I
)
 
a
t
 
4
0
°
C
 
o
n
 
a
 
6
0
0
 
M
H
z
 
(
A
)
,
 
7
0
0
 
M
H
z
 
(
B
)
,
 
9
0
0
 
M
H
z
 
(
C
)
 
o
r
 
o
n
 
a
 
8
0
0
 
M
H
z
 
N
M
R
 
s
p
e
c
t
r
o
m
e
t
e
r
 
(
D
-
I
)
,
 
a
l
l
 
e
q
u
i
p
p
e
d
 
w
i
t
h
 
 
c
r
y
o
g
e
n
i
c
 
1
H
 
[
1
3
C
/
1
5
N
]
 
t
r
i
p
l
e
-
r
e
s
o
n
a
n
c
e
 
p
r
o
b
e
s
.
 
 
F
i
g
.
 
5
.
 
C
o
m
b
i
n
a
t
o
r
i
a
l
 
l
a
b
e
l
l
i
n
g
 
a
p
p
r
o
a
c
h
.
 
E
x
a
m
p
l
e
 
o
f
 
a
 
c
o
m
b
i
n
a
t
o
r
i
a
l
 
l
a
b
e
l
l
i
n
g
 
s
c
h
e
m
e
 
w
i
t
h
 
t
h
r
e
e
 
d
i
f
f
e
r
e
n
t
i
a
l
l
y
 
1
5
N
 
a
n
d
 
1
3
C
 
l
a
b
e
l
l
e
d
 
s
a
m
p
l
e
s
 
o
f
 
t
h
e
 
t
e
l
l
u
r
i
t
e
 
t
r
a
n
s
p
o
r
t
e
r
 
∆
T
e
h
A
.
 
T
h
e
 
l
a
b
e
l
l
i
n
g
 
s
c
h
e
m
e
 
i
s
 
s
h
o
w
n
 
i
n
 
t
h
e
 
t
a
b
l
e
 
o
n
 
t
o
p
.
 
I
n
 
t
h
e
 
[
1
5
N
,
 
1
H
]
-
T
R
O
S
Y
 
s
p
e
c
t
r
a
,
 
b
a
c
k
b
o
n
e
 
a
m
i
d
e
 
p
r
o
t
o
n
s
 
o
f
 
t
h
e
 
1
5
N
-
l
a
b
e
l
l
e
d
 
a
m
i
n
o
 
a
c
i
d
s
 
a
r
e
 
v
i
s
i
b
l
e
.
 
T
h
e
 
c
r
o
s
s
e
d
 
l
i
n
e
s
 
i
n
d
i
c
a
t
e
 
t
h
e
 
p
e
a
k
 
t
o
 
b
e
c
o
m
e
 
i
d
e
n
t
i
f
i
e
d
.
 
T
h
e
 
i
n
d
i
c
a
t
e
d
 
p
e
a
k
 
a
t
 
p
o
s
i
t
i
o
n
 
1
1
7
.
5
/
7
.
7
8
 
i
s
 
i
d
e
n
t
i
f
i
e
d
 
a
s
 
p
h
e
n
y
l
a
l
a
n
i
n
e
 
a
s
 
i
t
 
i
s
 
p
r
e
s
e
n
t
 
i
n
 
s
a
m
p
l
e
s
 
1
 
a
n
d
 
2
,
 
b
u
t
 
n
o
t
 
i
n
 
s
a
m
p
l
e
 
3
.
 
T
h
e
 
c
o
r
r
e
s
p
o
n
d
i
n
g
 
H
N
C
O
 
s
p
e
c
t
r
a
 
s
h
o
w
 
t
h
e
 
a
m
i
d
e
 
c
r
o
s
s
p
e
a
k
s
 
a
f
t
e
r
 
c
a
r
b
o
n
y
l
 
t
r
a
n
s
f
e
r
 
(
b
i
g
 
a
r
r
o
w
)
 
a
n
d
 
i
n
d
i
c
a
t
e
 
t
h
a
t
 
t
h
e
 
p
r
e
c
e
d
i
n
g
 
r
e
s
i
d
u
e
 
o
f
 
t
h
i
s
 
p
h
e
n
y
l
a
l
a
n
i
n
e
 
m
u
s
t
 
b
e
 
a
 
g
l
y
c
i
n
e
,
 
a
s
 
n
o
 
c
r
o
s
s
p
e
a
k
s
 
a
r
e
 
v
i
s
i
b
l
e
 
i
n
 
s
a
m
p
l
e
 
2
 
a
n
d
 
3
 
w
i
t
h
o
u
t
 
1
3
C
-
g
l
y
c
i
n
e
.
 
T
h
e
 
a
n
a
l
y
s
e
d
 
p
h
e
n
y
l
a
l
a
n
i
n
e
 
r
e
s
i
d
u
e
 
c
a
n
 
n
o
w
 
b
e
 
l
o
c
a
l
i
z
e
d
 
i
n
 
a
 
G
l
y
-
P
h
e
 
p
a
i
r
 
i
n
 
t
h
e
 
p
r
i
m
a
r
y
 
s
e
q
u
e
n
c
e
 
w
h
i
c
h
 
i
n
 
t
h
a
t
 
e
x
a
m
p
l
e
 
w
a
s
 
i
d
e
n
t
i
f
i
e
d
 
a
s
 
P
h
e
9
7
 
o
f
 
∆
T
e
h
A
.
 
A
l
l
 
s
p
e
c
t
r
a
 
w
e
r
e
 
r
e
c
o
r
d
e
d
 
a
t
 
a
 
B
r
u
k
e
r
 
A
v
a
n
c
e
 
6
0
0
 
M
H
z
 
s
p
e
c
t
r
o
m
e
t
e
r
.
 
 
F
i
g
.
 
6
.
 
S
o
l
i
d
-
s
t
a
t
e
 
N
M
R
 
s
p
e
c
t
r
o
s
c
o
p
y
 
o
f
 
c
e
l
l
-
f
r
e
e
 
p
r
o
d
u
c
e
d
 
m
u
l
t
i
d
r
u
g
 
t
r
a
n
s
p
o
r
t
e
r
.
 
I
.
 
1
5
N
-
c
r
o
s
s
 
p
o
l
a
r
i
s
a
t
i
o
n
 
(
C
P
)
-
M
A
S
 
s
p
e
c
t
r
a
 
o
f
 
1
5
N
-
L
e
u
-
E
m
r
E
 
d
i
r
e
c
t
l
y
 
a
f
t
e
r
 
C
F
 
s
y
n
t
h
e
s
i
s
 
(
A
)
,
 
a
f
t
e
r
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
i
n
 
D
D
M
 
(
B
)
 
a
n
d
 
o
f
 
1
5
N
-
P
h
e
-
H
s
m
r
 
a
f
t
e
r
 
C
F
 
e
x
p
r
e
s
s
i
o
n
,
 
s
o
l
u
b
i
l
i
z
a
t
i
o
n
 
i
n
 
D
D
M
 
a
n
d
 
r
e
c
o
n
s
t
i
t
u
t
i
o
n
 
i
n
t
o
 
E
.
 
c
o
l
i
 
l
i
p
i
d
 
l
i
p
o
s
o
m
e
s
.
 
E
x
p
e
r
i
m
e
n
t
s
 
w
e
r
e
 
p
e
r
f
o
r
m
e
d
 
a
t
 
a
 
5
 
k
H
z
 
s
a
m
p
l
e
 
s
p
i
n
n
i
n
g
 
r
a
t
e
 
a
t
 
2
5
3
 
K
 
u
s
i
n
g
 
a
 
B
r
u
k
e
r
 
7
m
m
 
M
A
S
 
p
r
o
b
e
 
a
t
 
4
0
.
5
 
M
H
z
 
f
o
r
 
E
m
r
E
 
a
n
d
 
a
t
 
8
 
k
H
z
 
s
a
m
p
l
e
 
s
p
i
n
n
i
n
g
 
r
a
t
e
 
a
t
 
2
3
0
 
K
 
u
s
i
n
g
 
a
 
B
r
u
k
e
r
 
4
 
m
m
 
M
A
S
 
p
r
o
b
e
 
a
t
 
6
0
.
8
4
 
H
z
 
f
o
r
 
H
s
m
r
.
 
T
h
e
 
C
P
 
c
o
n
t
a
c
t
 
t
i
m
e
 
w
a
s
 
1
.
5
 
m
s
,
 
5
0
.
0
0
0
 
s
c
a
n
s
 
w
e
r
e
 
a
c
c
u
m
u
l
a
t
e
d
 
a
n
d
 
f
o
r
 
H
s
m
r
 
t
h
e
 
C
P
 
c
o
n
t
a
c
t
 
t
i
m
e
 
w
a
s
 
0
.
7
5
 
m
s
 
a
n
d
 
3
0
.
0
0
0
 
s
c
a
n
s
 
w
e
r
e
 
a
c
c
u
m
u
l
a
t
e
d
.
 
I
I
.
 
1
3
C
-
C
P
-
M
A
S
 
s
p
e
c
t
r
a
 
o
f
 
1
3
C
-
G
l
u
-
E
m
r
E
 
i
n
 
D
O
P
C
.
 
(
A
)
 
A
f
t
e
r
 
r
e
c
o
n
s
t
i
t
u
t
i
o
n
 
i
n
t
o
 
D
O
P
C
,
 
m
o
s
t
 
r
e
s
o
n
a
n
c
e
s
 
a
r
e
 
o
b
s
c
u
r
e
d
 
b
y
 
t
h
e
 
o
v
e
r
a
l
l
 
n
a
t
u
r
a
l
l
y
 
a
b
u
n
d
a
n
t
 
1
3
C
 
s
i
g
n
a
l
s
 
o
f
 
l
i
p
i
d
 
a
n
d
 
p
r
o
t
e
i
n
.
 
(
B
)
 
A
p
p
l
y
i
n
g
 
d
o
u
b
l
e
-
q
u
a
n
t
u
m
 
f
i
l
t
e
r
i
n
g
 
t
e
c
h
n
i
q
u
e
s
,
 
n
a
t
u
r
a
l
 
a
b
u
n
d
a
n
c
e
 
b
a
c
k
g
r
o
u
n
d
 
c
a
n
 
b
e
 
s
u
p
p
r
e
s
s
e
d
 
a
l
l
o
w
i
n
g
 
s
e
l
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
 
o
f
 
t
h
e
 
l
a
b
e
l
l
e
d
 
s
i
t
e
s
 
(
R
e
p
r
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Abstract
Cell-free expression techniques have emerged as promising tools for the production of membrane proteins for structural and func-
tional analysis. Elimination of toxic eVects and a variety of options to stabilize the synthesized proteins enable the synthesis of otherwise
diYcult to obtain proteins. ModiWcations in the reaction design result in preparative scale production rates of cell-free reactions and yield
in milligram amounts of membrane proteins per one millilitre of reaction volume. A diverse selection of detergents can be supplied into
the reaction system without inhibitory eVects to the translation machinery. This oVers the unique opportunity to produce a membrane
protein directly into micelles of a detergent of choice. We present detailed protocols for the cell-free production of membrane proteins in
diVerent modes and we summarize the current knowledge of this technique. A special emphasize will be on the production of soluble and
functionally folded membrane proteins in presence of suitable detergents. In addition, we will highlight the advantages of cell-free expres-
sion for the structural analysis of membrane proteins especially by liquid state nuclear magnetic resonance spectroscopy and we will dis-
cuss new strategies for structural approaches.
© 2006 Published by Elsevier Inc.
Keywords: Integral membrane proteins; Structural analysis; Solubilization; Reconstitution; Detergent; NMR spectroscopy; G-protein coupled receptors;
-barrel proteins; Multidrug resistance; Cell-free expression; Detergent micelles; Transporter; Liposomes; Labelling of proteins; Stable isotopes
1. Introduction
Membrane proteins (MPs) deWne the link between phys-
iological pathways in the cytoplasm and the extracellular
environment. Essential processes like perception and trans-
duction of external signals, import or export of substances
through the membrane or the generation of energy is asso-
ciated with MPs. Many modern drugs are directed against
MPs and this class of proteins is therefore an important tar-
get for medical and pharmaceutical research. However,
high resolution structures of MPs are still the very excep-
tion. A major bottleneck for structural analysis is the lim-
ited availability of suYcient amounts of protein samples.
The bacterial Escherichia coli expression system is most fre-
quently used for the production of recombinant proteins.
Its simplicity, low costs, the wealth of elaborated protocols,
the fast growth rates and often high productivity makes this
system highly competitive against most other expression
systems. However, in vivo expression systems based on pro-
karyotic or eukaryotic cells do not work for a wide range of
MPs, toxins or other problematic targets [1]. MPs often
aVect the physiology of the cell by insertion into the cellular
membranes or by blocking protein traYcking systems. Low
expression rates, aggregation or unfolding of the recombi-
* Corresponding author. Fax: +49 69 798 29632.
E-mail address: fbern@bpc.uni-frankfurt.de (F. Bernhard).
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nant MPs and even toxic eVects to the host cells upon over-
production are therefore frequent problems when MPs
have to be produced [2].
Cell-free (CF)1 protein synthesis provides a recently
developed and powerful alternative tool for protein pro-
duction  [3–5]. A unique advantage of CF systems is the
open access to the reaction at any time of the experiment.
This enables the addition of beneWcial compounds at
deWned concentrations and at any stage of the protein syn-
thesis. No membranes have to be penetrated and no selec-
tion of substances occurs by speciWc transport systems.
Metabolic conversion or even degradation of added sub-
stances is furthermore reduced due to the restricted enzy-
matic activity of the CF extracts. The only limitation is that
the supplemented compounds must not aVect the transcrip-
tion and translation machinery of the expression system.
Degradation of proteins or nucleic acids could be prevented
by addition of corresponding inhibitor cocktails. Addition
of chaperones like the GroEL/ES or DnaK/J-GrpE systems
could facilitate the folding eYciency of heterologous pro-
teins. SpeciWc cofactors, substrates or inhibitors might help
to stabilize the synthesized recombinant proteins. The addi-
tion of detergents or lipids enables the direct translation of
MPs into deWned hydrophobic environments. DisulWde
bridges that are essential for the functional folding of many
eukaryotic proteins are likely to become formed due to the
easy access of oxygen to the CF reaction [6–8].
The elimination of cytotoxic eVects is presumably one of
the major reasons for the rapidly increasing number of
diverse MPs of prokaryotic and eukaryotic origin that can
be produced in CF systems [9–14]. While still limited, the
reported examples of CF produced MPs already comprises
-helical and -barrel type MPs of prokaryotic as well as of
eukaryotic origins. One common characteristic is their
almost complete membrane integrated topology with only
small proposed external loop regions. Especially MPs that
will not or only at minor levels be synthesized in living
E. coli cells might therefore become targets for CF expres-
sion. This feature highlights CF expression as a promising
future technique for the high level production of otherwise
diYcult to obtain MPs. Moreover, additional beneWcial
characteristics like various options to protect and to stabi-
lize recombinant proteins, the possibility to translate MPs
into preformed micelles and the considerable advantages
upon speciWc labelling approaches of proteins make CF
expression as one of the currently most versatile techniques
for the preparative scale production of proteins.
This review summarizes the preparative scale production
of MPs in CF systems based on E. coli extracts. We will
emphasize rather on the set-up of individual CF expression
systems than on commercially available systems. To our
knowledge, there are currently no reported examples of the
preparative scale production of MPs in CF systems based
on wheat germ extracts. However, these systems might play
an important role in the near future, especially for the syn-
thesis of functionally folded eukaryotic MPs. Therefore, a
short overview about the key steps in wheat germ extract
preparation and in the reaction design will be provided.
2. Preparative scale cell-free expression systems
2.1. ConWguration and productivity of CF-systems
First generation CF expression systems have been batch-
formatted reactions containing all compounds in one com-
partment. The rapid depletion of precursors in combination
with the accumulation of inhibitory breakdown products
resulted in short reaction times of less than 1h and conse-
quently in only low product yields of often not more than
several micrograms of recombinant protein per one ml of
reaction [15]. CF expression systems have therefore been
used for a long time only for the analytical scale production
of proteins. The splitting of the CF system into a reaction
mixture (RM) holding all high molecular weight com-
pounds and into a feeding mixture (FM) containing the low
molecular precursors provided the basis for several new
reaction designs with considerably improved eYciencies
[16]. A common characteristic of preparative scale CF
expression systems is the extended supply of fresh precur-
sors combined with the continuous removal of deleterious
reaction by-products like pyrophosphate. The reaction
times are extended up to approx. 20h and allow the synthe-
sis of several milligram amounts of protein per 1ml of RM
[17,18]. A frequently used reaction design for the high level
production of proteins is the continuous-exchange cell-free
(CECF) system [16]. The Wxed volume compartments of
1 Abbreviations: AcP, acetyl phosphate; Brij35, polyoxyethylene-(23)-
lauryl-ether; Brij56, polyoxyethylene-(10)-cetyl-ether; Brij58, polyoxyeth-
ylene-(20)-cetyl-ether; Brij72, polyoxyethylene-(2)-stearyl-ether; Brij78,
polyoxyethylene-(20)-stearyl-ether; Brij97, polyoxyethylene-(10)-oleyl-
ether; Brij98, polyoxyethylene-(20)-oleyl-ether; CECF, continuous-ex-
change cell-free; CF, cell-free; CHAPS, 3-[(3-cholamidopropyl)dimethyl
ammonio]-1-propansulfonat; CMC, critical micellar concentration; C12E8,
polyoxyethylene-(8)-lauryl-ether; DHPC, 1,2-diheptanoyl-sn-glycero-3-
phosphocholine; diC6PC, 1,2-dihexanoyl-sn-glycero-3-phosphocholine;
diC8PC, 1,2-dioctanoyl-sn-glycero-3-phosphocholine; DDM, n-dodecyl-
-D-maltoside; DM, n-decyl--D-maltoside; DMPC, di-myristoyl-phos-
phatidyl-choline; DPC, dodecyl-phosphocholine; FID, free induction de-
cay; FM, feeding mixture; Genapol C 100, polyoxyethylene-(10)-dodecyl-
ether; Genapol X 100, polyoxyethylene-(10)-isotridecyl-ether; GPCR,
G-protein coupled receptor; HECAMEG, (6-O-(N-heptylcarbamoyl)-
methyl--D-glucopyranoside); HSQC, heteronuclear single quantum
correlation; LMPG, 1-myristoyl-2-hydroxy-sn-glycerol-3-[phosphor-rac-
(1-glycerol)]; LPPG, 1-palmitoyl-2-hydroxy-sn-glycerol-3-[phosphor-rac-
(1-glycerol)]; MM, master mixture; MP, membrane protein; MWCO,
molecular weight cut-oV; NG, n-nonyl--D-glucoside; NMR, nuclear mag-
netic resonance; NP40, nonylphenyl-polyethylene-glycol; NTP, nucleotide
triphosphate; -OG, n-octyl--D-glucopyranoside; OMP, outer membrane
protein; PCR, polymerase chain reaction; PEP, phosphoenol pyruvate;
RM, reaction mixture; SDS, sodium-dodecyl-sulfate; TB, terriWc broth;
Thesit, polyethylene-glycol 400 dodecylether; TMS, transmembrane seg-
ment; Triton X-100, polyethylene-glycol P-1,1,3,3-tetra-methyl-butylphe-
nyl-ether; TROSY, transverse relaxation optimized spectroscopy;
Tween20, polyoxyethylene-sorbitan-monolaurate 20; Tween40, polyoxy-
ethylene-sorbitan-monopalmitate 20; Tween60, polyoxyethylene-sorbitan-
monostearate 20; Tween80, polyoxyethylene-sorbitan-monoleate 20;
UTR, untranslated region.
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RM and FM are separated by a semipermeable membrane
with molecular weight cut-oVs (MWCOs) between 10 and
50kDa that ensures an eYcient exchange of compounds
(Fig. 1). The individual components of the translation
machinery obviously stick together in a macromolecular
complex and despite the relatively high MWCO of the
membrane, no signiWcant leakage of translation factors is
noticed. The reaction is incubated with intensive agitation
like stirring, shaking or rotating in order to provide an opti-
mal exchange between the two compartments. Commercial
CECF systems (Rapid Translation System (RTS) Roche
Diagnostics, Penzberg, Germany) as well as individually
prepared systems are highly productive [12,13,17]. How-
ever, it should be considered that several parameters of the
reaction like ion concentrations, the composition of the
energy system and the amino acid pool or even the buVer
system can be subject of intensive optimization steps before
the high level expression of a new protein target is achieved.
CF lysates are mostly prepared from E. coli cells, wheat
germs and to a lesser extent from rabbit reticulocytes
[4,19,20]. Eukaryotic backgrounds might be preferred for
the expression of eukaryotic proteins to provide the opti-
mal environment for their functional folding and to enable
posttranslational modiWcations. Low levels of endogenous
mRNAs in wheat germ extracts allow their use in pure
translation systems with added mRNA as template for
translation  [20]. Extended reaction times up to 60h can
yield in 1–4mg of recombinant protein per 1ml RM [21].
Most popular is the S30 extract of E. coli that contains the
soluble fraction of cell lysates after centrifugation at
30,000g and including all enzymes necessary for transcrip-
tion and translation [4]. CF expression systems based on
E. coli extracts are almost exclusively used as coupled tran-
scription/translation systems by providing DNA as tem-
plate in combination with the highly speciWc and eYcient
T7-RNA polymerase [22].
For speciWc purposes, the E. coli translation machinery
could alternatively be reconstituted almost completely
in vitro by combining the individually puriWed protein com-
ponents to isolated ribosomes [23]. All aminoacyl-tRNA-
synthetases and translation factors can be overproduced
separately in standard E. coli expression systems, puriWed
by virtue of terminal poly(His)6-tags and added to E. coli
S100 extracts containing the relatively pure ribosome frac-
tion. This PURE system (protein synthesis using recombi-
nant elements) enables the CF protein synthesis under
deWned conditions and allows detailed studies of folding
pathways or translation kinetics.
Fig. 1. Schematic conWguration of a coupled transcription/translation reaction in a CECF system. The CF reaction can be carried out in simple dialysis
tubes placed into suitable plastic vials that hold the FM. The complete set-up is incubated e.g., on a turning device that ensures continuous agitation of the
reaction and substance exchange between the two compartments.
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2.2. Preparation of cell-free lysates
CF lysates provide all the high molecular weight compo-
nents of the translation machinery. Endogenous low molec-
ular weight substances like amino acids and salts will be
removed by extensive dialysis during the preparation pro-
cedure. A “run-oV” step is furthermore implemented in
order to eliminate endogenous cellular mRNA. High salt
concentrations cause the dissociation of the ribosomes
from endogenous mRNA that will then subsequently
become degraded due to the high RNAse content of the
extract.
Escherichia coli extracts are relatively easy and fast to
prepare and the individual steps of standard protocols
include cell fermentation, cell disruption, run-oV procedure
and buVer exchange by dialysis [4,24]. Common sources for
CF extracts are E. coli BL21 derivatives or strains devoid of
major endogenous RNAses like A19 (Table 1). The cells
have to be grown with good aeration until mid-log phase at
37°C in rich medium like terriWc broth (TB), chilled down
rapidly and harvested by centrifugation. The time of har-
vest is somehow crucial and corresponds in TB medium to
an OD595 of approximately 3.5. Exceeding the optimal time
point of harvest can drastically reduce the eYciency of the
Wnal CF extract. Rapid chilling of the culture down to
below 10°C upon harvesting stalls further growth and con-
serves the active state of the cellular physiology. A 10L fer-
menter with TB medium should yield 50–70g wet-weight of
bacterial cells. The cell pellet is resuspended and washed
three times in ice cold S30-A buVer and it is Wnally sus-
pended in S30-B buVer pre-cooled at 4°C (Table 1). The
cells should be disrupted by passing through a pre-cooled
French-Press and not by soniWcation, as this treatment
could cause the disintegration of ribosomes. Cell-debris is
removed by centrifugation at 30,000g at 4°C for 30min and
the upper 2/3rd of the supernatant are transferred into a
fresh vial. The centrifugation step and transfer of superna-
tant is repeated once. For the “run oV” step the lysate is
adjusted to a Wnal concentration of 400mM NaCl and
incubated at 42°C for 45min in a water bath [12]. Besides
the elimination of endogenous mRNA, this treatment
causes a considerable precipitate. The turbid solution is
Wlled into a dialysis tube (MWCO 14kDa) and dialyzed at
4°C against 60 volumes of S30-C buVer with gentle stirring.
After one further exchange of the dialysis buVer the E. coli
S30-extract is harvested by centrifugation at 30,000g at 4°C
for 30min. The clear supernatant is transferred in suitable
aliquots into plastic tubes and frozen in liquid nitrogen.
The  Wnal protein concentration in the extract should be
between 30–50mg/ml and could be adjusted by ultraWltra-
tion. The complete protocol should yield some 50ml of CF
extract out of a 10L fermentation. We recommend to Wnish
Table 1
Materials, buVers and substances for the cell-free expression of membrane proteins
Source for S30 E. coli lysates:
A19 [rna19 gdh A2 his95 relA1 spoT1 metB1] E. coli Genetic Stock Center (E. coli Genetic Stock Center, New Haven, USA, CGSC No. 5997)
BL21 star [F-ompT hsdS B (rB–mB-) gal dcm rne131] Invitrogen, Karlsruhe, Germany, C6010-03
Materials for S30 extract preparation:
Fermenter
French Press cell disruption device
Dialysis tubes (MWCO 14kDa)
Devices for protein concentration by ultraWltration
CF reaction container:
Microdialysers (MWCO 15–25kDa) (Spectrum Labs, Rancho Dominguez, USA)
Dispodialysers (MWCO 15–25 kDa) (Spectrum Labs, Rancho Dominguez, USA)
Shaking, rolling or stirring device; e.g. Universal Turning Device (Vivascience, Göttingen, Germany; Cat. No. IV-76001061) placed in an incubator with 
temperature control
Standard glass or plastic vials
Chemicals for S30 extract preparation and set-up for cell-free expression:
Adenosine-5-triphosphate disodium salt, acetyl-phosphate, amino acids (Sigma–Aldrich, Taufkirchen, Germany), complete mini protease inhibitor 
(Roche Diagnostics GmbH, Mannheim, Germany), cytidine 5-triphosphate disodium salt, dithiothreitol, ethylenediamine-tetraaceticacid, folinic acid, 
guanosine 5-triphosphate disodium salt, HEPES, KCl, KOAc, Mg(OAc)2, liquid N2, NaN3, NaCl, -mercaptoethanol, phenylmethane-
sulfonylXuoride, phosphoenol-pyruvate, polyethyleneglykol 8000, pyruvate kinase, RNAsin (Amersham Biosciences, Freiburg, Germany), total E. coli 
tRNA (Roche Diagnostics GmbH, Mannheim, Germany), T7-RNA polymerase, uridine 5-triphosphate trisodium salt
Selected detergents:
-[4-(1,1,3,3-tetramethylbutyl)-phenyl]--hydroxy-poly(oxy-1,2-ethandiyl) (Triton X-100), digitonin, polyethylenglycododecylether (Brij35), 
polyoxyethylene-(20)-cetyl-ether (Brij58); polyoxyethylene-(20)-stearyl-ether (Brij78); polyoxyethylene-(20)-oleyl-ether (Brij98); (all Sigma–Aldrich, 
Taufkirchen, Germany); n-dodecylphosphocholine (DPC), 1-myristoyl-2-hydroxy-sn-glycero-3-[phosphor-rac-(1-glycerol)] (LMPG), (Avanti-Lipids, 
Alabaster, USA); n-dodecyl--D-maltoside (DDM); (Glycon Biochemicals, Luckenwalde, Germany)
BuVers/solutions:
S30-A buVer: 10mM Tris–acetate, pH 8.2, 14mM Mg(OAc)2, 0.6mM KCl, 6mM -mercaptoethanol
S30-B buVer: 10mM Tris–acetate, pH 8.2, 14mM Mg(OAc)2, 0.6mM KCl, 1mM DTT, 0.1mM phenylmethane-sulfonylXuoride
S30-C buVer: 10mM Tris–acetate, pH 8.2, 14mM Mg(OAc)2, 0.6mM KOAc, 0.5mM DTT. TB-medium (per litre): 24g yeast extract, 12g tryptone, 
4ml 100% glycerol, 100mM potassium phosphate buVer, pH 7.4
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the complete process consecutively but the interruption
after cell harvesting is also possible.
Expression platforms based on eukaryotic cell extracts
provide a higher stability of mRNA with reaction times of
several days [21]. However, Wnal yields of recombinant pro-
tein are still similar if compared to CF systems based on
E. coli extracts. A major disadvantage is the relatively com-
plicated and time-consuming extract preparation procedure
and high variations in the quality of diVerent extract
batches. Only a short overview of key steps in wheat germ
extract preparation is given below and more extended
protocols are available in the literature ([21,25]).
Winter wheat is preferred as source for extract prepara-
tion. Fractions containing wheat embryos are isolated from
ground seeds by Xotation in a mixture of carbon tetrachlo-
ride and cyclohexane. MagniWer lenses have to be used to
remove damaged embryos and distinct parts of endosperm
that will inhibit translation by presence of various inhibi-
tory proteins like e.g., ricin [26]. This step is highly critical
and it is the most laborious part. The puriWed embryos are
ground to a Wne powder in liquid nitrogen, resolubilized in
extraction buVer (40mM Hepes–KOH, pH 7.6, 100mM
KOAc 5mM Mg(OAc)2, 2mM CaCl2, 4mM DTT, 0.3mM
of each of the 20 amino acids) and pelleted by centrifuga-
tion. The supernatant is applied on a PD-10 column pre-
equilibrated with extraction buVer to remove inhibitory low
molecular weight substances from the extract. The extract is
Wnally concentrated to an A280 of at least 200/ml and stored
in aliquots at ¡80°C [27].
2.3. Design of DNA templates for cell-free expression
The transcription in E. coli coupled transcription/trans-
lation CF systems is operated by the phage T7-RNA poly-
merase. The puriWed enzyme has to be added into the RM
at relatively high Wnal concentrations between 4–10U/l
and detailed protocols for the overproduction and puriWca-
tion of the T7-RNA polymerase have been published [28].
The promotor elements of the target gene have to meet the
speciWc requirements of the T7-RNA polymerase. The ribo-
somal binding site has to be present in optimal distance to
the translational start codon and a transcriptional termina-
tor should be placed 3 to the reading frame to prevent
excessive consumption of NTP precursors. Some suitable
commercial vector series are pIVEX (Roche Diagnostics,
Penzberg, Germany), pDEST (Invitrogen, Carlsbad, USA)
or pET (MerckBioscience, Darmstadt, Germany). These
vector systems oVer furthermore the option to add a variety
of terminal tags to the target protein that might increase the
protein expression or that could facilitate puriWcation and
detection strategies.
The translation eYciency of mRNA templates in wheat
germ systems strongly depends on the 5- and 3- untrans-
lated regions (UTRs) [29]. Eukaryotic mRNAs are modi-
Wed after translation with a 5 cap (57 mGpppG) and a
3-polyadenylated tail that prevents degradation and
results in a better protein expression. The supply of pre-
modiWed mRNAs to CF reactions is useless because of the
eYcient deadenylation and decapping activity of extract
enzymes and higher concentrations of pre-modiWed
mRNAs are even inhibitory for the translation. This prob-
lem could be addressed by several strategies like the use of
phosphothionate mRNA [30], the modiWcation of the 3-
end of mRNA with adaptor DNA [31] and the immobiliza-
tion of mRNA on latex beads [32]. Alternatively, diVerent
UTRs could be used. Viral UTRs are generally good trans-
lation enhancers in the case of the cap-independent initia-
tion. EYcient 5-UTRs usually contain an increased A/T
content including motifs such as (AAC)n, (AAAC)n or
(AAAAC)n. Most popular is currently the OMEGA leader
derived from the tobacco mosaic virus [33]. The 3-UTRs
stabilize mRNA by the formation of complex secondary
structures and also viral 3-UTRs are frequently used [34].
2.4. Linear DNA as a template for cell-free expression
The possibility to use linear templates generated by PCR
in the CF-system eliminates time consuming cloning/sub-
cloning steps and allows the rapid screening of a variety of
expression constructs [5]. PCR products can furthermore be
directly used for CF expression without prior puriWcation
[35]. Multiple-step PCR protocols or the split primer PCR-
technique have to be employed to add the required rela-
tively long regulatory elements like T7-promoter and termi-
nator to the coding sequence. Several strategies have been
established in order to overcome the degradation of linear
DNA templates by endogenous nucleases. The Lambda
phage Gam protein is an inhibitor of exonuclease V (rec-
BCD) and its addition to the CF reaction stabilized linear
DNA [36]. Extract preparation from an engineered E. coli
strain devoid of the endA gene and containing a modiWed
recBCD operon resulted in protein yields comparable to
that obtained with plasmid templates in batch systems [37].
Stem loop structures at the 3-end of mRNAs also help to
reduce exonuclease mediated degradation [38]. CF
expression is predestined for high throughput (HT)
applications especially by usage of PCR generated DNA
templates [38–40].
2.5. Reaction conditions of E. coli cell-free expression 
systems
CF expression can be performed in small analytical scale
reactions with approximately 50–100l RM for optimiza-
tion reactions and in larger preparative scale reactions of
1–2ml RM for the production of protein. It should be con-
sidered that for almost each new protein target distinct
parameters like the concentrations of critical compounds or
the generation of an optimal expression construct might
need to be optimized in order to Wnd the best conditions for
high level expression. The CECF reaction has a very well
deWned optimum for Mg2+ and K+ ions usually between
13–15 and 280–300mM, respectively. For each new protein
target and also for each new batch of extract at least the
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concentrations of these two compounds should be opti-
mized for best expression rates. A RM/FM ratio between
1:10 and 1:20 for analytical scale reactions and commer-
cially available microdialysers (Spectrum Laboratories,
Rancho Dominguez, USA) with a MWCO between 15 and
25kDa as a reaction device can be recommended. Expres-
sion levels of several milligrams of protein per 1ml RM can
only be obtained if all system components are in optimal
conditions. The results can be scaled up into preparative
reactions of 1–2ml RM without signiWcant loss of
eYciency. Dispodialyser (Spectrum Laboratories, Rancho
Dominguez, USA) or even simple dialysis tubes are recom-
mended as preparative scale reaction containers (Fig. 1).
All stock solutions (Table 2) should be mixed carefully
after thawing and the enzymes, tRNA and the S30 extract
should be kept on ice. A master-mix (MM) including all
shared components of FM and RM should be prepared by
Wrst pipetting the higher volume components (e.g. KOAc;
MgO(Ac)2; PEG8000; NaN3). First the FM is completed
and pre-incubated in a water-bath at 30°C. Then the RM is
completed, mixed gently and kept on ice. The appropriate
volume of FM is Wlled into standard plastic or glass vials
that can be used as FM compartments. The RM is trans-
ferred into suitable dispodialyser or washed dialysis tubes
(Fig. 1). Air-bubbles that might restrict an eYcient
exchange between the two compartments should be
avoided. The reaction has to be incubated with intensive
agitation either on rolling or shaking devices or by
magnetic stirring. The incubation temperature is usually
between 20°C and 30°C and protein synthesis continues up
to 20h (Fig. 2). A RM/FM ratio of 1:17 can already result
in the production of several milligrams of protein per 1ml
RM, but the Wnal yields of recombinant protein per reac-
tion can easily be increased by using higher ratios or by
refreshing the FM after certain times of incubation.
Due to their low internal RNAse content, CF reactions
based on wheat germ extracts can be operated as transla-
tion system with supplied mRNA as a template. Transla-
Table 2
Standard protocol for an individual continuous exchange cell-free reaction
Approx. 140mM K+ are provided from other components (e.g. PEP, KOH), approx. 5mM Mg2+ are provided from other components (e.g. extract) and
Wnal concentrations might be adjusted according to the amino acid composition of the target protein.
Substance Stock solution Final concentration Notes, references or suggested supplier
RM
E. coli tRNA 40mg/ml 0.5mg/ml In distilled water; (Roche Diagnostics, Mannheim, Germany; No. 109550)
Pyruvate kinase 10mg/ml 0.04mg/ml (Roche Diagnostics GmbH, Mannheim, Germany; No. 109550)
T7-RNA-polymerase 40U/l6 U / l overproduction in E. coli [28]
RNAguard porcine 40U/l0 . 3 U / l (Amersham Biosciences, Freiburg, Germany; No. AP27-0816-01)
Plasmid vector 0.15mg/ml 0.015mg/ml T7 promoter regulatory region (e.g. pET vector series; Merck Biosciences, 
Darmstadt, Germany)
E. coli S30 extract 100% 35% (modiWed after: [4,12])
RM+FM
NTP-Mix ATP: 360mM ATP: 1.2mM pH 7.0 with NaOH
CTP, GTP, UTP: CTP, GTP, UTP:
240mM each 0.8mM each
DTT 500mM 2mM Depends on desired conditions
Folinic acid 10mg/ml 0.1mg/ml Ca2+ salt
PEG 8.000 40% 2% Dissolved at 30°C in distilled water
Sodium azide 10% 0.05% In distilled water
20 amino acid mix 4mM each 1mM each Made from individual 100mM stocks in distilled water, tyrosine as 20mM 
stock in distilled water, tryptophan as 100mM stock in 100mM Hepes, pH 
8.0 (remains turbid).
RCWMDE-Mix 16.7mM each 1.0mM each Arginine, cysteine, tryptophan, methionine, aspartic acid and glutamic acid 
are limiting due to instability [15,45]
Complete protease inhibitor 50-fold 1-fold In distilled water (Roche Diagnostics, Mannheim, Germany; No. 1836153)
Acetyl phosphate 1M 20mM K+ salt in distilled water, pH 7.0, with KOH
PEP 1M 20mM K+ salt in distilled water, pH 7.0, with KOH
Hepes buVer 2.5M 100mM pH 8.0, with KOH
KOAc 4M 280–300mM Subject of optimization
Mg(OAc)2 1M 13–15mM Subject of optimization
Fig. 2. Kinetics of cell-free production of the nucleoside transporter Tsx.
The diagram shows typical kinetics of protein production in a preparative
scale CECF system. The nucleoside transporter Tsx was synthesized in a
1ml CECF standard reaction without detergent over a time period of 21 h
at 30 °C.
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tion in a CECF system with wheat germ extract can
continue up to several days. In a standard protocol, the
Wnal concentration of the components in the RM are:
Hepes–KOH (pH 8.0) 40mM, amino acids 0.2mM each,
Mg(OAc)2 3.0mM, glycerine 2%, KOAc 80mM, ATP
1mM, GTP/CTP/UTP 0.8mM each, spermidin 0.15mM,
NaN3 0.03%, creatinephosphate 16mM, mRNA 250pmol/
ml, creatinephosphate kinase 0.1mg/ml, RNAse inhibitor
0.5U/ml, wheat germ extract at 30% of the RM volume [41].
The composition of the FM is identical with the exception
that the high-molecular weight compounds mRNA, crea-
tinephosphate kinase, RNAse inhibitor and wheat germ
extract are omitted. The reaction is incubated at 25°C with
intensive agitation. The Wnal concentrations of Mg2+ and
K+ ions are subject of optimization and they may vary in
the range between 1.5–3.5 and 60–120mM, respectively.
The optimal concentration of mRNA furthermore depends
on the speciWc UTR’s and coding sequences [42]. Short
expression times in wheat germ systems are mainly attrib-
uted to an increased hydrolysis of NTP precursors. Supply-
ing Cu(OAc)2 helps to reduce endogenous ATPase activity
and can successfully prolong the expression period [43,44].
2.6. Perspectives for the optimization of cell-free expression 
systems
The set-up of an eYcient CECF reaction is relatively
complicated and requires some experience. One focus of
further improvements is therefore an increased eYciency of
the easier to handle batch format CF systems. The exact
adjustment of critical ion concentrations and the increased
supply of some rapidly degraded amino acids (e.g. arginine,
cysteine, tryptophan, methionine, aspartic acid and glu-
tamic acid) considerably improved the translation eYciency
and extended reaction times [45]. More eYcient NTP regen-
eration systems can yield almost milligram amounts of pro-
tein per 1ml reaction in bacterial and wheat germ batch
systems [38,46]. Typical energy sources for the regeneration
of ATP in CECF systems are phosphoenol pyruvate (PEP)
[4], creatine phosphate [47] and acetyl phosphate (AcP) [48]
together with the corresponding enzymes pyruvate kinase,
creatine kinase and acetate kinase. These energy sources are
problematic in batch systems due to the rapid accumula-
tion of inorganic phosphate that inhibits protein synthesis
[49]. Few alternative energy systems have therefore been
established. The presence of pyruvate oxidase recycles inor-
ganic phosphate by condensation with added pyruvate into
acetyl phosphate, which then can be used again as energy
source for protein synthesis [49]. Another approach could
be the replacement of the energy source PEP by 3-phospho-
glycerate. This modiWcation extends batch reactions up to
2h if compared to 30–45min with PEP as conventional
energy source and results in higher yields [36]. In addition,
glucose-6-phosphate has been proposed as further option
of a secondary energy source superior to PEP or pyruvate
[49]. An economical improvement for CF protein synthesis
was recently proposed by using glucose as energy source
and nucleotide monophosphates instead of NTPs as
precursors [50]. The cost of reagents could thus be lowered
by over 75% at similar protein production yields.
The amino acid supply during CF-protein synthesis has
a crucial impact on the expression yields. Instability and
degradation can produce a rapid bias in the amino acid
concentration. Recombinant protein of 500g per ml could
be obtained in batch reactions by increasing the initial
amino acid concentration from 0.5 to 2mM [49,51].
Repeated addition of amino acids during the reaction also
increases protein yields [45]. Genetic engineering of the
genome of E. coli strains used as extract sources signiW-
cantly decreased the degradation of arginine, tryptophan
and serine in the reaction [52]. ModiWcations of the reaction
conditions provide further potentials for optimization.
Omitting PEG and HEPES as well as the addition of the
polycations spermidine and putrescine were proposed as
improvements of batch systems [53]. Optimized batch sys-
tems are already eYcient enough to produced suYcient
amounts of protein for structural analysis [54].
3. Cell-free preparation of membrane proteins
3.1. SpeciWc characteristics for the CF expression of MPs
The current variety of MPs produced on preparative scales
in CF systems comprises several bacterial multidrug trans-
porters [10,12,54,55], a bacterial light harvesting protein [9],
the mechanosensitive channel MscL [11], several eukaryotic
GPCRs [13,14] and the -barrel nucleoside transporter Tsx
[14]. CF expression allows the production of MPs at levels of
several mg/ml RM in two very diVerent modes (Fig. 3). First,
MP precipitates are produced in standard CF-systems due to
the lack of a hydrophobic environment. Second, hydrophobic
media like detergents or probably even lipids could be pro-
vided resulting in the production of already solubilized MPs.
The CF production of precipitated MPs resembles the forma-
tion of inclusion bodies that can frequently be observed upon
in vivo production of proteins in E. coli. However, CF gener-
ated MP precipitates might be structurally diVerent from
inclusion bodies as they usually do not need strong denatur-
ants like SDS to become solubilized. Mild detergents like
alkyl-glycosides, phosphocholines or alkyl-phosphoglycerols
could already be suYcient for the quantitative solubilization
of CF generated MP precipitates [10–12]. The harvested MP
precipitates should be washed for several times in an appro-
priate buVer (e.g. 15mM sodium phosphate, pH 6.8, 1mM
DTT) followed by centrifugation (5min, 5000g). Precipitated
impurities in the pellet could be removed by washing with a
detergent that has poor solubilization properties for the MP
(e.g. 3% n-octyl--glucopyranoside (-OG)). Finally the MP is
solubilized in buVer containing the detergent of choice (e.g.
2% 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glyc-
erol)] (LMPG)) in a volume identical to the volume of the
RM. Incubation on a shaker at 30°C for one hour is usually
suYcient for the quantitative solubilization. Residual pellet
can be removed by centrifugation.
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The eYciency of solubilization certainly depends on the
speciWc recombinant MP as well as on the type of detergent.
Precipitates from the small -helical multidrug transporter
EmrE can be solubilized in a variety of diVerent detergents
while the quantitative solubilization of precipitates from the
nucleoside transporter Tsx or from the mechanosensitive
channel MscL was restricted to only a small selection of
detergents like polyethylene-glycol P-1,1,3,3-tetramethyl-
butylphenyl-ether (Triton X-100) or LMPG. Long-chain
phosphoglycerols like LMPG and the closely related
detergent 1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-
(1-glycerol)] (LPPG) appear to be most versatile for the solu-
bilization of CF produced precipitates of structurally diverse
MPs. LMPG was highly eYcient in the solubilization of bac-
terial -helical and -barrel type MPs and it proved to be the
only detergent suitable for the quantitative solubilization of
several eukaryotic G-protein coupled receptors (GPCRs) [14].
3.2. CF expression of MPs in presence of detergents
The open nature of the CF expression set-up enables the
addition of deWned amounts of detergents directly into the
reaction [12–14]. The freshly translated proteins have thus
the opportunity to become embedded immediately into pre-
formed detergent micelles. This option to produce MPs in a
soluble form associated with a detergent of choice is a
unique characteristic for CF expression systems. Proteomi-
celles could be puriWed directly out of the RM and critical
steps like the destabilization and isolation of MPs from
membranes are eliminated. An indispensable prerequisite is
that the supplied detergent is tolerated by the CF system
even at concentrations exceeding several times the speciWc
critical micellar concentration (CMC) that deWnes the mini-
mal required eVective concentration for the solubilization
of proteins. Only few detergent types like dodecyl-phospho-
Fig. 3. Two modes of the cell-free production of membrane proteins. Both expression modes result in MPs solubilized in detergent micelles that can be
reconstituted into proteoliposomes for further functional and structural studies.
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choline (DPC) or -OG severely inhibit the CF protein pro-
duction already at low concentrations at or only slightly
above their speciWc CMCs. Fortunately, many other com-
monly used detergents are tolerated by CF expression sys-
tems and the optimal concentration ranges for a relatively
large group of detergents have been determined (Table 3)
Table 3
Cell-free expression of membrane proteins in the presence of detergents
S, soluble fraction; P, insoluble precipitated fraction; n.a., not available; n.r., not reported, 0, no detectable expression; 0+, less than 10g/ml; +, 10–100g/
ml; ++, 101–500g/ml; +++, 501–1000g/ml; ++++, 1001–2000g/ml; +++++, more than 2001g/ml.
Detergent name Optimal concentration Protein References cited
Short name [%] [mM] [x CMC]
None
Alkyl-glucosides
n-Dodecyl--D-maltoside DDM 0.08 (2.30) 12.1 EmrE +++++ 0 [10]
0.1 (2.87) 15.1 Tsx ++++ ++++ [14]
<1 (28.69) 151 2AR + + [13]
0.066 (1.89) 10 MscL n.r. n.r. [11]
n-decyl--D-maltoside DM 0.2 (4.14) 2.3 EmrE ++++ ++ [14]
n-octyl--D-glucopyranoside -OG 0.75 (25.65) 1.3 EmrE + 0 [14]
<1 (34.2) 1.8 M2 0+ 0+ [13]
0.4 (13.68) 0.7 EmrE n.r. n.r. [10]
0.877 (30) 1.6 MscL n.r. n.r. [11]
(6-O-(N-heptylcarbamoyl)-methyl-- HECAMEG <1 (29.82) 1.8 M2 + + [10]
D-glucopyranoside)
Steroid-derivatives
Digitonin Digitonin 0.4 (3.25) 4.5 Tsx ++++ +++ [14]
<1 (8.13) 11.1 2AR ++ ++ [13]
3-[(3-cholamidopropyl)dimethly- CHAPS 0.75 (12.20) 1.5 Tsx + ++ [14]
ammonio]-1-propansulfonat <1 (16.26) 2 NTR + + [13]
2.46 (40.01) 5 MscL n.r. n.r. [11]
Long chain-phosphoglycerols
1-myristoyl-2-hydroxy-sn-glycero-3- LMPG 0.01 (0.21) 4.2 Tsx ++ ++ [14]
[phospho-rac-(1-glycerol)]
1-palmitoyl-2-hydroxy-sn-glycero-3- LPPG 0.025 (0.49) n.a. V2R + +++++ [14]
[phospho-rac-(1-glycerol)]
Mono-/Bi-chain-phosphocholines:
1,2-dioctanoyl-sn-glycero-3-phosphocholine diC8PC 0.1 (1.96) 8.9 EmrE +++ +++++ [14]
1,2-diheptanoyl-sn-glycero-3-phosphocholine DHPC 0.2 (4.15) 3 Tsx +++ ++ [14]
1,2-dihexanoyl-sn-glycero-3-phosphocholine diC6PC 0.75 (16.54) 1.2 Tsx ++ ++ [14]
Dodecyl-phosphocholine DPC 0.1 (2.84) 1.5 EmrE 0+ +++ [14]
Polyoxyethylene-alkyl-ether:
polyoxyethylene-(8)-lauryl-ether, (C12/8)C 12E8 <1 (18.52) 260.8 NTR + ++ [13]
polyoxyethylene-(23)-lauryl-ether, (C12/23) Brij-35 0.1 (0.83) 10.4 EmrE +++++ + [14]
<1 (8.34) 104.2 2AR ++ ++ [13]
polyoxyethylene-(10)-dodecyl-ether, (C12/10) GPC-100 0.1 (1.59) 21.3 EmrE + ++ [14]
polyoxyethylene-(10)-isotridecyl-ether, (C13/10) GPX-100 0.1 (1.56) 10.4 Tsx +++ ++++
polyoxyethylene-(10)-cetyl-ether, (C16/10) Brij-56 0.01 (0.15) 4.2 V2R + 0+ [14]
polyoxyethylene-(20)-cetyl-ether, (C16/20) Brij-58 1.5 (13.36) 178.1 V2R +++++ + [14]
0.84 (0.75) 10 MscL n.r. n.r. [11]
polyoxyethylene-(2)-stearyl-ether, (C18/2) Brij-72 0.2 (5.57) n.a. V2R + + [14]
polyoxyethylene-(20)-stearyl-ether, (C18/20) Brij-78 1 (8.68) 188.8 V2R +++++ + [14]
polyoxyethylene-(10)-oleyl-ether, (C18-1/10) Brij-97 0.2 (2.82) 13 EmrE 0 +++++ [14]
polyoxyethylene-(20)-oleyl-ether, (C18-1/20) Brij-98 0.2 (1.74) 69.6 V2R +++++ + [14]
polyoxyethylene-sorbitan-monolaurate 20 Tween 20 <1 (8.14) 138 NTR + ++ [13]
0.1 (0.81) 13.8 Tsx 0 +++++ [14]
0.072 (0.59) 10 MscL n.r. n.r. [11]
polyoxyethylene-sorbitan-monopalmitate 40 Tween 40 <1 (7.79) 288.5 NTR + ++ [13]
polyoxyethylene-sorbitan-monostearate 60 Tween 60 <1 (7.62) 304.9 M2 + + [13]
polyoxyethylene-sorbitan monooleate 80 Tween 80 <1 (7.63) 636.1 NTR + ++ [13]
Polyethylene-glycol derivatives:
polyethylene-glycol P-1,1,3,3-tetramethyl- TX-100 0.2 (3.09) 13.4 MscL +++++ n.r. [11]
Butylphenyl-ether 0.1 (1.55) 6.7 Tsx ++++ ++++ [14]
<1 (15.46) 67.2 NTR + ++ [13]
Polyethylene-glycol 400 dedecyl-ether Thesit 0.1 (1.72) 17.2 Tsx ++ +++ [14]
Nonylphenyl-polyethylene-glycol NP40 0.1 (1.66) 9.8 EmrE + ++++ [14]
<1 (16.58) 97.6 2AR + ++ [13]
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[13,14]. The kinetics of MP solubilization versus the deter-
gent concentration shows two phases. Initially, the
eYciency of MP solubilization is linear to the amount of
added detergent until a certain threshold concentration has
been achieved (Fig. 4). Then the yield of solubilized MP
remains constant with further increased detergent concen-
trations and only additional empty micelles will be formed
until the detergent becomes toxic to the CF expression sys-
tem due to the inactivation of essential compounds. The
production kinetics has therefore a plateau-like appearance
and the maximal yield of soluble MP can be obtained over
a distinct concentration range of a speciWc detergent. It
should be considered that the complete solubilization of a
MP might not be possible and still some residual MP pre-
cipitate could remain even far above the threshold concen-
tration (Fig. 4).
Several elements of CF production of soluble MPs can
be subjected to optimization. Basic parameters are concen-
tration, type and chain length of the supplied detergent. For
initial screens it might be most straightforward to start with
detergent concentrations close to the maximal tolerated lev-
els to receive instantly the highest possible amounts of solu-
ble MP. The detergents should be prepared as highly
concentrated stock solutions in water and care should be
taken that organic solvents like chloroform have been com-
pletely removed e.g. by evaporation, in order to prevent an
inhibition of the CF reaction. Soluble protein fractions are
separated from precipitates after the reaction by centrifuga-
tion at 20,000g for 30min at room temperature. The pro-
duction of the MP should be quantiWed in both fractions by
SDS–PAGE analysis or by immunoassays. The Wnal deter-
gent concentration can then be decreased in subsequent
optimization reactions if desired.
The structure of the supplied detergent type can have a
major impact on the eYciency of solubilization as well as
on the functional folding of the synthesized MP. Some
proteins like the -helical multidrug transporter EmrE can
be expressed in soluble form with a diverse variety of
structurally diVerent detergents like alkyl-glucosides, phos-
phocholines, polyethylene-glycol derivatives or polyoxyeth-
ylenes. However, the soluble expression in preparative
scales of the majority of the MPs seems to be restricted to a
much smaller selection of detergents (Table 3). The supply
of many popular detergents that have been used in recent
times for the structural analysis of MPs like the alkyl-glu-
coside  n-dodecyl--D-maltoside (DDM) or the polyethyl-
ene-glycol derivative Triton X-100 result in the high level
soluble expression of speciWc MPs. CF expression in pres-
ence of DDM yielded milligram amounts of EmrE and of
the nucleoside transporter Tsx, but the detergent was rather
ineVective for the soluble expression of diVerent GPCRs
[13,14]. Tsx could furthermore only partially be solubilized
in DDM and approx. 50% of the synthesized protein still
remained as precipitate. Clearly outstanding with respect to
their ability to eYciently solubilize structurally diverse MPs
are the steroid-derivative Digitonin and various detergents
from the family of polyoxyethylene-alkyl-ethers like
polyoxyethylene-(23)-lauryl-ether (Brij-35), polyoxyethyl-
ene-(20)-cetyl-ether (Brij-58), polyoxyethylene-(20)-stearyl-
ether (Brij-78) and polyoxyethylene-(20)-oleyl-ether (Brij-
98) [13,14]. Out of more then 20 detergents, only Brij deriv-
atives have been successful in the quantitative soluble
expression of the human vasopressin type 2 receptor [14].
Brij derivatives having less than 10 polyoxyethylene groups
were not eVective. In addition, the solubilization of the
vasopressin type 2 receptor was modulated by the length of
the alkyl chain. As a general guideline, the eYciencies and
the optimal concentrations of the most useful detergents
for the solubilization of structurally diVerent MPs are com-
piled in Table 3.
In practice it is recommended to initially perform a set of
CF expression reactions in presence of the most promising
Fig. 4. Soluble expression of the nucleoside transporter Tsx at increased detergent concentrations. The yield of soluble expressed MP increases with the
Wnal concentration of Brij58 and reaches a plateau at approx. 47-fold CMC. The amount of soluble Tsx then remains constant upon further increased
detergent concentrations up to 178-fold CMC. The total amount of produced Tsx protein (soluble and precipitate) remains constant at each condition.
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detergents with each new MP target (Fig. 5). In case of the
nucleoside transporter Tsx, the yield of soluble protein in
presence of the detergents Brij58, Brij78 and Brij97 is com-
parable to that of the Tsx precipitate isolated out of a stan-
dard CF reaction without any detergent (Fig. 5). However,
generally some lower amounts of protein might be obtained
when choosing the soluble mode of expression if compared
to the expression as a precipitate.
After high level CF production strategies have been
established, the functional folding of the synthesized MP
should be analysed [10–14,56,57]. The modes of expression,
the origin of the CF extract, the solubilization procedures
of precipitates and the supplied detergent types are impor-
tant factors that could inXuence the folding pathway of a
protein. Circular dichroism spectra or two-dimensional
heteronuclear single-quantum correlation (HSQC) spectra
by solution nuclear magnetic resonance (NMR) spectros-
copy can give Wrst evidences of the presence of structural
elements  [12]. However, the development of functional
assays would be a very precious tool to prove the three-
dimensional folding of a protein into an active conforma-
tion. The transport of the substrate ethidium by EmrE
could be veriWed with samples that have been either pro-
duced in the soluble mode in presence of DDM [10] or with
proteoliposomes reconstituted from in DDM solubilized
precipitates [12]. On the other hand, the nucleoside trans-
porter Tsx could only be reconstituted in a highly active
form after its CF expression in the soluble mode in presence
of Triton X-100 [14]. While the soluble expression in pres-
ence of Brij35 still resulted in some residual activity, it was
not possible to detect activity from protein that has been
produced as a precipitate and solubilized in LMPG. This
example demonstrates the importance of initial expression
screens that should consider both, the high level production
and the functional folding of the MP. The available infor-
mation of CF expressed MPs that have been analysed by
functional assays is still limited to a few examples. How-
ever, it is already evident that structurally very diVerent
prokaryotic as well as eukaryotic MPs can be produced in
CF systems based on lysates of E. coli cells in both expres-
sion modes as functionally active proteins.
4. New perspectives for the structural analysis of cell-free 
produced membrane proteins
The CF expression of MPs oVers a high potential for
their structural analysis by NMR spectroscopy as well as
by X-ray crystallography. Protein samples that have been
eYciently labelled with stable isotopes or with non-natural
amino acids like selenomethionine can now be obtained in
less than 24 hours [54,58–60]. The recently presented crystal
structure of the small multidrug transporter EmrE at 3.7Å
resolution was solved by taking advantage of CF expres-
sion. The proposed active dimer was CF expressed directly
into di-myristoyl-phosphatidyl-choline (DMPC) liposomes
and crystals which were used for structure determination
were obtained in the presence of the detergent N-nonyl-
- D-glucoside (NG) [54].
Most of the few known NMR structures from MPs were
solved from bacterial -barrel proteins that have been pro-
duced as inclusion bodies in E. coli followed by refolding
procedures  [61,62]. The CF expression technique might
open new avenues for the determination of MP structures
by NMR spectroscopy as well as by X-ray crystallography
already solely because of the possibility to produce high
yields of functionally active MPs that are diYcult to obtain
with other expression systems. In addition, the speediness
of the reaction is highly competitive as the protein samples
are basically generated over night. Moreover, no special
equipment is required and the technique can principally be
established in standard biochemical labs within few days.
The most important feature however is the easiness and
eYciency in the synthesis of labelled protein samples. The
CF extract is completely devoid of amino acids due to
extensive dialysis steps during the preparation procedure.
As the operator has the complete control over the amino
acid pool of the CF reaction, any non-labelled amino acid
type can just be exchanged by its labelled derivative at the
Fig. 5. Detergent screen for the cell-free production of the nucleoside transporter Tsx. Coomassie-stained SDS–Page of CF produced Tsx protein: M,
marker; s, supernatant of standard reaction; p, pellet of standard reaction. Lanes 1–8 represent 0.8l of supernatant of CF expression in the presence of
diVerent type detergents: 1, 0.1% DDM; 2, 0.2% DHPC; 3, 0.4% Digitonin; 4, 0.1% Genapol X100; 5, 0.2% Brij58; 6, 1% Brij78; 7, 0.1% Brij97; 8, 0.5%
Brij98. The arrow indicates the overexpressed nucleoside transporter Tsx.
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initial set-up of the experiment. This instantly ensures the
100% label incorporation into the synthesized protein. The
speciWc labelling of any amino acid type and also of any
amino acid combinations of an expressed protein is thus as
eYcient as the production of non-labelled proteins [63].
Auxotrophic strains and minimal media that have to be
employed in conventional in vivo expression systems and
that often considerably reduce the yield of the recombinant
protein can be avoided. Scrambling problems are further-
more minimized as the metabolic activity of the CF extract
is very low [22]. The target protein is the only synthesized
protein in the system as all endogenous mRNA of the
extract was eliminated during the extract preparation. The
labelled protein could therefore be analysed by NMR spec-
troscopy directly in the RM without prior puriWcation as
no labelled background is present [64].
One major restriction for the determination of MP struc-
tures is the size limitation of proteins for NMR samples.
The rate of rotational tumbling of proteins decelerates with
increasing size, resulting in line broadening and lower reso-
lution. Because MPs need to be analysed in detergent
micelles, the signal resolution will be even more critical due
to the increased size of the protein/detergent complex. Fur-
thermore, MPs are mostly -helical proteins that show
rather narrow chemical shift dispersions with an extensive
signal overlap. The hydrophobic transmembrane segments
(TMSs) of MPs often contain cluster of similar amino acids
with equal chemical shifts that additionally contributes to
lower resolutions of corresponding NMR spectra. These
problems in combination with the low production rates of
many MPs in conventional in-vivo expression systems
prevented so far in most cases serious attempts for the
structural analysis of MPs by NMR.
Several limitations can now be addressed by virtue of
CF expression. First, the size limitation of the solubilized
protein samples can be approached by using speciWc deter-
gents. In a systematic screen for liquid-state NMR compat-
ible detergents with regard to long sample lifetimes,
Fig. 6. 1H–15N TROSY-HSQC spectra of cell-free expressed 2H–15N-TehA. The protein was expressed either in the unsoluble mode as precipitate and
resolubilized in LMPG or expressed in the soluble mode in the presence of Brij78, puriWed and the detergent was exchanged to LMPG. The concentration
of both samples was 0.5mM, dissolved in 25mM sodium phosphate buVer (pH 6.0) containing 3% LMPG. The spectra were measured at 318K on an
Avance 900MHz NMR spectrometer equipped with a cryogenic probe with eight scans per FID and 512 increments in the indirect dimension for the
insoluble expressed TehA and with four scans per FID and 300 increments in the indirect dimension for the soluble expressed transporter.
Fig. 7. Combinatorial labelling scheme of membrane proteins by cell-free expression. Example of an amino acid selective combinatorial labelling scheme
with three diVerentially [15N] and [13C]labelled samples of the tellurite transporter TehA. The labelling scheme is shown on the left side. The crossed dotted
lines indicate the peak to become identiWed. In the [15N, 1H]-TROSY spectra, backbone amide protons of the [15N]-labelled amino acids are visible. The
indicated peak at position 121.3/8.07 is identiWed as an alanine as it is present in all three spectra and only the amino acid alanine has been [15N]-labelled in
all three samples. The corresponding HNCO spectra show the amide crosspeaks after carbonyl transfer and indicate that the preceding residue of this ala-
nine must be a leucine because a HNCO peak is only observed for samples 2 and 3 containing 13C-leucine, but not for sample 1 without 13C-leucine. The
corresponding alanine (peak HN:8.07; N:121.3) can now be localized in a Leu–Ala pair in the primary sequence of the protein which in that example was
identiWed as Ala206 of TehA. All spectra were recorded at an Avance 600MHz spectrometer.
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maximal signal detection as well as high spectral resolution,
the class of lyso-phosphoglycerols including LMPG and
LPPG have been found to provide outstanding beneWts
[65,66]. LMPG micelles obviously do not restrict the tum-
bling rates of the inserted solubilized MP and therefore do
not result in increased line broadenings. LMPG and its
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derivatives were also found to be highly suitable for the sol-
ubilization of CF produced MP precipitates [14]. This
detergent type might be therefore one of the Wrst choices for
the structural analysis of larger MPs by liquid-state NMR
spectroscopy. A CF produced truncated 24kDa fragment
of the putative tellurite and multidrug transporter TehA of
E. coli containing seven TMSs was solubilized in LMPG
and analysed by NMR. The amide protons of the protein
backbone could be almost completely assigned by using a
rationally designed combinatorial labelling approach [63].
The spectral quality of TehA further depends on the mode
of CF expression. 1H–15N-HSQC spectra of TehA samples
produced in the soluble mode with 1% Brij-78 followed by
a buVer exchange against 3% LMPG showed a signiWcantly
better resolution if compared with samples that have been
prepared as CF precipitates and re-solubilized in LMPG
(Fig. 6).
The spectral overlap due to the -helical structure of
many MPs could be approached by a mixture of amino
acid speciWc and combinatorial labelling strategies [63]. A
simultaneous labelling of MPs with selected [15N]-labelled
amino acids in combination with distinct [13C]-labelled
amino acids can easily performed by CF expression (Fig. 7).
The application of two dimensional versions of HNCO
experiments helps to identify only those [15N]-labeled
amino acids that where N-terminally proceeded by a [13C]-
labeled amino acid type [63]. This strategy enables the
unambiguous identiWcation of consecutive amino acid pairs
that can be subsequently used as anchor points for further
backbone resonance assignments (Fig. 7). The TehA pro-
tein represents one of the largest -helical proteins cur-
rently analysed by NMR and its structural approach
demonstrates the powerful synergy of liquid-state NMR
and CF expression.
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3.06.1 Design and Generation of Vectors for High-Level Protein Expression in
Bacteria
Vectors are generally deﬁned as the basic vehicles that transport and deliver the target genes to be expressed into a
suitable host cell. They can be relatively complicated autonomously replicating elements much as plasmids, ba-
cteriophages, or viruses or they might consist of less complex DNA molecules that integrate into the host chromosome
or that are even not stable in the cellular background and provide only a transient expression of the target gene.
However, common characteristics are always a few basic requirements like selection marker, copy number, host range,
and origin of replication. The copy number is a key feature as it is linearly related to the gene dosage and thus clearly
affects the expression yields. In general, replicating vectors are present in multiple copies up to several hundred
molecules per single cell in case of common bacterial expression plasmids. The copy number together with the host
range of a DNA molecule is determined by the origin of replication, a sequence motif that is recognized by a speciﬁc
DNA polymerase. In addition, plasmids are classiﬁed into separate incompatibility groups based on their origin of
replication. Members of the same group are not compatible and cannot be permanently maintained in the same cell.
Integration vectors are devoid of any origins of replication and only present in one or few copies, although for speciﬁc
A0005
S0005
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cases techniques have been developed to increase the copy number by selective ampliﬁcation.
1,2 Vectors usually
contain selection markers that are indispensable to identify successfully transformed cells. Antibiotic resistance genes
encoding, e.g. for the enzyme b-lactamase, are frequently used especially for selection in bacteria. Genes encoding for
key enzymes in essential anabolic pathways are also suitable as selection markers if used in combination with spe-
cifically engineered auxotrophic host cells. A variety of comprehensive reviews of expression vectors suitable for the
most commonly used bacterial host Escherichia coli is available.
3–6
3.06.1.1 Promoters and Control of Gene Expression
Expression cassettes containing strong inducible promoters, a convenient multiple cloning site, and an efﬁcient
terminator of transcription, and located on a high copy vector are needed in order to obtain high yields of a recombinant
protein. Modiﬁcations are expression cassettes that provide dual promoters or multisystem expression vectors con-
taining promoters that are active in bacterial as well as in mammalian cells.
7 The possibility of efﬁciently inducing the
expression at a certain time point during the fermentation process is important as it minimizes metabolic burdens and
potential toxic effects of the protein product. Fine-tuning the induction conditions can signiﬁcantly optimize the
expression of foreign proteins.
8 Common inducers employ low-cost chemicals or sudden modiﬁcations of the growth
conditions. In fact, many promoters are suitable for producing proteins at high levels but they are difﬁcult to com-
pletely switch off.
9,10 Prototypes are the E. coli Plac promoter and its cAMP-independent PlacUV5 derivative that are
frequently in use for protein expression. Induction is performed by the nonhydrolyzable lactose analog isopropyl-b-D-1-
thiogalactopyranoside (IPTG) which releases the speciﬁc promoter-bound LacI repressor. Considerably increased
expression levels, e.g., of up to 30% of the total cellular protein, can be obtained with the related artiﬁcial Ptac and Ptrc
promoters consisting of synthetic fusions of the Plac with the Ptrp promoter.
6,9 The intrinsic leaky expression from lac-
derived promoters in noninduced cells can become cumbersome, sometimes causing a complete loss of protein
expression or a reduced viability of the culture.
7 The tight repression of weaker promoters can be achieved in host
strains containing the lacI
Q allele which ensures enhanced synthesis rates of the LacI repressor. Furthermore, the lacI or
lacI
Q genes can be placed on the expression vector in order to additionally increase the LacI copy numbers. Alter-
natively, an expression system under control of the promoters PT7 from phage T7, PBAD from the E. coli arabinose
operon, or PL and PR from the l phage might be preferred. The PL and PR promoters are among the strongest known in
E. coli. They are tightly regulated and can be induced by temperature switches from 301Ct o4 2 1C by virtue of a
temperature-sensitive version of the lcI repressor (cI857) and they allow a free choice of host strains.
11,12
The T7-promoter included in the pETsystem expression plasmids (Merck, Darmstadt, Germany) has become very
popular.
13,14 This promoter is specifically recognized only by the T7-RNA polymerase encoded by the T7 gene 1 which
can be provided either on a phage or plasmid vector or as integrated chromosomal copy in engineered host strains
carrying the prophage lDE3 under control of the IPTG inducible PlacUV5 promoter.
7,13,15 A variety of DE3 derivatives
in different cellular backgrounds (e.g., BL21, HMS174) is available (Merck, Darmstadt, Germany; Invitrogen, Car-
lsbad, CA). Virtually no background expression from the PT7 promoter can be observed in E. coli cells devoid of any T7-
polymerase. Residual T7-RNA polymerase produced by lDE3 host strains due to the leakiness of PlacUV5 can be
neutralized by coexpression of T7 lysozyme that efﬁciently binds to T7-RNA polymerase from compatible plasmids
like pLysS and pLysE (Merck, Darmstadt, Germany). Other mechanisms for the control of leaky expression have also
been proposed.
7 T7-RNA polymerase is extremely effective in the initiation of transcription and has a very processive
transcription elongation rate. This could result in the accumulation of large amounts of messenger RNA (mRNA)
causing a shortage of the cellular ribosomes. The unprotected mRNA is highly susceptible to degradation and can be
stabilized by using the RNaseE mutant strain BL21 (DE3) Star (Merck, Darmstadt, Germany) for expression.
The activity of many strong promoters cannot be modulated after induction. Recombinant proteins can therefore
accumulate very fast in the cell and the functional folding of the proteins might then not be able to keep pace. This
causes a high risk of unfolded protein precipitating in the host cell as nonsoluble inclusion bodies. In order to solve this
problem, a possible option could be the use of the PBAD promoter in combination with its regulator protein AraC. It
shows a very fast and tuneable response to changing concentrations of its inducer L-arabinose while heterogeneous cell
populations might also account for that effect.
16,17 This allows the modulation of the stability and folding properties of
a recombinant protein by controlling the rate of expression.
18 Corresponding vectors are commercially available
(Invitrogen, Carlsbad, CA). The PBAD promoter is subject to catabolite repression and a very tight repression can be
achieved in the presence of glucose, fructose, and similar metabolites. The rapid kinetics of regulation allows a fast and
efﬁcient switch of protein expression from on to off.
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3.06.1.2 Regulatory DNA Sequences Important for Protein Expression
Regulatory sequences especially in the 50 untranslated regions (UTR) are very different in E. coli if compared with
eukaryotic control regions. A ribosome binding site (RBS, Shine–Dalgarno sequence) with the highly conserved
consensus sequence 50-UAAGGAGG-30 needs to be present at 973bp upstream of the ﬁrst codon that deﬁnes the
initiation of translation. The RBS is complementary to the 30 end of the 16S ribosomal RNA (rRNA) and an interaction
is crucial for an efﬁcient initiation of translation. Stable mRNA secondary structures covering the RBS or the initiation
codon are usually detrimental to gene expression as they can interfere with ribosome binding. Expression constructs
therefore usually represent transcriptional fusions where the regulatory sequences of promoters or terminators are
provided by the expression cassette of the vector and only the coding sequence from the target gene has to be inserted.
Mammalian genes especially almost routinely require extensive modiﬁcation of additional regulatory regions in their
primary sequences prior to a high-level expression in E. coli. Strong translation initiation signals are an indispensable
prerequisite for high-level expression as the initiation rate can dramatically determine the ﬁnal expression level.
19 The
sequence context immediately surrounding the translational start codon (up to about the ﬁrst ten codons) is often
critical.
20–22 This area should preferably be free from any rigid secondary structure formation since those could
completely abolish any expression of the heterologous protein. Raising the numbers of adenosine residues in that area
generally reduces the probability of secondary structure formation. A detailed analysis and systematic modiﬁcation of
the translation initiation region can signiﬁcantly improve the expression. A practical approach for circumventing any
problems with a suboptimal initiation of translation would be to produce a heterologous protein as a fusion C-terminal
to a small leader peptide that is already codon-optimized. One possibility would be the T7 tag present in the cloning
regions of many commonly used expression vectors of the pET series (Merck, Darmstadt, Germany).
3.06.1.3 Codon Usage
A problem that frequently affects the yield of an expressed protein is the different codon usage of individual species.
23
A strong codon bias is most evident when prokaryotic and eukaryotic systems are compared. Codons that translate into
proline and arginine are particularly affected in expression of human genes in E. coli.
24 The transfer RNAs (tRNAs)
corresponding to rare codons are only found in minor populations in E. coli cells and coding sequences containing
several rare codons (especially in iterative arrangements) are likely to become poorly expressed. Besides premature
termination the misincorporation of a lysine residue in place of arginine at rare codon sites is a well-recognized problem
in the structural analysis of proteins resulting in undesired heterogeneous populations in recombinant protein sam-
ples.
24–28 One option for addressing this problem is the genetic manipulation of coding sequences according to the
codon preferences of the desired host cell. This approach certainly should be considered in the case of the de novo
synthesis of a gene in vitro.
29 However, the subsequent introduction of silent mutations in an already cloned gene can
be time-consuming as it probably requires multiple steps of mutagenesis. Alternatively, a eukaryotic gene can be
expressed in E. coli in the presence of a second compatible plasmid encoding for an additional set of tRNAs com-
plementary to rare codons.
30, 31 Specialized strains that are used for the high-level expression of rare codon containing
genes are BL21 CodonPlus (Stratagene, La Jolla, CA) and the Rosetta-2 derivatives of BL21 (Merck, Darmstadt,
Germany). The two strains harbor a plasmid containing extra copies of several rare codons. tRNAs that recognize.
3.06.1.4 Translational Fusion Constructs for Optimized Protein Expression
In many cases it is preferable to express a target protein as a single polypeptide chain covalently linked with a second
already well-deﬁned protein. Fusion strategies provide the advantage that the engineered fusion products combine the
properties of the individual proteins and thus permit high-level production of otherwise poorly synthesized recom-
binant proteins (Table 1). Target proteins with almost or completely unknown functions can be linked with the
beneﬁcial binding characteristics or optimal expression and stability properties of a fusion partner. The potential
beneﬁts of a fusion system include signiﬁcantly enhanced expression levels, fast puriﬁcation by means of afﬁnity
chromatography based on the binding properties of the fusion partner, increased probability of proper folding of the
attached target protein, prevention of inclusion body formation, and protection from proteolytic degradation.
34 In
addition, fusion partners can enable the immobilization of a protein to, e.g., biosensors for functional characterizations.
The majority of the common fusion systems place the target protein at the C-terminus of a fusion partner that most
likely ensures the transfer of better expression and stability characteristics. However, it should be borne in mind that
interference of the fusion partner with the activity of the target protein can occur in some cases and its localization
could make a difference. If possible, the effects of an attachment to either end of the target protein should therefore be
compared.
35
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Fusion partners can be classiﬁed into small peptide tags and into larger proteins that can have additional beneﬁts for
the solubility or the stability of the target protein (Table 1). Small peptide tags can principally become attached to
either end of a target protein while their accessibility can certainly differ depending on the speciﬁc tertiary structure of
the target protein. Those tags usually cover about ten amino acid residues and they are efﬁciently used for the fast and
convenient puriﬁcation and/or detection of target proteins.
36An advantage of using small peptide tags is that they
usually do not affect the activities of the recombinant protein and they need not be removed upon a structural and
functional characterization of the target protein. Extended processing and puriﬁcation steps can therefore be avoided.
Frequently employed puriﬁcation tags include poly(His)x tag consisting mostly of six consecutive histidine residues
and various forms of the biotin binding streptavidin peptide. Proteins containing poly(His)x tag derivatives usually
exhibit a high afﬁnity for Cu
2þ,N i
2þ,C o
2þ,o rZ n
2þ ions and can be puriﬁed from crude extract preparations by one-
step afﬁnity chromatography using metal-chelate resins even under denaturating conditions.
37 Also the exceptional
strong interaction between biotin and streptavidin (KD 10
 15M) ensures the highly selective binding of a fusion
protein. Speciﬁc antibodies directed against poly(His)x tags and Strep-tags are available (Qiagen, Hilden, Germany;
IBA GmbH, Go ¨ttingen, Germany) and the tags can thus be used for the puriﬁcation as well as for the detection of a
protein. An additional popular peptide tag used for the rapid identiﬁcation of expressed recombinant proteins by an
antibody reaction is the T7 tag inserted into many pET vectors (Merck, Darmstadt, Germany). Small peptide tags are
furthermore often combined with larger fusion partners in order to optimize the rapid puriﬁcation of the recombinant
protein.
38
Fusion proteins like glutathione S-transferase (GST), thioredoxin, ubiquitin, and others can signiﬁcantly increase
the expression yield of the attached target proteins (Table 1). Thioredoxin is a small monomer encoded by the trxA
gene which facilitates the soluble expression of a number of mammalian proteins including growth factors and
cytokines.
39,40 An afﬁnity resin for the fast puriﬁcation of thioredoxin fusions is commercially available (Invitrogen,
Carlsbad, CA). The ubiquitin of baker’s yeast Saccharomyces cerevisiae has been successfully used as a fusion tag for small
proteins in E. coli.
41 A further advantage of that system might be the use of the speciﬁc yeast ubiquitin hydrolase in
order to remove the tag after isolation of the fusion protein.
42 GST is popular as a puriﬁcation tag because of its high
afﬁnity to glutathione sepharose, and it is additionally effective as an enhancer for the translation efﬁciency and for the
solubility of the target protein.
35,43,44 The E. coli maltose binding protein (MBP) has an exceptional and relatively
general ability to promote the solubility and stability of the fused recombinant proteins.
38,45,46 The fusion proteins can
be easily puriﬁed by virtue of the MBP afﬁnity to immobilized amylose resin.
47 The MBP fusion system is available as a
kit (New England Biolabs, Frankfurt, Germany) which provides vectors for cytoplasmic or even periplasmic expression
by taking advantage of the native MBP leader peptide.
T0005 Table 1 Characteristics of popular fusion tags for the optimized expression of recombinant proteins.
Fusion tag Size
a Puriﬁcation Solubilization Stabilization Source
(His)x-tag 6–12 þ    Various suppliers
Strep-tag 6–12 þ    IBA GmbH
b
Protein D 110   7 þ Reference 32
Protein G(B1) 55   7 þ Reference 33
Glutathione S-transferase (GST) 230 þ 7 þ Various suppliers
Thioredoxin 109 þ 7 þ Various suppliers
DsbA 208  þ þ Merck
c
DsbC 235  þ þ Merck
c
MBP 395 þþ þ New England Biolabs
d
NusA 495  þ þ Merck
c
aSize in amino acid residues; the exact size depends on the individual cloning strategy.
bIBA GmbH, Go ¨ttingen, Germany.
cMerck, Darmstadt, Germany.
dNew England Biolabs, Frankfurt, Germany.
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Large fusion partners are usually not desired if a structural analysis by nuclear magnetic resonance (NMR) spec-
troscopy of the expressed protein is under consideration, as the increased number of signals would result in spectra that
are too crowded. The relatively small monomeric 11.6kDa bacteriophage l head protein D might be considered for this
purpose. It shows excellent expression properties, has high thermal stability, and mediates optimal initiation of trans-
lation while reducing the risk of inclusion-body formation and protein degradation.
32 Also the small protein G (B1
domain) has been presented as solubility-enhancement tag especially for NMR purposes.
33
It is often desired to remove the fusion partner after puriﬁcation in order to obtain a nonmodiﬁed target protein. For
that purpose, the recognition site for a highly speciﬁc ‘‘restriction protease’’ can be introduced in the linker between
the two proteins (Table 2). An elegant way that eliminates any additional incubation steps after puriﬁcation is the
intracellular cleavage of the fusion protein directly after translation by virtue of the low-level coexpression of a suitable
protease.
48,49 It should be considered that some proteases cleave in between their recognition sites and thus still leave
residues attached to the N-terminal end of the target protein (Table 2). In addition, it is important to realize that the
removal of the fusion partners can reintroduce the initial stability problems, and it may happen that the proteolytic
processing is accompanied by unfolding and precipitation of the target protein. The production of fusion proteins also
must not necessarily result in functional proteins. However, they still can provide a convenient means of generating
antibodies that are speciﬁc for the protein under study.
3.06.2 Preparative-Scale Protein Expression Techniques
The design and set-up of an ideal expression system depends on multiple factors and each step can inﬂuence the ﬁnal
success. Most system components can be considered as more or less independent modules that can be selected
according to the speciﬁc requirements (Table 3). High level of production of a protein often requires combinatorial
approaches where several individual parameters of an expression system have to be optimized. The expression in
cellular backgrounds especially by using E. coli strains is probably the ﬁrst method of choice in most cases: no other
system is comparable in speediness, simplicity, and cost-effectiveness. However, a valuable toolbox of microbial and
eukaryotic expression systems exists and the individual characteristics should carefully be considered in order to make
the optimal choice (Table 4). Multiple parallel approaches in order to identify the optimal expression technique for a
given protein might be the quickest route to success.
50–54 Speciﬁc applications like the production of modiﬁed
eukaryotic proteins or the expression of difﬁcult protein groups like membrane proteins or disulﬁde-bonded proteins
often require special adaptations and the most powerful and highly promising techniques have to be discussed.
3.06.2.1 Protein Expression in Escherichia coli
Protein expression in E. coli is easy to handle and often reveals a cost-effective and high-level production of het-
erologous proteins.
51,54 The cells can be grown to very high densities in inexpensive complex media within a short time
and yields of recombinant protein up to 1gl
 1 have been obtained.
17,55 Numerous elaborated protocols for the fast and
efﬁcient manipulation of E. coli have been established, a variety of options are possible in order to adapt the expression
system to the speciﬁc requirements (Table 3), and a wide collection of expression vectors with well-deﬁned and strong
promoters is available. Many different E. coli host strains optimized for a high level of expression of recombinant
T0010 Table 2 Frequently used restriction proteases suitable for the cleavage of fusion proteins.
Restriction protease Recognition site
a Source
Enterokinase D-D-D-D-K-k New England Biolabs
b
Factor Xa I-E/D-G-R-k Various providers
Thrombin L-V-P-R-k-G-S Various providers
Tobacco etch virus (TEV) protease E-N-L-Y-F-Q-k-G Invitrogen
c
PreScission protease L-E-V-L-F-Q-k-G-P Amersham Biosciences
d
aThe recognition sequence in the one letter code is given; the arrow indicates the site of proteolytic cleavage.
bNew England Biolabs, Frankfurt, Germany.
cInvitrogen, Carlsbad, CA.
dAmersham Biosciences, Freiburg, Germany.
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proteins are available from various suppliers (Invitrogen, Carlsbad, CA; Merck, Darmstadt, Germany; Stratagene, La
Jolla, CA). While it is true that some groups of proteins are more likely to become produced in E. coli than others, a
wealth of published experience exists that this organism is of importance for almost any application. Depending on the
desired protein product, a variety of proven optimization strategies are documented that can considerably accelerate
the high-level production of a recombinant protein in the desired form.
56
3.06.2.1.1 Inclusion Body Formation and Coexpression of Chaperoneas
Unfortunately a frequent observation in E. coli, especially in production of eukaryotic proteins, is the formation of
inclusion bodies, which are precipitates composed of unfolded and inactive recombinant protein.
4 Protein folding in
prokaryotes and eukaryotes follows different pathways. The biosynthesis of proteins in prokaryotes usually proceeds
very fast and can thus cause the precipitation of proteins that require a long time to achieve their functional folding. In
addition, speciﬁc cofactors, chaperones, or accessory proteins essential in order to complete the folding process of a
eukaryotic protein might be absent in the prokaryotic environment. A shortage of ligands or substrates could addi-
tionally increase the instability of an overproduced protein. Heterologous proteins expressed in E. coli therefore do not
fold spontaneously into a native and functional state even though they are produced at signiﬁcant levels.
Several protocols exist that result in the in vitro refolding of proteins out of isolated inclusion bodies.
57,58 However it
is generally intended to produce recombinant proteins in a folded and active state. Several pathways for the proper
folding of proteins in prokaryotes as well as in eukaryotes are well characterized and key enzymes have been identiﬁed
and cloned. Best studied are the prokaryotic GroEL/GroES and DnaK/DnaJ/GrpE systems.
59,61 GroEL/ES forms large
T0015 Table 3 Rational strategies for the design of a procaryotic expression system.
Parameters General options
System components
Host species Escherichia coli (general), Bacillus subtilis (e.g., export proteins), Lactobacillus
lactis (e.g., membrane proteins)
Host strain Protease deﬁciency, oxidizing cytoplasm, engineered genotype (e.g., DE3,
lacI
q)
Expression vector Copy number, selection marker, host range, compatibility
Expression cassette Promoter, induction conditions, available cloning site, peptide tags, or
fusion partners
Fermentation conditions Medium components, addition of cofactors, incubation temperature,
oxygen supply
Target gene sequence
Initation of translation Optimized environment of the translational start codon
Codon usage Silent mutagenesis, coexpression of rare codon tRNAs
Targeting Addition of export signal sequences
Translational fusions Addition of peptide tags or fusion proteins for better puriﬁcation and/or
stability
Protein characteristics
Low solubility/stability Prevention of inclusion bodies (e.g. coexpression of chaperones, addition
of solubility tags)
Membrane associated Construction of fusion proteins, speciﬁc host strains
Proteolytic degradation Construction of fusion proteins, speciﬁc host strains
Disulﬁde bridges Coexpression of chaperones, engineered host strains, periplasmic
expression
Modiﬁcation Coexpression of modifying enzymes, addition of cofactors
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multisubunit cylinders that actively promote the folding of many proteins through an ATP-dependent cycle.
61,62 The
DnaJ activated DnaK interacts with hydrophobic regions in nascent peptide chains and prevents intra- and inter-
molecular aggregations before the freshly synthesized proteins have adopted their native structure.
60 The nucleotide
exchange factor GrpE mediates the ﬁnal complex dissociation and proteins are released for a folding cycle. The
coexpression of cloned chaperones or other beneﬁcial ‘‘helper’’ proteins can be advantageous in enhancing the stability
or the general expression of recombinant proteins.
63–66 A variety of plasmids have been constructed that could be used
in order to express the most prevalent chaperone systems in combination with a target protein.
67,68 Boosting the
intracellular level of chaperones in E. coli can signiﬁcantly enhance the expression of soluble recombinant proteins.
69
Coexpression can be addressed principally either by bicistronic or by compatible dual-vector approaches.
70
Bicistronic vectors could contain several reading frames arranged as an operon that is controlled by a single promoter.
Unfortunately, genes that are located more distantly to the promoter are commonly much less expressed.
71 A single
dual-promoter expression vector that provides two cloning sites each having a separate promoter could alternatively be
considered.
72 The use of different induction mechanisms would additionally allow the ﬁne-tuning of the individual
expression levels. Coexpression by a dual-vector system usually employs two different compatible vectors for each
cloned target protein. However, one vector often becomes dominant because of differences in the copy numbers.
73
Such a bias in copy number may be balanced if different selection pressures are maintained.
74 Dual-vector systems can
further be used to express several individual subunits of a heteromeric protein complex in a single host cell.
73,74
T0020 Table 4 Comparative evaluation
a of expression systems.
Expression system
Parameter Bacterial Yeast Mammalian Viral Cell-free
System characteristics
Cost-effectiveness þþþ þþ þ þ þ
b
Robustness þþþ þþþ þ þ þ
Variety of vectors, host strains þþþ þþ þþ þþ þ
Speediness of protein production þþþ þþ þ þ þþþ
Set-up of reaction þþþ þþ þ þ þþ
High expression levels þþþ þþþ þ þþ þþ
Inclusion body formation þþ þ þ þ þ
Stabilization of recombinant proteins
c þþ þ þ þ þ
Speciﬁc applications
Posttranslational modiﬁcations  þ þ þ þþ þ þ
Secretion of proteins þþ þþ þ þþ  
Labeling of proteins þþ þ 77 þþþ
Membrane proteins þþ þ 7 þþþ
Disulﬁde-bridged proteins þþ þ þ þþ þ þ þ
Toxins 7     þþ þþþ
Proteins requiring cofactors þþ þ þ þ þ
aThe rating ranges from ‘þþþ’, best choice to ‘ ’, not recommended.
bCommercial systems are relatively expensive.
cStabilization by low intrinsic protease levels, by coexpression of additional proteins, or by the addition of stabilizing
compounds.
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3.06.2.1.2 Solubility Tags and Stable Expression of Recombinant Proteins
The expression of fusion proteins with a highly stable fusion partner at the N-terminal end of the target protein can
often provide a successful approach in order to produce soluble and folded heterologous proteins in E. coli.
44,75 A fusion
partner with a good probability for transmitting a higher solubility to covalently attached target proteins is the E. coli
MBP.
44 Precursors of mammalian proteinases show enhanced solubility even with C-terminal attached MBP.
76 Hy-
drophobic areas at the surface of MBP are supposed to confer a rather unspeciﬁc chaperone-like assistance in the
folding or refolding of aggregation-prone proteins in cis. Other fusion partners like thioredoxin, GST, phage l protein D,
or derivatives of DsbA can act in a similar way to prevent formation of inclusion bodies or to enhance the solubility of
speciﬁc target proteins, but they seem to be not nearly as generally efﬁcient as MBP.
37,38,44,46,75
The fermentation temperature may have a pronounced effect on yield, and on the folding and stability of recom-
binant proteins.
77 Temperatures below 301C can signiﬁcantly improve the solubility of a protein. A reduction of the
temperature down to 251C about 1 h before induction of expression can generally be recommended for the production
of critical proteins. The lack of essential cofactors such as hemes or ﬂavins or simply ions like Mg
2þ can further prevent
the folding process of a recombinant protein upon overexpression. Hence, the accumulation of unstable folding
intermediates may ﬁnally result in formation of inclusion bodies. The yields of soluble protein should be increased by
either enhancing the endogenous cofactor production or by an exogenous supply to the culture.
3.06.2.1.3 Targeting of Recombinant Proteins
In general, three compartments can be considered in E. coli for the targeting of the expressed protein: the cytoplasm,
the periplasm, and the export of the protein into the extracellular medium. Production of proteins in the periplasm has
the advantage that correct disulﬁde bonds can be formed due to its oxidizing environment and due to the presence of
disulﬁde isomerases.
78,79 The microenvironment of the periplasm can be manipulated much more easily with regard to
pH, redox state, and composition in order to optimize the folding of a recombinant protein or to prevent degradat-
ion.
80,81 The majority of proteins exported to the periplasm or to the outer membrane of E. coli use the general
secretory pathway consisting of an array of secretory (Sec) proteins located in the cytoplasm and in the inner mem-
brane.
82–84 One major targeting mechanism in E. coli is exempliﬁed by the attachment of speciﬁc
20–25 amino-acid-long
hydrophobic extensions known as signal or leader sequences to the N-terminus of a protein. The leader will be cleaved
off upon translocation thus leaving recombinant proteins with their natural N-terminal ends.
34 Direction of a recom-
binant protein into the periplasm can simply be anticipated by fusing a naturally occurring leader sequence of an
efﬁciently exported protein like OmpA, b-lactamase, or alkaline phosphatase to its N-terminus. However, the trans-
location process of the recombinant protein often interferes with the translocation machinery due to premature folding,
aggregation, or sterical blocking by bulky secondary structures. Successful and efﬁcient export can therefore hardly be
predicted. It is generally difﬁcult to facilitate the secretion of large amounts of protein and a decrease in the yield down
to at least 10% to that of the cytoplasmatic expression should be calculated. Secretion of proteins is also usually not
very efﬁcient in E. coli. Approaches to direct heterologous proteins to the extracellular space rely on gene fusion
technologies, on the use of dedicated translocators like hemolysin,
85 or on coexpression of proteins that damage the
outer membrane like Kil,
86 bacteriocin release proteins,
87,88 and the membrane protein TolAIII.
89
3.06.2.1.4 Expression of Membrane Proteins
Difﬁculties in obtaining sufﬁcient amounts of recombinant protein are most pronounced with membrane proteins
(Figure 1). Mechanisms of membrane targeting and processes leading to the membrane insertion of proteins signi-
ﬁcantly differ between prokaryotes and eukaryotes. Attachment and targeting by the signal recognition protein, a
prevalent mechanism in eukaryotes, does not occur in prokaryotes. Moreover, toxic effects of the overproduced proteins
frequently cause a reduced growth or even the death of the host cells. Selection strategies have resulted in the isolation
of the specially adapted mutant strains C41 (DE3) and C43 (DE3) from the common host strain BL21 (DE3), which
better tolerate the overproduction of membrane proteins.
90 These strains contain proliferated membranes, and re-
combinant proteins are further directed at elevated levels into inclusion bodies. Culture conditions and genetic
manipulations can therefore be crucial for obtaining high yields of a recombinant membrane protein.
91,92 Furthermore,
the assembly of membrane proteins in E. coli requires complex translocation machineries that may provide promising
targets for the optimization of expression.
93
3.06.2.1.5 Proteolytic Degradation of Recombinant Proteins
Abundant amounts of heterologous proteins are often prone to proteolytic degradation as they are recognized as
abnormal by the proteolytic machinery of the host cell. Early degradation is mainly connected with the ﬁve major ATP-
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F0005 Figure 1 Pathways for the production of membrane proteins in different expression systems. a, production as unsoluble
protein, followed by solubilization and reconstitution. The solubilization from inclusion bodies often requires the initial dena-
turation of the protein. b, isolation or production as soluble protein. Blue arrows indicate the individual puriﬁcation steps that
result in pure membrane protein solubilized in micelles.
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dependent systems: Lon/La, FtsH/HﬂB, ClpAP, ClpXP, and ClpYQ/HslUV.
94 Expression in protease-deﬁcient strains
could thus be advantageous in order to improve the yields of a recombinant protein, but those mutations often cause
growth deﬁciencies.
95 Protease-sensitive proteins could be targeted to the periplasmic space or into inclusion bodies
that generally are protected from proteolysis. A preferred strategy in order to prevent degradation is the production of
hybrid proteins by the generation of translational fusions.
96 A heterologous protein can thus be shielded by a covalently
attached protein that is normally abundant and very stable in the cell.
3.06.2.1.6 Expression of Disulﬁde-Bonded Proteins
The reducing environment of the E. coli cytoplasm and the presence of thioredoxins (TrxA) and glutaredoxins (GrxA-
C) that continuously reduce transiently formed disulﬁde bridges usually prevent the high-level production of oxidized
proteins.
79 Consequently, efﬁcient oxidation of recombinant proteins can be achieved by using strains that are de-
fective for some of the major reductases.
97 The BL21 Origami derivatives (Merck, Darmstadt, Germany) have been
engineered for a superior expression of disulﬁde-bonded proteins. These strains carry chromosomal mutations in the
thioredoxin reductase (trxB) and glutaredoxin reductase (gor) genes which are both necessary for the maintenance of a
reducing environment in the cytoplasm. Fermentation at reduced temperatures can also favor the oxidation of proteins.
An alternative approach is the export of recombinant proteins into the oxidizing environment of the periplasm. The
presence of disulﬁde oxidoreductase and oxidoisomerase (DsbA-C) systems that catalyze the formation and reshufﬂing
of disulﬁde bonds can considerably facilitate the oxidative folding steps of a recombinant protein in the periplasmic
compartment.
64,78,98,99 A further strategy would be the coexpression of oxidizing and disulﬁde-bridge shufﬂing chap-
erones like TrxA, DsbA, DsbC, or the human protein disulﬁde isomerase (PDI).
100,101
3.06.2.2 Protein Expression in Bacterial Hosts other than E. coli
A variety of bacterial expression hosts other than E. coli has been described, and high-level production of recombinant
proteins can be achieved with some of them. Limitations in the availability of genetic tools and of expression vectors
usually restrict more extensive applications. Nevertheless, obvious advantages of choosing non-E. coli hosts include:
enhanced expression rates due to a different codon usage, more industrial applications of recombinant proteins after
their production in a considered-as-safe organism, and increased efﬁciencies in the secretion of the target protein.
Several proteins could be produced in food-grade microorganisms such as lactic acid bacteria or Corynebacterium
glutamicum.
102–104 Lactococcus lactis has recently been proposed as a promising host for the overproduction of functional
membrane proteins of prokaryotic and eukaryotic origin and may represent an interesting alternative to other systems
(Figure 1).
105 Growth rates are similar to that of E. coli and essential techniques for genetic manipulations are
available. Expression vectors for lactic acid bacteria are often based on broad-range replicons that also replicate in E. coli
and a selection of inducible strong promoters is available.
104–107 The efﬁcient secretion systems of Bacillus subtilis and
probably also of some Streptomyces species make these organisms suitable as expression hosts especially for the pro-
duction of exported proteins.
108–110
3.06.2.3 Yeast Expression Systems
Eukaryotic expression systems are generally more difﬁcult to handle. Slow growth rates, higher costs, and lower
efﬁciencies are often attributes of eukaryotic expression systems and they are therefore usually consulted when the
expression of a recombinant protein in E. coli is unlikely for some reason or already has failed. Important and obvious
advantages of eukaryotic expression systems are the possibility of obtaining native-like modiﬁcation patterns of the
recombinant protein like glycosylation, phosphorylation, and lipidation. The folding pathway of eukaryotic proteins may
in addition depend on speciﬁc chaperone systems that do not occur in prokaryotes. The activation of proteins by an
attachment of cofactors is also often not possible in E. coli. An interesting alternative might be the use of expression
systems based on yeast cells. They resemble bacterial systems in many features but still contain important charac-
teristics of eukaryotic expression systems. Many basic mechanisms for the processing and targeting of proteins are very
similar to those in mammalian cells. Yeast cells contain an endoplasmatic reticulum and a membrane topology similar to
mammalian cells. Efﬁcient pathways for the posttranslational modiﬁcation of proteins are present and they are fre-
quently essential in order to maintain the stability or the activity of a protein. However, it should be considered that
the type of glycosylation in yeast cells sometimes differs from the pattern obtained in mammalian cells. The yeast
system can also be very powerful especially with regard to the production of large quantities of secreted proteins.
111–113
Several yeast species can be used for the production of recombinant proteins. Most popular are baker’s yeast
Saccharomyces cerevisiae
114,115 the species Pichia pastoris,
116,117 and Hansenula polymorpha.
118 Other species like Klyveromyces
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sp., Yarrowia lipolytica,
119 and Zygosaccharomyces bailii
120 might gain increasing interest in the next future. An evident
advantage is the unicellular organization of yeasts, which enables the direct transfer of many techniques and ma-
nipulations commonly applied for bacteria. Comprehensive protocols exist for the transformation of yeast with foreign
DNA. Furthermore, yeasts can be grown in relatively simple and inexpensive media and they reach high cell densities
in reasonable times.
An elaborate collection of expression vectors for yeasts is available. Common features are regulatory regions for
replication in E. coli and a prokaryotic selection marker. This enables the construction and propagation in bacterial cells.
The vectors are classiﬁed based on their mode of replication into the groups of episomally replicating vectors and
chromosomal integration vectors. Stable maintenance of high copy number requires regulatory sequences from the
endogenous yeast 2 micron plasmid, while origins of replication from yeast autonomous replicating sequence (ARS)
elements are much less stable with loss rates of up to 10% per generation. Integrative vectors are devoid of any origins
of replication and they can only be distributed to daughter cells if they integrate into the yeast chromosome by
homologous recombination. The efﬁciency of integration can thus considerably be increased if sequences homologous
to chromosomal areas are provided and multiple integrations can be frequent.
117,121 Transformed yeast cells can be
screened by a number of selection markers mainly based on auxotrophic deﬁciencies like HIS3, LEU2, LYS2, TRP1,
and URA3.
114 A set of inducible strong promoters is available. Commonly used are the methanol inducible alcohol
oxidase 1 (AOX1) and alcohol dehydrogenase promoters (ADH2), the metallothioneine promoter, and galactose in-
ducible promoters (GAL1, GAL7, Gal10).
117,122 Shuttle vector systems suitable for the dual protein expression in P.
pastoris as well as in E. coli are available for the convenient evaluation and rapid comparison of different expression hosts
without time-consuming subcloning steps.
123
Optimized fermenter cultures of P. pastoris are able to produce more than 1gl
 1 of recombinant protein and the
ability to grow on deﬁned minimal media makes this species suitable for the efﬁcient labeling of expressed proteins for
a structural analysis.
117,122,124 Interesting applications of yeast expression systems are the high secretion levels of
recombinant protein,
125,126 the production of disulﬁde-bonded proteins,
127 and their potential for the high-level
production of membrane proteins (Figure 1).
128
3.06.2.4 Mammalian Expression Systems
Expression in mammalian cells provides an environment mostly closely related to the native origin of many eukaryotic
proteins. A variety of genetically and phenotypically diverse mammalian cell lines have been used for protein pro-
duction.
129 Frequently used are baby hamster kidney (BHK) cells,
130 Chinese hamster ovary (CHO) cells,
131 human
embryonic kidney (HEK) 293 cells,
132 mouse L-cells,
133 and various myeloma cell lines, which are used to establish
relatively stable protein expression systems. Further cell lines for more speciﬁc applications are NIH 3T3 cells,
134
murine erythroleukemia (MEL) cells,
135 or lymphoblastoid cell lines like Namalwa
136 and RPMI 1788.
137 Main pa-
rameters for the high-level expression of recombinant proteins are the selected cell lines and the speciﬁc vector
characteristics.
138 Stable productive cell lines are established principally by selecting homogenous cell populations from
heterogeneous cell pools. The yield of recombinant protein can often increased by selective ampliﬁcation with agents
like methotrexate (MTX).
139
DNA can be transferred into mammalian cells by transfection of coated or encapsulated DNA particles which
become incorporated into the cells through endocytosis. Coprecipitation with calcium phosphate
140 or diethylami-
noethyl dextran
141 is also relatively simple and highly effective. Lipofection of compact liposome/nucleic acid com-
plexes and electroporation of cells are further powerful techniques.
142,143
3.06.2.4.1 Vector Design for Gene Transfer and Expression in Mammalian Cells
Transcriptional and translational control elements, RNA processing, gene copy numbers, stability of mRNA, the site of
chromosomal integration, and the impact of recombinant proteins in the host cell are important parameters for efﬁcient
gene expression in mammalian cells. A large number of vectors are available and key elements are strong promoters and
enhancers of the promoter activity.
144,145 Conserved and essential sequences of eukaryotic promoters are the TATAA
box and the CAAT box that are located approximately 30 and 80bp upstream of the mRNA initiation site, respectively.
Frequently used constitutive promoters are the adenovirus major late promoter, the human cytomegalovirus immediate
early promoter or the simian virus 40 (SV40) and Rous sarcoma virus (RSV) promoters. However, similar to bacterial
expression systems, an inducible system is desired in most cases as the produced proteins might become toxic to the
host cell.
146 The well-known bacterial lac promoter–repressor system was therefore adapted for its use in mammalian
cells yielding up to a 10000-20000-fold induction of gene expression.
147–149 Selection markers for successfully
transfected mammalian cells include the genes encoding for dihydrofolate reductase (DHFR), for aminoglycoside
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phosphotransferase providing neomycine or G418 resistance,
150 or for enzymes providing resistance against puromycin,
hygromycin, or placitidine.
144,151
Optimized splicing of introns present in most genes of higher eukaryotes is important. The presence of introns in
mRNAs may lead to a 10- to 20-fold increased expression rate.
152 Eukaryotic mRNAs have poly(A) tails attached to
their 30 end which modulate their stability and efﬁciency of translation.
153,154 Effective poly(A) attachment signals in
mammalian expression vectors are derived from the genes of mouse b-globulin,
155 herpes simplex virus thymidine
kinase,
156 bovine growth hormone,
157 or the SV40 early transcription unit.
158 The initiation of translation depends on a
conserved sequence enclosing the AUG start codon (CC(A/G)CCaugG), named the Kozak sequence.
159 Stable hairpin
structures of GC-rich regions in the 50 UTR can further negatively inﬂuence the efﬁciency of transcription.
160
3.06.2.4.2 Modiﬁed Mammalian Cell Expression Systems
The copy number of a heterologous gene may signiﬁcantly increase if it is physically linked to a chromosomal DNA
region that is subject of extensive ampliﬁcation processes. The associated target gene will then become coampliﬁed,
resulting in higher yields of recombinant protein due to the increased gene copy numbers. Spontaneous gene am-
pliﬁcation in mammalian cells is unfortunately only a rare event, but a variety of artiﬁcial gene ampliﬁcation techniques
have been developed that may ultimately lead to considerable gene ampliﬁcation frequencies.
161 A broad selection of
agents and treatments have been found to be active in inducing the ampliﬁcation of genomic regions. Reagents like
hydroxyurea, aphidicolin, hypoxia, and carcinogens or the treatment by Ultraviolet- or g-irradiation have been
used.
162,163 Frequently used gene ampliﬁcation systems take advantage of DHFR as a selectable marker present on the
expression vector. DHFR catalyzes the reduction of 5,6-dihydrofolate to 5,6,7,8-tetrahydrofolate, a biocatalyst for the
essential synthesis of glycine and thymidine monophosphate, and for purine biosynthesis. CHO cells carrying a DHFR
deﬁciency due to chemical mutagenesis are not able to grow in a medium depleted of nucleosides unless they carry a
functional DHFR gene through transfection.
139 The folic acid antagonist MTX binds and inhibits DHFR stoichio-
metrically. Therefore, stepwise-increased MTX concentrations in the medium can be used to effectively select
transfectants that amplify the DHFR gene, resulting in cell populations containing several hundreds of gene cop-
ies.
164,165 High levels of recombinant heterologous protein can be achieved by cotransfecting and cointegrating
plasmids carrying the DHFR marker and the gene of interest at the same site in the genome.
164 Also an expression
cassette including a promotorless DHFR gene can be used. The inserted gene of interest is in that case transcribed
from a strong promoter upstream of the DHFR open reading frame, producing a bicistronic message and thus protein
production dependent on MTX resistance.
166,167
A sophisticated technique for antibody production is the fusion of unrestricted and fast-growing myeloma cells with
other cells. Fused myeloma and plasma cells create antigen-speciﬁc hybridoma cell lines. These fast-growing secretory
cell lines are well suited for the expression of recombinant transfected genes and predestinated for the synthesis of
monoclonal antibodies.
168,169 A further positive aspect of hybridomas is their natural growth in suspension cultures that
saves time-consuming adaptation procedures in the case of large-scale production. The mouse myeloma cell line Sp2/0
Ag14 is a preferred choice for recombinant protein production. It contains deﬁciencies for synthesizing and secreting
endogenous immunoglobulin, is easy to transfect and can proliferate in large-scale serum-free cultures.
170
The use of powerful viral transcription/translation machineries is an elegant technique for the protein synthesis in a
mammalian expression system. COS AU :1 cell lines are most exclusively used for the transient expression of heterologous
genes dependent on expression of SV40 large T-antigen, although several cell lines are suitable.
171–175 Three cell lines
(COS-1, COS-3, and COS-7) have been established by transforming the African green monkey cell line CV-1, per-
missive for the lytic growth of SV40, with an origin-defective SV40 genome and thus creating a cell line harboring the
SV40 large T-antigen expression. Transfection with an expression plasmid containing a functional SV40 origin of
replication and the gene of interest enables the interaction between the SV40 large T-antigen and the SV40 origin of
replication and can ﬁnally yield high recombinant protein titers.
176–178 The plasmid replication in COS cells is highest
at about 48h after transfection and the system is not able to produce high amounts of protein over a prolonged period of
time.
129 This problem can be solved by using the COS system in extended and modiﬁed batch modes that allow
multiple harvests and that can result in the cumulative production of preparative amounts of recombinant pro-
tein.
179,180
3.06.2.5 Viral Expression Systems
Viral expression systems are elaborate ways to synthesize heterologous proteins. The systems take advantage of the
viral nature to introduce foreign DNA with high efﬁciency into host cells by infection combined with high replication
rates due to strong viral promoters. The most popular viral systems include the already mentioned monkey tumor virus
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SV40,
175 the baculovirus/insect cells system,
181 and the Semliki Forest virus (SFV) that is used with a wide range of
mammalian host cells.
182 Further less prevalent systems use the Epstein–Barr virus,
183 the cytomegalovirus (CMV),
RSV, or the SFV-related Sindbis virus.
184 Besides their application in expression systems viral vectors are widely used
for vaccines and gene therapies.
185
3.06.2.5.1 The Baculovirus Expression Vector System
Protein production in insect cells in combination with the baculovious expression vector system (BEVS) presents
several advantages like the ease of culture, a high tolerance to by-product concentrations, and high expression levels.
181
Baculoviruses belong to a family of double-stranded DNA viruses with large circular genomes of 120–180kbp.
186 They
are invertebrate-speciﬁc and the host range is restricted mainly to arthropods with about 600 insect species reported to
be targets of infection.
129 The characteristic production of large amounts of protein during the late phase of infection
has implicated their adaptation as vectors for heterologous gene expression. Probably best characterized is the
Autographa californica nuclear polyhydrosis virus (AcNPV). The two very late gene products, polyhedron and p10, are
expressed from strong promoters at levels up to 50% of the total protein content of the infected cell.
187 These proteins
are not essential for the formation of viral particles and are thus predestinated to become replaced by heterologous
gene products. Diverse expression vectors have been developed that depend on speciﬁc host cell lines for infection and
propagation.
188–191 The most frequently used insect cell lines are derived from Spodoptera frugiperda (SF9 and SF21) and
from Trichoplusia ni (Hi5 and MGI), having generation times up to 24h and requiring complex culture media.
187 Various
approaches of large-scale protein synthesis in insect cells have been reviewed.
181 Of great interest is the capability of
insect cells to perform posttranslational modiﬁcations. Cell lines optimized in order to obtain the most favorable
glycosylation patterns have been developed.
192,193 The demonstrated high level of expression of several functional G
protein-coupled receptors (GPCRs) makes baculovirus-based expression systems very attractive for the preparative
production of targets from this important class of membrane proteins (Figure 1).
194,195 Activation of the ‘‘late’’
polyhedron promoter lags signiﬁcantly behind the infection process and makes the insect/baculovirus system also
potentially useful for the expression of cytotoxic recombinant proteins. Recombinant proteins can even effectively
become secreted into the medium by adding a signal sequence like the honey bee (Apis mellifera) prepromelittin
secretory sequence.
196
3.06.2.5.2 Semliki Forest Virus Expression Systems
An effective and well-studied expression system for a rapid and high-level gene delivery is based on replication-
deﬁcient alphavirus vectors. These systems beneﬁt from an enormous RNA replication capacity in the cytoplasm that
consequently results in extreme expression levels. Most common are vectors of SFV, but similar expression systems
have been engineered for the Sindbis virus
197 or the Venezuelan equine encephalitis virus.
198 The pathogenic prop-
erties of wild-type SFV, an enveloped single-stranded RNA virus, include induction of neuronal apoptosis, demyeli-
nation in the central nervous system, and teratogenesis.
199 These viruses are capable of infecting a broad range of
mammalian, amphibian, reptilian, insect, avian, and ﬁsh cell lines. Mutant strains with drastically reduced virulence
have been made in order to use these pathogenic vectors for experimental gene delivery approaches.
A typical expression system consists of two plasmids based on complementary (cDNA) copies of the SFV
genome.
200 The expression vector, containing the SFV nonstructural genes (nsP1-4) and the strong SFV 26S promoter,
has a multilinker cloning region into which foreign genes can be inserted. The second helper vector contains the genes
for capsid and envelope proteins. The cotransfection of both vectors into BHK cells generates a high titer (10
9–
10
10particlesml
 1) of recombinant and infectious SFV particles.
201 The use of the two-vector system guarantees the
production of replication-deﬁcient particles since the RNA packaging signal is only present in the recombinant RNA of
the expression vector and no helper RNA will be packed. The infection of host cells will therefore lead to a rapid and
high-level expression of recombinant protein without the generation of virus succession. A further advantage is the
broad host range of SFV as parallel expression studies can be performed in different cell lines.
The SFV system suffers from safety risks and cytotoxicity, and novel less cytotoxic and temperature-sensitive
mutant vectors that are inactive at the blood temperature of 36–371C have been developed.
182,202 The addition of a
translation enhancement signal to the capsid gene resulted in ﬁve- to tenfold increased expression levels.
203 High
amounts of topologically different proteins have successfully been expressed with SFV vectors. Besides b-galactosidase
with a total cellular protein yield of approximately 25%, more than 50 GPCRs and several ion channels have been
expressed at high levels (Figure 1).
201
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3.06.2.6 Cell-Free Protein Expression
The described conventional in vivo technologies for protein production depend on the cellular integrity and are only
suitable for the production of proteins that do not affect the physiology of the host cell.
204,205 As already discussed,
these methods are limited for the expression of many proteins, e.g., by the formation of inclusion bodies,
206,207 by
protein instability due to proteolysis,
205,208 or by too low yields in case of most membrane proteins. High-level cell-free
(CF) expression systems are a promising new tool for the preparative production of difﬁcult proteins (Figure 2). CF
systems are principally independent of the cell physiology and they allow direct and immediate control of the reaction
at any time. A wide range of critical reaction parameters such as pH, redox potential, and ionic strength can be chosen
and adjusted according to the requirements of the speciﬁc target protein. Furthermore, any additives that might help to
stabilize the recombinant protein after translation can be supplied directly into the reaction and no transport problems
through cellular membranes have to be considered. Metabolic conversions or even the breakdown of added substances
is usually very low or even not detectable. Options of possible beneﬁcial compounds can include cofactors, ligands,
inhibitors, ions, chaperones, and even detergents. The complete and time-independent control in combination with
the high ﬂexibility of the reaction conditions provides a challenging opportunity for the preparative production of
formerly highly problematic proteins such as membrane proteins, toxins, or unstable proteins.
A unique characteristic of CFexpression techniques is the possibility of quickly and easily introducing speciﬁc labels
into a protein (Figure 2). Labeling of proteins with stable isotopes is indispensable for the structural and functional
analysis by NMR techniques and for drug screening and ligand interaction studies. Labeling of proteins with spectrally
enhanced amino acids can further be very helpful for the analysis of protein interaction studies.
209 The composition
and concentration of all low molecular weight substances in the CF reaction is fully deﬁned and the operator has
therefore complete control over the amino acid pool of the reaction. Any type of amino acid can thus easily be replaced
by a labeled derivative and a 100% label incorporation into the recombinant protein is ensured. The kinetics and
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F0010 Figure 2 Schematic illustration of cell-free protein synthesis in a bacterial coupled transcription and translation system. The
cell extract contains ribosomes, translation factors acetate kinase, and aminoacyl-tRNA synthetases (ARSs). T7 RNA polym-
erase and substrates like amino acids, the energy regenerating system components, nucleotide triphosphates (NTPs), tRNAs,
and salts are supplied and protein synthesis is initiated by adding template DNA. The incorporation of selected isotopic labeled
amino acids (red) can easily be achieved in the cell-free system, leading to a selectively isotopic labeled protein. Regeneration of
NTPs is accomplished by an ATP regenerating energy system (yellow) based on the hydrolysis of high-energy substrates in the
presence of their cognate kinases. To assist stability and folding of the target proteins, detergents, chaperones, and other
supplements may be added to the reaction mixture.
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efﬁciency of the production of labeled proteins equals those of the nonlabeled reactions and no laborious optimizations
have to be carried out. In contrast to conventional in vivo labeling systems, no switch to auxotrophic host strains and to
fermentations in minimal media is necessary. It should be emphasized that there is virtually no background labeling as
the target protein is the only protein that is synthesized in substantial amounts during CF synthesis. High-throughput
applications attract increasing attention due to the demands of proteomics associated research. CF synthesis also offers
a powerful approach as linear DNA templates simply generated by conventional polymerase chain reaction (PCR) can
directly be used for the expression of proteins.
210
3.06.2.6.1 Design of Cell-Free Expression Systems
CFexpression systems can be set up as pure translation systems with puriﬁed mRNA as a template, or alternatively as
coupled transcription–translation systems by adding plasmid or linear DNA as a template.
211,212 The simplest design of
CF expression is a batch mode reaction with one compartment holding a ﬁxed volume of reaction mixture (RM) in a
test-tube. While batch systems are easy to set up and highly suitable for high-throughput applications, they are limited
by the rapid accumulation of deleterious by-products like free phosphates from nucleotide consumption that appar-
ently form complexes with magnesium ions. In addition, substrates like nucleotide triphosphates (NTPs) and high-
energy phosphate donors are rapidly consumed even in the absence of protein synthesis.
213 The results are obtained in
relatively short reaction times that normally do not exceed 1h. Recent modiﬁcations of the batch system by using a
novel NTP regeneration system can help to prevent the accumulation of inorganic phosphate,
213 and the supple-
mentation of additional compounds can signiﬁcantly extend the reaction time and increase the yield of protein
synthesis.
214–219 Optimized CF batch systems have the potential to reach a high productivity and may become a
powerful technique in the future.
Extended reaction times in CF expression can be achieved by using a continuous-ﬂow CF (CFCF) translation
device.
220 A key feature is the continuous supply of energy and substrates concomitant with the removal of reaction by-
products. The immobilized RM is continuously perfused by a feeding mixture (FM) containing all low molecular
weight precursors and substrates and removing deleterious by-products of the protein production. The RM can
alternatively be separated from the FM by a membrane with a variable molecular weight cut-off between 10 and
300kDa.
221 However, reduced exchange rates by blocked membranes can cause signiﬁcant problems. The protein
synthesis in a CFCF system can continue for more than 20h and yields of up to 1mg recombinant protein per ml RM
are possible. The CFCF system can either be operated in the translating mode by adding mRNA,
222,223 or in the
coupled transcription–translation approach by the addition of phage RNA polymerases.
221,222,224 Many successfully
synthesized proteins like the bacteriophage MS2 coat protein,
220 the brome mosaic virus coat protein,
220 globin,
225
calcitonin,
222 DHFR,
222,226–228 chloramphenicol acetyltransferase,
222,221,229–231 interleukin-2,
232 and interleukin-6
223
demonstrate the enormous potential of CFCF protein synthesis.
The relatively complex reaction set-up of the continuous ﬂow mode is simpliﬁed in continuous-exchange CF
(CECF) expression systems.
230,233 The RM and FM compartments have ﬁxed volumes and are separated by a dialysis
membrane. The simplest device for a CECF set-up is a dialysis bag holding the RM that is placed in a suitable
container with the FM,
233 but commercially available dialyzers devices, such as the MicroDialyzer
s and Di-
spoDialyzer
s (Spectrum Laboratories, Breda, The Netherlands), can also be used successfully. An additional advantage
of the CECF set-up is the accumulation of the synthesized recombinant protein in the RM. High-level synthesis of up
to 6mg recombinant protein per ml RM has been reported.
230,234 Yields of 1–4mg per ml RM for several functionally
active proteins like the green ﬂuorescent protein, DHFR, luciferase, and RNA replicase of tobacco mosaic virus have
been obtained with eukaryotic wheat germ extracts.
235 The CECF system is commercially available as a kit (Roche
Diagnostics, Mannheim, Germany) but can also be set up individually.
233,236–238
3.06.2.6.2 Components of the Cell-Free Reaction
All elements involved in gene expression and protein synthesis have to be added to the RM where transcription and
translation takes place (Figure 2). Components like DNA, a highly processive RNA polymerase like the enzyme
encoded by the T7 bacteriophage, NTPs, mRNA, tRNA, aminoacyl tRNA synthetases (ARSs), ribosomes, transcription
and translation factors as well as amino acids have to be combined in an optimal pH and salt environment. The required
high amounts of free energy for the transcription and translation processes are provided by hydrolysis of the
triphosphates ATP and GTP. Crucial for each CF system is therefore an efﬁcient ATP regenerating energy system in
order to maintain the NTP concentrations over a long period of time. Conventional energy systems are based on high-
energy phosphate donors such as phosphoenol pyruvate in combination with pyruvate kinase,
211,239 creatine phosphate
and creatine kinase,
234 or acetyl phosphate with acetate kinase.
240
MDCH : 00079
S0115
P0205
P0210
P0215
S0120
P0220
Recombinant DNA and Protein Expression 15ELSEVIER FIRST PROOF
3.06.2.6.3 Preparation of Cell-Free Extracts
The quality of the cell extract is crucial for the success of a CF system. The extract represents usually a crude cell
lysate which contains most of the essential high molecular weight components for translation. Only T7 RNA po-
lymerase and certain enzymes for the energy regeneration have to be supplied. While many organisms could potentially
serve as an extract source, lysates based on the cell types of E. coli, wheat germ, and rabbit reticulocytes have been well
established.
The bacterial source of choice for the preparation of CF extracts are RNAse-deﬁcient E. coli strains, e.g., A19
236 or
BL21.
237,241 Extracts of E. coli S30 represent the soluble fraction after centrifugation of crude lysates at 30000g.
Endogenous mRNA is removed during a preincubation step of the cell extract either with high salt
236 or with added
nucleotides and amino acids. This ‘‘runoff’’ step releases endogenous mRNA from the ribosomes that will then
subsequently become destroyed by endogenous ribonucleases.
242 Alternatively, isolated ribosomes can be added to an
S100 extract, centrifuged at 100000g.
243,244 Extracts of E. coli are used in coupled transcription–translation CF systems
due to the favorable use of T7 RNA polymerase. Extracts of E. coli work well in a wide temperature range between 24
and 381C with an optimum at 371C.
242,244,245 Due to the relatively simple extract preparation procedure combined
with high productivity, the E. coli CF system is the most commonly used in vitro protein expression technique and up
to 6mg of protein per ml RM can be synthesized.
234
A well-deﬁned system using 31 individually puriﬁed enzymes isolated with conventional expression systems
together with puriﬁed ribosomes is termed the ‘‘protein synthesis using recombinant elements’’ (PURE) system.
246
The advantage of the PURE system is the absence of any inhibitory substances such as nucleases, proteases, and
enzymes that hydrolyze nucleoside triphosphates.
The most convenient and promising eukaryotic CF translation system is based on wheat germs isolated from dry
wheat seeds.
247 Recent modiﬁcations resulted in extracts with a high degree of stability and activity.
235 Important for
an enhanced translation efﬁciency in the wheat germ CF system are the 50 and 30 UTRs of eukaryotic mRNAs that play
a crucial role in the regulation of gene expression by controlling mRNA translational efﬁciency, stability, and local-
ization. An optimal 50 UTR that should therefore be added to mRNAs is the so-called omega sequence (O71) of
tobacco mosaic virus. For the 30 UTR the length is more important for an efﬁcient translation than the sequence.
248
Wheat germ extracts possess only low levels of endogenously expressed mRNAs and therefore can be directly used for
the expression of templates.
249 The optimal reaction temperature is in the range of 20–271C,
250,251 but can be
increased to up to 321C for higher expression of some templates.
252 The reaction continues up to 60 h and amounts of
1-4mg of recombinant protein per ml RM can be obtained.
235
Lysates of rabbit reticulocytes are obtained from blood cells of anemic rabbits that provide a high number of
reticulocytes or proerythrocytes. Endogenous mRNA is removed by treatment with micrococcal Ca
2þ-dependent
RNase.
253 The yields of recombinant protein can also be in the range of mg per ml RM, whereas the expression yields
of the wheat germ system are usually higher.
254 This system works in an optimal temperature range of 30–381C.
255
In principle, the choice of extract source, either prokaryotic or eukaryotic, for CF synthesis should be chosen
according to the origin and biochemical nature of the protein of interest. In general E. coli-based systems gain in terms
of their higher translation rates, better compatibility with combined transcription–translation formats, easier prep-
aration of extracts as well as reaction set-up, and the availability of mutants with reduced degradative activities. On the
other hand they suffer from high degradation of genetic messages, shorter lifetimes, and a great tendency of protein
aggregation. Eukaryotic extracts are mainly limited by lower translation rates and the complexity of the genetic
constructs that are required for an effective expression. Positive aspects of eukaryotic CF systems are their higher
stability and longer lifetime in addition to a better compatibility with eukaryotic mRNAs and the synthesis of
eukaryotic proteins.
CECF expression kits based on E. coli and wheat germ extracts are commercially available (Roche Diagnostics,
Mannheim, Germany). The successful production of more than 40 proteins of different origins, including various
enzymes, receptors, hormones, antibodies, and regulatory proteins has been shown by various laboratories.
256,257 Other
commercial systems like Expressway
TM (Invitrogen, Carlsbad, CA) focus on the batch mode with expression amounts
of up to 1mgml
 1.
3.06.2.6.4 Cell-Free Synthesis of Membrane Proteins
Membrane proteins today represent less than 1% of the available three-dimensional protein structures, although this is
in contrast to their immense medical importance as an estimate of 60-70% of current drug targets are based on
membrane proteins. The key bottleneck has been the lack of reliable technologies that ensure the production of a
broad variety of recombinant membrane proteins in the required amounts.
258 Toxicity to the host cell, protein
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aggregation, and miss-folding of overproduced membrane proteins very often result in low yields. Furthermore, the
overexpression of integral membrane proteins often causes cell death by overloading the cytoplasmic membranes or by
disrupting the membrane integrity. Two protein groups of outstanding pharmaceutical relevance are multidrug re-
sistance transporters of bacterial pathogens and GPCRs as the basic elements of the eukaryotic signal transduction
machinery. Preparative-scale expression of GPCRs has in most cases not been obtained and it is always subject of
tedious and long-lasting optimizations.
194,195,259 A promising perspective is that the newly developed CF translation
systems offer a powerful alternative for overcoming the tremendous expression barriers for membrane proteins (Figure
1). It has recently been shown that functionally active integral membrane proteins, especially small multidrug trans-
porters, GPCR proteins, a light-harvesting membrane protein, and ion channels were expressed in high yields of mg
amounts per ml RM in an E. coli-based CECF system.
236,238,260–262 The proteins could also be functionally recon-
stituted into proteoliposomes and isotopically labeled for NMR investigations.
236 Even the addition of mild detergents
does not interfere with the translation activity of the CECF systems and results directly in the soluble and functional
expression of several integral membrane proteins.
238,260,261 The combination of isotopic labeling and membrane protein
expression demonstrates the high potential of the CF method for functional and structural membrane protein research.
Finally it should be mentioned that the preparation of membrane protein samples ready for a structural analysis by, e.g.,
NMR techniques is possible in less than 2 days by using CF expression systems and the structural characterization of
even very difﬁcult protein families like the GPCR proteins becomes now feasible.
3.06.2.6.5 Cell-Free Synthesis of Disulﬁde-Bridged Proteins
Disulﬁde-bonded proteins are rarely expressed in traditional expression systems due to their requirements for oxidizing
conditions which in eukaryotes are only found in the lumen of the endoplasmatic reticulum (or in the periplasm of
prokaryotes). The open character of CF systems allows the direct addition of puriﬁed chaperones like the already
discussed eukaryotic protein disulﬁde isomerase (PDI) or bacterial Dsb derivatives with success of the functional
expression of single chain antibodies.
263 CF expression reactions are usually operated in the presence of reducing
agents like dithiothreitol that stabilize the protein transcription–translation machinery but provide less favorable
conditions for the synthesis of disulﬁde-bonded proteins. However, the use of a dithiothreitol-deﬁcient wheat germ
extract in the presence of the PDI chaperone efﬁciently synthesizes a single-chain antibody variable fragment with
dual disulﬁde bonds.
264 More recently, the problem of the CFexpression of disulﬁde-bonded proteins was overcome by
using a combination of iodoacetamide-treated extract, a suitable glutathione redox buffer, and the addition of disulﬁde
bond shufﬂing chaperones like Skp and DsbC.
265 A recombinant plasminogen activator protein with nine disulﬁde
bonds could productively be expressed with this approach.
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Summary
The main purpose of preparative production of recombinant proteins is as the ﬁrst prerequisite for drug target
screening purposes, but in addition it has many applications in structural and functional research. Despite numerous
attempts to streamline and to rationalize heterologous gene expression the vast majority of samples still have to be
treated more or less empirically and a number of systems and hosts have to be tested. Only about 20% of the
nonmembrane proteins in an organism may be instantly expressed in generalized standard systems in the amounts and
qualities sufﬁcient for a structural analysis: a high-level expression of membrane proteins is still the exception. The
optimal expression of proteins is therefore often simply a result of trial and error. The ideal choice of an expression
system with regard to control elements, vector characteristics, host environment, fermentation condition, and kinetics
of expression is crucial, as it determines the yield and the quality of the recombinant protein. Expression systems are
composed of relatively independent modules that can be optimized separately, and a good compromise between
workload and costs have to be found in a reasonable time. A wealth of options and strategies exists and usually
combined approaches have to be employed to become successful. This chapter is intended to serve as a guideline for
making decisions in order to obtain the highest yields of recombinant proteins and it provides an overview about the
currently most promising expression systems in bacterial and eukaryotic cells as well as in cell-free environments. We
concentrate on critical details and features that have to be considered upon the in vitro recombination of expression
vectors and during the process of protein production. Key elements of expression systems will be discussed individu-
ally; and modiﬁed techniques that have been approved for the production of distinct and difﬁcult groups of proteins,
e.g., membrane proteins or disulﬁde bonded proteins, will be especially highlighted. A special focus is also the
preparative scale cell-free production of recombinant proteins as this relatively new technique provides several unique
characteristics with a high potential for the future. However, this chapter does not cover downstream procedures in the
preparation of recombinant proteins like puriﬁcation strategies, nor does it include speciﬁc high-throughput ap-
proaches.
Keywords: baculovirus expression systems, cell-free expression, cell-lines, coexpression of proteins, disulﬁde
bridge formation, expression systems, expression vectors, fusion proteins, mammalian cell expression, membrane
proteins, promoter, protein overproduction, protein production in Escherichia coli, recombinant protein, semliki forest
virus expression systems, solubility tags, vector design, viral expression systems, yeast expression systems
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Nomenclature
ARSs aminoacyl-tRNA synthetases
BHK baby hamster kidney
CECF continuous-exchange cell-free
CF cell-free
CFCF continuous-ﬂow cell-free
CHO Chinese hamster ovary
DHFR dihydrofolate reductase
FM feeding mixture
GPCR G protein-coupled receptors
GST glutathione S-transferase
IPTG isopropyl-b-D-1-thiogalactopyranoside
mRNA messenger RNA
MTX methotrexate
NMR nuclear magnetic resonance
NTP nucleotide triphosphates
PDI protein disulﬁde isomerase
RBS ribosome binding site
RM reaction mixture
rRNA ribosomal RNA
SFV Semliki Forest virus
tRNA transfer RNA
UTR untranslated region
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10.1
Introduction
Nuclear magnetic resonance (NMR) spectroscopy has experienced a tremendous
growth over the past decade, and has been developed as a widely used technique
with enormous potential for the study of the structure and dynamics of biological
macromolecules. In particular, structural analysis of proteins has greatly bene-
ﬁted from recent advancements of high ﬁeld solution NMR. Improvements in the
hardware and the development of NMR spectrometers with ﬁeld strengths up to
900 MHz considerably increased the sensitivity and reduced the requirements for
high amounts of samples. Furthermore, major milestones in the study of proteins
have been the use of isotope labeling and the development of multidimensional
techniques. The structure of small proteins below a limit of approximately 10 kDa
could be analyzed without the need for special isotope labeling after the develop-
ment of homonuclear 1H two-dimensional (2-D) experiments in the late 1970s and
early 1980s. However, beyond that limit, the increased complexity due to line
broadening and 1H chemical shift overlap prevents detailed structural analysis
of larger proteins by these techniques. The structural analysis of large proteins
therefore requires multinuclear labeling and special strategies in order to replace
the prevalent NMR inactive isotopes 14N and 12C in proteins by the NMR active
isotopes 13C and 15N [1]. Protocols have been developed to generate either uni-
formly 13C/15N-labeled proteins or to introduce the label only at speciﬁc sites. In
addition, heteronuclear multidimensional NMR experiments have been designed
that utilize the relatively large one- and two-bond scalar couplings introduced by
the label [2, 3]. Using the 13C and/or 15N chemical shifts, the overlapping 1H res-
onances can now be routinely separated into three or four dimensions. The com-
bination of these techniques addresses the limitations imposed on the study of
large proteins and permits structure determination of proteins up to a molecular
weight of approximately 22 kDa [4, 5]. This limit could be extended up to 40 kDa
by the random incorporation of 2H into nonexchangeable sites of proteins [6–9].
In this chapter, recently developed strategies for the incorporation of 15N and
13C labels into proteins resulting in highly sensitive spectra and facilitating struc-
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269tural analysis of high-molecular-weight systems are discussed. Conventional label-
ing strategies require the overproduction of proteins in bacterial or eukaryotic ex-
pression systems and we give an overview of the most advanced systems as they
are indispensable prerequisites for the eﬃcient incorporation of isotopes into pro-
teins. In addition to structural studies, NMR plays an increasingly important role
in the description of protein dynamics, and relationships between dynamics and
function. We therefore also address techniques of selective isotope labeling for the
study of protein side-chain dynamics and protein–ligand interactions. The second
part of the chapter focuses on newly developed in vitro techniques, utilizing cell-
free extracts for the generation of protein samples. While cell-free production of
proteins in an analytical scale has been possible for several years, preparative pro-
tein production using extracts from Escherichia coli or other sources has become
one of the most powerful tools for the production of labeled samples suitable for
NMR analysis. We therefore will especially address the recent advancements in
cell-free expression and labeling strategies.
10.2
Expression Systems for the In Vivo Incorporation of 13C and 15N Labels into Proteins
Apart from technical barriers, the quality and stability of protein samples often
limit their analysis by NMR technologies. The relatively low sensitivity of most
NMR spectrometers requires sample concentrations starting from 0.2 mM and
many proteins aggregate long before they reach that limit. In addition, samples
must remain stable for at least several days until a complete set of measurements
is ﬁnished. In order to obtain optimal resolution, NMR analysis usually requires
relatively high temperatures of 15–25 C, which could also aﬀect protein stability.
Due to the high costs involved in the preparation of multinuclear-labeled proteins,
one sample should be used for several experiments and aggregation, denaturation
or even degradation of the proteins due to spurious amounts of proteases or due to
autoproteolysis needs to be reduced to a minimum. Reasonably high yields of
sample preparations are therefore required, which in conventional in vivo expres-
sion systems should reach a minimum of several milligrams of protein per liter of
culture medium. In order to obtain the best protein production rates, the choice of
the optimal expression system is therefore of primary importance. The most com-
monly used organism for labeled recombinant protein production is still the en-
terobacterium E. coli. An immense variety of expression systems and vectors have
been designed for protein production in E. coli, and this large selection is certainly
one of the major advantages for choosing an E. coli expression system. The pre-
dominant eukaryotic systems for protein production are based on the highly pro-
ductive species Pichia pastoris. Labeling of proteins in mammalian cells is only
rarely considered because of the high costs due to low yields concomitant with the
need for expensive labeling precursors.
Labeled protein samples were initially generated by growing the cells in deﬁned
minimal media supplemented with speciﬁcally labeled compounds. Common label
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labeling, and NaH13CO3,[ 13C]glycerol, [13C]glucose and [13C]acetate for carbon
labeling. A variety of supplements such as trace element mixtures and vitamin
cocktails have been tested to enhance the cellular growth in minimal media and to
improve the productivity. Furthermore, single- or double-labeled mixtures of amino
acids or complex algal or microbial hydrolyzates have been added to culture media
[10–13] in order to produce uniformly labeled proteins. In order to reduce the iso-
tope costs, cells may be grown in unlabeled rich media to high cell densities, har-
vested and then suspended in low volumes of labeled deﬁned medium for protein
production. High levels of isotope incorporation concomitant with a 4- to 8-fold
increase in yield were obtained in E. coli with this technique [14, 15].
10.2.1
Protein Production and 13C and 15N-labeling in E. coli Expression Systems
Techniques for isotope enrichment in E. coli have been available for several years
[16–18] and the vast majority of labeled proteins analyzed by NMR spectroscopy
are still being produced by heterologous expression in various E. coli hosts yielding
up to 50% of the total cell protein. Despite considerable improvements in eukary-
otic and cell-free expression systems, bacterial expression remains the fastest and
most economical system for the production of proteins. Standard methods of gen-
erating heteronuclear-labeled samples in E. coli use M9 minimal medium [19] or
modiﬁed derivatives of it – supplemented with [13C]glucose and [13C]glycerol for
carbon labeling, and (15NH4)2SO4 and 15NH4Cl for nitrogen labeling. An impor-
tant advantage when using E. coli expression is the elaborated selection of vectors
and host strains available. Upon overproduction of proteins, it is often essential
that the transcription of the target gene can be repressed as tightly as possible until
the cells reach the most suitable growth phase for induction. Leaky expression
prior to induction could either favor the accumulation of mutations in the target
gene in order to suppress the production of unwanted proteins, or even damage or
kill the cells due to toxic eﬀects.
The most popular inducible promoters in E. coli expression systems are listed in
Tab. 10.1. Repression of the strong E. coli lac promoter is performed by interaction
Tab. 10.1 Commonly used promoters for protein overproduction in E. coli.
Promoter Origin Repression Induction
Plac E. coli LacI isopropyl b-thiogalactoside
(IPTG)
Para E. coli AraR l-arabinose
Ptet E. coli, Tn10 TetR tetracycline
f1–f10 phage T7 of T7 RNA
polymerase
repression/inactivation requires T7 RNA polymerase,
IPTG
lPL phage ll cI repressor heat inducible, temperature
shift of 42 C
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coli RNA polymerase from binding. The LacI protein is released from its operator
by the addition of isopropyl b-thiogalactoside (IPTG), a nonmetabolizable analog of
the natural inducer. A disadvantage of the lac promoter is its relatively high back-
ground expression. This could be partly suppressed by an increasing copy number
of LacI in expression hosts either by introducing additional copies of the lacI gene
on a plasmid or by increasing the expression of the chromosomal lacI gene by an
up mutation of its native promoter, called lacIq. Several derivatives, like the tac
or trc promoter, have been constructed by fusion of Plac with other promoters, e.g.
from the tryptophan operon.
In expression systems based on the highly speciﬁc T7 promoters, the protein
production is induced by the supply of T7 RNA polymerase [20]. In principal, the
T7 RNA polymerase can be provided in several ways. A common method is the
expression in specially designed strains carrying a chromosomal copy of T7 gene 1,
encoding T7 RNA polymerase. This construct, termed ‘‘DE3’’, represents a tran-
scriptional fusion of gene 1 with the IPTG-inducible lac promoter. To ensure tight
repression, gene 1 is accompanied by an extra copy of the lacIq gene. In order to
eliminate any background of T7 RNA polymerase due to leaky expression, the
plasmid-borne gene encoding for T7 lysozyme can be provided. T7 lysozyme eﬃ-
ciently binds and inactivates T7 RNA polymerase, and this expression system even
allows the production and labeling of toxic proteins in E. coli.
While the structural analysis of the native protein is predominantly the major
task of a labeling approach, most samples were initially produced as translational
fusions to other proteins or to artiﬁcial peptide-tags (Tab. 10.2). Those strategies
can provide valuable advantages for the fast and eﬃcient puriﬁcation of the labeled
protein or for its stabilization [21]. Furthermore, the addition of a suitable fusion
partner to the N-terminus of the target protein can signiﬁcantly enhance its pro-
duction. Fusion proteins usually include a recognition site for a highly speciﬁc
protease like enterokinase or the TEV protease in the linker between the two pro-
teins. If necessary, the fusion partners could then be cleaved oﬀ from the target
proteins after puriﬁcation, leaving the nonmodiﬁed labeled protein for analysis.
Tab. 10.2 Popular tags and carrier proteins for protein overproduction in fusion systems.
Fusion Eﬀect on solubility
a Puriﬁcation
Poly(His)6-tag no eﬀect immobilized metal chelate chromatography
Strep-tag no eﬀect aﬃnity chromatography
Maltose-binding protein þþ aﬃnity chromatography
NusA þþ
Glutathione S-transferase þ aﬃnity chromatography
Thioredoxin þ
Protein G (B1 domain) þ
l head protein D þ
Protein A (Z domain) þ aﬃnity chromatography
aEﬀect on the solubility of the target protein.
10 13C- and 15N-Isotopic Labeling of Proteins 272The most frequent peptide-tag used for an easy puriﬁcation is a poly(His)6-tag
added to the N- or C-terminus of the protein. Such small tags usually do not dis-
turb the conformation or activity of proteins and their removal after puriﬁcation
might not even be necessary. Proteins containing a poly(His)6-tag can easily be
puriﬁed from a crude cell extract by forming a chelate complex with metal ions like
Ni2þ or Cu2þ immobilized on a chromatography column. The imidazole moieties
of adjacent histidine residues are crucial for ﬁrm chelate formation and the bound
proteins can later be eluted from the column with a competing imidazole gradient.
The production of proteins with a poly(His)6-tag has become a routine technique
for the heterologous expression of recombinant genes in any host.
Only approx. 25% of overproduced proteins are initially suitable or stable enough
for structural analysis [22] and most experiments must be optimized in order to
obtain suﬃcient yields of correctly folded proteins. General parameters of opti-
mization are the selection of suitable expression hosts and vectors, variation of
growth conditions and inducer concentrations, construction of fusion proteins, and
coexpression of helper proteins. A frequently encountered problem upon heterolo-
gous expression in E. coli is the formation of inclusion bodies – large aggregates
of unfolded inactive protein. Protein targeting as insoluble inclusion bodies could
be a strategy to circumvent bactericidal activities of the overproduced protein [23].
Several protocols have been described to solubilize inclusion bodies after puriﬁca-
tion in strong denaturants and to refold denatured proteins into their correct 3-D
conformation [24, 25]. However, for each protein the refolding strategy has to be
optimized and might represent an intensive laborious trial-and-error procedure
giving less than satisfactory results. Thus, it is often intended to maximize the
production of proteins in completely soluble form. Fortunately, in many cases, the
formation of inclusion bodies during expression can be prevented by C-terminal
linkage of the target protein to a highly soluble fusion partner. Several carrier pro-
teins are able to enhance the solubility of an otherwise insoluble proteins (Tab.
10.2); in systematic screens for proteins suitable to confer solubility on insoluble
target proteins fused to their C-terminal ends, the E. coli maltose-binding protein
MalE [26] and NusA [27] proved to be the most eﬃcient. As large carrier proteins
have to be removed through speciﬁc proteases prior to NMR analysis, the cleavage
of the fusion proteins can reintroduce problems with solubility and the released
target proteins sometimes tend to precipitate soon after they are no longer co-
valently attached to a carrier. In addition, the use of large carrier proteins would
waste a considerable amount of the precious label precursors. Smaller carrier pro-
teins like the phage l head protein D [28] or domains of Staphylococcus Protein A
[29] or Streptococcus Protein G [30] might therefore be used as noncleavable tags to
enhance the stability of smaller proteins or peptides. Fusions with the B1 domain
of Protein G even improved NMR spectra of labeled proteins [30]. As well as en-
hancing solubility, carrier proteins can be used to facilitate the production of small
peptides in E. coli and to stabilize them against degradation [23].
Misfolding can be a particular problem with the expression of eukaryotic pro-
teins in E. coli, especially if they have several disulﬁde bonds, consist of multiple
subunits or contain prosthetic groups. A popular strategy to address such problems
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produced protein depends on chaperones, the increase of chaperone concentra-
tions by coexpression of GroEL/ES, DnaKJ/GrpE or other chaperone systems could
be highly advantageous. Low production rates due to translational pausing or mis-
incorporation of amino acids as a result of rare codon usage of the overproduced
protein could be optimized by the coexpression of corresponding tRNAs. A fre-
quent problem, which in many cases still cannot be completely solved when using
E. coli expression systems, is the correct formation of disulﬁde bonds in proteins.
Strategies for the optimization of disulﬁde bond formation in vivo include the
export of overproduced proteins into the oxidizing periplasm by addition of appro-
priate export signal sequences, expression in specially designed strains lacking
thioredoxin and glutathione reductase and thus providing an oxidizing cellular en-
vironment [31], and coexpression of disulﬁde isomerases like the DsbA and DsbC
proteins of E. coli or the eukaryotic chaperone protein disulﬁde isomerase (PDI).
10.2.2
13C- and 15N-labeling of Proteins in P. pastoris
Yeast cells combine many advantages of prokaryotic and eukaryotic expression sys-
tems. They are small, robust and easy to handle. The growth rate of yeast cells is
much faster compared with other eukaryotic cells and the fermentation of yeast
cells is usually ﬁnished within a couple of days. Furthermore, yeasts do not require
complex supplements in the growth media and can be propagated in simple inex-
pensive media or on agar plates like E. coli cells. Their excellent growth on deﬁned
minimal media make them especially attractive for the production of labeled pro-
teins for NMR analysis. In addition, due to the secretion capabilities of P. pastoris,
recombinant proteins might be easily puriﬁed in a single step [32]. Many proteins
of eukaryotic origin need to undergo speciﬁc posttranslational modiﬁcations like
glycosylation or lipidation, disulﬁde bridge formation, or posttranslational process-
ing. The modiﬁcations are often essential for the stability or enzymatic activity of
proteins [33], or for the adoption of their native conformation. The failure to form
correct disulﬁde bridges can retard or even block the folding process of proteins,
resulting in the formation of inclusion bodies or in their degradation. The produc-
tion of modiﬁed proteins cannot be addressed in a satisfactory manner by using
Tab. 10.3 Modiﬁcations of E. coli expression systems.
Problems/requirements Modiﬁcations
Disulﬁde bridge formation expression in trx  and gor  strains, providing an oxidizing
environment in the cytoplasm
coexpression of disulﬁde isomerases like DsbA, DsbC or PDI
periplasmic expression using signal peptides
Chaperone-dependent folding coexpression of chaperones like GroELS and/or DnaKJ/GrpE
Rare codon usage coexpression of corresponding tRNAs
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pastoris may therefore be the method of choice when searching for a fast-growing
host with the potential for the production of modiﬁed and glycosylated proteins
[34, 35]. However, the fact that the protein modiﬁcation pattern obtained after ex-
pression in yeast might diﬀer from that usually present in the native protein has
to be considered, e.g. yeasts are only capable of attaching mannose-rich glycans,
representing the core polysaccharide of glycoproteins.
Labeling approaches should take into account that heterologous protein produc-
tion in P. pastoris is correlated with a high cell density. Up to 100-fold increased
yields can be obtained by fermentation of the cells in bioreactors as compared to
shake ﬂask cultures [36–38]. The induction of heterologous protein production
should be started after reaching high cell densities. Yields of more than 100 mg
protein/l culture medium have been reported [34, 38]. In shake ﬂasks, the reported
yields of uniformly labeled heterologous proteins vary from 2 mg/l in case of the
Vaccinia virus complement control protein [39] to up to 27 mg/l for tick anti-
coagulant protein [36]. The average protein yield in yeast using shake ﬂasks there-
fore only reaches the lower limit of comparable protein production in E. coli.I t
is furthermore important to realize that if compared with protein production in
E. coli, much higher amounts of labeled isotopes are required to obtain a reason-
able growth of the yeast cells, and at least 5- to 10-fold higher concentrations of
(15NH4)2SO4 and [13C]glucose are routinely used when growing the cells in shake
ﬂasks. To produce 90 mg of a 13C-labeled fragment of thrombomodulin in P.
pastoris,1 4 3g[ 13C]glycerol or 162 g [13C]glucose had to be used by growing the
cells in a 1.25-l fermentor [34]. Therefore, based on economic aspects, labeling
approaches with yeasts are only competitive in cases when the proteins cannot be
produced in E. coli.
In deﬁned minimal medium, the sole nitrogen source for P. pastoris usually is
NH4OH, which in addition serves as a base to neutralize considerable amounts of
acid produced by the yeast during growth [34]. However, due to economic reasons,
NH4OH has to be replaced by (15NH4)2SO4 for 15N-labeling of proteins in P. pas-
toris. The required high cell density demands the addition of high amounts of
(15NH4)2SO4 and more than 40-folds concentration as compared with fermenta-
tions of E. coli had to be used. To avoid any negative eﬀects on cell growth arising
from the increased ionic strength of the medium through the formation of K2SO4,
the (15NH4)2SO4 had to be added in several portions at diﬀerent times [38], and
optionally also in combination with an exchange of medium before induction of
protein expression [34].
For 13C-labeling of proteins using the strong AOX1 promoter, two usually carbon
sources are required during fermentation – glycerol or glucose to obtain a high cell
density and methanol for the induction of the AOX1 promoter. Although P. pastoris
is able to grow on methanol as the sole carbon source, the slow doubling time
would prevent high cell densities and requires the use of alternate carbon sources
like glycerol or glucose. While glucose could certainly help to increase the cell
density, it represses the strong AOX1 promoter, leading to a decrease in heterolo-
gous protein production. However, [13C]glucose could be used in labeling experi-
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cells may then be further fermented with [13C]glycerol as the carbon source and
induced with [13C]methanol [34]. Up to 30% of the carbon from the labeled pro-
tein originates from methanol and therefore it is crucial to induce the protein
production with [13C]-methanol in order to obtain fully labeled proteins, especially
when using a yeast strain with a mutþ genotype [34].
10.2.3
13C- and 15N-labeling of Proteins by Expression in Chinese Hamster Ovary
(CHO) Cells
Compared to yeast cells, CHO cells represent the alternative of a more advanced
system enabling the generation of labeled samples containing all of the possible
modiﬁcations speciﬁc to eukaryotic proteins. Like with yeast cells, recombinant
proteins can be eﬃciently secreted into the medium and protein production rates
of more than 100 mg/l from CHO cells have been reported [40]. However, mam-
malian cells usually require amino acids, vitamins, cofactors and in many cases a
complex serum as essential additives to the medium. To reduce costs, CHO cells
could also be grown by replacing the highly expensive isotopically labeled amino
acids with labeled bacterial hydrolyzates or algal extracts and suﬃcient yields of
recombinant protein highly enriched with isotopes can be obtained [10]. To avoid
dilution of the isotope label with unlabeled amino acids from the serum, a dialysis
step should be included to remove low-molecular-weight compounds from the
serum [10, 41]. A further important and probably cost-intensive factor is the re-
quirement of relatively high concentrations of labeled glutamine, which is essential
for the metabolic pathways of several amino acids and nucleic acid components.
Although CHO cells represent an expensive host for the generation of labeled
proteins, they might be the best choice for the overexpression of complex glyco-
proteins or of proteins that cannot be produced in E. coli [41–43].
10.2.4
13C- and 15N-labeling of Proteins in Other Organisms
A further option to produce labeled glycosylated proteins can be the over-
production in the slime mould Dictyostelium discoideum. This host is able to feed
on bacterial cells like E. coli that could then be pre-enriched with isotopic labels
using standard protocols. Suitable expression vectors for D. discoideum are available
and a glycosylated 16-kDa protein has already been labeled with 13C/15N to a high
extent [44]. As the growth rate of D. discoideum is rather low, the complete experi-
ment took more than 10 days. However, if compared to labeling approaches using
yeast cells as a host, lower amounts of labeled precursors are needed to obtain
suﬃcient protein for NMR measurements, and D. discoideum might therefore be
considered as an economic alternative to produce labeled glycoproteins.
While the previously discussed expression systems require relatively expensive
mixtures of labeled precursors, the photoautotrophic cyanobacterium Anabaena sp.
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nitrogen and carbon sources. A 24-kDa domain of the E. coli gyrase B subunit was
successfully overproduced in Anabaena sp. by using a specially designed shuttle
vector system and more than 90% 13C/15N label incorporation was obtained [45].
The yield of the protein (approximately 3–6 mg/l) was found to be comparable
to that obtained in E. coli. It is noteworthy that the expressed gene was under
control of the E. coli tac promoter, which is also functional in Anabaena. While
15N-labeling in Anabaena can be carried out with standard growth protocols, 13C-
labeling is problematic under aerobic conditions because of the ability of endoge-
nous CO2 ﬁxation, resulting in incomplete 13C-labeling of less than 30% [45].
However, 13C-enrichment of more than 90% could be obtained after growing the
Anabaena cells with nitrogen gas aeration under controlled anaerobic conditions.
The fermentation of Anabaena requires illumination and the duration is about 5
times longer compared to E. coli because of the slower doubling time. However,
as less expensive labeled precursors can be used, the cost could be reduced to
only about 10%. Heterologous protein production in Anabaena might therefore
be an option for proteins with a low production rate for which higher volumes
of medium have to be used. In addition, it has to be considered that the non-
protonated nature of the ﬁnal carbon supply might also be advantageous and
cost-eﬀective for the generation of perdeuterated protein samples necessary for
the structural analysis of large proteins or dynamic studies.
Although heterologous protein production is the most common approach, small
peptide products have also been labeled in their natural host. A crucial prerequisite
is that the organisms can be adapted to grow on deﬁned media supplemented with
suitable labeled precursors. Examples of successful approaches are the labeling of
cyclosporin A in Tolypocladium inﬂatum [46], alamethicin in Trichoderma viride [47],
bellenamine in Streptomyces nashvillensis [48] and cyanophycin in Synechocystis sp.
[49].
10.2.5
Strategies for the Production of Selectively 13C- and 15N-labeled Proteins
NMR spectra of uniformly labeled proteins become increasingly complex with the
increasing size of the proteins. Several methods have been established to selec-
tively label only speciﬁc domains, amino acids or even single nuclei of the protein
in order to simplify the spectral analysis. Using in vivo labeling techniques, this
can be done by feeding the host cells with speciﬁcally designed label precursors,
which are obtained in most cases by chemical synthesis. The resulting spectral
simpliﬁcation facilitates the unambiguous assignment of resonances in large pro-
teins. Choosing the correct labeling strategy can therefore be crucial to accelerate
the assignment of resonances in proteins.
10.2.5.1 Selective Labeling of Amino Acids
In principal, any amino acid residue in an overproduced protein can be speciﬁcally
labeled by providing excessive amounts of the amino acid containing the desired
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tiﬁed by comparison with spectra of a protein with other labeled amino acids and
such approaches could considerably accelerate the resonance assignments of large
proteins. However, the high costs for puriﬁed labeled amino acids prevent the ap-
plication of this technique for routine use of structure determinations. The selec-
tive labeling strategy is suited for the dynamic and functional analysis of selected
amino acid residues e.g. during ligand interactions. Speciﬁc labeling is also useful
in the analysis of protein denaturation. Unfolded proteins generally have a low
dispersion of resonances, but the tracking of a limited number of labeled residues,
ideally well distributed throughout the protein, could enable the analysis of the
unfolding process. In a previous study, selective labeling with [15N]isoleucine was
used to detect folding intermediates of a complex protein [50].
As an alternatively to speciﬁc labeling of amino acids, in reverse isotope labeling
an excess of one or several nonlabeled amino acids is added to a growth medium
in combination with commonly used general labeling compounds like 15NH4Cl or
[13C]glucose. An interesting application is the reverse labeling of aromatic residues
like phenylalanine or tyrosine as their side-chains are frequently involved in ligand-
binding interfaces or positioned in hydrophobic cores of proteins, making distance
restraints for the environment of these residues highly valuable [51, 52]. The re-
verse isotope-labeling approach clearly depends on the complexity of the analyzed
protein and is generally useful for smaller proteins containing only few of the
analyzed amino acid residues. The application of amino acid-speciﬁc or selective
isotope-labeling strategies is limited by scrambling eﬀects of the isotope label to
other types of residues. Speciﬁc auxotrophic mutants of E. coli can be used for the
overproduction and speciﬁc labeling of recombinant proteins in order to minimize
this problem, [53].
10.2.5.2 Speciﬁc Isotope Labeling with 13C
Amino acids labeled at selected carbon positions can be added to deﬁned growth
media for their incorporation into the recombinant protein. These partially labeled
compounds were usually generated by chemical synthesis and introduced to opti-
mize the spectral resolution of large proteins in speciﬁc NMR experiments. Aro-
matic side-chain protons may be diﬃcult to assign if the number of aromatic resi-
dues increases. Phenylalanine residues 13C-labeled only at the e position could
thus help to rapidly assign the aromatic ring protons [54]. Furthermore, fully 13C-
labeled proteins have undesirable 13Caa13Cb scalar couplings. Incorporation of
amino acids labeled in the 13C backbone overcome this problem [55]. Fractional
13C-labeling of amino acids can be achieved by growing the protein-producing cells
with a deﬁned mixture of 13C- and 12C-labeled carbon sources [56]. The analysis of
internal side-chain dynamics within proteins in uniformly 13C-labeled proteins is
also complicated due to interference eﬀects between diﬀerent contributing relax-
ation interactions as well as by contributions from 13Ca13C scalar and dipolar cou-
plings. To solve this problem, proteins can be synthesized with an alternating
12Ca13Ca12C-labeling pattern by an elaborate isotope labeling procedure using
either [2-13C]glycerol or [1,3-13C2]glycerol as the sole carbon source [57]. Further
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tive protonation to analyze the structure of large proteins [52].
10.2.5.3 Segmental Isotope Labeling
Despite advances in heteronuclear multidimensional NMR techniques, the in-
creased complexity of spectra due to a lack of resolution and increased overlap of
signals having similar chemical shifts still limits the structural analysis of large
proteins. However, a promising approach to further extend the actual size limit
of the structural evaluation of proteins by NMR spectroscopy is the segmental- or
block-labeling technique. In principal, partially labeled full-length proteins can be
produced by the posttranslational in vitro ligation of nonlabeled domains together
with a labeled domain obtained in diﬀerent expression experiments. Resonances of
single domains of larger proteins may be sequentially assigned and the complete
structure of the protein could be obtained by a combinatorial approach, dividing a
large target protein into parts of manageable size. In contrast to a structural eluci-
dation of isolated protein domains, one should bear in mind that the structure of
labeled domains with the segmental-labeling technique is analyzed in the context
of the complete protein, thus providing information of the structural and func-
tional interaction between domains while preserving the overall structural char-
acter of the protein. The ligation process is catalyzed by self-splicing enzymes – the
inteins [58]. Inteins are insertion sequences cleaved oﬀ after translation through
self-excision, leaving the ﬂanking protein regions, the exteins, joined together
through native peptide bond formation.
Depending on the nature of the intein and on the solubility of the target do-
mains, several modiﬁed protocols of the segmental labeling strategy have been
established.
. The intein is cut in the middle of the sequence within a ﬂexible loop region and
the two fragments are expressed separately as fusions to the target domains. The
isolated denatured proteins are mixed and the two intein fragments eﬃciently
associate during refolding, resulting in the ligation of the two target domains
[59, 60]. This strategy is especially applicable if the intein fusions are expressed
as insoluble inclusion bodies and if an eﬃcient protocol for refolding is avail-
able. Using diﬀerent inteins at each splice junction, even proteins containing
central labeled domains can be generated [61]. . The chemical ligation of folded proteins under native conditions uses an ethyl a-
thioester at the C-terminal end of a recombinant protein, generated by cleavage
of an intein fusion, for the ligation with a second protein or peptide containing a
cysteine residue at its N-terminal end [62]. Both ligation partners can be com-
bined in a correctly folded conformation at a physiological pH and this strategy
principally could be extended to link more than two domains together. . The mini intein from the dnaE gene of the cyanobacterium Synechocystis sp.
comprises less than 200 amino acid residues, and is divided into N- and C-
terminal fragments that are expressed separately. If combined after puriﬁcation,
the two fragments eﬃciently interact under native conditions to catalyze the
10.2 Expression Systems for the In Vivo Incorporation of 13C and 15N Labels into Proteins 279splicing and ligation reaction of covalently attached proteins [63, 64]. Target
domains to be ligated have to be expressed as fusion N- and C-terminal to the
intein fragments.
Although in vitro ligation yields as high as 90% have been obtained, several
potential problems should be considered when starting a segmental labeling ap-
proach. While most enzymatically important residues are located within the in-
teins, an eﬃcient excision and ligation mechanism also requires some residues
from the extein, and the reaction is therefore not completely independent of the
sequence of newly formed protein junctions [64]. The C-terminal extein requires a
cysteine, threonine or serine residue at its N-terminal end. This sequence require-
ment must not aﬀect the structure or activity of the analyzed protein. Refolding
and ligation conditions must be optimized for each individual protein, and the
splicing/ligation junction should be located in a loop region ensuring high ﬂexi-
bility. In principal, block labeling might apply best to proteins composed of in-
dependently folded domains having distinct biochemical properties.
10.3
Cell-free Isotope Labeling
Cell-free protein synthesis is an attractive and promising alternative to the con-
ventional technologies for protein production using bacterial or eukaryotic cell
cultures. In contrast to in vivo gene expression methods where protein synthesis
is carried out in the cellular context surrounded by cell walls and membranes,
cell-free protein synthesis provides a completely open system. This allows direct
control and access to the reaction at any time. Compounds to improve protein
production or to stabilize recombinant proteins, e.g. chaperones, chemicals, de-
tergents or protease inhibitors, can easily be added without considering side-eﬀects
of the cellular metabolism or transport problems through the cell membrane. Most
cellular functions with the exception of transcription and translation need not be
maintained during cell-free protein expression. In principal, applications can there-
fore be extended to proteins or conditions that would not be tolerated by living
organisms. While in vivo protein production is often limited by the formation of
insoluble inclusion bodies or protein instability caused by intracellular proteases,
the cell-free system oﬀers new possibilities for the synthesis of complex proteins
(Tab. 10.4). Protein folding and stability can be promoted by direct addition of
chaperones, PDIs or necessary cofactors. In contrast, overexpression of chaperones
in vivo can lead to cell ﬁlamentation or other undesirable phenotypes that can be
detrimental for the viability of E. coli cells and protein expression [65]. Reaction
parameters such as pH, redox potential and ionic strength can be determined
without concern for harmful eﬀects on the growth and viability of cells, and with
the certainty that these parameters will directly inﬂuence the relevant reactions.
This new opportunity of in vitro gene expression allows full control and high ﬂexi-
bility of conditions, and oﬀers new potentials for diﬃculties associated with cyto-
10 13C- and 15N-Isotopic Labeling of Proteins 280toxicity, proteolytic degradation or improper folding and aggregation of synthesized
proteins. The production of cytotoxic proteins [66], membrane proteins [67, 68] as
well as the production of functional antibodies using PDI and chaperones [69] or
functional viruses [70] had been reported. Most of all, cell-free protein synthesis
oﬀers completely new possibilities for the incorporation of labeled [71–74], glyco-
sylated [75, 76], modiﬁed or unnatural amino acids [77]. Another promising po-
tential for cell-free synthesis can be found in its suitability for high-throughput
expression of proteins by direct translation of linear polymerase chain reaction
(PCR) products [78]. Current limitations of cell-free systems are connected with
their high complexity, high costs and often low productivity.
10.3.1
Components of Cell-free Expression Systems
In cell-free protein production, all components involved in gene expression and
protein synthesis have to be added to the reaction mixture (Fig. 10.1). Components
like DNA, nucleotide triphosphates (NTPs), messenger RNA (mRNA), transfer
RNA (tRNA), aminoacyl-tRNA synthetases (ARSases), polymerases, ribosomes,
transcription and translation factors like initiation factors (IFs), elongation factors
(EFs) or release factors (RFs) and amino acids have to be optimized with regard
to their concentration, and optimal salt and pH environment. The process of
transcription/translation requires large amounts of free energy supplied by the
hydrolysis of the triphosphates ATP and GTP. Therefore, in vitro protein synthesis
requires an ATP-regenerating energy system to maintain the triphosphate concen-
tration. For this purpose, high-energy phosphate donors such as acetyl phosphate
Tab. 10.4 Potential advantages and disadvantages of cell-free protein synthesis.
Potential advantages Disadvantages
Completely open system (easy
access) ! customization of reaction
conditions to synthesized protein
Incorporation of labeled, glycoslylated,
modiﬁed or unnatural amino acids
Direct translation of PCR
products ! high-throughput screening
Production of toxic proteins
Production of membrane bound proteins
Expression of proteins requiring cofactors
Easy addition of chaperones or PDI
Miniaturization (e.g. 50 ml reactions)
Working without living organisms ! no
growth restrictions
Allowing a direct isolation of products to
shorten time required for preparing
puriﬁed proteins
Often low productivity
Complex system compared to in vivo protein
synthesis
Expensive reaction compared to in vivo expression
Small number of commercial systems and kits
Diﬃcult standardization because of multitude of
reaction components
High costs
10.3 Cell-free Isotope Labeling 281(AcP), creatine phosphate (CrP) or phosphoenol pyruvate (PEP) in the presence of
their kinases (acetate kinase, creatine kinase and pyruvate kinase) have been used.
A crucial component is a cell extract based on crude cell lysate which contains
the necessary reaction components such as IFs, EFs, RFs, ARSases, tRNA and
ate kinase
Fig. 10.1 Schematic to illustrate cell-free
protein synthesis, showing the coupled process
of transcription and translation in a bacterial
system. Initially, cells are grown, lysed and the
cell extract is prepared containing ribosomes,
translation factors like initiation factors (IFs),
elongation factors (EFs) and release factors
(RFs), acetate kinase and aminoacyl-tRNA
synthetases (ARSases). Substrates like amino
acids, the energy-regenerating system
components or nucleoside triphosphates
(NTPs) and salts are then added to the extract,
and protein synthesis is initiated by adding the
template DNA. The DNA is transcribed by an
added RNA polymerase. Added tRNA is loaded
with amino acids by ARSases and they are
used in the translation of mRNA. The incor-
poration of some stable isotope-labeled
amino acids (dark) can easily be done in the
cell-free system, leading to a selective isotope-
labeled protein. Regeneration of ATP and GTP
and even the NTPs in the cell-free system is
achieved by an ATP-regenerating energy sys-
tem based on the hydrolysis of high-energy
substrates in the presence of their kinases.
Chaperones can easily be added to the reaction
mixture to assist the folding of the target
protein.
10 13C- and 15N-Isotopic Labeling of Proteins 282enzymes for energy regeneration like acetate kinase. Cell-free expression systems
are classiﬁed according to the origin of their extract. In principle, functional in
vitro systems can be prepared from any cell type, but many factors contribute to the
protein production eﬃciency. The most common in vitro reactions are based on
extracts made from E. coli, wheat germ or rabbit reticulocyte lysates (Tab. 10.5).
E. coli extracts consist of the so-called S30 supernatant fraction, named after the
soluble fraction when centrifuged at 30,000 g, containing endogenous ribosomes,
enzymes like acetate kinase and factors necessary for transcription and translation,
ARSases, tRNA and mRNA. Endogenous mRNA is removed from the ribosomes
during preincubation of the crude cell extract in a ‘‘run-oﬀ’’ step and destroyed
by endogenous ribonucleases [79]. Another way to deploy bacterial extracts is de-
scribed in the Gold–Schweiger system [80, 81]. Ribosomes are added to the super-
Tab. 10.5 Bacterial and eukaryotic cell-free expression systems.
Bacterial systems Eukaryotic systems
Escherichia coli Wheat germ Rabbit reticulocyte
S30 extract preparation S100 extract preparation Wheat germ extract Rabbit reticulocyte lysates
Supernatant fraction at
30,000 g centrifugation of
E. coli extract
preincubated to detract
endogenous DNA and
mRNA
Supernatant fraction at
100,000 g centrifugation
deprived of all nucleic
acids, e.g. by DEAE
cellulose treatment
Directly used for
expression of
endogenous or
exogenous
templates
Treated with micrococcal
Ca2þ dependent
RNase
Contains: RNA polymerase,
ribosomes, tRNAs,
ARSases, translation
factors
Contains: RNA polymerases,
ARSases and translation
factors
Contains:
Ribosomes,
tRNAs, ARSases,
translation factors
Contains: Ribosomes,
tRNAs, ARSases,
translation factors
Ribosomes, tRNAs added
24–38 C (optimum at 37 C)
a 24–38 C (optimum at 37 C)
a 20–27 Cu pt o3 2  C
a 30–38 C
a
[79, 82, 83, 132, 133]
b [80, 81]
b [85–87]
b [82, 89, 98, 113]
b
aReaction temperature.
bReferences.
To be added:
DNA (plasmid with appropriate promotor for SP6, T7 RNA-
polymerase) þ polymerase (bacteriophage SP6 or T7 RNA polymerase)
or mRNA.
Amino acids.
Energy components: ATP and GTP.
NTP-regeneration system: PEP þ PK or CP þ CrP or AcP.
Formyltetrahydrofolate or its congener, e.g. methenyltetrahydrofolate or
folinic acid.
SH-compound: mercaptoethanol or dithiothreitol.
Mg2þ and Kþ in optimal concentrations.
In some cases:
Ca2þ and NH4
þ in optimal concentrations.
cAMP.
Polyamines, e.g. spermidine.
10.3 Cell-free Isotope Labeling 283natant fraction of a S100 extract especially puriﬁed from endogenous amino acids
and nucleic acids by ion-exchange chromatography. This system provides a very
low background due to endogenous synthesis and better-controlled conditions at
the expense of more complicated preparation.
The E. coli system functions well in a temperature range of 24–38 C with an
optimum at 37 C [79, 82, 83]. Wheat germ extract possesses a low level of endo-
genously expressed messengers and therefore can be directly used for expression
of endogenous [84] or exogenous templates. In the wheat germ system, the opti-
mum temperature is in the range 20–27 C [85, 86], but can be increased to
up to 32 C for higher expression of some templates [87]. Reticulocyte extract is
prepared by directly lysing blood cells of anemic rabbits; this increases the num-
ber of proerythrocytes or reticulocytes that are subsequently treated with micro-
coccal Ca2þ-dependent RNase to remove endogenous mRNA [88]. This system
works in a temperature range of 30–38 C [89]. With regard to the reaction tem-
perature, it should be noted that apart from any eﬀect on the enzymatic process of
transcription/translation and mRNA degradation, the temperature aﬀects the fold-
ing of the synthesized protein. To assist the folding of proteins, chaperones like the
GroEL/ES system [90] or DnaK and DnaJ [69] can be added to the reaction mix-
ture. Usually, lower temperatures will lead to higher yields of recombinant protein
in the absence of chaperones, but not necessarily in their presence [91]. Further-
more, to assist disulﬁde bond formation, PDI can be added to the transcription/
translation mixture [69].
Less common translation systems based on yeast extracts [92], mammalian cells
like human HeLa and mouse L-cells [93] or on tobacco chloroplasts, which strongly
depend on exogenously added mRNA [94], have high levels of degradation and
relatively low protein yields. With regard to the cell-free labeling of proteins, only
E. coli and wheat germ extracts have been used. Using a very elaborate approach,
Shimizu et al. developed a cell-free translation system reconstructed from puriﬁed
poly(His)-tagged translation factors [95]. Their system, termed the ‘‘protein syn-
thesis using recombinant elements’’ (PURE) system, contains 32 individually pu-
riﬁed components with high speciﬁc activity, allowing eﬃcient protein production.
An advantage of the PURE system, apart from the absence of inhibitory substances
such as nucleases, proteases and enzymes that hydrolyze nucleoside triphosphates,
is the simple puriﬁcation of the synthesized protein by removing tagged protein
factors by aﬃnity chromatography.
One limitation of the cell-free system is the degradation of exogenous added
mRNA. Various RNase activities present in cell extracts usually restrict the life-
time of mRNA, and subsequently the eﬃciency of protein synthesis is inhibited.
This problem could be solved by the periodical reintroduction of messengers into
the reaction mixture in a simple translation system [96]. Coupled transcription–
translation systems, where mRNA is continuously synthesized from DNA tem-
plates added to the reaction mixture, can be advantageous to translation systems
containing presynthesized messengers. Direct transcription in the reaction mixture
may be executed from appropriate promoters by endogenous E. coli RNA polymer-
ase, or by exogenous phage RNA polymerase in bacterial systems [97] or in eu-
10 13C- and 15N-Isotopic Labeling of Proteins 284karyotic systems [82, 98]. To avoid rapid messenger degradation, especially in E.
coli cell-free systems, partially ribonuclease-depleted extracts or RNase inhibitors
are used. A good choice of template DNA in the prokaryotic system is circular
plasmid DNA. In the wheat germ system with lower nuclease activities, both
plasmid DNAs [99] and linear PCR fragments function well [100–102]. The trans-
lational eﬃciency of mRNA depends on its structural features. Most cDNA se-
quences can be suﬃciently well expressed without addition of translational en-
hancers. The sequence of interest only needs to be provided with a favorable Kozak
sequence in eukaryotic cell-free systems and the Shine–Dalgarno sequence in
prokaryotic cell-free systems, which are the respective sequences upstream of the
ATG codon responsible for translation initiation.
A further problem in cell-free protein synthesis is the high consumption of bio-
chemical energy provided by ATP and GTP. Creatine phosphate concomitant with
creatine kinase is usually used for ATP and GTP regeneration in eukaryotic cell-
free systems, whereas the combination of PEP and pyruvate kinase, acetyl phos-
phate and acetate kinase or a combination of both has been applied for bacterial in
vitro protein synthesis. The acetyl phosphate energy system may have the advan-
tage that the ATP level is maintained twice as long as in the presence of PEP. Since
acetate kinase is present at suﬃcient levels in bacterial extracts, it does not need to
be added exogenously in the E. coli system [103]. Studies of the biochemical energy
levels in diﬀerent cell-free systems observed a high rate of triphosphate hydrolysis
to mono- and diphosphates during protein synthesis in wheat germ extracts [104]
as well as in an E. coli S30 extract [105]. It is reported that more than 80% of ATP
and GTP hydrolysis in the wheat germ system initially occurs independently of
protein synthesis and it was suggested that acid phosphatases are responsible for
the nonspeciﬁc hydrolysis of the nucleotide triphosphates [86, 104].
Recent extensive studies to increase the protein yield of cell-free reactions have
focused on the composition of the reaction mixture, especially the amino acids
composition [106, 107], and methods to prepare the cell extract. For example, en-
dogenous phosphatases have been removed by using S30 extract prepared from the
spheroplasts of E. coli [108] or by immunodepletion of the phosphatase [109]. Ap-
proaches to concentrate the extract components by ultraﬁltration [110] or by dialy-
sis [74] have also been reported.
10.3.2
Cell-free Expression Techniques
In cell-free reactions carried out in a ‘‘batch’’ mode, the reaction conditions change
as a result of substrate consumption and the accumulation of products. Translation
stops as soon as any essential substrate is exhausted, or any product or by-product
reaches an inhibiting concentration. Actually, the bacterial cell-free systems are
active only for 10–30 min at 37 C. Systems based on rabbit reticulocyte lysates or
wheat germ extract are typically capable of working for up to 1 h. However, in vitro
protein-synthesizing systems in batch mode work well for most analytical pur-
poses, but short lifetimes and low productivities limit their application for the
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10 13C- and 15N-Isotopic Labeling of Proteins 286synthesis of preparative amounts of protein. The reasons for the low yield are
degradation of mRNA, depletion of nucleotide triphosphates and accumulation
of their hydrolyzates. Prolonged reaction times in cell-free expression were ﬁrst
achieved by Spirin et al. [111–113] by using a continuous-ﬂow cell-free (CFCF)
translation device (Fig. 10.2A). The basic idea is to continuously supply amino
acids, energy-regenerating components (AcP, CrP or PEP) and NTPs in a feeding
solution, and continuously remove small molecule byproducts (mainly products of
triphosphate hydrolysis like inorganic phosphates and nucleoside monophosphates)
by active (forced) ﬂow of the feeding solution across an ultraﬁltration membrane
(molecular weight cut-oﬀ in the range of 10–300 kDa). In this case, all products,
including the protein synthesized, are continuously removed from the reaction
compartment if the pore size is large enough (Fig. 10.2A). Permanent stirring of
the reaction mixture and in some set-ups upright ﬂow of the feeding solution are
applied to minimize membrane clogging [114]. The CFCF system can function for
more than 20 hours and results in preparative protein expression of about 0.1–1
mg protein/ml reaction volume or higher. The template for this system can either
be mRNA [113, 115], DNA transcribed by endogenous bacterial RNA polymerase
or added phage RNA polymerase [82, 113, 114], or self-replicating RNA [116].
Using the CFCF system, proteins like bacteriophage MS2 coat protein [111], brome
mosaic virus coat protein [111], calcitonin polypeptide [113], globin [117], func-
tionally active dihydrofolate reductase (DHFR) [112, 113, 118, 119], chloram-
phenicol acetyltransferase (CAT) [105, 113, 114, 116, 120, 121] interleukin (IL)-2
[122] and IL-6 [115] have successfully been synthesized.
The important advantage of the CFCF system is the continuous removal of syn-
thesized proteins from the reaction mixture, which can result in 80–85% purity of
the protein product as previously demonstrated in the outﬂow of a bacterial CFCF
system synthesizing DHFR [119] and in a wheat germ CFCF system synthesizing
IL-6 [115]. The synthesized protein diﬀuses out of the CFCF reactor in a large vol-
ume of the eﬄuent and is quite diluted. To reduce the dilution eﬀect, the so-called
Y-ﬂow reactor with a split outﬂow has been proposed [123]. The Y-ﬂow reactor (Fig.
2B) has two membranes with diﬀerent pore sizes. Initially the low-molecular-
weight products are removed through a small-pore membrane at a high rate and
the synthesized protein is subsequently collected through a large-pore membrane
at a low rate. Here, the ﬂow of the protein product is controlled by a separate
pump. Nevertheless, a number of laboratories attempting CFCF expression have
had diﬃculties in establishing this complex system. The main problems are
RNA degradation when using bacterial extracts, even in the coupled transcription/
translation mode, and low eﬃciency of initiation complex formation, which might
cause leakage and therefore loss of some translation components by ultraﬁltration
or the blockage of the ultraﬁltration membrane [91].
However, there is an alternative way of carrying out prolonged protein synthesis,
namely by using diﬀusion instead of pumping to supply substrates and remove
low-molecular-weight products (Fig. 2C). This set-up, using a reaction mixture
separated from a feeding solution by applying a dialysis membrane, is called a
continuous-exchange cell-free system (CECF) [124] or a semicontinuous-ﬂow cell-
10.3 Cell-free Isotope Labeling 287free system (SFCF) [121]. The simplest device for the continuous supply of sub-
strates and the removal of low-molecular-weight products by passive exchange
with a feeding mixture is a dialysis bag [124]. In practice, simple homemade
dialysis bags or standard commercial dialyzers, such as the MicroDialyzer2 and
DispoDialyzer2 from Spectrum, can be used successfully. The pore size of the
reactor membranes is usually in the range of 10–50 kDa. However, better perfor-
mance of reactors with a larger pore membrane has been reported [74]. Stirring of
either the feeding solution or both, the feeding and reaction mixture, is necessary
for eﬃcient supply of substrates.
Using this approach, Kim and Choi [121] reported the synthesis of 1.2 mg/ml of
CAT over 14 h in E. coli S30 extract. The product yield, quantiﬁed by ELISA, ex-
ceeded the yield of the analogous batch reaction by 10–12 times. More recently,
Kigawa et al. [74] succeeded in synthesizing CAT and Ras proteins in amounts up
to 6 mg/ml over 18 h in their version of the bacterial CECF system, and Madin
et al. [96] reached yields of 1–4 mg/ml for several functionally active proteins like
DHFR, green ﬂuorescent protein (GFP), luciferase and RNA replicase of tobacco
mosaic virus (TMV). Figure 10.3 describes the cell-free synthesis of GFP in a CECF
method using a MicroDialyzer2.
Fig. 10.3 Cell-free synthesis of GFP in a
bacterial CECF system using a 100-ml
MicroDialyzer2. The kinetic points display the
mean of three reactions and error bars
indicating the deviation of the mean. The
reaction was carried out at 30 C using a 17-
fold amount of feeding mixture compared to
the reaction mixture volume and under the
following reaction conditions: 0.05% NaN3,2 %
phosphoenolglycol, 196 mM folinic acid, 2 mM
1.4-dithiothreitol, 1.2 mM ATP, 0.8 mM each of
CTP, GTP and UTP, 20 mM PEP, 20 mM acetyl
phosphate, 1 mM of each amino acid, except
the amino acids arginine, aspartic acid,
cysteine, glutamic acid, methionine and
tryptophan, for which 2 mM was used, 100
mM HEPES–KOH (pH 8.0), 2.8 mM EDTA, 1 
complete protease inhibitor (Roche), 280 mM
Kþ,1 3m MM g 2þ,4 0mg/ml pyruvate kinase,
500 mg/ml tRNA (E. coli), 3 U/ml T7-RNA
polymerase, 0.3 U/ml RNasin, 35% S30 extract
(E. coli) and 15 mg/ml plasmid.
10 13C- and 15N-Isotopic Labeling of Proteins 288The advantage of the CECF system is the accumulation of the synthesized prod-
uct in the reaction mixture. The synthesis of proteins and polypeptides fused with
GFP provide a direct and demonstrative way to visualize product accumulation by
ﬂuorescence of the GFP moiety. The synthesis of a HIV protein, the so-called Nef
antigen, fused with GFP [125] and an antibacterial polypeptide Cecropin P1 fused
with GFP [126], both in the bacterial CECF T7 transcription/translation system,
have been reported.
Reactors combining both exchange and ﬂow have also been developed. In one
version, the reaction mixture is encapsulated into polysaccharide minivesicles that
can be packed into a column, where feeding solution is passed through the column
(Fig. 10.2D). In this case, product–substrate exchange across the vesicle walls takes
place during the ﬂow [113]. More sophisticated versions of the CECF reactor are
being developed in order to meet the demands of scientists and biotechnologists.
The ﬁrst commercial CECF reactor has recently been launched on the market by
Roche Diagnostics. The Roche CECF system promises a high protein yield of more
than 2 mg/ml. Other commercial systems focus on the batch mode, where recent
improvements have been made. For example, a novel NTP regeneration system,
avoiding accumulation of inorganic phosphate by adding pyruvate oxidase, which
generates AcP from pyruvate and inorganic phosphate directly in the reaction
mixture, has been proposed by Kim and Swartz [127]. Later they showed that ad-
dition of oxalate, a potent inhibitor of PEP synthetase, substantially increases the
yield of CAT synthesis through the enhanced supply of ATP by about 47% [128].
Furthermore, Kim and Swartz developed a ‘‘fed-batch’’ mode where coordinated
addition of PEP, magnesium, and the amino acids arginine, cysteine and trypto-
phan resulted in a ﬁnal concentration of cell-free synthesized CAT that was more
than 4-fold compared to a batch reaction [107]. As a result of these improvements
it became possible to synthesize about 350 mg/ml CAT [107] or 450 mg/ml recom-
binant DNA human protein thrombopoietin [106] in a batch reaction.
10.3.3
Speciﬁc Applications of the Cell-free Labeling Technique
Conventional in vivo labeling techniques are often accompanied by low protein
yields due to retarded growth in a minimal medium and, in the case of selective
isotope labeling, by scrambling eﬀects that drastically reduce the eﬃciency and
selectivity of labeling. A major advantage of cell-free labeling techniques therefore
is the absence of any scrambling eﬀects or metabolic conversion of labeled amino
acids [71, 73, 129]. The selective incorporation of isotope-labeled amino acids in
cell-free synthesized proteins for NMR research has already been demonstrated by
several groups [71, 73, 74, 129–131]. Similarly, in the reverse isotope-labeling
technique, most amino acids are single or dual (15N, 13C) labeled, except for a
few residues [74]. Figure 10.4(A) illustrates the 2-D 1Ha15N heteronuclear single-
quantum correlation spectroscopy (HSQC) NMR spectra of the cell-free reverse
isotope-labeled C-terminal DNA-binding domain of the transcriptional response
regulator RcsB (cRcsB) which has been uniformly 15N-labeled except for aspar-
10.3 Cell-free Isotope Labeling 289Fig. 10.4 Comparison of the 2-D 1Ha15N
HSQC spectra of the in vitro and in vivo
generated puriﬁed C-terminal domain of the
bacterial transcriptional regulator RcsB
(cRcsB) using a Bruker DRX-800 MHz NMR
spectrometer with a cryoprobe. (A) Cell-free
15N-reverse isotopic-labeled cRcsB synthe-
sized in an optimized CECF system using a
DispoDialyzer2. All amino acids except
asparagine (N) and glutamine (Q) were 15N-
labeled. As expected, the N and Q residues
(circles) are absent in the 2-D 1Ha15N HSQC
spectrum. (B) Uniformly 15N isotopic-labeled
cRcsB expressed in vivo. This spectrum is in
good agreement with that of the reverse cell-
free isotopically labeled cRcsB, and N and Q
residues can easily be identiﬁed. (NMR spectra
kindly provided by Frank L€ o ohr.)
10 13C- and 15N-Isotopic Labeling of Proteins 290agine (N) and glutamine (Q) residues. The uniformly 15N-labeled cRcsB expressed
in vivo is shown in Fig. 10.4(B). The 2-D 1Ha15N HSQC spectrum of the labeled
cRcsB protein synthesized in vitro is consistent with that of the uniformly labeled
protein synthesized in vivo (only the asparagine and glutamine peaks are missing).
Cell-free expression is highly suited for the generation of protein samples labeled
only at distinct residues. Site-speciﬁc labeling is extremely useful to simplify the
observation and resonance assignment procedures for speciﬁed amino acid resi-
dues of particular interest, and can also be used for analyzing local structures of
large proteins and protein–protein interactions. Ellman et al. demonstrated for the
ﬁrst time the incorporation of a particular 13C-labeled residue at a suppressible
termination codon by translating the modiﬁed sequence in an in vitro system sup-
plemented with the charged suppressor tRNA. Subsequently it became possible to
track the labeled residues upon denaturation and refolding of the protein by NMR
spectroscopy [130]. Milligram quantities of site-speciﬁc isotope labeled protein can
be obtained in a cell-free system involving the amber suppression strategy [73].
The E. coli amber suppressor tRNA can be prepared by in vitro transcription with
T7 RNA polymerase and later aminoacylated with the appropriate puriﬁed E. coli
amino ARSase and the cognate labeled amino acid. The codon for the selected
amino acid residue in the protein was previously changed into an amber codon by
standard techniques.
Segmental labeling in vivo is limited by speciﬁc requirements like organization
of the target protein into domains, presence of speciﬁc residues and folding prob-
lems. Pavlov et al. suggested a cell-free technique based on in vitro translation
of matrix-coupled mRNAs, which principally is devoid of any sequence and con-
formational requirements [72]. The size of the labeled region is controlled by co-
don usage and no intrinsic upper limit to the size of proteins that can be isotope-
labeled in selected regions exists. This method is based on the usage of translation
mixtures depleted of either one amino acid and/or its tRNA and/or its amino
ARSase and consists of three steps. Using column-coupled template RNA the re-
action mixture can easily be exchanged. Initially, the unlabeled N-terminal region,
using an unlabeled reaction mixture, is synthesized up to the ﬁrst codon without
a matching amino acyl-tRNA in the extract. Here the ribosomes pause and the
translation mixture can be exchanged against a mix containing isotope-labeled
amino acids, now deﬁcient for a diﬀerent amino acid, tRNA or amino ARSase.
Translation resumes, thereby labeling the region until the ribosomes encounter the
next codon without the corresponding tRNA. In the last step, the C-terminal part
is synthesized without any label and the protein is released from the ribosome.
However, the technique results in low protein yields, as it can, at the very best,
produce protein stoichiometric to the immobilized mRNA.
A very promising advantage of cell-free isotope labeling is the possibility of in
situ NMR measurement as described by Guignard et al. They showed NMR analy-
sis of in vitro-synthesized proteins without any chromatographic puriﬁcation and
with minimal sample handling using an optimized CECF reaction combined with
the sensitivity of a cryoprobe [131]. As expected, they observed no cross peak
for any excess 15N amino acid and only the target protein was enriched with the
10.3 Cell-free Isotope Labeling 291isotope-labeled residues. They suggest a new possibility for inexpensive high-
throughput protein analysis applicable in large-scale proteomics, where selectively
labeled proteins can be expressed in 0.5 ml of reaction medium using small quan-
tities of labeled amino acids and analyzed by NMR. All steps from the expression
to the completed NMR spectra were done in less than 24 h.
Due to the exceptional advantages of cell-free protein synthesis, isotope labeling
can be achieved for proteins that are normally diﬃcult to express. Using cell-free
labeling techniques, it might become possible to synthesize and isotope label pro-
teins that are toxic, require cofactors or chaperones for adopting an active confor-
mation, or even membrane proteins. Subunit labeling of oligomers, further re-
search on disulﬁde bridge formation or protein oxidation should be possible in the
near future.
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Membrane proteins represent one of the biggest challenges in
the area of structural biology based on the fact that they are hard
to express, to purify, and difficult to analyze by high-resolution
structural methods. Recently, the development of efficient cell-free
transcription/translation protocols for the expression of milligram
amounts of membrane proteins that cannot be expressed in sufficient
quantities in vivo has opened a new avenue toward high-resolution
structural investigations by X-ray crystallography and NMR
spectroscopy.1,2 To understand the function of membrane proteins,
detailed investigations of their structure and interaction with their
binding partners are necessary. NMR spectroscopy is an ideal tool
for such investigations since it can provide both the structure and
information about binding sites through chemical shift mapping.
The basis for such detailed investigations is, however, the assign-
ment of a protein’s resonances. Unfortunately, R-helical proteins
tend to display narrower chemical shift dispersion3-5 as compared
to that of proteins containing â-sheets. Since the majority of integral
membrane proteins consists exclusively of R-helices, their NMR
spectra tend to show a significant degree of peak overlap. The
overlap problem is further aggravated by the often considerable
size of the proteins and further enhanced by the fact that the proteins
have to be solubilized in detergent micelles, which significantly
increases the molecular weight of the protein/micelle particles,
resulting in broader line width. Combined, these disadvantages of
membrane proteins pose a considerable challenge for the chemical
shift assignment, suggesting that new assignment strategies might
be necessary in order to make backbone assignment of membrane
proteins as routine a task as backbone assignment of soluble
proteins. In this communication, we describe our efforts to assign
the completely R-helical integral membrane protein TehA based
on a combination of standard heteronuclear triple resonance
experiments and a combinatorial labeling scheme.
The bacterial protein TehA is a 36 kDa membrane protein that
shows limited homology to the family of small multidrug resistance
proteins (SMR).6 Its overexpression in bacteria confers resistance
to tellurite compounds as well as to lipophilic cationic dyes. In
vivo experiments have demonstrated that a 24 kDa fragment of
TehA, which contains seven out of the 10 predicted transmembrane
helices, shows the same biological effects as the full length protein.
Therefore, we have focused on this 24 kDa fragment. For the
expression and labeling with NMR active isotopes, we have
employed an in vitro transcription/translation system based on E.
coli S30 extracts, which yields 3 mg of TehA protein per milliliter
of reaction volume.1 Figure 1 shows the [15N,1H] TROSY spectrum
of a 2H/13C/15N triple-labeled sample of the 24 kDa TehA fragment,
demonstrating the relatively narrow chemical shift dispersion and
peak overlap in the middle of the spectrum.
To assign the backbone of the protein, we have measured HNCA,
HN(CO)CA, HNCACB, HN(CO)CACB, HNCO, and HN(CA)CO
spectra. In addition, we used a 2H/15N-labeled sample to measure
a 15N-edited NOESY-TROSY and a [15N,1H] HMQC-NOESY-
TROSY experiment. On the basis of the combination of these
experiments, we were able to assign 55% of the protein’s backbone
unambiguously. However, severe overlap, as well as the absence
of some peaks, prevented us from obtaining more assignments. To
close these gaps, we have expressed several amino acid type
selective-labeled samples. However, despite the labeling of 10
different amino acid types (W, A, V, T, S, R, M, L, I, F), only an
additional 10% of unambiguous assignments could be obtained.
The main reason for the failure of the selective labeling procedure
to result in higher assignment yields was that, in many cases, the
N- and C-terminal connectivities to an identified amino acid type
were not unambiguous, resulting in more than one possible
sequence-specific assignment. To solve this problem, we decided
to use a specific labeling procedure based on the simultaneous
labeling of certain amino acid types with 15N and other amino acid
types with 13C on the backbone carbonyls, which has been used in
previous applications for site-specific labeling.7-9 By measuring
two-dimensional versions of an HNCO experiment, it is possible
to select only those 15N-labeled amino acids that are N-terminally
preceded by a 13C-labeled amino acid type. If that combination
occurs only once in the entire protein, that amino acid is site
specifically assigned and can be used as an anchor point for further
sequence-specific assignments. To optimize this procedure and to
minimize the number of samples that have to be produced, we
employed a combinatorial approach. As summarized in Table 1,
we produced three different samples, each one labeled with two to
three different 15N-labeled amino acid types and in addition with
two different 13C-carbonyl-labeled amino acid types. By measuring
Figure 1. [15N,1H] TROSY spectrum of the 24 kDa fragment of TehA.
The concentration of the protein was 0.6 mM, dissolved in 25 mM potassium
phosphate buffer (pH 6) containing 5% LMPG (1-myristoyl-2-hydroxy-
sn-glycero-3-[phosphor-rac-(1-glycerol)]). The spectrum was measured at
40 °C on a 800 MHz NMR instrument with 4 scans per FID and 300
increments in the indirect dimension.
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spectrum for each of the three samples (Figure 2), the sequence-
specific assignment for eight new amino acids could be obtained,
which served as specific starting points for more residues, bringing
the total backbone assignment to 85% (in addition the assignment
for 14 amino acids previously assigned could be confirmed). The
amino acid types used for this combinatorial specific labeling
approach were selected by an algorithm programmed in Matlab
(http://www.biophyschem.uni-frankfurt.de/AK_Doetsch/projects/
download/combilabel.m). The input for this algorithm are the amino
acid sequence and the unassigned sequence stretches. On the basis
of this information, the algorithm calculates the optimal combination
of 15N- and 13C-labeled amino acids that will provide the most new
specific assignments. Of the remaining 15% of backbone resonances
that could not be assigned, 10% are not visible even in a two-
dimensional TROSY spectrum while 5% are visible, but do not
show sequential connectivities. These 5% can, in principle, be
assigned with the specific labeling method. This, however, basically
requires one sample per assignment.
Reinvestigation of our data showed that the combination of the
nonselective triple resonance experiments with the combinatorial
specific labeling strategy would have produced the same level of
overall backbone assignment (85%) as the combination of all three
assignment strategies (nonselective triple resonance experiments,
amino acid type selective labeling, and combinatorial specific
labeling). We, therefore, propose as the most straightforward
strategy for the backbone assignment of membrane proteins the
combination of nonselective triple resonance experiments and a
combinatorial specific labeling protocol based on the production
of proteins with an in vitro transcription/translation system.
Recently, specific labeling in combination with triple resonance
experiments has been used to accelerate the assignment process,8
and a partial assignment procedure based entirely on the use of a
combinatorial specific labeling scheme has been proposed for the
selective assignment of certain amino acids in soluble proteins.9
While a pure combinatorial approach is very efficient and useful
for applications that only require the assignments of the amide
proton and nitrogen frequencies (such as binding assays), full
structure determinations are increasingly based on the use of 13C
backbone chemical shifts as structural parameters. In particular,
for membrane proteins, the use of 13CR and 13Câ chemical shifts
as indicators of the secondary structure is very important.3,5 These
chemical shifts are automatically provided by the nonselective triple
resonance experiments. Furthermore, typically only 40-50% of all
amino acids of a protein are part of a unique amino acid pair within
the sequence and can, therefore, be unambiguously assigned solely
based on combinatorial specific labeling pattern.9 In the case of
TehA, 95 pairs were unique corresponding to 43.4%; 35 pairs
occurred twice, 9 pairs three times, and 6 pairs more than three
times. By first assigning as many resonances as possible with the
nonspecific triple resonance experiments and using an optimization
procedure to pick from the remaining sequence stretches those
amino acid combinations with the highest number of unique pairs,
this problem of multiple possible assignments can be almost
completely avoided.
This combinatorial labeling scheme relies on the use of a cell-
free transcription/translation system for the production of the protein
samples. In principle, amino acid type selective labeling is also
possible in auxotrophic bacteria;10 however, the available strains
are only auxotrophic for certain types of amino acids, thus limiting
the potential labeling combinations. In contrast, cross labeling in
in vitro transcription/translation reactions is negligible.11 Further-
more, the small amounts of labeled amino acids that are used make
selective labeling in this system far less expensive than in cellular
systems. Finally, producing NMR samples with an in vitro
transcription/translation system is very fast. A typical NMR sample
can be produced in less than 24 h since no complicated cell
disruption and purification schemes are involved. In fact, since the
produced protein is the only labeled macromolecule in the reaction
mixture, NMR spectra can, in principle, be measured without any
chromatographic purification.11 We, therefore, believe that the
combination of cell-free transcription/translation with standard NMR
triple resonance experiments and combinatorial labeling schemes
will provide a very efficient avenue toward the backbone assignment
of membrane proteins.
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Figure 2. Results of the combinatorial labeling scheme. A, C, and E show
TROSY spectra of samples 1-3, and B, D, and F the corresponding HNCO
spectra. The circle indicates the resonance position of alanine 48, which in
TehA is preceded by leucine 47.
Table 1. Labeling Schemes Used for the Combinatorial Labeling
amino acid type sample 1 sample 2 sample 3
alanine 15N 15N 15N
phenylalanine 15N 15N
isoleucine 15N 15N
serine 13C 13C
leucine 13C 13C
glycine 13C
valine 13C
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Despite major technical advance in methods used for structural investigations of proteins structure
determination of membrane proteins still poses a signiﬁcant challenge. Recently, the application of cell-
freeexpressionsystemstomembraneproteinshasdemonstratedthatthistechniquecanbeusedtoproduce
quantities sufﬁcient for structural investigations for many different membrane proteins. In particular for
NMR spectroscopy, cell-free expression provides major advantages since it allows for amino acid type
selective and even aminoacid position speciﬁc labeling. In this mini-reviewwe discuss the combination of
cell-free membrane protein expression and liquid state NMR spectroscopy. Copyright  2006 John Wiley
& Sons, Ltd.
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INTRODUCTION
Structure determination of membrane proteins still poses a
very signiﬁcant technical challenge despite the rapid tech-
nical advances in methods such as X-ray crystallography,
electron microscopy and NMR spectroscopy. Problems in
working with membrane proteins arise at all levels, starting
from expressing quantities sufﬁcient for structural anal-
ysis, solubilization and puriﬁcation as well as obtaining
two- or three-dimensional crystals or solutions amenable
to liquid state NMR investigations.1 Recent advances in
production systems have at least provided new possibil-
ities for the expression of large amounts of membrane
proteins.2–5 In particular, the use of cell-free expression
systems holds promise to solve the protein production
problem for many membrane proteins.6–13 In combination
with NMR spectroscopy, cell-free expression systems also
provide a very efﬁcient technique for selective labeling of
certain amino acid types or even for speciﬁc amino acid
positions, thus enabling efﬁcient backbone assignment.13,14
In this mini-review we will summarize the new advances
in these cell-free expression systems and discuss the con-
sequences of their application for structural investigations
of membrane proteins in combination with NMR spec-
troscopy.
ŁCorrespondence to: Volker D¨ otsch, Institute for Biophysical
Chemistry and Center for Biomolecular Magnetic Resonance,
Johann Wolfgang Goethe University, Marie-Curie Str. 9, 60439
Frankfurt, Germany. E-mail: vdoetsch@em.uni-frankfurt.de
CELL-FREE EXPRESSION SYSTEMS
Expression of large quantities of integral membrane proteins
for structural investigations has been achieved with several
different organisms. These include the most-often-used
organisms, bacteria, in particular, Escherichia coli,a sw e l l
as yeast and higher eukaryotic cells such as SF9 insect cells.
In many cases, however, no or only small quantities of
integralmembraneproteins – onlydetectablebywesternblot
analysis – areexpressedinthesecellularsystems.Reasonsfor
the low expression levels are, for example, toxic effects of the
insertion of membrane proteins into the cellular membrane,
inefﬁcienttransportoftheoverexpressedmembraneproteins
within the cell to the cellular membrane, poor growth
of overexpressing strains and the generally unfavorable
impact on the cellular metabolism. Obviously, some of
these problems such as cellular transport and toxicity are
eliminated in cell-free expression systems, making them a
favorable alternative to the established cellular expression
systems. Cell-free expression systems basically consist of a
cellular extract containing the macromolecular transcription
and translation machinery as well as additional high
molecular weight components (tRNAs, pyruvate kinase
and T7 RNA polymerase) and small molecules (amino
acids, nucleotides, ions).15 Currently, extracts for large-scale
protein expression are mainly prepared from two different
cellular systems. The ﬁrst one is based on wheat germs16,17
and the second one on E. coli18–21 w h i c hw eh a v eu s e df o r
the experiments described in this review.
From a technical standpoint, in vitro cell-free expression
systems can be divided into two classes: batch systems and
Copyright  2006 John Wiley & Sons, Ltd.S18 A. Koglin et al.
continuous-exchange systems.6,16,20,21 In the batch system all
the macromolecular components of the extracts are mixed
with the low molecular compounds such as amino acids
and nucleotides in one reaction chamber. In contrast, in the
continuous-exchange system the macromolecular compo-
nents (reaction mixture) and the low molecular compounds
(feeding mixture) are separated into two different compart-
ments that are connected by a dialysis membrane of a certain
cutoff size. This arrangement ensures the continuous supply
of fresh low molecular weight precursors into the reac-
tion mixture concomitant with the removal of inhibitory
by-products like pyrophosphate. In our setup we use a reac-
tion mixture to feeding mixture ratio of 1:17, which in our
hands provides the optimal efﬁciency yielding up to 6 mg
of membrane protein per single milliliter of reaction mix-
ture. This yield can, in principle, be further increased if the
entire feeding mixture gets replaced with a fresh one after
approximately 4 to 6 h. However, the yield of protein after
exchangeofthefeedingmixturewillbeonlysomeadditional
20%. In case the amount of reaction mixture (in particular,
the extract) is the limiting factor, exchanging the feeding
mixture, however, is an option for maximizing the yield.
Whiletheuseofcell-freeexpressionsystemsintheﬁeldof
structural biology has steadily increased over the last years,
it has only recently been applied for the expression of mem-
braneproteins. NMR-basedstructural investigations have so
farmainlyfocusedonbacterialˇ-barrelproteinswhichcanbe
expressedin sufﬁcient quantitiesinE. colias inclusion bodies
and can be efﬁciently refolded and solubilized.21–25 Only a
few˛-helicalmembraneproteinswithuptothreetransmem-
brane helices have been studied by NMR spectroscopy.26–28
However, ˛-elical proteins represent by far the largest group
of integral membrane proteins and include such important
classes as G-protein-coupled receptors (GPCR) and different
categories of transporters. We have, therefore, investigated
the possibility of expressing larger ˛-helical integral mem-
brane proteins in a continuous-exchange, cell-free system.
Figure 1 shows the results for the expression of different
classes of membrane proteins, including EmrE, SugE (bac-
terial small multidrug transporter), YﬁK (bacterial amino
acid transporter), TehA (bacterial transporter involved in
heavy-metalresistance)andaeukaryoticGPCR (vasopressin
receptor type 2). All these proteins are produced in the
cell-free system in quantities ranging from 1 to 5 mg.8 Com-
parison of these yields with expression tests of the same
constructs in E. coli showed that with the exception of EmrE
none of the other proteins could be expressed in appreciable
amounts. Other reports have described the successful cell-
free expression of functional GPCRs (ˇ-adrenergic receptor,
muscarinic acetylcholine receptor, neurotensin receptor).11
Using a commercial cell-free expression system large quan-
tities of small bacterial multidrug transporters, including
EmrE,10 of the mechanosensitive channel MscL7 and of a
bacterial light-harvesting protein12 have also been obtained.
While use of a cell-free expression system can – at least
for a signiﬁcant number of membrane proteins – solve
the problem of having to produce sufﬁcient quantities
for structural investigations, it does not automatically
solve the problem of solubilization. Membrane proteins
Figure 1. Examples of proteins expressed with the
continuous-exchange, cell-free expression system. Lane 1:
molecular weight marker; lane 2: crude lysate after expression
of YﬁK; lane 3: soluble fraction of the YﬁK expression reaction;
lane 4: pellet of the YﬁK expression reaction; lane 5: TehA; lane
6: truncation mutant of TehA, lacking the C-terminal three
transmembrane helices; lane 7: EmrE; lane 8: SugE; lane 9:
porcine vasopressin receptor type 2.
expressed with a cell-free expression system are produced
as precipitates.8 Fortunately, however, these precipitates
behave very differently from inclusion bodies obtained in
E. coli. While proteins produced in inclusion bodies have
to be solubilized with denaturation agents like urea or
guanidinium hydrochloride and then refolded by buffer
exchange, the pellets obtained from the cell-free expression
system do not need any denaturation–refolding procedure
in order to become solubilized. Instead the precipitates
readily dissolve aftergentlemixing withmild detergents.6–13
However, not every detergent can dissolve every membrane
protein pellet. Washing the pellet with a detergent that
does not dissolve the membrane protein but other proteins
that are contained in the pellet can thus be used as an
additional puriﬁcation step. Figure 2 shows such a case.
Incubation of the bacterial amino acid transporter YﬁK
with the detergent n-nonyl-ˇ-maltoside (NM) does not
dissolve the pellet but removes impurities. LMPG on the
other hand, readily dissolves the YﬁK precipitate. Similarly,
Fig. 2 demonstrates that other integral membrane proteins
produced with the cell-free expression system can be
resolubilized with different detergents. Further puriﬁcation
ofthesolubilizedmembraneproteinscanthenbeachievedby
standardproteinpuriﬁcationmethodssuchasNichelateand
size exclusion chromatography. In principle, puriﬁcation is
not even required in the case of isotopically labeled samples
for heteronuclear NMR measurements because all other
macromolecular components are unlabeled. Only the amino
acids that have been added in an isotopically labeled form to
the feeding mixture and their potential metabolic products
can produce background signals in NMR experiments with
the crude reaction mixture of cell-free expression systems.29
These small molecules can, however, be efﬁciently removed
by dialysis.
One of the most signiﬁcant advantages of the cell-free
system is the fact that it constitutes an ‘open system’
that allows for the addition of additional factors to the
mixture, such as protease inhibitors or RNase inhibitors.
In the case of expressing integral membrane proteins the
Copyright  2006 John Wiley & Sons, Ltd. Magn. Reson. Chem. 2006; 44:S17–S23Cell-free expression combined with NMR S19
Figure 2. Examples of solubilization of different membrane
proteins with mild detergents after expression with a cell-free
expression system. Lane 1: molecular weight marker; lane 2:
YﬁK solubilized in 1% LMPG; lane 3: supernatant after washing
the YﬁK pellet with 1% NM; lane 4: YﬁK solubilized in 1%
LMPG after washing with 1% NM showing a reduced amount
of impurities; lane 5: TehA in 1% (n-dodecyl ˇ-D-maltose)
DDM; lane 6: truncation mutant of TehA lacking the C-terminal
three transmembrane helices solubilized in 5% LMPG; lane 7:
E m r Ei n2 %D D M ;l a n e8 :S u g Ei n2 %D D M ;l a n e9 :p o r c i n e
vasopressin receptor in 5% LMPG.
addition of detergents to the reaction directly could, in
principle, preventthe formationof a precipitate and produce
a micelle-solubilized membrane protein sample directly.
We have tested the possibility of producing micelle bound
membrane proteins by adding different detergents directly
to the mixture with three different integral membrane
proteins: the ˛-helical small multidrug transporter EmrE
from E. coli,t h eˇ-barrel outer membrane protein Tsx from
E. coli and the porcine GPCR vasopressin receptor type 2.9
While several different types of detergents from different
chemical classes are capable of producing high yields of
solubilized proteinin allthreecases, severalotherdetergents
inhibit the expression independent of the protein type.
Members of this latter class of detergents often have a
high critical micellar concentration (CMC). Examples are
ˇ-OG and CHAPS, and also phosphocholine derivatives
like DPC which have a relatively low CMC. Detergents
that can be used for producing large amounts of solubly
expressed membrane proteins are, in particular, different
members of the long chain polyoxyethylene-alkyl-ether
group like Brij35, Brij58, Brij78 and Brij98 as well as the
steroid derivative digitonin. Similar results were obtained
by Ishihara and coworkers with three different GPCRs.11
While a wide variety of different detergents are capable
of solubilizing membrane proteins, functional tests have to
be carried out in each case to ensure that the solubilized
protein is active. Investigation of the functional state of the
ˇ-barrel protein TSX solubilized with different detergents
and reconstituted in black lipid membranes, for example,
has shown that it is active when solubilized in TX100 but
not in LMPG micelles.9 For other proteins other detergents
will be optimal (Brij type detergents, for example, for some
GPCRs11). Unfortunately, however, activity assays are not
available for all membrane proteins. While binding studies
(e.g. with GPCRs) are relatively easy to perform both in
micelles aswellasreconstitutedin membranes,10,11 transport
assays for membrane proteins involved in transport are
difﬁcult to establish.8
A recent investigation of the suitability of different
detergents for NMR-based structural investigation of mem-
brane proteins has shown that LMPG and LPPG are the
best suited.30 Unfortunately, none of these is suitable for
soluble expression of membrane proteins in cell-free expres-
sion systems. This problem can, however, be overcome by
exchanging the detergent during puriﬁcation.
NMR INVESTIGATIONS OF a-HELICAL
MEMBRANE PROTEINS
While high expression levels and efﬁcient procedures for
solubilizing membrane proteins are necessary prerequisites
for obtaining a high-resolution structure, they are by no
means sufﬁcient. In contrast to soluble proteins for which
recent technical advances make structure determination
either by X-ray crystallography or by NMR spectroscopy
often straightforward, applying the same techniques to
integral membrane proteins poses additional technical
challenges. For NMR spectroscopy the often large size of
integral membrane proteins resulting in slow rotational
tumbling and concomitant broad linewidth constitutes a
signiﬁcant problem. This problem is aggravated by the fact
that membrane proteins have to be solubilized in micelles,
which contribute considerably to the overall molecular
weightoftheprotein/micelleparticle.Furthermore,˛-helical
proteins tend to display narrower chemical shift dispersions,
resulting inpeakoverlap,andthetransmembranesectionsof
these proteins consist predominantly of hydrophobic amino
acidsoftenleadingtoclusteringofidenticalaminoacidswith
very similar chemical shifts. An example of a spectrum of an
all ˛-helical integral membrane protein, TehA, is shown
in Fig. 3. TehA is a 36 kDa protein that is involved in
detoxifying tellurite compounds in bacteria, although the
exact mechanism is currently not known.31,32 In addition, it
cantransportquaternaryorganiccationssuchascrystalviolet
and ethidium bromide. The wild-type protein consists of ten
transmembrane helices. In vivo experiments, however, have
demonstratedthatexpressionofthesevenN-terminalhelices
is sufﬁcient to confer tellurite resistance to the bacterial cell.
For our NMR investigations of the TehA protein we have,
therefore, used a truncation mutant that contains only the
ﬁrst seven transmembrane helices (219 amino acids).13 The
NMR sample used in the spectrum shown in Fig. 3 was
produced in our cell-free expression system by adding a
mixture of all 20 amino acids, 15N-labeled and deuterated,
to the feeding mixture. Adding 1% of Brij-78 to the reaction
mixture resulted in a soluble protein, which was puriﬁed by
Ni chelate chromatography. After exchanging the detergent
with 3% LMPG, the ﬁnal concentration of the NMR sample
was 0.6 mM. The spectrum of the solubilized protein shows
many resolved peaks but also regions with very signiﬁcant
peak overlap as expected for an all ˛-helical protein of 219
amino acids packed into a micelle.
In order to obtain the backbone assignment we initially
measured a set of standard triple resonance experiments,
including HNCA, HNCOCA, HNCACB, HNCOCACB,
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Figure 3. [15N,1H]-TROSY spectrum of the solubly expressed
2H/15N-labeled 24 kDa fragment of TehA. The concentration of
the protein was 0.5 mM, dissolved in 25 mM potassium
phosphate buffer (pH 6) containing 3% LMPG. The spectrum
was measured at 40 °C on a 900 MHz NMR instrument with
four scans per free induction decay (FID) and 300 increments
in the indirect dimension.
HNCO and HNCACO, as well as a 15N-edited [1H,1H]-
NOESY-TROSY experiment. Figure 4 shows [13C,1H] planes
taken from an HNCACB spectrum, demonstrating the high
quality of the spectra, which allowed us to assign 55% of the
amino acid backbone resonances. The main reason why we
did not achieve a higher percentage is the extensive overlap
in the spectra. One of the advantages of the cell-free sys-
tem is that it allows for efﬁcient amino acid type selective
labeling with almost all amino acid types by minimizing
metabolic scrambling. In contrast, amino acid type selec-
tive labeling in bacteria is restricted to certain amino acid
types,orrequiresauxotrophicstrains.33–35Using thecell-free
expression system we prepared ten different samples each
labeled with a different amino acid type (W, A, V, T, S, R,
M, L, I, F). Despite these efforts these samples provided only
10% additional backbone assignments. The main reason for
the failure of the selective labeling procedure to result in
higher assignment yields was that in many cases the N-a n d
C-terminal connectivities to an identiﬁed amino acid type
were not unambiguous. A possible solution of this prob-
lem is a site-speciﬁc labeling procedure. Such site-speciﬁc
labeling is possible with the methods developed in the labo-
ratory of Peter Schultz, which are based on the use of special
tRNAs that recognize a stop codon to introduce a labeled
amino acid at the site of this stop codon.36 Unfortunately,
the preparation of such tRNAs is a relatively complicated
technique. NMR spectroscopy provides an alternative to
site-speciﬁc identiﬁcation. This method is based on simul-
taneous labeling of a protein with one type of 15N-labeled
amino acid and another type of a 13C-labeled amino acid.
By measuring two-dimensional versions of an HNCO exper-
iment it is possible to select only those 15N-labeled amino
acids that are N-terminally preceded by a 13C-labeled amino
acid type.13,37–40 This method has been used in the past to
accelerate the backbone assignment of soluble proteins39 or
to obtain as many assignments as possible without the use
of triple resonance experiments.38 A disadvantage of this
speciﬁc-site labeling scheme is that it, in principle, requires
one sample per assignment which would be, even with the
use of a cell-free expression system, quite labor intensive. In
order to make site-speciﬁc labeling more efﬁcient we have
used a combinatorial approach based on simultaneously
Figure 4. [13C,1H] planes taken from an HNCACB experiment measured with a 2H/13C/15N-labeled sample of the 24 kDa fragment
of TehA on a 900 MHz instrument.
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labeling several different amino acids with 15No rw i t h13C.
By preparing three different samples, each one labeled in
a different combination of 15No r13C labeled amino acids,
the assignment of unique combinations can be achieved by
analyzing the three different [15N,1H]-TROSY and the three
different two-dimensional HNCO spectra.13 Altogether, this
procedure yielded 22 site-speciﬁc assignments, 8 of which
werenew,while theremaining 14had alreadybeenassigned
previously with the help of triple resonance experiments.
For these 14 amino acids the site-speciﬁc labeling proce-
dure conﬁrmed the previous assignment. Using the eight
new assignments as anchor points, the overall percentage
of backbone assignment could be extended to 85%. Of the
remaining15%ofbackboneresonancesthatarenotassigned,
10% are not visible even in 2D TROSY experiments, while
5% could in principle be assigned, which, however, required
the preparation of one sample per assignment.
One problem that limits the maximum number of
assignments that can be obtained from a combinatorial
labeling approach is that many amino acid pairs occur
more than once in the protein sequence, thus preventing
an unambiguous assignment.13,38 In the case of TehA 95,
amino acid pairs were unique corresponding to 43.4% while
35 pairs occurred twice, 9 pairs three times and 6 pairs more
than three times. This statistic is typical for an average
protein and has been seen also with soluble proteins.38
As a consequence, the complete assignment of a protein’s
backbone cannot be obtained from such a combinatorial
labeling approach alone, but needs additional information
as input. Therefore, we suggest using a combination of
nonselective standard triple resonance experiments and site-
speciﬁc labeling for the backbone assignment of membrane
proteins.Inordertominimizethenumberofsamplesneeded
for the combinatorial assignment procedure we further
suggest the assignment of as many backbone resonances as
possible through nonselective triple resonance experiments
in the ﬁrst stage of the assignment process and the use of the
site-speciﬁc labeling method to ﬁll in the gaps.
Figure 5. Comparison of TROSY spectra of the 24 kDa fragment of TehA in its reduced, diamagnetic form (left) and in its
paramagnetic form with a spin label (MTSL) attached (right). The signiﬁcant overlap of the fully labeled spectrum makes amino acid
type selective labeling necessary. Two different experiments are shown. The site of the spin label attachment as well as the type of
labeling pattern is indicated on the left. Peaks that are completely absent in the paramagnetic spectrum are labeled with an orange
symbol and those that show signiﬁcant line broadening with a yellow symbol. The spectra were measured on an 800 MHz
instrument. The assignment of these affected peaks is shown in the diamagnetic spectrum.
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Following the sequential assignment of 85% of the back-
bone resonances, we have started to analyze both the
secondary structure as well as to explore techniques to
obtain information about the three-dimensional structure
of the entire protein. Analysis of the secondary structure
is mainly based on the 13C˛ and 13Cˇ chemical shifts as
well as the pattern of sequential NOEs in the 15N-edited
[1H,1H]-NOESY spectrum, following the same procedures
that have been developed for soluble proteins. Investigation
of the three-dimensional structure, on the other hand, has to
rely on different strategies. Because of the limited chemical
shift dispersion observed in the spectra of ˛-helical integral
membrane proteins, assignment of the side chain resonances
will be possible for very few residues only. In addition,
the high molecular weight of the micelle/protein particles
requires deuteration, which eliminates most of the protons
that can be used in classical 1H–1H NOE-based structure
determinationprocedures.Whilemeasuringresidualdipolar
couplings26,41,42 as well as incorporating selectively proto-
nated amino acids (e.g. Ile, Leu and Val with protonated
methyl groups) into deuterated proteins43–45 are options
for obtaining structural information, distance constraints
derived from paramagnetic relaxation enhancement experi-
ments could become important and might replace to a large
extent NOE-based distance constraints in structural studies
of membrane proteins.46–48 This type of distance constraints
has been developed with soluble proteins that are too big
for classical structure determination procedures.46 In these
experiments the line broadening effect of a paramagnetic
tag (e.g. 1-oxy(-2,2,5,5-tetramethyl-3-pyrroline-3-methyl)
methanethiosulfonate (MTSL)) that is attached to a protein
through a speciﬁc cysteine side chain on the surrounding
amide protons is investigated. Since this line broadening is
proportional to 1/r6, a quantitative measurement of the line
broadening can be used for obtaining distance constraints.
This method has been successfully used in the structure
determination of the membrane-associated protein Mystic48
andinthereﬁnementoftheoutermembraneˇ-barrelprotein
OmpA.49 Wehavealsostartedtouseparamagneticrelaxation
enhancement to obtain distance constraints for the structure
determinationofTehA.Forthispurposewehavemutatedall
threenaturally occurring cysteinestoalaninesandhaverein-
troduced a cysteine residue at speciﬁc locations, mostly at
the beginning or the end of helices. Because of the signiﬁcant
peakoverlapinthe[15N,1H]-TROSYspectrumwecannotuse
a fully 15N-labeled sample for these investigations but have
to rely on our cell-free expression system to prepare several
samples each labeled selectively with a different amino acid.
Figure 5 shows as an example a comparison of the [15N,1H]-
TROSY spectra of TehA, labeled with a paramagnetic tag
at amino acid position 11 or 98 and the same sample after
reducing the spin label to a diamagnetic compound with
ascorbic acid.
In this review we have focused on discussing the
combination of cell-free expression systems with liquid
state NMR spectroscopy for structural investigations of
membrane proteins. In particular, for NMR spectroscopy
the possibility to obtain amino acid type selective labeled
protein samples for almost all amino acid types without
metabolic scrambling is a very signiﬁcant advantage over
cellular based expression systems. Additional advantages
are the very efﬁcient production of proteins in these cell-free
systems, which does not require cell disruption or time-
consuming unfolding and refolding procedures.
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Mit neuer Methode lassen sich Membranproteine “knacken”. Erstmals können 
ausreichende Mengen begehrter Proteine produziert werden – Auszeichnung für 
Christian Klammt. Forschung Frankfurt, 3, 9-10. (2005) 
 Ihre Wasser ab-
weisende Natur
und ihr begrenztes
Vorkommen in den
Lipidschichten
von Zellen machen
Membranproteine
äußerst schwer zu-
gänglich.
Aussagen zur entwicklungsbiologi-
schen Rolle der jeweiligen Gene,
weil sämtliche Mutationen in jeder
einzelnen Zelle des Gesamtorganis-
mus’ vorhanden sind und nicht –
wie bei einer Vielzahl menschlicher
Erkrankungen – nur in bestimmten
Geweben auftreten und sich erst im
Laufe des Lebens entwickeln. Im
Rahmen des Forschungsprojekts
EUCOMM werden nun Verfahren
eingesetzt, die zeitlich und gewebe-
spezifisch kontrollierbare (konditio-
nale) Mutationen auslösen.
An dem auf Initiative des Deut-
schen Genfallenkonsortiums ins 
Leben gerufenen Projekt sind die
wichtigsten europäischen Mausmu-
tagenesezentren beteiligt. In dem
EUCOMM arbeiten zehn For-
schungsgruppen aus vier europäi-
schen Ländern unter der Leitung
des GSF-Forschungszentrums für
Umwelt und Gesundheit in Neuher-
berg und des Sanger Instituts des
Wellcome Trusts in Hinxton mit der
Biotechnologiefirma GeneBridges
zusammen. Darüber hinaus sind
Wissenschaftler des Universitätskli-
nikums Frankfurt, des Max-Planck-
Instituts für Molekulare Genetik,
Berlin, der Technischen Universität
Dresden, des Institute Clinique de
la Souris, Straßburg, des Europä-
ischen Laboratoriums für Moleku-
larbiologie (EMBL), Monteronton-
do, der Mammalian Genetics Unit
des Medical Research Councils
(MRC), Harwell und des Deutschen
Ressourcenzentrums für Genomfor-
schung(RZPD), Heidelberg, in die
Zusammenarbeit eingebunden. ◆
M
embranproteine lassen sich in
konventionellen zellulären
»Proteinfabriken« nur sehr schwer
produzieren. Daher gingen Wissen-
schaftler am Institut für Biophysi-
kalische Chemie der Universität
Frankfurt jetzt einen völlig neuen
unkonventionellen Weg, um die
insbesondere für die Entwicklung
zielgenauer Medikamente entschei-
denden Schlüsselproteine zu erzeu-
gen. Christian Klammt hat in seiner
Doktorarbeit in der Arbeitsgruppe
von Dr.Frank Bernhard eine neue
Technik zur Produktion größerer
Mengen funktioneller Membran-
proteine etabliert. Für seinen Bei-
trag zu diesem Thema wurde
Klammt mit dem auf 10000 Euro
dotierten FEBS Journal Preis für
den besten Artikel im Journal der
»Federation of European Biochemi-
cal Societies« im Jahr 2004 ausge-
zeichnet. Christian Klammt ist der
erste Träger dieser 2004 erstmals
ausgelobten Anerkennung.
Membranproteine sind die zen-
tralen Schlüsselelemente in der
Kommunikation jeder Zelle mit ih-
rer Außenwelt. Eingebettet in das
Wasser abweisende Milieu von Li-
pid-Membranen sind sie an der äu-
ßersten Zellgrenze lokalisiert und
besitzen eine fundamentale Rolle in
vielen lebenswichtigen Prozessen:
Jegliche Aufnahme externer Reize,
sei es hören, fühlen, schmecken
oder riechen, wird letztlich durch
Membranproteine vermittelt und
durch sie in das Zellinnere weiterge-
leitet. Ebenso werden essenzielle
zelluläre Transportmechanismen,
zum Beispiel von Nährstoffen, Hor-
monen, aber auch von Medikamen-
ten, durch Membranproteine kon-
trolliert. Es erscheint daher nicht
verwunderlich, dass gegenwärtig
schätzungsweise mehr als 60 Pro-
zent aller modernen Pharmazeutika
in ihrer Wirkungsweise unmittelbar
an Membranproteinen ansetzen. 
Im krassen Gegensatz zu ihrer
Bedeutung steht jedoch die wissen-
schaftliche Erforschung von Mem-
branproteinen. Dabei ist insbeson-
dere die Kenntnis der Morphologie,
der dreidimensionalen Struktur der
Proteine, eine unerlässliche Voraus-
setzung für ein Verständnis ihrer
Funktion und für die Entwicklung
von Arzneistoffen und Therapiean-
sätzen. Während jeder Mensch etwa
10000 verschiedene Membranpro-
teine besitzt, sind jedoch zurzeit
weltweit trotz intensivster Bemü-
hungen lediglich die Strukturen
von nicht mehr als 40 Membran-
proteinen aufgeklärt. Anders als
normale Proteine besitzen Mem-
branproteine naturgemäß eine
stark Wasser abweisende Oberflä-
che, was ihre konventionelle Syn-
these schwierig macht. Da die Wirts-
zellen oft sehr schnell absterben,
können Proteinmengen, die für ei-
ne Strukturanalyse erforderlich 
wären, nicht einmal annähernd er-
reicht werden. »Die Präparation
ausreichender Substanzmengen ist
eine der größten Barrieren für die
Erforschung von Membranprotei-
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Mit neuer Methode lassen sich
Membranproteine »knacken«
Erstmals können ausreichende Mengen begehrter Proteine produziert
werden–Auszeichnung für Christian Klammt 
Modell Membranproteine
Rezeptor
Transporter
Membran Ligandnen«, kommentiert Prof. Dr. Robert
Tampé, Sprecher des Sonderfor-
schungsbereichs »Functional Mem-
brane Proteomics« an der Universi-
tät Frankfurt.
Der Clou der von Klammt ent-
wickelten Methode besteht in der
Verwendung von selbst präparier-
ten zellfreien Extrakten, in denen
die gesamte Maschinerie zur Syn-
these von Proteinen enthalten ist.
»Dadurch werden toxische Effekte
vollständig ausgeschaltet und wir
können nun Membranproteine 
unterschiedlichster Art quasi über
Nacht in großen Mengen herstel-
len«, erläutert der Preisträger. Die
Technik ist zudem relativ preiswert
und kann ohne weiteres in jedem
durchschnittlichen biochemischen
Labor in wenigen Tagen etabliert
werden. Entsprechend groß ist
auch die internationale Resonanz
auf diese Arbeit. »Wir haben nahe-
zu täglich Anfragen von anderen
Labors, die Protokolle anfordern
oder uns Mitarbeiter zum Erlernen
der Technik schicken wollen«, re-
sümiert Dr.Frank Bernhard.
Insbesondere für die Struktur-
analyse mit Hilfe der Kernmagneti-
schen Resonanz Spektroskopie (Nu-
clear Magnetic Resonance, NMR)–
die Universität Frankfurt ist hier ein
europäisches Zentrum – bieten sich
mit der entwickelten Technologie
vielfältige neue Ansätze. »Es ist fas-
zinierend: Proben, die bis vor kur-
zem nicht machbar waren oder de-
ren Herstellung zumindest Monate
dauerte, sind jetzt in wenigen Stun-
den möglich«, bestätigt Prof.Dr.
Volker Dötsch, Professor am Institut
für Biophysikalische Chemie und
Mitglied des Zentrums für Biomole-
kulare Magnetische Reonanz
(BMRZ). Und sein Kollege Prof.
Dr.Clemens Glaubitz fügt hinzu:
»Das Potenzial der zellfreien Pro-
duktion von Membranproteinen
für die NMR ist noch nicht ab-
schätzbar«.
Grundlegende Resultate dieses
von der Deutschen Forschungsge-
meinschaft im Rahmen des Sonder-
forschungsbereichs 628 geförderten
Projekts wurden im Wissenschafts-
journal der »Federation of Europe-
an Biochemical Societies« (FEBS
Journal, früher European Journal
of Biochemistry) publiziert: »High
level cell-free expression and speci-
fic labelling of integral membrane
proteins«, Christian Klammt, Frank
Löhr, Birgit Schäfer, Winfried Haa-
se, Volker Dötsch, Heinz Rüterjans,
Clemens Glaubitz and Frank Bern-
hard. European Journal of Bioche-
mistry (2004) 271, Seite 568–580.
Für diese Arbeit wurde nun Christi-
an Klammt ausgezeichnet. Das For-
schungsvorhaben profitierte we-
sentlich von einer von Prof. Dr.
Heinz Rüterjans initiierte Koopera-
tion des Instituts für Biophysikali-
sche Chemie mit dem »Institute for
Protein Research« in Pushchino/
Moskau. Die Arbeit ist ein Gemein-
schaftsprojekt zwischen den Abtei-
lungen Dötsch (Lösungs-NMR) und
Glaubitz (Festkörper-NMR) des In-
stituts für Biophysikalische Chemie
und des Max-Planck-Instituts für
Biophysik und dokumentiert das
Synergiepotenzialinnerhalbdes neu
gegründeten Sonderforschungs-
bereichs 628 und des »Center for
Membrane Proteomics« am Stand-
ort der Universität Frankfurt. ◆
Nachrichten
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In der ersten Liga dabei
Institut für Religionsphilosophische Forschung gewinnt
weltweiten Wettbewerb um Templeton Research Lectures
Preisverleihung:
Dr.Richard 
Perham, Chairman
of the Editorial
Board and Editor-
in-Chief of the
FEBS Journal,
zeichnet den
Frankfurter Wis-
senschaftler
Christian Klammt
(rechts) für den
besten Artikel im
Journal der »Fede-
ration of European
Biochemical So-
cieties« im Jahr
2004 aus.
B
eherrscht die Materie den
Geist? Biofakt oder Artefakt–
sind wir auf dem Weg zu einem
neuen Begriff des Lebens? Gibt es
eine biologische Basis für den Glau-
ben? Die spannenden Fragen, die
Geisteswissenschaften und Natur-
wissenschaften gleichermaßen be-
schäftigen, sind formuliert, und 
damit hat das Frankfurter Organisa-
tionskomitee der Templeton Lectu-
res auch das Programm für die
kommenden drei Jahre umrissen.
Insgesamt hat das Institut für Religi-
onsphilosophische Forschung (IRF)
der Johann Wolfgang Goethe-Uni-
versität zunächst fast 400000 Dollar
zur Verfügung, um im Dialog mit
den Naturwissenschaften Antwor-
ten auf die schwierigen Fragen zum
menschlichen Bewusstsein und zu
den materiellen Bedingtheiten un-
seres Denksystems zu finden. Diese
Summe kann sich durch Verlänge-
rung der Förderung um ein viertes
Jahr bis auf 500000 Dollar erhöhen.
Frankfurt hat, gemeinsam mit
der Vanderbilt University, Knoxville
(USA), den weltweiten Wettbewerb
mit namhaften Universitäten für
sich entschieden und wurde mit
den Templeton Research Lectures
in das Programm des Metanexus
Institutes, Philadelphia (USA), auf-
genommen. Finanziell unterstützt
wird dieses Programm von der
Templeton Foundation; sie fördert
globale Initiativen, die sich mit
Grenzfragen zwischen Theologie
und Naturwissenschaften auseinan-
dersetzen. »Dass wir uns als Philo-
sophen und Religionswissenschaft-
ler mit den Nahtstellen zwischen
Geistes- und Naturwissenschaften
beschäftigen, gehört zur Frankfur-
ter Tradition der Kritischen Theorie.
So werden wir auch die Dominanz
der Naturwissenschaften, wenn es
um die Erklärung der Welt und der
individuellen Existenz geht, im kri-
tischen Diskurs beleuchten«, erläu-
tert der Direktor des Instituts für
Religionsphilosophische Forschung,
Prof. Dr. Thomas M. Schmidt, der
gemeinsam mit dem Theologen 
Dr. Michael Parker den erfolgrei-
chen Antrag für die Templeton 
Research Lectures gestellt hat. Das
Programm trägt den Titel »Ko-
Schöpfer oder Produkt der Natur?
Die menschliche Person im Licht
von Neurophilosophie, Biofaktizi-
tät und Evolutionsbiologie«.Christian Klammt, Westerbachstrasse 268d, 65936 Frankfurt am Main 
Telefon: 069-344118, Email: c.klammt@bpc.uni-frankfurt.de 
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Ich erkläre hiermit an Eides statt, dass ich die vorgelegte Dissertation über „Functional 
and structural analysis of cell-free produced transporters and G-protein coupled 
receptors: Development of new techniques for the fast and efficient production of 
integral membrane proteins (Funktionelle und strukturelle Analyse von zellfrei 
produzierten Transportern und G-Protein gekoppelten Rezeptoren: Entwicklung neuer 
Techniken zur schnellen und effizienten Produktion von integralen 
Membranproteinen)“ selbständig angefertigt und mich anderer Hilfsmittel als der in ihr 
angegebenen nicht bedient habe. Ich erkläre weiterhin, dass Entlehnungen aus Schriften, 
soweit sie in der Dissertation nicht ausdrücklich als solche bezeichnet sind, nicht 
stattgefunden haben. Ich habe bisher an keiner anderen Universität ein Gesuch um 
Zulassung zur Promotion eingereicht oder die vorliegende oder eine andere Arbeit als 
Dissertation vorgelegt. 
 
 
 
 
Frankfurt am Main, den 21. September 2006 
 
Christian Klammt 